[
    {
        "id": "civic.eid:238",
        "type": "VariationNeoplasmTherapeuticResponseStatement",
        "description": "The T790M mutation in EGFR has been shown to confer resistance to the tyrosine kinase inhibitor erlotinib, and patients harboring this mutation that are placed on the drug are likely to relapse.",
        "method": "metakb.method:1",
        "is_reported_in": [
            {
                "id": "civic.source:167",
                "type": "Document",
                "label": "Denis et al., 2015, Clin. Chim. Acta",
                "xrefs": [
                    "pmid:25668228"
                ],
                "title": "EGFR T790M resistance mutation in non small-cell lung carcinoma."
            }
        ],
        "evidence_level": {
            "id": "vicc:e00001",
            "type": "Coding",
            "label": "authoritative evidence"
        },
        "target_proposition": {
            "id": "proposition:DBx_D7JPPPE0dTTK1bfQDhyUMNPebSvz",
            "type": "VariationNeoplasmTherapeuticResponseProposition",
            "subject": "ga4gh:VA.lvgJx0agONKtOZizHmwQiO3tkZ5UB7YV",
            "predicate": "predicts_resistance_to",
            "object": {
                "id": "rxcui:337525",
                "type": "Therapeutic"
            },
            "neoplasm_type_qualifier": {
                "id": "ncit:C2926",
                "type": "Disease"
            }
        },
        "direction": "supports",
        "subject_descriptor": "civic.vid:34",
        "neoplasm_type_descriptor": {
            "id": "civic.did:8",
            "type": "DiseaseDescriptor",
            "label": "Lung Non-small Cell Carcinoma",
            "xrefs": [
                "DOID:3908"
            ],
            "disease": "ncit:C2926"
        },
        "object_descriptor": {
            "id": "civic.tid:15",
            "type": "TherapeuticDescriptor",
            "label": "Erlotinib",
            "extensions": [
                {
                    "type": "Extension",
                    "name": "regulatory_approval",
                    "value": {
                        "approval_rating": "FDA",
                        "has_indications": [
                            {
                                "id": "hemonc:642",
                                "type": "DiseaseDescriptor",
                                "label": "Non-small cell lung cancer",
                                "disease": "ncit:C2926"
                            },
                            {
                                "id": "hemonc:648",
                                "type": "DiseaseDescriptor",
                                "label": "Pancreatic cancer",
                                "disease": "ncit:C43298"
                            }
                        ]
                    }
                }
            ],
            "xrefs": [
                "ncit:C65530"
            ],
            "therapeutic": "rxcui:337525"
        }
    },
    {
        "id": "civic.eid:2258",
        "type": "VariationNeoplasmTherapeuticResponseStatement",
        "description": "In a study of patients receiving melphalan-based therapy, those with KRAS codon 12 mutations were less likely to have a positive response than those with wildtype KRAS (26.9% vs. 58.3%, P=0.015).",
        "method": "metakb.method:1",
        "is_reported_in": [
            {
                "id": "civic.source:1417",
                "type": "Document",
                "label": "Greco et al., 2009, J. Exp. Clin. Cancer Res.",
                "xrefs": [
                    "pmc:PMC2663546",
                    "pmid:19284554"
                ],
                "title": "Reduction of serum IGF-I levels in patients affected with Monoclonal Gammopathies of undetermined significance or Multiple Myeloma. Comparison with bFGF, VEGF and K-ras gene mutation."
            }
        ],
        "evidence_level": {
            "id": "vicc:e00005",
            "type": "Coding",
            "label": "clinical cohort evidence"
        },
        "target_proposition": {
            "id": "proposition:JpdscSmtl0tP4LlgMLwyPbbZcZkyaIFx",
            "type": "VariationNeoplasmTherapeuticResponseProposition",
            "subject": "ga4gh:VA.rpL2_d2q0gdks_VPk_0JVl90aJG9-bEd",
            "predicate": "predicts_resistance_to",
            "object": {
                "id": "rxcui:6718",
                "type": "Therapeutic"
            },
            "neoplasm_type_qualifier": {
                "id": "ncit:C3242",
                "type": "Disease"
            }
        },
        "direction": "supports",
        "subject_descriptor": "civic.vid:78",
        "neoplasm_type_descriptor": {
            "id": "civic.did:41",
            "type": "DiseaseDescriptor",
            "label": "Multiple Myeloma",
            "xrefs": [
                "DOID:9538"
            ],
            "disease": "ncit:C3242"
        },
        "object_descriptor": {
            "id": "civic.tid:328",
            "type": "TherapeuticDescriptor",
            "label": "Melphalan",
            "extensions": [
                {
                    "type": "Extension",
                    "name": "regulatory_approval",
                    "value": {
                        "approval_rating": "FDA",
                        "has_indications": [
                            {
                                "id": "hemonc:633",
                                "type": "DiseaseDescriptor",
                                "label": "Multiple myeloma",
                                "disease": "ncit:C3242"
                            },
                            {
                                "id": "hemonc:645",
                                "type": "DiseaseDescriptor",
                                "label": "Ovarian cancer",
                                "disease": "ncit:C7431"
                            }
                        ]
                    }
                }
            ],
            "xrefs": [
                "ncit:C633"
            ],
            "alternate_labels": [
                "4-[bis(2-chloroethyl)amino]-L-phenylalanine",
                "Alanine Nitrogen Mustard",
                "CB-3025",
                "L-PAM",
                "L-Phenylalanine Mustard",
                "L-Sarcolysin",
                "L-Sarcolysin Phenylalanine Mustard",
                "L-Sarcolysine",
                "Melphalanum",
                "P-di(chloroethyl)amino-L-phenylalanine",
                "Phenylalanine Mustard",
                "Phenylalanine Nitrogen Mustard",
                "Sarcoclorin",
                "Sarkolysin",
                "WR-19813"
            ],
            "therapeutic": "rxcui:6718"
        }
    },
    {
        "id": "civic.eid:2274",
        "type": "VariationNeoplasmTherapeuticResponseStatement",
        "description": "In a study of patients receiving melphalan-based therapy, those with KRAS codon 12 mutations were less likely to have a positive response than those with wildtype KRAS (26.9% vs. 58.3%, P=0.015).",
        "method": "metakb.method:1",
        "is_reported_in": [
            {
                "id": "civic.source:1417",
                "type": "Document",
                "label": "Greco et al., 2009, J. Exp. Clin. Cancer Res.",
                "xrefs": [
                    "pmc:PMC2663546",
                    "pmid:19284554"
                ],
                "title": "Reduction of serum IGF-I levels in patients affected with Monoclonal Gammopathies of undetermined significance or Multiple Myeloma. Comparison with bFGF, VEGF and K-ras gene mutation."
            }
        ],
        "evidence_level": {
            "id": "vicc:e00005",
            "type": "Coding",
            "label": "clinical cohort evidence"
        },
        "target_proposition": {
            "id": "proposition:DADVpjI5RMfxgPq1_fZCX1MHAPT7OvPJ",
            "type": "VariationNeoplasmTherapeuticResponseProposition",
            "subject": "ga4gh:VA.QVdzWvpiRTgBHwV39EuVg6VZVGOLxdUS",
            "predicate": "predicts_resistance_to",
            "object": {
                "id": "rxcui:6718",
                "type": "Therapeutic"
            },
            "neoplasm_type_qualifier": {
                "id": "ncit:C3242",
                "type": "Disease"
            }
        },
        "direction": "supports",
        "subject_descriptor": "civic.vid:913",
        "neoplasm_type_descriptor": {
            "id": "civic.did:41",
            "type": "DiseaseDescriptor",
            "label": "Multiple Myeloma",
            "xrefs": [
                "DOID:9538"
            ],
            "disease": "ncit:C3242"
        },
        "object_descriptor": {
            "id": "civic.tid:328",
            "type": "TherapeuticDescriptor",
            "label": "Melphalan",
            "extensions": [
                {
                    "type": "Extension",
                    "name": "regulatory_approval",
                    "value": {
                        "approval_rating": "FDA",
                        "has_indications": [
                            {
                                "id": "hemonc:633",
                                "type": "DiseaseDescriptor",
                                "label": "Multiple myeloma",
                                "disease": "ncit:C3242"
                            },
                            {
                                "id": "hemonc:645",
                                "type": "DiseaseDescriptor",
                                "label": "Ovarian cancer",
                                "disease": "ncit:C7431"
                            }
                        ]
                    }
                }
            ],
            "xrefs": [
                "ncit:C633"
            ],
            "alternate_labels": [
                "4-[bis(2-chloroethyl)amino]-L-phenylalanine",
                "Alanine Nitrogen Mustard",
                "CB-3025",
                "L-PAM",
                "L-Phenylalanine Mustard",
                "L-Sarcolysin",
                "L-Sarcolysin Phenylalanine Mustard",
                "L-Sarcolysine",
                "Melphalanum",
                "P-di(chloroethyl)amino-L-phenylalanine",
                "Phenylalanine Mustard",
                "Phenylalanine Nitrogen Mustard",
                "Sarcoclorin",
                "Sarkolysin",
                "WR-19813"
            ],
            "therapeutic": "rxcui:6718"
        }
    },
    {
        "id": "civic.eid:3693",
        "type": "VariationNeoplasmTherapeuticResponseStatement",
        "description": "In a retrospective study of 148 treatment naive metastatic colorectal cancer patients, patients with RAS mutations (n=10), including KRAS A146T, KRAS G13D, NRAS G12D and NRAS Q179*, treated with FOLFOX4 plus cetuximab were associated with decreased overall survival (16.3mo vs. 28.5mo, HR:0.43, 95% CI:0.20-0.89, P=0.020) and decreased progression free survival (7.2mo vs. 9.7mo, HR:0.56, 95% CI:0.27-1.16, P=0.11), as compared to patients with wild-type KRAS and NRAS.",
        "method": "metakb.method:1",
        "is_reported_in": [
            {
                "id": "civic.source:1920",
                "type": "Document",
                "label": "Kaczirek et al., 2015, Clin Colorectal Cancer",
                "xrefs": [
                    "pmid:25666295"
                ],
                "title": "FOLFOX4 Plus Cetuximab for Patients With Previously Untreated Metastatic Colorectal Cancer According to Tumor RAS and BRAF Mutation Status: Updated Analysis of the CECOG/CORE 1.2.002 Study."
            }
        ],
        "evidence_level": {
            "id": "vicc:e00005",
            "type": "Coding",
            "label": "clinical cohort evidence"
        },
        "target_proposition": {
            "id": "proposition:6qY8-4NR1mnWEhFHeATXrfoNLxo3J0hE",
            "type": "VariationNeoplasmTherapeuticResponseProposition",
            "subject": "ga4gh:VA.Om0yyht6SnNmdAVYgTuYIXptr3aYzSx5",
            "predicate": "predicts_resistance_to",
            "object": {
                "id": "rxcui:318341",
                "type": "Therapeutic"
            },
            "neoplasm_type_qualifier": {
                "id": "ncit:C4978",
                "type": "Disease"
            }
        },
        "direction": "supports",
        "subject_descriptor": "civic.vid:878",
        "neoplasm_type_descriptor": {
            "id": "civic.did:11",
            "type": "DiseaseDescriptor",
            "label": "Colorectal Cancer",
            "xrefs": [
                "DOID:9256"
            ],
            "disease": "ncit:C4978"
        },
        "object_descriptor": {
            "id": "civic.tid:16",
            "type": "TherapeuticDescriptor",
            "label": "Cetuximab",
            "extensions": [
                {
                    "type": "Extension",
                    "name": "regulatory_approval",
                    "value": {
                        "approval_rating": "ChEMBL",
                        "has_indications": [
                            {
                                "id": "mesh:D002294",
                                "type": "DiseaseDescriptor",
                                "label": "Carcinoma, Squamous Cell",
                                "disease": "ncit:C2929"
                            },
                            {
                                "id": "mesh:D009369",
                                "type": "DiseaseDescriptor",
                                "label": "Neoplasms",
                                "disease": "ncit:C3262"
                            },
                            {
                                "id": "mesh:D015179",
                                "type": "DiseaseDescriptor",
                                "label": "Colorectal Neoplasms",
                                "disease": "ncit:C2956"
                            },
                            {
                                "id": "mesh:D006258",
                                "type": "DiseaseDescriptor",
                                "label": "Head and Neck Neoplasms",
                                "disease": "ncit:C4013"
                            }
                        ]
                    }
                }
            ],
            "xrefs": [
                "ncit:C1723"
            ],
            "alternate_labels": [
                "Cetuximab Biosimilar CDP-1",
                "Cetuximab Biosimilar CMAB009",
                "Cetuximab Biosimilar KL 140",
                "Chimeric Anti-EGFR Monoclonal Antibody",
                "Chimeric MoAb C225",
                "Chimeric Monoclonal Antibody C225",
                "Erbitux",
                "IMC-C225"
            ],
            "therapeutic": "rxcui:318341"
        }
    },
    {
        "id": "civic.eid:3882",
        "type": "VariationNeoplasmTherapeuticResponseStatement",
        "description": "In a retrospective study of 148 treatment naive metastatic colorectal cancer patients, patients with RAS mutations (n=10), including KRAS A146T, KRAS G13D, NRAS G12D and NRAS Q179*, treated with FOLFOX4 plus cetuximab were associated with decreased overall survival (16.3mo vs. 28.5mo, HR:0.43, 95% CI:0.20-0.89, P=0.020) and decreased progression free survival (7.2mo vs. 9.7mo, HR:0.56, 95% CI:0.27-1.16, P=0.11), as compared to patients with wild-type KRAS and NRAS.",
        "method": "metakb.method:1",
        "is_reported_in": [
            {
                "id": "civic.source:1920",
                "type": "Document",
                "label": "Kaczirek et al., 2015, Clin Colorectal Cancer",
                "xrefs": [
                    "pmid:25666295"
                ],
                "title": "FOLFOX4 Plus Cetuximab for Patients With Previously Untreated Metastatic Colorectal Cancer According to Tumor RAS and BRAF Mutation Status: Updated Analysis of the CECOG/CORE 1.2.002 Study."
            }
        ],
        "evidence_level": {
            "id": "vicc:e00005",
            "type": "Coding",
            "label": "clinical cohort evidence"
        },
        "target_proposition": {
            "id": "proposition:e_3NNapOoNeeZi1MoruyXk6xCAWRhh2Q",
            "type": "VariationNeoplasmTherapeuticResponseProposition",
            "subject": "ga4gh:VA.tO-mdKyTxDxR376-vWkR2RgI2gpOvBhQ",
            "predicate": "predicts_resistance_to",
            "object": {
                "id": "rxcui:318341",
                "type": "Therapeutic"
            },
            "neoplasm_type_qualifier": {
                "id": "ncit:C4978",
                "type": "Disease"
            }
        },
        "direction": "supports",
        "subject_descriptor": "civic.vid:81",
        "neoplasm_type_descriptor": {
            "id": "civic.did:11",
            "type": "DiseaseDescriptor",
            "label": "Colorectal Cancer",
            "xrefs": [
                "DOID:9256"
            ],
            "disease": "ncit:C4978"
        },
        "object_descriptor": {
            "id": "civic.tid:16",
            "type": "TherapeuticDescriptor",
            "label": "Cetuximab",
            "extensions": [
                {
                    "type": "Extension",
                    "name": "regulatory_approval",
                    "value": {
                        "approval_rating": "ChEMBL",
                        "has_indications": [
                            {
                                "id": "mesh:D002294",
                                "type": "DiseaseDescriptor",
                                "label": "Carcinoma, Squamous Cell",
                                "disease": "ncit:C2929"
                            },
                            {
                                "id": "mesh:D009369",
                                "type": "DiseaseDescriptor",
                                "label": "Neoplasms",
                                "disease": "ncit:C3262"
                            },
                            {
                                "id": "mesh:D015179",
                                "type": "DiseaseDescriptor",
                                "label": "Colorectal Neoplasms",
                                "disease": "ncit:C2956"
                            },
                            {
                                "id": "mesh:D006258",
                                "type": "DiseaseDescriptor",
                                "label": "Head and Neck Neoplasms",
                                "disease": "ncit:C4013"
                            }
                        ]
                    }
                }
            ],
            "xrefs": [
                "ncit:C1723"
            ],
            "alternate_labels": [
                "Cetuximab Biosimilar CDP-1",
                "Cetuximab Biosimilar CMAB009",
                "Cetuximab Biosimilar KL 140",
                "Chimeric Anti-EGFR Monoclonal Antibody",
                "Chimeric MoAb C225",
                "Chimeric Monoclonal Antibody C225",
                "Erbitux",
                "IMC-C225"
            ],
            "therapeutic": "rxcui:318341"
        }
    },
    {
        "id": "civic.eid:15",
        "type": "VariationNeoplasmTherapeuticResponseStatement",
        "description": "GIST cancer with D842V mutation is resistant to imatinib.",
        "method": "metakb.method:1",
        "is_reported_in": [
            {
                "id": "civic.source:61",
                "type": "Document",
                "label": "Corless et al., 2005, J. Clin. Oncol.",
                "xrefs": [
                    "pmid:15928335"
                ],
                "title": "PDGFRA mutations in gastrointestinal stromal tumors: frequency, spectrum and in vitro sensitivity to imatinib."
            }
        ],
        "evidence_level": {
            "id": "vicc:e00005",
            "type": "Coding",
            "label": "clinical cohort evidence"
        },
        "target_proposition": {
            "id": "proposition:XT63NpvH0QMWWy8SjzzSDlRwhki6ikVG",
            "type": "VariationNeoplasmTherapeuticResponseProposition",
            "subject": "ga4gh:VA.CaTuLaWlUwLb32qfYTW2udl2Iy02ccN6",
            "predicate": "predicts_resistance_to",
            "object": {
                "id": "rxcui:282388",
                "type": "Therapeutic"
            },
            "neoplasm_type_qualifier": {
                "id": "ncit:C3868",
                "type": "Disease"
            }
        },
        "direction": "supports",
        "subject_descriptor": "civic.vid:99",
        "neoplasm_type_descriptor": {
            "id": "civic.did:2",
            "type": "DiseaseDescriptor",
            "label": "Gastrointestinal Stromal Tumor",
            "xrefs": [
                "DOID:9253"
            ],
            "disease": "ncit:C3868"
        },
        "object_descriptor": {
            "id": "civic.tid:5",
            "type": "TherapeuticDescriptor",
            "label": "Imatinib",
            "extensions": [
                {
                    "type": "Extension",
                    "name": "regulatory_approval",
                    "value": {
                        "approval_rating": "FDA",
                        "has_indications": [
                            {
                                "id": "hemonc:667",
                                "type": "DiseaseDescriptor",
                                "label": "Soft tissue sarcoma",
                                "disease": "ncit:C9306"
                            },
                            {
                                "id": "hemonc:602",
                                "type": "DiseaseDescriptor",
                                "label": "Gastrointestinal stromal tumor",
                                "disease": "ncit:C3868"
                            },
                            {
                                "id": "hemonc:616",
                                "type": "DiseaseDescriptor",
                                "label": "Hypereosinophilic syndrome",
                                "disease": "ncit:C27038"
                            },
                            {
                                "id": "hemonc:33893",
                                "type": "DiseaseDescriptor",
                                "label": "Chronic myelogenous leukemia pediatric",
                                "disease": null
                            },
                            {
                                "id": "hemonc:634",
                                "type": "DiseaseDescriptor",
                                "label": "Myelodysplastic syndrome",
                                "disease": "ncit:C3247"
                            },
                            {
                                "id": "hemonc:24309",
                                "type": "DiseaseDescriptor",
                                "label": "Acute lymphoblastic leukemia",
                                "disease": "ncit:C3167"
                            },
                            {
                                "id": "hemonc:582",
                                "type": "DiseaseDescriptor",
                                "label": "Chronic myelogenous leukemia",
                                "disease": "ncit:C3174"
                            },
                            {
                                "id": "hemonc:669",
                                "type": "DiseaseDescriptor",
                                "label": "Systemic mastocytosis",
                                "disease": "ncit:C9235"
                            }
                        ]
                    }
                }
            ],
            "xrefs": [
                "ncit:C62035"
            ],
            "alternate_labels": [
                "4-[(4-Methyl-1-piperazinyl)methyl]-N-[4-methyl-3-[[4-(3-pyridinyl)-2-pyrimidinyl]amino]phenyl]benzamide"
            ],
            "therapeutic": "rxcui:282388"
        }
    },
    {
        "id": "civic.eid:16",
        "type": "VariationNeoplasmTherapeuticResponseStatement",
        "description": "While cancer with PDGFRA V561D mutation is known to be sensitive to Imatinib, double mutation of V561D and D842V mutants are resistant to imatinib.",
        "method": "metakb.method:1",
        "is_reported_in": [
            {
                "id": "civic.source:62",
                "type": "Document",
                "label": "Heinrich et al., 2006, J. Clin. Oncol.",
                "xrefs": [
                    "pmid:16954519"
                ],
                "title": "Molecular correlates of imatinib resistance in gastrointestinal stromal tumors."
            }
        ],
        "evidence_level": {
            "id": "vicc:e00005",
            "type": "Coding",
            "label": "clinical cohort evidence"
        },
        "target_proposition": {
            "id": "proposition:XT63NpvH0QMWWy8SjzzSDlRwhki6ikVG",
            "type": "VariationNeoplasmTherapeuticResponseProposition",
            "subject": "ga4gh:VA.CaTuLaWlUwLb32qfYTW2udl2Iy02ccN6",
            "predicate": "predicts_resistance_to",
            "object": {
                "id": "rxcui:282388",
                "type": "Therapeutic"
            },
            "neoplasm_type_qualifier": {
                "id": "ncit:C3868",
                "type": "Disease"
            }
        },
        "direction": "supports",
        "subject_descriptor": "civic.vid:99",
        "neoplasm_type_descriptor": {
            "id": "civic.did:2",
            "type": "DiseaseDescriptor",
            "label": "Gastrointestinal Stromal Tumor",
            "xrefs": [
                "DOID:9253"
            ],
            "disease": "ncit:C3868"
        },
        "object_descriptor": {
            "id": "civic.tid:5",
            "type": "TherapeuticDescriptor",
            "label": "Imatinib",
            "extensions": [
                {
                    "type": "Extension",
                    "name": "regulatory_approval",
                    "value": {
                        "approval_rating": "FDA",
                        "has_indications": [
                            {
                                "id": "hemonc:667",
                                "type": "DiseaseDescriptor",
                                "label": "Soft tissue sarcoma",
                                "disease": "ncit:C9306"
                            },
                            {
                                "id": "hemonc:602",
                                "type": "DiseaseDescriptor",
                                "label": "Gastrointestinal stromal tumor",
                                "disease": "ncit:C3868"
                            },
                            {
                                "id": "hemonc:616",
                                "type": "DiseaseDescriptor",
                                "label": "Hypereosinophilic syndrome",
                                "disease": "ncit:C27038"
                            },
                            {
                                "id": "hemonc:33893",
                                "type": "DiseaseDescriptor",
                                "label": "Chronic myelogenous leukemia pediatric",
                                "disease": null
                            },
                            {
                                "id": "hemonc:634",
                                "type": "DiseaseDescriptor",
                                "label": "Myelodysplastic syndrome",
                                "disease": "ncit:C3247"
                            },
                            {
                                "id": "hemonc:24309",
                                "type": "DiseaseDescriptor",
                                "label": "Acute lymphoblastic leukemia",
                                "disease": "ncit:C3167"
                            },
                            {
                                "id": "hemonc:582",
                                "type": "DiseaseDescriptor",
                                "label": "Chronic myelogenous leukemia",
                                "disease": "ncit:C3174"
                            },
                            {
                                "id": "hemonc:669",
                                "type": "DiseaseDescriptor",
                                "label": "Systemic mastocytosis",
                                "disease": "ncit:C9235"
                            }
                        ]
                    }
                }
            ],
            "xrefs": [
                "ncit:C62035"
            ],
            "alternate_labels": [
                "4-[(4-Methyl-1-piperazinyl)methyl]-N-[4-methyl-3-[[4-(3-pyridinyl)-2-pyrimidinyl]amino]phenyl]benzamide"
            ],
            "therapeutic": "rxcui:282388"
        }
    },
    {
        "id": "civic.eid:240",
        "type": "VariationNeoplasmTherapeuticResponseStatement",
        "description": "In Lung Cancer patients with acquired resistance to Dacomitinib (PF00299804), MET amplification and EGFR T790M were found to be the primary drivers of resistance.",
        "method": "metakb.method:1",
        "is_reported_in": [
            {
                "id": "civic.source:169",
                "type": "Document",
                "label": "Sequist et al., 2011, Sci Transl Med",
                "xrefs": [
                    "pmc:PMC3132801",
                    "pmid:21430269"
                ],
                "title": "Genotypic and histological evolution of lung cancers acquiring resistance to EGFR inhibitors."
            }
        ],
        "evidence_level": {
            "id": "vicc:e00005",
            "type": "Coding",
            "label": "clinical cohort evidence"
        },
        "target_proposition": {
            "id": "proposition:hqKqOwifiGbqT9f1RkM254mj9y9i0n8k",
            "type": "VariationNeoplasmTherapeuticResponseProposition",
            "subject": "ga4gh:VA.lvgJx0agONKtOZizHmwQiO3tkZ5UB7YV",
            "predicate": "predicts_resistance_to",
            "object": {
                "id": "rxcui:2058848",
                "type": "Therapeutic"
            },
            "neoplasm_type_qualifier": {
                "id": "ncit:C2926",
                "type": "Disease"
            }
        },
        "direction": "supports",
        "subject_descriptor": "civic.vid:34",
        "neoplasm_type_descriptor": {
            "id": "civic.did:8",
            "type": "DiseaseDescriptor",
            "label": "Lung Non-small Cell Carcinoma",
            "xrefs": [
                "DOID:3908"
            ],
            "disease": "ncit:C2926"
        },
        "object_descriptor": {
            "id": "civic.tid:44",
            "type": "TherapeuticDescriptor",
            "label": "Dacomitinib",
            "extensions": [
                {
                    "type": "Extension",
                    "name": "regulatory_approval",
                    "value": {
                        "approval_rating": "FDA",
                        "has_indications": [
                            {
                                "id": "hemonc:642",
                                "type": "DiseaseDescriptor",
                                "label": "Non-small cell lung cancer",
                                "disease": "ncit:C2926"
                            }
                        ]
                    }
                }
            ],
            "xrefs": [
                "ncit:C53398"
            ],
            "alternate_labels": [
                "(2E)-N-(4-((3-Chloro-4-Fluorophenyl)Amino)-7-Methoxyquinazolin-6-yl)-4-Piperidin-1-ylbut-2-Enamide",
                "EGFR Inhibitor PF-00299804",
                "PF-00299804",
                "PF-00299804-03",
                "PF-299804",
                "Vizimpro"
            ],
            "therapeutic": "rxcui:2058848"
        }
    },
    {
        "id": "civic.eid:436",
        "type": "VariationNeoplasmTherapeuticResponseStatement",
        "description": "Whole exome sequencing of 6 chronic lymphocytic leukemia patients with acquired resistance to ibrutinib determined 5/6 patients harbored a C481S mutation in BTK.",
        "method": "metakb.method:1",
        "is_reported_in": [
            {
                "id": "civic.source:259",
                "type": "Document",
                "label": "Woyach et al., 2014, N. Engl. J. Med.",
                "xrefs": [
                    "pmc:PMC4144824",
                    "pmid:24869598"
                ],
                "title": "Resistance mechanisms for the Bruton's tyrosine kinase inhibitor ibrutinib."
            }
        ],
        "evidence_level": {
            "id": "vicc:e00005",
            "type": "Coding",
            "label": "clinical cohort evidence"
        },
        "target_proposition": {
            "id": "proposition:GPAQHGiWQ8y6XdICe033kijlKRPP8Awk",
            "type": "VariationNeoplasmTherapeuticResponseProposition",
            "subject": "ga4gh:VA.N7eoPAzmgrcdHMkpaz2z4H1RW4LpBFfY",
            "predicate": "predicts_resistance_to",
            "object": {
                "id": "rxcui:1442981",
                "type": "Therapeutic"
            },
            "neoplasm_type_qualifier": {
                "id": "ncit:C3163",
                "type": "Disease"
            }
        },
        "direction": "supports",
        "subject_descriptor": "civic.vid:168",
        "neoplasm_type_descriptor": {
            "id": "civic.did:52",
            "type": "DiseaseDescriptor",
            "label": "Chronic Lymphocytic Leukemia",
            "xrefs": [
                "DOID:1040"
            ],
            "disease": "ncit:C3163"
        },
        "object_descriptor": {
            "id": "civic.tid:227",
            "type": "TherapeuticDescriptor",
            "label": "Ibrutinib",
            "extensions": [
                {
                    "type": "Extension",
                    "name": "regulatory_approval",
                    "value": {
                        "approval_rating": "ChEMBL",
                        "has_indications": [
                            {
                                "id": "mesh:D015451",
                                "type": "DiseaseDescriptor",
                                "label": "Leukemia, Lymphocytic, Chronic, B-Cell",
                                "disease": "ncit:C3163"
                            },
                            {
                                "id": "mesh:D020522",
                                "type": "DiseaseDescriptor",
                                "label": "Lymphoma, Mantle-Cell",
                                "disease": "ncit:C4337"
                            },
                            {
                                "id": "mesh:D008258",
                                "type": "DiseaseDescriptor",
                                "label": "Waldenstrom Macroglobulinemia",
                                "disease": "ncit:C80307"
                            }
                        ]
                    }
                }
            ],
            "xrefs": [
                "ncit:C81934"
            ],
            "alternate_labels": [
                "2-Propen-1-one, 1-((3R)-3-(4-amino-3-(4-phenoxyphenyl)-1h-pyrazolo(3,4-d)pyrimidin-1-yl)-1-piperidinyl)-",
                "BTK Inhibitor PCI-32765",
                "CRA-032765",
                "Imbruvica",
                "PCI-32765"
            ],
            "therapeutic": "rxcui:1442981"
        }
    },
    {
        "id": "civic.eid:676",
        "type": "VariationNeoplasmTherapeuticResponseStatement",
        "description": "The ERCC2 K751Q variant was significantly correlated with a lower response to cisplatin chemotherapy in osteosarcoma patients and shorter event-free survival. 91 osteosarcoma patients with a median age of 15 years were followed in this study.",
        "method": "metakb.method:1",
        "is_reported_in": [
            {
                "id": "civic.source:430",
                "type": "Document",
                "label": "Caronia et al., 2009, Pharmacogenomics J.",
                "xrefs": [
                    "pmid:19434073"
                ],
                "title": "Common variations in ERCC2 are associated with response to cisplatin chemotherapy and clinical outcome in osteosarcoma patients."
            }
        ],
        "evidence_level": {
            "id": "vicc:e00005",
            "type": "Coding",
            "label": "clinical cohort evidence"
        },
        "target_proposition": {
            "id": "proposition:WfAs-Y6VHjREHF0LGziJ3ZdQhbfmBsdu",
            "type": "VariationNeoplasmTherapeuticResponseProposition",
            "subject": "ga4gh:VA.fzUnu0PBAjqQ3qMW1KgvUQae4U3pSAjM",
            "predicate": "predicts_resistance_to",
            "object": {
                "id": "rxcui:2555",
                "type": "Therapeutic"
            },
            "neoplasm_type_qualifier": {
                "id": "ncit:C9145",
                "type": "Disease"
            }
        },
        "direction": "supports",
        "subject_descriptor": "civic.vid:264",
        "neoplasm_type_descriptor": {
            "id": "civic.did:134",
            "type": "DiseaseDescriptor",
            "label": "Osteosarcoma",
            "xrefs": [
                "DOID:3347"
            ],
            "disease": "ncit:C9145"
        },
        "object_descriptor": {
            "id": "civic.tid:326",
            "type": "TherapeuticDescriptor",
            "label": "Cisplatin",
            "extensions": [
                {
                    "type": "Extension",
                    "name": "regulatory_approval",
                    "value": {
                        "approval_rating": "FDA",
                        "has_indications": [
                            {
                                "id": "hemonc:569",
                                "type": "DiseaseDescriptor",
                                "label": "Bladder cancer",
                                "disease": "ncit:C9334"
                            },
                            {
                                "id": "hemonc:671",
                                "type": "DiseaseDescriptor",
                                "label": "Testicular cancer",
                                "disease": "ncit:C7251"
                            },
                            {
                                "id": "hemonc:645",
                                "type": "DiseaseDescriptor",
                                "label": "Ovarian cancer",
                                "disease": "ncit:C7431"
                            }
                        ]
                    }
                }
            ],
            "xrefs": [
                "ncit:C376"
            ],
            "alternate_labels": [
                "(SP-4-2)-Diamminedichloroplatinum",
                "Abiplatin",
                "Blastolem",
                "Briplatin",
                "CDDP",
                "Cis-diammine-dichloroplatinum",
                "Cis-diamminedichloridoplatinum",
                "Cis-diamminedichloro Platinum (II)",
                "Cis-diamminedichloroplatinum",
                "Cis-dichloroammine Platinum (II)",
                "Cis-platinous Diamine Dichloride",
                "Cis-platinum",
                "Cis-platinum II",
                "Cis-platinum II Diamine Dichloride",
                "Cismaplat",
                "Cisplatina",
                "Cisplatinum",
                "Cisplatyl",
                "Citoplatino",
                "Citosin",
                "Cysplatyna",
                "DDP",
                "Lederplatin",
                "Metaplatin",
                "Neoplatin",
                "Peyrone's Chloride",
                "Peyrone's Salt",
                "Placis",
                "Plastistil",
                "Platamine",
                "Platiblastin",
                "Platiblastin-S",
                "Platinex",
                "Platinol",
                "Platinol- AQ",
                "Platinol-AQ",
                "Platinol-AQ VHA Plus",
                "Platinoxan",
                "Platinum",
                "Platinum Diamminodichloride",
                "Platinum, Diaminedichloro-, Cis- (8CI)",
                "Platiran",
                "Platistin",
                "Platosin"
            ],
            "therapeutic": "rxcui:2555"
        }
    },
    {
        "id": "civic.eid:738",
        "type": "VariationNeoplasmTherapeuticResponseStatement",
        "description": "823 patients with GIST under therapy with imatinib were genotyped for this study. 18 patients (2%) with PDGFRA mutations were identified. In D842V-mutant GISTs, PFS (median 3.8 months) and OS (median 25.2 months) were significantly poorer than Non-D842V mutated (PFS median 29.5 months OS median 59.8 months).",
        "method": "metakb.method:1",
        "is_reported_in": [
            {
                "id": "civic.source:486",
                "type": "Document",
                "label": "Yoo et al., 2016, Cancer Res Treat",
                "xrefs": [
                    "pmc:PMC4843750",
                    "pmid:26130666"
                ],
                "title": "Efficacy of Imatinib in Patients with Platelet-Derived Growth Factor Receptor Alpha-Mutated Gastrointestinal Stromal Tumors."
            }
        ],
        "evidence_level": {
            "id": "vicc:e00005",
            "type": "Coding",
            "label": "clinical cohort evidence"
        },
        "target_proposition": {
            "id": "proposition:XT63NpvH0QMWWy8SjzzSDlRwhki6ikVG",
            "type": "VariationNeoplasmTherapeuticResponseProposition",
            "subject": "ga4gh:VA.CaTuLaWlUwLb32qfYTW2udl2Iy02ccN6",
            "predicate": "predicts_resistance_to",
            "object": {
                "id": "rxcui:282388",
                "type": "Therapeutic"
            },
            "neoplasm_type_qualifier": {
                "id": "ncit:C3868",
                "type": "Disease"
            }
        },
        "direction": "supports",
        "subject_descriptor": "civic.vid:99",
        "neoplasm_type_descriptor": {
            "id": "civic.did:2",
            "type": "DiseaseDescriptor",
            "label": "Gastrointestinal Stromal Tumor",
            "xrefs": [
                "DOID:9253"
            ],
            "disease": "ncit:C3868"
        },
        "object_descriptor": {
            "id": "civic.tid:5",
            "type": "TherapeuticDescriptor",
            "label": "Imatinib",
            "extensions": [
                {
                    "type": "Extension",
                    "name": "regulatory_approval",
                    "value": {
                        "approval_rating": "FDA",
                        "has_indications": [
                            {
                                "id": "hemonc:667",
                                "type": "DiseaseDescriptor",
                                "label": "Soft tissue sarcoma",
                                "disease": "ncit:C9306"
                            },
                            {
                                "id": "hemonc:602",
                                "type": "DiseaseDescriptor",
                                "label": "Gastrointestinal stromal tumor",
                                "disease": "ncit:C3868"
                            },
                            {
                                "id": "hemonc:616",
                                "type": "DiseaseDescriptor",
                                "label": "Hypereosinophilic syndrome",
                                "disease": "ncit:C27038"
                            },
                            {
                                "id": "hemonc:33893",
                                "type": "DiseaseDescriptor",
                                "label": "Chronic myelogenous leukemia pediatric",
                                "disease": null
                            },
                            {
                                "id": "hemonc:634",
                                "type": "DiseaseDescriptor",
                                "label": "Myelodysplastic syndrome",
                                "disease": "ncit:C3247"
                            },
                            {
                                "id": "hemonc:24309",
                                "type": "DiseaseDescriptor",
                                "label": "Acute lymphoblastic leukemia",
                                "disease": "ncit:C3167"
                            },
                            {
                                "id": "hemonc:582",
                                "type": "DiseaseDescriptor",
                                "label": "Chronic myelogenous leukemia",
                                "disease": "ncit:C3174"
                            },
                            {
                                "id": "hemonc:669",
                                "type": "DiseaseDescriptor",
                                "label": "Systemic mastocytosis",
                                "disease": "ncit:C9235"
                            }
                        ]
                    }
                }
            ],
            "xrefs": [
                "ncit:C62035"
            ],
            "alternate_labels": [
                "4-[(4-Methyl-1-piperazinyl)methyl]-N-[4-methyl-3-[[4-(3-pyridinyl)-2-pyrimidinyl]amino]phenyl]benzamide"
            ],
            "therapeutic": "rxcui:282388"
        }
    },
    {
        "id": "civic.eid:1181",
        "type": "VariationNeoplasmTherapeuticResponseStatement",
        "description": "Meta-analysis encompassing eight randomized controlled trials (n = 5967) for assessment of both overall survival (OS) and progression-free survival (PFS) of patients with KRAS mutant metastatic colorectal cancer. For other KRAS MT the hazard ratio for OS benefit with addition of anti-EGFR mAb therapy was 1.06 (95% confidence interval [CI]; 0.96, 1.17), compared to 1.08 (95% CI; 0.73, 1.60) for KRAS G13D [test for interaction p=0.99]. In contrast, the hazard ratio for KRAS wild-type (WT) tumours was 0.85 (95% CI; 0.76, 0.95). Regarding PFS benefit with anti-EGFR mAbs, the hazard ratio was 1.07 (95% CI; 0.92, 1.26) for other KRAS MT, 0.96 (95% CI; 0.73, 1.27) for KRAS G13D, and 0.68 (95% CI; 0.54, 0.85) for KRAS wild-type. Again, the test for interaction (p=0.46) demonstrated no significant difference in PFS benefit for anti-EGFR mAb therapy between KRAS G13D and other KRAS MT.",
        "method": "metakb.method:1",
        "is_reported_in": [
            {
                "id": "civic.source:814",
                "type": "Document",
                "label": "Rowland et al., 2016, Eur. J. Cancer",
                "xrefs": [
                    "pmid:26812186"
                ],
                "title": "Meta-analysis comparing the efficacy of anti-EGFR monoclonal antibody therapy between KRAS G13D and other KRAS mutant metastatic colorectal cancer tumours."
            }
        ],
        "evidence_level": {
            "id": "vicc:e00005",
            "type": "Coding",
            "label": "clinical cohort evidence"
        },
        "target_proposition": {
            "id": "proposition:e_3NNapOoNeeZi1MoruyXk6xCAWRhh2Q",
            "type": "VariationNeoplasmTherapeuticResponseProposition",
            "subject": "ga4gh:VA.tO-mdKyTxDxR376-vWkR2RgI2gpOvBhQ",
            "predicate": "predicts_resistance_to",
            "object": {
                "id": "rxcui:318341",
                "type": "Therapeutic"
            },
            "neoplasm_type_qualifier": {
                "id": "ncit:C4978",
                "type": "Disease"
            }
        },
        "direction": "supports",
        "subject_descriptor": "civic.vid:81",
        "neoplasm_type_descriptor": {
            "id": "civic.did:11",
            "type": "DiseaseDescriptor",
            "label": "Colorectal Cancer",
            "xrefs": [
                "DOID:9256"
            ],
            "disease": "ncit:C4978"
        },
        "object_descriptor": {
            "id": "civic.tid:16",
            "type": "TherapeuticDescriptor",
            "label": "Cetuximab",
            "extensions": [
                {
                    "type": "Extension",
                    "name": "regulatory_approval",
                    "value": {
                        "approval_rating": "ChEMBL",
                        "has_indications": [
                            {
                                "id": "mesh:D002294",
                                "type": "DiseaseDescriptor",
                                "label": "Carcinoma, Squamous Cell",
                                "disease": "ncit:C2929"
                            },
                            {
                                "id": "mesh:D009369",
                                "type": "DiseaseDescriptor",
                                "label": "Neoplasms",
                                "disease": "ncit:C3262"
                            },
                            {
                                "id": "mesh:D015179",
                                "type": "DiseaseDescriptor",
                                "label": "Colorectal Neoplasms",
                                "disease": "ncit:C2956"
                            },
                            {
                                "id": "mesh:D006258",
                                "type": "DiseaseDescriptor",
                                "label": "Head and Neck Neoplasms",
                                "disease": "ncit:C4013"
                            }
                        ]
                    }
                }
            ],
            "xrefs": [
                "ncit:C1723"
            ],
            "alternate_labels": [
                "Cetuximab Biosimilar CDP-1",
                "Cetuximab Biosimilar CMAB009",
                "Cetuximab Biosimilar KL 140",
                "Chimeric Anti-EGFR Monoclonal Antibody",
                "Chimeric MoAb C225",
                "Chimeric Monoclonal Antibody C225",
                "Erbitux",
                "IMC-C225"
            ],
            "therapeutic": "rxcui:318341"
        }
    },
    {
        "id": "civic.eid:1770",
        "type": "VariationNeoplasmTherapeuticResponseStatement",
        "description": "In a trial of 308 patients with chronic lymphocytic leukemia treated with ibrutinib, 31 discontinued treatment due to disease progression (13 CLL progression, 18 Richter\u2019s transformation). 11/13 patients were deep sequenced for BTK and PLCG2. 9 patients were identified with BTK mutations (C481S in 8 patients). In 5 patients, C481S was the sole abnormality.",
        "method": "metakb.method:1",
        "is_reported_in": [
            {
                "id": "civic.source:1237",
                "type": "Document",
                "label": "Maddocks et al., 2015, JAMA Oncol",
                "xrefs": [
                    "pmc:PMC4520535",
                    "pmid:26182309"
                ],
                "title": "Etiology of Ibrutinib Therapy Discontinuation and Outcomes in Patients With Chronic Lymphocytic Leukemia."
            }
        ],
        "evidence_level": {
            "id": "vicc:e00005",
            "type": "Coding",
            "label": "clinical cohort evidence"
        },
        "target_proposition": {
            "id": "proposition:GPAQHGiWQ8y6XdICe033kijlKRPP8Awk",
            "type": "VariationNeoplasmTherapeuticResponseProposition",
            "subject": "ga4gh:VA.N7eoPAzmgrcdHMkpaz2z4H1RW4LpBFfY",
            "predicate": "predicts_resistance_to",
            "object": {
                "id": "rxcui:1442981",
                "type": "Therapeutic"
            },
            "neoplasm_type_qualifier": {
                "id": "ncit:C3163",
                "type": "Disease"
            }
        },
        "direction": "supports",
        "subject_descriptor": "civic.vid:168",
        "neoplasm_type_descriptor": {
            "id": "civic.did:52",
            "type": "DiseaseDescriptor",
            "label": "Chronic Lymphocytic Leukemia",
            "xrefs": [
                "DOID:1040"
            ],
            "disease": "ncit:C3163"
        },
        "object_descriptor": {
            "id": "civic.tid:227",
            "type": "TherapeuticDescriptor",
            "label": "Ibrutinib",
            "extensions": [
                {
                    "type": "Extension",
                    "name": "regulatory_approval",
                    "value": {
                        "approval_rating": "ChEMBL",
                        "has_indications": [
                            {
                                "id": "mesh:D015451",
                                "type": "DiseaseDescriptor",
                                "label": "Leukemia, Lymphocytic, Chronic, B-Cell",
                                "disease": "ncit:C3163"
                            },
                            {
                                "id": "mesh:D020522",
                                "type": "DiseaseDescriptor",
                                "label": "Lymphoma, Mantle-Cell",
                                "disease": "ncit:C4337"
                            },
                            {
                                "id": "mesh:D008258",
                                "type": "DiseaseDescriptor",
                                "label": "Waldenstrom Macroglobulinemia",
                                "disease": "ncit:C80307"
                            }
                        ]
                    }
                }
            ],
            "xrefs": [
                "ncit:C81934"
            ],
            "alternate_labels": [
                "2-Propen-1-one, 1-((3R)-3-(4-amino-3-(4-phenoxyphenyl)-1h-pyrazolo(3,4-d)pyrimidin-1-yl)-1-piperidinyl)-",
                "BTK Inhibitor PCI-32765",
                "CRA-032765",
                "Imbruvica",
                "PCI-32765"
            ],
            "therapeutic": "rxcui:1442981"
        }
    },
    {
        "id": "civic.eid:1863",
        "type": "VariationNeoplasmTherapeuticResponseStatement",
        "description": "Patients with advanced NSCLC and acquired resistance to EGFR TKI (gefitinib or erlotinib) were analyzed for T790M mutations.  Of the 70 patients analyzed, 36 (51%) had the T790M mutation and 34 (49%) were T790M-negative.  There was no significant difference in the median post-progression or overall survival between patients with T790M mutation and without T790M mutation for initial TKI treatment.  However, subsequent treatment with afatinib showed partial response in six patients where 1/21(5%) were in the T790M-positive group and 5/13 (38%) were in the T790M-negative group (P=0.01).",
        "method": "metakb.method:1",
        "is_reported_in": [
            {
                "id": "civic.source:1282",
                "type": "Document",
                "label": "Sun et al., 2013, Lung Cancer",
                "xrefs": [
                    "pmid:24035188"
                ],
                "title": "Clinical implications of T790M mutation in patients with acquired resistance to EGFR tyrosine kinase inhibitors."
            }
        ],
        "evidence_level": {
            "id": "vicc:e00005",
            "type": "Coding",
            "label": "clinical cohort evidence"
        },
        "target_proposition": {
            "id": "proposition:Cjf96A9wqWIQMgUTz28OTg6JDrFqFPnQ",
            "type": "VariationNeoplasmTherapeuticResponseProposition",
            "subject": "ga4gh:VA.lvgJx0agONKtOZizHmwQiO3tkZ5UB7YV",
            "predicate": "predicts_resistance_to",
            "object": {
                "id": "rxcui:1430438",
                "type": "Therapeutic"
            },
            "neoplasm_type_qualifier": {
                "id": "ncit:C2926",
                "type": "Disease"
            }
        },
        "direction": "supports",
        "subject_descriptor": "civic.vid:34",
        "neoplasm_type_descriptor": {
            "id": "civic.did:8",
            "type": "DiseaseDescriptor",
            "label": "Lung Non-small Cell Carcinoma",
            "xrefs": [
                "DOID:3908"
            ],
            "disease": "ncit:C2926"
        },
        "object_descriptor": {
            "id": "civic.tid:146",
            "type": "TherapeuticDescriptor",
            "label": "Afatinib",
            "extensions": [
                {
                    "type": "Extension",
                    "name": "regulatory_approval",
                    "value": {
                        "approval_rating": "FDA",
                        "has_indications": [
                            {
                                "id": "hemonc:642",
                                "type": "DiseaseDescriptor",
                                "label": "Non-small cell lung cancer",
                                "disease": "ncit:C2926"
                            },
                            {
                                "id": "hemonc:25316",
                                "type": "DiseaseDescriptor",
                                "label": "Non-small cell lung cancer squamous",
                                "disease": null
                            }
                        ]
                    }
                }
            ],
            "xrefs": [
                "ncit:C66940"
            ],
            "alternate_labels": [
                "(2e)-N-(4-(3-Chloro-4-Fluoroanilino)-7-(((3s)-Oxolan-3-yl)Oxy)Quinoxazolin-6-yl)-4-(Dimethylamino)But-2-Enamide",
                "BIBW 2992",
                "BIBW2992"
            ],
            "therapeutic": "rxcui:1430438"
        }
    },
    {
        "id": "civic.eid:83",
        "type": "VariationNeoplasmTherapeuticResponseStatement",
        "description": "This was a retrospective analysis of genetic markers in 503 metastatic colorectal cancer patients who participated in the CORRECT phase III trial of regorafenib. PIK3CA mutations were identified in the tumors of 84 patients, including 27 with PIK3CA E542K. Authors found a clinical benefit of regorafenib across PIK3CA mutated and wildtype subgroups (progression free survival with regorafenib vs placebo: mutant HR: 0.54, wildtype HR: 0.50, P=0.85). Authors do not provide direct comparison between patients with wildtype and PIK3CA E542K patients. Note that it's unclear how many PIK3CA wildtype patients harbor KRAS mutations, though authors' suggest that regorafenib induces clinical benefit regardless of KRAS or PIK3CA mutation status.",
        "method": "metakb.method:1",
        "is_reported_in": [
            {
                "id": "civic.source:4081",
                "type": "Document",
                "label": "Tabernero et al., 2015, Lancet Oncol",
                "xrefs": [
                    "pmc:PMC7513622",
                    "pmid:26184520"
                ],
                "title": "Analysis of circulating DNA and protein biomarkers to predict the clinical activity of regorafenib and assess prognosis in patients with metastatic colorectal cancer: a retrospective, exploratory analysis of the CORRECT trial."
            }
        ],
        "evidence_level": {
            "id": "vicc:e00005",
            "type": "Coding",
            "label": "clinical cohort evidence"
        },
        "target_proposition": {
            "id": "proposition:jN12JixBjoBNeeqiD0URb-S9W9vM1byW",
            "type": "VariationNeoplasmTherapeuticResponseProposition",
            "subject": "ga4gh:VA.RTy0UiMi4D-aTPKvZBR3e3FXhFy4doaD",
            "predicate": "predicts_resistance_to",
            "object": {
                "id": "rxcui:1312397",
                "type": "Therapeutic"
            },
            "neoplasm_type_qualifier": {
                "id": "ncit:C4978",
                "type": "Disease"
            }
        },
        "direction": "opposes",
        "subject_descriptor": "civic.vid:103",
        "neoplasm_type_descriptor": {
            "id": "civic.did:11",
            "type": "DiseaseDescriptor",
            "label": "Colorectal Cancer",
            "xrefs": [
                "DOID:9256"
            ],
            "disease": "ncit:C4978"
        },
        "object_descriptor": {
            "id": "civic.tid:27",
            "type": "TherapeuticDescriptor",
            "label": "Regorafenib",
            "extensions": [
                {
                    "type": "Extension",
                    "name": "regulatory_approval",
                    "value": {
                        "approval_rating": "ChEMBL",
                        "has_indications": [
                            {
                                "id": "mesh:D009369",
                                "type": "DiseaseDescriptor",
                                "label": "Neoplasms",
                                "disease": "ncit:C3262"
                            },
                            {
                                "id": "mesh:D015179",
                                "type": "DiseaseDescriptor",
                                "label": "Colorectal Neoplasms",
                                "disease": "ncit:C2956"
                            }
                        ]
                    }
                }
            ],
            "xrefs": [
                "ncit:C78204"
            ],
            "alternate_labels": [
                "4-(4-(((4-chloro-3-(trifluoromethyl)phenyl)carbamoyl)amino)-3-fluorophenoxy)-N-methylpyridine-2-carboxamide",
                "BAY 73-4506",
                "REGORAFENIB ANHYDROUS",
                "Stivarga"
            ],
            "therapeutic": "rxcui:1312397"
        }
    },
    {
        "id": "civic.eid:126",
        "type": "VariationNeoplasmTherapeuticResponseStatement",
        "description": "This was a retrospective study of 691 cetuximab treated patients with metastatic, chemotherapy refractory colorectal cancer. Of those, 30 patients harbored BRAF V600E, were KRAS, NRAS and PIK3CA wt, and had individual response data. One patient (who harbored BRAF V600E in low copy number) responded, 11 had stable disease, and 18 progressed. Treatments included cetuximab + irinotecan (n=20), cetuximab monotherapy (n=5), cetuximab + FOLFIRI (n=4), and cetuximab + oxaliplatin + 5FU (n=1). Median PFS was 8 weeks (2-32 weeks), median OS was 25 weeks (4-237 weeks), and median number of previous chemotherapy lines was 2 (0-4). Median age was 61 years old (42-78) and there were 16 males and 14 females. Authors concluded that BRAF mutation (23/24 of mutants were BRAF V600E) was strongly associated with poor response to cetuximab and suggested that mutation status of BRAF is more informative than those of NRAS and PIK3CA exon 20 for predicting cetuximab response (second only to KRAS).",
        "method": "metakb.method:1",
        "is_reported_in": [
            {
                "id": "civic.source:76",
                "type": "Document",
                "label": "De Roock et al., 2010, Lancet Oncol.",
                "xrefs": [
                    "pmid:20619739"
                ],
                "title": "Effects of KRAS, BRAF, NRAS, and PIK3CA mutations on the efficacy of cetuximab plus chemotherapy in chemotherapy-refractory metastatic colorectal cancer: a retrospective consortium analysis."
            }
        ],
        "evidence_level": {
            "id": "vicc:e00005",
            "type": "Coding",
            "label": "clinical cohort evidence"
        },
        "target_proposition": {
            "id": "proposition:8gj1z2Oih-yf5hY6eLNk8fzdRkUTHc8M",
            "type": "VariationNeoplasmTherapeuticResponseProposition",
            "subject": "ga4gh:VA.h313H4CQh6pogbbSJ3H5pI1cPoh9YMm_",
            "predicate": "predicts_resistance_to",
            "object": {
                "id": "rxcui:318341",
                "type": "Therapeutic"
            },
            "neoplasm_type_qualifier": {
                "id": "ncit:C4978",
                "type": "Disease"
            }
        },
        "direction": "supports",
        "subject_descriptor": "civic.vid:12",
        "neoplasm_type_descriptor": {
            "id": "civic.did:11",
            "type": "DiseaseDescriptor",
            "label": "Colorectal Cancer",
            "xrefs": [
                "DOID:9256"
            ],
            "disease": "ncit:C4978"
        },
        "object_descriptor": {
            "id": "civic.tid:16",
            "type": "TherapeuticDescriptor",
            "label": "Cetuximab",
            "extensions": [
                {
                    "type": "Extension",
                    "name": "regulatory_approval",
                    "value": {
                        "approval_rating": "ChEMBL",
                        "has_indications": [
                            {
                                "id": "mesh:D002294",
                                "type": "DiseaseDescriptor",
                                "label": "Carcinoma, Squamous Cell",
                                "disease": "ncit:C2929"
                            },
                            {
                                "id": "mesh:D009369",
                                "type": "DiseaseDescriptor",
                                "label": "Neoplasms",
                                "disease": "ncit:C3262"
                            },
                            {
                                "id": "mesh:D015179",
                                "type": "DiseaseDescriptor",
                                "label": "Colorectal Neoplasms",
                                "disease": "ncit:C2956"
                            },
                            {
                                "id": "mesh:D006258",
                                "type": "DiseaseDescriptor",
                                "label": "Head and Neck Neoplasms",
                                "disease": "ncit:C4013"
                            }
                        ]
                    }
                }
            ],
            "xrefs": [
                "ncit:C1723"
            ],
            "alternate_labels": [
                "Cetuximab Biosimilar CDP-1",
                "Cetuximab Biosimilar CMAB009",
                "Cetuximab Biosimilar KL 140",
                "Chimeric Anti-EGFR Monoclonal Antibody",
                "Chimeric MoAb C225",
                "Chimeric Monoclonal Antibody C225",
                "Erbitux",
                "IMC-C225"
            ],
            "therapeutic": "rxcui:318341"
        }
    },
    {
        "id": "civic.eid:239",
        "type": "VariationNeoplasmTherapeuticResponseStatement",
        "description": "In non-small cell lung cancer, the appearance of T790M mutation leads to resistance to gefitinib.",
        "method": "metakb.method:1",
        "is_reported_in": [
            {
                "id": "civic.source:168",
                "type": "Document",
                "label": "Kobayashi et al., 2005, N. Engl. J. Med.",
                "xrefs": [
                    "pmid:15728811"
                ],
                "title": "EGFR mutation and resistance of non-small-cell lung cancer to gefitinib."
            }
        ],
        "evidence_level": {
            "id": "vicc:e00005",
            "type": "Coding",
            "label": "clinical cohort evidence"
        },
        "target_proposition": {
            "id": "proposition:ubBKghiT5mGCQMsup4qNdWzTBY-OMFzG",
            "type": "VariationNeoplasmTherapeuticResponseProposition",
            "subject": "ga4gh:VA.lvgJx0agONKtOZizHmwQiO3tkZ5UB7YV",
            "predicate": "predicts_resistance_to",
            "object": {
                "id": "rxcui:328134",
                "type": "Therapeutic"
            },
            "neoplasm_type_qualifier": {
                "id": "ncit:C2926",
                "type": "Disease"
            }
        },
        "direction": "supports",
        "subject_descriptor": "civic.vid:34",
        "neoplasm_type_descriptor": {
            "id": "civic.did:8",
            "type": "DiseaseDescriptor",
            "label": "Lung Non-small Cell Carcinoma",
            "xrefs": [
                "DOID:3908"
            ],
            "disease": "ncit:C2926"
        },
        "object_descriptor": {
            "id": "civic.tid:14",
            "type": "TherapeuticDescriptor",
            "label": "Gefitinib",
            "extensions": [
                {
                    "type": "Extension",
                    "name": "regulatory_approval",
                    "value": {
                        "approval_rating": "FDA",
                        "has_indications": [
                            {
                                "id": "hemonc:642",
                                "type": "DiseaseDescriptor",
                                "label": "Non-small cell lung cancer",
                                "disease": "ncit:C2926"
                            }
                        ]
                    }
                }
            ],
            "xrefs": [
                "ncit:C1855"
            ],
            "alternate_labels": [
                "4-(3'-Chloro-4'-fluoroanilino)-7-methoxy-6-(3-morpholinopropoxy)quinazoline",
                "Iressa",
                "N-(3-chloro-4-fluorophenyl)-7-methoxy-6-[3-(4-morpholin) Propoxy]-4-quinazolinamine",
                "ZD 1839",
                "ZD1839"
            ],
            "therapeutic": "rxcui:328134"
        }
    },
    {
        "id": "civic.eid:964",
        "type": "VariationNeoplasmTherapeuticResponseStatement",
        "description": "An EGFR resistance mutation, C797S, was discovered by deep sequencing of cell-free plasma DNA (cfDNA) from patients with advanced lung cancer whose tumors had developed resistance to osimertinib. Expression of this mutant EGFR construct in a cell line rendered it resistant to osimertinib. ddPCR on serial cfDNA specimens collected from 15 osimertinib-treated subjects (all positive for T790M before treatment) revealed 6 cases with acquired C797S mutation.",
        "method": "metakb.method:1",
        "is_reported_in": [
            {
                "id": "civic.source:666",
                "type": "Document",
                "label": "Thress et al., 2015, Nat. Med.",
                "xrefs": [
                    "pmc:PMC4771182",
                    "pmid:25939061"
                ],
                "title": "Acquired EGFR C797S mutation mediates resistance to AZD9291 in non-small cell lung cancer harboring EGFR T790M."
            }
        ],
        "evidence_level": {
            "id": "vicc:e00005",
            "type": "Coding",
            "label": "clinical cohort evidence"
        },
        "target_proposition": {
            "id": "proposition:7ju0gPvZ0teo6gPF5K4KpcTAgv68UqdM",
            "type": "VariationNeoplasmTherapeuticResponseProposition",
            "subject": "ga4gh:VA.xBOuXRHMA9-vqyYsZPx1_E6lOIoZZbs0",
            "predicate": "predicts_resistance_to",
            "object": {
                "id": "rxcui:1721560",
                "type": "Therapeutic"
            },
            "neoplasm_type_qualifier": {
                "id": "ncit:C2926",
                "type": "Disease"
            }
        },
        "direction": "supports",
        "subject_descriptor": "civic.vid:415",
        "neoplasm_type_descriptor": {
            "id": "civic.did:8",
            "type": "DiseaseDescriptor",
            "label": "Lung Non-small Cell Carcinoma",
            "xrefs": [
                "DOID:3908"
            ],
            "disease": "ncit:C2926"
        },
        "object_descriptor": {
            "id": "civic.tid:187",
            "type": "TherapeuticDescriptor",
            "label": "Osimertinib",
            "extensions": [
                {
                    "type": "Extension",
                    "name": "regulatory_approval",
                    "value": {
                        "approval_rating": "FDA",
                        "has_indications": [
                            {
                                "id": "hemonc:642",
                                "type": "DiseaseDescriptor",
                                "label": "Non-small cell lung cancer",
                                "disease": "ncit:C2926"
                            }
                        ]
                    }
                }
            ],
            "xrefs": [
                "ncit:C116377"
            ],
            "alternate_labels": [
                "2-Propenamide, N-(2-((2-(dimethylamino)ethyl)methylamino)-4-methoxy-5-((4-(1-methyl-1H-indol-3-yl)-2-pyrimidinyl)amino)phenyl)-",
                "AZD-9291",
                "AZD9291",
                "Mereletinib",
                "Tagrisso"
            ],
            "therapeutic": "rxcui:1721560"
        }
    },
    {
        "id": "civic.eid:1180",
        "type": "VariationNeoplasmTherapeuticResponseStatement",
        "description": "12 patients with KRAS G13D mutant, metastatic colorectal cancer were treated with single agent cetuximab in a prospective phase II study. The primary endpoint of the trial was 4-month progression-free survival, with a benefit to treatment evaluated to be 50% of patients were progression free at this point. None of 12 patients achieved response by RECIST 1.1 criteria and three patients (25%) were progression-free at 4 months, with disease control rate at 6 months reaching 0%. Median PFS and OS were 1.9 (95% CI 1.7\u20133.8) and 7.2 months (95% CI 5.7\u20139.7).",
        "method": "metakb.method:1",
        "is_reported_in": [
            {
                "id": "civic.source:813",
                "type": "Document",
                "label": "Schirripa et al., 2015, Ann. Oncol.",
                "xrefs": [
                    "pmid:26371285"
                ],
                "title": "Phase II study of single-agent cetuximab in KRAS G13D mutant metastatic colorectal cancer."
            }
        ],
        "evidence_level": {
            "id": "vicc:e00005",
            "type": "Coding",
            "label": "clinical cohort evidence"
        },
        "target_proposition": {
            "id": "proposition:e_3NNapOoNeeZi1MoruyXk6xCAWRhh2Q",
            "type": "VariationNeoplasmTherapeuticResponseProposition",
            "subject": "ga4gh:VA.tO-mdKyTxDxR376-vWkR2RgI2gpOvBhQ",
            "predicate": "predicts_resistance_to",
            "object": {
                "id": "rxcui:318341",
                "type": "Therapeutic"
            },
            "neoplasm_type_qualifier": {
                "id": "ncit:C4978",
                "type": "Disease"
            }
        },
        "direction": "supports",
        "subject_descriptor": "civic.vid:81",
        "neoplasm_type_descriptor": {
            "id": "civic.did:11",
            "type": "DiseaseDescriptor",
            "label": "Colorectal Cancer",
            "xrefs": [
                "DOID:9256"
            ],
            "disease": "ncit:C4978"
        },
        "object_descriptor": {
            "id": "civic.tid:16",
            "type": "TherapeuticDescriptor",
            "label": "Cetuximab",
            "extensions": [
                {
                    "type": "Extension",
                    "name": "regulatory_approval",
                    "value": {
                        "approval_rating": "ChEMBL",
                        "has_indications": [
                            {
                                "id": "mesh:D002294",
                                "type": "DiseaseDescriptor",
                                "label": "Carcinoma, Squamous Cell",
                                "disease": "ncit:C2929"
                            },
                            {
                                "id": "mesh:D009369",
                                "type": "DiseaseDescriptor",
                                "label": "Neoplasms",
                                "disease": "ncit:C3262"
                            },
                            {
                                "id": "mesh:D015179",
                                "type": "DiseaseDescriptor",
                                "label": "Colorectal Neoplasms",
                                "disease": "ncit:C2956"
                            },
                            {
                                "id": "mesh:D006258",
                                "type": "DiseaseDescriptor",
                                "label": "Head and Neck Neoplasms",
                                "disease": "ncit:C4013"
                            }
                        ]
                    }
                }
            ],
            "xrefs": [
                "ncit:C1723"
            ],
            "alternate_labels": [
                "Cetuximab Biosimilar CDP-1",
                "Cetuximab Biosimilar CMAB009",
                "Cetuximab Biosimilar KL 140",
                "Chimeric Anti-EGFR Monoclonal Antibody",
                "Chimeric MoAb C225",
                "Chimeric Monoclonal Antibody C225",
                "Erbitux",
                "IMC-C225"
            ],
            "therapeutic": "rxcui:318341"
        }
    },
    {
        "id": "civic.eid:1669",
        "type": "VariationNeoplasmTherapeuticResponseStatement",
        "description": "In this study, the investigators followed 10 patients treated with vemurafenib, and then they collected biopsies of lesions that progressed. In one of these patients, they identified the L505H mutation.",
        "method": "metakb.method:1",
        "is_reported_in": [
            {
                "id": "civic.source:1130",
                "type": "Document",
                "label": "Hoogstraat et al., 2015, Pigment Cell Melanoma Res",
                "xrefs": [
                    "pmid:25515853"
                ],
                "title": "Detailed imaging and genetic analysis reveal a secondary BRAF(L505H) resistance mutation and extensive intrapatient heterogeneity in metastatic BRAF mutant melanoma patients treated with vemurafenib."
            }
        ],
        "evidence_level": {
            "id": "vicc:e00005",
            "type": "Coding",
            "label": "clinical cohort evidence"
        },
        "target_proposition": {
            "id": "proposition:a2WBx7VottAegcHIRlfFZAWx8QZjtcgb",
            "type": "VariationNeoplasmTherapeuticResponseProposition",
            "subject": "ga4gh:VA.X09E2r2MjKn-w1Ggsuy0XMWJ5_-lr-gd",
            "predicate": "predicts_resistance_to",
            "object": {
                "id": "rxcui:1147220",
                "type": "Therapeutic"
            },
            "neoplasm_type_qualifier": {
                "id": "ncit:C3224",
                "type": "Disease"
            }
        },
        "direction": "supports",
        "subject_descriptor": "civic.vid:658",
        "neoplasm_type_descriptor": {
            "id": "civic.did:7",
            "type": "DiseaseDescriptor",
            "label": "Melanoma",
            "xrefs": [
                "DOID:1909"
            ],
            "disease": "ncit:C3224"
        },
        "object_descriptor": {
            "id": "civic.tid:4",
            "type": "TherapeuticDescriptor",
            "label": "Vemurafenib",
            "extensions": [
                {
                    "type": "Extension",
                    "name": "regulatory_approval",
                    "value": {
                        "approval_rating": "FDA",
                        "has_indications": [
                            {
                                "id": "hemonc:629",
                                "type": "DiseaseDescriptor",
                                "label": "Melanoma",
                                "disease": "ncit:C3224"
                            },
                            {
                                "id": "hemonc:594",
                                "type": "DiseaseDescriptor",
                                "label": "Erdheim-Chester disease",
                                "disease": "ncit:C53972"
                            }
                        ]
                    }
                }
            ],
            "xrefs": [
                "ncit:C64768"
            ],
            "alternate_labels": [
                "1-propanesulfonamide, N-(3-((5-(4-chlorophenyl)-1h-pyrrolo(2,3-b)pyridin-3-yl)carbonyl)-2,4-difluorophenyl)-",
                "BRAF (V600E) Kinase Inhibitor RO5185426",
                "BRAF(V600E) Kinase Inhibitor RO5185426",
                "PLX-4032",
                "PLX4032",
                "RG 7204",
                "RG7204",
                "RO 5185426",
                "Zelboraf"
            ],
            "therapeutic": "rxcui:1147220"
        }
    },
    {
        "id": "civic.eid:2117",
        "type": "VariationNeoplasmTherapeuticResponseStatement",
        "description": "Of 100 metastatic colorectal cancer patients treated with oxaliplatin-based first-line therapy, the 6 patients with either BRAF V600E or D594K had reduced progression-free survival compared to 94 patients with wildtype BRAF (5.0mo vs. 11.7mo, HR:6.4, 95%CI:2.6-15.6, P<0.0001).",
        "method": "metakb.method:1",
        "is_reported_in": [
            {
                "id": "civic.source:1479",
                "type": "Document",
                "label": "Souglakos et al., 2009, Br. J. Cancer",
                "xrefs": [
                    "pmc:PMC2720232",
                    "pmid:19603024"
                ],
                "title": "Prognostic and predictive value of common mutations for treatment response and survival in patients with metastatic colorectal cancer."
            }
        ],
        "evidence_level": {
            "id": "vicc:e00005",
            "type": "Coding",
            "label": "clinical cohort evidence"
        },
        "target_proposition": {
            "id": "proposition:pTlGntSf9CNnSxqN-KDNOwSbw5SBwFer",
            "type": "VariationNeoplasmTherapeuticResponseProposition",
            "subject": "ga4gh:VA.h313H4CQh6pogbbSJ3H5pI1cPoh9YMm_",
            "predicate": "predicts_resistance_to",
            "object": {
                "id": "rxcui:32592",
                "type": "Therapeutic"
            },
            "neoplasm_type_qualifier": {
                "id": "ncit:C4978",
                "type": "Disease"
            }
        },
        "direction": "supports",
        "subject_descriptor": "civic.vid:12",
        "neoplasm_type_descriptor": {
            "id": "civic.did:11",
            "type": "DiseaseDescriptor",
            "label": "Colorectal Cancer",
            "xrefs": [
                "DOID:9256"
            ],
            "disease": "ncit:C4978"
        },
        "object_descriptor": {
            "id": "civic.tid:237",
            "type": "TherapeuticDescriptor",
            "label": "Oxaliplatin",
            "extensions": [
                {
                    "type": "Extension",
                    "name": "regulatory_approval",
                    "value": {
                        "approval_rating": "FDA",
                        "has_indications": [
                            {
                                "id": "hemonc:46096",
                                "type": "DiseaseDescriptor",
                                "label": "Colorectal cancer",
                                "disease": "ncit:C4978"
                            },
                            {
                                "id": "hemonc:585",
                                "type": "DiseaseDescriptor",
                                "label": "Colon cancer",
                                "disease": "ncit:C9242"
                            }
                        ]
                    }
                }
            ],
            "xrefs": [
                "ncit:C1181"
            ],
            "alternate_labels": [
                "1-OHP",
                "Ai Heng",
                "Aiheng",
                "DACPLAT",
                "Dacotin",
                "Diaminocyclohexane Oxalatoplatinum",
                "ELOXATIN",
                "Eloxatine",
                "JM-83",
                "Oxalato (1R,2R-cyclohexanediamine)platinum(II)",
                "Oxalato (trans-l-1,2-diaminocyclohexane)platinum(II)",
                "Oxalatoplatin",
                "Oxalatoplatinum",
                "RP 54780",
                "RP-54780",
                "SR-96669",
                "Trans-l DACH Oxalatoplatinum",
                "Trans-l Diaminocyclohexane Oxalatoplatinum",
                "[(1R,-2R)-1,2-cyclohexanediamine-N,N'][oxalato (2--)-O,O']platinum",
                "[SP-4-2-(1R-trans)]-(1,2,cyclohexanediamine-N,N')[ethanedioato(2--)-O,O']platinum"
            ],
            "therapeutic": "rxcui:32592"
        }
    },
    {
        "id": "civic.eid:2118",
        "type": "VariationNeoplasmTherapeuticResponseStatement",
        "description": "The presence of BRAF V600E or D594K was associated with reduced progression-free survival in 5 patients with metastatic colorectal cancer treated with irinotecan-based first line therapy (3.5mo vs. 12.8mo, HR:4.1, 95%CI:1.5-11.3, P=0.006) when compared to 39 patients with wildtype BRAF.",
        "method": "metakb.method:1",
        "is_reported_in": [
            {
                "id": "civic.source:1479",
                "type": "Document",
                "label": "Souglakos et al., 2009, Br. J. Cancer",
                "xrefs": [
                    "pmc:PMC2720232",
                    "pmid:19603024"
                ],
                "title": "Prognostic and predictive value of common mutations for treatment response and survival in patients with metastatic colorectal cancer."
            }
        ],
        "evidence_level": {
            "id": "vicc:e00005",
            "type": "Coding",
            "label": "clinical cohort evidence"
        },
        "target_proposition": {
            "id": "proposition:nPdmybPCZyKW4yNXRp7f6s80BEM2XZhf",
            "type": "VariationNeoplasmTherapeuticResponseProposition",
            "subject": "ga4gh:VA.h313H4CQh6pogbbSJ3H5pI1cPoh9YMm_",
            "predicate": "predicts_resistance_to",
            "object": {
                "id": "rxcui:153329",
                "type": "Therapeutic"
            },
            "neoplasm_type_qualifier": {
                "id": "ncit:C4978",
                "type": "Disease"
            }
        },
        "direction": "supports",
        "subject_descriptor": "civic.vid:12",
        "neoplasm_type_descriptor": {
            "id": "civic.did:11",
            "type": "DiseaseDescriptor",
            "label": "Colorectal Cancer",
            "xrefs": [
                "DOID:9256"
            ],
            "disease": "ncit:C4978"
        },
        "object_descriptor": {
            "id": "civic.tid:101",
            "type": "TherapeuticDescriptor",
            "label": "Irinotecan",
            "extensions": [
                {
                    "type": "Extension",
                    "name": "regulatory_approval",
                    "value": {
                        "approval_rating": "FDA",
                        "has_indications": [
                            {
                                "id": "hemonc:46096",
                                "type": "DiseaseDescriptor",
                                "label": "Colorectal cancer",
                                "disease": "ncit:C4978"
                            }
                        ]
                    }
                }
            ],
            "xrefs": [
                "ncit:C62040"
            ],
            "alternate_labels": [
                "(+)-(4S)-4,11-diethyl-4-hydroxy-9-[(4-piperidino-piperidino)carbonyloxy]-1H-pyrano[3',4':6,7]indolizino[1,2-b]quinol-3,14,(4H,12H)-dione",
                "(+)-7-ethyl-10-hydroxycamptothecine 10-[1,4'-bipiperidine]-1'-carboxylate",
                "7-ethyl-10-[4-(1-piperidino)-1-piperidino]carbonyloxycamptothecin",
                "[1,4'-bipiperidine]-1'-carboxylic Acid (S)-4,11-diethyl-3,4,12,14-tetrahydro-4-hydroxy-3,14-dioxo-1H-pyrano[3',4':6,7]indolizino[1,2-b]quinolin-9-yl Ester"
            ],
            "therapeutic": "rxcui:153329"
        }
    },
    {
        "id": "civic.eid:2207",
        "type": "VariationNeoplasmTherapeuticResponseStatement",
        "description": "This was a retrospective study of 691 cetuximab treated patients with metastatic colorectal cancer. Of those, 76 patients harbored KRAS G12D, were BRAF, NRAS and PIK3CA wt, and had individual response data. Five patients had partial response, 34 had stable disease, and 37 progressed. Treatments included cetuximab + irinotecan (n=61), cetuximab + FOLFIRI (n=6), cetuximab monotherapy (n=5), cetuximab + oxaliplatin + 5FU (n=2), cetuximab + 5FU (n=1), cetuximab + oxaliplatin + bevacizumab (n=1). Median PFS was 12 weeks (3-169 weeks), median OS was 31 weeks (6-232 weeks), and median number of previous chemotherapy lines was 2 (0-5). Median age was 62 years old (32-86), and there were 43 males and 33 females. Using these data and data from the larger cohort, authors concluded that KRAS mutation was strongly associated with poor response to cetuximab and suggested that mutation status of KRAS is the most informative compared to BRAF, NRAS, and PIK3CA exon 20 for predicting cetuximab response.",
        "method": "metakb.method:1",
        "is_reported_in": [
            {
                "id": "civic.source:76",
                "type": "Document",
                "label": "De Roock et al., 2010, Lancet Oncol.",
                "xrefs": [
                    "pmid:20619739"
                ],
                "title": "Effects of KRAS, BRAF, NRAS, and PIK3CA mutations on the efficacy of cetuximab plus chemotherapy in chemotherapy-refractory metastatic colorectal cancer: a retrospective consortium analysis."
            }
        ],
        "evidence_level": {
            "id": "vicc:e00005",
            "type": "Coding",
            "label": "clinical cohort evidence"
        },
        "target_proposition": {
            "id": "proposition:TlVywyQ5mWBwUhE0EKa8yL3QHFB9EZJE",
            "type": "VariationNeoplasmTherapeuticResponseProposition",
            "subject": "ga4gh:VA.jSiuIG2uZEbml8MfCtZi3J9jPBCBiaPw",
            "predicate": "predicts_resistance_to",
            "object": {
                "id": "rxcui:318341",
                "type": "Therapeutic"
            },
            "neoplasm_type_qualifier": {
                "id": "ncit:C4978",
                "type": "Disease"
            }
        },
        "direction": "supports",
        "subject_descriptor": "civic.vid:79",
        "neoplasm_type_descriptor": {
            "id": "civic.did:11",
            "type": "DiseaseDescriptor",
            "label": "Colorectal Cancer",
            "xrefs": [
                "DOID:9256"
            ],
            "disease": "ncit:C4978"
        },
        "object_descriptor": {
            "id": "civic.tid:16",
            "type": "TherapeuticDescriptor",
            "label": "Cetuximab",
            "extensions": [
                {
                    "type": "Extension",
                    "name": "regulatory_approval",
                    "value": {
                        "approval_rating": "ChEMBL",
                        "has_indications": [
                            {
                                "id": "mesh:D002294",
                                "type": "DiseaseDescriptor",
                                "label": "Carcinoma, Squamous Cell",
                                "disease": "ncit:C2929"
                            },
                            {
                                "id": "mesh:D009369",
                                "type": "DiseaseDescriptor",
                                "label": "Neoplasms",
                                "disease": "ncit:C3262"
                            },
                            {
                                "id": "mesh:D015179",
                                "type": "DiseaseDescriptor",
                                "label": "Colorectal Neoplasms",
                                "disease": "ncit:C2956"
                            },
                            {
                                "id": "mesh:D006258",
                                "type": "DiseaseDescriptor",
                                "label": "Head and Neck Neoplasms",
                                "disease": "ncit:C4013"
                            }
                        ]
                    }
                }
            ],
            "xrefs": [
                "ncit:C1723"
            ],
            "alternate_labels": [
                "Cetuximab Biosimilar CDP-1",
                "Cetuximab Biosimilar CMAB009",
                "Cetuximab Biosimilar KL 140",
                "Chimeric Anti-EGFR Monoclonal Antibody",
                "Chimeric MoAb C225",
                "Chimeric Monoclonal Antibody C225",
                "Erbitux",
                "IMC-C225"
            ],
            "therapeutic": "rxcui:318341"
        }
    },
    {
        "id": "civic.eid:2219",
        "type": "VariationNeoplasmTherapeuticResponseStatement",
        "description": "This was a retrospective study of 691 cetuximab treated patients with metastatic colorectal cancer. Of those, 39 patients harbored KRAS G12V, were BRAF, NRAS and PIK3CA wt, and had individual response data. Three patients had partial response, 16 had stable disease, and 20 progressed. Treatments included cetuximab + irinotecan (n=30), cetuximab + FOLFIRI (n=2), cetuximab monotherapy (n=2), cetuximab + oxaliplatin + 5FU (n=2), cetuximab + 5FU (n=1), cetuximab + irinotecan + oxaliplatin + 5FU + bevacizumab (n=1), and cetuximab+irinotecan+oxaliplatin+5FU (n=1). Median PFS was 12 weeks (1-37 weeks), median OS was 32 weeks (4-77 weeks), and median number of previous chemotherapy lines was 2 (0-5). Median age was 63 years old (34-76), and there were 21 males and 18 females. Authors concluded that KRAS mutation was strongly associated with poor response to cetuximab and suggested that mutation status of KRAS is the most informative compared to BRAF, NRAS, and PIK3CA exon 20 for predicting cetuximab response.",
        "method": "metakb.method:1",
        "is_reported_in": [
            {
                "id": "civic.source:76",
                "type": "Document",
                "label": "De Roock et al., 2010, Lancet Oncol.",
                "xrefs": [
                    "pmid:20619739"
                ],
                "title": "Effects of KRAS, BRAF, NRAS, and PIK3CA mutations on the efficacy of cetuximab plus chemotherapy in chemotherapy-refractory metastatic colorectal cancer: a retrospective consortium analysis."
            }
        ],
        "evidence_level": {
            "id": "vicc:e00005",
            "type": "Coding",
            "label": "clinical cohort evidence"
        },
        "target_proposition": {
            "id": "proposition:Mbn5sm4UhaBWJ4Btlb5mp7j_hP_fjlsP",
            "type": "VariationNeoplasmTherapeuticResponseProposition",
            "subject": "ga4gh:VA.VBKi2jNxAs378IqOBsveoPrYQjWPngQq",
            "predicate": "predicts_resistance_to",
            "object": {
                "id": "rxcui:318341",
                "type": "Therapeutic"
            },
            "neoplasm_type_qualifier": {
                "id": "ncit:C4978",
                "type": "Disease"
            }
        },
        "direction": "supports",
        "subject_descriptor": "civic.vid:425",
        "neoplasm_type_descriptor": {
            "id": "civic.did:11",
            "type": "DiseaseDescriptor",
            "label": "Colorectal Cancer",
            "xrefs": [
                "DOID:9256"
            ],
            "disease": "ncit:C4978"
        },
        "object_descriptor": {
            "id": "civic.tid:16",
            "type": "TherapeuticDescriptor",
            "label": "Cetuximab",
            "extensions": [
                {
                    "type": "Extension",
                    "name": "regulatory_approval",
                    "value": {
                        "approval_rating": "ChEMBL",
                        "has_indications": [
                            {
                                "id": "mesh:D002294",
                                "type": "DiseaseDescriptor",
                                "label": "Carcinoma, Squamous Cell",
                                "disease": "ncit:C2929"
                            },
                            {
                                "id": "mesh:D009369",
                                "type": "DiseaseDescriptor",
                                "label": "Neoplasms",
                                "disease": "ncit:C3262"
                            },
                            {
                                "id": "mesh:D015179",
                                "type": "DiseaseDescriptor",
                                "label": "Colorectal Neoplasms",
                                "disease": "ncit:C2956"
                            },
                            {
                                "id": "mesh:D006258",
                                "type": "DiseaseDescriptor",
                                "label": "Head and Neck Neoplasms",
                                "disease": "ncit:C4013"
                            }
                        ]
                    }
                }
            ],
            "xrefs": [
                "ncit:C1723"
            ],
            "alternate_labels": [
                "Cetuximab Biosimilar CDP-1",
                "Cetuximab Biosimilar CMAB009",
                "Cetuximab Biosimilar KL 140",
                "Chimeric Anti-EGFR Monoclonal Antibody",
                "Chimeric MoAb C225",
                "Chimeric Monoclonal Antibody C225",
                "Erbitux",
                "IMC-C225"
            ],
            "therapeutic": "rxcui:318341"
        }
    },
    {
        "id": "civic.eid:3881",
        "type": "VariationNeoplasmTherapeuticResponseStatement",
        "description": "This was a retrospective study of 691 cetuximab treated patients with metastatic colorectal cancer. Of those, 50 patients harbored KRAS G13D, were BRAF, NRAS and PIK3CA wt, and had individual response data. Nine patients had partial response, 19 had stable disease, and 22 progressed. Treatments included cetuximab + irinotecan (n=38), cetuximab + FOLFIRI (n=5), cetuximab monotherapy (n=4), cetuximab + oxaliplatin + 5FU (n=2), and cetuximab + irinotecan + oxaliplatin + 5FU (n=1). Median PFS was 16 weeks (3-101 weeks), median OS was 33 weeks (3-161 weeks), and median number of previous chemotherapy lines was 2 (0-4). Median age was 65 years old (34-78), and there were 29 males and 20 females. Authors concluded that KRAS mutation was strongly associated with poor response to cetuximab and suggested that mutation status of KRAS is the most informative compared to BRAF, NRAS, and PIK3CA exon 20 for predicting cetuximab response.",
        "method": "metakb.method:1",
        "is_reported_in": [
            {
                "id": "civic.source:76",
                "type": "Document",
                "label": "De Roock et al., 2010, Lancet Oncol.",
                "xrefs": [
                    "pmid:20619739"
                ],
                "title": "Effects of KRAS, BRAF, NRAS, and PIK3CA mutations on the efficacy of cetuximab plus chemotherapy in chemotherapy-refractory metastatic colorectal cancer: a retrospective consortium analysis."
            }
        ],
        "evidence_level": {
            "id": "vicc:e00005",
            "type": "Coding",
            "label": "clinical cohort evidence"
        },
        "target_proposition": {
            "id": "proposition:e_3NNapOoNeeZi1MoruyXk6xCAWRhh2Q",
            "type": "VariationNeoplasmTherapeuticResponseProposition",
            "subject": "ga4gh:VA.tO-mdKyTxDxR376-vWkR2RgI2gpOvBhQ",
            "predicate": "predicts_resistance_to",
            "object": {
                "id": "rxcui:318341",
                "type": "Therapeutic"
            },
            "neoplasm_type_qualifier": {
                "id": "ncit:C4978",
                "type": "Disease"
            }
        },
        "direction": "supports",
        "subject_descriptor": "civic.vid:81",
        "neoplasm_type_descriptor": {
            "id": "civic.did:11",
            "type": "DiseaseDescriptor",
            "label": "Colorectal Cancer",
            "xrefs": [
                "DOID:9256"
            ],
            "disease": "ncit:C4978"
        },
        "object_descriptor": {
            "id": "civic.tid:16",
            "type": "TherapeuticDescriptor",
            "label": "Cetuximab",
            "extensions": [
                {
                    "type": "Extension",
                    "name": "regulatory_approval",
                    "value": {
                        "approval_rating": "ChEMBL",
                        "has_indications": [
                            {
                                "id": "mesh:D002294",
                                "type": "DiseaseDescriptor",
                                "label": "Carcinoma, Squamous Cell",
                                "disease": "ncit:C2929"
                            },
                            {
                                "id": "mesh:D009369",
                                "type": "DiseaseDescriptor",
                                "label": "Neoplasms",
                                "disease": "ncit:C3262"
                            },
                            {
                                "id": "mesh:D015179",
                                "type": "DiseaseDescriptor",
                                "label": "Colorectal Neoplasms",
                                "disease": "ncit:C2956"
                            },
                            {
                                "id": "mesh:D006258",
                                "type": "DiseaseDescriptor",
                                "label": "Head and Neck Neoplasms",
                                "disease": "ncit:C4013"
                            }
                        ]
                    }
                }
            ],
            "xrefs": [
                "ncit:C1723"
            ],
            "alternate_labels": [
                "Cetuximab Biosimilar CDP-1",
                "Cetuximab Biosimilar CMAB009",
                "Cetuximab Biosimilar KL 140",
                "Chimeric Anti-EGFR Monoclonal Antibody",
                "Chimeric MoAb C225",
                "Chimeric Monoclonal Antibody C225",
                "Erbitux",
                "IMC-C225"
            ],
            "therapeutic": "rxcui:318341"
        }
    },
    {
        "id": "civic.eid:4006",
        "type": "VariationNeoplasmTherapeuticResponseStatement",
        "description": "This was a retrospective study of 691 cetuximab treated patients with metastatic, chemotherapy refractory colorectal cancer. Of those, 16 patients harbored KRAS G12S, were BRAF, NRAS and PIK3CA wt, and had individual response data. Nine patients had stable disease and seven progressed. Treatments included cetuximab + irinotecan (n=13), cetuximab + FOLFIRI (n=1), cetuximab+5FU (n=1), cetuximab + irinotecan + oxaliplatin + bevacizumab (n=1). Median PFS was 12 weeks (2-50 weeks), median OS was 25 weeks (10-135 weeks), and median number of previous chemotherapy lines was 2 (1-6). Median age was 59 years old (31-69), and there were 9 males and 7 females. Using these data and data from the larger cohort, authors concluded that KRAS mutation was strongly associated with poor response to cetuximab and suggested that mutation status of KRAS is the most informative compared to BRAF, NRAS, and PIK3CA exon 20 for predicting cetuximab response.",
        "method": "metakb.method:1",
        "is_reported_in": [
            {
                "id": "civic.source:76",
                "type": "Document",
                "label": "De Roock et al., 2010, Lancet Oncol.",
                "xrefs": [
                    "pmid:20619739"
                ],
                "title": "Effects of KRAS, BRAF, NRAS, and PIK3CA mutations on the efficacy of cetuximab plus chemotherapy in chemotherapy-refractory metastatic colorectal cancer: a retrospective consortium analysis."
            }
        ],
        "evidence_level": {
            "id": "vicc:e00005",
            "type": "Coding",
            "label": "clinical cohort evidence"
        },
        "target_proposition": {
            "id": "proposition:n5yAWUbB1phBm0bV3_URu8KuM2Eu_Tw4",
            "type": "VariationNeoplasmTherapeuticResponseProposition",
            "subject": "ga4gh:VA.QVdzWvpiRTgBHwV39EuVg6VZVGOLxdUS",
            "predicate": "predicts_resistance_to",
            "object": {
                "id": "rxcui:318341",
                "type": "Therapeutic"
            },
            "neoplasm_type_qualifier": {
                "id": "ncit:C4978",
                "type": "Disease"
            }
        },
        "direction": "supports",
        "subject_descriptor": "civic.vid:913",
        "neoplasm_type_descriptor": {
            "id": "civic.did:11",
            "type": "DiseaseDescriptor",
            "label": "Colorectal Cancer",
            "xrefs": [
                "DOID:9256"
            ],
            "disease": "ncit:C4978"
        },
        "object_descriptor": {
            "id": "civic.tid:16",
            "type": "TherapeuticDescriptor",
            "label": "Cetuximab",
            "extensions": [
                {
                    "type": "Extension",
                    "name": "regulatory_approval",
                    "value": {
                        "approval_rating": "ChEMBL",
                        "has_indications": [
                            {
                                "id": "mesh:D002294",
                                "type": "DiseaseDescriptor",
                                "label": "Carcinoma, Squamous Cell",
                                "disease": "ncit:C2929"
                            },
                            {
                                "id": "mesh:D009369",
                                "type": "DiseaseDescriptor",
                                "label": "Neoplasms",
                                "disease": "ncit:C3262"
                            },
                            {
                                "id": "mesh:D015179",
                                "type": "DiseaseDescriptor",
                                "label": "Colorectal Neoplasms",
                                "disease": "ncit:C2956"
                            },
                            {
                                "id": "mesh:D006258",
                                "type": "DiseaseDescriptor",
                                "label": "Head and Neck Neoplasms",
                                "disease": "ncit:C4013"
                            }
                        ]
                    }
                }
            ],
            "xrefs": [
                "ncit:C1723"
            ],
            "alternate_labels": [
                "Cetuximab Biosimilar CDP-1",
                "Cetuximab Biosimilar CMAB009",
                "Cetuximab Biosimilar KL 140",
                "Chimeric Anti-EGFR Monoclonal Antibody",
                "Chimeric MoAb C225",
                "Chimeric Monoclonal Antibody C225",
                "Erbitux",
                "IMC-C225"
            ],
            "therapeutic": "rxcui:318341"
        }
    },
    {
        "id": "civic.eid:4429",
        "type": "VariationNeoplasmTherapeuticResponseStatement",
        "description": "This was a retrospective study of 691 cetuximab treated patients with metastatic colorectal cancer. Of those, 22 patients harbored KRAS G12A, were BRAF, NRAS and PIK3CA wt, and had individual response data. Three patients had partial response, 12 had stable disease, and seven progressed. Treatments included cetuximab + irinotecan (n=18), cetuximab monotherapy (n=1), cetuximab + FOLFIRI (n=2), and cetuximab + oxaliplatin + 5FU (n=1). Median PFS was 18 weeks (1-34 weeks), median OS was 35 weeks (1-143 weeks), and median number of previous chemotherapy lines was 2 (0-5). Median age was 62 years old (22-77) and there were 11 males and 11 females. Using these data and data from the larger cohort, authors concluded that KRAS mutation was strongly associated with poor response to cetuximab and suggested that mutation status of KRAS is the most informative compared to BRAF, NRAS, and PIK3CA exon 20 for predicting cetuximab response.",
        "method": "metakb.method:1",
        "is_reported_in": [
            {
                "id": "civic.source:76",
                "type": "Document",
                "label": "De Roock et al., 2010, Lancet Oncol.",
                "xrefs": [
                    "pmid:20619739"
                ],
                "title": "Effects of KRAS, BRAF, NRAS, and PIK3CA mutations on the efficacy of cetuximab plus chemotherapy in chemotherapy-refractory metastatic colorectal cancer: a retrospective consortium analysis."
            }
        ],
        "evidence_level": {
            "id": "vicc:e00005",
            "type": "Coding",
            "label": "clinical cohort evidence"
        },
        "target_proposition": {
            "id": "proposition:BT_V6YJrOawOoh3NYM52rlSdoheOx1hr",
            "type": "VariationNeoplasmTherapeuticResponseProposition",
            "subject": "ga4gh:VA.U3kUAWKJKEeDyAbv3JsDVQlu9HeEG0WJ",
            "predicate": "predicts_resistance_to",
            "object": {
                "id": "rxcui:318341",
                "type": "Therapeutic"
            },
            "neoplasm_type_qualifier": {
                "id": "ncit:C4978",
                "type": "Disease"
            }
        },
        "direction": "supports",
        "subject_descriptor": "civic.vid:148",
        "neoplasm_type_descriptor": {
            "id": "civic.did:11",
            "type": "DiseaseDescriptor",
            "label": "Colorectal Cancer",
            "xrefs": [
                "DOID:9256"
            ],
            "disease": "ncit:C4978"
        },
        "object_descriptor": {
            "id": "civic.tid:16",
            "type": "TherapeuticDescriptor",
            "label": "Cetuximab",
            "extensions": [
                {
                    "type": "Extension",
                    "name": "regulatory_approval",
                    "value": {
                        "approval_rating": "ChEMBL",
                        "has_indications": [
                            {
                                "id": "mesh:D002294",
                                "type": "DiseaseDescriptor",
                                "label": "Carcinoma, Squamous Cell",
                                "disease": "ncit:C2929"
                            },
                            {
                                "id": "mesh:D009369",
                                "type": "DiseaseDescriptor",
                                "label": "Neoplasms",
                                "disease": "ncit:C3262"
                            },
                            {
                                "id": "mesh:D015179",
                                "type": "DiseaseDescriptor",
                                "label": "Colorectal Neoplasms",
                                "disease": "ncit:C2956"
                            },
                            {
                                "id": "mesh:D006258",
                                "type": "DiseaseDescriptor",
                                "label": "Head and Neck Neoplasms",
                                "disease": "ncit:C4013"
                            }
                        ]
                    }
                }
            ],
            "xrefs": [
                "ncit:C1723"
            ],
            "alternate_labels": [
                "Cetuximab Biosimilar CDP-1",
                "Cetuximab Biosimilar CMAB009",
                "Cetuximab Biosimilar KL 140",
                "Chimeric Anti-EGFR Monoclonal Antibody",
                "Chimeric MoAb C225",
                "Chimeric Monoclonal Antibody C225",
                "Erbitux",
                "IMC-C225"
            ],
            "therapeutic": "rxcui:318341"
        }
    },
    {
        "id": "civic.eid:6402",
        "type": "VariationNeoplasmTherapeuticResponseStatement",
        "description": "The presence of BRAF V600E or D594K was associated with reduced progression-free survival in 5 patients with metastatic colorectal cancer treated with irinotecan-based first line therapy (3.5mo vs. 12.8mo, HR:4.1, 95%CI:1.5-11.3, P=0.006) when compared to 39 patients with wildtype BRAF.",
        "method": "metakb.method:1",
        "is_reported_in": [
            {
                "id": "civic.source:1479",
                "type": "Document",
                "label": "Souglakos et al., 2009, Br. J. Cancer",
                "xrefs": [
                    "pmc:PMC2720232",
                    "pmid:19603024"
                ],
                "title": "Prognostic and predictive value of common mutations for treatment response and survival in patients with metastatic colorectal cancer."
            }
        ],
        "evidence_level": {
            "id": "vicc:e00005",
            "type": "Coding",
            "label": "clinical cohort evidence"
        },
        "target_proposition": {
            "id": "proposition:dXc2_1ToYTAOWxuuzopACZUzTLyTjVBD",
            "type": "VariationNeoplasmTherapeuticResponseProposition",
            "subject": "ga4gh:VA.Sx0r938r9xS6vFaqkhckqW4t9q11m69b",
            "predicate": "predicts_resistance_to",
            "object": {
                "id": "rxcui:153329",
                "type": "Therapeutic"
            },
            "neoplasm_type_qualifier": {
                "id": "ncit:C4978",
                "type": "Disease"
            }
        },
        "direction": "supports",
        "subject_descriptor": "civic.vid:2398",
        "neoplasm_type_descriptor": {
            "id": "civic.did:11",
            "type": "DiseaseDescriptor",
            "label": "Colorectal Cancer",
            "xrefs": [
                "DOID:9256"
            ],
            "disease": "ncit:C4978"
        },
        "object_descriptor": {
            "id": "civic.tid:101",
            "type": "TherapeuticDescriptor",
            "label": "Irinotecan",
            "extensions": [
                {
                    "type": "Extension",
                    "name": "regulatory_approval",
                    "value": {
                        "approval_rating": "FDA",
                        "has_indications": [
                            {
                                "id": "hemonc:46096",
                                "type": "DiseaseDescriptor",
                                "label": "Colorectal cancer",
                                "disease": "ncit:C4978"
                            }
                        ]
                    }
                }
            ],
            "xrefs": [
                "ncit:C62040"
            ],
            "alternate_labels": [
                "(+)-(4S)-4,11-diethyl-4-hydroxy-9-[(4-piperidino-piperidino)carbonyloxy]-1H-pyrano[3',4':6,7]indolizino[1,2-b]quinol-3,14,(4H,12H)-dione",
                "(+)-7-ethyl-10-hydroxycamptothecine 10-[1,4'-bipiperidine]-1'-carboxylate",
                "7-ethyl-10-[4-(1-piperidino)-1-piperidino]carbonyloxycamptothecin",
                "[1,4'-bipiperidine]-1'-carboxylic Acid (S)-4,11-diethyl-3,4,12,14-tetrahydro-4-hydroxy-3,14-dioxo-1H-pyrano[3',4':6,7]indolizino[1,2-b]quinolin-9-yl Ester"
            ],
            "therapeutic": "rxcui:153329"
        }
    },
    {
        "id": "civic.eid:6403",
        "type": "VariationNeoplasmTherapeuticResponseStatement",
        "description": "Of 100 metastatic colorectal cancer patients treated with oxaliplatin-based first-line therapy, the 6 patients with either BRAF V600E or D594K had reduced progression-free survival compared to 94 patients with wildtype BRAF (5.0mo vs. 11.7mo, HR:6.4, 95%CI:2.6-15.6, P<0.0001).",
        "method": "metakb.method:1",
        "is_reported_in": [
            {
                "id": "civic.source:1479",
                "type": "Document",
                "label": "Souglakos et al., 2009, Br. J. Cancer",
                "xrefs": [
                    "pmc:PMC2720232",
                    "pmid:19603024"
                ],
                "title": "Prognostic and predictive value of common mutations for treatment response and survival in patients with metastatic colorectal cancer."
            }
        ],
        "evidence_level": {
            "id": "vicc:e00005",
            "type": "Coding",
            "label": "clinical cohort evidence"
        },
        "target_proposition": {
            "id": "proposition:gYa_LRk4mCgVU4O90nSQoNlrpu8YiIy2",
            "type": "VariationNeoplasmTherapeuticResponseProposition",
            "subject": "ga4gh:VA.Sx0r938r9xS6vFaqkhckqW4t9q11m69b",
            "predicate": "predicts_resistance_to",
            "object": {
                "id": "rxcui:32592",
                "type": "Therapeutic"
            },
            "neoplasm_type_qualifier": {
                "id": "ncit:C4978",
                "type": "Disease"
            }
        },
        "direction": "supports",
        "subject_descriptor": "civic.vid:2398",
        "neoplasm_type_descriptor": {
            "id": "civic.did:11",
            "type": "DiseaseDescriptor",
            "label": "Colorectal Cancer",
            "xrefs": [
                "DOID:9256"
            ],
            "disease": "ncit:C4978"
        },
        "object_descriptor": {
            "id": "civic.tid:237",
            "type": "TherapeuticDescriptor",
            "label": "Oxaliplatin",
            "extensions": [
                {
                    "type": "Extension",
                    "name": "regulatory_approval",
                    "value": {
                        "approval_rating": "FDA",
                        "has_indications": [
                            {
                                "id": "hemonc:46096",
                                "type": "DiseaseDescriptor",
                                "label": "Colorectal cancer",
                                "disease": "ncit:C4978"
                            },
                            {
                                "id": "hemonc:585",
                                "type": "DiseaseDescriptor",
                                "label": "Colon cancer",
                                "disease": "ncit:C9242"
                            }
                        ]
                    }
                }
            ],
            "xrefs": [
                "ncit:C1181"
            ],
            "alternate_labels": [
                "1-OHP",
                "Ai Heng",
                "Aiheng",
                "DACPLAT",
                "Dacotin",
                "Diaminocyclohexane Oxalatoplatinum",
                "ELOXATIN",
                "Eloxatine",
                "JM-83",
                "Oxalato (1R,2R-cyclohexanediamine)platinum(II)",
                "Oxalato (trans-l-1,2-diaminocyclohexane)platinum(II)",
                "Oxalatoplatin",
                "Oxalatoplatinum",
                "RP 54780",
                "RP-54780",
                "SR-96669",
                "Trans-l DACH Oxalatoplatinum",
                "Trans-l Diaminocyclohexane Oxalatoplatinum",
                "[(1R,-2R)-1,2-cyclohexanediamine-N,N'][oxalato (2--)-O,O']platinum",
                "[SP-4-2-(1R-trans)]-(1,2,cyclohexanediamine-N,N')[ethanedioato(2--)-O,O']platinum"
            ],
            "therapeutic": "rxcui:32592"
        }
    },
    {
        "id": "civic.eid:806",
        "type": "VariationNeoplasmTherapeuticResponseStatement",
        "description": "This is a retrospective analysis of 98 patients with metastatic colorectal cancer and KRAS mutations. 23 (23.5%) had KRAS p.G13D-mutated tumors. Of the 98 patients, 31 patients received cetuximab, of these, 9 (29.0%) had KRAS p.G13D mutations. Univariate analysis did not show any differences between these groups. Multivariate analysis showed a trend towards better PFS among patients with a G13D mutation (PFS: HR=0.29; 95% CI: 0.08-1.10; P=0.07; OS: HR=0.23; 95% CI: 0.04-1.54; P=0.13).",
        "method": "metakb.method:1",
        "is_reported_in": [
            {
                "id": "civic.source:540",
                "type": "Document",
                "label": "Osumi et al., 2015, Mol Clin Oncol",
                "xrefs": [
                    "pmc:PMC4534836",
                    "pmid:26623049"
                ],
                "title": "Cetuximab treatment for metastatic colorectal cancer with KRAS p.G13D mutations improves progression-free survival."
            }
        ],
        "evidence_level": {
            "id": "vicc:e00005",
            "type": "Coding",
            "label": "clinical cohort evidence"
        },
        "target_proposition": {
            "id": "proposition:e_3NNapOoNeeZi1MoruyXk6xCAWRhh2Q",
            "type": "VariationNeoplasmTherapeuticResponseProposition",
            "subject": "ga4gh:VA.tO-mdKyTxDxR376-vWkR2RgI2gpOvBhQ",
            "predicate": "predicts_resistance_to",
            "object": {
                "id": "rxcui:318341",
                "type": "Therapeutic"
            },
            "neoplasm_type_qualifier": {
                "id": "ncit:C4978",
                "type": "Disease"
            }
        },
        "direction": "opposes",
        "subject_descriptor": "civic.vid:81",
        "neoplasm_type_descriptor": {
            "id": "civic.did:11",
            "type": "DiseaseDescriptor",
            "label": "Colorectal Cancer",
            "xrefs": [
                "DOID:9256"
            ],
            "disease": "ncit:C4978"
        },
        "object_descriptor": {
            "id": "civic.tid:16",
            "type": "TherapeuticDescriptor",
            "label": "Cetuximab",
            "extensions": [
                {
                    "type": "Extension",
                    "name": "regulatory_approval",
                    "value": {
                        "approval_rating": "ChEMBL",
                        "has_indications": [
                            {
                                "id": "mesh:D002294",
                                "type": "DiseaseDescriptor",
                                "label": "Carcinoma, Squamous Cell",
                                "disease": "ncit:C2929"
                            },
                            {
                                "id": "mesh:D009369",
                                "type": "DiseaseDescriptor",
                                "label": "Neoplasms",
                                "disease": "ncit:C3262"
                            },
                            {
                                "id": "mesh:D015179",
                                "type": "DiseaseDescriptor",
                                "label": "Colorectal Neoplasms",
                                "disease": "ncit:C2956"
                            },
                            {
                                "id": "mesh:D006258",
                                "type": "DiseaseDescriptor",
                                "label": "Head and Neck Neoplasms",
                                "disease": "ncit:C4013"
                            }
                        ]
                    }
                }
            ],
            "xrefs": [
                "ncit:C1723"
            ],
            "alternate_labels": [
                "Cetuximab Biosimilar CDP-1",
                "Cetuximab Biosimilar CMAB009",
                "Cetuximab Biosimilar KL 140",
                "Chimeric Anti-EGFR Monoclonal Antibody",
                "Chimeric MoAb C225",
                "Chimeric Monoclonal Antibody C225",
                "Erbitux",
                "IMC-C225"
            ],
            "therapeutic": "rxcui:318341"
        }
    },
    {
        "id": "civic.eid:994",
        "type": "VariationNeoplasmTherapeuticResponseStatement",
        "description": "This was a phase I expansion and pharmacodynamic study of oral MEK inhibitor RO4987655 on advanced cancer. Of 17 patients with BRAF V600E melanoma, 4 achieved partial response, 5 experienced stable disease lasting longer than 16 weeks, and 8 experienced disease progression (including 2 with prior vemurafenib treatment). One of the partial responders had a concomitant EGFR mutation, and two of the stable disease patients had other concomitant mutations (in RET or MET). The median days on treatment was 113 (18-366) for BRAF V600E melanoma patients and 107 (17-323) for BRAF V600 wildtype patients (n=23). Patients with BRAF V600E mutant melanoma experienced similar response rates (24% vs 20%) and rates of metabolic response measured by decrease in FDG uptake assessed by FDG-PET (86% vs 75%) compared to non-BRAF mutant patients. Patients with melanoma, either BRAF wt or V600E, experienced significant decreases in Ki67 expression by day 15 of MEK inhibitor treatment (P<0.02). The authors conclude that RO4987655 has clinical activity in BRAF V600E and BRAF wt melanoma.",
        "method": "metakb.method:1",
        "is_reported_in": [
            {
                "id": "civic.source:688",
                "type": "Document",
                "label": "Zimmer et al., 2014, Clin. Cancer Res.",
                "xrefs": [
                    "pmid:24947927"
                ],
                "title": "Phase I expansion and pharmacodynamic study of the oral MEK inhibitor RO4987655 (CH4987655) in selected patients with advanced cancer with RAS-RAF mutations."
            }
        ],
        "evidence_level": {
            "id": "vicc:e00005",
            "type": "Coding",
            "label": "clinical cohort evidence"
        },
        "target_proposition": {
            "id": "proposition:djOJ2oYcLngj6KQyDSAlkEvE_xndUSAl",
            "type": "VariationNeoplasmTherapeuticResponseProposition",
            "subject": "ga4gh:VA.h313H4CQh6pogbbSJ3H5pI1cPoh9YMm_",
            "predicate": "predicts_resistance_to",
            "object": {
                "id": "ncit:C82696",
                "type": "Therapeutic"
            },
            "neoplasm_type_qualifier": {
                "id": "ncit:C3224",
                "type": "Disease"
            }
        },
        "direction": "opposes",
        "subject_descriptor": "civic.vid:12",
        "neoplasm_type_descriptor": {
            "id": "civic.did:7",
            "type": "DiseaseDescriptor",
            "label": "Melanoma",
            "xrefs": [
                "DOID:1909"
            ],
            "disease": "ncit:C3224"
        },
        "object_descriptor": {
            "id": "civic.tid:243",
            "type": "TherapeuticDescriptor",
            "label": "MEK Inhibitor RO4987655",
            "xrefs": [
                "ncit:C82696"
            ],
            "alternate_labels": [
                "RO-4987655",
                "RO4987655"
            ],
            "therapeutic": "ncit:C82696"
        }
    },
    {
        "id": "civic.eid:2008",
        "type": "VariationNeoplasmTherapeuticResponseStatement",
        "description": "In recurrent lung cancer patients treated with the epidermal growth factor receptor tyrosine kinase inhibitor gefitinib, patients with KRAS mutations had a lower frequency of partial response (PR) and stable disease (SD) and a higher rate of progressive disease (PD) (PR:0, SD:1, PD:15 vs. PR:24, SD:8, PD:14; P=0.0274) compared to wildtype KRAS patients. Patients with KRAS mutations also had a shorter overall survival compared to wildtype KRAS patients (HR:2.542, 95% CI:1.048-6.168, P=0.0390).",
        "method": "metakb.method:1",
        "is_reported_in": [
            {
                "id": "civic.source:1416",
                "type": "Document",
                "label": "Endoh et al., 2006, J Thorac Oncol",
                "xrefs": [
                    "pmid:17409929"
                ],
                "title": "PTEN and PIK3CA expression is associated with prolonged survival after gefitinib treatment in EGFR-mutated lung cancer patients."
            }
        ],
        "evidence_level": {
            "id": "vicc:e00005",
            "type": "Coding",
            "label": "clinical cohort evidence"
        },
        "target_proposition": {
            "id": "proposition:lhywRIjI5US6eddI5ChJBdGiVcQ5dX0g",
            "type": "VariationNeoplasmTherapeuticResponseProposition",
            "subject": "ga4gh:VA.U3kUAWKJKEeDyAbv3JsDVQlu9HeEG0WJ",
            "predicate": "predicts_resistance_to",
            "object": {
                "id": "rxcui:328134",
                "type": "Therapeutic"
            },
            "neoplasm_type_qualifier": {
                "id": "ncit:C7377",
                "type": "Disease"
            }
        },
        "direction": "supports",
        "subject_descriptor": "civic.vid:148",
        "neoplasm_type_descriptor": {
            "id": "civic.did:23",
            "type": "DiseaseDescriptor",
            "label": "Lung Cancer",
            "xrefs": [
                "DOID:1324"
            ],
            "disease": "ncit:C7377"
        },
        "object_descriptor": {
            "id": "civic.tid:14",
            "type": "TherapeuticDescriptor",
            "label": "Gefitinib",
            "extensions": [
                {
                    "type": "Extension",
                    "name": "regulatory_approval",
                    "value": {
                        "approval_rating": "FDA",
                        "has_indications": [
                            {
                                "id": "hemonc:642",
                                "type": "DiseaseDescriptor",
                                "label": "Non-small cell lung cancer",
                                "disease": "ncit:C2926"
                            }
                        ]
                    }
                }
            ],
            "xrefs": [
                "ncit:C1855"
            ],
            "alternate_labels": [
                "4-(3'-Chloro-4'-fluoroanilino)-7-methoxy-6-(3-morpholinopropoxy)quinazoline",
                "Iressa",
                "N-(3-chloro-4-fluorophenyl)-7-methoxy-6-[3-(4-morpholin) Propoxy]-4-quinazolinamine",
                "ZD 1839",
                "ZD1839"
            ],
            "therapeutic": "rxcui:328134"
        }
    },
    {
        "id": "civic.eid:2009",
        "type": "VariationNeoplasmTherapeuticResponseStatement",
        "description": "In a study of patients receiving melphalan-based therapy, those with KRAS codon 12 mutations were less likely to have a positive response than those with wildtype KRAS (26.9% vs. 58.3%, P=0.015).",
        "method": "metakb.method:1",
        "is_reported_in": [
            {
                "id": "civic.source:1417",
                "type": "Document",
                "label": "Greco et al., 2009, J. Exp. Clin. Cancer Res.",
                "xrefs": [
                    "pmc:PMC2663546",
                    "pmid:19284554"
                ],
                "title": "Reduction of serum IGF-I levels in patients affected with Monoclonal Gammopathies of undetermined significance or Multiple Myeloma. Comparison with bFGF, VEGF and K-ras gene mutation."
            }
        ],
        "evidence_level": {
            "id": "vicc:e00005",
            "type": "Coding",
            "label": "clinical cohort evidence"
        },
        "target_proposition": {
            "id": "proposition:Tw0j-lqFEJG91PXFplmJiTzsyomYoUag",
            "type": "VariationNeoplasmTherapeuticResponseProposition",
            "subject": "ga4gh:VA.U3kUAWKJKEeDyAbv3JsDVQlu9HeEG0WJ",
            "predicate": "predicts_resistance_to",
            "object": {
                "id": "rxcui:6718",
                "type": "Therapeutic"
            },
            "neoplasm_type_qualifier": {
                "id": "ncit:C3242",
                "type": "Disease"
            }
        },
        "direction": "supports",
        "subject_descriptor": "civic.vid:148",
        "neoplasm_type_descriptor": {
            "id": "civic.did:41",
            "type": "DiseaseDescriptor",
            "label": "Multiple Myeloma",
            "xrefs": [
                "DOID:9538"
            ],
            "disease": "ncit:C3242"
        },
        "object_descriptor": {
            "id": "civic.tid:328",
            "type": "TherapeuticDescriptor",
            "label": "Melphalan",
            "extensions": [
                {
                    "type": "Extension",
                    "name": "regulatory_approval",
                    "value": {
                        "approval_rating": "FDA",
                        "has_indications": [
                            {
                                "id": "hemonc:633",
                                "type": "DiseaseDescriptor",
                                "label": "Multiple myeloma",
                                "disease": "ncit:C3242"
                            },
                            {
                                "id": "hemonc:645",
                                "type": "DiseaseDescriptor",
                                "label": "Ovarian cancer",
                                "disease": "ncit:C7431"
                            }
                        ]
                    }
                }
            ],
            "xrefs": [
                "ncit:C633"
            ],
            "alternate_labels": [
                "4-[bis(2-chloroethyl)amino]-L-phenylalanine",
                "Alanine Nitrogen Mustard",
                "CB-3025",
                "L-PAM",
                "L-Phenylalanine Mustard",
                "L-Sarcolysin",
                "L-Sarcolysin Phenylalanine Mustard",
                "L-Sarcolysine",
                "Melphalanum",
                "P-di(chloroethyl)amino-L-phenylalanine",
                "Phenylalanine Mustard",
                "Phenylalanine Nitrogen Mustard",
                "Sarcoclorin",
                "Sarkolysin",
                "WR-19813"
            ],
            "therapeutic": "rxcui:6718"
        }
    },
    {
        "id": "civic.eid:2240",
        "type": "VariationNeoplasmTherapeuticResponseStatement",
        "description": "In recurrent lung cancer patients treated with the epidermal growth factor receptor tyrosine kinase inhibitor gefitinib, patients with KRAS mutations had a lower frequency of partial response (PR) and stable disease (SD) and a higher rate of progressive disease (PD) (PR:0, SD:1, PD:15 vs. PR:24, SD:8, PD:14; P=0.0274) compared to wildtype KRAS patients. Patients with KRAS mutations also had a shorter overall survival compared to wildtype KRAS patients (HR:2.542, 95% CI:1.048-6.168, P=0.0390).",
        "method": "metakb.method:1",
        "is_reported_in": [
            {
                "id": "civic.source:1416",
                "type": "Document",
                "label": "Endoh et al., 2006, J Thorac Oncol",
                "xrefs": [
                    "pmid:17409929"
                ],
                "title": "PTEN and PIK3CA expression is associated with prolonged survival after gefitinib treatment in EGFR-mutated lung cancer patients."
            }
        ],
        "evidence_level": {
            "id": "vicc:e00005",
            "type": "Coding",
            "label": "clinical cohort evidence"
        },
        "target_proposition": {
            "id": "proposition:ySRFiqA_9snwkXUfRXG0-xvoctIHF4px",
            "type": "VariationNeoplasmTherapeuticResponseProposition",
            "subject": "ga4gh:VA.jSiuIG2uZEbml8MfCtZi3J9jPBCBiaPw",
            "predicate": "predicts_resistance_to",
            "object": {
                "id": "rxcui:328134",
                "type": "Therapeutic"
            },
            "neoplasm_type_qualifier": {
                "id": "ncit:C7377",
                "type": "Disease"
            }
        },
        "direction": "supports",
        "subject_descriptor": "civic.vid:79",
        "neoplasm_type_descriptor": {
            "id": "civic.did:23",
            "type": "DiseaseDescriptor",
            "label": "Lung Cancer",
            "xrefs": [
                "DOID:1324"
            ],
            "disease": "ncit:C7377"
        },
        "object_descriptor": {
            "id": "civic.tid:14",
            "type": "TherapeuticDescriptor",
            "label": "Gefitinib",
            "extensions": [
                {
                    "type": "Extension",
                    "name": "regulatory_approval",
                    "value": {
                        "approval_rating": "FDA",
                        "has_indications": [
                            {
                                "id": "hemonc:642",
                                "type": "DiseaseDescriptor",
                                "label": "Non-small cell lung cancer",
                                "disease": "ncit:C2926"
                            }
                        ]
                    }
                }
            ],
            "xrefs": [
                "ncit:C1855"
            ],
            "alternate_labels": [
                "4-(3'-Chloro-4'-fluoroanilino)-7-methoxy-6-(3-morpholinopropoxy)quinazoline",
                "Iressa",
                "N-(3-chloro-4-fluorophenyl)-7-methoxy-6-[3-(4-morpholin) Propoxy]-4-quinazolinamine",
                "ZD 1839",
                "ZD1839"
            ],
            "therapeutic": "rxcui:328134"
        }
    },
    {
        "id": "civic.eid:2247",
        "type": "VariationNeoplasmTherapeuticResponseStatement",
        "description": "In a study of patients receiving melphalan-based therapy, those with KRAS codon 12 mutations were less likely to have a positive response than those with wildtype KRAS (26.9% vs. 58.3%, P=0.015).",
        "method": "metakb.method:1",
        "is_reported_in": [
            {
                "id": "civic.source:1417",
                "type": "Document",
                "label": "Greco et al., 2009, J. Exp. Clin. Cancer Res.",
                "xrefs": [
                    "pmc:PMC2663546",
                    "pmid:19284554"
                ],
                "title": "Reduction of serum IGF-I levels in patients affected with Monoclonal Gammopathies of undetermined significance or Multiple Myeloma. Comparison with bFGF, VEGF and K-ras gene mutation."
            }
        ],
        "evidence_level": {
            "id": "vicc:e00005",
            "type": "Coding",
            "label": "clinical cohort evidence"
        },
        "target_proposition": {
            "id": "proposition:1Sa3QxRYxqz93Sii4mEhoHsVJVgyduzJ",
            "type": "VariationNeoplasmTherapeuticResponseProposition",
            "subject": "ga4gh:VA.jSiuIG2uZEbml8MfCtZi3J9jPBCBiaPw",
            "predicate": "predicts_resistance_to",
            "object": {
                "id": "rxcui:6718",
                "type": "Therapeutic"
            },
            "neoplasm_type_qualifier": {
                "id": "ncit:C3242",
                "type": "Disease"
            }
        },
        "direction": "supports",
        "subject_descriptor": "civic.vid:79",
        "neoplasm_type_descriptor": {
            "id": "civic.did:41",
            "type": "DiseaseDescriptor",
            "label": "Multiple Myeloma",
            "xrefs": [
                "DOID:9538"
            ],
            "disease": "ncit:C3242"
        },
        "object_descriptor": {
            "id": "civic.tid:328",
            "type": "TherapeuticDescriptor",
            "label": "Melphalan",
            "extensions": [
                {
                    "type": "Extension",
                    "name": "regulatory_approval",
                    "value": {
                        "approval_rating": "FDA",
                        "has_indications": [
                            {
                                "id": "hemonc:633",
                                "type": "DiseaseDescriptor",
                                "label": "Multiple myeloma",
                                "disease": "ncit:C3242"
                            },
                            {
                                "id": "hemonc:645",
                                "type": "DiseaseDescriptor",
                                "label": "Ovarian cancer",
                                "disease": "ncit:C7431"
                            }
                        ]
                    }
                }
            ],
            "xrefs": [
                "ncit:C633"
            ],
            "alternate_labels": [
                "4-[bis(2-chloroethyl)amino]-L-phenylalanine",
                "Alanine Nitrogen Mustard",
                "CB-3025",
                "L-PAM",
                "L-Phenylalanine Mustard",
                "L-Sarcolysin",
                "L-Sarcolysin Phenylalanine Mustard",
                "L-Sarcolysine",
                "Melphalanum",
                "P-di(chloroethyl)amino-L-phenylalanine",
                "Phenylalanine Mustard",
                "Phenylalanine Nitrogen Mustard",
                "Sarcoclorin",
                "Sarkolysin",
                "WR-19813"
            ],
            "therapeutic": "rxcui:6718"
        }
    },
    {
        "id": "civic.eid:2257",
        "type": "VariationNeoplasmTherapeuticResponseStatement",
        "description": "In recurrent lung cancer patients treated with the epidermal growth factor receptor tyrosine kinase inhibitor gefitinib, patients with KRAS mutations had a lower frequency of partial response (PR) and stable disease (SD) and a higher rate of progressive disease (PD) (PR:0, SD:1, PD:15 vs. PR:24, SD:8, PD:14; P=0.0274) compared to wildtype KRAS patients. Patients with KRAS mutations also had a shorter overall survival compared to wildtype KRAS patients (HR:2.542, 95% CI:1.048-6.168, P=0.0390).",
        "method": "metakb.method:1",
        "is_reported_in": [
            {
                "id": "civic.source:1416",
                "type": "Document",
                "label": "Endoh et al., 2006, J Thorac Oncol",
                "xrefs": [
                    "pmid:17409929"
                ],
                "title": "PTEN and PIK3CA expression is associated with prolonged survival after gefitinib treatment in EGFR-mutated lung cancer patients."
            }
        ],
        "evidence_level": {
            "id": "vicc:e00005",
            "type": "Coding",
            "label": "clinical cohort evidence"
        },
        "target_proposition": {
            "id": "proposition:wd9JALmQuWP0_xgJwMPOMvYt3VsKvheY",
            "type": "VariationNeoplasmTherapeuticResponseProposition",
            "subject": "ga4gh:VA.rpL2_d2q0gdks_VPk_0JVl90aJG9-bEd",
            "predicate": "predicts_resistance_to",
            "object": {
                "id": "rxcui:328134",
                "type": "Therapeutic"
            },
            "neoplasm_type_qualifier": {
                "id": "ncit:C7377",
                "type": "Disease"
            }
        },
        "direction": "supports",
        "subject_descriptor": "civic.vid:78",
        "neoplasm_type_descriptor": {
            "id": "civic.did:23",
            "type": "DiseaseDescriptor",
            "label": "Lung Cancer",
            "xrefs": [
                "DOID:1324"
            ],
            "disease": "ncit:C7377"
        },
        "object_descriptor": {
            "id": "civic.tid:14",
            "type": "TherapeuticDescriptor",
            "label": "Gefitinib",
            "extensions": [
                {
                    "type": "Extension",
                    "name": "regulatory_approval",
                    "value": {
                        "approval_rating": "FDA",
                        "has_indications": [
                            {
                                "id": "hemonc:642",
                                "type": "DiseaseDescriptor",
                                "label": "Non-small cell lung cancer",
                                "disease": "ncit:C2926"
                            }
                        ]
                    }
                }
            ],
            "xrefs": [
                "ncit:C1855"
            ],
            "alternate_labels": [
                "4-(3'-Chloro-4'-fluoroanilino)-7-methoxy-6-(3-morpholinopropoxy)quinazoline",
                "Iressa",
                "N-(3-chloro-4-fluorophenyl)-7-methoxy-6-[3-(4-morpholin) Propoxy]-4-quinazolinamine",
                "ZD 1839",
                "ZD1839"
            ],
            "therapeutic": "rxcui:328134"
        }
    },
    {
        "id": "civic.eid:2273",
        "type": "VariationNeoplasmTherapeuticResponseStatement",
        "description": "In recurrent lung cancer patients treated with the epidermal growth factor receptor tyrosine kinase inhibitor gefitinib, patients with KRAS mutations had a lower frequency of partial response (PR) and stable disease (SD) and a higher rate of progressive disease (PD) (PR:0, SD:1, PD:15 vs. PR:24, SD:8, PD:14; P=0.0274) compared to wildtype KRAS patients. Patients with KRAS mutations also had a shorter overall survival compared to wildtype KRAS patients (HR:2.542, 95% CI:1.048-6.168, P=0.0390).",
        "method": "metakb.method:1",
        "is_reported_in": [
            {
                "id": "civic.source:1416",
                "type": "Document",
                "label": "Endoh et al., 2006, J Thorac Oncol",
                "xrefs": [
                    "pmid:17409929"
                ],
                "title": "PTEN and PIK3CA expression is associated with prolonged survival after gefitinib treatment in EGFR-mutated lung cancer patients."
            }
        ],
        "evidence_level": {
            "id": "vicc:e00005",
            "type": "Coding",
            "label": "clinical cohort evidence"
        },
        "target_proposition": {
            "id": "proposition:JlKdIPCecc4X3EEzPaLwETdeH3oYHmw-",
            "type": "VariationNeoplasmTherapeuticResponseProposition",
            "subject": "ga4gh:VA.QVdzWvpiRTgBHwV39EuVg6VZVGOLxdUS",
            "predicate": "predicts_resistance_to",
            "object": {
                "id": "rxcui:328134",
                "type": "Therapeutic"
            },
            "neoplasm_type_qualifier": {
                "id": "ncit:C7377",
                "type": "Disease"
            }
        },
        "direction": "supports",
        "subject_descriptor": "civic.vid:913",
        "neoplasm_type_descriptor": {
            "id": "civic.did:23",
            "type": "DiseaseDescriptor",
            "label": "Lung Cancer",
            "xrefs": [
                "DOID:1324"
            ],
            "disease": "ncit:C7377"
        },
        "object_descriptor": {
            "id": "civic.tid:14",
            "type": "TherapeuticDescriptor",
            "label": "Gefitinib",
            "extensions": [
                {
                    "type": "Extension",
                    "name": "regulatory_approval",
                    "value": {
                        "approval_rating": "FDA",
                        "has_indications": [
                            {
                                "id": "hemonc:642",
                                "type": "DiseaseDescriptor",
                                "label": "Non-small cell lung cancer",
                                "disease": "ncit:C2926"
                            }
                        ]
                    }
                }
            ],
            "xrefs": [
                "ncit:C1855"
            ],
            "alternate_labels": [
                "4-(3'-Chloro-4'-fluoroanilino)-7-methoxy-6-(3-morpholinopropoxy)quinazoline",
                "Iressa",
                "N-(3-chloro-4-fluorophenyl)-7-methoxy-6-[3-(4-morpholin) Propoxy]-4-quinazolinamine",
                "ZD 1839",
                "ZD1839"
            ],
            "therapeutic": "rxcui:328134"
        }
    },
    {
        "id": "civic.eid:2159",
        "type": "VariationNeoplasmTherapeuticResponseStatement",
        "description": "In a study of 14 patients with progressive non-small cell lung cancer during gefitinib,  comparison of DNA sequences from the original diagnostic biopsy specimen and the second biopsy specimen demonstrated that 7 patients acquired a new EGFR-T790M mutation.",
        "method": "metakb.method:1",
        "is_reported_in": [
            {
                "id": "civic.source:1524",
                "type": "Document",
                "label": "Kosaka et al., 2006, Clin. Cancer Res.",
                "xrefs": [
                    "pmid:17020982"
                ],
                "title": "Analysis of epidermal growth factor receptor gene mutation in patients with non-small cell lung cancer and acquired resistance to gefitinib."
            }
        ],
        "evidence_level": {
            "id": "vicc:e00008",
            "type": "Coding",
            "label": "case study evidence"
        },
        "target_proposition": {
            "id": "proposition:ubBKghiT5mGCQMsup4qNdWzTBY-OMFzG",
            "type": "VariationNeoplasmTherapeuticResponseProposition",
            "subject": "ga4gh:VA.lvgJx0agONKtOZizHmwQiO3tkZ5UB7YV",
            "predicate": "predicts_resistance_to",
            "object": {
                "id": "rxcui:328134",
                "type": "Therapeutic"
            },
            "neoplasm_type_qualifier": {
                "id": "ncit:C2926",
                "type": "Disease"
            }
        },
        "direction": "supports",
        "subject_descriptor": "civic.vid:34",
        "neoplasm_type_descriptor": {
            "id": "civic.did:8",
            "type": "DiseaseDescriptor",
            "label": "Lung Non-small Cell Carcinoma",
            "xrefs": [
                "DOID:3908"
            ],
            "disease": "ncit:C2926"
        },
        "object_descriptor": {
            "id": "civic.tid:14",
            "type": "TherapeuticDescriptor",
            "label": "Gefitinib",
            "extensions": [
                {
                    "type": "Extension",
                    "name": "regulatory_approval",
                    "value": {
                        "approval_rating": "FDA",
                        "has_indications": [
                            {
                                "id": "hemonc:642",
                                "type": "DiseaseDescriptor",
                                "label": "Non-small cell lung cancer",
                                "disease": "ncit:C2926"
                            }
                        ]
                    }
                }
            ],
            "xrefs": [
                "ncit:C1855"
            ],
            "alternate_labels": [
                "4-(3'-Chloro-4'-fluoroanilino)-7-methoxy-6-(3-morpholinopropoxy)quinazoline",
                "Iressa",
                "N-(3-chloro-4-fluorophenyl)-7-methoxy-6-[3-(4-morpholin) Propoxy]-4-quinazolinamine",
                "ZD 1839",
                "ZD1839"
            ],
            "therapeutic": "rxcui:328134"
        }
    },
    {
        "id": "civic.eid:2232",
        "type": "VariationNeoplasmTherapeuticResponseStatement",
        "description": "In a retrospective study of 427 metastatic colorectal patients, KRAS mutations were observed in 43% of the tumor samples. Patients with mutations in codon 12 or 13 of KRAS were associated with reduced response to panitumumab compared to wildtype KRAS (HR:0.99, 95% CI:0.73-1.36 vs. HR:0.45, 95% CI:0.34-0.59; P<0.0001). Additionally, patients with KRAS mutations showed no significant improvement between treatment with panitumumab and best supportive care alone (PFS: 7.4 wk vs 7.3 wk).",
        "method": "metakb.method:1",
        "is_reported_in": [
            {
                "id": "civic.source:1412",
                "type": "Document",
                "label": "Amado et al., 2008, J. Clin. Oncol.",
                "xrefs": [
                    "pmid:18316791"
                ],
                "title": "Wild-type KRAS is required for panitumumab efficacy in patients with metastatic colorectal cancer."
            }
        ],
        "evidence_level": {
            "id": "vicc:e00008",
            "type": "Coding",
            "label": "case study evidence"
        },
        "target_proposition": {
            "id": "proposition:xTALYouVRGlRIOMLO_Z-_53DLegLgV5C",
            "type": "VariationNeoplasmTherapeuticResponseProposition",
            "subject": "ga4gh:VA.VBKi2jNxAs378IqOBsveoPrYQjWPngQq",
            "predicate": "predicts_resistance_to",
            "object": {
                "id": "rxcui:263034",
                "type": "Therapeutic"
            },
            "neoplasm_type_qualifier": {
                "id": "ncit:C4978",
                "type": "Disease"
            }
        },
        "direction": "supports",
        "subject_descriptor": "civic.vid:425",
        "neoplasm_type_descriptor": {
            "id": "civic.did:11",
            "type": "DiseaseDescriptor",
            "label": "Colorectal Cancer",
            "xrefs": [
                "DOID:9256"
            ],
            "disease": "ncit:C4978"
        },
        "object_descriptor": {
            "id": "civic.tid:28",
            "type": "TherapeuticDescriptor",
            "label": "Panitumumab",
            "extensions": [
                {
                    "type": "Extension",
                    "name": "regulatory_approval",
                    "value": {
                        "approval_rating": "ChEMBL",
                        "has_indications": [
                            {
                                "id": "mesh:D009369",
                                "type": "DiseaseDescriptor",
                                "label": "Neoplasms",
                                "disease": "ncit:C3262"
                            },
                            {
                                "id": "mesh:D015179",
                                "type": "DiseaseDescriptor",
                                "label": "Colorectal Neoplasms",
                                "disease": "ncit:C2956"
                            }
                        ]
                    }
                }
            ],
            "xrefs": [
                "ncit:C1857"
            ],
            "alternate_labels": [
                "ABX-EGF",
                "ABX-EGF Monoclonal Antibody",
                "ABX-EGF, Clone E7.6.3",
                "E7.6.3",
                "Human IgG2K Monoclonal Antibody",
                "MoAb ABX-EGF",
                "MoAb E7.6.3",
                "Monoclonal Antibody ABX-EGF",
                "Monoclonal Antibody E7.6.3",
                "Vectibix"
            ],
            "therapeutic": "rxcui:263034"
        }
    },
    {
        "id": "civic.eid:2236",
        "type": "VariationNeoplasmTherapeuticResponseStatement",
        "description": "In a retrospective study of 427 metastatic colorectal patients, KRAS mutations were observed in 43% of the tumor samples. Patients with mutations in codon 12 or 13 of KRAS were associated with reduced response to panitumumab compared to wildtype KRAS (HR:0.99, 95% CI:0.73-1.36 vs. HR:0.45, 95% CI:0.34-0.59; P<0.0001). Additionally, patients with KRAS mutations showed no significant improvement between treatment with panitumumab and best supportive care alone (PFS: 7.4 wk vs 7.3 wk).",
        "method": "metakb.method:1",
        "is_reported_in": [
            {
                "id": "civic.source:1412",
                "type": "Document",
                "label": "Amado et al., 2008, J. Clin. Oncol.",
                "xrefs": [
                    "pmid:18316791"
                ],
                "title": "Wild-type KRAS is required for panitumumab efficacy in patients with metastatic colorectal cancer."
            }
        ],
        "evidence_level": {
            "id": "vicc:e00008",
            "type": "Coding",
            "label": "case study evidence"
        },
        "target_proposition": {
            "id": "proposition:I3aHgqvm6GcTQHLdR2Z2inCkSEooTm-C",
            "type": "VariationNeoplasmTherapeuticResponseProposition",
            "subject": "ga4gh:VA.jSiuIG2uZEbml8MfCtZi3J9jPBCBiaPw",
            "predicate": "predicts_resistance_to",
            "object": {
                "id": "rxcui:263034",
                "type": "Therapeutic"
            },
            "neoplasm_type_qualifier": {
                "id": "ncit:C4978",
                "type": "Disease"
            }
        },
        "direction": "supports",
        "subject_descriptor": "civic.vid:79",
        "neoplasm_type_descriptor": {
            "id": "civic.did:11",
            "type": "DiseaseDescriptor",
            "label": "Colorectal Cancer",
            "xrefs": [
                "DOID:9256"
            ],
            "disease": "ncit:C4978"
        },
        "object_descriptor": {
            "id": "civic.tid:28",
            "type": "TherapeuticDescriptor",
            "label": "Panitumumab",
            "extensions": [
                {
                    "type": "Extension",
                    "name": "regulatory_approval",
                    "value": {
                        "approval_rating": "ChEMBL",
                        "has_indications": [
                            {
                                "id": "mesh:D009369",
                                "type": "DiseaseDescriptor",
                                "label": "Neoplasms",
                                "disease": "ncit:C3262"
                            },
                            {
                                "id": "mesh:D015179",
                                "type": "DiseaseDescriptor",
                                "label": "Colorectal Neoplasms",
                                "disease": "ncit:C2956"
                            }
                        ]
                    }
                }
            ],
            "xrefs": [
                "ncit:C1857"
            ],
            "alternate_labels": [
                "ABX-EGF",
                "ABX-EGF Monoclonal Antibody",
                "ABX-EGF, Clone E7.6.3",
                "E7.6.3",
                "Human IgG2K Monoclonal Antibody",
                "MoAb ABX-EGF",
                "MoAb E7.6.3",
                "Monoclonal Antibody ABX-EGF",
                "Monoclonal Antibody E7.6.3",
                "Vectibix"
            ],
            "therapeutic": "rxcui:263034"
        }
    },
    {
        "id": "civic.eid:2253",
        "type": "VariationNeoplasmTherapeuticResponseStatement",
        "description": "In a retrospective study of 427 metastatic colorectal patients, KRAS mutations were observed in 43% of the tumor samples. Patients with mutations in codon 12 or 13 of KRAS were associated with reduced response to panitumumab compared to wildtype KRAS (HR:0.99, 95% CI:0.73-1.36 vs. HR:0.45, 95% CI:0.34-0.59; P<0.0001). Additionally, patients with KRAS mutations showed no significant improvement between treatment with panitumumab and best supportive care alone (PFS: 7.4 wk vs 7.3 wk).",
        "method": "metakb.method:1",
        "is_reported_in": [
            {
                "id": "civic.source:1412",
                "type": "Document",
                "label": "Amado et al., 2008, J. Clin. Oncol.",
                "xrefs": [
                    "pmid:18316791"
                ],
                "title": "Wild-type KRAS is required for panitumumab efficacy in patients with metastatic colorectal cancer."
            }
        ],
        "evidence_level": {
            "id": "vicc:e00008",
            "type": "Coding",
            "label": "case study evidence"
        },
        "target_proposition": {
            "id": "proposition:VucLsGxegHDayF4LgNO1NkdtSAxP4rAF",
            "type": "VariationNeoplasmTherapeuticResponseProposition",
            "subject": "ga4gh:VA.rpL2_d2q0gdks_VPk_0JVl90aJG9-bEd",
            "predicate": "predicts_resistance_to",
            "object": {
                "id": "rxcui:263034",
                "type": "Therapeutic"
            },
            "neoplasm_type_qualifier": {
                "id": "ncit:C4978",
                "type": "Disease"
            }
        },
        "direction": "supports",
        "subject_descriptor": "civic.vid:78",
        "neoplasm_type_descriptor": {
            "id": "civic.did:11",
            "type": "DiseaseDescriptor",
            "label": "Colorectal Cancer",
            "xrefs": [
                "DOID:9256"
            ],
            "disease": "ncit:C4978"
        },
        "object_descriptor": {
            "id": "civic.tid:28",
            "type": "TherapeuticDescriptor",
            "label": "Panitumumab",
            "extensions": [
                {
                    "type": "Extension",
                    "name": "regulatory_approval",
                    "value": {
                        "approval_rating": "ChEMBL",
                        "has_indications": [
                            {
                                "id": "mesh:D009369",
                                "type": "DiseaseDescriptor",
                                "label": "Neoplasms",
                                "disease": "ncit:C3262"
                            },
                            {
                                "id": "mesh:D015179",
                                "type": "DiseaseDescriptor",
                                "label": "Colorectal Neoplasms",
                                "disease": "ncit:C2956"
                            }
                        ]
                    }
                }
            ],
            "xrefs": [
                "ncit:C1857"
            ],
            "alternate_labels": [
                "ABX-EGF",
                "ABX-EGF Monoclonal Antibody",
                "ABX-EGF, Clone E7.6.3",
                "E7.6.3",
                "Human IgG2K Monoclonal Antibody",
                "MoAb ABX-EGF",
                "MoAb E7.6.3",
                "Monoclonal Antibody ABX-EGF",
                "Monoclonal Antibody E7.6.3",
                "Vectibix"
            ],
            "therapeutic": "rxcui:263034"
        }
    },
    {
        "id": "civic.eid:2264",
        "type": "VariationNeoplasmTherapeuticResponseStatement",
        "description": "In a retrospective study of 427 metastatic colorectal patients, KRAS mutations were observed in 43% of the tumor samples. Patients with mutations in codon 12 or 13 of KRAS were associated with reduced response to panitumumab compared to wildtype KRAS (HR:0.99, 95% CI:0.73-1.36 vs. HR:0.45, 95% CI:0.34-0.59; P<0.0001). Additionally, patients with KRAS mutations showed no significant improvement between treatment with panitumumab and best supportive care alone (PFS: 7.4 wk vs 7.3 wk).",
        "method": "metakb.method:1",
        "is_reported_in": [
            {
                "id": "civic.source:1412",
                "type": "Document",
                "label": "Amado et al., 2008, J. Clin. Oncol.",
                "xrefs": [
                    "pmid:18316791"
                ],
                "title": "Wild-type KRAS is required for panitumumab efficacy in patients with metastatic colorectal cancer."
            }
        ],
        "evidence_level": {
            "id": "vicc:e00008",
            "type": "Coding",
            "label": "case study evidence"
        },
        "target_proposition": {
            "id": "proposition:3oWMCbd4O3Y7pcH-ZokoRgQd47iXgLbX",
            "type": "VariationNeoplasmTherapeuticResponseProposition",
            "subject": "ga4gh:VA._AIonI6Sp_E7tTUN81jJbNG3tERDCkVk",
            "predicate": "predicts_resistance_to",
            "object": {
                "id": "rxcui:263034",
                "type": "Therapeutic"
            },
            "neoplasm_type_qualifier": {
                "id": "ncit:C4978",
                "type": "Disease"
            }
        },
        "direction": "supports",
        "subject_descriptor": "civic.vid:530",
        "neoplasm_type_descriptor": {
            "id": "civic.did:11",
            "type": "DiseaseDescriptor",
            "label": "Colorectal Cancer",
            "xrefs": [
                "DOID:9256"
            ],
            "disease": "ncit:C4978"
        },
        "object_descriptor": {
            "id": "civic.tid:28",
            "type": "TherapeuticDescriptor",
            "label": "Panitumumab",
            "extensions": [
                {
                    "type": "Extension",
                    "name": "regulatory_approval",
                    "value": {
                        "approval_rating": "ChEMBL",
                        "has_indications": [
                            {
                                "id": "mesh:D009369",
                                "type": "DiseaseDescriptor",
                                "label": "Neoplasms",
                                "disease": "ncit:C3262"
                            },
                            {
                                "id": "mesh:D015179",
                                "type": "DiseaseDescriptor",
                                "label": "Colorectal Neoplasms",
                                "disease": "ncit:C2956"
                            }
                        ]
                    }
                }
            ],
            "xrefs": [
                "ncit:C1857"
            ],
            "alternate_labels": [
                "ABX-EGF",
                "ABX-EGF Monoclonal Antibody",
                "ABX-EGF, Clone E7.6.3",
                "E7.6.3",
                "Human IgG2K Monoclonal Antibody",
                "MoAb ABX-EGF",
                "MoAb E7.6.3",
                "Monoclonal Antibody ABX-EGF",
                "Monoclonal Antibody E7.6.3",
                "Vectibix"
            ],
            "therapeutic": "rxcui:263034"
        }
    },
    {
        "id": "civic.eid:2269",
        "type": "VariationNeoplasmTherapeuticResponseStatement",
        "description": "In a retrospective study of 427 metastatic colorectal patients, KRAS mutations were observed in 43% of the tumor samples. Patients with mutations in codon 12 or 13 of KRAS were associated with reduced response to panitumumab compared to wildtype KRAS (HR:0.99, 95% CI:0.73-1.36 vs. HR:0.45, 95% CI:0.34-0.59; P<0.0001). Additionally, patients with KRAS mutations showed no significant improvement between treatment with panitumumab and best supportive care alone (PFS: 7.4 wk vs 7.3 wk).",
        "method": "metakb.method:1",
        "is_reported_in": [
            {
                "id": "civic.source:1412",
                "type": "Document",
                "label": "Amado et al., 2008, J. Clin. Oncol.",
                "xrefs": [
                    "pmid:18316791"
                ],
                "title": "Wild-type KRAS is required for panitumumab efficacy in patients with metastatic colorectal cancer."
            }
        ],
        "evidence_level": {
            "id": "vicc:e00008",
            "type": "Coding",
            "label": "case study evidence"
        },
        "target_proposition": {
            "id": "proposition:iQA8YjyfGY0-bu-OCXWl6xouT0UO19rK",
            "type": "VariationNeoplasmTherapeuticResponseProposition",
            "subject": "ga4gh:VA.QVdzWvpiRTgBHwV39EuVg6VZVGOLxdUS",
            "predicate": "predicts_resistance_to",
            "object": {
                "id": "rxcui:263034",
                "type": "Therapeutic"
            },
            "neoplasm_type_qualifier": {
                "id": "ncit:C4978",
                "type": "Disease"
            }
        },
        "direction": "supports",
        "subject_descriptor": "civic.vid:913",
        "neoplasm_type_descriptor": {
            "id": "civic.did:11",
            "type": "DiseaseDescriptor",
            "label": "Colorectal Cancer",
            "xrefs": [
                "DOID:9256"
            ],
            "disease": "ncit:C4978"
        },
        "object_descriptor": {
            "id": "civic.tid:28",
            "type": "TherapeuticDescriptor",
            "label": "Panitumumab",
            "extensions": [
                {
                    "type": "Extension",
                    "name": "regulatory_approval",
                    "value": {
                        "approval_rating": "ChEMBL",
                        "has_indications": [
                            {
                                "id": "mesh:D009369",
                                "type": "DiseaseDescriptor",
                                "label": "Neoplasms",
                                "disease": "ncit:C3262"
                            },
                            {
                                "id": "mesh:D015179",
                                "type": "DiseaseDescriptor",
                                "label": "Colorectal Neoplasms",
                                "disease": "ncit:C2956"
                            }
                        ]
                    }
                }
            ],
            "xrefs": [
                "ncit:C1857"
            ],
            "alternate_labels": [
                "ABX-EGF",
                "ABX-EGF Monoclonal Antibody",
                "ABX-EGF, Clone E7.6.3",
                "E7.6.3",
                "Human IgG2K Monoclonal Antibody",
                "MoAb ABX-EGF",
                "MoAb E7.6.3",
                "Monoclonal Antibody ABX-EGF",
                "Monoclonal Antibody E7.6.3",
                "Vectibix"
            ],
            "therapeutic": "rxcui:263034"
        }
    },
    {
        "id": "civic.eid:3851",
        "type": "VariationNeoplasmTherapeuticResponseStatement",
        "description": "In a retrospective study of 23 patients with BRAF V600 mutation (a known vemurafenib sensitizing mutation) that developed cutaneous squamous-cell carcinoma upon treatment with vemurafenib monotherapy, a patient harboring HRAS G13D co-mutation (n=1) was reported to be resistant to vemurafenib treatment.",
        "method": "metakb.method:1",
        "is_reported_in": [
            {
                "id": "civic.source:1924",
                "type": "Document",
                "label": "Su et al., 2012, N. Engl. J. Med.",
                "xrefs": [
                    "pmc:PMC3724537",
                    "pmid:22256804"
                ],
                "title": "RAS mutations in cutaneous squamous-cell carcinomas in patients treated with BRAF inhibitors."
            }
        ],
        "evidence_level": {
            "id": "vicc:e00008",
            "type": "Coding",
            "label": "case study evidence"
        },
        "target_proposition": {
            "id": "proposition:zAqZlmlqHmJZ6cu6GP2gFIjwi_N7eU64",
            "type": "VariationNeoplasmTherapeuticResponseProposition",
            "subject": "ga4gh:VA.Z1VxpmB2Ui54Nd4GCsBXMjb2WDaCU7Ja",
            "predicate": "predicts_resistance_to",
            "object": {
                "id": "rxcui:1147220",
                "type": "Therapeutic"
            },
            "neoplasm_type_qualifier": {
                "id": "ncit:C4819",
                "type": "Disease"
            }
        },
        "direction": "supports",
        "subject_descriptor": "civic.vid:274",
        "neoplasm_type_descriptor": {
            "id": "civic.did:130",
            "type": "DiseaseDescriptor",
            "label": "Skin Squamous Cell Carcinoma",
            "xrefs": [
                "DOID:3151"
            ],
            "disease": "ncit:C4819"
        },
        "object_descriptor": {
            "id": "civic.tid:4",
            "type": "TherapeuticDescriptor",
            "label": "Vemurafenib",
            "extensions": [
                {
                    "type": "Extension",
                    "name": "regulatory_approval",
                    "value": {
                        "approval_rating": "FDA",
                        "has_indications": [
                            {
                                "id": "hemonc:629",
                                "type": "DiseaseDescriptor",
                                "label": "Melanoma",
                                "disease": "ncit:C3224"
                            },
                            {
                                "id": "hemonc:594",
                                "type": "DiseaseDescriptor",
                                "label": "Erdheim-Chester disease",
                                "disease": "ncit:C53972"
                            }
                        ]
                    }
                }
            ],
            "xrefs": [
                "ncit:C64768"
            ],
            "alternate_labels": [
                "1-propanesulfonamide, N-(3-((5-(4-chlorophenyl)-1h-pyrrolo(2,3-b)pyridin-3-yl)carbonyl)-2,4-difluorophenyl)-",
                "BRAF (V600E) Kinase Inhibitor RO5185426",
                "BRAF(V600E) Kinase Inhibitor RO5185426",
                "PLX-4032",
                "PLX4032",
                "RG 7204",
                "RG7204",
                "RO 5185426",
                "Zelboraf"
            ],
            "therapeutic": "rxcui:1147220"
        }
    },
    {
        "id": "civic.eid:3862",
        "type": "VariationNeoplasmTherapeuticResponseStatement",
        "description": "In a colorectal cancer patient with a KRAS Q61H mutation, KRAS Q61H was reported to be refractory to cetuximab treatment. The patient was treated with cetuximab and irinotecan for 18 months, had a partial response to therapy and then experienced progressive disease with a re-biopsy of the tumor identifying a KRAS Q61H mutation.",
        "method": "metakb.method:1",
        "is_reported_in": [
            {
                "id": "civic.source:2008",
                "type": "Document",
                "label": "Misale et al., 2012, Nature",
                "xrefs": [
                    "pmc:PMC3927413",
                    "pmid:22722830"
                ],
                "title": "Emergence of KRAS mutations and acquired resistance to anti-EGFR therapy in colorectal cancer."
            }
        ],
        "evidence_level": {
            "id": "vicc:e00008",
            "type": "Coding",
            "label": "case study evidence"
        },
        "target_proposition": {
            "id": "proposition:1yWKPSBahwElWmJvwd0pVW6T6ROCFha4",
            "type": "VariationNeoplasmTherapeuticResponseProposition",
            "subject": "ga4gh:VA.tLDWoYXQHs6bKtABt0_xJU86pLjjCdgX",
            "predicate": "predicts_resistance_to",
            "object": {
                "id": "rxcui:318341",
                "type": "Therapeutic"
            },
            "neoplasm_type_qualifier": {
                "id": "ncit:C4978",
                "type": "Disease"
            }
        },
        "direction": "supports",
        "subject_descriptor": "civic.vid:907",
        "neoplasm_type_descriptor": {
            "id": "civic.did:11",
            "type": "DiseaseDescriptor",
            "label": "Colorectal Cancer",
            "xrefs": [
                "DOID:9256"
            ],
            "disease": "ncit:C4978"
        },
        "object_descriptor": {
            "id": "civic.tid:16",
            "type": "TherapeuticDescriptor",
            "label": "Cetuximab",
            "extensions": [
                {
                    "type": "Extension",
                    "name": "regulatory_approval",
                    "value": {
                        "approval_rating": "ChEMBL",
                        "has_indications": [
                            {
                                "id": "mesh:D002294",
                                "type": "DiseaseDescriptor",
                                "label": "Carcinoma, Squamous Cell",
                                "disease": "ncit:C2929"
                            },
                            {
                                "id": "mesh:D009369",
                                "type": "DiseaseDescriptor",
                                "label": "Neoplasms",
                                "disease": "ncit:C3262"
                            },
                            {
                                "id": "mesh:D015179",
                                "type": "DiseaseDescriptor",
                                "label": "Colorectal Neoplasms",
                                "disease": "ncit:C2956"
                            },
                            {
                                "id": "mesh:D006258",
                                "type": "DiseaseDescriptor",
                                "label": "Head and Neck Neoplasms",
                                "disease": "ncit:C4013"
                            }
                        ]
                    }
                }
            ],
            "xrefs": [
                "ncit:C1723"
            ],
            "alternate_labels": [
                "Cetuximab Biosimilar CDP-1",
                "Cetuximab Biosimilar CMAB009",
                "Cetuximab Biosimilar KL 140",
                "Chimeric Anti-EGFR Monoclonal Antibody",
                "Chimeric MoAb C225",
                "Chimeric Monoclonal Antibody C225",
                "Erbitux",
                "IMC-C225"
            ],
            "therapeutic": "rxcui:318341"
        }
    },
    {
        "id": "civic.eid:4273",
        "type": "VariationNeoplasmTherapeuticResponseStatement",
        "description": "In stage IV lung adenocarcinoma patients (n=2) harboring EGFR S768I mutation, EGFR S768I was associated with progressive disease after 1 month of erlotinib monotherapy; the patient was previously treated with standard chemotherapy.",
        "method": "metakb.method:1",
        "is_reported_in": [
            {
                "id": "civic.source:2079",
                "type": "Document",
                "label": "Lund-Iversen et al., 2012, J Thorac Oncol",
                "xrefs": [
                    "pmid:22895145"
                ],
                "title": "Clinicopathological characteristics of 11 NSCLC patients with EGFR-exon 20 mutations."
            }
        ],
        "evidence_level": {
            "id": "vicc:e00008",
            "type": "Coding",
            "label": "case study evidence"
        },
        "target_proposition": {
            "id": "proposition:2dL3r0uETV52mLhqtEoUb1OnIv78WZvH",
            "type": "VariationNeoplasmTherapeuticResponseProposition",
            "subject": "ga4gh:VA.2TmSETRJQzrU-OXco267vKiGgGY4qCLK",
            "predicate": "predicts_resistance_to",
            "object": {
                "id": "rxcui:337525",
                "type": "Therapeutic"
            },
            "neoplasm_type_qualifier": {
                "id": "ncit:C3512",
                "type": "Disease"
            }
        },
        "direction": "supports",
        "subject_descriptor": "civic.vid:562",
        "neoplasm_type_descriptor": {
            "id": "civic.did:30",
            "type": "DiseaseDescriptor",
            "label": "Lung Adenocarcinoma",
            "xrefs": [
                "DOID:3910"
            ],
            "disease": "ncit:C3512"
        },
        "object_descriptor": {
            "id": "civic.tid:15",
            "type": "TherapeuticDescriptor",
            "label": "Erlotinib",
            "extensions": [
                {
                    "type": "Extension",
                    "name": "regulatory_approval",
                    "value": {
                        "approval_rating": "FDA",
                        "has_indications": [
                            {
                                "id": "hemonc:642",
                                "type": "DiseaseDescriptor",
                                "label": "Non-small cell lung cancer",
                                "disease": "ncit:C2926"
                            },
                            {
                                "id": "hemonc:648",
                                "type": "DiseaseDescriptor",
                                "label": "Pancreatic cancer",
                                "disease": "ncit:C43298"
                            }
                        ]
                    }
                }
            ],
            "xrefs": [
                "ncit:C65530"
            ],
            "therapeutic": "rxcui:337525"
        }
    },
    {
        "id": "civic.eid:4643",
        "type": "VariationNeoplasmTherapeuticResponseStatement",
        "description": "In a lung adenocarcinoma patient harboring EGFR D770_N771insGT mutation, EGFR D770_N771insGT was associated with lack of response to treatment with erlotinib monotherapy.",
        "method": "metakb.method:1",
        "is_reported_in": [
            {
                "id": "civic.source:2116",
                "type": "Document",
                "label": "Arcila et al., 2013, Mol. Cancer Ther.",
                "xrefs": [
                    "pmc:PMC3714231",
                    "pmid:23371856"
                ],
                "title": "EGFR exon 20 insertion mutations in lung adenocarcinomas: prevalence, molecular heterogeneity, and clinicopathologic characteristics."
            }
        ],
        "evidence_level": {
            "id": "vicc:e00008",
            "type": "Coding",
            "label": "case study evidence"
        },
        "target_proposition": {
            "id": "proposition:Cn2JdNHiv-Zi07qYy4rdKm6rPwhJ-wBU",
            "type": "VariationNeoplasmTherapeuticResponseProposition",
            "subject": "ga4gh:VA.p8Y2dQ5nBfPI0l2GzPViuwrBnVv7jPO1",
            "predicate": "predicts_resistance_to",
            "object": {
                "id": "rxcui:337525",
                "type": "Therapeutic"
            },
            "neoplasm_type_qualifier": {
                "id": "ncit:C3512",
                "type": "Disease"
            }
        },
        "direction": "supports",
        "subject_descriptor": "civic.vid:1566",
        "neoplasm_type_descriptor": {
            "id": "civic.did:30",
            "type": "DiseaseDescriptor",
            "label": "Lung Adenocarcinoma",
            "xrefs": [
                "DOID:3910"
            ],
            "disease": "ncit:C3512"
        },
        "object_descriptor": {
            "id": "civic.tid:15",
            "type": "TherapeuticDescriptor",
            "label": "Erlotinib",
            "extensions": [
                {
                    "type": "Extension",
                    "name": "regulatory_approval",
                    "value": {
                        "approval_rating": "FDA",
                        "has_indications": [
                            {
                                "id": "hemonc:642",
                                "type": "DiseaseDescriptor",
                                "label": "Non-small cell lung cancer",
                                "disease": "ncit:C2926"
                            },
                            {
                                "id": "hemonc:648",
                                "type": "DiseaseDescriptor",
                                "label": "Pancreatic cancer",
                                "disease": "ncit:C43298"
                            }
                        ]
                    }
                }
            ],
            "xrefs": [
                "ncit:C65530"
            ],
            "therapeutic": "rxcui:337525"
        }
    },
    {
        "id": "civic.eid:4654",
        "type": "VariationNeoplasmTherapeuticResponseStatement",
        "description": "An Arab basal cell carcinoma patient harboring SMO L412F mutation was associated with response to vismodegib monotherapy. Prior to the identification of the mutation, the patient was treated with acitretin, but did not achieve any response.",
        "method": "metakb.method:1",
        "is_reported_in": [
            {
                "id": "civic.source:2117",
                "type": "Document",
                "label": "Khamaysi et al., 2016, Br. J. Dermatol.",
                "xrefs": [
                    "pmid:26822128"
                ],
                "title": "Segmental basal cell naevus syndrome caused by an activating mutation in smoothened."
            }
        ],
        "evidence_level": {
            "id": "vicc:e00008",
            "type": "Coding",
            "label": "case study evidence"
        },
        "target_proposition": {
            "id": "proposition:h9ZSDTDg9jNJDXIzMlKZUPlbeN0EIxaG",
            "type": "VariationNeoplasmTherapeuticResponseProposition",
            "subject": "ga4gh:VA.8f8ZfbLyMJvGCXConL8k3JWsKG430vJp",
            "predicate": "predicts_resistance_to",
            "object": {
                "id": "rxcui:1242987",
                "type": "Therapeutic"
            },
            "neoplasm_type_qualifier": {
                "id": "ncit:C2921",
                "type": "Disease"
            }
        },
        "direction": "supports",
        "subject_descriptor": "civic.vid:1570",
        "neoplasm_type_descriptor": {
            "id": "civic.did:314",
            "type": "DiseaseDescriptor",
            "label": "Basal Cell Carcinoma",
            "xrefs": [
                "DOID:2513"
            ],
            "disease": "ncit:C2921"
        },
        "object_descriptor": {
            "id": "civic.tid:190",
            "type": "TherapeuticDescriptor",
            "label": "Vismodegib",
            "extensions": [
                {
                    "type": "Extension",
                    "name": "regulatory_approval",
                    "value": {
                        "approval_rating": "FDA",
                        "has_indications": [
                            {
                                "id": "hemonc:587",
                                "type": "DiseaseDescriptor",
                                "label": "Cutaneous basal cell carcinoma",
                                "disease": null
                            }
                        ]
                    }
                }
            ],
            "xrefs": [
                "ncit:C74038"
            ],
            "alternate_labels": [
                "2-chloro-N-[4-chloro-3-(pyridin-2-yl)phenyl]-4-(methylsulfonyl)benzamide",
                "Erivedge",
                "GDC-0449",
                "Hedgehog Antagonist GDC-0449"
            ],
            "therapeutic": "rxcui:1242987"
        }
    },
    {
        "id": "civic.eid:1110",
        "type": "VariationNeoplasmTherapeuticResponseStatement",
        "description": "The pretreatment tumor contained a somatic nonsense mutation (Q1178*) in the tumor-suppressor gene TSC2 that inactivates the gene, allowing for activation of the mTOR pathway and resulting in sensitivity to mTOR inhibition by everolimus. The patient received a sustained response to everolimus for 18 months, after which time resistance developed. The resistant tumor had a somatic mutation in MTOR (F2108L), that was not detected in the pretreatment tumor.",
        "method": "metakb.method:1",
        "is_reported_in": [
            {
                "id": "civic.source:372",
                "type": "Document",
                "label": "Wagle et al., 2014, N. Engl. J. Med.",
                "xrefs": [
                    "pmc:PMC4564868",
                    "pmid:25295501"
                ],
                "title": "Response and acquired resistance to everolimus in anaplastic thyroid cancer."
            }
        ],
        "evidence_level": {
            "id": "vicc:e00008",
            "type": "Coding",
            "label": "case study evidence"
        },
        "target_proposition": {
            "id": "proposition:Wibt9Z1e2xJfokJ7b5d1U9XPhMeDwYcm",
            "type": "VariationNeoplasmTherapeuticResponseProposition",
            "subject": "ga4gh:VA.mWN-AFixmkqHVuKjA0fLe3k2r13MWdhF",
            "predicate": "predicts_resistance_to",
            "object": {
                "id": "rxcui:141704",
                "type": "Therapeutic"
            },
            "neoplasm_type_qualifier": {
                "id": "ncit:C4815",
                "type": "Disease"
            }
        },
        "direction": "supports",
        "subject_descriptor": "civic.vid:470",
        "neoplasm_type_descriptor": {
            "id": "civic.did:155",
            "type": "DiseaseDescriptor",
            "label": "Thyroid Gland Carcinoma",
            "xrefs": [
                "DOID:3963"
            ],
            "disease": "ncit:C4815"
        },
        "object_descriptor": {
            "id": "civic.tid:41",
            "type": "TherapeuticDescriptor",
            "label": "Everolimus",
            "extensions": [
                {
                    "type": "Extension",
                    "name": "regulatory_approval",
                    "value": {
                        "approval_rating": "FDA",
                        "has_indications": [
                            {
                                "id": "hemonc:45070",
                                "type": "DiseaseDescriptor",
                                "label": "Subependymal giant cell astrocytoma",
                                "disease": "ncit:C3696"
                            },
                            {
                                "id": "hemonc:572",
                                "type": "DiseaseDescriptor",
                                "label": "Breast cancer",
                                "disease": "ncit:C9335"
                            },
                            {
                                "id": "hemonc:647",
                                "type": "DiseaseDescriptor",
                                "label": "Pancreatic NET",
                                "disease": "ncit:C27720"
                            },
                            {
                                "id": "hemonc:641",
                                "type": "DiseaseDescriptor",
                                "label": "Neuroendocrine tumor",
                                "disease": "ncit:C3809"
                            },
                            {
                                "id": "hemonc:660",
                                "type": "DiseaseDescriptor",
                                "label": "Renal cell carcinoma",
                                "disease": "ncit:C9385"
                            }
                        ]
                    }
                }
            ],
            "xrefs": [
                "ncit:C48387"
            ],
            "alternate_labels": [
                "(1R,9S,12S,15R,16E,18R,19R,21R,23S,24E,26E,28E,30S,32S,35R)-1,18-Dihydroxy-12-((1R)-2-((1S,3R,4R)-4-(2-hydroxyethoxy)-3-methoxycyclohexyl)-1-methylethyl)-19,30-dimethoxy-15,17,21,23,29,35-hexamethyl-11,36-dioxa-4-azatricyclo(30.3.1.04,9)hexatriaconta-16,24,26,28-tetraene-2,3,10,14,20-pentaone",
                "42-O-(2-Hydroxy)ethyl Rapamycin",
                "Afinitor",
                "Certican",
                "RAD 001",
                "RAD001",
                "Votubia",
                "Zortress"
            ],
            "therapeutic": "rxcui:141704"
        }
    },
    {
        "id": "civic.eid:717",
        "type": "VariationNeoplasmTherapeuticResponseStatement",
        "description": "In-vitro studies found this mutation to confer resistance to cetuximab. 2 of 10 patients studied also harbored EGFR S492R and were resistant to cetuximab therapy. Panitumumab was still active in-vitro and in one patient.",
        "method": "metakb.method:1",
        "is_reported_in": [
            {
                "id": "civic.source:472",
                "type": "Document",
                "label": "Montagut et al., 2012, Nat. Med.",
                "xrefs": [
                    "pmid:22270724"
                ],
                "title": "Identification of a mutation in the extracellular domain of the Epidermal Growth Factor Receptor conferring cetuximab resistance in colorectal cancer."
            }
        ],
        "evidence_level": {
            "id": "vicc:e00008",
            "type": "Coding",
            "label": "case study evidence"
        },
        "target_proposition": {
            "id": "proposition:If7Ryn_0-J-IXHcI7vcuv1sEnZ21XDOv",
            "type": "VariationNeoplasmTherapeuticResponseProposition",
            "subject": "ga4gh:VA.VDg4To7ePAbIjjPfop3VmeFbcUpvgsf5",
            "predicate": "predicts_resistance_to",
            "object": {
                "id": "rxcui:318341",
                "type": "Therapeutic"
            },
            "neoplasm_type_qualifier": {
                "id": "ncit:C4978",
                "type": "Disease"
            }
        },
        "direction": "supports",
        "subject_descriptor": "civic.vid:453",
        "neoplasm_type_descriptor": {
            "id": "civic.did:11",
            "type": "DiseaseDescriptor",
            "label": "Colorectal Cancer",
            "xrefs": [
                "DOID:9256"
            ],
            "disease": "ncit:C4978"
        },
        "object_descriptor": {
            "id": "civic.tid:16",
            "type": "TherapeuticDescriptor",
            "label": "Cetuximab",
            "extensions": [
                {
                    "type": "Extension",
                    "name": "regulatory_approval",
                    "value": {
                        "approval_rating": "ChEMBL",
                        "has_indications": [
                            {
                                "id": "mesh:D002294",
                                "type": "DiseaseDescriptor",
                                "label": "Carcinoma, Squamous Cell",
                                "disease": "ncit:C2929"
                            },
                            {
                                "id": "mesh:D009369",
                                "type": "DiseaseDescriptor",
                                "label": "Neoplasms",
                                "disease": "ncit:C3262"
                            },
                            {
                                "id": "mesh:D015179",
                                "type": "DiseaseDescriptor",
                                "label": "Colorectal Neoplasms",
                                "disease": "ncit:C2956"
                            },
                            {
                                "id": "mesh:D006258",
                                "type": "DiseaseDescriptor",
                                "label": "Head and Neck Neoplasms",
                                "disease": "ncit:C4013"
                            }
                        ]
                    }
                }
            ],
            "xrefs": [
                "ncit:C1723"
            ],
            "alternate_labels": [
                "Cetuximab Biosimilar CDP-1",
                "Cetuximab Biosimilar CMAB009",
                "Cetuximab Biosimilar KL 140",
                "Chimeric Anti-EGFR Monoclonal Antibody",
                "Chimeric MoAb C225",
                "Chimeric Monoclonal Antibody C225",
                "Erbitux",
                "IMC-C225"
            ],
            "therapeutic": "rxcui:318341"
        }
    },
    {
        "id": "civic.eid:1567",
        "type": "VariationNeoplasmTherapeuticResponseStatement",
        "description": "Paired tumor samples were analyzed from four patients with metastatic melanoma and initial response with a subsequent relapse under pembrolizumab (PD-1 checkpoint inhibitor) therapy. Baseline biopsies were obtained before therapy initiation with pembrolizumab (before prior vemurafenib treatment in patient 1).\nA JAK1 Q503* mutation was observed at the time of relapse in patient 1. This mutation was one of 3 new homozygous mutations in this patient (53 new mutations total) and the tumor was described to be genetically similar to the pre-treatment tumor. CRIPR-Cas9 mediated modelling of the JAK1 mutation in a melanoma cell line led to a loss of response to interferon alpha, beta and gamma.",
        "method": "metakb.method:1",
        "is_reported_in": [
            {
                "id": "civic.source:1036",
                "type": "Document",
                "label": "Zaretsky et al., 2016, N. Engl. J. Med.",
                "xrefs": [
                    "pmid:27433843"
                ],
                "title": "Mutations Associated with Acquired Resistance to PD-1 Blockade in Melanoma."
            }
        ],
        "evidence_level": {
            "id": "vicc:e00008",
            "type": "Coding",
            "label": "case study evidence"
        },
        "target_proposition": {
            "id": "proposition:sIdoMs5TCwEAskNfJbQb8x3JZ9J6MaG9",
            "type": "VariationNeoplasmTherapeuticResponseProposition",
            "subject": "ga4gh:VA.gD8UzOyMtXmMKb7c5EEWhUeh73s4bS-3",
            "predicate": "predicts_resistance_to",
            "object": {
                "id": "rxcui:1547545",
                "type": "Therapeutic"
            },
            "neoplasm_type_qualifier": {
                "id": "ncit:C3510",
                "type": "Disease"
            }
        },
        "direction": "supports",
        "subject_descriptor": "civic.vid:614",
        "neoplasm_type_descriptor": {
            "id": "civic.did:206",
            "type": "DiseaseDescriptor",
            "label": "Skin Melanoma",
            "xrefs": [
                "DOID:8923"
            ],
            "disease": "ncit:C3510"
        },
        "object_descriptor": {
            "id": "civic.tid:138",
            "type": "TherapeuticDescriptor",
            "label": "Pembrolizumab",
            "extensions": [
                {
                    "type": "Extension",
                    "name": "regulatory_approval",
                    "value": {
                        "approval_rating": "ChEMBL",
                        "has_indications": [
                            {
                                "id": "mesh:D008545",
                                "type": "DiseaseDescriptor",
                                "label": "Melanoma",
                                "disease": "ncit:C3224"
                            },
                            {
                                "id": "mesh:D009369",
                                "type": "DiseaseDescriptor",
                                "label": "Neoplasms",
                                "disease": "ncit:C3262"
                            }
                        ]
                    }
                }
            ],
            "xrefs": [
                "ncit:C106432"
            ],
            "alternate_labels": [
                "Immunoglobulin G4, Anti-(Human Programmed Cell Death 1); Humanized Mouse Monoclonal (228-L-proline(H10-S>P))gamma 4 Heavy Chain (134-218')-disulfide With Humanized Mouse Monoclonal Kappa Light Chain Dimer (226-226'':229-229'')-bisdisulfide",
                "Keytruda",
                "Lambrolizumab",
                "MK-3475",
                "SCH 900475"
            ],
            "therapeutic": "rxcui:1547545"
        }
    },
    {
        "id": "civic.eid:1602",
        "type": "VariationNeoplasmTherapeuticResponseStatement",
        "description": "A patient with BRAF-mutant melanoma relapsed after treatment with PLX4032 (vemurafenib). The MAP2K1 C121S mutation was identified as a relapse-specific variant and was undetectable in the pre-treatment tumor. In vitro experiments showed that the C121S mutation increased kinase activity and conferred resistance to PLX4032.",
        "method": "metakb.method:1",
        "is_reported_in": [
            {
                "id": "civic.source:1062",
                "type": "Document",
                "label": "Wagle et al., 2011, J. Clin. Oncol.",
                "xrefs": [
                    "pmc:PMC3157968",
                    "pmid:21383288"
                ],
                "title": "Dissecting therapeutic resistance to RAF inhibition in melanoma by tumor genomic profiling."
            }
        ],
        "evidence_level": {
            "id": "vicc:e00008",
            "type": "Coding",
            "label": "case study evidence"
        },
        "target_proposition": {
            "id": "proposition:a0Te09vtxFhjZyPzoNvzjxKgOzajrZa2",
            "type": "VariationNeoplasmTherapeuticResponseProposition",
            "subject": "ga4gh:VA.UzMvDxAVEEQbq31meAbiBkIvleY7w-ke",
            "predicate": "predicts_resistance_to",
            "object": {
                "id": "rxcui:1147220",
                "type": "Therapeutic"
            },
            "neoplasm_type_qualifier": {
                "id": "ncit:C3224",
                "type": "Disease"
            }
        },
        "direction": "supports",
        "subject_descriptor": "civic.vid:627",
        "neoplasm_type_descriptor": {
            "id": "civic.did:7",
            "type": "DiseaseDescriptor",
            "label": "Melanoma",
            "xrefs": [
                "DOID:1909"
            ],
            "disease": "ncit:C3224"
        },
        "object_descriptor": {
            "id": "civic.tid:4",
            "type": "TherapeuticDescriptor",
            "label": "Vemurafenib",
            "extensions": [
                {
                    "type": "Extension",
                    "name": "regulatory_approval",
                    "value": {
                        "approval_rating": "FDA",
                        "has_indications": [
                            {
                                "id": "hemonc:629",
                                "type": "DiseaseDescriptor",
                                "label": "Melanoma",
                                "disease": "ncit:C3224"
                            },
                            {
                                "id": "hemonc:594",
                                "type": "DiseaseDescriptor",
                                "label": "Erdheim-Chester disease",
                                "disease": "ncit:C53972"
                            }
                        ]
                    }
                }
            ],
            "xrefs": [
                "ncit:C64768"
            ],
            "alternate_labels": [
                "1-propanesulfonamide, N-(3-((5-(4-chlorophenyl)-1h-pyrrolo(2,3-b)pyridin-3-yl)carbonyl)-2,4-difluorophenyl)-",
                "BRAF (V600E) Kinase Inhibitor RO5185426",
                "BRAF(V600E) Kinase Inhibitor RO5185426",
                "PLX-4032",
                "PLX4032",
                "RG 7204",
                "RG7204",
                "RO 5185426",
                "Zelboraf"
            ],
            "therapeutic": "rxcui:1147220"
        }
    },
    {
        "id": "civic.eid:1865",
        "type": "VariationNeoplasmTherapeuticResponseStatement",
        "description": "Case report of a patient with lung adenocarcinoma harboring both a mutation in EGFR and an amplification of MET. After progression on erlotinib the patient was treated with combined type I MET (savolitinib) and EGFR (osimertinib) inhibition and responded. When resistance developed, a new MET kinase domain mutation, D1228V, was detected. Drug binding predictions and in vitro studies demonstrated that the D1228V mutation induces resistance to type I but not type II MET TKIs. The patient was treated with erlotinib (EGFR TKI) combined with cabozantinib, a type II MET inhibitor, and had a response which continued at the time of report (5 months).",
        "method": "metakb.method:1",
        "is_reported_in": [
            {
                "id": "civic.source:1283",
                "type": "Document",
                "label": "Bahcall et al., 2016, Cancer Discov",
                "xrefs": [
                    "pmc:PMC5140694",
                    "pmid:27694386"
                ],
                "title": "Acquired METD1228V Mutation and Resistance to MET Inhibition in Lung Cancer."
            }
        ],
        "evidence_level": {
            "id": "vicc:e00008",
            "type": "Coding",
            "label": "case study evidence"
        },
        "target_proposition": {
            "id": "proposition:L7uGOs_conFCEd6Q432NsWTr2eYB4PR5",
            "type": "VariationNeoplasmTherapeuticResponseProposition",
            "subject": "ga4gh:VA.lqT_dLf_cLMUusUMgp51UIRu2qJSkolF",
            "predicate": "predicts_resistance_to",
            "object": {
                "id": "ncit:C104732",
                "type": "Therapeutic"
            },
            "neoplasm_type_qualifier": {
                "id": "ncit:C2926",
                "type": "Disease"
            }
        },
        "direction": "supports",
        "subject_descriptor": "civic.vid:798",
        "neoplasm_type_descriptor": {
            "id": "civic.did:8",
            "type": "DiseaseDescriptor",
            "label": "Lung Non-small Cell Carcinoma",
            "xrefs": [
                "DOID:3908"
            ],
            "disease": "ncit:C2926"
        },
        "object_descriptor": {
            "id": "civic.tid:425",
            "type": "TherapeuticDescriptor",
            "label": "Savolitinib",
            "xrefs": [
                "ncit:C104732"
            ],
            "alternate_labels": [
                "AZD 6094",
                "AZD6094",
                "HMPL-504",
                "Volitinib"
            ],
            "therapeutic": "ncit:C104732"
        }
    },
    {
        "id": "civic.eid:1985",
        "type": "VariationNeoplasmTherapeuticResponseStatement",
        "description": "Case report of a patient with CLL and Richter-transformed relapse under ibrutinib (after an initial partial response for 10 months). Sequencing of sequential samples of this patient revealed a novel BTK T316 mutation at relapse (allele frequency of 75%). Characterization of this mutation showed that is was located on the SH2 domain, not associated with Ibrutinib binding. Introduction of this mutation in an Ibrutinib-sensitive lymphoma cell line showed resistance comparable to the known C481 resistance mutations, which was also confirmed by absence of downstream signaling.",
        "method": "metakb.method:1",
        "is_reported_in": [
            {
                "id": "civic.source:1395",
                "type": "Document",
                "label": "Sharma et al., 2016, Oncotarget",
                "xrefs": [
                    "pmid:27626698"
                ],
                "title": "Identification of a structurally novel BTK mutation that drives ibrutinib resistance in CLL."
            }
        ],
        "evidence_level": {
            "id": "vicc:e00008",
            "type": "Coding",
            "label": "case study evidence"
        },
        "target_proposition": {
            "id": "proposition:Z3lh2cro4iOxW_zB3G2e5EVH0SWGYmWX",
            "type": "VariationNeoplasmTherapeuticResponseProposition",
            "subject": "ga4gh:VA.Kzx-ci9KIT2zSj9-X9wYEtbbyxmjyfdb",
            "predicate": "predicts_resistance_to",
            "object": {
                "id": "rxcui:1442981",
                "type": "Therapeutic"
            },
            "neoplasm_type_qualifier": {
                "id": "ncit:C3163",
                "type": "Disease"
            }
        },
        "direction": "supports",
        "subject_descriptor": "civic.vid:870",
        "neoplasm_type_descriptor": {
            "id": "civic.did:52",
            "type": "DiseaseDescriptor",
            "label": "Chronic Lymphocytic Leukemia",
            "xrefs": [
                "DOID:1040"
            ],
            "disease": "ncit:C3163"
        },
        "object_descriptor": {
            "id": "civic.tid:227",
            "type": "TherapeuticDescriptor",
            "label": "Ibrutinib",
            "extensions": [
                {
                    "type": "Extension",
                    "name": "regulatory_approval",
                    "value": {
                        "approval_rating": "ChEMBL",
                        "has_indications": [
                            {
                                "id": "mesh:D015451",
                                "type": "DiseaseDescriptor",
                                "label": "Leukemia, Lymphocytic, Chronic, B-Cell",
                                "disease": "ncit:C3163"
                            },
                            {
                                "id": "mesh:D020522",
                                "type": "DiseaseDescriptor",
                                "label": "Lymphoma, Mantle-Cell",
                                "disease": "ncit:C4337"
                            },
                            {
                                "id": "mesh:D008258",
                                "type": "DiseaseDescriptor",
                                "label": "Waldenstrom Macroglobulinemia",
                                "disease": "ncit:C80307"
                            }
                        ]
                    }
                }
            ],
            "xrefs": [
                "ncit:C81934"
            ],
            "alternate_labels": [
                "2-Propen-1-one, 1-((3R)-3-(4-amino-3-(4-phenoxyphenyl)-1h-pyrazolo(3,4-d)pyrimidin-1-yl)-1-piperidinyl)-",
                "BTK Inhibitor PCI-32765",
                "CRA-032765",
                "Imbruvica",
                "PCI-32765"
            ],
            "therapeutic": "rxcui:1442981"
        }
    },
    {
        "id": "civic.eid:4494",
        "type": "VariationNeoplasmTherapeuticResponseStatement",
        "description": "2 patients with EGFR D770_N771insGL mutant lung adenocarcinoma were treated with first line erlotinib.\n\nA 45 year old male never smoker had progressive disease as best response with +24% change to target lesions, progression free survival of 3.8 months, and still alive at study end after 39.3 months. \n\nA 79 year old female never smoker had progressive disease as best response with +13% change to target lesions, progression free survival of 6 months and overall survival of 14 months.",
        "method": "metakb.method:1",
        "is_reported_in": [
            {
                "id": "civic.source:1230",
                "type": "Document",
                "label": "Yasuda et al., 2013, Sci Transl Med",
                "xrefs": [
                    "pmc:PMC3954775",
                    "pmid:24353160"
                ],
                "title": "Structural, biochemical, and clinical characterization of epidermal growth factor receptor (EGFR) exon 20 insertion mutations in lung cancer."
            }
        ],
        "evidence_level": {
            "id": "vicc:e00008",
            "type": "Coding",
            "label": "case study evidence"
        },
        "target_proposition": {
            "id": "proposition:5POxMtlqwrFz_3hrTR7oVYoJxKFHPmIR",
            "type": "VariationNeoplasmTherapeuticResponseProposition",
            "subject": "ga4gh:VA.Daydg17safvIKs_ENTrvKpfoSooKgImP",
            "predicate": "predicts_resistance_to",
            "object": {
                "id": "rxcui:337525",
                "type": "Therapeutic"
            },
            "neoplasm_type_qualifier": {
                "id": "ncit:C3512",
                "type": "Disease"
            }
        },
        "direction": "supports",
        "subject_descriptor": "civic.vid:1514",
        "neoplasm_type_descriptor": {
            "id": "civic.did:30",
            "type": "DiseaseDescriptor",
            "label": "Lung Adenocarcinoma",
            "xrefs": [
                "DOID:3910"
            ],
            "disease": "ncit:C3512"
        },
        "object_descriptor": {
            "id": "civic.tid:15",
            "type": "TherapeuticDescriptor",
            "label": "Erlotinib",
            "extensions": [
                {
                    "type": "Extension",
                    "name": "regulatory_approval",
                    "value": {
                        "approval_rating": "FDA",
                        "has_indications": [
                            {
                                "id": "hemonc:642",
                                "type": "DiseaseDescriptor",
                                "label": "Non-small cell lung cancer",
                                "disease": "ncit:C2926"
                            },
                            {
                                "id": "hemonc:648",
                                "type": "DiseaseDescriptor",
                                "label": "Pancreatic cancer",
                                "disease": "ncit:C43298"
                            }
                        ]
                    }
                }
            ],
            "xrefs": [
                "ncit:C65530"
            ],
            "therapeutic": "rxcui:337525"
        }
    },
    {
        "id": "civic.eid:4801",
        "type": "VariationNeoplasmTherapeuticResponseStatement",
        "description": "In a study of 19 non-small cell lung carcinoma patients with EGFR exon 20 insertion mutation and treated with erlotinib monotherapy, patients with EGFR D770delinsGY mutation (n=2) experienced progressive disease. Both patients were white females, had adenocarcinoma, and were treated with erlotinib as first line therapy. One was 76 years old with 6 former pack years, 38.1% increase in target lesion, 1 month PFS and 12 month OS. The other was 67 years old with 2 former pack years, 6.0% increase in target lesion, 1 month PFS and 1.5 month OS.",
        "method": "metakb.method:1",
        "is_reported_in": [
            {
                "id": "civic.source:1230",
                "type": "Document",
                "label": "Yasuda et al., 2013, Sci Transl Med",
                "xrefs": [
                    "pmc:PMC3954775",
                    "pmid:24353160"
                ],
                "title": "Structural, biochemical, and clinical characterization of epidermal growth factor receptor (EGFR) exon 20 insertion mutations in lung cancer."
            }
        ],
        "evidence_level": {
            "id": "vicc:e00008",
            "type": "Coding",
            "label": "case study evidence"
        },
        "target_proposition": {
            "id": "proposition:dMuMhA4dc9z7Qk2ouWLAi6ANkBahfIj5",
            "type": "VariationNeoplasmTherapeuticResponseProposition",
            "subject": "ga4gh:VA.HwbhKSEjn4cE_4hdFVIyX4CZSCorC0Wb",
            "predicate": "predicts_resistance_to",
            "object": {
                "id": "rxcui:337525",
                "type": "Therapeutic"
            },
            "neoplasm_type_qualifier": {
                "id": "ncit:C3512",
                "type": "Disease"
            }
        },
        "direction": "supports",
        "subject_descriptor": "civic.vid:2214",
        "neoplasm_type_descriptor": {
            "id": "civic.did:30",
            "type": "DiseaseDescriptor",
            "label": "Lung Adenocarcinoma",
            "xrefs": [
                "DOID:3910"
            ],
            "disease": "ncit:C3512"
        },
        "object_descriptor": {
            "id": "civic.tid:15",
            "type": "TherapeuticDescriptor",
            "label": "Erlotinib",
            "extensions": [
                {
                    "type": "Extension",
                    "name": "regulatory_approval",
                    "value": {
                        "approval_rating": "FDA",
                        "has_indications": [
                            {
                                "id": "hemonc:642",
                                "type": "DiseaseDescriptor",
                                "label": "Non-small cell lung cancer",
                                "disease": "ncit:C2926"
                            },
                            {
                                "id": "hemonc:648",
                                "type": "DiseaseDescriptor",
                                "label": "Pancreatic cancer",
                                "disease": "ncit:C43298"
                            }
                        ]
                    }
                }
            ],
            "xrefs": [
                "ncit:C65530"
            ],
            "therapeutic": "rxcui:337525"
        }
    },
    {
        "id": "civic.eid:6260",
        "type": "VariationNeoplasmTherapeuticResponseStatement",
        "description": "In a retrospective study of 44 relapsed melanoma patients with BRAF V600E/K (known BRAF inhibitor sensitizing mutations), AKT1 Q79K was associated with acquired resistance to BRAF inhibitor (dabrafenib) monotherapy in one patient. This patient was a 38 year old female with stage IV M1a melanoma who took dabrafenib (35 mg twice daily to 100 mg three times a day). The best overall response was a 100% reduction in the sum of target lesions, and progression free survival lasted 119 days. Prior to dabrafenib monotherapy, this patient's baseline tumor harbored BRAF V600K\u2014no other somatic alterations were noted. Following relapse, the patient gained AKT1 Q79K in one of two disease progressive tumors. Whole exome sequencing and Sanger re-sequencing were used for all tumors. The authors hypothesized that disruptions in the PI3K-PTEN-AKT pathway represent a core mechanism of acquired resistance to BRAF inhibitor therapy.",
        "method": "metakb.method:1",
        "is_reported_in": [
            {
                "id": "civic.source:1941",
                "type": "Document",
                "label": "Shi et al., 2014, Cancer Discov",
                "xrefs": [
                    "pmc:PMC3936420",
                    "pmid:24265155"
                ],
                "title": "Acquired resistance and clonal evolution in melanoma during BRAF inhibitor therapy."
            }
        ],
        "evidence_level": {
            "id": "vicc:e00008",
            "type": "Coding",
            "label": "case study evidence"
        },
        "target_proposition": {
            "id": "proposition:rAg1gtlW24oGh-BElsHefLVPFzkuv0dp",
            "type": "VariationNeoplasmTherapeuticResponseProposition",
            "subject": "ga4gh:VA.gI0FOE6Esplrs92wp0CJWOeriC8srpYN",
            "predicate": "predicts_resistance_to",
            "object": {
                "id": "rxcui:1424911",
                "type": "Therapeutic"
            },
            "neoplasm_type_qualifier": {
                "id": "ncit:C3224",
                "type": "Disease"
            }
        },
        "direction": "supports",
        "subject_descriptor": "civic.vid:169",
        "neoplasm_type_descriptor": {
            "id": "civic.did:7",
            "type": "DiseaseDescriptor",
            "label": "Melanoma",
            "xrefs": [
                "DOID:1909"
            ],
            "disease": "ncit:C3224"
        },
        "object_descriptor": {
            "id": "civic.tid:22",
            "type": "TherapeuticDescriptor",
            "label": "Dabrafenib",
            "extensions": [
                {
                    "type": "Extension",
                    "name": "regulatory_approval",
                    "value": {
                        "approval_rating": "FDA",
                        "has_indications": [
                            {
                                "id": "hemonc:675",
                                "type": "DiseaseDescriptor",
                                "label": "Thyroid cancer",
                                "disease": "ncit:C7510"
                            },
                            {
                                "id": "hemonc:629",
                                "type": "DiseaseDescriptor",
                                "label": "Melanoma",
                                "disease": "ncit:C3224"
                            },
                            {
                                "id": "hemonc:642",
                                "type": "DiseaseDescriptor",
                                "label": "Non-small cell lung cancer",
                                "disease": "ncit:C2926"
                            }
                        ]
                    }
                }
            ],
            "xrefs": [
                "ncit:C82386"
            ],
            "alternate_labels": [
                "BRAF Inhibitor GSK2118436",
                "Benzenesulfonamide, N-(3-(5-(2-amino-4-pyrimidinyl)-2-(1,1-dimethylethyl)-4-thiazolyl)-2-fluorophenyl)-2,6-difluoro-",
                "GSK-2118436",
                "GSK-2118436A",
                "GSK2118436"
            ],
            "therapeutic": "rxcui:1424911"
        }
    },
    {
        "id": "civic.eid:6268",
        "type": "VariationNeoplasmTherapeuticResponseStatement",
        "description": "In a retrospective study of 44 relapsed melanoma patients harboring BRAF V600E/K (known BRAF inhibitor sensitizing mutations), PREX2 R172I was associated with a case of acquired resistance to BRAF inhibitor (vemurafenib) monotherapy in one patient. This patient was an 83 year old male with stage IV M1c melanoma who took vemurafenib (960mg twice daily). The best overall response was a 5% increase in sum of target lesions, and progression free survival lasted 132 days. Prior to vemurafenib monotherapy, this patient harbored BRAF V600K and no other somatic genetic alterations noted in the baseline tumor. Following relapse, the patient gained PREX2 R172I in one of two disease progressive tumors. Whole exome sequencing and Sanger re-sequencing were used for all tumors. The authors indicated that the biology behind this potential resistance mutation was unknown.",
        "method": "metakb.method:1",
        "is_reported_in": [
            {
                "id": "civic.source:1941",
                "type": "Document",
                "label": "Shi et al., 2014, Cancer Discov",
                "xrefs": [
                    "pmc:PMC3936420",
                    "pmid:24265155"
                ],
                "title": "Acquired resistance and clonal evolution in melanoma during BRAF inhibitor therapy."
            }
        ],
        "evidence_level": {
            "id": "vicc:e00008",
            "type": "Coding",
            "label": "case study evidence"
        },
        "target_proposition": {
            "id": "proposition:vAAn80PZ7PFi5-5VnMLIHAiAlvzUo0sl",
            "type": "VariationNeoplasmTherapeuticResponseProposition",
            "subject": "ga4gh:VA.AkAaSQnClitRy1XGwEM4IeqbjC9uZIKq",
            "predicate": "predicts_resistance_to",
            "object": {
                "id": "rxcui:1147220",
                "type": "Therapeutic"
            },
            "neoplasm_type_qualifier": {
                "id": "ncit:C3224",
                "type": "Disease"
            }
        },
        "direction": "supports",
        "subject_descriptor": "civic.vid:2364",
        "neoplasm_type_descriptor": {
            "id": "civic.did:7",
            "type": "DiseaseDescriptor",
            "label": "Melanoma",
            "xrefs": [
                "DOID:1909"
            ],
            "disease": "ncit:C3224"
        },
        "object_descriptor": {
            "id": "civic.tid:4",
            "type": "TherapeuticDescriptor",
            "label": "Vemurafenib",
            "extensions": [
                {
                    "type": "Extension",
                    "name": "regulatory_approval",
                    "value": {
                        "approval_rating": "FDA",
                        "has_indications": [
                            {
                                "id": "hemonc:629",
                                "type": "DiseaseDescriptor",
                                "label": "Melanoma",
                                "disease": "ncit:C3224"
                            },
                            {
                                "id": "hemonc:594",
                                "type": "DiseaseDescriptor",
                                "label": "Erdheim-Chester disease",
                                "disease": "ncit:C53972"
                            }
                        ]
                    }
                }
            ],
            "xrefs": [
                "ncit:C64768"
            ],
            "alternate_labels": [
                "1-propanesulfonamide, N-(3-((5-(4-chlorophenyl)-1h-pyrrolo(2,3-b)pyridin-3-yl)carbonyl)-2,4-difluorophenyl)-",
                "BRAF (V600E) Kinase Inhibitor RO5185426",
                "BRAF(V600E) Kinase Inhibitor RO5185426",
                "PLX-4032",
                "PLX4032",
                "RG 7204",
                "RG7204",
                "RO 5185426",
                "Zelboraf"
            ],
            "therapeutic": "rxcui:1147220"
        }
    },
    {
        "id": "civic.eid:8063",
        "type": "VariationNeoplasmTherapeuticResponseStatement",
        "description": "Among 32 colorectal cancer patients with acquired resistance (PFS > 12 weeks) to cetuximab, one was determined to have V955I mutation. V995I allelic fractions low at start of treatment but increased in frequency during treatment. PolyPhen-2 and SIFT functional predict folding changes to activation-loop domain. DiFi cells transfected with PIK3CA V955I plasmid assayed with western blot for pAKT (phosphorylated AKT) and pERK showed increased phosphorylation, which was not affected by the addition of cetuximab. PIK3CA V955I transfected cells also promoted cell viability in the presence of cetuximab.",
        "method": "metakb.method:1",
        "is_reported_in": [
            {
                "id": "civic.source:2196",
                "type": "Document",
                "label": "Xu et al., 2017, Clin. Cancer Res.",
                "xrefs": [
                    "pmc:PMC5559326",
                    "pmid:28424201"
                ],
                "title": "PIK3CA Mutations Contribute to Acquired Cetuximab Resistance in Patients with Metastatic Colorectal Cancer."
            }
        ],
        "evidence_level": {
            "id": "vicc:e00008",
            "type": "Coding",
            "label": "case study evidence"
        },
        "target_proposition": {
            "id": "proposition:4zzn6nhDPTY4ICjVhkr8PaM6dmYSw1tb",
            "type": "VariationNeoplasmTherapeuticResponseProposition",
            "subject": "ga4gh:VA.LPyMFKyhP-q86-yaOeAAhUwuux-Lhjr2",
            "predicate": "predicts_resistance_to",
            "object": {
                "id": "rxcui:318341",
                "type": "Therapeutic"
            },
            "neoplasm_type_qualifier": {
                "id": "ncit:C4978",
                "type": "Disease"
            }
        },
        "direction": "supports",
        "subject_descriptor": "civic.vid:3001",
        "neoplasm_type_descriptor": {
            "id": "civic.did:11",
            "type": "DiseaseDescriptor",
            "label": "Colorectal Cancer",
            "xrefs": [
                "DOID:9256"
            ],
            "disease": "ncit:C4978"
        },
        "object_descriptor": {
            "id": "civic.tid:16",
            "type": "TherapeuticDescriptor",
            "label": "Cetuximab",
            "extensions": [
                {
                    "type": "Extension",
                    "name": "regulatory_approval",
                    "value": {
                        "approval_rating": "ChEMBL",
                        "has_indications": [
                            {
                                "id": "mesh:D002294",
                                "type": "DiseaseDescriptor",
                                "label": "Carcinoma, Squamous Cell",
                                "disease": "ncit:C2929"
                            },
                            {
                                "id": "mesh:D009369",
                                "type": "DiseaseDescriptor",
                                "label": "Neoplasms",
                                "disease": "ncit:C3262"
                            },
                            {
                                "id": "mesh:D015179",
                                "type": "DiseaseDescriptor",
                                "label": "Colorectal Neoplasms",
                                "disease": "ncit:C2956"
                            },
                            {
                                "id": "mesh:D006258",
                                "type": "DiseaseDescriptor",
                                "label": "Head and Neck Neoplasms",
                                "disease": "ncit:C4013"
                            }
                        ]
                    }
                }
            ],
            "xrefs": [
                "ncit:C1723"
            ],
            "alternate_labels": [
                "Cetuximab Biosimilar CDP-1",
                "Cetuximab Biosimilar CMAB009",
                "Cetuximab Biosimilar KL 140",
                "Chimeric Anti-EGFR Monoclonal Antibody",
                "Chimeric MoAb C225",
                "Chimeric Monoclonal Antibody C225",
                "Erbitux",
                "IMC-C225"
            ],
            "therapeutic": "rxcui:318341"
        }
    },
    {
        "id": "civic.eid:10031",
        "type": "VariationNeoplasmTherapeuticResponseStatement",
        "description": "A cohort of 32 colorectal cancer patients with acquired resistance to cetuximab (PFS > 12 weeks) was analyzed for resistance mutations using targeted deep sequencing of ctDNA. Three patients had the PIK3CA p.K944N mutation. Cell viability studies of DiFi cells transfected with this PIK3CA variant confirmed resistance.",
        "method": "metakb.method:1",
        "is_reported_in": [
            {
                "id": "civic.source:2196",
                "type": "Document",
                "label": "Xu et al., 2017, Clin. Cancer Res.",
                "xrefs": [
                    "pmc:PMC5559326",
                    "pmid:28424201"
                ],
                "title": "PIK3CA Mutations Contribute to Acquired Cetuximab Resistance in Patients with Metastatic Colorectal Cancer."
            }
        ],
        "evidence_level": {
            "id": "vicc:e00008",
            "type": "Coding",
            "label": "case study evidence"
        },
        "target_proposition": {
            "id": "proposition:Z9yil0tW5SjZ-pTZIEyBjTaacaOJk3wV",
            "type": "VariationNeoplasmTherapeuticResponseProposition",
            "subject": "ga4gh:VA.4Q-bwKEnaKVDJpNy-l10AjtCY_h-qI4R",
            "predicate": "predicts_resistance_to",
            "object": {
                "id": "rxcui:318341",
                "type": "Therapeutic"
            },
            "neoplasm_type_qualifier": {
                "id": "ncit:C4978",
                "type": "Disease"
            }
        },
        "direction": "supports",
        "subject_descriptor": "civic.vid:3666",
        "neoplasm_type_descriptor": {
            "id": "civic.did:11",
            "type": "DiseaseDescriptor",
            "label": "Colorectal Cancer",
            "xrefs": [
                "DOID:9256"
            ],
            "disease": "ncit:C4978"
        },
        "object_descriptor": {
            "id": "civic.tid:16",
            "type": "TherapeuticDescriptor",
            "label": "Cetuximab",
            "extensions": [
                {
                    "type": "Extension",
                    "name": "regulatory_approval",
                    "value": {
                        "approval_rating": "ChEMBL",
                        "has_indications": [
                            {
                                "id": "mesh:D002294",
                                "type": "DiseaseDescriptor",
                                "label": "Carcinoma, Squamous Cell",
                                "disease": "ncit:C2929"
                            },
                            {
                                "id": "mesh:D009369",
                                "type": "DiseaseDescriptor",
                                "label": "Neoplasms",
                                "disease": "ncit:C3262"
                            },
                            {
                                "id": "mesh:D015179",
                                "type": "DiseaseDescriptor",
                                "label": "Colorectal Neoplasms",
                                "disease": "ncit:C2956"
                            },
                            {
                                "id": "mesh:D006258",
                                "type": "DiseaseDescriptor",
                                "label": "Head and Neck Neoplasms",
                                "disease": "ncit:C4013"
                            }
                        ]
                    }
                }
            ],
            "xrefs": [
                "ncit:C1723"
            ],
            "alternate_labels": [
                "Cetuximab Biosimilar CDP-1",
                "Cetuximab Biosimilar CMAB009",
                "Cetuximab Biosimilar KL 140",
                "Chimeric Anti-EGFR Monoclonal Antibody",
                "Chimeric MoAb C225",
                "Chimeric Monoclonal Antibody C225",
                "Erbitux",
                "IMC-C225"
            ],
            "therapeutic": "rxcui:318341"
        }
    },
    {
        "id": "civic.eid:10032",
        "type": "VariationNeoplasmTherapeuticResponseStatement",
        "description": "A cohort of 32 colorectal cancer patients with acquired resistance to cetuximab (PFS > 12 weeks) was analyzed for resistance mutations using targeted deep sequencing of ctDNA. One patient had the PIK3CA F930S mutation. Cell viability studies of DiFi cells transfected with this PIK3CA variant confirmed resistance.",
        "method": "metakb.method:1",
        "is_reported_in": [
            {
                "id": "civic.source:2196",
                "type": "Document",
                "label": "Xu et al., 2017, Clin. Cancer Res.",
                "xrefs": [
                    "pmc:PMC5559326",
                    "pmid:28424201"
                ],
                "title": "PIK3CA Mutations Contribute to Acquired Cetuximab Resistance in Patients with Metastatic Colorectal Cancer."
            }
        ],
        "evidence_level": {
            "id": "vicc:e00008",
            "type": "Coding",
            "label": "case study evidence"
        },
        "target_proposition": {
            "id": "proposition:o5dcEBANq0FrxXFYnYC25-K7fc2TnUPh",
            "type": "VariationNeoplasmTherapeuticResponseProposition",
            "subject": "ga4gh:VA.JxkEmK0vRwDDZ76leuqKeqRO1j9ixgkj",
            "predicate": "predicts_resistance_to",
            "object": {
                "id": "rxcui:318341",
                "type": "Therapeutic"
            },
            "neoplasm_type_qualifier": {
                "id": "ncit:C4978",
                "type": "Disease"
            }
        },
        "direction": "supports",
        "subject_descriptor": "civic.vid:3667",
        "neoplasm_type_descriptor": {
            "id": "civic.did:11",
            "type": "DiseaseDescriptor",
            "label": "Colorectal Cancer",
            "xrefs": [
                "DOID:9256"
            ],
            "disease": "ncit:C4978"
        },
        "object_descriptor": {
            "id": "civic.tid:16",
            "type": "TherapeuticDescriptor",
            "label": "Cetuximab",
            "extensions": [
                {
                    "type": "Extension",
                    "name": "regulatory_approval",
                    "value": {
                        "approval_rating": "ChEMBL",
                        "has_indications": [
                            {
                                "id": "mesh:D002294",
                                "type": "DiseaseDescriptor",
                                "label": "Carcinoma, Squamous Cell",
                                "disease": "ncit:C2929"
                            },
                            {
                                "id": "mesh:D009369",
                                "type": "DiseaseDescriptor",
                                "label": "Neoplasms",
                                "disease": "ncit:C3262"
                            },
                            {
                                "id": "mesh:D015179",
                                "type": "DiseaseDescriptor",
                                "label": "Colorectal Neoplasms",
                                "disease": "ncit:C2956"
                            },
                            {
                                "id": "mesh:D006258",
                                "type": "DiseaseDescriptor",
                                "label": "Head and Neck Neoplasms",
                                "disease": "ncit:C4013"
                            }
                        ]
                    }
                }
            ],
            "xrefs": [
                "ncit:C1723"
            ],
            "alternate_labels": [
                "Cetuximab Biosimilar CDP-1",
                "Cetuximab Biosimilar CMAB009",
                "Cetuximab Biosimilar KL 140",
                "Chimeric Anti-EGFR Monoclonal Antibody",
                "Chimeric MoAb C225",
                "Chimeric Monoclonal Antibody C225",
                "Erbitux",
                "IMC-C225"
            ],
            "therapeutic": "rxcui:318341"
        }
    },
    {
        "id": "civic.eid:10033",
        "type": "VariationNeoplasmTherapeuticResponseStatement",
        "description": "A cohort of 32 colorectal cancer patients with acquired resistance to cetuximab (PFS > 12 weeks) was analyzed for resistance mutations using targeted deep sequencing of ctDNA. One patient had the PIK3CA p.V955G mutation. Cell viability studies of DiFi cells transfected with this PIK3CA variant confirmed resistance.",
        "method": "metakb.method:1",
        "is_reported_in": [
            {
                "id": "civic.source:2196",
                "type": "Document",
                "label": "Xu et al., 2017, Clin. Cancer Res.",
                "xrefs": [
                    "pmc:PMC5559326",
                    "pmid:28424201"
                ],
                "title": "PIK3CA Mutations Contribute to Acquired Cetuximab Resistance in Patients with Metastatic Colorectal Cancer."
            }
        ],
        "evidence_level": {
            "id": "vicc:e00008",
            "type": "Coding",
            "label": "case study evidence"
        },
        "target_proposition": {
            "id": "proposition:dpFtjq3qEt5cGafeaqvolEvYD8UH5kSh",
            "type": "VariationNeoplasmTherapeuticResponseProposition",
            "subject": "ga4gh:VA.S2W-KxLNmACCpYyeh4UOUdwN_bysLlEs",
            "predicate": "predicts_resistance_to",
            "object": {
                "id": "rxcui:318341",
                "type": "Therapeutic"
            },
            "neoplasm_type_qualifier": {
                "id": "ncit:C4978",
                "type": "Disease"
            }
        },
        "direction": "supports",
        "subject_descriptor": "civic.vid:3668",
        "neoplasm_type_descriptor": {
            "id": "civic.did:11",
            "type": "DiseaseDescriptor",
            "label": "Colorectal Cancer",
            "xrefs": [
                "DOID:9256"
            ],
            "disease": "ncit:C4978"
        },
        "object_descriptor": {
            "id": "civic.tid:16",
            "type": "TherapeuticDescriptor",
            "label": "Cetuximab",
            "extensions": [
                {
                    "type": "Extension",
                    "name": "regulatory_approval",
                    "value": {
                        "approval_rating": "ChEMBL",
                        "has_indications": [
                            {
                                "id": "mesh:D002294",
                                "type": "DiseaseDescriptor",
                                "label": "Carcinoma, Squamous Cell",
                                "disease": "ncit:C2929"
                            },
                            {
                                "id": "mesh:D009369",
                                "type": "DiseaseDescriptor",
                                "label": "Neoplasms",
                                "disease": "ncit:C3262"
                            },
                            {
                                "id": "mesh:D015179",
                                "type": "DiseaseDescriptor",
                                "label": "Colorectal Neoplasms",
                                "disease": "ncit:C2956"
                            },
                            {
                                "id": "mesh:D006258",
                                "type": "DiseaseDescriptor",
                                "label": "Head and Neck Neoplasms",
                                "disease": "ncit:C4013"
                            }
                        ]
                    }
                }
            ],
            "xrefs": [
                "ncit:C1723"
            ],
            "alternate_labels": [
                "Cetuximab Biosimilar CDP-1",
                "Cetuximab Biosimilar CMAB009",
                "Cetuximab Biosimilar KL 140",
                "Chimeric Anti-EGFR Monoclonal Antibody",
                "Chimeric MoAb C225",
                "Chimeric Monoclonal Antibody C225",
                "Erbitux",
                "IMC-C225"
            ],
            "therapeutic": "rxcui:318341"
        }
    },
    {
        "id": "civic.eid:10034",
        "type": "VariationNeoplasmTherapeuticResponseStatement",
        "description": "A cohort of 32 colorectal cancer patients with acquired resistance to cetuximab (PFS > 12 weeks) was analyzed for resistance mutations using targeted deep sequencing of ctDNA. One patient had the PIK3CA p.K966E mutation. Cell viability studies of DiFi cells transfected with this PIK3CA variant confirmed resistance.",
        "method": "metakb.method:1",
        "is_reported_in": [
            {
                "id": "civic.source:2196",
                "type": "Document",
                "label": "Xu et al., 2017, Clin. Cancer Res.",
                "xrefs": [
                    "pmc:PMC5559326",
                    "pmid:28424201"
                ],
                "title": "PIK3CA Mutations Contribute to Acquired Cetuximab Resistance in Patients with Metastatic Colorectal Cancer."
            }
        ],
        "evidence_level": {
            "id": "vicc:e00008",
            "type": "Coding",
            "label": "case study evidence"
        },
        "target_proposition": {
            "id": "proposition:JF4Ccbia4N46J3F0KPnvt-NEdIL4l8p1",
            "type": "VariationNeoplasmTherapeuticResponseProposition",
            "subject": "ga4gh:VA.gKmU-nQnXJ7DYihjcPCkYoHsgK_gv--z",
            "predicate": "predicts_resistance_to",
            "object": {
                "id": "rxcui:318341",
                "type": "Therapeutic"
            },
            "neoplasm_type_qualifier": {
                "id": "ncit:C4978",
                "type": "Disease"
            }
        },
        "direction": "supports",
        "subject_descriptor": "civic.vid:3669",
        "neoplasm_type_descriptor": {
            "id": "civic.did:11",
            "type": "DiseaseDescriptor",
            "label": "Colorectal Cancer",
            "xrefs": [
                "DOID:9256"
            ],
            "disease": "ncit:C4978"
        },
        "object_descriptor": {
            "id": "civic.tid:16",
            "type": "TherapeuticDescriptor",
            "label": "Cetuximab",
            "extensions": [
                {
                    "type": "Extension",
                    "name": "regulatory_approval",
                    "value": {
                        "approval_rating": "ChEMBL",
                        "has_indications": [
                            {
                                "id": "mesh:D002294",
                                "type": "DiseaseDescriptor",
                                "label": "Carcinoma, Squamous Cell",
                                "disease": "ncit:C2929"
                            },
                            {
                                "id": "mesh:D009369",
                                "type": "DiseaseDescriptor",
                                "label": "Neoplasms",
                                "disease": "ncit:C3262"
                            },
                            {
                                "id": "mesh:D015179",
                                "type": "DiseaseDescriptor",
                                "label": "Colorectal Neoplasms",
                                "disease": "ncit:C2956"
                            },
                            {
                                "id": "mesh:D006258",
                                "type": "DiseaseDescriptor",
                                "label": "Head and Neck Neoplasms",
                                "disease": "ncit:C4013"
                            }
                        ]
                    }
                }
            ],
            "xrefs": [
                "ncit:C1723"
            ],
            "alternate_labels": [
                "Cetuximab Biosimilar CDP-1",
                "Cetuximab Biosimilar CMAB009",
                "Cetuximab Biosimilar KL 140",
                "Chimeric Anti-EGFR Monoclonal Antibody",
                "Chimeric MoAb C225",
                "Chimeric Monoclonal Antibody C225",
                "Erbitux",
                "IMC-C225"
            ],
            "therapeutic": "rxcui:318341"
        }
    },
    {
        "id": "civic.eid:699",
        "type": "VariationNeoplasmTherapeuticResponseStatement",
        "description": "Case report of a patient with metastatic colorectal carcinoma and a novel HRAS G13D mutation showed resistance to treatment with panitumumab. In vitro models of HRAS G13D confirmed resistance mechanism in the same study.",
        "method": "metakb.method:1",
        "is_reported_in": [
            {
                "id": "civic.source:457",
                "type": "Document",
                "label": "Boidot et al., 2016, Int J Colorectal Dis",
                "xrefs": [
                    "pmid:26561417"
                ],
                "title": "HRAS G13D, a new mutation implicated in the resistance to anti-EGFR therapies in colorectal cancer, a case report."
            }
        ],
        "evidence_level": {
            "id": "vicc:e00008",
            "type": "Coding",
            "label": "case study evidence"
        },
        "target_proposition": {
            "id": "proposition:AuHEXBQgFAO6g47meIkb0Q2hZESBp3ru",
            "type": "VariationNeoplasmTherapeuticResponseProposition",
            "subject": "ga4gh:VA.Z1VxpmB2Ui54Nd4GCsBXMjb2WDaCU7Ja",
            "predicate": "predicts_resistance_to",
            "object": {
                "id": "ncit:C2167",
                "type": "Therapeutic"
            },
            "neoplasm_type_qualifier": {
                "id": "ncit:C4978",
                "type": "Disease"
            }
        },
        "direction": "supports",
        "subject_descriptor": "civic.vid:274",
        "neoplasm_type_descriptor": {
            "id": "civic.did:11",
            "type": "DiseaseDescriptor",
            "label": "Colorectal Cancer",
            "xrefs": [
                "DOID:9256"
            ],
            "disease": "ncit:C4978"
        },
        "object_descriptor": {
            "id": "civic.tid:145",
            "type": "TherapeuticDescriptor",
            "label": "Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor",
            "xrefs": [
                "ncit:C2167"
            ],
            "therapeutic": "ncit:C2167"
        }
    },
    {
        "id": "civic.eid:745",
        "type": "VariationNeoplasmTherapeuticResponseStatement",
        "description": "In this case report, the D473H mutation was reported as an acquired mechanism of resistance to the hedgehog pathway inhibitor GDC-0449 (vismodegib).",
        "method": "metakb.method:1",
        "is_reported_in": [
            {
                "id": "civic.source:492",
                "type": "Document",
                "label": "Yauch et al., 2009, Science",
                "xrefs": [
                    "pmid:19726788"
                ],
                "title": "Smoothened mutation confers resistance to a Hedgehog pathway inhibitor in medulloblastoma."
            }
        ],
        "evidence_level": {
            "id": "vicc:e00008",
            "type": "Coding",
            "label": "case study evidence"
        },
        "target_proposition": {
            "id": "proposition:Ysdl5vPKj6I2wZBPjaA27R9iRrKjUM9m",
            "type": "VariationNeoplasmTherapeuticResponseProposition",
            "subject": "ga4gh:VA.hyt2pj4IH9Y-SEnEF-jNElPBrIIxBwwy",
            "predicate": "predicts_resistance_to",
            "object": {
                "id": "rxcui:1242987",
                "type": "Therapeutic"
            },
            "neoplasm_type_qualifier": {
                "id": "ncit:C3222",
                "type": "Disease"
            }
        },
        "direction": "supports",
        "subject_descriptor": "civic.vid:299",
        "neoplasm_type_descriptor": {
            "id": "civic.did:361",
            "type": "DiseaseDescriptor",
            "label": "Medulloblastoma",
            "xrefs": [
                "DOID:50902"
            ],
            "disease": "ncit:C3222"
        },
        "object_descriptor": {
            "id": "civic.tid:190",
            "type": "TherapeuticDescriptor",
            "label": "Vismodegib",
            "extensions": [
                {
                    "type": "Extension",
                    "name": "regulatory_approval",
                    "value": {
                        "approval_rating": "FDA",
                        "has_indications": [
                            {
                                "id": "hemonc:587",
                                "type": "DiseaseDescriptor",
                                "label": "Cutaneous basal cell carcinoma",
                                "disease": null
                            }
                        ]
                    }
                }
            ],
            "xrefs": [
                "ncit:C74038"
            ],
            "alternate_labels": [
                "2-chloro-N-[4-chloro-3-(pyridin-2-yl)phenyl]-4-(methylsulfonyl)benzamide",
                "Erivedge",
                "GDC-0449",
                "Hedgehog Antagonist GDC-0449"
            ],
            "therapeutic": "rxcui:1242987"
        }
    },
    {
        "id": "civic.eid:1333",
        "type": "VariationNeoplasmTherapeuticResponseStatement",
        "description": "A participant in Children's Oncology Group (COG) study AVDL0912 with measurable neuroblastoma mutated at ALK F1245C was administered crizotinib at 100mg twice daily.  The patient showed progressive disease as best response after two 28-day cycles on crizotinib.",
        "method": "metakb.method:1",
        "is_reported_in": [
            {
                "id": "civic.source:859",
                "type": "Document",
                "label": "Moss\u00e9 et al., 2013, Lancet Oncol.",
                "xrefs": [
                    "pmc:PMC3730818",
                    "pmid:23598171"
                ],
                "title": "Safety and activity of crizotinib for paediatric patients with refractory solid tumours or anaplastic large-cell lymphoma: a Children's Oncology Group phase 1 consortium study."
            }
        ],
        "evidence_level": {
            "id": "vicc:e00008",
            "type": "Coding",
            "label": "case study evidence"
        },
        "target_proposition": {
            "id": "proposition:xseKpkbROqvfzfA6Pah46F_CMCHcq6rn",
            "type": "VariationNeoplasmTherapeuticResponseProposition",
            "subject": "ga4gh:VA.vCqbachGaFmgPnncXcegGSNZIU9BaO8E",
            "predicate": "predicts_resistance_to",
            "object": {
                "id": "rxcui:1148495",
                "type": "Therapeutic"
            },
            "neoplasm_type_qualifier": {
                "id": "ncit:C3270",
                "type": "Disease"
            }
        },
        "direction": "supports",
        "subject_descriptor": "civic.vid:549",
        "neoplasm_type_descriptor": {
            "id": "civic.did:13",
            "type": "DiseaseDescriptor",
            "label": "Neuroblastoma",
            "xrefs": [
                "DOID:769"
            ],
            "disease": "ncit:C3270"
        },
        "object_descriptor": {
            "id": "civic.tid:12",
            "type": "TherapeuticDescriptor",
            "label": "Crizotinib",
            "extensions": [
                {
                    "type": "Extension",
                    "name": "regulatory_approval",
                    "value": {
                        "approval_rating": "FDA",
                        "has_indications": [
                            {
                                "id": "hemonc:642",
                                "type": "DiseaseDescriptor",
                                "label": "Non-small cell lung cancer",
                                "disease": "ncit:C2926"
                            },
                            {
                                "id": "hemonc:25958",
                                "type": "DiseaseDescriptor",
                                "label": "Anaplastic large cell lymphoma pediatric",
                                "disease": null
                            }
                        ]
                    }
                }
            ],
            "xrefs": [
                "ncit:C74061"
            ],
            "alternate_labels": [
                "(R)-3-(1-(2,6-Dichloro-3-Fluorophenyl)Ethoxy)-5-(1-(Piperidin-4-Yl)-1h-Pyrazol-4-Yl)Pyridin-2-Amine",
                "2-Pyridinamine, 3-((1R)-1-(2,6-Dichloro-3-Fluorophenyl)Ethoxy)-5-(1-(4-Piperidinyl)-1H-Pyrazol-4-yl)-",
                "MET Tyrosine Kinase Inhibitor PF-02341066",
                "PF-02341066",
                "PF-2341066",
                "Xalkori"
            ],
            "therapeutic": "rxcui:1148495"
        }
    },
    {
        "id": "civic.eid:1556",
        "type": "VariationNeoplasmTherapeuticResponseStatement",
        "description": "Three children with relapsed or refractory FLT3-ITD-positive AML were treated with sorafenib. FLT3 mutations were assessed before treatment and at the time of resistance. During the initiation of the treatment, all three patients had undetectable levels of FLT3 (D835H) mutations, however, after resistance developed, the mutation frequency rose to 33.1%, 35.7%, and 11.0% in the three patients. Ba/F3 cells expressing FLT3 mutants were resistant to sorafenib-dependent inhibition of cell viability",
        "method": "metakb.method:1",
        "is_reported_in": [
            {
                "id": "civic.source:1028",
                "type": "Document",
                "label": "Baker et al., 2013, Clin. Cancer Res.",
                "xrefs": [
                    "pmc:PMC3878304",
                    "pmid:23969938"
                ],
                "title": "Emergence of polyclonal FLT3 tyrosine kinase domain mutations during sequential therapy with sorafenib and sunitinib in FLT3-ITD-positive acute myeloid leukemia."
            }
        ],
        "evidence_level": {
            "id": "vicc:e00008",
            "type": "Coding",
            "label": "case study evidence"
        },
        "target_proposition": {
            "id": "proposition:RafMy31EgQle50CWDXXFTz1hVoyjjrnU",
            "type": "VariationNeoplasmTherapeuticResponseProposition",
            "subject": "ga4gh:VA.MswFBbwawqmZ-OcumYQ5lb69AVzAq2GV",
            "predicate": "predicts_resistance_to",
            "object": {
                "id": "rxcui:495881",
                "type": "Therapeutic"
            },
            "neoplasm_type_qualifier": {
                "id": "ncit:C3171",
                "type": "Disease"
            }
        },
        "direction": "supports",
        "subject_descriptor": "civic.vid:612",
        "neoplasm_type_descriptor": {
            "id": "civic.did:3",
            "type": "DiseaseDescriptor",
            "label": "Acute Myeloid Leukemia",
            "xrefs": [
                "DOID:9119"
            ],
            "disease": "ncit:C3171"
        },
        "object_descriptor": {
            "id": "civic.tid:6",
            "type": "TherapeuticDescriptor",
            "label": "Sorafenib",
            "extensions": [
                {
                    "type": "Extension",
                    "name": "regulatory_approval",
                    "value": {
                        "approval_rating": "FDA",
                        "has_indications": [
                            {
                                "id": "hemonc:612",
                                "type": "DiseaseDescriptor",
                                "label": "Hepatocellular carcinoma",
                                "disease": "ncit:C3099"
                            },
                            {
                                "id": "hemonc:65823",
                                "type": "DiseaseDescriptor",
                                "label": "Thyroid cancer differentiated",
                                "disease": null
                            },
                            {
                                "id": "hemonc:660",
                                "type": "DiseaseDescriptor",
                                "label": "Renal cell carcinoma",
                                "disease": "ncit:C9385"
                            }
                        ]
                    }
                }
            ],
            "xrefs": [
                "ncit:C61948"
            ],
            "alternate_labels": [
                "BA4 43 9006",
                "BAY 43-9006",
                "Bay-439006"
            ],
            "therapeutic": "rxcui:495881"
        }
    },
    {
        "id": "civic.eid:1999",
        "type": "VariationNeoplasmTherapeuticResponseStatement",
        "description": "One patient participating in a large retrospective study of cetuximab in metastatic, treatment refractory colorectal cancer had a tumor which harbored PIK3CA C420R and was wildtype for KRAS, BRAF and NRAS. This patient was was a 60 year old female treated with cetuximab monotherapy as 5th line therapy who experienced partial response and had PFS of 31 weeks and OS of 59 weeks.",
        "method": "metakb.method:1",
        "is_reported_in": [
            {
                "id": "civic.source:76",
                "type": "Document",
                "label": "De Roock et al., 2010, Lancet Oncol.",
                "xrefs": [
                    "pmid:20619739"
                ],
                "title": "Effects of KRAS, BRAF, NRAS, and PIK3CA mutations on the efficacy of cetuximab plus chemotherapy in chemotherapy-refractory metastatic colorectal cancer: a retrospective consortium analysis."
            }
        ],
        "evidence_level": {
            "id": "vicc:e00008",
            "type": "Coding",
            "label": "case study evidence"
        },
        "target_proposition": {
            "id": "proposition:DxRN1dtNb6rSRRYLvHfmU4_kZ9uYgQnH",
            "type": "VariationNeoplasmTherapeuticResponseProposition",
            "subject": "ga4gh:VA.gSEj555FrQu0uZMZcSDcGpE5p5TdBwX7",
            "predicate": "predicts_resistance_to",
            "object": {
                "id": "rxcui:318341",
                "type": "Therapeutic"
            },
            "neoplasm_type_qualifier": {
                "id": "ncit:C4978",
                "type": "Disease"
            }
        },
        "direction": "opposes",
        "subject_descriptor": "civic.vid:931",
        "neoplasm_type_descriptor": {
            "id": "civic.did:11",
            "type": "DiseaseDescriptor",
            "label": "Colorectal Cancer",
            "xrefs": [
                "DOID:9256"
            ],
            "disease": "ncit:C4978"
        },
        "object_descriptor": {
            "id": "civic.tid:16",
            "type": "TherapeuticDescriptor",
            "label": "Cetuximab",
            "extensions": [
                {
                    "type": "Extension",
                    "name": "regulatory_approval",
                    "value": {
                        "approval_rating": "ChEMBL",
                        "has_indications": [
                            {
                                "id": "mesh:D002294",
                                "type": "DiseaseDescriptor",
                                "label": "Carcinoma, Squamous Cell",
                                "disease": "ncit:C2929"
                            },
                            {
                                "id": "mesh:D009369",
                                "type": "DiseaseDescriptor",
                                "label": "Neoplasms",
                                "disease": "ncit:C3262"
                            },
                            {
                                "id": "mesh:D015179",
                                "type": "DiseaseDescriptor",
                                "label": "Colorectal Neoplasms",
                                "disease": "ncit:C2956"
                            },
                            {
                                "id": "mesh:D006258",
                                "type": "DiseaseDescriptor",
                                "label": "Head and Neck Neoplasms",
                                "disease": "ncit:C4013"
                            }
                        ]
                    }
                }
            ],
            "xrefs": [
                "ncit:C1723"
            ],
            "alternate_labels": [
                "Cetuximab Biosimilar CDP-1",
                "Cetuximab Biosimilar CMAB009",
                "Cetuximab Biosimilar KL 140",
                "Chimeric Anti-EGFR Monoclonal Antibody",
                "Chimeric MoAb C225",
                "Chimeric Monoclonal Antibody C225",
                "Erbitux",
                "IMC-C225"
            ],
            "therapeutic": "rxcui:318341"
        }
    },
    {
        "id": "civic.eid:2178",
        "type": "VariationNeoplasmTherapeuticResponseStatement",
        "description": "Three patients participating in a large retrospective study of EGFR monoclonal antibodies in metastatic, treatment refractory colorectal cancer had tumors which harbored KRAS G13D, were wildtype for NRAS, BRAF and PIK3CA, and had individual response data. All three patients were males treated with panitumumab monotherapy. Their characteristics are as follows: 51 year old who experienced progressive disease (PFS: 8 weeks; OS: 24 weeks) and had three prior lines of chemotherapy; 54 year old who experienced progressive disease (PFS: 8 weeks; OS: 17 weeks) and had two prior lines of chemotherapy; 52 year old who experienced stable disease (PFS: 12 weeks; OS: 46 weeks) and had two prior lines of chemotherapy. Per the authors criteria, the clinical benefit rate is 1/3 and the response rate is 0/3.",
        "method": "metakb.method:1",
        "is_reported_in": [
            {
                "id": "civic.source:76",
                "type": "Document",
                "label": "De Roock et al., 2010, Lancet Oncol.",
                "xrefs": [
                    "pmid:20619739"
                ],
                "title": "Effects of KRAS, BRAF, NRAS, and PIK3CA mutations on the efficacy of cetuximab plus chemotherapy in chemotherapy-refractory metastatic colorectal cancer: a retrospective consortium analysis."
            }
        ],
        "evidence_level": {
            "id": "vicc:e00008",
            "type": "Coding",
            "label": "case study evidence"
        },
        "target_proposition": {
            "id": "proposition:TJ5-PSDc8zeTAKDG-tlAZNEaEEk0dbBs",
            "type": "VariationNeoplasmTherapeuticResponseProposition",
            "subject": "ga4gh:VA.tO-mdKyTxDxR376-vWkR2RgI2gpOvBhQ",
            "predicate": "predicts_resistance_to",
            "object": {
                "id": "rxcui:263034",
                "type": "Therapeutic"
            },
            "neoplasm_type_qualifier": {
                "id": "ncit:C4978",
                "type": "Disease"
            }
        },
        "direction": "supports",
        "subject_descriptor": "civic.vid:81",
        "neoplasm_type_descriptor": {
            "id": "civic.did:11",
            "type": "DiseaseDescriptor",
            "label": "Colorectal Cancer",
            "xrefs": [
                "DOID:9256"
            ],
            "disease": "ncit:C4978"
        },
        "object_descriptor": {
            "id": "civic.tid:28",
            "type": "TherapeuticDescriptor",
            "label": "Panitumumab",
            "extensions": [
                {
                    "type": "Extension",
                    "name": "regulatory_approval",
                    "value": {
                        "approval_rating": "ChEMBL",
                        "has_indications": [
                            {
                                "id": "mesh:D009369",
                                "type": "DiseaseDescriptor",
                                "label": "Neoplasms",
                                "disease": "ncit:C3262"
                            },
                            {
                                "id": "mesh:D015179",
                                "type": "DiseaseDescriptor",
                                "label": "Colorectal Neoplasms",
                                "disease": "ncit:C2956"
                            }
                        ]
                    }
                }
            ],
            "xrefs": [
                "ncit:C1857"
            ],
            "alternate_labels": [
                "ABX-EGF",
                "ABX-EGF Monoclonal Antibody",
                "ABX-EGF, Clone E7.6.3",
                "E7.6.3",
                "Human IgG2K Monoclonal Antibody",
                "MoAb ABX-EGF",
                "MoAb E7.6.3",
                "Monoclonal Antibody ABX-EGF",
                "Monoclonal Antibody E7.6.3",
                "Vectibix"
            ],
            "therapeutic": "rxcui:263034"
        }
    },
    {
        "id": "civic.eid:2193",
        "type": "VariationNeoplasmTherapeuticResponseStatement",
        "description": "One patient participating in a large retrospective study of EGFR monoclonal antibodies in metastatic, treatment refractory colorectal cancer had a tumor which harbored KRAS G12D, was wildtype for NRAS, BRAF and PIK3CA, and had individual response data. This patient was was a 55 year old female treated with panitumumab monotherapy as 3rd line therapy who experienced progressive disease (PFS: 8 weeks; OS: 9 weeks).",
        "method": "metakb.method:1",
        "is_reported_in": [
            {
                "id": "civic.source:76",
                "type": "Document",
                "label": "De Roock et al., 2010, Lancet Oncol.",
                "xrefs": [
                    "pmid:20619739"
                ],
                "title": "Effects of KRAS, BRAF, NRAS, and PIK3CA mutations on the efficacy of cetuximab plus chemotherapy in chemotherapy-refractory metastatic colorectal cancer: a retrospective consortium analysis."
            }
        ],
        "evidence_level": {
            "id": "vicc:e00008",
            "type": "Coding",
            "label": "case study evidence"
        },
        "target_proposition": {
            "id": "proposition:I3aHgqvm6GcTQHLdR2Z2inCkSEooTm-C",
            "type": "VariationNeoplasmTherapeuticResponseProposition",
            "subject": "ga4gh:VA.jSiuIG2uZEbml8MfCtZi3J9jPBCBiaPw",
            "predicate": "predicts_resistance_to",
            "object": {
                "id": "rxcui:263034",
                "type": "Therapeutic"
            },
            "neoplasm_type_qualifier": {
                "id": "ncit:C4978",
                "type": "Disease"
            }
        },
        "direction": "supports",
        "subject_descriptor": "civic.vid:79",
        "neoplasm_type_descriptor": {
            "id": "civic.did:11",
            "type": "DiseaseDescriptor",
            "label": "Colorectal Cancer",
            "xrefs": [
                "DOID:9256"
            ],
            "disease": "ncit:C4978"
        },
        "object_descriptor": {
            "id": "civic.tid:28",
            "type": "TherapeuticDescriptor",
            "label": "Panitumumab",
            "extensions": [
                {
                    "type": "Extension",
                    "name": "regulatory_approval",
                    "value": {
                        "approval_rating": "ChEMBL",
                        "has_indications": [
                            {
                                "id": "mesh:D009369",
                                "type": "DiseaseDescriptor",
                                "label": "Neoplasms",
                                "disease": "ncit:C3262"
                            },
                            {
                                "id": "mesh:D015179",
                                "type": "DiseaseDescriptor",
                                "label": "Colorectal Neoplasms",
                                "disease": "ncit:C2956"
                            }
                        ]
                    }
                }
            ],
            "xrefs": [
                "ncit:C1857"
            ],
            "alternate_labels": [
                "ABX-EGF",
                "ABX-EGF Monoclonal Antibody",
                "ABX-EGF, Clone E7.6.3",
                "E7.6.3",
                "Human IgG2K Monoclonal Antibody",
                "MoAb ABX-EGF",
                "MoAb E7.6.3",
                "Monoclonal Antibody ABX-EGF",
                "Monoclonal Antibody E7.6.3",
                "Vectibix"
            ],
            "therapeutic": "rxcui:263034"
        }
    },
    {
        "id": "civic.eid:2217",
        "type": "VariationNeoplasmTherapeuticResponseStatement",
        "description": "This was a retrospective study of 691 cetuximab treated patients with metastatic, chemotherapy refractory colorectal cancer. Of those, 16 patients harbored PIK3CA E545K (exon 10), were wt for BRAF, NRAS and PIK3CA, and had individual response data. Five patients had partial response, six had stable disease, and five progressed, resulting in a response rate of 5/16 and a clinical benefit rate of 11/16 according to author criteria. Treatments included cetuximab + irinotecan (n=13), cetuximab monotherapy (n=1), cetuximab + bevacizumab (n=1), and cetuximab + oxaliplatin + 5FU (n=1). Median PFS was 24 weeks (2-60 weeks), median OS was 43 weeks (9-107 weeks), and median number of previous chemotherapy lines was 2 (1-5). Median age was 58 years old (43-79), and there were 10 males and 6 females. Using these and data from the larger cohort, authors concluded that PIK3CA exon 10 (listed as exon 9 in source) mutations are associated with weak or no resistance to cetuximab.",
        "method": "metakb.method:1",
        "is_reported_in": [
            {
                "id": "civic.source:76",
                "type": "Document",
                "label": "De Roock et al., 2010, Lancet Oncol.",
                "xrefs": [
                    "pmid:20619739"
                ],
                "title": "Effects of KRAS, BRAF, NRAS, and PIK3CA mutations on the efficacy of cetuximab plus chemotherapy in chemotherapy-refractory metastatic colorectal cancer: a retrospective consortium analysis."
            }
        ],
        "evidence_level": {
            "id": "vicc:e00008",
            "type": "Coding",
            "label": "case study evidence"
        },
        "target_proposition": {
            "id": "proposition:DisSodA1O6oYQj07rHVUrYng93QMjPR5",
            "type": "VariationNeoplasmTherapeuticResponseProposition",
            "subject": "ga4gh:VA.5zBiXnk0ZRCfFqRnK0fQHQwAGBWW4JE8",
            "predicate": "predicts_resistance_to",
            "object": {
                "id": "rxcui:318341",
                "type": "Therapeutic"
            },
            "neoplasm_type_qualifier": {
                "id": "ncit:C4978",
                "type": "Disease"
            }
        },
        "direction": "opposes",
        "subject_descriptor": "civic.vid:104",
        "neoplasm_type_descriptor": {
            "id": "civic.did:11",
            "type": "DiseaseDescriptor",
            "label": "Colorectal Cancer",
            "xrefs": [
                "DOID:9256"
            ],
            "disease": "ncit:C4978"
        },
        "object_descriptor": {
            "id": "civic.tid:16",
            "type": "TherapeuticDescriptor",
            "label": "Cetuximab",
            "extensions": [
                {
                    "type": "Extension",
                    "name": "regulatory_approval",
                    "value": {
                        "approval_rating": "ChEMBL",
                        "has_indications": [
                            {
                                "id": "mesh:D002294",
                                "type": "DiseaseDescriptor",
                                "label": "Carcinoma, Squamous Cell",
                                "disease": "ncit:C2929"
                            },
                            {
                                "id": "mesh:D009369",
                                "type": "DiseaseDescriptor",
                                "label": "Neoplasms",
                                "disease": "ncit:C3262"
                            },
                            {
                                "id": "mesh:D015179",
                                "type": "DiseaseDescriptor",
                                "label": "Colorectal Neoplasms",
                                "disease": "ncit:C2956"
                            },
                            {
                                "id": "mesh:D006258",
                                "type": "DiseaseDescriptor",
                                "label": "Head and Neck Neoplasms",
                                "disease": "ncit:C4013"
                            }
                        ]
                    }
                }
            ],
            "xrefs": [
                "ncit:C1723"
            ],
            "alternate_labels": [
                "Cetuximab Biosimilar CDP-1",
                "Cetuximab Biosimilar CMAB009",
                "Cetuximab Biosimilar KL 140",
                "Chimeric Anti-EGFR Monoclonal Antibody",
                "Chimeric MoAb C225",
                "Chimeric Monoclonal Antibody C225",
                "Erbitux",
                "IMC-C225"
            ],
            "therapeutic": "rxcui:318341"
        }
    },
    {
        "id": "civic.eid:2886",
        "type": "VariationNeoplasmTherapeuticResponseStatement",
        "description": "FFPE tumor specimens from 295 melanoma patients were screened for KIT amplification and mutation. Of these, 51 patients had variants in KIT and 28 of these were treated with imatinib mesylate at 400 mg orally, twice daily with 25 patients eligible for response evaluation. None of the patients had mutations in BRAF, NRAS, or GNAQ. Two patients achieved a durable complete response, two achieved a durable partial response, and 5 achieved stable disease >12 weeks with a median survival of 46.3 weeks. One patient harboring a somatic D820Y mutation at roughly 50% variant allele frequency (1:1 with wild type) displayed Imatinib mesylate\u2013resistance and disease progression, which is consistent with resistant mechanisms described in Gastro-Intestinal Stromal Tumors.",
        "method": "metakb.method:1",
        "is_reported_in": [
            {
                "id": "civic.source:1593",
                "type": "Document",
                "label": "Carvajal et al., 2011, JAMA",
                "xrefs": [
                    "pmc:PMC3986039",
                    "pmid:21642685"
                ],
                "title": "KIT as a therapeutic target in metastatic melanoma."
            }
        ],
        "evidence_level": {
            "id": "vicc:e00008",
            "type": "Coding",
            "label": "case study evidence"
        },
        "target_proposition": {
            "id": "proposition:r3XYgl8t7o71XRLz8naYNzrtncFK0XgS",
            "type": "VariationNeoplasmTherapeuticResponseProposition",
            "subject": "ga4gh:VA.k2xXiu-T1lSzrMEKj4oJo8vrUM0mG7A4",
            "predicate": "predicts_resistance_to",
            "object": {
                "id": "rxcui:282388",
                "type": "Therapeutic"
            },
            "neoplasm_type_qualifier": {
                "id": "ncit:C3224",
                "type": "Disease"
            }
        },
        "direction": "supports",
        "subject_descriptor": "civic.vid:986",
        "neoplasm_type_descriptor": {
            "id": "civic.did:7",
            "type": "DiseaseDescriptor",
            "label": "Melanoma",
            "xrefs": [
                "DOID:1909"
            ],
            "disease": "ncit:C3224"
        },
        "object_descriptor": {
            "id": "civic.tid:5",
            "type": "TherapeuticDescriptor",
            "label": "Imatinib",
            "extensions": [
                {
                    "type": "Extension",
                    "name": "regulatory_approval",
                    "value": {
                        "approval_rating": "FDA",
                        "has_indications": [
                            {
                                "id": "hemonc:667",
                                "type": "DiseaseDescriptor",
                                "label": "Soft tissue sarcoma",
                                "disease": "ncit:C9306"
                            },
                            {
                                "id": "hemonc:602",
                                "type": "DiseaseDescriptor",
                                "label": "Gastrointestinal stromal tumor",
                                "disease": "ncit:C3868"
                            },
                            {
                                "id": "hemonc:616",
                                "type": "DiseaseDescriptor",
                                "label": "Hypereosinophilic syndrome",
                                "disease": "ncit:C27038"
                            },
                            {
                                "id": "hemonc:33893",
                                "type": "DiseaseDescriptor",
                                "label": "Chronic myelogenous leukemia pediatric",
                                "disease": null
                            },
                            {
                                "id": "hemonc:634",
                                "type": "DiseaseDescriptor",
                                "label": "Myelodysplastic syndrome",
                                "disease": "ncit:C3247"
                            },
                            {
                                "id": "hemonc:24309",
                                "type": "DiseaseDescriptor",
                                "label": "Acute lymphoblastic leukemia",
                                "disease": "ncit:C3167"
                            },
                            {
                                "id": "hemonc:582",
                                "type": "DiseaseDescriptor",
                                "label": "Chronic myelogenous leukemia",
                                "disease": "ncit:C3174"
                            },
                            {
                                "id": "hemonc:669",
                                "type": "DiseaseDescriptor",
                                "label": "Systemic mastocytosis",
                                "disease": "ncit:C9235"
                            }
                        ]
                    }
                }
            ],
            "xrefs": [
                "ncit:C62035"
            ],
            "alternate_labels": [
                "4-[(4-Methyl-1-piperazinyl)methyl]-N-[4-methyl-3-[[4-(3-pyridinyl)-2-pyrimidinyl]amino]phenyl]benzamide"
            ],
            "therapeutic": "rxcui:282388"
        }
    },
    {
        "id": "civic.eid:2918",
        "type": "VariationNeoplasmTherapeuticResponseStatement",
        "description": "147 patients with advanced, unresectable GISTs were enrolled onto a randomized, phase II clinical study of imatinib (CSTI571-B2222). Specimens from 43 pretreatment and/or imatinib-resistant tumors were analyzed to identify molecular correlates of imatinib resistance. N822K was observed as a secondary KIT mutation in two patients with secondary imatinib resistance and one patient with primary resistance, and also as a primary mutation in a patient with primary resistance. The mutation was shown to occur at a hotspot (N822) of previously reported secondary KIT mutations in imatinib resistant GISTs. When co-expressed with V560D (imatinib sensitive) in vitro N822K showed moderate imatinib resistance.",
        "method": "metakb.method:1",
        "is_reported_in": [
            {
                "id": "civic.source:62",
                "type": "Document",
                "label": "Heinrich et al., 2006, J. Clin. Oncol.",
                "xrefs": [
                    "pmid:16954519"
                ],
                "title": "Molecular correlates of imatinib resistance in gastrointestinal stromal tumors."
            }
        ],
        "evidence_level": {
            "id": "vicc:e00008",
            "type": "Coding",
            "label": "case study evidence"
        },
        "target_proposition": {
            "id": "proposition:_yAwjBoY6zpFg6I7nBWC1bWYBOfd-f0-",
            "type": "VariationNeoplasmTherapeuticResponseProposition",
            "subject": "ga4gh:VA.x1hF9GSdbmVTlsrasMgH_mt4t2-TmEn1",
            "predicate": "predicts_resistance_to",
            "object": {
                "id": "rxcui:282388",
                "type": "Therapeutic"
            },
            "neoplasm_type_qualifier": {
                "id": "ncit:C3868",
                "type": "Disease"
            }
        },
        "direction": "supports",
        "subject_descriptor": "civic.vid:1263",
        "neoplasm_type_descriptor": {
            "id": "civic.did:2",
            "type": "DiseaseDescriptor",
            "label": "Gastrointestinal Stromal Tumor",
            "xrefs": [
                "DOID:9253"
            ],
            "disease": "ncit:C3868"
        },
        "object_descriptor": {
            "id": "civic.tid:5",
            "type": "TherapeuticDescriptor",
            "label": "Imatinib",
            "extensions": [
                {
                    "type": "Extension",
                    "name": "regulatory_approval",
                    "value": {
                        "approval_rating": "FDA",
                        "has_indications": [
                            {
                                "id": "hemonc:667",
                                "type": "DiseaseDescriptor",
                                "label": "Soft tissue sarcoma",
                                "disease": "ncit:C9306"
                            },
                            {
                                "id": "hemonc:602",
                                "type": "DiseaseDescriptor",
                                "label": "Gastrointestinal stromal tumor",
                                "disease": "ncit:C3868"
                            },
                            {
                                "id": "hemonc:616",
                                "type": "DiseaseDescriptor",
                                "label": "Hypereosinophilic syndrome",
                                "disease": "ncit:C27038"
                            },
                            {
                                "id": "hemonc:33893",
                                "type": "DiseaseDescriptor",
                                "label": "Chronic myelogenous leukemia pediatric",
                                "disease": null
                            },
                            {
                                "id": "hemonc:634",
                                "type": "DiseaseDescriptor",
                                "label": "Myelodysplastic syndrome",
                                "disease": "ncit:C3247"
                            },
                            {
                                "id": "hemonc:24309",
                                "type": "DiseaseDescriptor",
                                "label": "Acute lymphoblastic leukemia",
                                "disease": "ncit:C3167"
                            },
                            {
                                "id": "hemonc:582",
                                "type": "DiseaseDescriptor",
                                "label": "Chronic myelogenous leukemia",
                                "disease": "ncit:C3174"
                            },
                            {
                                "id": "hemonc:669",
                                "type": "DiseaseDescriptor",
                                "label": "Systemic mastocytosis",
                                "disease": "ncit:C9235"
                            }
                        ]
                    }
                }
            ],
            "xrefs": [
                "ncit:C62035"
            ],
            "alternate_labels": [
                "4-[(4-Methyl-1-piperazinyl)methyl]-N-[4-methyl-3-[[4-(3-pyridinyl)-2-pyrimidinyl]amino]phenyl]benzamide"
            ],
            "therapeutic": "rxcui:282388"
        }
    },
    {
        "id": "civic.eid:2919",
        "type": "VariationNeoplasmTherapeuticResponseStatement",
        "description": "147 patients with advanced, unresectable GISTs were enrolled onto a randomized, phase II clinical study of imatinib (CSTI571-B2222). Specimens from 43 pretreatment and/or imatinib-resistant tumors were analyzed to identify molecular correlates of imatinib resistance. Y823D was observed as a secondary KIT mutation in five patients with secondary imatinib resistance. The mutation was shown to occur at a hotspot (Y823) of previously reported secondary KIT mutations in imatinib resistant GISTs. When co-expressed with V560D (imatinib sensitive) in vitro Y823D showed \"extreme\" imatinib resistance.",
        "method": "metakb.method:1",
        "is_reported_in": [
            {
                "id": "civic.source:62",
                "type": "Document",
                "label": "Heinrich et al., 2006, J. Clin. Oncol.",
                "xrefs": [
                    "pmid:16954519"
                ],
                "title": "Molecular correlates of imatinib resistance in gastrointestinal stromal tumors."
            }
        ],
        "evidence_level": {
            "id": "vicc:e00008",
            "type": "Coding",
            "label": "case study evidence"
        },
        "target_proposition": {
            "id": "proposition:y8dg5O6sg3JDkIJejEb8AmxQExHs8CmW",
            "type": "VariationNeoplasmTherapeuticResponseProposition",
            "subject": "ga4gh:VA.lKdmdWowkrPgjRq61xYdyrqn1cEO-9v5",
            "predicate": "predicts_resistance_to",
            "object": {
                "id": "rxcui:282388",
                "type": "Therapeutic"
            },
            "neoplasm_type_qualifier": {
                "id": "ncit:C3868",
                "type": "Disease"
            }
        },
        "direction": "supports",
        "subject_descriptor": "civic.vid:989",
        "neoplasm_type_descriptor": {
            "id": "civic.did:2",
            "type": "DiseaseDescriptor",
            "label": "Gastrointestinal Stromal Tumor",
            "xrefs": [
                "DOID:9253"
            ],
            "disease": "ncit:C3868"
        },
        "object_descriptor": {
            "id": "civic.tid:5",
            "type": "TherapeuticDescriptor",
            "label": "Imatinib",
            "extensions": [
                {
                    "type": "Extension",
                    "name": "regulatory_approval",
                    "value": {
                        "approval_rating": "FDA",
                        "has_indications": [
                            {
                                "id": "hemonc:667",
                                "type": "DiseaseDescriptor",
                                "label": "Soft tissue sarcoma",
                                "disease": "ncit:C9306"
                            },
                            {
                                "id": "hemonc:602",
                                "type": "DiseaseDescriptor",
                                "label": "Gastrointestinal stromal tumor",
                                "disease": "ncit:C3868"
                            },
                            {
                                "id": "hemonc:616",
                                "type": "DiseaseDescriptor",
                                "label": "Hypereosinophilic syndrome",
                                "disease": "ncit:C27038"
                            },
                            {
                                "id": "hemonc:33893",
                                "type": "DiseaseDescriptor",
                                "label": "Chronic myelogenous leukemia pediatric",
                                "disease": null
                            },
                            {
                                "id": "hemonc:634",
                                "type": "DiseaseDescriptor",
                                "label": "Myelodysplastic syndrome",
                                "disease": "ncit:C3247"
                            },
                            {
                                "id": "hemonc:24309",
                                "type": "DiseaseDescriptor",
                                "label": "Acute lymphoblastic leukemia",
                                "disease": "ncit:C3167"
                            },
                            {
                                "id": "hemonc:582",
                                "type": "DiseaseDescriptor",
                                "label": "Chronic myelogenous leukemia",
                                "disease": "ncit:C3174"
                            },
                            {
                                "id": "hemonc:669",
                                "type": "DiseaseDescriptor",
                                "label": "Systemic mastocytosis",
                                "disease": "ncit:C9235"
                            }
                        ]
                    }
                }
            ],
            "xrefs": [
                "ncit:C62035"
            ],
            "alternate_labels": [
                "4-[(4-Methyl-1-piperazinyl)methyl]-N-[4-methyl-3-[[4-(3-pyridinyl)-2-pyrimidinyl]amino]phenyl]benzamide"
            ],
            "therapeutic": "rxcui:282388"
        }
    },
    {
        "id": "civic.eid:2920",
        "type": "VariationNeoplasmTherapeuticResponseStatement",
        "description": "147 patients with advanced, unresectable GISTs were enrolled onto a randomized, phase II clinical study of imatinib (CSTI571-B2222). Specimens from 43 pretreatment and/or imatinib-resistant tumors were analyzed to identify molecular correlates of imatinib resistance. C809G was observed as a secondary KIT mutation in one patient with secondary imatinib resistance. In vitro, C809G showed imatinib resistance both in isolation and when coexpressed with K642E + N822H (the primary KIT mutations, found on the same allele, for this patient).",
        "method": "metakb.method:1",
        "is_reported_in": [
            {
                "id": "civic.source:62",
                "type": "Document",
                "label": "Heinrich et al., 2006, J. Clin. Oncol.",
                "xrefs": [
                    "pmid:16954519"
                ],
                "title": "Molecular correlates of imatinib resistance in gastrointestinal stromal tumors."
            }
        ],
        "evidence_level": {
            "id": "vicc:e00008",
            "type": "Coding",
            "label": "case study evidence"
        },
        "target_proposition": {
            "id": "proposition:cXfRrQPvj5EL4d6myGAct1uaSUdUYUb_",
            "type": "VariationNeoplasmTherapeuticResponseProposition",
            "subject": "ga4gh:VA.Ngswf8Gwjbd8yulTDd9v5u5oAYy95ffd",
            "predicate": "predicts_resistance_to",
            "object": {
                "id": "rxcui:282388",
                "type": "Therapeutic"
            },
            "neoplasm_type_qualifier": {
                "id": "ncit:C3868",
                "type": "Disease"
            }
        },
        "direction": "supports",
        "subject_descriptor": "civic.vid:1264",
        "neoplasm_type_descriptor": {
            "id": "civic.did:2",
            "type": "DiseaseDescriptor",
            "label": "Gastrointestinal Stromal Tumor",
            "xrefs": [
                "DOID:9253"
            ],
            "disease": "ncit:C3868"
        },
        "object_descriptor": {
            "id": "civic.tid:5",
            "type": "TherapeuticDescriptor",
            "label": "Imatinib",
            "extensions": [
                {
                    "type": "Extension",
                    "name": "regulatory_approval",
                    "value": {
                        "approval_rating": "FDA",
                        "has_indications": [
                            {
                                "id": "hemonc:667",
                                "type": "DiseaseDescriptor",
                                "label": "Soft tissue sarcoma",
                                "disease": "ncit:C9306"
                            },
                            {
                                "id": "hemonc:602",
                                "type": "DiseaseDescriptor",
                                "label": "Gastrointestinal stromal tumor",
                                "disease": "ncit:C3868"
                            },
                            {
                                "id": "hemonc:616",
                                "type": "DiseaseDescriptor",
                                "label": "Hypereosinophilic syndrome",
                                "disease": "ncit:C27038"
                            },
                            {
                                "id": "hemonc:33893",
                                "type": "DiseaseDescriptor",
                                "label": "Chronic myelogenous leukemia pediatric",
                                "disease": null
                            },
                            {
                                "id": "hemonc:634",
                                "type": "DiseaseDescriptor",
                                "label": "Myelodysplastic syndrome",
                                "disease": "ncit:C3247"
                            },
                            {
                                "id": "hemonc:24309",
                                "type": "DiseaseDescriptor",
                                "label": "Acute lymphoblastic leukemia",
                                "disease": "ncit:C3167"
                            },
                            {
                                "id": "hemonc:582",
                                "type": "DiseaseDescriptor",
                                "label": "Chronic myelogenous leukemia",
                                "disease": "ncit:C3174"
                            },
                            {
                                "id": "hemonc:669",
                                "type": "DiseaseDescriptor",
                                "label": "Systemic mastocytosis",
                                "disease": "ncit:C9235"
                            }
                        ]
                    }
                }
            ],
            "xrefs": [
                "ncit:C62035"
            ],
            "alternate_labels": [
                "4-[(4-Methyl-1-piperazinyl)methyl]-N-[4-methyl-3-[[4-(3-pyridinyl)-2-pyrimidinyl]amino]phenyl]benzamide"
            ],
            "therapeutic": "rxcui:282388"
        }
    },
    {
        "id": "civic.eid:2921",
        "type": "VariationNeoplasmTherapeuticResponseStatement",
        "description": "147 patients with advanced, unresectable GISTs were enrolled onto a randomized, phase II clinical study of imatinib (CSTI571-B2222). Specimens from 43 pretreatment and/or imatinib-resistant tumors were analyzed to identify molecular correlates of imatinib resistance. D820A was observed as a secondary KIT mutation in one patient with secondary imatinib resistance. The mutation was shown to occur at a hotspot (D820) of previously reported secondary KIT mutations in imatinib resistant GISTs. A cell line derived from a separate patient with the same primary (V560D) and secondary (D820A) mutations showed moderately increased resistance to imatinib compared to reports for GIST lines with primary exon 11 KIT mutations alone.",
        "method": "metakb.method:1",
        "is_reported_in": [
            {
                "id": "civic.source:62",
                "type": "Document",
                "label": "Heinrich et al., 2006, J. Clin. Oncol.",
                "xrefs": [
                    "pmid:16954519"
                ],
                "title": "Molecular correlates of imatinib resistance in gastrointestinal stromal tumors."
            }
        ],
        "evidence_level": {
            "id": "vicc:e00008",
            "type": "Coding",
            "label": "case study evidence"
        },
        "target_proposition": {
            "id": "proposition:ne0wPuerJDe_Oy2KnuiahJ_osyosqBAd",
            "type": "VariationNeoplasmTherapeuticResponseProposition",
            "subject": "ga4gh:VA.N2jbfonrm2l9DY5w196I8E3q8GqLDt54",
            "predicate": "predicts_resistance_to",
            "object": {
                "id": "rxcui:282388",
                "type": "Therapeutic"
            },
            "neoplasm_type_qualifier": {
                "id": "ncit:C3868",
                "type": "Disease"
            }
        },
        "direction": "supports",
        "subject_descriptor": "civic.vid:1265",
        "neoplasm_type_descriptor": {
            "id": "civic.did:2",
            "type": "DiseaseDescriptor",
            "label": "Gastrointestinal Stromal Tumor",
            "xrefs": [
                "DOID:9253"
            ],
            "disease": "ncit:C3868"
        },
        "object_descriptor": {
            "id": "civic.tid:5",
            "type": "TherapeuticDescriptor",
            "label": "Imatinib",
            "extensions": [
                {
                    "type": "Extension",
                    "name": "regulatory_approval",
                    "value": {
                        "approval_rating": "FDA",
                        "has_indications": [
                            {
                                "id": "hemonc:667",
                                "type": "DiseaseDescriptor",
                                "label": "Soft tissue sarcoma",
                                "disease": "ncit:C9306"
                            },
                            {
                                "id": "hemonc:602",
                                "type": "DiseaseDescriptor",
                                "label": "Gastrointestinal stromal tumor",
                                "disease": "ncit:C3868"
                            },
                            {
                                "id": "hemonc:616",
                                "type": "DiseaseDescriptor",
                                "label": "Hypereosinophilic syndrome",
                                "disease": "ncit:C27038"
                            },
                            {
                                "id": "hemonc:33893",
                                "type": "DiseaseDescriptor",
                                "label": "Chronic myelogenous leukemia pediatric",
                                "disease": null
                            },
                            {
                                "id": "hemonc:634",
                                "type": "DiseaseDescriptor",
                                "label": "Myelodysplastic syndrome",
                                "disease": "ncit:C3247"
                            },
                            {
                                "id": "hemonc:24309",
                                "type": "DiseaseDescriptor",
                                "label": "Acute lymphoblastic leukemia",
                                "disease": "ncit:C3167"
                            },
                            {
                                "id": "hemonc:582",
                                "type": "DiseaseDescriptor",
                                "label": "Chronic myelogenous leukemia",
                                "disease": "ncit:C3174"
                            },
                            {
                                "id": "hemonc:669",
                                "type": "DiseaseDescriptor",
                                "label": "Systemic mastocytosis",
                                "disease": "ncit:C9235"
                            }
                        ]
                    }
                }
            ],
            "xrefs": [
                "ncit:C62035"
            ],
            "alternate_labels": [
                "4-[(4-Methyl-1-piperazinyl)methyl]-N-[4-methyl-3-[[4-(3-pyridinyl)-2-pyrimidinyl]amino]phenyl]benzamide"
            ],
            "therapeutic": "rxcui:282388"
        }
    },
    {
        "id": "civic.eid:2922",
        "type": "VariationNeoplasmTherapeuticResponseStatement",
        "description": "147 patients with advanced, unresectable GISTs were enrolled onto a randomized, phase II clinical study of imatinib (CSTI571-B2222). Specimens from 43 pretreatment and/or imatinib-resistant tumors were analyzed to identify molecular correlates of imatinib resistance. D820G was observed as a secondary KIT mutation in two patients with secondary imatinib resistance. The mutation was shown to occur at a hotspot (D820) of previously reported secondary KIT mutations in imatinib resistant GISTs. When co-expressed with V560D (imatinib sensitive) in vitro D820G showed \"extreme\" imatinib resistance.",
        "method": "metakb.method:1",
        "is_reported_in": [
            {
                "id": "civic.source:62",
                "type": "Document",
                "label": "Heinrich et al., 2006, J. Clin. Oncol.",
                "xrefs": [
                    "pmid:16954519"
                ],
                "title": "Molecular correlates of imatinib resistance in gastrointestinal stromal tumors."
            }
        ],
        "evidence_level": {
            "id": "vicc:e00008",
            "type": "Coding",
            "label": "case study evidence"
        },
        "target_proposition": {
            "id": "proposition:86V_SWpUj65nFzrCvW_8nnslYd1bTZ5r",
            "type": "VariationNeoplasmTherapeuticResponseProposition",
            "subject": "ga4gh:VA.xTOqcm23tQTngix3Db7HBb2KnlBuezej",
            "predicate": "predicts_resistance_to",
            "object": {
                "id": "rxcui:282388",
                "type": "Therapeutic"
            },
            "neoplasm_type_qualifier": {
                "id": "ncit:C3868",
                "type": "Disease"
            }
        },
        "direction": "supports",
        "subject_descriptor": "civic.vid:1266",
        "neoplasm_type_descriptor": {
            "id": "civic.did:2",
            "type": "DiseaseDescriptor",
            "label": "Gastrointestinal Stromal Tumor",
            "xrefs": [
                "DOID:9253"
            ],
            "disease": "ncit:C3868"
        },
        "object_descriptor": {
            "id": "civic.tid:5",
            "type": "TherapeuticDescriptor",
            "label": "Imatinib",
            "extensions": [
                {
                    "type": "Extension",
                    "name": "regulatory_approval",
                    "value": {
                        "approval_rating": "FDA",
                        "has_indications": [
                            {
                                "id": "hemonc:667",
                                "type": "DiseaseDescriptor",
                                "label": "Soft tissue sarcoma",
                                "disease": "ncit:C9306"
                            },
                            {
                                "id": "hemonc:602",
                                "type": "DiseaseDescriptor",
                                "label": "Gastrointestinal stromal tumor",
                                "disease": "ncit:C3868"
                            },
                            {
                                "id": "hemonc:616",
                                "type": "DiseaseDescriptor",
                                "label": "Hypereosinophilic syndrome",
                                "disease": "ncit:C27038"
                            },
                            {
                                "id": "hemonc:33893",
                                "type": "DiseaseDescriptor",
                                "label": "Chronic myelogenous leukemia pediatric",
                                "disease": null
                            },
                            {
                                "id": "hemonc:634",
                                "type": "DiseaseDescriptor",
                                "label": "Myelodysplastic syndrome",
                                "disease": "ncit:C3247"
                            },
                            {
                                "id": "hemonc:24309",
                                "type": "DiseaseDescriptor",
                                "label": "Acute lymphoblastic leukemia",
                                "disease": "ncit:C3167"
                            },
                            {
                                "id": "hemonc:582",
                                "type": "DiseaseDescriptor",
                                "label": "Chronic myelogenous leukemia",
                                "disease": "ncit:C3174"
                            },
                            {
                                "id": "hemonc:669",
                                "type": "DiseaseDescriptor",
                                "label": "Systemic mastocytosis",
                                "disease": "ncit:C9235"
                            }
                        ]
                    }
                }
            ],
            "xrefs": [
                "ncit:C62035"
            ],
            "alternate_labels": [
                "4-[(4-Methyl-1-piperazinyl)methyl]-N-[4-methyl-3-[[4-(3-pyridinyl)-2-pyrimidinyl]amino]phenyl]benzamide"
            ],
            "therapeutic": "rxcui:282388"
        }
    },
    {
        "id": "civic.eid:2923",
        "type": "VariationNeoplasmTherapeuticResponseStatement",
        "description": "147 patients with advanced, unresectable GISTs were enrolled onto a randomized, phase II clinical study of imatinib (CSTI571-B2222). Specimens from 43 pretreatment and/or imatinib-resistant tumors were analyzed to identify molecular correlates of imatinib resistance. D816H was observed as a secondary KIT mutation in two patients with secondary imatinib resistance. The mutation was shown to occur at a hotspot (D816) of previously reported secondary KIT mutations in imatinib resistant GISTs. When co-expressed with V560D (imatinib sensitive) in vitro D816H showed \"extreme\" imatinib resistance. It was also highly resistant in isolation.",
        "method": "metakb.method:1",
        "is_reported_in": [
            {
                "id": "civic.source:62",
                "type": "Document",
                "label": "Heinrich et al., 2006, J. Clin. Oncol.",
                "xrefs": [
                    "pmid:16954519"
                ],
                "title": "Molecular correlates of imatinib resistance in gastrointestinal stromal tumors."
            }
        ],
        "evidence_level": {
            "id": "vicc:e00008",
            "type": "Coding",
            "label": "case study evidence"
        },
        "target_proposition": {
            "id": "proposition:yj5C5eKEKkDRQAwZUVupFKQHm-s4-6S2",
            "type": "VariationNeoplasmTherapeuticResponseProposition",
            "subject": "ga4gh:VA.RQAhdmX7Am7xNvM-DGvM4gPqYrq1ZD25",
            "predicate": "predicts_resistance_to",
            "object": {
                "id": "rxcui:282388",
                "type": "Therapeutic"
            },
            "neoplasm_type_qualifier": {
                "id": "ncit:C3868",
                "type": "Disease"
            }
        },
        "direction": "supports",
        "subject_descriptor": "civic.vid:983",
        "neoplasm_type_descriptor": {
            "id": "civic.did:2",
            "type": "DiseaseDescriptor",
            "label": "Gastrointestinal Stromal Tumor",
            "xrefs": [
                "DOID:9253"
            ],
            "disease": "ncit:C3868"
        },
        "object_descriptor": {
            "id": "civic.tid:5",
            "type": "TherapeuticDescriptor",
            "label": "Imatinib",
            "extensions": [
                {
                    "type": "Extension",
                    "name": "regulatory_approval",
                    "value": {
                        "approval_rating": "FDA",
                        "has_indications": [
                            {
                                "id": "hemonc:667",
                                "type": "DiseaseDescriptor",
                                "label": "Soft tissue sarcoma",
                                "disease": "ncit:C9306"
                            },
                            {
                                "id": "hemonc:602",
                                "type": "DiseaseDescriptor",
                                "label": "Gastrointestinal stromal tumor",
                                "disease": "ncit:C3868"
                            },
                            {
                                "id": "hemonc:616",
                                "type": "DiseaseDescriptor",
                                "label": "Hypereosinophilic syndrome",
                                "disease": "ncit:C27038"
                            },
                            {
                                "id": "hemonc:33893",
                                "type": "DiseaseDescriptor",
                                "label": "Chronic myelogenous leukemia pediatric",
                                "disease": null
                            },
                            {
                                "id": "hemonc:634",
                                "type": "DiseaseDescriptor",
                                "label": "Myelodysplastic syndrome",
                                "disease": "ncit:C3247"
                            },
                            {
                                "id": "hemonc:24309",
                                "type": "DiseaseDescriptor",
                                "label": "Acute lymphoblastic leukemia",
                                "disease": "ncit:C3167"
                            },
                            {
                                "id": "hemonc:582",
                                "type": "DiseaseDescriptor",
                                "label": "Chronic myelogenous leukemia",
                                "disease": "ncit:C3174"
                            },
                            {
                                "id": "hemonc:669",
                                "type": "DiseaseDescriptor",
                                "label": "Systemic mastocytosis",
                                "disease": "ncit:C9235"
                            }
                        ]
                    }
                }
            ],
            "xrefs": [
                "ncit:C62035"
            ],
            "alternate_labels": [
                "4-[(4-Methyl-1-piperazinyl)methyl]-N-[4-methyl-3-[[4-(3-pyridinyl)-2-pyrimidinyl]amino]phenyl]benzamide"
            ],
            "therapeutic": "rxcui:282388"
        }
    },
    {
        "id": "civic.eid:2924",
        "type": "VariationNeoplasmTherapeuticResponseStatement",
        "description": "147 patients with advanced, unresectable GISTs were enrolled onto a randomized, phase II clinical study of imatinib (CSTI571-B2222). Specimens from 43 pretreatment and/or imatinib-resistant tumors were analyzed to identify molecular correlates of imatinib resistance. T670I was observed as a secondary KIT mutation in one patient with secondary imatinib resistance. The mutation was shown to occur at a hotspot (T670) of previously reported secondary KIT mutations in imatinib resistant GISTs. When co-expressed with V560D (imatinib sensitive) in vitro T670I showed \"extreme\" imatinib resistance. It also showed resistance in isolation.",
        "method": "metakb.method:1",
        "is_reported_in": [
            {
                "id": "civic.source:62",
                "type": "Document",
                "label": "Heinrich et al., 2006, J. Clin. Oncol.",
                "xrefs": [
                    "pmid:16954519"
                ],
                "title": "Molecular correlates of imatinib resistance in gastrointestinal stromal tumors."
            }
        ],
        "evidence_level": {
            "id": "vicc:e00008",
            "type": "Coding",
            "label": "case study evidence"
        },
        "target_proposition": {
            "id": "proposition:JDcfHBvflIH4S_Pj1ZEfO1ViJiZTLwol",
            "type": "VariationNeoplasmTherapeuticResponseProposition",
            "subject": "ga4gh:VA.i9jXgMZM9ZFX7HMNEDN7npl5Cl5zSgy6",
            "predicate": "predicts_resistance_to",
            "object": {
                "id": "rxcui:282388",
                "type": "Therapeutic"
            },
            "neoplasm_type_qualifier": {
                "id": "ncit:C3868",
                "type": "Disease"
            }
        },
        "direction": "supports",
        "subject_descriptor": "civic.vid:1267",
        "neoplasm_type_descriptor": {
            "id": "civic.did:2",
            "type": "DiseaseDescriptor",
            "label": "Gastrointestinal Stromal Tumor",
            "xrefs": [
                "DOID:9253"
            ],
            "disease": "ncit:C3868"
        },
        "object_descriptor": {
            "id": "civic.tid:5",
            "type": "TherapeuticDescriptor",
            "label": "Imatinib",
            "extensions": [
                {
                    "type": "Extension",
                    "name": "regulatory_approval",
                    "value": {
                        "approval_rating": "FDA",
                        "has_indications": [
                            {
                                "id": "hemonc:667",
                                "type": "DiseaseDescriptor",
                                "label": "Soft tissue sarcoma",
                                "disease": "ncit:C9306"
                            },
                            {
                                "id": "hemonc:602",
                                "type": "DiseaseDescriptor",
                                "label": "Gastrointestinal stromal tumor",
                                "disease": "ncit:C3868"
                            },
                            {
                                "id": "hemonc:616",
                                "type": "DiseaseDescriptor",
                                "label": "Hypereosinophilic syndrome",
                                "disease": "ncit:C27038"
                            },
                            {
                                "id": "hemonc:33893",
                                "type": "DiseaseDescriptor",
                                "label": "Chronic myelogenous leukemia pediatric",
                                "disease": null
                            },
                            {
                                "id": "hemonc:634",
                                "type": "DiseaseDescriptor",
                                "label": "Myelodysplastic syndrome",
                                "disease": "ncit:C3247"
                            },
                            {
                                "id": "hemonc:24309",
                                "type": "DiseaseDescriptor",
                                "label": "Acute lymphoblastic leukemia",
                                "disease": "ncit:C3167"
                            },
                            {
                                "id": "hemonc:582",
                                "type": "DiseaseDescriptor",
                                "label": "Chronic myelogenous leukemia",
                                "disease": "ncit:C3174"
                            },
                            {
                                "id": "hemonc:669",
                                "type": "DiseaseDescriptor",
                                "label": "Systemic mastocytosis",
                                "disease": "ncit:C9235"
                            }
                        ]
                    }
                }
            ],
            "xrefs": [
                "ncit:C62035"
            ],
            "alternate_labels": [
                "4-[(4-Methyl-1-piperazinyl)methyl]-N-[4-methyl-3-[[4-(3-pyridinyl)-2-pyrimidinyl]amino]phenyl]benzamide"
            ],
            "therapeutic": "rxcui:282388"
        }
    },
    {
        "id": "civic.eid:3824",
        "type": "VariationNeoplasmTherapeuticResponseStatement",
        "description": "One patient participating in a large retrospective study of EGFR monoclonal antibodies in metastatic, treatment refractory colorectal cancer had a tumor which harbored KRAS G12V, was wildtype for NRAS, BRAF and PIK3CA, and had individual response data. This patient was was a 78 year old female treated with panitumumab monotherapy as 2nd line therapy who experienced progressive disease (PFS: 5 weeks).",
        "method": "metakb.method:1",
        "is_reported_in": [
            {
                "id": "civic.source:76",
                "type": "Document",
                "label": "De Roock et al., 2010, Lancet Oncol.",
                "xrefs": [
                    "pmid:20619739"
                ],
                "title": "Effects of KRAS, BRAF, NRAS, and PIK3CA mutations on the efficacy of cetuximab plus chemotherapy in chemotherapy-refractory metastatic colorectal cancer: a retrospective consortium analysis."
            }
        ],
        "evidence_level": {
            "id": "vicc:e00008",
            "type": "Coding",
            "label": "case study evidence"
        },
        "target_proposition": {
            "id": "proposition:xTALYouVRGlRIOMLO_Z-_53DLegLgV5C",
            "type": "VariationNeoplasmTherapeuticResponseProposition",
            "subject": "ga4gh:VA.VBKi2jNxAs378IqOBsveoPrYQjWPngQq",
            "predicate": "predicts_resistance_to",
            "object": {
                "id": "rxcui:263034",
                "type": "Therapeutic"
            },
            "neoplasm_type_qualifier": {
                "id": "ncit:C4978",
                "type": "Disease"
            }
        },
        "direction": "supports",
        "subject_descriptor": "civic.vid:425",
        "neoplasm_type_descriptor": {
            "id": "civic.did:11",
            "type": "DiseaseDescriptor",
            "label": "Colorectal Cancer",
            "xrefs": [
                "DOID:9256"
            ],
            "disease": "ncit:C4978"
        },
        "object_descriptor": {
            "id": "civic.tid:28",
            "type": "TherapeuticDescriptor",
            "label": "Panitumumab",
            "extensions": [
                {
                    "type": "Extension",
                    "name": "regulatory_approval",
                    "value": {
                        "approval_rating": "ChEMBL",
                        "has_indications": [
                            {
                                "id": "mesh:D009369",
                                "type": "DiseaseDescriptor",
                                "label": "Neoplasms",
                                "disease": "ncit:C3262"
                            },
                            {
                                "id": "mesh:D015179",
                                "type": "DiseaseDescriptor",
                                "label": "Colorectal Neoplasms",
                                "disease": "ncit:C2956"
                            }
                        ]
                    }
                }
            ],
            "xrefs": [
                "ncit:C1857"
            ],
            "alternate_labels": [
                "ABX-EGF",
                "ABX-EGF Monoclonal Antibody",
                "ABX-EGF, Clone E7.6.3",
                "E7.6.3",
                "Human IgG2K Monoclonal Antibody",
                "MoAb ABX-EGF",
                "MoAb E7.6.3",
                "Monoclonal Antibody ABX-EGF",
                "Monoclonal Antibody E7.6.3",
                "Vectibix"
            ],
            "therapeutic": "rxcui:263034"
        }
    },
    {
        "id": "civic.eid:3827",
        "type": "VariationNeoplasmTherapeuticResponseStatement",
        "description": "One patient participating in a large retrospective study of EGFR monoclonal antibodies in metastatic colorectal cancer had a tumor which harbored BRAF V600E, was wildtype for NRAS, KRAS and PIK3CA, and had individual response data. This patient was was a male treated with panitumumab monotherapy as 1st line therapy who experienced progressive disease (PFS: 7 weeks; OS: 10 weeks).",
        "method": "metakb.method:1",
        "is_reported_in": [
            {
                "id": "civic.source:76",
                "type": "Document",
                "label": "De Roock et al., 2010, Lancet Oncol.",
                "xrefs": [
                    "pmid:20619739"
                ],
                "title": "Effects of KRAS, BRAF, NRAS, and PIK3CA mutations on the efficacy of cetuximab plus chemotherapy in chemotherapy-refractory metastatic colorectal cancer: a retrospective consortium analysis."
            }
        ],
        "evidence_level": {
            "id": "vicc:e00008",
            "type": "Coding",
            "label": "case study evidence"
        },
        "target_proposition": {
            "id": "proposition:m9yuxxn52Rx8DMOMGQB7KMd2rtdsRMEB",
            "type": "VariationNeoplasmTherapeuticResponseProposition",
            "subject": "ga4gh:VA.h313H4CQh6pogbbSJ3H5pI1cPoh9YMm_",
            "predicate": "predicts_resistance_to",
            "object": {
                "id": "rxcui:263034",
                "type": "Therapeutic"
            },
            "neoplasm_type_qualifier": {
                "id": "ncit:C4978",
                "type": "Disease"
            }
        },
        "direction": "supports",
        "subject_descriptor": "civic.vid:12",
        "neoplasm_type_descriptor": {
            "id": "civic.did:11",
            "type": "DiseaseDescriptor",
            "label": "Colorectal Cancer",
            "xrefs": [
                "DOID:9256"
            ],
            "disease": "ncit:C4978"
        },
        "object_descriptor": {
            "id": "civic.tid:28",
            "type": "TherapeuticDescriptor",
            "label": "Panitumumab",
            "extensions": [
                {
                    "type": "Extension",
                    "name": "regulatory_approval",
                    "value": {
                        "approval_rating": "ChEMBL",
                        "has_indications": [
                            {
                                "id": "mesh:D009369",
                                "type": "DiseaseDescriptor",
                                "label": "Neoplasms",
                                "disease": "ncit:C3262"
                            },
                            {
                                "id": "mesh:D015179",
                                "type": "DiseaseDescriptor",
                                "label": "Colorectal Neoplasms",
                                "disease": "ncit:C2956"
                            }
                        ]
                    }
                }
            ],
            "xrefs": [
                "ncit:C1857"
            ],
            "alternate_labels": [
                "ABX-EGF",
                "ABX-EGF Monoclonal Antibody",
                "ABX-EGF, Clone E7.6.3",
                "E7.6.3",
                "Human IgG2K Monoclonal Antibody",
                "MoAb ABX-EGF",
                "MoAb E7.6.3",
                "Monoclonal Antibody ABX-EGF",
                "Monoclonal Antibody E7.6.3",
                "Vectibix"
            ],
            "therapeutic": "rxcui:263034"
        }
    },
    {
        "id": "civic.eid:3847",
        "type": "VariationNeoplasmTherapeuticResponseStatement",
        "description": "One patient participating in a large retrospective study of cetuximab in metastatic, treatment refractory colorectal cancer had a tumor which harbored PIK3CA G1049R (exon 20), was wildtype for KRAS, BRAF and NRAS, and had individual response data. This patient was was a 69 year old male treated with cetuximab + FOLFIRI as 3rd line therapy who experienced progressive disease and had PFS of 13 weeks and OS of 36 weeks. Using this information and data from the larger cohort, authors concluded that PIK3CA exon 21 (listed as exon 20 in source) mutations predict poor response to cetuximab.",
        "method": "metakb.method:1",
        "is_reported_in": [
            {
                "id": "civic.source:76",
                "type": "Document",
                "label": "De Roock et al., 2010, Lancet Oncol.",
                "xrefs": [
                    "pmid:20619739"
                ],
                "title": "Effects of KRAS, BRAF, NRAS, and PIK3CA mutations on the efficacy of cetuximab plus chemotherapy in chemotherapy-refractory metastatic colorectal cancer: a retrospective consortium analysis."
            }
        ],
        "evidence_level": {
            "id": "vicc:e00008",
            "type": "Coding",
            "label": "case study evidence"
        },
        "target_proposition": {
            "id": "proposition:mrankJpi2MPmuhdG1Cr-3pIoQlbvao4x",
            "type": "VariationNeoplasmTherapeuticResponseProposition",
            "subject": "ga4gh:VA.vxWenCx5Zh7thv9vYTHJsjn12LIMFve1",
            "predicate": "predicts_resistance_to",
            "object": {
                "id": "rxcui:318341",
                "type": "Therapeutic"
            },
            "neoplasm_type_qualifier": {
                "id": "ncit:C4978",
                "type": "Disease"
            }
        },
        "direction": "supports",
        "subject_descriptor": "civic.vid:940",
        "neoplasm_type_descriptor": {
            "id": "civic.did:11",
            "type": "DiseaseDescriptor",
            "label": "Colorectal Cancer",
            "xrefs": [
                "DOID:9256"
            ],
            "disease": "ncit:C4978"
        },
        "object_descriptor": {
            "id": "civic.tid:16",
            "type": "TherapeuticDescriptor",
            "label": "Cetuximab",
            "extensions": [
                {
                    "type": "Extension",
                    "name": "regulatory_approval",
                    "value": {
                        "approval_rating": "ChEMBL",
                        "has_indications": [
                            {
                                "id": "mesh:D002294",
                                "type": "DiseaseDescriptor",
                                "label": "Carcinoma, Squamous Cell",
                                "disease": "ncit:C2929"
                            },
                            {
                                "id": "mesh:D009369",
                                "type": "DiseaseDescriptor",
                                "label": "Neoplasms",
                                "disease": "ncit:C3262"
                            },
                            {
                                "id": "mesh:D015179",
                                "type": "DiseaseDescriptor",
                                "label": "Colorectal Neoplasms",
                                "disease": "ncit:C2956"
                            },
                            {
                                "id": "mesh:D006258",
                                "type": "DiseaseDescriptor",
                                "label": "Head and Neck Neoplasms",
                                "disease": "ncit:C4013"
                            }
                        ]
                    }
                }
            ],
            "xrefs": [
                "ncit:C1723"
            ],
            "alternate_labels": [
                "Cetuximab Biosimilar CDP-1",
                "Cetuximab Biosimilar CMAB009",
                "Cetuximab Biosimilar KL 140",
                "Chimeric Anti-EGFR Monoclonal Antibody",
                "Chimeric MoAb C225",
                "Chimeric Monoclonal Antibody C225",
                "Erbitux",
                "IMC-C225"
            ],
            "therapeutic": "rxcui:318341"
        }
    },
    {
        "id": "civic.eid:4082",
        "type": "VariationNeoplasmTherapeuticResponseStatement",
        "description": "Patients 11, 69, and 73 from a larger cohort of genotyped patients (n= 78) with imatinib resistant or intolerant gastrointestinal stromal tumors (GISTs) harbored a primary (pre-imatinib treatment) KIT W557_K558 deletion. Following failure of imatinib, the GIST was again genotyped, but no secondary mutations were found. Patient 11 started on 25 mg sunitinib daily, for a two week on/two week off schedule. Patients 69 and 73 were on a 50 mg sunitib per day for four weeks on/ two weeks off. All three patients experienced stable disease for less than 6 months. Time to progression for patients 11, 69, and 73: 8, 22, and 10 weeks. Overall survival for patients 11, 69, and 73: 10, 38, and 19 weeks (Table A1).",
        "method": "metakb.method:1",
        "is_reported_in": [
            {
                "id": "civic.source:965",
                "type": "Document",
                "label": "Heinrich et al., 2008, J. Clin. Oncol.",
                "xrefs": [
                    "pmc:PMC2651076",
                    "pmid:18955458"
                ],
                "title": "Primary and secondary kinase genotypes correlate with the biological and clinical activity of sunitinib in imatinib-resistant gastrointestinal stromal tumor."
            }
        ],
        "evidence_level": {
            "id": "vicc:e00008",
            "type": "Coding",
            "label": "case study evidence"
        },
        "target_proposition": {
            "id": "proposition:42ngEl1uFcVFPYb3HrPHjg84zoNQY7dE",
            "type": "VariationNeoplasmTherapeuticResponseProposition",
            "subject": "ga4gh:VA.2gBgJAKNHo14J6N0g8ZYsewGjZK1O2tQ",
            "predicate": "predicts_resistance_to",
            "object": {
                "id": "rxcui:357977",
                "type": "Therapeutic"
            },
            "neoplasm_type_qualifier": {
                "id": "ncit:C3868",
                "type": "Disease"
            }
        },
        "direction": "supports",
        "subject_descriptor": "civic.vid:961",
        "neoplasm_type_descriptor": {
            "id": "civic.did:2",
            "type": "DiseaseDescriptor",
            "label": "Gastrointestinal Stromal Tumor",
            "xrefs": [
                "DOID:9253"
            ],
            "disease": "ncit:C3868"
        },
        "object_descriptor": {
            "id": "civic.tid:157",
            "type": "TherapeuticDescriptor",
            "label": "Sunitinib",
            "extensions": [
                {
                    "type": "Extension",
                    "name": "regulatory_approval",
                    "value": {
                        "approval_rating": "FDA",
                        "has_indications": [
                            {
                                "id": "hemonc:602",
                                "type": "DiseaseDescriptor",
                                "label": "Gastrointestinal stromal tumor",
                                "disease": "ncit:C3868"
                            },
                            {
                                "id": "hemonc:647",
                                "type": "DiseaseDescriptor",
                                "label": "Pancreatic NET",
                                "disease": "ncit:C27720"
                            },
                            {
                                "id": "hemonc:660",
                                "type": "DiseaseDescriptor",
                                "label": "Renal cell carcinoma",
                                "disease": "ncit:C9385"
                            }
                        ]
                    }
                }
            ],
            "xrefs": [
                "ncit:C71622"
            ],
            "alternate_labels": [
                "1H-Pyrrole-3-carboxamide, N-(2-(diethylamino)ethyl)-5-((Z)-(5-fluoro-1,2-dihydro-2-oxo-3H-indol-3-ylidene)methyl)-2,4-dimethyl-"
            ],
            "therapeutic": "rxcui:357977"
        }
    },
    {
        "id": "civic.eid:4122",
        "type": "VariationNeoplasmTherapeuticResponseStatement",
        "description": "Patient 72 from a larger cohort of genotyped patients (n= 78) with imatinib resistant or intolerant gastrointestinal stromal tumors (GISTs) harbored a primary (pre-imatinib treatment) KIT V560D mutation. Following failure of imatinib, the GIST was again genotyped, but no secondary mutations were found. The patient took 50 mg sunitinib per day on a treatment schedule of four weeks on/two weeks off. The patient experienced progressive disease. Time to progression and overall survival were 9 and 33 weeks.",
        "method": "metakb.method:1",
        "is_reported_in": [
            {
                "id": "civic.source:965",
                "type": "Document",
                "label": "Heinrich et al., 2008, J. Clin. Oncol.",
                "xrefs": [
                    "pmc:PMC2651076",
                    "pmid:18955458"
                ],
                "title": "Primary and secondary kinase genotypes correlate with the biological and clinical activity of sunitinib in imatinib-resistant gastrointestinal stromal tumor."
            }
        ],
        "evidence_level": {
            "id": "vicc:e00008",
            "type": "Coding",
            "label": "case study evidence"
        },
        "target_proposition": {
            "id": "proposition:5XJJA5aUZQ7YwsALFLWBl5feaClNaexc",
            "type": "VariationNeoplasmTherapeuticResponseProposition",
            "subject": "ga4gh:VA.RiEsKFN3rMG6tsUuTa8OiOOucsjmMOVc",
            "predicate": "predicts_resistance_to",
            "object": {
                "id": "rxcui:357977",
                "type": "Therapeutic"
            },
            "neoplasm_type_qualifier": {
                "id": "ncit:C3868",
                "type": "Disease"
            }
        },
        "direction": "supports",
        "subject_descriptor": "civic.vid:971",
        "neoplasm_type_descriptor": {
            "id": "civic.did:2",
            "type": "DiseaseDescriptor",
            "label": "Gastrointestinal Stromal Tumor",
            "xrefs": [
                "DOID:9253"
            ],
            "disease": "ncit:C3868"
        },
        "object_descriptor": {
            "id": "civic.tid:157",
            "type": "TherapeuticDescriptor",
            "label": "Sunitinib",
            "extensions": [
                {
                    "type": "Extension",
                    "name": "regulatory_approval",
                    "value": {
                        "approval_rating": "FDA",
                        "has_indications": [
                            {
                                "id": "hemonc:602",
                                "type": "DiseaseDescriptor",
                                "label": "Gastrointestinal stromal tumor",
                                "disease": "ncit:C3868"
                            },
                            {
                                "id": "hemonc:647",
                                "type": "DiseaseDescriptor",
                                "label": "Pancreatic NET",
                                "disease": "ncit:C27720"
                            },
                            {
                                "id": "hemonc:660",
                                "type": "DiseaseDescriptor",
                                "label": "Renal cell carcinoma",
                                "disease": "ncit:C9385"
                            }
                        ]
                    }
                }
            ],
            "xrefs": [
                "ncit:C71622"
            ],
            "alternate_labels": [
                "1H-Pyrrole-3-carboxamide, N-(2-(diethylamino)ethyl)-5-((Z)-(5-fluoro-1,2-dihydro-2-oxo-3H-indol-3-ylidene)methyl)-2,4-dimethyl-"
            ],
            "therapeutic": "rxcui:357977"
        }
    },
    {
        "id": "civic.eid:4288",
        "type": "VariationNeoplasmTherapeuticResponseStatement",
        "description": "This study analyzed patients with non small cell lung cancer (NSCLC) who were positive for EML4-ALK fusions (ALK+) and progressed on crizotinib monotherapy. One patient was biopsied twice following crizotinib progression and once pre-treatment. This patient was a 27 year old female with one pack year who experienced partial response on crizotinib as 4th line therapy. The patient's pre-crizotinib biopsy was ALK+ and lacked the EGFR mutation. A biopsy taken after 63 days on crizotinib showed EGFR L858R mutation and lacked ALK gene rearrangement by FISH (ALK Loss). Of note, a second post-treatment biopsy (after 113 on crizotinib) showed ALK rearrangement but lacked EGFR mutation. The authors interpreted the emergence of an ALK negative tumor (first post-critozitinib biopsy) as evidence of a separate oncogenic driver (EGFR L858R).",
        "method": "metakb.method:1",
        "is_reported_in": [
            {
                "id": "civic.source:507",
                "type": "Document",
                "label": "Doebele et al., 2012, Clin. Cancer Res.",
                "xrefs": [
                    "pmc:PMC3311875",
                    "pmid:22235099"
                ],
                "title": "Mechanisms of resistance to crizotinib in patients with ALK gene rearranged non-small cell lung cancer."
            }
        ],
        "evidence_level": {
            "id": "vicc:e00008",
            "type": "Coding",
            "label": "case study evidence"
        },
        "target_proposition": {
            "id": "proposition:L6YKV_Vwsky2D9Mm2R2NJrQahYJQcc7D",
            "type": "VariationNeoplasmTherapeuticResponseProposition",
            "subject": "ga4gh:VA.g4fsoMUU_nKYxJrf-6Ah9J76mjF988xC",
            "predicate": "predicts_resistance_to",
            "object": {
                "id": "rxcui:1148495",
                "type": "Therapeutic"
            },
            "neoplasm_type_qualifier": {
                "id": "ncit:C2926",
                "type": "Disease"
            }
        },
        "direction": "supports",
        "subject_descriptor": "civic.vid:33",
        "neoplasm_type_descriptor": {
            "id": "civic.did:8",
            "type": "DiseaseDescriptor",
            "label": "Lung Non-small Cell Carcinoma",
            "xrefs": [
                "DOID:3908"
            ],
            "disease": "ncit:C2926"
        },
        "object_descriptor": {
            "id": "civic.tid:12",
            "type": "TherapeuticDescriptor",
            "label": "Crizotinib",
            "extensions": [
                {
                    "type": "Extension",
                    "name": "regulatory_approval",
                    "value": {
                        "approval_rating": "FDA",
                        "has_indications": [
                            {
                                "id": "hemonc:642",
                                "type": "DiseaseDescriptor",
                                "label": "Non-small cell lung cancer",
                                "disease": "ncit:C2926"
                            },
                            {
                                "id": "hemonc:25958",
                                "type": "DiseaseDescriptor",
                                "label": "Anaplastic large cell lymphoma pediatric",
                                "disease": null
                            }
                        ]
                    }
                }
            ],
            "xrefs": [
                "ncit:C74061"
            ],
            "alternate_labels": [
                "(R)-3-(1-(2,6-Dichloro-3-Fluorophenyl)Ethoxy)-5-(1-(Piperidin-4-Yl)-1h-Pyrazol-4-Yl)Pyridin-2-Amine",
                "2-Pyridinamine, 3-((1R)-1-(2,6-Dichloro-3-Fluorophenyl)Ethoxy)-5-(1-(4-Piperidinyl)-1H-Pyrazol-4-yl)-",
                "MET Tyrosine Kinase Inhibitor PF-02341066",
                "PF-02341066",
                "PF-2341066",
                "Xalkori"
            ],
            "therapeutic": "rxcui:1148495"
        }
    },
    {
        "id": "civic.eid:4424",
        "type": "VariationNeoplasmTherapeuticResponseStatement",
        "description": "This was a retrospective study of 691 cetuximab treated patients with metastatic colorectal cancer. Of those, 7 patients harbored PIK3CA E542K (exon 10), were wt for BRAF, NRAS and PIK3CA, and had individual response data. Two patients had partial response, three had stable disease, and two progressed, resulting in a response rate of 2/7 and a clinical benefit rate of 5/7 according to author criteria. Treatments included cetuximab + irinotecan (n=5), cetuximab + FOLFIRI (n=1), and cetuximab monotherapy (n=1). Median PFS was 34 weeks (17-48 weeks), median OS was 46 weeks (27-91 weeks), and median number of previous chemotherapy lines was 2 (0-4). Median age was 59 years old (53-74), and there were 6 females and one male. Using these and data from the larger cohort, authors concluded that PIK3CA exon 10 (listed as exon 9 in source) mutations are associated with weak or no resistance to cetuximab.",
        "method": "metakb.method:1",
        "is_reported_in": [
            {
                "id": "civic.source:76",
                "type": "Document",
                "label": "De Roock et al., 2010, Lancet Oncol.",
                "xrefs": [
                    "pmid:20619739"
                ],
                "title": "Effects of KRAS, BRAF, NRAS, and PIK3CA mutations on the efficacy of cetuximab plus chemotherapy in chemotherapy-refractory metastatic colorectal cancer: a retrospective consortium analysis."
            }
        ],
        "evidence_level": {
            "id": "vicc:e00008",
            "type": "Coding",
            "label": "case study evidence"
        },
        "target_proposition": {
            "id": "proposition:tvn8MjblI8tiqgqbvKy7Sz0E7ZZZ14eb",
            "type": "VariationNeoplasmTherapeuticResponseProposition",
            "subject": "ga4gh:VA.RTy0UiMi4D-aTPKvZBR3e3FXhFy4doaD",
            "predicate": "predicts_resistance_to",
            "object": {
                "id": "rxcui:318341",
                "type": "Therapeutic"
            },
            "neoplasm_type_qualifier": {
                "id": "ncit:C4978",
                "type": "Disease"
            }
        },
        "direction": "opposes",
        "subject_descriptor": "civic.vid:103",
        "neoplasm_type_descriptor": {
            "id": "civic.did:11",
            "type": "DiseaseDescriptor",
            "label": "Colorectal Cancer",
            "xrefs": [
                "DOID:9256"
            ],
            "disease": "ncit:C4978"
        },
        "object_descriptor": {
            "id": "civic.tid:16",
            "type": "TherapeuticDescriptor",
            "label": "Cetuximab",
            "extensions": [
                {
                    "type": "Extension",
                    "name": "regulatory_approval",
                    "value": {
                        "approval_rating": "ChEMBL",
                        "has_indications": [
                            {
                                "id": "mesh:D002294",
                                "type": "DiseaseDescriptor",
                                "label": "Carcinoma, Squamous Cell",
                                "disease": "ncit:C2929"
                            },
                            {
                                "id": "mesh:D009369",
                                "type": "DiseaseDescriptor",
                                "label": "Neoplasms",
                                "disease": "ncit:C3262"
                            },
                            {
                                "id": "mesh:D015179",
                                "type": "DiseaseDescriptor",
                                "label": "Colorectal Neoplasms",
                                "disease": "ncit:C2956"
                            },
                            {
                                "id": "mesh:D006258",
                                "type": "DiseaseDescriptor",
                                "label": "Head and Neck Neoplasms",
                                "disease": "ncit:C4013"
                            }
                        ]
                    }
                }
            ],
            "xrefs": [
                "ncit:C1723"
            ],
            "alternate_labels": [
                "Cetuximab Biosimilar CDP-1",
                "Cetuximab Biosimilar CMAB009",
                "Cetuximab Biosimilar KL 140",
                "Chimeric Anti-EGFR Monoclonal Antibody",
                "Chimeric MoAb C225",
                "Chimeric Monoclonal Antibody C225",
                "Erbitux",
                "IMC-C225"
            ],
            "therapeutic": "rxcui:318341"
        }
    },
    {
        "id": "civic.eid:4493",
        "type": "VariationNeoplasmTherapeuticResponseStatement",
        "description": "A 61 year old male never smoker with EGFR H773_V774insNPH mutant lung adenocarcinoma was treated with fourth line erlotinib and had progressive disease as best response, progression free survival of 1.6 months, and overall survival of 4.4 months.",
        "method": "metakb.method:1",
        "is_reported_in": [
            {
                "id": "civic.source:1230",
                "type": "Document",
                "label": "Yasuda et al., 2013, Sci Transl Med",
                "xrefs": [
                    "pmc:PMC3954775",
                    "pmid:24353160"
                ],
                "title": "Structural, biochemical, and clinical characterization of epidermal growth factor receptor (EGFR) exon 20 insertion mutations in lung cancer."
            }
        ],
        "evidence_level": {
            "id": "vicc:e00008",
            "type": "Coding",
            "label": "case study evidence"
        },
        "target_proposition": {
            "id": "proposition:-4Sl8WTmDjamvXDEGrnKM3745KA3ru1w",
            "type": "VariationNeoplasmTherapeuticResponseProposition",
            "subject": "ga4gh:VA.M8PexLRl72ptK5F806FDVtZ061KiX5HQ",
            "predicate": "predicts_resistance_to",
            "object": {
                "id": "rxcui:337525",
                "type": "Therapeutic"
            },
            "neoplasm_type_qualifier": {
                "id": "ncit:C3512",
                "type": "Disease"
            }
        },
        "direction": "supports",
        "subject_descriptor": "civic.vid:1513",
        "neoplasm_type_descriptor": {
            "id": "civic.did:30",
            "type": "DiseaseDescriptor",
            "label": "Lung Adenocarcinoma",
            "xrefs": [
                "DOID:3910"
            ],
            "disease": "ncit:C3512"
        },
        "object_descriptor": {
            "id": "civic.tid:15",
            "type": "TherapeuticDescriptor",
            "label": "Erlotinib",
            "extensions": [
                {
                    "type": "Extension",
                    "name": "regulatory_approval",
                    "value": {
                        "approval_rating": "FDA",
                        "has_indications": [
                            {
                                "id": "hemonc:642",
                                "type": "DiseaseDescriptor",
                                "label": "Non-small cell lung cancer",
                                "disease": "ncit:C2926"
                            },
                            {
                                "id": "hemonc:648",
                                "type": "DiseaseDescriptor",
                                "label": "Pancreatic cancer",
                                "disease": "ncit:C43298"
                            }
                        ]
                    }
                }
            ],
            "xrefs": [
                "ncit:C65530"
            ],
            "therapeutic": "rxcui:337525"
        }
    },
    {
        "id": "civic.eid:4597",
        "type": "VariationNeoplasmTherapeuticResponseStatement",
        "description": "Patients 29 and 66 from a larger cohort of genotyped patients (n= 78) with imatinib resistant or intolerant gastrointestinal stromal tumors (GISTs) harbored a primary (pre-imatinib treatment) PDGFRA D842V mutation. Following failure of imatinib, the GIST was again genotyped, but no secondary mutations were found. Patients took 50 mg sunitib per day. Patient 29 was on a treatment schedule of two weeks on/two weeks off, and patient 66 was scheduled for four weeks on/two weeks off.  Patient 29 experienced stable disease for less than 6 months and patient 66 experienced disease progression. Time to progression was censored at 0.1 weeks for patient 29 and was 10 weeks for patient 66. Overall survival was 99 and censored at 129 weeks for patients 29 and 66.",
        "method": "metakb.method:1",
        "is_reported_in": [
            {
                "id": "civic.source:965",
                "type": "Document",
                "label": "Heinrich et al., 2008, J. Clin. Oncol.",
                "xrefs": [
                    "pmc:PMC2651076",
                    "pmid:18955458"
                ],
                "title": "Primary and secondary kinase genotypes correlate with the biological and clinical activity of sunitinib in imatinib-resistant gastrointestinal stromal tumor."
            }
        ],
        "evidence_level": {
            "id": "vicc:e00008",
            "type": "Coding",
            "label": "case study evidence"
        },
        "target_proposition": {
            "id": "proposition:SZjWnrjmNxW_4rBawkxP-gtOZe0bOTT2",
            "type": "VariationNeoplasmTherapeuticResponseProposition",
            "subject": "ga4gh:VA.CaTuLaWlUwLb32qfYTW2udl2Iy02ccN6",
            "predicate": "predicts_resistance_to",
            "object": {
                "id": "rxcui:357977",
                "type": "Therapeutic"
            },
            "neoplasm_type_qualifier": {
                "id": "ncit:C3868",
                "type": "Disease"
            }
        },
        "direction": "supports",
        "subject_descriptor": "civic.vid:99",
        "neoplasm_type_descriptor": {
            "id": "civic.did:2",
            "type": "DiseaseDescriptor",
            "label": "Gastrointestinal Stromal Tumor",
            "xrefs": [
                "DOID:9253"
            ],
            "disease": "ncit:C3868"
        },
        "object_descriptor": {
            "id": "civic.tid:157",
            "type": "TherapeuticDescriptor",
            "label": "Sunitinib",
            "extensions": [
                {
                    "type": "Extension",
                    "name": "regulatory_approval",
                    "value": {
                        "approval_rating": "FDA",
                        "has_indications": [
                            {
                                "id": "hemonc:602",
                                "type": "DiseaseDescriptor",
                                "label": "Gastrointestinal stromal tumor",
                                "disease": "ncit:C3868"
                            },
                            {
                                "id": "hemonc:647",
                                "type": "DiseaseDescriptor",
                                "label": "Pancreatic NET",
                                "disease": "ncit:C27720"
                            },
                            {
                                "id": "hemonc:660",
                                "type": "DiseaseDescriptor",
                                "label": "Renal cell carcinoma",
                                "disease": "ncit:C9385"
                            }
                        ]
                    }
                }
            ],
            "xrefs": [
                "ncit:C71622"
            ],
            "alternate_labels": [
                "1H-Pyrrole-3-carboxamide, N-(2-(diethylamino)ethyl)-5-((Z)-(5-fluoro-1,2-dihydro-2-oxo-3H-indol-3-ylidene)methyl)-2,4-dimethyl-"
            ],
            "therapeutic": "rxcui:357977"
        }
    },
    {
        "id": "civic.eid:4802",
        "type": "VariationNeoplasmTherapeuticResponseStatement",
        "description": "A 79 year old Asian male never smoker with not otherwise specified NSCLC harboring EGFR P772_H773insYNP mutation was given erlotinib as first line treatment, and had progressive disease as best response with +2.3% change to target lesions, progression free survival of 2.1 months and overall survival of 16.5 months.",
        "method": "metakb.method:1",
        "is_reported_in": [
            {
                "id": "civic.source:1230",
                "type": "Document",
                "label": "Yasuda et al., 2013, Sci Transl Med",
                "xrefs": [
                    "pmc:PMC3954775",
                    "pmid:24353160"
                ],
                "title": "Structural, biochemical, and clinical characterization of epidermal growth factor receptor (EGFR) exon 20 insertion mutations in lung cancer."
            }
        ],
        "evidence_level": {
            "id": "vicc:e00008",
            "type": "Coding",
            "label": "case study evidence"
        },
        "target_proposition": {
            "id": "proposition:KnyilFF7X7efVgJFQbkdZP_wAlmuLhh4",
            "type": "VariationNeoplasmTherapeuticResponseProposition",
            "subject": "ga4gh:VA.T8W7v7wFSIueQhXivzirzxnG5lZemOzY",
            "predicate": "predicts_resistance_to",
            "object": {
                "id": "rxcui:337525",
                "type": "Therapeutic"
            },
            "neoplasm_type_qualifier": {
                "id": "ncit:C2926",
                "type": "Disease"
            }
        },
        "direction": "supports",
        "subject_descriptor": "civic.vid:1667",
        "neoplasm_type_descriptor": {
            "id": "civic.did:8",
            "type": "DiseaseDescriptor",
            "label": "Lung Non-small Cell Carcinoma",
            "xrefs": [
                "DOID:3908"
            ],
            "disease": "ncit:C2926"
        },
        "object_descriptor": {
            "id": "civic.tid:15",
            "type": "TherapeuticDescriptor",
            "label": "Erlotinib",
            "extensions": [
                {
                    "type": "Extension",
                    "name": "regulatory_approval",
                    "value": {
                        "approval_rating": "FDA",
                        "has_indications": [
                            {
                                "id": "hemonc:642",
                                "type": "DiseaseDescriptor",
                                "label": "Non-small cell lung cancer",
                                "disease": "ncit:C2926"
                            },
                            {
                                "id": "hemonc:648",
                                "type": "DiseaseDescriptor",
                                "label": "Pancreatic cancer",
                                "disease": "ncit:C43298"
                            }
                        ]
                    }
                }
            ],
            "xrefs": [
                "ncit:C65530"
            ],
            "therapeutic": "rxcui:337525"
        }
    },
    {
        "id": "civic.eid:10035",
        "type": "VariationNeoplasmTherapeuticResponseStatement",
        "description": "A cohort of 32 colorectal cancer patients with acquired resistance to cetuximab (PFS > 12 weeks) was analyzed. 1 patient had the PIK3CA p.L938* mutation. Cell viability studies of DiFi cells transfected with this PIK3CA variant did not exhibit resistance.",
        "method": "metakb.method:1",
        "is_reported_in": [
            {
                "id": "civic.source:2196",
                "type": "Document",
                "label": "Xu et al., 2017, Clin. Cancer Res.",
                "xrefs": [
                    "pmc:PMC5559326",
                    "pmid:28424201"
                ],
                "title": "PIK3CA Mutations Contribute to Acquired Cetuximab Resistance in Patients with Metastatic Colorectal Cancer."
            }
        ],
        "evidence_level": {
            "id": "vicc:e00008",
            "type": "Coding",
            "label": "case study evidence"
        },
        "target_proposition": {
            "id": "proposition:mxD0UM6JTShy5_X_aWEtJkKP5VZNdvmt",
            "type": "VariationNeoplasmTherapeuticResponseProposition",
            "subject": "ga4gh:VA.6qUj0X0feKveHQmxs3MEu81dnZXKpuqz",
            "predicate": "predicts_resistance_to",
            "object": {
                "id": "rxcui:318341",
                "type": "Therapeutic"
            },
            "neoplasm_type_qualifier": {
                "id": "ncit:C4978",
                "type": "Disease"
            }
        },
        "direction": "opposes",
        "subject_descriptor": "civic.vid:3670",
        "neoplasm_type_descriptor": {
            "id": "civic.did:11",
            "type": "DiseaseDescriptor",
            "label": "Colorectal Cancer",
            "xrefs": [
                "DOID:9256"
            ],
            "disease": "ncit:C4978"
        },
        "object_descriptor": {
            "id": "civic.tid:16",
            "type": "TherapeuticDescriptor",
            "label": "Cetuximab",
            "extensions": [
                {
                    "type": "Extension",
                    "name": "regulatory_approval",
                    "value": {
                        "approval_rating": "ChEMBL",
                        "has_indications": [
                            {
                                "id": "mesh:D002294",
                                "type": "DiseaseDescriptor",
                                "label": "Carcinoma, Squamous Cell",
                                "disease": "ncit:C2929"
                            },
                            {
                                "id": "mesh:D009369",
                                "type": "DiseaseDescriptor",
                                "label": "Neoplasms",
                                "disease": "ncit:C3262"
                            },
                            {
                                "id": "mesh:D015179",
                                "type": "DiseaseDescriptor",
                                "label": "Colorectal Neoplasms",
                                "disease": "ncit:C2956"
                            },
                            {
                                "id": "mesh:D006258",
                                "type": "DiseaseDescriptor",
                                "label": "Head and Neck Neoplasms",
                                "disease": "ncit:C4013"
                            }
                        ]
                    }
                }
            ],
            "xrefs": [
                "ncit:C1723"
            ],
            "alternate_labels": [
                "Cetuximab Biosimilar CDP-1",
                "Cetuximab Biosimilar CMAB009",
                "Cetuximab Biosimilar KL 140",
                "Chimeric Anti-EGFR Monoclonal Antibody",
                "Chimeric MoAb C225",
                "Chimeric Monoclonal Antibody C225",
                "Erbitux",
                "IMC-C225"
            ],
            "therapeutic": "rxcui:318341"
        }
    },
    {
        "id": "civic.eid:91",
        "type": "VariationNeoplasmTherapeuticResponseStatement",
        "description": "In a patient with V600E-positive NSCLC, KRAS G12D seemed to confer resistance to dabrafenib.",
        "method": "metakb.method:1",
        "is_reported_in": [
            {
                "id": "civic.source:101",
                "type": "Document",
                "label": "Rudin et al., 2013, J Thorac Oncol",
                "xrefs": [
                    "pmc:PMC3634121",
                    "pmid:23524406"
                ],
                "title": "Molecular characterization of acquired resistance to the BRAF inhibitor dabrafenib in a patient with BRAF-mutant non-small-cell lung cancer."
            }
        ],
        "evidence_level": {
            "id": "vicc:e00008",
            "type": "Coding",
            "label": "case study evidence"
        },
        "target_proposition": {
            "id": "proposition:li7U3CZvtp7Uv2IaeT8h_eArR3ypuXG9",
            "type": "VariationNeoplasmTherapeuticResponseProposition",
            "subject": "ga4gh:VA.h313H4CQh6pogbbSJ3H5pI1cPoh9YMm_",
            "predicate": "predicts_resistance_to",
            "object": {
                "id": "rxcui:1424911",
                "type": "Therapeutic"
            },
            "neoplasm_type_qualifier": {
                "id": "ncit:C2926",
                "type": "Disease"
            }
        },
        "direction": "supports",
        "subject_descriptor": "civic.vid:12",
        "neoplasm_type_descriptor": {
            "id": "civic.did:8",
            "type": "DiseaseDescriptor",
            "label": "Lung Non-small Cell Carcinoma",
            "xrefs": [
                "DOID:3908"
            ],
            "disease": "ncit:C2926"
        },
        "object_descriptor": {
            "id": "civic.tid:22",
            "type": "TherapeuticDescriptor",
            "label": "Dabrafenib",
            "extensions": [
                {
                    "type": "Extension",
                    "name": "regulatory_approval",
                    "value": {
                        "approval_rating": "FDA",
                        "has_indications": [
                            {
                                "id": "hemonc:675",
                                "type": "DiseaseDescriptor",
                                "label": "Thyroid cancer",
                                "disease": "ncit:C7510"
                            },
                            {
                                "id": "hemonc:629",
                                "type": "DiseaseDescriptor",
                                "label": "Melanoma",
                                "disease": "ncit:C3224"
                            },
                            {
                                "id": "hemonc:642",
                                "type": "DiseaseDescriptor",
                                "label": "Non-small cell lung cancer",
                                "disease": "ncit:C2926"
                            }
                        ]
                    }
                }
            ],
            "xrefs": [
                "ncit:C82386"
            ],
            "alternate_labels": [
                "BRAF Inhibitor GSK2118436",
                "Benzenesulfonamide, N-(3-(5-(2-amino-4-pyrimidinyl)-2-(1,1-dimethylethyl)-4-thiazolyl)-2-fluorophenyl)-2,6-difluoro-",
                "GSK-2118436",
                "GSK-2118436A",
                "GSK2118436"
            ],
            "therapeutic": "rxcui:1424911"
        }
    },
    {
        "id": "civic.eid:1131",
        "type": "VariationNeoplasmTherapeuticResponseStatement",
        "description": "A 43-year-old female was diagnosed with an adenocarcinoma of the ascending colon and received 6-months of adjuvant chemotherapy. After 5 years of completion of adjuvant chemotherapy, the disease relapsed. EGFR was assessed by immunohistochemistry, and the patient was subsequently treated with the anti-EGFR monoclonal antibody panitumumab. However, there was a rapid clinical worsening, which may possibly be attributed to a somatic mutation in KRAS (Q22*).",
        "method": "metakb.method:1",
        "is_reported_in": [
            {
                "id": "civic.source:782",
                "type": "Document",
                "label": "Palmirotta et al., 2009, Anticancer Res.",
                "xrefs": [
                    "pmid:19661358"
                ],
                "title": "A novel K-ras mutation in colorectal cancer. A case report and literature review."
            }
        ],
        "evidence_level": {
            "id": "vicc:e00008",
            "type": "Coding",
            "label": "case study evidence"
        },
        "target_proposition": {
            "id": "proposition:bxDZ2bvbSuGTxTiBtsKID5lEX12z0Hbq",
            "type": "VariationNeoplasmTherapeuticResponseProposition",
            "subject": "ga4gh:VA.Nep4la-HCabJwJ4g_Ur7HQrTpT4TeHUQ",
            "predicate": "predicts_resistance_to",
            "object": {
                "id": "rxcui:263034",
                "type": "Therapeutic"
            },
            "neoplasm_type_qualifier": {
                "id": "ncit:C7966",
                "type": "Disease"
            }
        },
        "direction": "supports",
        "subject_descriptor": "civic.vid:479",
        "neoplasm_type_descriptor": {
            "id": "civic.did:691",
            "type": "DiseaseDescriptor",
            "label": "Colon Mucinous Adenocarcinoma",
            "xrefs": [
                "DOID:3029"
            ],
            "disease": "ncit:C7966"
        },
        "object_descriptor": {
            "id": "civic.tid:28",
            "type": "TherapeuticDescriptor",
            "label": "Panitumumab",
            "extensions": [
                {
                    "type": "Extension",
                    "name": "regulatory_approval",
                    "value": {
                        "approval_rating": "ChEMBL",
                        "has_indications": [
                            {
                                "id": "mesh:D009369",
                                "type": "DiseaseDescriptor",
                                "label": "Neoplasms",
                                "disease": "ncit:C3262"
                            },
                            {
                                "id": "mesh:D015179",
                                "type": "DiseaseDescriptor",
                                "label": "Colorectal Neoplasms",
                                "disease": "ncit:C2956"
                            }
                        ]
                    }
                }
            ],
            "xrefs": [
                "ncit:C1857"
            ],
            "alternate_labels": [
                "ABX-EGF",
                "ABX-EGF Monoclonal Antibody",
                "ABX-EGF, Clone E7.6.3",
                "E7.6.3",
                "Human IgG2K Monoclonal Antibody",
                "MoAb ABX-EGF",
                "MoAb E7.6.3",
                "Monoclonal Antibody ABX-EGF",
                "Monoclonal Antibody E7.6.3",
                "Vectibix"
            ],
            "therapeutic": "rxcui:263034"
        }
    },
    {
        "id": "civic.eid:1533",
        "type": "VariationNeoplasmTherapeuticResponseStatement",
        "description": "A 26-year old patient presented with vemurafenib resistant BRAF-mutated (V600E) cutaneous melanoma. Five of his metastases were evaluated using whole genome sequencing. A GNAQ (Q209P) mutation was identified as unanimously present in all five tumors.",
        "method": "metakb.method:1",
        "is_reported_in": [
            {
                "id": "civic.source:1021",
                "type": "Document",
                "label": "Turajlic et al., 2014, Ann. Oncol.",
                "xrefs": [
                    "pmc:PMC3999800",
                    "pmid:24504448"
                ],
                "title": "Whole-genome sequencing reveals complex mechanisms of intrinsic resistance to BRAF inhibition."
            }
        ],
        "evidence_level": {
            "id": "vicc:e00008",
            "type": "Coding",
            "label": "case study evidence"
        },
        "target_proposition": {
            "id": "proposition:lhaf-VxwRcFEIpRj8iAvQPUn33sytU37",
            "type": "VariationNeoplasmTherapeuticResponseProposition",
            "subject": "ga4gh:VA.QYkNQvhUn7ivhb5plpyq7Hb9EpKTXT91",
            "predicate": "predicts_resistance_to",
            "object": {
                "id": "rxcui:1147220",
                "type": "Therapeutic"
            },
            "neoplasm_type_qualifier": {
                "id": "ncit:C3510",
                "type": "Disease"
            }
        },
        "direction": "supports",
        "subject_descriptor": "civic.vid:604",
        "neoplasm_type_descriptor": {
            "id": "civic.did:206",
            "type": "DiseaseDescriptor",
            "label": "Skin Melanoma",
            "xrefs": [
                "DOID:8923"
            ],
            "disease": "ncit:C3510"
        },
        "object_descriptor": {
            "id": "civic.tid:4",
            "type": "TherapeuticDescriptor",
            "label": "Vemurafenib",
            "extensions": [
                {
                    "type": "Extension",
                    "name": "regulatory_approval",
                    "value": {
                        "approval_rating": "FDA",
                        "has_indications": [
                            {
                                "id": "hemonc:629",
                                "type": "DiseaseDescriptor",
                                "label": "Melanoma",
                                "disease": "ncit:C3224"
                            },
                            {
                                "id": "hemonc:594",
                                "type": "DiseaseDescriptor",
                                "label": "Erdheim-Chester disease",
                                "disease": "ncit:C53972"
                            }
                        ]
                    }
                }
            ],
            "xrefs": [
                "ncit:C64768"
            ],
            "alternate_labels": [
                "1-propanesulfonamide, N-(3-((5-(4-chlorophenyl)-1h-pyrrolo(2,3-b)pyridin-3-yl)carbonyl)-2,4-difluorophenyl)-",
                "BRAF (V600E) Kinase Inhibitor RO5185426",
                "BRAF(V600E) Kinase Inhibitor RO5185426",
                "PLX-4032",
                "PLX4032",
                "RG 7204",
                "RG7204",
                "RO 5185426",
                "Zelboraf"
            ],
            "therapeutic": "rxcui:1147220"
        }
    },
    {
        "id": "civic.eid:1580",
        "type": "VariationNeoplasmTherapeuticResponseStatement",
        "description": "One patient enrolled in a clinical study to evaluate vemurafenib treatment of BRAF V600E mutant hairy-cell leukemia developed resistance to vemurafenib retreatment. 300-gene targeted sequencing of the patient\u2019s genome revealed activating subclonal KRAS mutations (KRAS G12D, 15.2% allele frequency; KRAS K117N, 1.2%), as well as a RUNX1 A55E mutation (5.9%) that had not been seen prior to vemurafenib treatment or at remission. BRAF V600E allele frequency was detectable (2.4%) at the time of remission but dramatically increased at relapse (64.9%).",
        "method": "metakb.method:1",
        "is_reported_in": [
            {
                "id": "civic.source:1043",
                "type": "Document",
                "label": "Tiacci et al., 2015, N. Engl. J. Med.",
                "xrefs": [
                    "pmc:PMC4811324",
                    "pmid:26352686"
                ],
                "title": "Targeting Mutant BRAF in Relapsed or Refractory Hairy-Cell Leukemia."
            }
        ],
        "evidence_level": {
            "id": "vicc:e00008",
            "type": "Coding",
            "label": "case study evidence"
        },
        "target_proposition": {
            "id": "proposition:IOLIOANuVbafVrWrPiUYF1w61-U2ernz",
            "type": "VariationNeoplasmTherapeuticResponseProposition",
            "subject": "ga4gh:VA.jSiuIG2uZEbml8MfCtZi3J9jPBCBiaPw",
            "predicate": "predicts_resistance_to",
            "object": {
                "id": "rxcui:1147220",
                "type": "Therapeutic"
            },
            "neoplasm_type_qualifier": {
                "id": "ncit:C7402",
                "type": "Disease"
            }
        },
        "direction": "supports",
        "subject_descriptor": "civic.vid:79",
        "neoplasm_type_descriptor": {
            "id": "civic.did:665",
            "type": "DiseaseDescriptor",
            "label": "Hairy Cell Leukemia",
            "xrefs": [
                "DOID:285"
            ],
            "disease": "ncit:C7402"
        },
        "object_descriptor": {
            "id": "civic.tid:4",
            "type": "TherapeuticDescriptor",
            "label": "Vemurafenib",
            "extensions": [
                {
                    "type": "Extension",
                    "name": "regulatory_approval",
                    "value": {
                        "approval_rating": "FDA",
                        "has_indications": [
                            {
                                "id": "hemonc:629",
                                "type": "DiseaseDescriptor",
                                "label": "Melanoma",
                                "disease": "ncit:C3224"
                            },
                            {
                                "id": "hemonc:594",
                                "type": "DiseaseDescriptor",
                                "label": "Erdheim-Chester disease",
                                "disease": "ncit:C53972"
                            }
                        ]
                    }
                }
            ],
            "xrefs": [
                "ncit:C64768"
            ],
            "alternate_labels": [
                "1-propanesulfonamide, N-(3-((5-(4-chlorophenyl)-1h-pyrrolo(2,3-b)pyridin-3-yl)carbonyl)-2,4-difluorophenyl)-",
                "BRAF (V600E) Kinase Inhibitor RO5185426",
                "BRAF(V600E) Kinase Inhibitor RO5185426",
                "PLX-4032",
                "PLX4032",
                "RG 7204",
                "RG7204",
                "RO 5185426",
                "Zelboraf"
            ],
            "therapeutic": "rxcui:1147220"
        }
    },
    {
        "id": "civic.eid:1652",
        "type": "VariationNeoplasmTherapeuticResponseStatement",
        "description": "Case report of a patient with NSCLC harboring a MET exon 14 skipping mutation and initial response to crizotinib. A second biopsy at the time of progression revealed an acquired MET D1228N mutation.",
        "method": "metakb.method:1",
        "is_reported_in": [
            {
                "id": "civic.source:1116",
                "type": "Document",
                "label": "Heist et al., 2016, J Thorac Oncol",
                "xrefs": [
                    "pmid:27343442"
                ],
                "title": "Acquired Resistance to Crizotinib in NSCLC with MET\u00a0Exon 14 Skipping."
            }
        ],
        "evidence_level": {
            "id": "vicc:e00008",
            "type": "Coding",
            "label": "case study evidence"
        },
        "target_proposition": {
            "id": "proposition:28STe92mypTQ6Hc3eGEZwMwdSdbTIDrp",
            "type": "VariationNeoplasmTherapeuticResponseProposition",
            "subject": "ga4gh:VA.wlreUeNuU4y1nx3PP5s4polEIruvosqO",
            "predicate": "predicts_resistance_to",
            "object": {
                "id": "rxcui:1148495",
                "type": "Therapeutic"
            },
            "neoplasm_type_qualifier": {
                "id": "ncit:C2926",
                "type": "Disease"
            }
        },
        "direction": "supports",
        "subject_descriptor": "civic.vid:649",
        "neoplasm_type_descriptor": {
            "id": "civic.did:8",
            "type": "DiseaseDescriptor",
            "label": "Lung Non-small Cell Carcinoma",
            "xrefs": [
                "DOID:3908"
            ],
            "disease": "ncit:C2926"
        },
        "object_descriptor": {
            "id": "civic.tid:12",
            "type": "TherapeuticDescriptor",
            "label": "Crizotinib",
            "extensions": [
                {
                    "type": "Extension",
                    "name": "regulatory_approval",
                    "value": {
                        "approval_rating": "FDA",
                        "has_indications": [
                            {
                                "id": "hemonc:642",
                                "type": "DiseaseDescriptor",
                                "label": "Non-small cell lung cancer",
                                "disease": "ncit:C2926"
                            },
                            {
                                "id": "hemonc:25958",
                                "type": "DiseaseDescriptor",
                                "label": "Anaplastic large cell lymphoma pediatric",
                                "disease": null
                            }
                        ]
                    }
                }
            ],
            "xrefs": [
                "ncit:C74061"
            ],
            "alternate_labels": [
                "(R)-3-(1-(2,6-Dichloro-3-Fluorophenyl)Ethoxy)-5-(1-(Piperidin-4-Yl)-1h-Pyrazol-4-Yl)Pyridin-2-Amine",
                "2-Pyridinamine, 3-((1R)-1-(2,6-Dichloro-3-Fluorophenyl)Ethoxy)-5-(1-(4-Piperidinyl)-1H-Pyrazol-4-yl)-",
                "MET Tyrosine Kinase Inhibitor PF-02341066",
                "PF-02341066",
                "PF-2341066",
                "Xalkori"
            ],
            "therapeutic": "rxcui:1148495"
        }
    },
    {
        "id": "civic.eid:1715",
        "type": "VariationNeoplasmTherapeuticResponseStatement",
        "description": "Case report of a 59-year-old white female patient (60 pack-years) with a CUP-syndrome. Molecular profiling identified both MET amplification (16 copies) and a KRAS G12V mutation. The patient was treated with crizotinib and experienced a complete normalization of tumor metabolic activity for more than 19 months. Other identified aberrations include CCND1 amplification (8 copies), MYC amplification (9 copies) as well as KRAS G12V, TP53 R273L and CARD11 N184S.",
        "method": "metakb.method:1",
        "is_reported_in": [
            {
                "id": "civic.source:1158",
                "type": "Document",
                "label": "Palma et al., 2014, Case Rep Oncol",
                "xrefs": [
                    "pmc:PMC4164090",
                    "pmid:25232318"
                ],
                "title": "Durable Response to Crizotinib in a MET-Amplified, KRAS-Mutated Carcinoma of Unknown Primary."
            }
        ],
        "evidence_level": {
            "id": "vicc:e00008",
            "type": "Coding",
            "label": "case study evidence"
        },
        "target_proposition": {
            "id": "proposition:FyoQ1mmJYBU7dNqx-juMjfERBPABDVvc",
            "type": "VariationNeoplasmTherapeuticResponseProposition",
            "subject": "ga4gh:VA.VBKi2jNxAs378IqOBsveoPrYQjWPngQq",
            "predicate": "predicts_resistance_to",
            "object": {
                "id": "rxcui:1148495",
                "type": "Therapeutic"
            },
            "neoplasm_type_qualifier": {
                "id": "ncit:C9305",
                "type": "Disease"
            }
        },
        "direction": "opposes",
        "subject_descriptor": "civic.vid:425",
        "neoplasm_type_descriptor": {
            "id": "civic.did:216",
            "type": "DiseaseDescriptor",
            "label": "Cancer",
            "xrefs": [
                "DOID:162"
            ],
            "disease": "ncit:C9305"
        },
        "object_descriptor": {
            "id": "civic.tid:12",
            "type": "TherapeuticDescriptor",
            "label": "Crizotinib",
            "extensions": [
                {
                    "type": "Extension",
                    "name": "regulatory_approval",
                    "value": {
                        "approval_rating": "FDA",
                        "has_indications": [
                            {
                                "id": "hemonc:642",
                                "type": "DiseaseDescriptor",
                                "label": "Non-small cell lung cancer",
                                "disease": "ncit:C2926"
                            },
                            {
                                "id": "hemonc:25958",
                                "type": "DiseaseDescriptor",
                                "label": "Anaplastic large cell lymphoma pediatric",
                                "disease": null
                            }
                        ]
                    }
                }
            ],
            "xrefs": [
                "ncit:C74061"
            ],
            "alternate_labels": [
                "(R)-3-(1-(2,6-Dichloro-3-Fluorophenyl)Ethoxy)-5-(1-(Piperidin-4-Yl)-1h-Pyrazol-4-Yl)Pyridin-2-Amine",
                "2-Pyridinamine, 3-((1R)-1-(2,6-Dichloro-3-Fluorophenyl)Ethoxy)-5-(1-(4-Piperidinyl)-1H-Pyrazol-4-yl)-",
                "MET Tyrosine Kinase Inhibitor PF-02341066",
                "PF-02341066",
                "PF-2341066",
                "Xalkori"
            ],
            "therapeutic": "rxcui:1148495"
        }
    },
    {
        "id": "civic.eid:2184",
        "type": "VariationNeoplasmTherapeuticResponseStatement",
        "description": "Five patients participating in a large retrospective study of cetuximab in metastatic, treatment refractory colorectal cancer had tumors which harbored NRAS Q61R and were wildtype for KRAS, BRAF and PIK3CA. Overall, one patient experienced stable disease, and the other four experienced progressive disease.The five patients whose tumors harbored NRAS Q61R included a 65 year old male treated with cetuximab monotherapy as a 3rd line treatment who experienced progressive disease and had PFS of 6 weeks and OS of 41 weeks; a 47 year old female treated with cetuximab and ironotecan as a 5th line therapy who experienced progressive disease and had PFS of 4 weeks and OS of 10 weeks; a 60 year old female treated with cetuximab and ironotecan as a 3rd line therapy who experienced stable disease and had PFS of 24 weeks and OS of 38 weeks; a 47 year old female treated with cetuximab and ironotecan as a 3rd line therapy who experienced progressive disease and had PFS of 14 weeks and OS of 18 weeks; and a 77 year old male treated with cetuximab monotherapy as a 1st line therapy who experienced progressive disease and had PFS of 7 weeks and OS of 67 weeks.",
        "method": "metakb.method:1",
        "is_reported_in": [
            {
                "id": "civic.source:76",
                "type": "Document",
                "label": "De Roock et al., 2010, Lancet Oncol.",
                "xrefs": [
                    "pmid:20619739"
                ],
                "title": "Effects of KRAS, BRAF, NRAS, and PIK3CA mutations on the efficacy of cetuximab plus chemotherapy in chemotherapy-refractory metastatic colorectal cancer: a retrospective consortium analysis."
            }
        ],
        "evidence_level": {
            "id": "vicc:e00008",
            "type": "Coding",
            "label": "case study evidence"
        },
        "target_proposition": {
            "id": "proposition:e6ctjf6Fon57nawx9EmeoJi44AZDEjK0",
            "type": "VariationNeoplasmTherapeuticResponseProposition",
            "subject": "ga4gh:VA.RI834ljUlgAn9ez2JG32bVVchgx-t7Pp",
            "predicate": "predicts_resistance_to",
            "object": {
                "id": "rxcui:318341",
                "type": "Therapeutic"
            },
            "neoplasm_type_qualifier": {
                "id": "ncit:C4978",
                "type": "Disease"
            }
        },
        "direction": "supports",
        "subject_descriptor": "civic.vid:96",
        "neoplasm_type_descriptor": {
            "id": "civic.did:11",
            "type": "DiseaseDescriptor",
            "label": "Colorectal Cancer",
            "xrefs": [
                "DOID:9256"
            ],
            "disease": "ncit:C4978"
        },
        "object_descriptor": {
            "id": "civic.tid:16",
            "type": "TherapeuticDescriptor",
            "label": "Cetuximab",
            "extensions": [
                {
                    "type": "Extension",
                    "name": "regulatory_approval",
                    "value": {
                        "approval_rating": "ChEMBL",
                        "has_indications": [
                            {
                                "id": "mesh:D002294",
                                "type": "DiseaseDescriptor",
                                "label": "Carcinoma, Squamous Cell",
                                "disease": "ncit:C2929"
                            },
                            {
                                "id": "mesh:D009369",
                                "type": "DiseaseDescriptor",
                                "label": "Neoplasms",
                                "disease": "ncit:C3262"
                            },
                            {
                                "id": "mesh:D015179",
                                "type": "DiseaseDescriptor",
                                "label": "Colorectal Neoplasms",
                                "disease": "ncit:C2956"
                            },
                            {
                                "id": "mesh:D006258",
                                "type": "DiseaseDescriptor",
                                "label": "Head and Neck Neoplasms",
                                "disease": "ncit:C4013"
                            }
                        ]
                    }
                }
            ],
            "xrefs": [
                "ncit:C1723"
            ],
            "alternate_labels": [
                "Cetuximab Biosimilar CDP-1",
                "Cetuximab Biosimilar CMAB009",
                "Cetuximab Biosimilar KL 140",
                "Chimeric Anti-EGFR Monoclonal Antibody",
                "Chimeric MoAb C225",
                "Chimeric Monoclonal Antibody C225",
                "Erbitux",
                "IMC-C225"
            ],
            "therapeutic": "rxcui:318341"
        }
    },
    {
        "id": "civic.eid:2268",
        "type": "VariationNeoplasmTherapeuticResponseStatement",
        "description": "In recurrent lung cancer patients treated with the epidermal growth factor receptor tyrosine kinase inhibitor gefitinib, patients with KRAS mutations had a lower frequency of partial response (PR) and stable disease (SD) and a higher rate of progressive disease (PD) (PR:0, SD:1, PD:15 vs. PR:24, SD:8, PD:14; P=0.0274) compared to wildtype KRAS patients. Patients with KRAS mutations also had a shorter overall survival compared to wildtype KRAS patients (HR:2.542, 95% CI:1.048-6.168, P=0.0390).",
        "method": "metakb.method:1",
        "is_reported_in": [
            {
                "id": "civic.source:1416",
                "type": "Document",
                "label": "Endoh et al., 2006, J Thorac Oncol",
                "xrefs": [
                    "pmid:17409929"
                ],
                "title": "PTEN and PIK3CA expression is associated with prolonged survival after gefitinib treatment in EGFR-mutated lung cancer patients."
            }
        ],
        "evidence_level": {
            "id": "vicc:e00008",
            "type": "Coding",
            "label": "case study evidence"
        },
        "target_proposition": {
            "id": "proposition:z-9bakdouJQGd7vpwnPFCSMX1OLTxfHE",
            "type": "VariationNeoplasmTherapeuticResponseProposition",
            "subject": "ga4gh:VA.VBKi2jNxAs378IqOBsveoPrYQjWPngQq",
            "predicate": "predicts_resistance_to",
            "object": {
                "id": "rxcui:328134",
                "type": "Therapeutic"
            },
            "neoplasm_type_qualifier": {
                "id": "ncit:C7377",
                "type": "Disease"
            }
        },
        "direction": "supports",
        "subject_descriptor": "civic.vid:425",
        "neoplasm_type_descriptor": {
            "id": "civic.did:23",
            "type": "DiseaseDescriptor",
            "label": "Lung Cancer",
            "xrefs": [
                "DOID:1324"
            ],
            "disease": "ncit:C7377"
        },
        "object_descriptor": {
            "id": "civic.tid:14",
            "type": "TherapeuticDescriptor",
            "label": "Gefitinib",
            "extensions": [
                {
                    "type": "Extension",
                    "name": "regulatory_approval",
                    "value": {
                        "approval_rating": "FDA",
                        "has_indications": [
                            {
                                "id": "hemonc:642",
                                "type": "DiseaseDescriptor",
                                "label": "Non-small cell lung cancer",
                                "disease": "ncit:C2926"
                            }
                        ]
                    }
                }
            ],
            "xrefs": [
                "ncit:C1855"
            ],
            "alternate_labels": [
                "4-(3'-Chloro-4'-fluoroanilino)-7-methoxy-6-(3-morpholinopropoxy)quinazoline",
                "Iressa",
                "N-(3-chloro-4-fluorophenyl)-7-methoxy-6-[3-(4-morpholin) Propoxy]-4-quinazolinamine",
                "ZD 1839",
                "ZD1839"
            ],
            "therapeutic": "rxcui:328134"
        }
    },
    {
        "id": "civic.eid:2478",
        "type": "VariationNeoplasmTherapeuticResponseStatement",
        "description": "This prospective study of 127 patients with metastatic gastrointestinal stromal tumors (GISTs) examined the relationship between kinase (KIT and PDGFRA) genotype and treatment outcome for patients enrolled in a randomized phase II trial of imatinib (CSTI571B 2222). Three patients' GISTs harbored PDGFRA D842V. Two of these patients experienced progressive disease and one was unassessable. The authors conclude that this finding is consistent with the work of others suggesting that PDGFRA D842V is an imatinib resistant variant in GIST.",
        "method": "metakb.method:1",
        "is_reported_in": [
            {
                "id": "civic.source:412",
                "type": "Document",
                "label": "Heinrich et al., 2003, J. Clin. Oncol.",
                "xrefs": [
                    "pmid:14645423"
                ],
                "title": "Kinase mutations and imatinib response in patients with metastatic gastrointestinal stromal tumor."
            }
        ],
        "evidence_level": {
            "id": "vicc:e00008",
            "type": "Coding",
            "label": "case study evidence"
        },
        "target_proposition": {
            "id": "proposition:XT63NpvH0QMWWy8SjzzSDlRwhki6ikVG",
            "type": "VariationNeoplasmTherapeuticResponseProposition",
            "subject": "ga4gh:VA.CaTuLaWlUwLb32qfYTW2udl2Iy02ccN6",
            "predicate": "predicts_resistance_to",
            "object": {
                "id": "rxcui:282388",
                "type": "Therapeutic"
            },
            "neoplasm_type_qualifier": {
                "id": "ncit:C3868",
                "type": "Disease"
            }
        },
        "direction": "supports",
        "subject_descriptor": "civic.vid:99",
        "neoplasm_type_descriptor": {
            "id": "civic.did:2",
            "type": "DiseaseDescriptor",
            "label": "Gastrointestinal Stromal Tumor",
            "xrefs": [
                "DOID:9253"
            ],
            "disease": "ncit:C3868"
        },
        "object_descriptor": {
            "id": "civic.tid:5",
            "type": "TherapeuticDescriptor",
            "label": "Imatinib",
            "extensions": [
                {
                    "type": "Extension",
                    "name": "regulatory_approval",
                    "value": {
                        "approval_rating": "FDA",
                        "has_indications": [
                            {
                                "id": "hemonc:667",
                                "type": "DiseaseDescriptor",
                                "label": "Soft tissue sarcoma",
                                "disease": "ncit:C9306"
                            },
                            {
                                "id": "hemonc:602",
                                "type": "DiseaseDescriptor",
                                "label": "Gastrointestinal stromal tumor",
                                "disease": "ncit:C3868"
                            },
                            {
                                "id": "hemonc:616",
                                "type": "DiseaseDescriptor",
                                "label": "Hypereosinophilic syndrome",
                                "disease": "ncit:C27038"
                            },
                            {
                                "id": "hemonc:33893",
                                "type": "DiseaseDescriptor",
                                "label": "Chronic myelogenous leukemia pediatric",
                                "disease": null
                            },
                            {
                                "id": "hemonc:634",
                                "type": "DiseaseDescriptor",
                                "label": "Myelodysplastic syndrome",
                                "disease": "ncit:C3247"
                            },
                            {
                                "id": "hemonc:24309",
                                "type": "DiseaseDescriptor",
                                "label": "Acute lymphoblastic leukemia",
                                "disease": "ncit:C3167"
                            },
                            {
                                "id": "hemonc:582",
                                "type": "DiseaseDescriptor",
                                "label": "Chronic myelogenous leukemia",
                                "disease": "ncit:C3174"
                            },
                            {
                                "id": "hemonc:669",
                                "type": "DiseaseDescriptor",
                                "label": "Systemic mastocytosis",
                                "disease": "ncit:C9235"
                            }
                        ]
                    }
                }
            ],
            "xrefs": [
                "ncit:C62035"
            ],
            "alternate_labels": [
                "4-[(4-Methyl-1-piperazinyl)methyl]-N-[4-methyl-3-[[4-(3-pyridinyl)-2-pyrimidinyl]amino]phenyl]benzamide"
            ],
            "therapeutic": "rxcui:282388"
        }
    },
    {
        "id": "civic.eid:4062",
        "type": "VariationNeoplasmTherapeuticResponseStatement",
        "description": "Patient 3 from a larger cohort of genotyped patients (n= 78) with imatinib resistant or intolerant gastrointestinal stromal tumors (GISTs) harbored a primary (pre-imatinib treatment) KIT K550_K558 deletion. Following failure of imatinib, the GIST was again genotyped, but no secondary mutations were found. The patient started on 50mg sunitinib on a schedule of two weeks on/two weeks off. This patient experienced stable disease less than 6 months; time to progresssion of 14 weeks and overall survival of 17 weeks (Table A1).",
        "method": "metakb.method:1",
        "is_reported_in": [
            {
                "id": "civic.source:965",
                "type": "Document",
                "label": "Heinrich et al., 2008, J. Clin. Oncol.",
                "xrefs": [
                    "pmc:PMC2651076",
                    "pmid:18955458"
                ],
                "title": "Primary and secondary kinase genotypes correlate with the biological and clinical activity of sunitinib in imatinib-resistant gastrointestinal stromal tumor."
            }
        ],
        "evidence_level": {
            "id": "vicc:e00008",
            "type": "Coding",
            "label": "case study evidence"
        },
        "target_proposition": {
            "id": "proposition:gWJHtupQAO9uBFFboaJpeI2WBrF3gDtH",
            "type": "VariationNeoplasmTherapeuticResponseProposition",
            "subject": "ga4gh:VA.bcNVpvlsyCl2O_-CbWhoREwx5q691o1O",
            "predicate": "predicts_resistance_to",
            "object": {
                "id": "rxcui:357977",
                "type": "Therapeutic"
            },
            "neoplasm_type_qualifier": {
                "id": "ncit:C3868",
                "type": "Disease"
            }
        },
        "direction": "supports",
        "subject_descriptor": "civic.vid:949",
        "neoplasm_type_descriptor": {
            "id": "civic.did:2",
            "type": "DiseaseDescriptor",
            "label": "Gastrointestinal Stromal Tumor",
            "xrefs": [
                "DOID:9253"
            ],
            "disease": "ncit:C3868"
        },
        "object_descriptor": {
            "id": "civic.tid:157",
            "type": "TherapeuticDescriptor",
            "label": "Sunitinib",
            "extensions": [
                {
                    "type": "Extension",
                    "name": "regulatory_approval",
                    "value": {
                        "approval_rating": "FDA",
                        "has_indications": [
                            {
                                "id": "hemonc:602",
                                "type": "DiseaseDescriptor",
                                "label": "Gastrointestinal stromal tumor",
                                "disease": "ncit:C3868"
                            },
                            {
                                "id": "hemonc:647",
                                "type": "DiseaseDescriptor",
                                "label": "Pancreatic NET",
                                "disease": "ncit:C27720"
                            },
                            {
                                "id": "hemonc:660",
                                "type": "DiseaseDescriptor",
                                "label": "Renal cell carcinoma",
                                "disease": "ncit:C9385"
                            }
                        ]
                    }
                }
            ],
            "xrefs": [
                "ncit:C71622"
            ],
            "alternate_labels": [
                "1H-Pyrrole-3-carboxamide, N-(2-(diethylamino)ethyl)-5-((Z)-(5-fluoro-1,2-dihydro-2-oxo-3H-indol-3-ylidene)methyl)-2,4-dimethyl-"
            ],
            "therapeutic": "rxcui:357977"
        }
    },
    {
        "id": "civic.eid:4095",
        "type": "VariationNeoplasmTherapeuticResponseStatement",
        "description": "Patient 47 from a larger cohort of genotyped patients (n= 78) with imatinib resistant or intolerant gastrointestinal stromal tumors (GISTs) harbored a primary (pre-imatinib treatment) KIT K558_V559 deletion. Following failure of imatinib, the GIST was again genotyped, but no secondary mutations were found. The patient took 50 mg sunitinib per day on a treatment schedule of two weeks on/one week off.  The patient experienced progressive disease. Time to progression was censored at 5 weeks, and overall survival was 60 weeks.",
        "method": "metakb.method:1",
        "is_reported_in": [
            {
                "id": "civic.source:965",
                "type": "Document",
                "label": "Heinrich et al., 2008, J. Clin. Oncol.",
                "xrefs": [
                    "pmc:PMC2651076",
                    "pmid:18955458"
                ],
                "title": "Primary and secondary kinase genotypes correlate with the biological and clinical activity of sunitinib in imatinib-resistant gastrointestinal stromal tumor."
            }
        ],
        "evidence_level": {
            "id": "vicc:e00008",
            "type": "Coding",
            "label": "case study evidence"
        },
        "target_proposition": {
            "id": "proposition:GgHLc3HQwRhvGVmRyipo1dgeIppZHx9q",
            "type": "VariationNeoplasmTherapeuticResponseProposition",
            "subject": "ga4gh:VA.pE9Bl5DqO_qy0NWTGv1zfMullzdE6tT3",
            "predicate": "predicts_resistance_to",
            "object": {
                "id": "rxcui:357977",
                "type": "Therapeutic"
            },
            "neoplasm_type_qualifier": {
                "id": "ncit:C3868",
                "type": "Disease"
            }
        },
        "direction": "supports",
        "subject_descriptor": "civic.vid:964",
        "neoplasm_type_descriptor": {
            "id": "civic.did:2",
            "type": "DiseaseDescriptor",
            "label": "Gastrointestinal Stromal Tumor",
            "xrefs": [
                "DOID:9253"
            ],
            "disease": "ncit:C3868"
        },
        "object_descriptor": {
            "id": "civic.tid:157",
            "type": "TherapeuticDescriptor",
            "label": "Sunitinib",
            "extensions": [
                {
                    "type": "Extension",
                    "name": "regulatory_approval",
                    "value": {
                        "approval_rating": "FDA",
                        "has_indications": [
                            {
                                "id": "hemonc:602",
                                "type": "DiseaseDescriptor",
                                "label": "Gastrointestinal stromal tumor",
                                "disease": "ncit:C3868"
                            },
                            {
                                "id": "hemonc:647",
                                "type": "DiseaseDescriptor",
                                "label": "Pancreatic NET",
                                "disease": "ncit:C27720"
                            },
                            {
                                "id": "hemonc:660",
                                "type": "DiseaseDescriptor",
                                "label": "Renal cell carcinoma",
                                "disease": "ncit:C9385"
                            }
                        ]
                    }
                }
            ],
            "xrefs": [
                "ncit:C71622"
            ],
            "alternate_labels": [
                "1H-Pyrrole-3-carboxamide, N-(2-(diethylamino)ethyl)-5-((Z)-(5-fluoro-1,2-dihydro-2-oxo-3H-indol-3-ylidene)methyl)-2,4-dimethyl-"
            ],
            "therapeutic": "rxcui:357977"
        }
    },
    {
        "id": "civic.eid:4136",
        "type": "VariationNeoplasmTherapeuticResponseStatement",
        "description": "Patient 29 from a larger cohort of genotyped patients (n= 78) with imatinib resistant or intolerant gastrointestinal stromal tumors (GISTs) harbored a primary (pre-imatinib treatment) KIT L576P mutation. Following failure of imatinib, the GIST was again genotyped, but no secondary mutations were found. The patient took 50 mg sunitinib per day on a treatment schedule of two weeks on/two weeks off.  The patient experienced stable disease for less than 6 months. Time to progression and overall survival were 31 and 29 weeks.",
        "method": "metakb.method:1",
        "is_reported_in": [
            {
                "id": "civic.source:965",
                "type": "Document",
                "label": "Heinrich et al., 2008, J. Clin. Oncol.",
                "xrefs": [
                    "pmc:PMC2651076",
                    "pmid:18955458"
                ],
                "title": "Primary and secondary kinase genotypes correlate with the biological and clinical activity of sunitinib in imatinib-resistant gastrointestinal stromal tumor."
            }
        ],
        "evidence_level": {
            "id": "vicc:e00008",
            "type": "Coding",
            "label": "case study evidence"
        },
        "target_proposition": {
            "id": "proposition:P4mSroiD2YiIvTxDmoQNboXdHRz08Cwo",
            "type": "VariationNeoplasmTherapeuticResponseProposition",
            "subject": "ga4gh:VA.1i40nlLTUTxkw3VAG3tTQSuNjTWnMdy5",
            "predicate": "predicts_resistance_to",
            "object": {
                "id": "rxcui:357977",
                "type": "Therapeutic"
            },
            "neoplasm_type_qualifier": {
                "id": "ncit:C3868",
                "type": "Disease"
            }
        },
        "direction": "supports",
        "subject_descriptor": "civic.vid:72",
        "neoplasm_type_descriptor": {
            "id": "civic.did:2",
            "type": "DiseaseDescriptor",
            "label": "Gastrointestinal Stromal Tumor",
            "xrefs": [
                "DOID:9253"
            ],
            "disease": "ncit:C3868"
        },
        "object_descriptor": {
            "id": "civic.tid:157",
            "type": "TherapeuticDescriptor",
            "label": "Sunitinib",
            "extensions": [
                {
                    "type": "Extension",
                    "name": "regulatory_approval",
                    "value": {
                        "approval_rating": "FDA",
                        "has_indications": [
                            {
                                "id": "hemonc:602",
                                "type": "DiseaseDescriptor",
                                "label": "Gastrointestinal stromal tumor",
                                "disease": "ncit:C3868"
                            },
                            {
                                "id": "hemonc:647",
                                "type": "DiseaseDescriptor",
                                "label": "Pancreatic NET",
                                "disease": "ncit:C27720"
                            },
                            {
                                "id": "hemonc:660",
                                "type": "DiseaseDescriptor",
                                "label": "Renal cell carcinoma",
                                "disease": "ncit:C9385"
                            }
                        ]
                    }
                }
            ],
            "xrefs": [
                "ncit:C71622"
            ],
            "alternate_labels": [
                "1H-Pyrrole-3-carboxamide, N-(2-(diethylamino)ethyl)-5-((Z)-(5-fluoro-1,2-dihydro-2-oxo-3H-indol-3-ylidene)methyl)-2,4-dimethyl-"
            ],
            "therapeutic": "rxcui:357977"
        }
    },
    {
        "id": "civic.eid:4142",
        "type": "VariationNeoplasmTherapeuticResponseStatement",
        "description": "Patient 74 from a larger cohort of genotyped patients (n= 78) with imatinib resistant or intolerant gastrointestinal stromal tumors (GISTs) harbored a primary (pre-imatinib treatment) KIT D579 deletion. Following failure of imatinib, the GIST was again genotyped, but no secondary mutations were found. The patient took 50 mg sunitinib per day on a treatment schedule of four weeks on/two weeks off. The patient experienced stable disease for less than six months. Time to progression was censored at 10 weeks and overall survival was 85 weeks.",
        "method": "metakb.method:1",
        "is_reported_in": [
            {
                "id": "civic.source:965",
                "type": "Document",
                "label": "Heinrich et al., 2008, J. Clin. Oncol.",
                "xrefs": [
                    "pmc:PMC2651076",
                    "pmid:18955458"
                ],
                "title": "Primary and secondary kinase genotypes correlate with the biological and clinical activity of sunitinib in imatinib-resistant gastrointestinal stromal tumor."
            }
        ],
        "evidence_level": {
            "id": "vicc:e00008",
            "type": "Coding",
            "label": "case study evidence"
        },
        "target_proposition": {
            "id": "proposition:AQto6_krKeJbZRuGttKdQKE2iR7t-u47",
            "type": "VariationNeoplasmTherapeuticResponseProposition",
            "subject": "ga4gh:VA.oToThcBUs1VzesQkoIWDju4gFbvODfyg",
            "predicate": "predicts_resistance_to",
            "object": {
                "id": "rxcui:357977",
                "type": "Therapeutic"
            },
            "neoplasm_type_qualifier": {
                "id": "ncit:C3868",
                "type": "Disease"
            }
        },
        "direction": "supports",
        "subject_descriptor": "civic.vid:977",
        "neoplasm_type_descriptor": {
            "id": "civic.did:2",
            "type": "DiseaseDescriptor",
            "label": "Gastrointestinal Stromal Tumor",
            "xrefs": [
                "DOID:9253"
            ],
            "disease": "ncit:C3868"
        },
        "object_descriptor": {
            "id": "civic.tid:157",
            "type": "TherapeuticDescriptor",
            "label": "Sunitinib",
            "extensions": [
                {
                    "type": "Extension",
                    "name": "regulatory_approval",
                    "value": {
                        "approval_rating": "FDA",
                        "has_indications": [
                            {
                                "id": "hemonc:602",
                                "type": "DiseaseDescriptor",
                                "label": "Gastrointestinal stromal tumor",
                                "disease": "ncit:C3868"
                            },
                            {
                                "id": "hemonc:647",
                                "type": "DiseaseDescriptor",
                                "label": "Pancreatic NET",
                                "disease": "ncit:C27720"
                            },
                            {
                                "id": "hemonc:660",
                                "type": "DiseaseDescriptor",
                                "label": "Renal cell carcinoma",
                                "disease": "ncit:C9385"
                            }
                        ]
                    }
                }
            ],
            "xrefs": [
                "ncit:C71622"
            ],
            "alternate_labels": [
                "1H-Pyrrole-3-carboxamide, N-(2-(diethylamino)ethyl)-5-((Z)-(5-fluoro-1,2-dihydro-2-oxo-3H-indol-3-ylidene)methyl)-2,4-dimethyl-"
            ],
            "therapeutic": "rxcui:357977"
        }
    },
    {
        "id": "civic.eid:7288",
        "type": "VariationNeoplasmTherapeuticResponseStatement",
        "description": "Patient 36 from a larger cohort of genotyped patients (n= 78) with imatinib resistant or intolerant gastrointestinal stromal tumors (GISTs) harbored a primary (pre-imatinib treatment) KIT V555_V559 deletion. Following failure of imatinib, the GIST was again genotyped, but no secondary mutations were found. The patient took 50 mg sunitinib per day on a treatment schedule of four weeks on/two weeks off.  The patient experienced progressive disease. Time to progression and overall survival were 10 and 108 weeks.",
        "method": "metakb.method:1",
        "is_reported_in": [
            {
                "id": "civic.source:965",
                "type": "Document",
                "label": "Heinrich et al., 2008, J. Clin. Oncol.",
                "xrefs": [
                    "pmc:PMC2651076",
                    "pmid:18955458"
                ],
                "title": "Primary and secondary kinase genotypes correlate with the biological and clinical activity of sunitinib in imatinib-resistant gastrointestinal stromal tumor."
            }
        ],
        "evidence_level": {
            "id": "vicc:e00008",
            "type": "Coding",
            "label": "case study evidence"
        },
        "target_proposition": {
            "id": "proposition:beL5xPqP7Yb8E-bx3SL-sZtMNsaJ2RuC",
            "type": "VariationNeoplasmTherapeuticResponseProposition",
            "subject": "ga4gh:VA.ATm0fufjEXHMpM_23Zg4F9-VBD5Ci_8d",
            "predicate": "predicts_resistance_to",
            "object": {
                "id": "rxcui:357977",
                "type": "Therapeutic"
            },
            "neoplasm_type_qualifier": {
                "id": "ncit:C3868",
                "type": "Disease"
            }
        },
        "direction": "supports",
        "subject_descriptor": "civic.vid:2695",
        "neoplasm_type_descriptor": {
            "id": "civic.did:2",
            "type": "DiseaseDescriptor",
            "label": "Gastrointestinal Stromal Tumor",
            "xrefs": [
                "DOID:9253"
            ],
            "disease": "ncit:C3868"
        },
        "object_descriptor": {
            "id": "civic.tid:157",
            "type": "TherapeuticDescriptor",
            "label": "Sunitinib",
            "extensions": [
                {
                    "type": "Extension",
                    "name": "regulatory_approval",
                    "value": {
                        "approval_rating": "FDA",
                        "has_indications": [
                            {
                                "id": "hemonc:602",
                                "type": "DiseaseDescriptor",
                                "label": "Gastrointestinal stromal tumor",
                                "disease": "ncit:C3868"
                            },
                            {
                                "id": "hemonc:647",
                                "type": "DiseaseDescriptor",
                                "label": "Pancreatic NET",
                                "disease": "ncit:C27720"
                            },
                            {
                                "id": "hemonc:660",
                                "type": "DiseaseDescriptor",
                                "label": "Renal cell carcinoma",
                                "disease": "ncit:C9385"
                            }
                        ]
                    }
                }
            ],
            "xrefs": [
                "ncit:C71622"
            ],
            "alternate_labels": [
                "1H-Pyrrole-3-carboxamide, N-(2-(diethylamino)ethyl)-5-((Z)-(5-fluoro-1,2-dihydro-2-oxo-3H-indol-3-ylidene)methyl)-2,4-dimethyl-"
            ],
            "therapeutic": "rxcui:357977"
        }
    },
    {
        "id": "civic.eid:8185",
        "type": "VariationNeoplasmTherapeuticResponseStatement",
        "description": "The effective cohort in this study was 11 CLL patients who were first treated with ibrutinib and then on progression treated with venetoclax until progression. Patient samples were sequenced before and after progression on venetoclax. The previously described BCL2 G101V mutation was observed in 1 patient at progression",
        "method": "metakb.method:1",
        "is_reported_in": [
            {
                "id": "civic.source:3376",
                "type": "Document",
                "label": "Lucas et al., 2020, Blood",
                "xrefs": [
                    "pmid:32232486"
                ],
                "title": "Novel BCL2 mutations in venetoclax-resistant, ibrutinib-resistant CLL patients with BTK/PLCG2 mutations."
            }
        ],
        "evidence_level": {
            "id": "vicc:e00008",
            "type": "Coding",
            "label": "case study evidence"
        },
        "target_proposition": {
            "id": "proposition:1908XknC4RFiIq__2oShugEQ7Cy6H-_b",
            "type": "VariationNeoplasmTherapeuticResponseProposition",
            "subject": "ga4gh:VA.W2DykRCbXOXmqZLLiZeELFbtnqJvuqOW",
            "predicate": "predicts_resistance_to",
            "object": {
                "id": "rxcui:1747556",
                "type": "Therapeutic"
            },
            "neoplasm_type_qualifier": {
                "id": "ncit:C27911",
                "type": "Disease"
            }
        },
        "direction": "supports",
        "subject_descriptor": "civic.vid:2960",
        "neoplasm_type_descriptor": {
            "id": "civic.did:191",
            "type": "DiseaseDescriptor",
            "label": "Chronic Lymphocytic Leukemia/small Lymphocytic Lymphoma",
            "xrefs": [
                "DOID:6354"
            ],
            "disease": "ncit:C27911"
        },
        "object_descriptor": {
            "id": "civic.tid:574",
            "type": "TherapeuticDescriptor",
            "label": "Venetoclax",
            "extensions": [
                {
                    "type": "Extension",
                    "name": "regulatory_approval",
                    "value": {
                        "approval_rating": "FDA",
                        "has_indications": [
                            {
                                "id": "hemonc:581",
                                "type": "DiseaseDescriptor",
                                "label": "Chronic lymphocytic leukemia",
                                "disease": "ncit:C3163"
                            },
                            {
                                "id": "hemonc:552",
                                "type": "DiseaseDescriptor",
                                "label": "Acute myeloid leukemia",
                                "disease": "ncit:C3171"
                            }
                        ]
                    }
                }
            ],
            "xrefs": [
                "ncit:C103147"
            ],
            "alternate_labels": [
                "4-(4-((2-(4-Chlorophenyl)-4,4-dimethylcyclohex-1-en-1-yl)methyl)piperazin-1-yl)-N-((3-nitro-4-((tetrahydro-2H-pyran-4-ylmethyl)amino)phenyl)sulfonyl)-2-(1H-pyrrolo(2,3-b)pyridin-5-yloxy)benzamide",
                "ABT-0199",
                "ABT-199",
                "ABT199",
                "GDC-0199",
                "RG7601",
                "Venclexta",
                "Venclyxto"
            ],
            "therapeutic": "rxcui:1747556"
        }
    },
    {
        "id": "civic.eid:8375",
        "type": "VariationNeoplasmTherapeuticResponseStatement",
        "description": "This study identified BCL2 F104I mutation in one Follicular Lymphoma patient who developed resistance to venetoclax. Codon 104 is located at the venetoclax binding site of BCL2.",
        "method": "metakb.method:1",
        "is_reported_in": [
            {
                "id": "civic.source:3502",
                "type": "Document",
                "label": "Blombery et al., 2019, Br. J. Haematol.",
                "xrefs": [
                    "pmid:31234236"
                ],
                "title": "Characterization of a novel venetoclax resistance mutation (BCL2 Phe104Ile) observed in follicular lymphoma."
            }
        ],
        "evidence_level": {
            "id": "vicc:e00008",
            "type": "Coding",
            "label": "case study evidence"
        },
        "target_proposition": {
            "id": "proposition:b-ICx3_0XquQYSfb0KiMLHPo_W7H6wlC",
            "type": "VariationNeoplasmTherapeuticResponseProposition",
            "subject": "ga4gh:VA._ZzqdXiiqCOs9iTFtw5ac6N6_lT9vbfe",
            "predicate": "predicts_resistance_to",
            "object": {
                "id": "rxcui:1747556",
                "type": "Therapeutic"
            },
            "neoplasm_type_qualifier": {
                "id": "ncit:C3209",
                "type": "Disease"
            }
        },
        "direction": "supports",
        "subject_descriptor": "civic.vid:3082",
        "neoplasm_type_descriptor": {
            "id": "civic.did:51",
            "type": "DiseaseDescriptor",
            "label": "Follicular Lymphoma",
            "xrefs": [
                "DOID:50873"
            ],
            "disease": "ncit:C3209"
        },
        "object_descriptor": {
            "id": "civic.tid:574",
            "type": "TherapeuticDescriptor",
            "label": "Venetoclax",
            "extensions": [
                {
                    "type": "Extension",
                    "name": "regulatory_approval",
                    "value": {
                        "approval_rating": "FDA",
                        "has_indications": [
                            {
                                "id": "hemonc:581",
                                "type": "DiseaseDescriptor",
                                "label": "Chronic lymphocytic leukemia",
                                "disease": "ncit:C3163"
                            },
                            {
                                "id": "hemonc:552",
                                "type": "DiseaseDescriptor",
                                "label": "Acute myeloid leukemia",
                                "disease": "ncit:C3171"
                            }
                        ]
                    }
                }
            ],
            "xrefs": [
                "ncit:C103147"
            ],
            "alternate_labels": [
                "4-(4-((2-(4-Chlorophenyl)-4,4-dimethylcyclohex-1-en-1-yl)methyl)piperazin-1-yl)-N-((3-nitro-4-((tetrahydro-2H-pyran-4-ylmethyl)amino)phenyl)sulfonyl)-2-(1H-pyrrolo(2,3-b)pyridin-5-yloxy)benzamide",
                "ABT-0199",
                "ABT-199",
                "ABT199",
                "GDC-0199",
                "RG7601",
                "Venclexta",
                "Venclyxto"
            ],
            "therapeutic": "rxcui:1747556"
        }
    },
    {
        "id": "civic.eid:1396",
        "type": "VariationNeoplasmTherapeuticResponseStatement",
        "description": "Case report of a patient with stage IV lung adenocarcinoma and a 15\u2013base pair deletion in EGFR exon 19. Partial response with erlotinib was achieved for 15 months after initial chemotherapy. After further progression, rebiopsy additionally identified the EGFR T790M mutation and the patient received several cycles of chemotherapy and targeted therapy including afatinib, cetuximab, erlotinib, AZD9291. She was treated with AZD9291 for 9 months until disease progression. Repeat biopsy detected EGFRC797S mutation additionally to both aforementioned EGFR aberrations. In addition, PTEN Y27C and CTNNB1 S37F mutations were present in all 3 samples, and a TSC2 N486I was seen in the third biopsy sample only",
        "method": "metakb.method:1",
        "is_reported_in": [
            {
                "id": "civic.source:946",
                "type": "Document",
                "label": "Yu et al., 2015, JAMA Oncol",
                "xrefs": [
                    "pmc:PMC4665629",
                    "pmid:26181354"
                ],
                "title": "Acquired Resistance of EGFR-Mutant Lung Cancer to a T790M-Specific EGFR Inhibitor: Emergence of a Third Mutation (C797S) in the EGFR Tyrosine Kinase Domain."
            }
        ],
        "evidence_level": {
            "id": "vicc:e00008",
            "type": "Coding",
            "label": "case study evidence"
        },
        "target_proposition": {
            "id": "proposition:3wMlYtsfA0N3xrZv3C5yjv6DPAD2Psnb",
            "type": "VariationNeoplasmTherapeuticResponseProposition",
            "subject": "ga4gh:VA.xBOuXRHMA9-vqyYsZPx1_E6lOIoZZbs0",
            "predicate": "predicts_resistance_to",
            "object": {
                "id": "rxcui:1721560",
                "type": "Therapeutic"
            },
            "neoplasm_type_qualifier": {
                "id": "ncit:C3512",
                "type": "Disease"
            }
        },
        "direction": "supports",
        "subject_descriptor": "civic.vid:415",
        "neoplasm_type_descriptor": {
            "id": "civic.did:30",
            "type": "DiseaseDescriptor",
            "label": "Lung Adenocarcinoma",
            "xrefs": [
                "DOID:3910"
            ],
            "disease": "ncit:C3512"
        },
        "object_descriptor": {
            "id": "civic.tid:187",
            "type": "TherapeuticDescriptor",
            "label": "Osimertinib",
            "extensions": [
                {
                    "type": "Extension",
                    "name": "regulatory_approval",
                    "value": {
                        "approval_rating": "FDA",
                        "has_indications": [
                            {
                                "id": "hemonc:642",
                                "type": "DiseaseDescriptor",
                                "label": "Non-small cell lung cancer",
                                "disease": "ncit:C2926"
                            }
                        ]
                    }
                }
            ],
            "xrefs": [
                "ncit:C116377"
            ],
            "alternate_labels": [
                "2-Propenamide, N-(2-((2-(dimethylamino)ethyl)methylamino)-4-methoxy-5-((4-(1-methyl-1H-indol-3-yl)-2-pyrimidinyl)amino)phenyl)-",
                "AZD-9291",
                "AZD9291",
                "Mereletinib",
                "Tagrisso"
            ],
            "therapeutic": "rxcui:1721560"
        }
    },
    {
        "id": "civic.eid:2934",
        "type": "VariationNeoplasmTherapeuticResponseStatement",
        "description": "Resistance to crizotinib developed in a patient with metastatic lung adenocarcinoma harboring a CD74-ROS1 rearrangement who had initially shown a dramatic response to treatment. A biopsy of a resistant tumor showed an acquired G2032R mutation in the ROS1 kinase domain. Although this mutation does not lie at the gatekeeper residue, it confers resistance to ROS1 kinase inhibition through steric interference with drug binding. The same resistance mutation was observed at all the metastatic sites that were examined at autopsy, suggesting that this mutation was an early event in the clonal evolution of resistance.",
        "method": "metakb.method:1",
        "is_reported_in": [
            {
                "id": "civic.source:381",
                "type": "Document",
                "label": "Awad et al., 2013, N. Engl. J. Med.",
                "xrefs": [
                    "pmc:PMC3878821",
                    "pmid:23724914"
                ],
                "title": "Acquired resistance to crizotinib from a mutation in CD74-ROS1."
            }
        ],
        "evidence_level": {
            "id": "vicc:e00008",
            "type": "Coding",
            "label": "case study evidence"
        },
        "target_proposition": {
            "id": "proposition:1CEPHzEDc_HEY_V69jdLm_0j452OoEGz",
            "type": "VariationNeoplasmTherapeuticResponseProposition",
            "subject": "ga4gh:VA.5CsNnz26PLs2l1QXVplEHgNRPXpEX9oz",
            "predicate": "predicts_resistance_to",
            "object": {
                "id": "rxcui:1148495",
                "type": "Therapeutic"
            },
            "neoplasm_type_qualifier": {
                "id": "ncit:C3512",
                "type": "Disease"
            }
        },
        "direction": "supports",
        "subject_descriptor": "civic.vid:1271",
        "neoplasm_type_descriptor": {
            "id": "civic.did:30",
            "type": "DiseaseDescriptor",
            "label": "Lung Adenocarcinoma",
            "xrefs": [
                "DOID:3910"
            ],
            "disease": "ncit:C3512"
        },
        "object_descriptor": {
            "id": "civic.tid:12",
            "type": "TherapeuticDescriptor",
            "label": "Crizotinib",
            "extensions": [
                {
                    "type": "Extension",
                    "name": "regulatory_approval",
                    "value": {
                        "approval_rating": "FDA",
                        "has_indications": [
                            {
                                "id": "hemonc:642",
                                "type": "DiseaseDescriptor",
                                "label": "Non-small cell lung cancer",
                                "disease": "ncit:C2926"
                            },
                            {
                                "id": "hemonc:25958",
                                "type": "DiseaseDescriptor",
                                "label": "Anaplastic large cell lymphoma pediatric",
                                "disease": null
                            }
                        ]
                    }
                }
            ],
            "xrefs": [
                "ncit:C74061"
            ],
            "alternate_labels": [
                "(R)-3-(1-(2,6-Dichloro-3-Fluorophenyl)Ethoxy)-5-(1-(Piperidin-4-Yl)-1h-Pyrazol-4-Yl)Pyridin-2-Amine",
                "2-Pyridinamine, 3-((1R)-1-(2,6-Dichloro-3-Fluorophenyl)Ethoxy)-5-(1-(4-Piperidinyl)-1H-Pyrazol-4-yl)-",
                "MET Tyrosine Kinase Inhibitor PF-02341066",
                "PF-02341066",
                "PF-2341066",
                "Xalkori"
            ],
            "therapeutic": "rxcui:1148495"
        }
    },
    {
        "id": "civic.eid:3842",
        "type": "VariationNeoplasmTherapeuticResponseStatement",
        "description": "One patient participating in a large retrospective study of cetuximab in metastatic, treatment refractory colorectal cancer had a tumor which harbored NRAS G13R, was wildtype for KRAS, BRAF and PIK3CA, and had individual response data. This patient was was a 50 year old male treated with panitumumab monotherapy as 3rd line therapy (discontinued for toxic/biochemical reasons) who experienced stable disease (PFS: 22 weeks; OS: 74 weeks). Authors considered stable disease as both clinical benefit and non-response",
        "method": "metakb.method:1",
        "is_reported_in": [
            {
                "id": "civic.source:76",
                "type": "Document",
                "label": "De Roock et al., 2010, Lancet Oncol.",
                "xrefs": [
                    "pmid:20619739"
                ],
                "title": "Effects of KRAS, BRAF, NRAS, and PIK3CA mutations on the efficacy of cetuximab plus chemotherapy in chemotherapy-refractory metastatic colorectal cancer: a retrospective consortium analysis."
            }
        ],
        "evidence_level": {
            "id": "vicc:e00008",
            "type": "Coding",
            "label": "case study evidence"
        },
        "target_proposition": {
            "id": "proposition:J_mkvnkTX-U3wggh8vsxUw11FCl2Fqc0",
            "type": "VariationNeoplasmTherapeuticResponseProposition",
            "subject": "ga4gh:VA.6ZS84FXRs9aO5v0z-XrD3UPSBr3DivZf",
            "predicate": "predicts_resistance_to",
            "object": {
                "id": "rxcui:263034",
                "type": "Therapeutic"
            },
            "neoplasm_type_qualifier": {
                "id": "ncit:C4978",
                "type": "Disease"
            }
        },
        "direction": "supports",
        "subject_descriptor": "civic.vid:896",
        "neoplasm_type_descriptor": {
            "id": "civic.did:11",
            "type": "DiseaseDescriptor",
            "label": "Colorectal Cancer",
            "xrefs": [
                "DOID:9256"
            ],
            "disease": "ncit:C4978"
        },
        "object_descriptor": {
            "id": "civic.tid:28",
            "type": "TherapeuticDescriptor",
            "label": "Panitumumab",
            "extensions": [
                {
                    "type": "Extension",
                    "name": "regulatory_approval",
                    "value": {
                        "approval_rating": "ChEMBL",
                        "has_indications": [
                            {
                                "id": "mesh:D009369",
                                "type": "DiseaseDescriptor",
                                "label": "Neoplasms",
                                "disease": "ncit:C3262"
                            },
                            {
                                "id": "mesh:D015179",
                                "type": "DiseaseDescriptor",
                                "label": "Colorectal Neoplasms",
                                "disease": "ncit:C2956"
                            }
                        ]
                    }
                }
            ],
            "xrefs": [
                "ncit:C1857"
            ],
            "alternate_labels": [
                "ABX-EGF",
                "ABX-EGF Monoclonal Antibody",
                "ABX-EGF, Clone E7.6.3",
                "E7.6.3",
                "Human IgG2K Monoclonal Antibody",
                "MoAb ABX-EGF",
                "MoAb E7.6.3",
                "Monoclonal Antibody ABX-EGF",
                "Monoclonal Antibody E7.6.3",
                "Vectibix"
            ],
            "therapeutic": "rxcui:263034"
        }
    },
    {
        "id": "civic.eid:4047",
        "type": "VariationNeoplasmTherapeuticResponseStatement",
        "description": "Three patients participating in a large retrospective study of cetuximab in metastatic, treatment refractory colorectal cancer had tumors which harbored PIK3CA N345K, were wildtype for KRAS, BRAF and NRAS, and had individual response data. Patient characteristics are as follows: a 48 year old female treated with cetuximab + irinotecan as 3rd line therapy who experienced stable disease (PFS: 72 weeks, OS: 105 weeks); a 46 year old male treated with cetuximab monotherapy as 5th line therapy who experienced stable disease (PFS: 24 weeks, OS: 57 weeks); a 61 year old female treated with cetuximab + irinotecan as 3rd line therapy who experienced progressive disease (PFS: 12 weeks, OS: 45 weeks). The response rate was 0/3 and the clinical benefit rate was 2/3 according to author criteria.",
        "method": "metakb.method:1",
        "is_reported_in": [
            {
                "id": "civic.source:76",
                "type": "Document",
                "label": "De Roock et al., 2010, Lancet Oncol.",
                "xrefs": [
                    "pmid:20619739"
                ],
                "title": "Effects of KRAS, BRAF, NRAS, and PIK3CA mutations on the efficacy of cetuximab plus chemotherapy in chemotherapy-refractory metastatic colorectal cancer: a retrospective consortium analysis."
            }
        ],
        "evidence_level": {
            "id": "vicc:e00008",
            "type": "Coding",
            "label": "case study evidence"
        },
        "target_proposition": {
            "id": "proposition:rVF9idZgAaQMyRCt9jxUhPlu9AbDEvIv",
            "type": "VariationNeoplasmTherapeuticResponseProposition",
            "subject": "ga4gh:VA.HH5UAG0bBYrpvHa1oxXJ1rvff1bkgh3N",
            "predicate": "predicts_resistance_to",
            "object": {
                "id": "rxcui:318341",
                "type": "Therapeutic"
            },
            "neoplasm_type_qualifier": {
                "id": "ncit:C4978",
                "type": "Disease"
            }
        },
        "direction": "supports",
        "subject_descriptor": "civic.vid:930",
        "neoplasm_type_descriptor": {
            "id": "civic.did:11",
            "type": "DiseaseDescriptor",
            "label": "Colorectal Cancer",
            "xrefs": [
                "DOID:9256"
            ],
            "disease": "ncit:C4978"
        },
        "object_descriptor": {
            "id": "civic.tid:16",
            "type": "TherapeuticDescriptor",
            "label": "Cetuximab",
            "extensions": [
                {
                    "type": "Extension",
                    "name": "regulatory_approval",
                    "value": {
                        "approval_rating": "ChEMBL",
                        "has_indications": [
                            {
                                "id": "mesh:D002294",
                                "type": "DiseaseDescriptor",
                                "label": "Carcinoma, Squamous Cell",
                                "disease": "ncit:C2929"
                            },
                            {
                                "id": "mesh:D009369",
                                "type": "DiseaseDescriptor",
                                "label": "Neoplasms",
                                "disease": "ncit:C3262"
                            },
                            {
                                "id": "mesh:D015179",
                                "type": "DiseaseDescriptor",
                                "label": "Colorectal Neoplasms",
                                "disease": "ncit:C2956"
                            },
                            {
                                "id": "mesh:D006258",
                                "type": "DiseaseDescriptor",
                                "label": "Head and Neck Neoplasms",
                                "disease": "ncit:C4013"
                            }
                        ]
                    }
                }
            ],
            "xrefs": [
                "ncit:C1723"
            ],
            "alternate_labels": [
                "Cetuximab Biosimilar CDP-1",
                "Cetuximab Biosimilar CMAB009",
                "Cetuximab Biosimilar KL 140",
                "Chimeric Anti-EGFR Monoclonal Antibody",
                "Chimeric MoAb C225",
                "Chimeric Monoclonal Antibody C225",
                "Erbitux",
                "IMC-C225"
            ],
            "therapeutic": "rxcui:318341"
        }
    },
    {
        "id": "civic.eid:4475",
        "type": "VariationNeoplasmTherapeuticResponseStatement",
        "description": "In this retrospective study, imatinib-resistant or -intolerant patients, with chronic phase CML and BCR-ABL fusions, were treated with bosutanib monotherapy. Complete hematologic response (CHR) and major cytogenetic response (MCyR) were comparable for patients with Abl1 mutation versus without. The authors conclude that bosutanib is effective across all BCR-ABL mutations observed except T315I. Of patients with L298V evaluated, 1/1 had a complete hematologic response and 0/1 had a major cytogenetic response.",
        "method": "metakb.method:1",
        "is_reported_in": [
            {
                "id": "civic.source:1996",
                "type": "Document",
                "label": "Cortes et al., 2011, Blood",
                "xrefs": [
                    "pmc:PMC4916618",
                    "pmid:21865346"
                ],
                "title": "Safety and efficacy of bosutinib (SKI-606) in chronic phase Philadelphia chromosome-positive chronic myeloid leukemia patients with resistance or intolerance to imatinib."
            }
        ],
        "evidence_level": {
            "id": "vicc:e00008",
            "type": "Coding",
            "label": "case study evidence"
        },
        "target_proposition": {
            "id": "proposition:7LWMkzreOqsxfBBc2J2pkyzIQE8mSinH",
            "type": "VariationNeoplasmTherapeuticResponseProposition",
            "subject": "ga4gh:VA.hn3DNg2NmqN3kJG0GMqDgwHf7ikewT6n",
            "predicate": "predicts_resistance_to",
            "object": {
                "id": "rxcui:1307619",
                "type": "Therapeutic"
            },
            "neoplasm_type_qualifier": {
                "id": "ncit:C3174",
                "type": "Disease"
            }
        },
        "direction": "opposes",
        "subject_descriptor": "civic.vid:1506",
        "neoplasm_type_descriptor": {
            "id": "civic.did:4",
            "type": "DiseaseDescriptor",
            "label": "Chronic Myeloid Leukemia",
            "xrefs": [
                "DOID:8552"
            ],
            "disease": "ncit:C3174"
        },
        "object_descriptor": {
            "id": "civic.tid:520",
            "type": "TherapeuticDescriptor",
            "label": "Bosutinib",
            "extensions": [
                {
                    "type": "Extension",
                    "name": "regulatory_approval",
                    "value": {
                        "approval_rating": "ChEMBL",
                        "has_indications": [
                            {
                                "id": "EFO:0000339",
                                "type": "DiseaseDescriptor",
                                "label": "chronic myelogenous leukemia",
                                "disease": "ncit:C3174"
                            },
                            {
                                "id": "mesh:D009369",
                                "type": "DiseaseDescriptor",
                                "label": "Neoplasms",
                                "disease": "ncit:C3262"
                            }
                        ]
                    }
                }
            ],
            "xrefs": [
                "ncit:C60809"
            ],
            "alternate_labels": [
                "4-Anilino-3-quinolinecarbonitrile",
                "4-Anilinobenzo(g)quinoline-3-carbonitrile",
                "4-[(2,4-dichloro-5-methoxyphenyl)amino]-6-methoxy-7-[3-(4-methylpiperazin-1-yl)propoxy]quinoline-3-carbonitrile",
                "Bosulif",
                "SKI 606",
                "SKI-606"
            ],
            "therapeutic": "rxcui:1307619"
        }
    },
    {
        "id": "civic.eid:4768",
        "type": "VariationNeoplasmTherapeuticResponseStatement",
        "description": "This was a retrospective study of dasatinib and/or nilotinib-resistant or -intolerant patients pretreated with imatinib aimed at evaluating the efficacy of bosutanib monotherapy. All patients had chronic phase CML and BCR-ABL fusions. Complete hematologic response (CHR) and major cytogenetic response (MCyR) were comparable for patients with Abl1 mutation versus without. Of patients with C475V, 1/1 had a CHR and 1/1 had a MCyR. 9 patients in this study had multiple kinase domain mutations, but it was not indicated when mutations were co-occuring.",
        "method": "metakb.method:1",
        "is_reported_in": [
            {
                "id": "civic.source:1997",
                "type": "Document",
                "label": "Khoury et al., 2012, Blood",
                "xrefs": [
                    "pmc:PMC4916559",
                    "pmid:22371878"
                ],
                "title": "Bosutinib is active in chronic phase chronic myeloid leukemia after imatinib and dasatinib and/or nilotinib therapy failure."
            }
        ],
        "evidence_level": {
            "id": "vicc:e00008",
            "type": "Coding",
            "label": "case study evidence"
        },
        "target_proposition": {
            "id": "proposition:uAUFd3G713OgSifeqn-1SFpQMkgksdl8",
            "type": "VariationNeoplasmTherapeuticResponseProposition",
            "subject": "ga4gh:VA.AHjZBfY5TFrI_jqv4JDA9cYRcszQgGEs",
            "predicate": "predicts_resistance_to",
            "object": {
                "id": "rxcui:1307619",
                "type": "Therapeutic"
            },
            "neoplasm_type_qualifier": {
                "id": "ncit:C3174",
                "type": "Disease"
            }
        },
        "direction": "opposes",
        "subject_descriptor": "civic.vid:1639",
        "neoplasm_type_descriptor": {
            "id": "civic.did:4",
            "type": "DiseaseDescriptor",
            "label": "Chronic Myeloid Leukemia",
            "xrefs": [
                "DOID:8552"
            ],
            "disease": "ncit:C3174"
        },
        "object_descriptor": {
            "id": "civic.tid:520",
            "type": "TherapeuticDescriptor",
            "label": "Bosutinib",
            "extensions": [
                {
                    "type": "Extension",
                    "name": "regulatory_approval",
                    "value": {
                        "approval_rating": "ChEMBL",
                        "has_indications": [
                            {
                                "id": "EFO:0000339",
                                "type": "DiseaseDescriptor",
                                "label": "chronic myelogenous leukemia",
                                "disease": "ncit:C3174"
                            },
                            {
                                "id": "mesh:D009369",
                                "type": "DiseaseDescriptor",
                                "label": "Neoplasms",
                                "disease": "ncit:C3262"
                            }
                        ]
                    }
                }
            ],
            "xrefs": [
                "ncit:C60809"
            ],
            "alternate_labels": [
                "4-Anilino-3-quinolinecarbonitrile",
                "4-Anilinobenzo(g)quinoline-3-carbonitrile",
                "4-[(2,4-dichloro-5-methoxyphenyl)amino]-6-methoxy-7-[3-(4-methylpiperazin-1-yl)propoxy]quinoline-3-carbonitrile",
                "Bosulif",
                "SKI 606",
                "SKI-606"
            ],
            "therapeutic": "rxcui:1307619"
        }
    },
    {
        "id": "civic.eid:6977",
        "type": "VariationNeoplasmTherapeuticResponseStatement",
        "description": "In a study of 39 chronic phase CML patients with BCR-ABL variants, C475V was seen in a single imatinib resistant patient that was also resistant or intolerant to dasatinib and/or nilotinib treatment. Nine patients in this study had multiple kinase domain mutations, but it was not indicated when mutations were co-occuring.",
        "method": "metakb.method:1",
        "is_reported_in": [
            {
                "id": "civic.source:1997",
                "type": "Document",
                "label": "Khoury et al., 2012, Blood",
                "xrefs": [
                    "pmc:PMC4916559",
                    "pmid:22371878"
                ],
                "title": "Bosutinib is active in chronic phase chronic myeloid leukemia after imatinib and dasatinib and/or nilotinib therapy failure."
            }
        ],
        "evidence_level": {
            "id": "vicc:e00008",
            "type": "Coding",
            "label": "case study evidence"
        },
        "target_proposition": {
            "id": "proposition:OkCSaam8k4VEyisfYEPWWicwq7a91GE7",
            "type": "VariationNeoplasmTherapeuticResponseProposition",
            "subject": "ga4gh:VA.AHjZBfY5TFrI_jqv4JDA9cYRcszQgGEs",
            "predicate": "predicts_resistance_to",
            "object": {
                "id": "rxcui:282388",
                "type": "Therapeutic"
            },
            "neoplasm_type_qualifier": {
                "id": "ncit:C3174",
                "type": "Disease"
            }
        },
        "direction": "supports",
        "subject_descriptor": "civic.vid:1639",
        "neoplasm_type_descriptor": {
            "id": "civic.did:4",
            "type": "DiseaseDescriptor",
            "label": "Chronic Myeloid Leukemia",
            "xrefs": [
                "DOID:8552"
            ],
            "disease": "ncit:C3174"
        },
        "object_descriptor": {
            "id": "civic.tid:537",
            "type": "TherapeuticDescriptor",
            "label": "Imatinib Mesylate",
            "extensions": [
                {
                    "type": "Extension",
                    "name": "regulatory_approval",
                    "value": {
                        "approval_rating": "FDA",
                        "has_indications": [
                            {
                                "id": "hemonc:667",
                                "type": "DiseaseDescriptor",
                                "label": "Soft tissue sarcoma",
                                "disease": "ncit:C9306"
                            },
                            {
                                "id": "hemonc:602",
                                "type": "DiseaseDescriptor",
                                "label": "Gastrointestinal stromal tumor",
                                "disease": "ncit:C3868"
                            },
                            {
                                "id": "hemonc:616",
                                "type": "DiseaseDescriptor",
                                "label": "Hypereosinophilic syndrome",
                                "disease": "ncit:C27038"
                            },
                            {
                                "id": "hemonc:33893",
                                "type": "DiseaseDescriptor",
                                "label": "Chronic myelogenous leukemia pediatric",
                                "disease": null
                            },
                            {
                                "id": "hemonc:634",
                                "type": "DiseaseDescriptor",
                                "label": "Myelodysplastic syndrome",
                                "disease": "ncit:C3247"
                            },
                            {
                                "id": "hemonc:24309",
                                "type": "DiseaseDescriptor",
                                "label": "Acute lymphoblastic leukemia",
                                "disease": "ncit:C3167"
                            },
                            {
                                "id": "hemonc:582",
                                "type": "DiseaseDescriptor",
                                "label": "Chronic myelogenous leukemia",
                                "disease": "ncit:C3174"
                            },
                            {
                                "id": "hemonc:669",
                                "type": "DiseaseDescriptor",
                                "label": "Systemic mastocytosis",
                                "disease": "ncit:C9235"
                            }
                        ]
                    }
                }
            ],
            "xrefs": [
                "ncit:C1687"
            ],
            "alternate_labels": [
                "4-[(4-Methyl-1-piperazinyl)methyl]-N-[4-methyl-3-[[4-(3-pyridinyl)-2-pyrimidinyl]amino]phenyl]benzamide Monomethanesulfonate",
                "CGP 57148",
                "CGP57148B",
                "Gleevec",
                "Glivec",
                "STI 571",
                "STI-571",
                "STI571"
            ],
            "therapeutic": "rxcui:282388"
        }
    },
    {
        "id": "civic.eid:2251",
        "type": "VariationNeoplasmTherapeuticResponseStatement",
        "description": "In in vitro experiments, myeloma cell lines expressing activating NRAS and KRAS mutations are less sensitive to the apoptosis-inducing effects of dexamethasone, doxorubicin, and melphalan in comparison to cells with wildtype RAS.",
        "method": "metakb.method:1",
        "is_reported_in": [
            {
                "id": "civic.source:1421",
                "type": "Document",
                "label": "Rowley et al., 2002, Oncogene",
                "xrefs": [
                    "pmid:12483530"
                ],
                "title": "Activation of N-ras and K-ras induced by interleukin-6 in a myeloma cell line: implications for disease progression and therapeutic response."
            }
        ],
        "evidence_level": {
            "id": "vicc:e00009",
            "type": "Coding",
            "label": "preclinical evidence"
        },
        "target_proposition": {
            "id": "proposition:1Sa3QxRYxqz93Sii4mEhoHsVJVgyduzJ",
            "type": "VariationNeoplasmTherapeuticResponseProposition",
            "subject": "ga4gh:VA.jSiuIG2uZEbml8MfCtZi3J9jPBCBiaPw",
            "predicate": "predicts_resistance_to",
            "object": {
                "id": "rxcui:6718",
                "type": "Therapeutic"
            },
            "neoplasm_type_qualifier": {
                "id": "ncit:C3242",
                "type": "Disease"
            }
        },
        "direction": "supports",
        "subject_descriptor": "civic.vid:79",
        "neoplasm_type_descriptor": {
            "id": "civic.did:41",
            "type": "DiseaseDescriptor",
            "label": "Multiple Myeloma",
            "xrefs": [
                "DOID:9538"
            ],
            "disease": "ncit:C3242"
        },
        "object_descriptor": {
            "id": "civic.tid:328",
            "type": "TherapeuticDescriptor",
            "label": "Melphalan",
            "extensions": [
                {
                    "type": "Extension",
                    "name": "regulatory_approval",
                    "value": {
                        "approval_rating": "FDA",
                        "has_indications": [
                            {
                                "id": "hemonc:633",
                                "type": "DiseaseDescriptor",
                                "label": "Multiple myeloma",
                                "disease": "ncit:C3242"
                            },
                            {
                                "id": "hemonc:645",
                                "type": "DiseaseDescriptor",
                                "label": "Ovarian cancer",
                                "disease": "ncit:C7431"
                            }
                        ]
                    }
                }
            ],
            "xrefs": [
                "ncit:C633"
            ],
            "alternate_labels": [
                "4-[bis(2-chloroethyl)amino]-L-phenylalanine",
                "Alanine Nitrogen Mustard",
                "CB-3025",
                "L-PAM",
                "L-Phenylalanine Mustard",
                "L-Sarcolysin",
                "L-Sarcolysin Phenylalanine Mustard",
                "L-Sarcolysine",
                "Melphalanum",
                "P-di(chloroethyl)amino-L-phenylalanine",
                "Phenylalanine Mustard",
                "Phenylalanine Nitrogen Mustard",
                "Sarcoclorin",
                "Sarkolysin",
                "WR-19813"
            ],
            "therapeutic": "rxcui:6718"
        }
    },
    {
        "id": "civic.eid:2262",
        "type": "VariationNeoplasmTherapeuticResponseStatement",
        "description": "In in vitro experiments, myeloma cell lines expressing activating NRAS and KRAS mutations are less sensitive to the apoptosis-inducing effects of dexamethasone, doxorubicin, and melphalan in comparison to cells with wildtype RAS.",
        "method": "metakb.method:1",
        "is_reported_in": [
            {
                "id": "civic.source:1421",
                "type": "Document",
                "label": "Rowley et al., 2002, Oncogene",
                "xrefs": [
                    "pmid:12483530"
                ],
                "title": "Activation of N-ras and K-ras induced by interleukin-6 in a myeloma cell line: implications for disease progression and therapeutic response."
            }
        ],
        "evidence_level": {
            "id": "vicc:e00009",
            "type": "Coding",
            "label": "preclinical evidence"
        },
        "target_proposition": {
            "id": "proposition:JpdscSmtl0tP4LlgMLwyPbbZcZkyaIFx",
            "type": "VariationNeoplasmTherapeuticResponseProposition",
            "subject": "ga4gh:VA.rpL2_d2q0gdks_VPk_0JVl90aJG9-bEd",
            "predicate": "predicts_resistance_to",
            "object": {
                "id": "rxcui:6718",
                "type": "Therapeutic"
            },
            "neoplasm_type_qualifier": {
                "id": "ncit:C3242",
                "type": "Disease"
            }
        },
        "direction": "supports",
        "subject_descriptor": "civic.vid:78",
        "neoplasm_type_descriptor": {
            "id": "civic.did:41",
            "type": "DiseaseDescriptor",
            "label": "Multiple Myeloma",
            "xrefs": [
                "DOID:9538"
            ],
            "disease": "ncit:C3242"
        },
        "object_descriptor": {
            "id": "civic.tid:328",
            "type": "TherapeuticDescriptor",
            "label": "Melphalan",
            "extensions": [
                {
                    "type": "Extension",
                    "name": "regulatory_approval",
                    "value": {
                        "approval_rating": "FDA",
                        "has_indications": [
                            {
                                "id": "hemonc:633",
                                "type": "DiseaseDescriptor",
                                "label": "Multiple myeloma",
                                "disease": "ncit:C3242"
                            },
                            {
                                "id": "hemonc:645",
                                "type": "DiseaseDescriptor",
                                "label": "Ovarian cancer",
                                "disease": "ncit:C7431"
                            }
                        ]
                    }
                }
            ],
            "xrefs": [
                "ncit:C633"
            ],
            "alternate_labels": [
                "4-[bis(2-chloroethyl)amino]-L-phenylalanine",
                "Alanine Nitrogen Mustard",
                "CB-3025",
                "L-PAM",
                "L-Phenylalanine Mustard",
                "L-Sarcolysin",
                "L-Sarcolysin Phenylalanine Mustard",
                "L-Sarcolysine",
                "Melphalanum",
                "P-di(chloroethyl)amino-L-phenylalanine",
                "Phenylalanine Mustard",
                "Phenylalanine Nitrogen Mustard",
                "Sarcoclorin",
                "Sarkolysin",
                "WR-19813"
            ],
            "therapeutic": "rxcui:6718"
        }
    },
    {
        "id": "civic.eid:3852",
        "type": "VariationNeoplasmTherapeuticResponseStatement",
        "description": "In an in vitro study, Colo-320, SW48, and CaCO2 cell lines expressing HRAS G13D mutation were associated with resistance to cetuximab treatment, as compared to Colo-320, SW48, and CaCO2 cells expressing wild-type HRAS.",
        "method": "metakb.method:1",
        "is_reported_in": [
            {
                "id": "civic.source:457",
                "type": "Document",
                "label": "Boidot et al., 2016, Int J Colorectal Dis",
                "xrefs": [
                    "pmid:26561417"
                ],
                "title": "HRAS G13D, a new mutation implicated in the resistance to anti-EGFR therapies in colorectal cancer, a case report."
            }
        ],
        "evidence_level": {
            "id": "vicc:e00009",
            "type": "Coding",
            "label": "preclinical evidence"
        },
        "target_proposition": {
            "id": "proposition:rl15SJVWBcTSoLV9ekPoImS2oHUvoDKe",
            "type": "VariationNeoplasmTherapeuticResponseProposition",
            "subject": "ga4gh:VA.Z1VxpmB2Ui54Nd4GCsBXMjb2WDaCU7Ja",
            "predicate": "predicts_resistance_to",
            "object": {
                "id": "rxcui:318341",
                "type": "Therapeutic"
            },
            "neoplasm_type_qualifier": {
                "id": "ncit:C4978",
                "type": "Disease"
            }
        },
        "direction": "supports",
        "subject_descriptor": "civic.vid:274",
        "neoplasm_type_descriptor": {
            "id": "civic.did:11",
            "type": "DiseaseDescriptor",
            "label": "Colorectal Cancer",
            "xrefs": [
                "DOID:9256"
            ],
            "disease": "ncit:C4978"
        },
        "object_descriptor": {
            "id": "civic.tid:16",
            "type": "TherapeuticDescriptor",
            "label": "Cetuximab",
            "extensions": [
                {
                    "type": "Extension",
                    "name": "regulatory_approval",
                    "value": {
                        "approval_rating": "ChEMBL",
                        "has_indications": [
                            {
                                "id": "mesh:D002294",
                                "type": "DiseaseDescriptor",
                                "label": "Carcinoma, Squamous Cell",
                                "disease": "ncit:C2929"
                            },
                            {
                                "id": "mesh:D009369",
                                "type": "DiseaseDescriptor",
                                "label": "Neoplasms",
                                "disease": "ncit:C3262"
                            },
                            {
                                "id": "mesh:D015179",
                                "type": "DiseaseDescriptor",
                                "label": "Colorectal Neoplasms",
                                "disease": "ncit:C2956"
                            },
                            {
                                "id": "mesh:D006258",
                                "type": "DiseaseDescriptor",
                                "label": "Head and Neck Neoplasms",
                                "disease": "ncit:C4013"
                            }
                        ]
                    }
                }
            ],
            "xrefs": [
                "ncit:C1723"
            ],
            "alternate_labels": [
                "Cetuximab Biosimilar CDP-1",
                "Cetuximab Biosimilar CMAB009",
                "Cetuximab Biosimilar KL 140",
                "Chimeric Anti-EGFR Monoclonal Antibody",
                "Chimeric MoAb C225",
                "Chimeric Monoclonal Antibody C225",
                "Erbitux",
                "IMC-C225"
            ],
            "therapeutic": "rxcui:318341"
        }
    },
    {
        "id": "civic.eid:3878",
        "type": "VariationNeoplasmTherapeuticResponseStatement",
        "description": "In an in vitro study, a Lim1215 colorectal cancer cell line endogenously expressing KRAS G13D mutation demonstrated resistance to cetuximab treatment, compared to Lim1215 parental cells expressing wild-type KRAS. Resistance was determined by assessing cell viability.",
        "method": "metakb.method:1",
        "is_reported_in": [
            {
                "id": "civic.source:2008",
                "type": "Document",
                "label": "Misale et al., 2012, Nature",
                "xrefs": [
                    "pmc:PMC3927413",
                    "pmid:22722830"
                ],
                "title": "Emergence of KRAS mutations and acquired resistance to anti-EGFR therapy in colorectal cancer."
            }
        ],
        "evidence_level": {
            "id": "vicc:e00009",
            "type": "Coding",
            "label": "preclinical evidence"
        },
        "target_proposition": {
            "id": "proposition:e_3NNapOoNeeZi1MoruyXk6xCAWRhh2Q",
            "type": "VariationNeoplasmTherapeuticResponseProposition",
            "subject": "ga4gh:VA.tO-mdKyTxDxR376-vWkR2RgI2gpOvBhQ",
            "predicate": "predicts_resistance_to",
            "object": {
                "id": "rxcui:318341",
                "type": "Therapeutic"
            },
            "neoplasm_type_qualifier": {
                "id": "ncit:C4978",
                "type": "Disease"
            }
        },
        "direction": "supports",
        "subject_descriptor": "civic.vid:81",
        "neoplasm_type_descriptor": {
            "id": "civic.did:11",
            "type": "DiseaseDescriptor",
            "label": "Colorectal Cancer",
            "xrefs": [
                "DOID:9256"
            ],
            "disease": "ncit:C4978"
        },
        "object_descriptor": {
            "id": "civic.tid:16",
            "type": "TherapeuticDescriptor",
            "label": "Cetuximab",
            "extensions": [
                {
                    "type": "Extension",
                    "name": "regulatory_approval",
                    "value": {
                        "approval_rating": "ChEMBL",
                        "has_indications": [
                            {
                                "id": "mesh:D002294",
                                "type": "DiseaseDescriptor",
                                "label": "Carcinoma, Squamous Cell",
                                "disease": "ncit:C2929"
                            },
                            {
                                "id": "mesh:D009369",
                                "type": "DiseaseDescriptor",
                                "label": "Neoplasms",
                                "disease": "ncit:C3262"
                            },
                            {
                                "id": "mesh:D015179",
                                "type": "DiseaseDescriptor",
                                "label": "Colorectal Neoplasms",
                                "disease": "ncit:C2956"
                            },
                            {
                                "id": "mesh:D006258",
                                "type": "DiseaseDescriptor",
                                "label": "Head and Neck Neoplasms",
                                "disease": "ncit:C4013"
                            }
                        ]
                    }
                }
            ],
            "xrefs": [
                "ncit:C1723"
            ],
            "alternate_labels": [
                "Cetuximab Biosimilar CDP-1",
                "Cetuximab Biosimilar CMAB009",
                "Cetuximab Biosimilar KL 140",
                "Chimeric Anti-EGFR Monoclonal Antibody",
                "Chimeric MoAb C225",
                "Chimeric Monoclonal Antibody C225",
                "Erbitux",
                "IMC-C225"
            ],
            "therapeutic": "rxcui:318341"
        }
    },
    {
        "id": "civic.eid:4275",
        "type": "VariationNeoplasmTherapeuticResponseStatement",
        "description": "In an in vitro study, a Ba/F3 cell line expressing EGFR D770_N771insSVD demonstrated reduced sensitivity to erlotinib treatment (IC50=3.187\ufffdM), comparable to Ba/F3 cells expressing EGFR L858R and T790M co-mutation (T790M is a known resistant mutation to 1st and 2nd generation EGFR tyrosine kinase inhibitors; IC50=4.155\ufffdM). Resistance was determined by assessing cell proliferation, EGFR, AKT and ERK phosphorylation.",
        "method": "metakb.method:1",
        "is_reported_in": [
            {
                "id": "civic.source:1230",
                "type": "Document",
                "label": "Yasuda et al., 2013, Sci Transl Med",
                "xrefs": [
                    "pmc:PMC3954775",
                    "pmid:24353160"
                ],
                "title": "Structural, biochemical, and clinical characterization of epidermal growth factor receptor (EGFR) exon 20 insertion mutations in lung cancer."
            }
        ],
        "evidence_level": {
            "id": "vicc:e00009",
            "type": "Coding",
            "label": "preclinical evidence"
        },
        "target_proposition": {
            "id": "proposition:I-O-rFrpcn2PWnlSGceqgDqpvugLi8gY",
            "type": "VariationNeoplasmTherapeuticResponseProposition",
            "subject": "ga4gh:VA.7mGWSx_S9atbu6nmmozfM0lGdON1_B1M",
            "predicate": "predicts_resistance_to",
            "object": {
                "id": "rxcui:337525",
                "type": "Therapeutic"
            },
            "neoplasm_type_qualifier": {
                "id": "ncit:C2926",
                "type": "Disease"
            }
        },
        "direction": "supports",
        "subject_descriptor": "civic.vid:1445",
        "neoplasm_type_descriptor": {
            "id": "civic.did:8",
            "type": "DiseaseDescriptor",
            "label": "Lung Non-small Cell Carcinoma",
            "xrefs": [
                "DOID:3908"
            ],
            "disease": "ncit:C2926"
        },
        "object_descriptor": {
            "id": "civic.tid:15",
            "type": "TherapeuticDescriptor",
            "label": "Erlotinib",
            "extensions": [
                {
                    "type": "Extension",
                    "name": "regulatory_approval",
                    "value": {
                        "approval_rating": "FDA",
                        "has_indications": [
                            {
                                "id": "hemonc:642",
                                "type": "DiseaseDescriptor",
                                "label": "Non-small cell lung cancer",
                                "disease": "ncit:C2926"
                            },
                            {
                                "id": "hemonc:648",
                                "type": "DiseaseDescriptor",
                                "label": "Pancreatic cancer",
                                "disease": "ncit:C43298"
                            }
                        ]
                    }
                }
            ],
            "xrefs": [
                "ncit:C65530"
            ],
            "therapeutic": "rxcui:337525"
        }
    },
    {
        "id": "civic.eid:4276",
        "type": "VariationNeoplasmTherapeuticResponseStatement",
        "description": "In an in vitro study, a Ba/F3 cell line expressing EGFR H773_V774insH demonstrated reduced sensitivity to erlotinib treatment (IC50=3.902\ufffdM), comparable to Ba/F3 cells expressing EGFR L858R and T790M co-mutation (T790M is a known resistant mutation to 1st and 2nd generation EGFR tyrosine kinase inhibitors; IC50=4.155\ufffdM). Resistance was determined by assessing cell proliferation, EGFR, AKT and ERK phosphorylation.",
        "method": "metakb.method:1",
        "is_reported_in": [
            {
                "id": "civic.source:1230",
                "type": "Document",
                "label": "Yasuda et al., 2013, Sci Transl Med",
                "xrefs": [
                    "pmc:PMC3954775",
                    "pmid:24353160"
                ],
                "title": "Structural, biochemical, and clinical characterization of epidermal growth factor receptor (EGFR) exon 20 insertion mutations in lung cancer."
            }
        ],
        "evidence_level": {
            "id": "vicc:e00009",
            "type": "Coding",
            "label": "preclinical evidence"
        },
        "target_proposition": {
            "id": "proposition:tAUDE3IbJ1kw4s__ICwhWSnVDc2zf5hr",
            "type": "VariationNeoplasmTherapeuticResponseProposition",
            "subject": "ga4gh:VA.42kjfaZSad5lp3V-01dETLJd1nsBcU0k",
            "predicate": "predicts_resistance_to",
            "object": {
                "id": "rxcui:337525",
                "type": "Therapeutic"
            },
            "neoplasm_type_qualifier": {
                "id": "ncit:C2926",
                "type": "Disease"
            }
        },
        "direction": "supports",
        "subject_descriptor": "civic.vid:1446",
        "neoplasm_type_descriptor": {
            "id": "civic.did:8",
            "type": "DiseaseDescriptor",
            "label": "Lung Non-small Cell Carcinoma",
            "xrefs": [
                "DOID:3908"
            ],
            "disease": "ncit:C2926"
        },
        "object_descriptor": {
            "id": "civic.tid:15",
            "type": "TherapeuticDescriptor",
            "label": "Erlotinib",
            "extensions": [
                {
                    "type": "Extension",
                    "name": "regulatory_approval",
                    "value": {
                        "approval_rating": "FDA",
                        "has_indications": [
                            {
                                "id": "hemonc:642",
                                "type": "DiseaseDescriptor",
                                "label": "Non-small cell lung cancer",
                                "disease": "ncit:C2926"
                            },
                            {
                                "id": "hemonc:648",
                                "type": "DiseaseDescriptor",
                                "label": "Pancreatic cancer",
                                "disease": "ncit:C43298"
                            }
                        ]
                    }
                }
            ],
            "xrefs": [
                "ncit:C65530"
            ],
            "therapeutic": "rxcui:337525"
        }
    },
    {
        "id": "civic.eid:4496",
        "type": "VariationNeoplasmTherapeuticResponseStatement",
        "description": "In an in vitro study, a Ba/F3 cell line expressing EGFR N826S demonstrated reduced sensitivity to erlotinib treatment, compared to Ba/F3 cells expressing a known sensitizing mutation (EGFR L858R). Sensitivity was determined by assessing cell proliferation, the IC50 of erlotinib for EGFR N826S and EGFR L858R expressing cells were 505 nmol/L and 6 nmol/L, respectively.",
        "method": "metakb.method:1",
        "is_reported_in": [
            {
                "id": "civic.source:1528",
                "type": "Document",
                "label": "Kancha et al., 2009, Clin. Cancer Res.",
                "xrefs": [
                    "pmid:19147750"
                ],
                "title": "Functional analysis of epidermal growth factor receptor (EGFR) mutations and potential implications for EGFR targeted therapy."
            }
        ],
        "evidence_level": {
            "id": "vicc:e00009",
            "type": "Coding",
            "label": "preclinical evidence"
        },
        "target_proposition": {
            "id": "proposition:zXyPJBZeTDeQ1UbaBeoiQ8bRIXH6Bf6s",
            "type": "VariationNeoplasmTherapeuticResponseProposition",
            "subject": "ga4gh:VA.n1UECm1S3T-cN7jwEzR_mNZASK1itHDz",
            "predicate": "predicts_resistance_to",
            "object": {
                "id": "rxcui:337525",
                "type": "Therapeutic"
            },
            "neoplasm_type_qualifier": {
                "id": "ncit:C2926",
                "type": "Disease"
            }
        },
        "direction": "supports",
        "subject_descriptor": "civic.vid:1188",
        "neoplasm_type_descriptor": {
            "id": "civic.did:8",
            "type": "DiseaseDescriptor",
            "label": "Lung Non-small Cell Carcinoma",
            "xrefs": [
                "DOID:3908"
            ],
            "disease": "ncit:C2926"
        },
        "object_descriptor": {
            "id": "civic.tid:15",
            "type": "TherapeuticDescriptor",
            "label": "Erlotinib",
            "extensions": [
                {
                    "type": "Extension",
                    "name": "regulatory_approval",
                    "value": {
                        "approval_rating": "FDA",
                        "has_indications": [
                            {
                                "id": "hemonc:642",
                                "type": "DiseaseDescriptor",
                                "label": "Non-small cell lung cancer",
                                "disease": "ncit:C2926"
                            },
                            {
                                "id": "hemonc:648",
                                "type": "DiseaseDescriptor",
                                "label": "Pancreatic cancer",
                                "disease": "ncit:C43298"
                            }
                        ]
                    }
                }
            ],
            "xrefs": [
                "ncit:C65530"
            ],
            "therapeutic": "rxcui:337525"
        }
    },
    {
        "id": "civic.eid:4653",
        "type": "VariationNeoplasmTherapeuticResponseStatement",
        "description": "In an in vitro study, mouse embryonic fibroblasts (MEFs), null for the Smo mouse gene expressing SMO L412F mutation, demonstrated resistance to vismodegib treatment (IC50: >320 nmol/L vs. 8.23 nmol/L) compared to MEFs expressing wild-type SMO. Resistance was determined by assessing GLI1 mRNA expression levels.",
        "method": "metakb.method:1",
        "is_reported_in": [
            {
                "id": "civic.source:493",
                "type": "Document",
                "label": "Atwood et al., 2015, Cancer Cell",
                "xrefs": [
                    "pmc:PMC4357167",
                    "pmid:25759020"
                ],
                "title": "Smoothened variants explain the majority of drug resistance in basal cell carcinoma."
            }
        ],
        "evidence_level": {
            "id": "vicc:e00009",
            "type": "Coding",
            "label": "preclinical evidence"
        },
        "target_proposition": {
            "id": "proposition:h9ZSDTDg9jNJDXIzMlKZUPlbeN0EIxaG",
            "type": "VariationNeoplasmTherapeuticResponseProposition",
            "subject": "ga4gh:VA.8f8ZfbLyMJvGCXConL8k3JWsKG430vJp",
            "predicate": "predicts_resistance_to",
            "object": {
                "id": "rxcui:1242987",
                "type": "Therapeutic"
            },
            "neoplasm_type_qualifier": {
                "id": "ncit:C2921",
                "type": "Disease"
            }
        },
        "direction": "supports",
        "subject_descriptor": "civic.vid:1570",
        "neoplasm_type_descriptor": {
            "id": "civic.did:314",
            "type": "DiseaseDescriptor",
            "label": "Basal Cell Carcinoma",
            "xrefs": [
                "DOID:2513"
            ],
            "disease": "ncit:C2921"
        },
        "object_descriptor": {
            "id": "civic.tid:190",
            "type": "TherapeuticDescriptor",
            "label": "Vismodegib",
            "extensions": [
                {
                    "type": "Extension",
                    "name": "regulatory_approval",
                    "value": {
                        "approval_rating": "FDA",
                        "has_indications": [
                            {
                                "id": "hemonc:587",
                                "type": "DiseaseDescriptor",
                                "label": "Cutaneous basal cell carcinoma",
                                "disease": null
                            }
                        ]
                    }
                }
            ],
            "xrefs": [
                "ncit:C74038"
            ],
            "alternate_labels": [
                "2-chloro-N-[4-chloro-3-(pyridin-2-yl)phenyl]-4-(methylsulfonyl)benzamide",
                "Erivedge",
                "GDC-0449",
                "Hedgehog Antagonist GDC-0449"
            ],
            "therapeutic": "rxcui:1242987"
        }
    },
    {
        "id": "civic.eid:4799",
        "type": "VariationNeoplasmTherapeuticResponseStatement",
        "description": "In an in vitro study, a Ba/F3 cell line expressing EGFR M766_A767insAI demonstrated reduced sensitivity to erlotinib treatment (IC50=3.403\ufffdM), comparable to Ba/F3 cells expressing EGFR L858R and T790M co-mutation (T790M is a known resistant mutation to 1st and 2nd generation EGFR tyrosine kinase inhibitors; IC50=4.155\ufffdM). Resistance was determined by assessing cell proliferation, EGFR, AKT and ERK phosphorylation.",
        "method": "metakb.method:1",
        "is_reported_in": [
            {
                "id": "civic.source:1230",
                "type": "Document",
                "label": "Yasuda et al., 2013, Sci Transl Med",
                "xrefs": [
                    "pmc:PMC3954775",
                    "pmid:24353160"
                ],
                "title": "Structural, biochemical, and clinical characterization of epidermal growth factor receptor (EGFR) exon 20 insertion mutations in lung cancer."
            }
        ],
        "evidence_level": {
            "id": "vicc:e00009",
            "type": "Coding",
            "label": "preclinical evidence"
        },
        "target_proposition": {
            "id": "proposition:8YIPHaXac1NC90KdW9FyuSSlJ_4l93VJ",
            "type": "VariationNeoplasmTherapeuticResponseProposition",
            "subject": "ga4gh:VA.fh5YuhsxAYO5fM2TAnC_B64fecZt_Hpg",
            "predicate": "predicts_resistance_to",
            "object": {
                "id": "rxcui:337525",
                "type": "Therapeutic"
            },
            "neoplasm_type_qualifier": {
                "id": "ncit:C2926",
                "type": "Disease"
            }
        },
        "direction": "supports",
        "subject_descriptor": "civic.vid:1664",
        "neoplasm_type_descriptor": {
            "id": "civic.did:8",
            "type": "DiseaseDescriptor",
            "label": "Lung Non-small Cell Carcinoma",
            "xrefs": [
                "DOID:3908"
            ],
            "disease": "ncit:C2926"
        },
        "object_descriptor": {
            "id": "civic.tid:15",
            "type": "TherapeuticDescriptor",
            "label": "Erlotinib",
            "extensions": [
                {
                    "type": "Extension",
                    "name": "regulatory_approval",
                    "value": {
                        "approval_rating": "FDA",
                        "has_indications": [
                            {
                                "id": "hemonc:642",
                                "type": "DiseaseDescriptor",
                                "label": "Non-small cell lung cancer",
                                "disease": "ncit:C2926"
                            },
                            {
                                "id": "hemonc:648",
                                "type": "DiseaseDescriptor",
                                "label": "Pancreatic cancer",
                                "disease": "ncit:C43298"
                            }
                        ]
                    }
                }
            ],
            "xrefs": [
                "ncit:C65530"
            ],
            "therapeutic": "rxcui:337525"
        }
    },
    {
        "id": "civic.eid:4800",
        "type": "VariationNeoplasmTherapeuticResponseStatement",
        "description": "In an in vitro study, a Ba/F3 cell line expressing EGFR Y764_V765insHH demonstrated reduced sensitivity to erlotinib treatment (IC50=3.845\ufffdM), comparable to Ba/F3 cells expressing EGFR L858R and T790M co-mutation (T790M is a known resistant mutation to 1st and 2nd generations EGFR tyrosine kinase inhibitors; IC50=4.155\ufffdM). Resistance was determined by assessing cell proliferation, EGFR, AKT and ERK phosphorylation.",
        "method": "metakb.method:1",
        "is_reported_in": [
            {
                "id": "civic.source:1230",
                "type": "Document",
                "label": "Yasuda et al., 2013, Sci Transl Med",
                "xrefs": [
                    "pmc:PMC3954775",
                    "pmid:24353160"
                ],
                "title": "Structural, biochemical, and clinical characterization of epidermal growth factor receptor (EGFR) exon 20 insertion mutations in lung cancer."
            }
        ],
        "evidence_level": {
            "id": "vicc:e00009",
            "type": "Coding",
            "label": "preclinical evidence"
        },
        "target_proposition": {
            "id": "proposition:vyph_wdBk5fhsiaoiyETTCiJFW-u7pd3",
            "type": "VariationNeoplasmTherapeuticResponseProposition",
            "subject": "ga4gh:VA.uCosmcfK9BBelNIYMnmfyt99VCrN-evo",
            "predicate": "predicts_resistance_to",
            "object": {
                "id": "rxcui:337525",
                "type": "Therapeutic"
            },
            "neoplasm_type_qualifier": {
                "id": "ncit:C2926",
                "type": "Disease"
            }
        },
        "direction": "supports",
        "subject_descriptor": "civic.vid:1665",
        "neoplasm_type_descriptor": {
            "id": "civic.did:8",
            "type": "DiseaseDescriptor",
            "label": "Lung Non-small Cell Carcinoma",
            "xrefs": [
                "DOID:3908"
            ],
            "disease": "ncit:C2926"
        },
        "object_descriptor": {
            "id": "civic.tid:15",
            "type": "TherapeuticDescriptor",
            "label": "Erlotinib",
            "extensions": [
                {
                    "type": "Extension",
                    "name": "regulatory_approval",
                    "value": {
                        "approval_rating": "FDA",
                        "has_indications": [
                            {
                                "id": "hemonc:642",
                                "type": "DiseaseDescriptor",
                                "label": "Non-small cell lung cancer",
                                "disease": "ncit:C2926"
                            },
                            {
                                "id": "hemonc:648",
                                "type": "DiseaseDescriptor",
                                "label": "Pancreatic cancer",
                                "disease": "ncit:C43298"
                            }
                        ]
                    }
                }
            ],
            "xrefs": [
                "ncit:C65530"
            ],
            "therapeutic": "rxcui:337525"
        }
    },
    {
        "id": "civic.eid:241",
        "type": "VariationNeoplasmTherapeuticResponseStatement",
        "description": "The L755S mutation was shown to confer resistance to lapatinib in MCF10A cell lines retrovirally transduced with wildtype or mutant ERBB2.",
        "method": "metakb.method:1",
        "is_reported_in": [
            {
                "id": "civic.source:170",
                "type": "Document",
                "label": "Bose et al., 2013, Cancer Discov",
                "xrefs": [
                    "pmc:PMC3570596",
                    "pmid:23220880"
                ],
                "title": "Activating HER2 mutations in HER2 gene amplification negative breast cancer."
            }
        ],
        "evidence_level": {
            "id": "vicc:e00009",
            "type": "Coding",
            "label": "preclinical evidence"
        },
        "target_proposition": {
            "id": "proposition:7moptChVfqiycrzl50WUxBJWXk6UIkOO",
            "type": "VariationNeoplasmTherapeuticResponseProposition",
            "subject": "ga4gh:VA.Gb-3idkBuAo7OTK9h1VU76Re2uWRfCnk",
            "predicate": "predicts_resistance_to",
            "object": {
                "id": "rxcui:480167",
                "type": "Therapeutic"
            },
            "neoplasm_type_qualifier": {
                "id": "ncit:C9335",
                "type": "Disease"
            }
        },
        "direction": "supports",
        "subject_descriptor": "civic.vid:39",
        "neoplasm_type_descriptor": {
            "id": "civic.did:22",
            "type": "DiseaseDescriptor",
            "label": "Breast Cancer",
            "xrefs": [
                "DOID:1612"
            ],
            "disease": "ncit:C9335"
        },
        "object_descriptor": {
            "id": "civic.tid:45",
            "type": "TherapeuticDescriptor",
            "label": "Lapatinib",
            "extensions": [
                {
                    "type": "Extension",
                    "name": "regulatory_approval",
                    "value": {
                        "approval_rating": "FDA",
                        "has_indications": [
                            {
                                "id": "hemonc:572",
                                "type": "DiseaseDescriptor",
                                "label": "Breast cancer",
                                "disease": "ncit:C9335"
                            }
                        ]
                    }
                }
            ],
            "xrefs": [
                "ncit:C26653"
            ],
            "alternate_labels": [
                "GSK572016",
                "GW 2016",
                "GW2016",
                "GW572016"
            ],
            "therapeutic": "rxcui:480167"
        }
    },
    {
        "id": "civic.eid:7416",
        "type": "VariationNeoplasmTherapeuticResponseStatement",
        "description": "A preclinical study tested the effects of a tyrosine kinase inhibitor (TKI) on Ba/F3 cell lines with representative primary imatinib-sensitizing mutation del 557-558, which induced IL-3 independent growth, and secondary mutation T670I. The cells were tested for Imatinib resistance. Ba/F3 cells with del 557-558/T670I mutations (IC50 = >10000 nM) showed resistance towards Imatinib compared to Ba/F3 cells with del 557-558 alone (IC50 = 27 +- 8 nM). Similarly, patient-derived GIST-T1/670 cells with 560-578 deletion/T670I mutations (IC50 > 5000 nM) did show resistance towards Imatinib compared to GIST-T1 cells with 560-578 deletion (IC50 = 30 nM). Del 557-558/T670I cells were implanted into mice and treated with Imatinib. Imatinib was not effective in treating the del 557-558/T670I cells in mice as tumor volume progressively increased. In addition, Ba/F3 cells were mutagenized with N-ethyl-N-nitrosourea and incubated with varying concentrations of Imatinib. In Imatinib incubated cells, T670I mutations were seen in approximately 80% of the resistant cell populations.",
        "method": "metakb.method:1",
        "is_reported_in": [
            {
                "id": "civic.source:2042",
                "type": "Document",
                "label": "Garner et al., 2014, Clin. Cancer Res.",
                "xrefs": [
                    "pmc:PMC4233175",
                    "pmid:25239608"
                ],
                "title": "Ponatinib inhibits polyclonal drug-resistant KIT oncoproteins and shows therapeutic potential in heavily pretreated gastrointestinal stromal tumor (GIST) patients."
            }
        ],
        "evidence_level": {
            "id": "vicc:e00009",
            "type": "Coding",
            "label": "preclinical evidence"
        },
        "target_proposition": {
            "id": "proposition:JDcfHBvflIH4S_Pj1ZEfO1ViJiZTLwol",
            "type": "VariationNeoplasmTherapeuticResponseProposition",
            "subject": "ga4gh:VA.i9jXgMZM9ZFX7HMNEDN7npl5Cl5zSgy6",
            "predicate": "predicts_resistance_to",
            "object": {
                "id": "rxcui:282388",
                "type": "Therapeutic"
            },
            "neoplasm_type_qualifier": {
                "id": "ncit:C3868",
                "type": "Disease"
            }
        },
        "direction": "supports",
        "subject_descriptor": "civic.vid:1267",
        "neoplasm_type_descriptor": {
            "id": "civic.did:2",
            "type": "DiseaseDescriptor",
            "label": "Gastrointestinal Stromal Tumor",
            "xrefs": [
                "DOID:9253"
            ],
            "disease": "ncit:C3868"
        },
        "object_descriptor": {
            "id": "civic.tid:5",
            "type": "TherapeuticDescriptor",
            "label": "Imatinib",
            "extensions": [
                {
                    "type": "Extension",
                    "name": "regulatory_approval",
                    "value": {
                        "approval_rating": "FDA",
                        "has_indications": [
                            {
                                "id": "hemonc:667",
                                "type": "DiseaseDescriptor",
                                "label": "Soft tissue sarcoma",
                                "disease": "ncit:C9306"
                            },
                            {
                                "id": "hemonc:602",
                                "type": "DiseaseDescriptor",
                                "label": "Gastrointestinal stromal tumor",
                                "disease": "ncit:C3868"
                            },
                            {
                                "id": "hemonc:616",
                                "type": "DiseaseDescriptor",
                                "label": "Hypereosinophilic syndrome",
                                "disease": "ncit:C27038"
                            },
                            {
                                "id": "hemonc:33893",
                                "type": "DiseaseDescriptor",
                                "label": "Chronic myelogenous leukemia pediatric",
                                "disease": null
                            },
                            {
                                "id": "hemonc:634",
                                "type": "DiseaseDescriptor",
                                "label": "Myelodysplastic syndrome",
                                "disease": "ncit:C3247"
                            },
                            {
                                "id": "hemonc:24309",
                                "type": "DiseaseDescriptor",
                                "label": "Acute lymphoblastic leukemia",
                                "disease": "ncit:C3167"
                            },
                            {
                                "id": "hemonc:582",
                                "type": "DiseaseDescriptor",
                                "label": "Chronic myelogenous leukemia",
                                "disease": "ncit:C3174"
                            },
                            {
                                "id": "hemonc:669",
                                "type": "DiseaseDescriptor",
                                "label": "Systemic mastocytosis",
                                "disease": "ncit:C9235"
                            }
                        ]
                    }
                }
            ],
            "xrefs": [
                "ncit:C62035"
            ],
            "alternate_labels": [
                "4-[(4-Methyl-1-piperazinyl)methyl]-N-[4-methyl-3-[[4-(3-pyridinyl)-2-pyrimidinyl]amino]phenyl]benzamide"
            ],
            "therapeutic": "rxcui:282388"
        }
    },
    {
        "id": "civic.eid:136",
        "type": "VariationNeoplasmTherapeuticResponseStatement",
        "description": "Cells harboring KRAS G12V mutation were insensitive to cetuximab treatment in isogenic SW48 cells and in a mouse xenograft model.",
        "method": "metakb.method:1",
        "is_reported_in": [
            {
                "id": "civic.source:123",
                "type": "Document",
                "label": "De Roock et al., 2010, JAMA",
                "xrefs": [
                    "pmid:20978259"
                ],
                "title": "Association of KRAS p.G13D mutation with outcome in patients with chemotherapy-refractory metastatic colorectal cancer treated with cetuximab."
            }
        ],
        "evidence_level": {
            "id": "vicc:e00009",
            "type": "Coding",
            "label": "preclinical evidence"
        },
        "target_proposition": {
            "id": "proposition:Mbn5sm4UhaBWJ4Btlb5mp7j_hP_fjlsP",
            "type": "VariationNeoplasmTherapeuticResponseProposition",
            "subject": "ga4gh:VA.VBKi2jNxAs378IqOBsveoPrYQjWPngQq",
            "predicate": "predicts_resistance_to",
            "object": {
                "id": "rxcui:318341",
                "type": "Therapeutic"
            },
            "neoplasm_type_qualifier": {
                "id": "ncit:C4978",
                "type": "Disease"
            }
        },
        "direction": "supports",
        "subject_descriptor": "civic.vid:425",
        "neoplasm_type_descriptor": {
            "id": "civic.did:11",
            "type": "DiseaseDescriptor",
            "label": "Colorectal Cancer",
            "xrefs": [
                "DOID:9256"
            ],
            "disease": "ncit:C4978"
        },
        "object_descriptor": {
            "id": "civic.tid:16",
            "type": "TherapeuticDescriptor",
            "label": "Cetuximab",
            "extensions": [
                {
                    "type": "Extension",
                    "name": "regulatory_approval",
                    "value": {
                        "approval_rating": "ChEMBL",
                        "has_indications": [
                            {
                                "id": "mesh:D002294",
                                "type": "DiseaseDescriptor",
                                "label": "Carcinoma, Squamous Cell",
                                "disease": "ncit:C2929"
                            },
                            {
                                "id": "mesh:D009369",
                                "type": "DiseaseDescriptor",
                                "label": "Neoplasms",
                                "disease": "ncit:C3262"
                            },
                            {
                                "id": "mesh:D015179",
                                "type": "DiseaseDescriptor",
                                "label": "Colorectal Neoplasms",
                                "disease": "ncit:C2956"
                            },
                            {
                                "id": "mesh:D006258",
                                "type": "DiseaseDescriptor",
                                "label": "Head and Neck Neoplasms",
                                "disease": "ncit:C4013"
                            }
                        ]
                    }
                }
            ],
            "xrefs": [
                "ncit:C1723"
            ],
            "alternate_labels": [
                "Cetuximab Biosimilar CDP-1",
                "Cetuximab Biosimilar CMAB009",
                "Cetuximab Biosimilar KL 140",
                "Chimeric Anti-EGFR Monoclonal Antibody",
                "Chimeric MoAb C225",
                "Chimeric Monoclonal Antibody C225",
                "Erbitux",
                "IMC-C225"
            ],
            "therapeutic": "rxcui:318341"
        }
    },
    {
        "id": "civic.eid:439",
        "type": "VariationNeoplasmTherapeuticResponseStatement",
        "description": "The AKT1 Q79K mutation has been shown to confer resistance to BRAF inhibitors (vemurafenib) in melanoma cell line M229.",
        "method": "metakb.method:1",
        "is_reported_in": [
            {
                "id": "civic.source:261",
                "type": "Document",
                "label": "Shi et al., 2014, Cancer Discov",
                "xrefs": [
                    "pmc:PMC3893054",
                    "pmid:24265152"
                ],
                "title": "A novel AKT1 mutant amplifies an adaptive melanoma response to BRAF inhibition."
            }
        ],
        "evidence_level": {
            "id": "vicc:e00009",
            "type": "Coding",
            "label": "preclinical evidence"
        },
        "target_proposition": {
            "id": "proposition:w-TRxF-vzBMkYBkX0mtGfCnMKrt2yDXz",
            "type": "VariationNeoplasmTherapeuticResponseProposition",
            "subject": "ga4gh:VA.gI0FOE6Esplrs92wp0CJWOeriC8srpYN",
            "predicate": "predicts_resistance_to",
            "object": {
                "id": "rxcui:1147220",
                "type": "Therapeutic"
            },
            "neoplasm_type_qualifier": {
                "id": "ncit:C3224",
                "type": "Disease"
            }
        },
        "direction": "supports",
        "subject_descriptor": "civic.vid:169",
        "neoplasm_type_descriptor": {
            "id": "civic.did:7",
            "type": "DiseaseDescriptor",
            "label": "Melanoma",
            "xrefs": [
                "DOID:1909"
            ],
            "disease": "ncit:C3224"
        },
        "object_descriptor": {
            "id": "civic.tid:4",
            "type": "TherapeuticDescriptor",
            "label": "Vemurafenib",
            "extensions": [
                {
                    "type": "Extension",
                    "name": "regulatory_approval",
                    "value": {
                        "approval_rating": "FDA",
                        "has_indications": [
                            {
                                "id": "hemonc:629",
                                "type": "DiseaseDescriptor",
                                "label": "Melanoma",
                                "disease": "ncit:C3224"
                            },
                            {
                                "id": "hemonc:594",
                                "type": "DiseaseDescriptor",
                                "label": "Erdheim-Chester disease",
                                "disease": "ncit:C53972"
                            }
                        ]
                    }
                }
            ],
            "xrefs": [
                "ncit:C64768"
            ],
            "alternate_labels": [
                "1-propanesulfonamide, N-(3-((5-(4-chlorophenyl)-1h-pyrrolo(2,3-b)pyridin-3-yl)carbonyl)-2,4-difluorophenyl)-",
                "BRAF (V600E) Kinase Inhibitor RO5185426",
                "BRAF(V600E) Kinase Inhibitor RO5185426",
                "PLX-4032",
                "PLX4032",
                "RG 7204",
                "RG7204",
                "RO 5185426",
                "Zelboraf"
            ],
            "therapeutic": "rxcui:1147220"
        }
    },
    {
        "id": "civic.eid:1080",
        "type": "VariationNeoplasmTherapeuticResponseStatement",
        "description": "In this preclinical study of the effects of cetuximab, panitumumab or sym004 on various EGFR mutations in colorectal cancer. The S492R mutation was sensitive to Sym004 and panitumumab treatment but resistant to cetuximab. Experiments include flow cytometry binding assay, kinase phosphorylation, cell viability, downstream signalling.",
        "method": "metakb.method:1",
        "is_reported_in": [
            {
                "id": "civic.source:746",
                "type": "Document",
                "label": "S\u00e1nchez-Mart\u00edn et al., 2016, Clin. Cancer Res.",
                "xrefs": [
                    "pmid:26888827"
                ],
                "title": "The First-in-class Anti-EGFR Antibody Mixture Sym004 Overcomes Cetuximab Resistance Mediated by EGFR Extracellular Domain Mutations in Colorectal Cancer."
            }
        ],
        "evidence_level": {
            "id": "vicc:e00009",
            "type": "Coding",
            "label": "preclinical evidence"
        },
        "target_proposition": {
            "id": "proposition:If7Ryn_0-J-IXHcI7vcuv1sEnZ21XDOv",
            "type": "VariationNeoplasmTherapeuticResponseProposition",
            "subject": "ga4gh:VA.VDg4To7ePAbIjjPfop3VmeFbcUpvgsf5",
            "predicate": "predicts_resistance_to",
            "object": {
                "id": "rxcui:318341",
                "type": "Therapeutic"
            },
            "neoplasm_type_qualifier": {
                "id": "ncit:C4978",
                "type": "Disease"
            }
        },
        "direction": "supports",
        "subject_descriptor": "civic.vid:453",
        "neoplasm_type_descriptor": {
            "id": "civic.did:11",
            "type": "DiseaseDescriptor",
            "label": "Colorectal Cancer",
            "xrefs": [
                "DOID:9256"
            ],
            "disease": "ncit:C4978"
        },
        "object_descriptor": {
            "id": "civic.tid:16",
            "type": "TherapeuticDescriptor",
            "label": "Cetuximab",
            "extensions": [
                {
                    "type": "Extension",
                    "name": "regulatory_approval",
                    "value": {
                        "approval_rating": "ChEMBL",
                        "has_indications": [
                            {
                                "id": "mesh:D002294",
                                "type": "DiseaseDescriptor",
                                "label": "Carcinoma, Squamous Cell",
                                "disease": "ncit:C2929"
                            },
                            {
                                "id": "mesh:D009369",
                                "type": "DiseaseDescriptor",
                                "label": "Neoplasms",
                                "disease": "ncit:C3262"
                            },
                            {
                                "id": "mesh:D015179",
                                "type": "DiseaseDescriptor",
                                "label": "Colorectal Neoplasms",
                                "disease": "ncit:C2956"
                            },
                            {
                                "id": "mesh:D006258",
                                "type": "DiseaseDescriptor",
                                "label": "Head and Neck Neoplasms",
                                "disease": "ncit:C4013"
                            }
                        ]
                    }
                }
            ],
            "xrefs": [
                "ncit:C1723"
            ],
            "alternate_labels": [
                "Cetuximab Biosimilar CDP-1",
                "Cetuximab Biosimilar CMAB009",
                "Cetuximab Biosimilar KL 140",
                "Chimeric Anti-EGFR Monoclonal Antibody",
                "Chimeric MoAb C225",
                "Chimeric Monoclonal Antibody C225",
                "Erbitux",
                "IMC-C225"
            ],
            "therapeutic": "rxcui:318341"
        }
    },
    {
        "id": "civic.eid:1543",
        "type": "VariationNeoplasmTherapeuticResponseStatement",
        "description": "MCF-7 breast cancer cell line was exposed to mTOR inhibitors AZD8055 or rapamycin until resistance developed. Deep sequencing revealed an MTOR F2108L mutation in rapamycin-resistant clones (RR2 cells). Downstream signalling was independent of inhibitor presence in these clones and expression of the mutations in MDA-MB-468 cells led to resistance.",
        "method": "metakb.method:1",
        "is_reported_in": [
            {
                "id": "civic.source:1025",
                "type": "Document",
                "label": "Rodrik-Outmezguine et al., 2016, Nature",
                "xrefs": [
                    "pmc:PMC4902179",
                    "pmid:27279227"
                ],
                "title": "Overcoming mTOR resistance mutations with a new-generation mTOR inhibitor."
            }
        ],
        "evidence_level": {
            "id": "vicc:e00009",
            "type": "Coding",
            "label": "preclinical evidence"
        },
        "target_proposition": {
            "id": "proposition:a4rggeKnMZvvdvYVkd50VHibsIs6PhpS",
            "type": "VariationNeoplasmTherapeuticResponseProposition",
            "subject": "ga4gh:VA.mWN-AFixmkqHVuKjA0fLe3k2r13MWdhF",
            "predicate": "predicts_resistance_to",
            "object": {
                "id": "rxcui:35302",
                "type": "Therapeutic"
            },
            "neoplasm_type_qualifier": {
                "id": "ncit:C9335",
                "type": "Disease"
            }
        },
        "direction": "supports",
        "subject_descriptor": "civic.vid:470",
        "neoplasm_type_descriptor": {
            "id": "civic.did:22",
            "type": "DiseaseDescriptor",
            "label": "Breast Cancer",
            "xrefs": [
                "DOID:1612"
            ],
            "disease": "ncit:C9335"
        },
        "object_descriptor": {
            "id": "civic.tid:469",
            "type": "TherapeuticDescriptor",
            "label": "Sirolimus",
            "extensions": [
                {
                    "type": "Extension",
                    "name": "regulatory_approval",
                    "value": {
                        "approval_rating": "FDA",
                        "has_indications": [
                            {
                                "id": "hemonc:37829",
                                "type": "DiseaseDescriptor",
                                "label": "PEComa",
                                "disease": "ncit:C38150"
                            }
                        ]
                    }
                }
            ],
            "xrefs": [
                "ncit:C1212"
            ],
            "alternate_labels": [
                "9,10,12,13,14,21,22,23,24,25,26,27,32,33,34,34a-Hexadecahydro-9,27-dihydroxy-3-((1R)-2-((1S,3R,4R)-4-hydroxy-3-methoxycyclohexyl)-1-methylethyl)-10,21-dimethoxy-6,8,12,14,20,26-hexamethyl-23,27-epoxy-3H-pyrido(2,1-c)(1,4)oxaazacyclohentriacontine-1,5,11,2",
                "AY 22989",
                "RAPA",
                "RAPAMYCIN",
                "Rapamune",
                "SILA 9268A",
                "WY-090217"
            ],
            "therapeutic": "rxcui:35302"
        }
    },
    {
        "id": "civic.eid:1544",
        "type": "VariationNeoplasmTherapeuticResponseStatement",
        "description": "MCF-7 breast cancer cell line was exposed to mTOR inhibitor AZD8055 until resistance developed. Deep sequencing revealed an MTOR M2327I mutation in the AZD8055-resistant clone. Downstream signalling was independent of inhibitor presence in these clones and expression of the mutation in MDA-MB-468 cells led to resistance. Tumor volume grew more rapidly in mice with xenografts of M2327I mTOR mutant MCF7 cells treated with AZD8055 than rapamycin or RapaLink-1 treatment.",
        "method": "metakb.method:1",
        "is_reported_in": [
            {
                "id": "civic.source:1025",
                "type": "Document",
                "label": "Rodrik-Outmezguine et al., 2016, Nature",
                "xrefs": [
                    "pmc:PMC4902179",
                    "pmid:27279227"
                ],
                "title": "Overcoming mTOR resistance mutations with a new-generation mTOR inhibitor."
            }
        ],
        "evidence_level": {
            "id": "vicc:e00009",
            "type": "Coding",
            "label": "preclinical evidence"
        },
        "target_proposition": {
            "id": "proposition:NVSsPbTF7GWPLnRRjQc4VoVGuV3HMQF4",
            "type": "VariationNeoplasmTherapeuticResponseProposition",
            "subject": "ga4gh:VA.PngdxFdLfRjz--M1ZiXdtsq3D4ixwAFH",
            "predicate": "predicts_resistance_to",
            "object": {
                "id": "ncit:C78856",
                "type": "Therapeutic"
            },
            "neoplasm_type_qualifier": {
                "id": "ncit:C9335",
                "type": "Disease"
            }
        },
        "direction": "supports",
        "subject_descriptor": "civic.vid:609",
        "neoplasm_type_descriptor": {
            "id": "civic.did:22",
            "type": "DiseaseDescriptor",
            "label": "Breast Cancer",
            "xrefs": [
                "DOID:1612"
            ],
            "disease": "ncit:C9335"
        },
        "object_descriptor": {
            "id": "civic.tid:124",
            "type": "TherapeuticDescriptor",
            "label": "MTOR Kinase Inhibitor AZD8055",
            "xrefs": [
                "ncit:C78856"
            ],
            "alternate_labels": [
                "AZD-8055",
                "AZD8055"
            ],
            "therapeutic": "ncit:C78856"
        }
    },
    {
        "id": "civic.eid:1547",
        "type": "VariationNeoplasmTherapeuticResponseStatement",
        "description": "MCF-7 breast cancer cell line was exposed to mTOR inhibitor rapamycin until resistance developed. Deep sequencing revealed an MTOR A2034V mutation in the resistant clone. Downstream signalling was independent of inhibitor presence in these clones and expression of the mutation in MDA-MB-468 cells led to resistance. Xenografts of these cells were more resistant to rapamycin than AZD8055 or RapaLink-1 treatment.",
        "method": "metakb.method:1",
        "is_reported_in": [
            {
                "id": "civic.source:1025",
                "type": "Document",
                "label": "Rodrik-Outmezguine et al., 2016, Nature",
                "xrefs": [
                    "pmc:PMC4902179",
                    "pmid:27279227"
                ],
                "title": "Overcoming mTOR resistance mutations with a new-generation mTOR inhibitor."
            }
        ],
        "evidence_level": {
            "id": "vicc:e00009",
            "type": "Coding",
            "label": "preclinical evidence"
        },
        "target_proposition": {
            "id": "proposition:A0I3ii7GZQzWu6qD-drOUKEdGccZgAa0",
            "type": "VariationNeoplasmTherapeuticResponseProposition",
            "subject": "ga4gh:VA.KZBatARL-UIC5KRXOStcro4yQL1964Tq",
            "predicate": "predicts_resistance_to",
            "object": {
                "id": "rxcui:35302",
                "type": "Therapeutic"
            },
            "neoplasm_type_qualifier": {
                "id": "ncit:C9335",
                "type": "Disease"
            }
        },
        "direction": "supports",
        "subject_descriptor": "civic.vid:610",
        "neoplasm_type_descriptor": {
            "id": "civic.did:22",
            "type": "DiseaseDescriptor",
            "label": "Breast Cancer",
            "xrefs": [
                "DOID:1612"
            ],
            "disease": "ncit:C9335"
        },
        "object_descriptor": {
            "id": "civic.tid:469",
            "type": "TherapeuticDescriptor",
            "label": "Sirolimus",
            "extensions": [
                {
                    "type": "Extension",
                    "name": "regulatory_approval",
                    "value": {
                        "approval_rating": "FDA",
                        "has_indications": [
                            {
                                "id": "hemonc:37829",
                                "type": "DiseaseDescriptor",
                                "label": "PEComa",
                                "disease": "ncit:C38150"
                            }
                        ]
                    }
                }
            ],
            "xrefs": [
                "ncit:C1212"
            ],
            "alternate_labels": [
                "9,10,12,13,14,21,22,23,24,25,26,27,32,33,34,34a-Hexadecahydro-9,27-dihydroxy-3-((1R)-2-((1S,3R,4R)-4-hydroxy-3-methoxycyclohexyl)-1-methylethyl)-10,21-dimethoxy-6,8,12,14,20,26-hexamethyl-23,27-epoxy-3H-pyrido(2,1-c)(1,4)oxaazacyclohentriacontine-1,5,11,2",
                "AY 22989",
                "RAPA",
                "RAPAMYCIN",
                "Rapamune",
                "SILA 9268A",
                "WY-090217"
            ],
            "therapeutic": "rxcui:35302"
        }
    },
    {
        "id": "civic.eid:1668",
        "type": "VariationNeoplasmTherapeuticResponseStatement",
        "description": "Using a mutation screen in the BRAFV600E melanoma cell line A375, the L505H variant was identified as conferring resistance to vemurafenib. Analysis of the mutation in T293 cell lines found that the L505H mutant alone or with V600e had greater kinase activity and increased the levels of phospho-MEK. Finally, transduction of Ba/F3 cells with BRAF V600E/L505H IL3 independent proliferation.",
        "method": "metakb.method:1",
        "is_reported_in": [
            {
                "id": "civic.source:1129",
                "type": "Document",
                "label": "Wagenaar et al., 2014, Pigment Cell Melanoma Res",
                "xrefs": [
                    "pmc:PMC4260813",
                    "pmid:24112705"
                ],
                "title": "Resistance to vemurafenib resulting from a novel mutation in the BRAFV600E kinase domain."
            }
        ],
        "evidence_level": {
            "id": "vicc:e00009",
            "type": "Coding",
            "label": "preclinical evidence"
        },
        "target_proposition": {
            "id": "proposition:a2WBx7VottAegcHIRlfFZAWx8QZjtcgb",
            "type": "VariationNeoplasmTherapeuticResponseProposition",
            "subject": "ga4gh:VA.X09E2r2MjKn-w1Ggsuy0XMWJ5_-lr-gd",
            "predicate": "predicts_resistance_to",
            "object": {
                "id": "rxcui:1147220",
                "type": "Therapeutic"
            },
            "neoplasm_type_qualifier": {
                "id": "ncit:C3224",
                "type": "Disease"
            }
        },
        "direction": "supports",
        "subject_descriptor": "civic.vid:658",
        "neoplasm_type_descriptor": {
            "id": "civic.did:7",
            "type": "DiseaseDescriptor",
            "label": "Melanoma",
            "xrefs": [
                "DOID:1909"
            ],
            "disease": "ncit:C3224"
        },
        "object_descriptor": {
            "id": "civic.tid:4",
            "type": "TherapeuticDescriptor",
            "label": "Vemurafenib",
            "extensions": [
                {
                    "type": "Extension",
                    "name": "regulatory_approval",
                    "value": {
                        "approval_rating": "FDA",
                        "has_indications": [
                            {
                                "id": "hemonc:629",
                                "type": "DiseaseDescriptor",
                                "label": "Melanoma",
                                "disease": "ncit:C3224"
                            },
                            {
                                "id": "hemonc:594",
                                "type": "DiseaseDescriptor",
                                "label": "Erdheim-Chester disease",
                                "disease": "ncit:C53972"
                            }
                        ]
                    }
                }
            ],
            "xrefs": [
                "ncit:C64768"
            ],
            "alternate_labels": [
                "1-propanesulfonamide, N-(3-((5-(4-chlorophenyl)-1h-pyrrolo(2,3-b)pyridin-3-yl)carbonyl)-2,4-difluorophenyl)-",
                "BRAF (V600E) Kinase Inhibitor RO5185426",
                "BRAF(V600E) Kinase Inhibitor RO5185426",
                "PLX-4032",
                "PLX4032",
                "RG 7204",
                "RG7204",
                "RO 5185426",
                "Zelboraf"
            ],
            "therapeutic": "rxcui:1147220"
        }
    },
    {
        "id": "civic.eid:2041",
        "type": "VariationNeoplasmTherapeuticResponseStatement",
        "description": "This preclinical study tested the efficacy on several breast cancer cell lines of GDC-0941 (pictilisib), a selective inhibitor of all four isoforms of class I PI3-kinases over a range of IC50 values. Sensitivity and resistance was categorized as less than and more than an IC50 of 1umol/L, respectively, with a maximum tested concentration of 20 umol/L. MDA-MB-231 is a basal-type breast cancer cell line which harbors KRAS G13D, and it had an ICD50 of 20uM. To evaluate in vivo efficacy, cells were injected in the mammary fat pad of SCID mice and allowed to grow. Mice injected with MDA-MB-231 and treated with pictilisib saw no reduction in tumor volume compared to untreated control. There was no effect on G1 arrest in pictilisib treated cells; however, phosphorylated AKT (S473) was substantially reduced following pictilisib. Authors note that basal breast cancer cell lines were generally more resistant to pictilisib than luminal lines (p=0.02), and concluded that this cell line was resistant to pictilisib.",
        "method": "metakb.method:1",
        "is_reported_in": [
            {
                "id": "civic.source:1435",
                "type": "Document",
                "label": "O'Brien et al., 2010, Clin. Cancer Res.",
                "xrefs": [
                    "pmid:20453058"
                ],
                "title": "Predictive biomarkers of sensitivity to the phosphatidylinositol 3' kinase inhibitor GDC-0941 in breast cancer preclinical models."
            }
        ],
        "evidence_level": {
            "id": "vicc:e00009",
            "type": "Coding",
            "label": "preclinical evidence"
        },
        "target_proposition": {
            "id": "proposition:zf1UasnISiwqEF7dT71b_YcBFer3NU16",
            "type": "VariationNeoplasmTherapeuticResponseProposition",
            "subject": "ga4gh:VA.tO-mdKyTxDxR376-vWkR2RgI2gpOvBhQ",
            "predicate": "predicts_resistance_to",
            "object": {
                "id": "ncit:C165479",
                "type": "Therapeutic"
            },
            "neoplasm_type_qualifier": {
                "id": "ncit:C9335",
                "type": "Disease"
            }
        },
        "direction": "supports",
        "subject_descriptor": "civic.vid:81",
        "neoplasm_type_descriptor": {
            "id": "civic.did:22",
            "type": "DiseaseDescriptor",
            "label": "Breast Cancer",
            "xrefs": [
                "DOID:1612"
            ],
            "disease": "ncit:C9335"
        },
        "object_descriptor": {
            "id": "civic.tid:141",
            "type": "TherapeuticDescriptor",
            "label": "Pictilisib",
            "therapeutic": "ncit:C165479"
        }
    },
    {
        "id": "civic.eid:2160",
        "type": "VariationNeoplasmTherapeuticResponseStatement",
        "description": "In an in vitro study using NCI-H1666 cells (wildtype EGFR) and NCI-H1975 cells (EGFR-L858R/T790M), inhibition of cell growth was used as an assay to determine sensitivity to reversible tyrosine kinase inhibitor drugs. Cells with an EGFR L858R/T790M mutation demonstrated a reduced response to lapatinib (IC50: >4000nM vs. 534nM) compared to wildtype EGFR cells. Similarly, NIH-3T3 ectopically expression EGFR-L858R/T790M showed reduced sensistivity to lapatinib compared to EGFR wt or L585R mutant cells. These results were further confirmed in a Ba/F3 cell line model",
        "method": "metakb.method:1",
        "is_reported_in": [
            {
                "id": "civic.source:1525",
                "type": "Document",
                "label": "Li et al., 2008, Oncogene",
                "xrefs": [
                    "pmc:PMC2748240",
                    "pmid:18408761"
                ],
                "title": "BIBW2992, an irreversible EGFR/HER2 inhibitor highly effective in preclinical lung cancer models."
            }
        ],
        "evidence_level": {
            "id": "vicc:e00009",
            "type": "Coding",
            "label": "preclinical evidence"
        },
        "target_proposition": {
            "id": "proposition:Fo0nIHYyqvFpc9aVaxSbnQXoEApb3Li4",
            "type": "VariationNeoplasmTherapeuticResponseProposition",
            "subject": "ga4gh:VA.lvgJx0agONKtOZizHmwQiO3tkZ5UB7YV",
            "predicate": "predicts_resistance_to",
            "object": {
                "id": "rxcui:480167",
                "type": "Therapeutic"
            },
            "neoplasm_type_qualifier": {
                "id": "ncit:C2926",
                "type": "Disease"
            }
        },
        "direction": "supports",
        "subject_descriptor": "civic.vid:34",
        "neoplasm_type_descriptor": {
            "id": "civic.did:8",
            "type": "DiseaseDescriptor",
            "label": "Lung Non-small Cell Carcinoma",
            "xrefs": [
                "DOID:3908"
            ],
            "disease": "ncit:C2926"
        },
        "object_descriptor": {
            "id": "civic.tid:45",
            "type": "TherapeuticDescriptor",
            "label": "Lapatinib",
            "extensions": [
                {
                    "type": "Extension",
                    "name": "regulatory_approval",
                    "value": {
                        "approval_rating": "FDA",
                        "has_indications": [
                            {
                                "id": "hemonc:572",
                                "type": "DiseaseDescriptor",
                                "label": "Breast cancer",
                                "disease": "ncit:C9335"
                            }
                        ]
                    }
                }
            ],
            "xrefs": [
                "ncit:C26653"
            ],
            "alternate_labels": [
                "GSK572016",
                "GW 2016",
                "GW2016",
                "GW572016"
            ],
            "therapeutic": "rxcui:480167"
        }
    },
    {
        "id": "civic.eid:3042",
        "type": "VariationNeoplasmTherapeuticResponseStatement",
        "description": "Subset of 58 cancer cell lines with unaltered TP53 is sensitive to MDM2 Inhibitor AMGMDS3. None of 115 cancer cell lines with TP53 mutation and absence of WT allele are sensitive to MDM2 Inhibitor. TP53 R248Q loss of function mutation is present in 5 cell lines and all are insensitive to MDM2 Inhibitor AMGMDS3.",
        "method": "metakb.method:1",
        "is_reported_in": [
            {
                "id": "civic.source:1696",
                "type": "Document",
                "label": "Saiki et al., 2015, Oncotarget",
                "xrefs": [
                    "pmc:PMC4480710",
                    "pmid:25730903"
                ],
                "title": "Identifying the determinants of response to MDM2 inhibition."
            }
        ],
        "evidence_level": {
            "id": "vicc:e00009",
            "type": "Coding",
            "label": "preclinical evidence"
        },
        "target_proposition": {
            "id": "proposition:ndpbySy-bUU8OXBLIUFMLrO4xI2pWuCr",
            "type": "VariationNeoplasmTherapeuticResponseProposition",
            "subject": "ga4gh:VA.KGNX46jwzV5U7UlIgco_QUaTev8HzOw3",
            "predicate": "predicts_resistance_to",
            "object": {
                "id": "ncit:C171616",
                "type": "Therapeutic"
            },
            "neoplasm_type_qualifier": {
                "id": "ncit:C9305",
                "type": "Disease"
            }
        },
        "direction": "supports",
        "subject_descriptor": "civic.vid:117",
        "neoplasm_type_descriptor": {
            "id": "civic.did:216",
            "type": "DiseaseDescriptor",
            "label": "Cancer",
            "xrefs": [
                "DOID:162"
            ],
            "disease": "ncit:C9305"
        },
        "object_descriptor": {
            "id": "civic.tid:20623",
            "type": "TherapeuticDescriptor",
            "label": "MDM2 Inhibitor AMGMDS3",
            "xrefs": [
                "ncit:C171616"
            ],
            "alternate_labels": [
                "2-[(2S,3R,4S)-2,3-bis(3-chlorophenyl)-1-[(2S)-1-ethoxy-1-oxobutan-2-yl]-4-methyl-6-oxopiperidin-4-yl]acetic Acid",
                "AMGMDS3",
                "Q59770979"
            ],
            "therapeutic": "ncit:C171616"
        }
    },
    {
        "id": "civic.eid:3989",
        "type": "VariationNeoplasmTherapeuticResponseStatement",
        "description": "In an in vitro study to identify cetuximab-resistant clones following continuous drug treatment, a resistant clone of the Lim1215 colorectal cancer cell line was identified to have the KRAS G12R mutation. No G12R was detected in the parental line despite high-resolution evaluation. Additionally, endogenously expressing KRAS G12R (knock-in) mutation demonstrated resistance to cetuximab treatment, compared to Lim1215 parental cells expressing wild-type KRAS. Resistance was determined by assessing cell viability.",
        "method": "metakb.method:1",
        "is_reported_in": [
            {
                "id": "civic.source:2008",
                "type": "Document",
                "label": "Misale et al., 2012, Nature",
                "xrefs": [
                    "pmc:PMC3927413",
                    "pmid:22722830"
                ],
                "title": "Emergence of KRAS mutations and acquired resistance to anti-EGFR therapy in colorectal cancer."
            }
        ],
        "evidence_level": {
            "id": "vicc:e00009",
            "type": "Coding",
            "label": "preclinical evidence"
        },
        "target_proposition": {
            "id": "proposition:Bi1mjZlYKP-tBpvOySQtT8DFv_Yq5Ao6",
            "type": "VariationNeoplasmTherapeuticResponseProposition",
            "subject": "ga4gh:VA._AIonI6Sp_E7tTUN81jJbNG3tERDCkVk",
            "predicate": "predicts_resistance_to",
            "object": {
                "id": "rxcui:318341",
                "type": "Therapeutic"
            },
            "neoplasm_type_qualifier": {
                "id": "ncit:C4978",
                "type": "Disease"
            }
        },
        "direction": "supports",
        "subject_descriptor": "civic.vid:530",
        "neoplasm_type_descriptor": {
            "id": "civic.did:11",
            "type": "DiseaseDescriptor",
            "label": "Colorectal Cancer",
            "xrefs": [
                "DOID:9256"
            ],
            "disease": "ncit:C4978"
        },
        "object_descriptor": {
            "id": "civic.tid:16",
            "type": "TherapeuticDescriptor",
            "label": "Cetuximab",
            "extensions": [
                {
                    "type": "Extension",
                    "name": "regulatory_approval",
                    "value": {
                        "approval_rating": "ChEMBL",
                        "has_indications": [
                            {
                                "id": "mesh:D002294",
                                "type": "DiseaseDescriptor",
                                "label": "Carcinoma, Squamous Cell",
                                "disease": "ncit:C2929"
                            },
                            {
                                "id": "mesh:D009369",
                                "type": "DiseaseDescriptor",
                                "label": "Neoplasms",
                                "disease": "ncit:C3262"
                            },
                            {
                                "id": "mesh:D015179",
                                "type": "DiseaseDescriptor",
                                "label": "Colorectal Neoplasms",
                                "disease": "ncit:C2956"
                            },
                            {
                                "id": "mesh:D006258",
                                "type": "DiseaseDescriptor",
                                "label": "Head and Neck Neoplasms",
                                "disease": "ncit:C4013"
                            }
                        ]
                    }
                }
            ],
            "xrefs": [
                "ncit:C1723"
            ],
            "alternate_labels": [
                "Cetuximab Biosimilar CDP-1",
                "Cetuximab Biosimilar CMAB009",
                "Cetuximab Biosimilar KL 140",
                "Chimeric Anti-EGFR Monoclonal Antibody",
                "Chimeric MoAb C225",
                "Chimeric Monoclonal Antibody C225",
                "Erbitux",
                "IMC-C225"
            ],
            "therapeutic": "rxcui:318341"
        }
    },
    {
        "id": "civic.eid:4510",
        "type": "VariationNeoplasmTherapeuticResponseStatement",
        "description": "A preclinical study tested the effects of a tyrosine kinase inhibitor (TKI) on Ba/F3 cell lines with representative primary regorafenib-sensitizing mutation del 557-558, which induced IL-3 independent growth, and secondary mutation T670I. The cells were tested for Regorafenib resistance. Ba/F3 cells with del 557-558/T670I mutations (IC50 = 132 +- 25 nM) did show resistance towards  Regorafenib  compared to Ba/F3 cells with del 557-558 alone (IC50 = 30 +- 14 nM). In addition, Ba/F3 cells were mutagenized with N-ethyl-N-nitrosourea and incubated with varying concentrations of Regorafenib. In Regorafenib incubated cells, T670I mutations were seen in approximately 10% of the resistant cell populations. The results suggest that T670I does induce regorafenib resistance in del 557-558/T670I cells.",
        "method": "metakb.method:1",
        "is_reported_in": [
            {
                "id": "civic.source:2042",
                "type": "Document",
                "label": "Garner et al., 2014, Clin. Cancer Res.",
                "xrefs": [
                    "pmc:PMC4233175",
                    "pmid:25239608"
                ],
                "title": "Ponatinib inhibits polyclonal drug-resistant KIT oncoproteins and shows therapeutic potential in heavily pretreated gastrointestinal stromal tumor (GIST) patients."
            }
        ],
        "evidence_level": {
            "id": "vicc:e00009",
            "type": "Coding",
            "label": "preclinical evidence"
        },
        "target_proposition": {
            "id": "proposition:mIkVYpeIHQcL2MUMxM7d9_VeQiNBmccK",
            "type": "VariationNeoplasmTherapeuticResponseProposition",
            "subject": "ga4gh:VA.i9jXgMZM9ZFX7HMNEDN7npl5Cl5zSgy6",
            "predicate": "predicts_resistance_to",
            "object": {
                "id": "rxcui:1312397",
                "type": "Therapeutic"
            },
            "neoplasm_type_qualifier": {
                "id": "ncit:C3868",
                "type": "Disease"
            }
        },
        "direction": "supports",
        "subject_descriptor": "civic.vid:1267",
        "neoplasm_type_descriptor": {
            "id": "civic.did:2",
            "type": "DiseaseDescriptor",
            "label": "Gastrointestinal Stromal Tumor",
            "xrefs": [
                "DOID:9253"
            ],
            "disease": "ncit:C3868"
        },
        "object_descriptor": {
            "id": "civic.tid:27",
            "type": "TherapeuticDescriptor",
            "label": "Regorafenib",
            "extensions": [
                {
                    "type": "Extension",
                    "name": "regulatory_approval",
                    "value": {
                        "approval_rating": "ChEMBL",
                        "has_indications": [
                            {
                                "id": "mesh:D009369",
                                "type": "DiseaseDescriptor",
                                "label": "Neoplasms",
                                "disease": "ncit:C3262"
                            },
                            {
                                "id": "mesh:D015179",
                                "type": "DiseaseDescriptor",
                                "label": "Colorectal Neoplasms",
                                "disease": "ncit:C2956"
                            }
                        ]
                    }
                }
            ],
            "xrefs": [
                "ncit:C78204"
            ],
            "alternate_labels": [
                "4-(4-(((4-chloro-3-(trifluoromethyl)phenyl)carbamoyl)amino)-3-fluorophenoxy)-N-methylpyridine-2-carboxamide",
                "BAY 73-4506",
                "REGORAFENIB ANHYDROUS",
                "Stivarga"
            ],
            "therapeutic": "rxcui:1312397"
        }
    },
    {
        "id": "civic.eid:4879",
        "type": "VariationNeoplasmTherapeuticResponseStatement",
        "description": "Subset of 58 cancer cell lines with unaltered TP53 is sensitive to MDM2 Inhibitor AMGMDS3. None of 115 cancer cell lines with TP53 mutation and absence of WT allele are sensitive to MDM2 Inhibitor. TP53 R248W loss of function mutation is present in 4 cell lines and all are insensitive to MDM2 Inhibitor AMGMDS3.",
        "method": "metakb.method:1",
        "is_reported_in": [
            {
                "id": "civic.source:1696",
                "type": "Document",
                "label": "Saiki et al., 2015, Oncotarget",
                "xrefs": [
                    "pmc:PMC4480710",
                    "pmid:25730903"
                ],
                "title": "Identifying the determinants of response to MDM2 inhibition."
            }
        ],
        "evidence_level": {
            "id": "vicc:e00009",
            "type": "Coding",
            "label": "preclinical evidence"
        },
        "target_proposition": {
            "id": "proposition:nF4eDhAfT8qpX0MkVmApgDeoKwzKH8ap",
            "type": "VariationNeoplasmTherapeuticResponseProposition",
            "subject": "ga4gh:VA.D4ygEfF35Dv0cNd8fIoOLhDPqxVSxpob",
            "predicate": "predicts_resistance_to",
            "object": {
                "id": "ncit:C171616",
                "type": "Therapeutic"
            },
            "neoplasm_type_qualifier": {
                "id": "ncit:C9305",
                "type": "Disease"
            }
        },
        "direction": "supports",
        "subject_descriptor": "civic.vid:118",
        "neoplasm_type_descriptor": {
            "id": "civic.did:216",
            "type": "DiseaseDescriptor",
            "label": "Cancer",
            "xrefs": [
                "DOID:162"
            ],
            "disease": "ncit:C9305"
        },
        "object_descriptor": {
            "id": "civic.tid:20623",
            "type": "TherapeuticDescriptor",
            "label": "MDM2 Inhibitor AMGMDS3",
            "xrefs": [
                "ncit:C171616"
            ],
            "alternate_labels": [
                "2-[(2S,3R,4S)-2,3-bis(3-chlorophenyl)-1-[(2S)-1-ethoxy-1-oxobutan-2-yl]-4-methyl-6-oxopiperidin-4-yl]acetic Acid",
                "AMGMDS3",
                "Q59770979"
            ],
            "therapeutic": "ncit:C171616"
        }
    },
    {
        "id": "civic.eid:4880",
        "type": "VariationNeoplasmTherapeuticResponseStatement",
        "description": "Subset of 58 cancer cell lines with unaltered TP53 is sensitive to MDM2 Inhibitor AMGMDS3. None of 115 cancer cell lines with TP53 mutation and absence of WT allele are sensitive to MDM2 Inhibitor. TP53 R175H loss of function mutation is present in 4 cell lines and all are insensitive to MDM2 Inhibitor AMGMDS3.",
        "method": "metakb.method:1",
        "is_reported_in": [
            {
                "id": "civic.source:1696",
                "type": "Document",
                "label": "Saiki et al., 2015, Oncotarget",
                "xrefs": [
                    "pmc:PMC4480710",
                    "pmid:25730903"
                ],
                "title": "Identifying the determinants of response to MDM2 inhibition."
            }
        ],
        "evidence_level": {
            "id": "vicc:e00009",
            "type": "Coding",
            "label": "preclinical evidence"
        },
        "target_proposition": {
            "id": "proposition:1Mq74SHjNixk7JBTpGqAKCxC2E4GgMhm",
            "type": "VariationNeoplasmTherapeuticResponseProposition",
            "subject": "ga4gh:VA.bpTmcx3yG0E4BahBLrCmkeqlsfNBeqHE",
            "predicate": "predicts_resistance_to",
            "object": {
                "id": "ncit:C171616",
                "type": "Therapeutic"
            },
            "neoplasm_type_qualifier": {
                "id": "ncit:C9305",
                "type": "Disease"
            }
        },
        "direction": "supports",
        "subject_descriptor": "civic.vid:116",
        "neoplasm_type_descriptor": {
            "id": "civic.did:216",
            "type": "DiseaseDescriptor",
            "label": "Cancer",
            "xrefs": [
                "DOID:162"
            ],
            "disease": "ncit:C9305"
        },
        "object_descriptor": {
            "id": "civic.tid:20623",
            "type": "TherapeuticDescriptor",
            "label": "MDM2 Inhibitor AMGMDS3",
            "xrefs": [
                "ncit:C171616"
            ],
            "alternate_labels": [
                "2-[(2S,3R,4S)-2,3-bis(3-chlorophenyl)-1-[(2S)-1-ethoxy-1-oxobutan-2-yl]-4-methyl-6-oxopiperidin-4-yl]acetic Acid",
                "AMGMDS3",
                "Q59770979"
            ],
            "therapeutic": "ncit:C171616"
        }
    },
    {
        "id": "civic.eid:4881",
        "type": "VariationNeoplasmTherapeuticResponseStatement",
        "description": "Subset of 58 cancer cell lines with unaltered TP53 is sensitive to MDM2 Inhibitor AMGMDS3. None of 115 cancer cell lines with TP53 mutation and absence of WT allele are sensitive to MDM2 Inhibitor. TP53 R273C loss of function mutation is present in 2 cell lines and all are insensitive to MDM2 Inhibitor AMGMDS3.",
        "method": "metakb.method:1",
        "is_reported_in": [
            {
                "id": "civic.source:1696",
                "type": "Document",
                "label": "Saiki et al., 2015, Oncotarget",
                "xrefs": [
                    "pmc:PMC4480710",
                    "pmid:25730903"
                ],
                "title": "Identifying the determinants of response to MDM2 inhibition."
            }
        ],
        "evidence_level": {
            "id": "vicc:e00009",
            "type": "Coding",
            "label": "preclinical evidence"
        },
        "target_proposition": {
            "id": "proposition:QeAR3v-hDrTGs4HRT2bgcamh8K1VruST",
            "type": "VariationNeoplasmTherapeuticResponseProposition",
            "subject": "ga4gh:VA.AXS1g9tgzIx75-Vv9T9DjEt4On7db0_k",
            "predicate": "predicts_resistance_to",
            "object": {
                "id": "ncit:C171616",
                "type": "Therapeutic"
            },
            "neoplasm_type_qualifier": {
                "id": "ncit:C9305",
                "type": "Disease"
            }
        },
        "direction": "supports",
        "subject_descriptor": "civic.vid:121",
        "neoplasm_type_descriptor": {
            "id": "civic.did:216",
            "type": "DiseaseDescriptor",
            "label": "Cancer",
            "xrefs": [
                "DOID:162"
            ],
            "disease": "ncit:C9305"
        },
        "object_descriptor": {
            "id": "civic.tid:20623",
            "type": "TherapeuticDescriptor",
            "label": "MDM2 Inhibitor AMGMDS3",
            "xrefs": [
                "ncit:C171616"
            ],
            "alternate_labels": [
                "2-[(2S,3R,4S)-2,3-bis(3-chlorophenyl)-1-[(2S)-1-ethoxy-1-oxobutan-2-yl]-4-methyl-6-oxopiperidin-4-yl]acetic Acid",
                "AMGMDS3",
                "Q59770979"
            ],
            "therapeutic": "ncit:C171616"
        }
    },
    {
        "id": "civic.eid:4882",
        "type": "VariationNeoplasmTherapeuticResponseStatement",
        "description": "Subset of 58 cancer cell lines with unaltered TP53 is sensitive to MDM2 Inhibitor AMGMDS3. None of 115 cancer cell lines with TP53 mutation and absence of WT allele are sensitive to MDM2 Inhibitor. TP53 R273H loss of function mutation is present in 7 cell lines and all are insensitive to MDM2 Inhibitor AMGMDS3.",
        "method": "metakb.method:1",
        "is_reported_in": [
            {
                "id": "civic.source:1696",
                "type": "Document",
                "label": "Saiki et al., 2015, Oncotarget",
                "xrefs": [
                    "pmc:PMC4480710",
                    "pmid:25730903"
                ],
                "title": "Identifying the determinants of response to MDM2 inhibition."
            }
        ],
        "evidence_level": {
            "id": "vicc:e00009",
            "type": "Coding",
            "label": "preclinical evidence"
        },
        "target_proposition": {
            "id": "proposition:_kWtSWT7euhMaK5xat6ES0xUPE4-E_dP",
            "type": "VariationNeoplasmTherapeuticResponseProposition",
            "subject": "ga4gh:VA.GMSpJl-n2YHDTV8gGYODNruwMz3gjWEm",
            "predicate": "predicts_resistance_to",
            "object": {
                "id": "ncit:C171616",
                "type": "Therapeutic"
            },
            "neoplasm_type_qualifier": {
                "id": "ncit:C9305",
                "type": "Disease"
            }
        },
        "direction": "supports",
        "subject_descriptor": "civic.vid:122",
        "neoplasm_type_descriptor": {
            "id": "civic.did:216",
            "type": "DiseaseDescriptor",
            "label": "Cancer",
            "xrefs": [
                "DOID:162"
            ],
            "disease": "ncit:C9305"
        },
        "object_descriptor": {
            "id": "civic.tid:20623",
            "type": "TherapeuticDescriptor",
            "label": "MDM2 Inhibitor AMGMDS3",
            "xrefs": [
                "ncit:C171616"
            ],
            "alternate_labels": [
                "2-[(2S,3R,4S)-2,3-bis(3-chlorophenyl)-1-[(2S)-1-ethoxy-1-oxobutan-2-yl]-4-methyl-6-oxopiperidin-4-yl]acetic Acid",
                "AMGMDS3",
                "Q59770979"
            ],
            "therapeutic": "ncit:C171616"
        }
    },
    {
        "id": "civic.eid:4883",
        "type": "VariationNeoplasmTherapeuticResponseStatement",
        "description": "Subset of 58 cancer cell lines with unaltered TP53 is sensitive to MDM2 Inhibitor AMGMDS3. None of 115 cancer cell lines with TP53 mutation and absence of WT allele are sensitive to MDM2 Inhibitor. TP53 G245S loss of function mutation is present in 3 cell lines and all are insensitive to MDM2 Inhibitor AMGMDS3.",
        "method": "metakb.method:1",
        "is_reported_in": [
            {
                "id": "civic.source:1696",
                "type": "Document",
                "label": "Saiki et al., 2015, Oncotarget",
                "xrefs": [
                    "pmc:PMC4480710",
                    "pmid:25730903"
                ],
                "title": "Identifying the determinants of response to MDM2 inhibition."
            }
        ],
        "evidence_level": {
            "id": "vicc:e00009",
            "type": "Coding",
            "label": "preclinical evidence"
        },
        "target_proposition": {
            "id": "proposition:urHDmftcSIKlvXrx4I4T9nzLFnT7x8Aa",
            "type": "VariationNeoplasmTherapeuticResponseProposition",
            "subject": "ga4gh:VA.rOFjD5FoaN3D0Uq4KtRsgnIfTmszXAiV",
            "predicate": "predicts_resistance_to",
            "object": {
                "id": "ncit:C171616",
                "type": "Therapeutic"
            },
            "neoplasm_type_qualifier": {
                "id": "ncit:C9305",
                "type": "Disease"
            }
        },
        "direction": "supports",
        "subject_descriptor": "civic.vid:879",
        "neoplasm_type_descriptor": {
            "id": "civic.did:216",
            "type": "DiseaseDescriptor",
            "label": "Cancer",
            "xrefs": [
                "DOID:162"
            ],
            "disease": "ncit:C9305"
        },
        "object_descriptor": {
            "id": "civic.tid:20623",
            "type": "TherapeuticDescriptor",
            "label": "MDM2 Inhibitor AMGMDS3",
            "xrefs": [
                "ncit:C171616"
            ],
            "alternate_labels": [
                "2-[(2S,3R,4S)-2,3-bis(3-chlorophenyl)-1-[(2S)-1-ethoxy-1-oxobutan-2-yl]-4-methyl-6-oxopiperidin-4-yl]acetic Acid",
                "AMGMDS3",
                "Q59770979"
            ],
            "therapeutic": "ncit:C171616"
        }
    },
    {
        "id": "civic.eid:4884",
        "type": "VariationNeoplasmTherapeuticResponseStatement",
        "description": "Subset of 58 cancer cell lines with unaltered TP53 is sensitive to MDM2 Inhibitor AMGMDS3. None of 115 cancer cell lines with TP53 mutation and absence of WT allele are sensitive to MDM2 Inhibitor. TP53 Y220C loss of function mutation is present in 1 cell line and it is insensitive to MDM2 Inhibitor AMGMDS3.",
        "method": "metakb.method:1",
        "is_reported_in": [
            {
                "id": "civic.source:1696",
                "type": "Document",
                "label": "Saiki et al., 2015, Oncotarget",
                "xrefs": [
                    "pmc:PMC4480710",
                    "pmid:25730903"
                ],
                "title": "Identifying the determinants of response to MDM2 inhibition."
            }
        ],
        "evidence_level": {
            "id": "vicc:e00009",
            "type": "Coding",
            "label": "preclinical evidence"
        },
        "target_proposition": {
            "id": "proposition:mKGmrFoSbjYs16z3LUrwEXjUCsXZUkMd",
            "type": "VariationNeoplasmTherapeuticResponseProposition",
            "subject": "ga4gh:VA.uI4nm8TgYWMXJIEl6R66zPRs7uJgguRF",
            "predicate": "predicts_resistance_to",
            "object": {
                "id": "ncit:C171616",
                "type": "Therapeutic"
            },
            "neoplasm_type_qualifier": {
                "id": "ncit:C9305",
                "type": "Disease"
            }
        },
        "direction": "supports",
        "subject_descriptor": "civic.vid:922",
        "neoplasm_type_descriptor": {
            "id": "civic.did:216",
            "type": "DiseaseDescriptor",
            "label": "Cancer",
            "xrefs": [
                "DOID:162"
            ],
            "disease": "ncit:C9305"
        },
        "object_descriptor": {
            "id": "civic.tid:20623",
            "type": "TherapeuticDescriptor",
            "label": "MDM2 Inhibitor AMGMDS3",
            "xrefs": [
                "ncit:C171616"
            ],
            "alternate_labels": [
                "2-[(2S,3R,4S)-2,3-bis(3-chlorophenyl)-1-[(2S)-1-ethoxy-1-oxobutan-2-yl]-4-methyl-6-oxopiperidin-4-yl]acetic Acid",
                "AMGMDS3",
                "Q59770979"
            ],
            "therapeutic": "ncit:C171616"
        }
    },
    {
        "id": "civic.eid:4887",
        "type": "VariationNeoplasmTherapeuticResponseStatement",
        "description": "Subset of 58 cancer cell lines with unaltered TP53 is sensitive to MDM2 Inhibitor AMGMDS3. None of 115 cancer cell lines with TP53 mutation and absence of WT allele are sensitive to MDM2 Inhibitor. TP53 V157F loss of function mutation is present in 1 cell line and it is insensitive to MDM2 Inhibitor AMGMDS3.",
        "method": "metakb.method:1",
        "is_reported_in": [
            {
                "id": "civic.source:1696",
                "type": "Document",
                "label": "Saiki et al., 2015, Oncotarget",
                "xrefs": [
                    "pmc:PMC4480710",
                    "pmid:25730903"
                ],
                "title": "Identifying the determinants of response to MDM2 inhibition."
            }
        ],
        "evidence_level": {
            "id": "vicc:e00009",
            "type": "Coding",
            "label": "preclinical evidence"
        },
        "target_proposition": {
            "id": "proposition:GzjAOuSvR0hnnLzmFJJToE-yMHLxo796",
            "type": "VariationNeoplasmTherapeuticResponseProposition",
            "subject": "ga4gh:VA.Afs5D-JAwDCg1ORV4VeoEhr3DKze6zti",
            "predicate": "predicts_resistance_to",
            "object": {
                "id": "ncit:C171616",
                "type": "Therapeutic"
            },
            "neoplasm_type_qualifier": {
                "id": "ncit:C9305",
                "type": "Disease"
            }
        },
        "direction": "supports",
        "subject_descriptor": "civic.vid:1092",
        "neoplasm_type_descriptor": {
            "id": "civic.did:216",
            "type": "DiseaseDescriptor",
            "label": "Cancer",
            "xrefs": [
                "DOID:162"
            ],
            "disease": "ncit:C9305"
        },
        "object_descriptor": {
            "id": "civic.tid:20623",
            "type": "TherapeuticDescriptor",
            "label": "MDM2 Inhibitor AMGMDS3",
            "xrefs": [
                "ncit:C171616"
            ],
            "alternate_labels": [
                "2-[(2S,3R,4S)-2,3-bis(3-chlorophenyl)-1-[(2S)-1-ethoxy-1-oxobutan-2-yl]-4-methyl-6-oxopiperidin-4-yl]acetic Acid",
                "AMGMDS3",
                "Q59770979"
            ],
            "therapeutic": "ncit:C171616"
        }
    },
    {
        "id": "civic.eid:4888",
        "type": "VariationNeoplasmTherapeuticResponseStatement",
        "description": "Subset of 58 cancer cell lines with unaltered TP53 is sensitive to MDM2 Inhibitor AMGMDS3. None of 115 cancer cell lines with TP53 mutation and absence of WT allele are sensitive to MDM2 Inhibitor. TP53 R249S loss of function mutation is present in 1 cell line and it is insensitive to MDM2 Inhibitor AMGMDS3.",
        "method": "metakb.method:1",
        "is_reported_in": [
            {
                "id": "civic.source:1696",
                "type": "Document",
                "label": "Saiki et al., 2015, Oncotarget",
                "xrefs": [
                    "pmc:PMC4480710",
                    "pmid:25730903"
                ],
                "title": "Identifying the determinants of response to MDM2 inhibition."
            }
        ],
        "evidence_level": {
            "id": "vicc:e00009",
            "type": "Coding",
            "label": "preclinical evidence"
        },
        "target_proposition": {
            "id": "proposition:0caeCFcI3TDEzD5dilVz-z8msHSPA-2g",
            "type": "VariationNeoplasmTherapeuticResponseProposition",
            "subject": "ga4gh:VA.XiQps_3vcKddUX5OQmrKWilNU58Yrkjo",
            "predicate": "predicts_resistance_to",
            "object": {
                "id": "ncit:C171616",
                "type": "Therapeutic"
            },
            "neoplasm_type_qualifier": {
                "id": "ncit:C9305",
                "type": "Disease"
            }
        },
        "direction": "supports",
        "subject_descriptor": "civic.vid:1696",
        "neoplasm_type_descriptor": {
            "id": "civic.did:216",
            "type": "DiseaseDescriptor",
            "label": "Cancer",
            "xrefs": [
                "DOID:162"
            ],
            "disease": "ncit:C9305"
        },
        "object_descriptor": {
            "id": "civic.tid:20623",
            "type": "TherapeuticDescriptor",
            "label": "MDM2 Inhibitor AMGMDS3",
            "xrefs": [
                "ncit:C171616"
            ],
            "alternate_labels": [
                "2-[(2S,3R,4S)-2,3-bis(3-chlorophenyl)-1-[(2S)-1-ethoxy-1-oxobutan-2-yl]-4-methyl-6-oxopiperidin-4-yl]acetic Acid",
                "AMGMDS3",
                "Q59770979"
            ],
            "therapeutic": "ncit:C171616"
        }
    },
    {
        "id": "civic.eid:4889",
        "type": "VariationNeoplasmTherapeuticResponseStatement",
        "description": "Subset of 58 cancer cell lines with unaltered TP53 is sensitive to MDM2 Inhibitor AMGMDS3. None of 115 cancer cell lines with TP53 mutation and absence of WT allele are sensitive to MDM2 Inhibitor. TP53 R280K loss of function mutation is present in 1 cell line and it is insensitive to MDM2 Inhibitor AMGMDS3.",
        "method": "metakb.method:1",
        "is_reported_in": [
            {
                "id": "civic.source:1696",
                "type": "Document",
                "label": "Saiki et al., 2015, Oncotarget",
                "xrefs": [
                    "pmc:PMC4480710",
                    "pmid:25730903"
                ],
                "title": "Identifying the determinants of response to MDM2 inhibition."
            }
        ],
        "evidence_level": {
            "id": "vicc:e00009",
            "type": "Coding",
            "label": "preclinical evidence"
        },
        "target_proposition": {
            "id": "proposition:gUTF2DuOHMpVh_meBYP2ZGZVA6sr-0uw",
            "type": "VariationNeoplasmTherapeuticResponseProposition",
            "subject": "ga4gh:VA.TbP1zhWcRgAo8pHzTVrK2yGVeMQJ0H6J",
            "predicate": "predicts_resistance_to",
            "object": {
                "id": "ncit:C171616",
                "type": "Therapeutic"
            },
            "neoplasm_type_qualifier": {
                "id": "ncit:C9305",
                "type": "Disease"
            }
        },
        "direction": "supports",
        "subject_descriptor": "civic.vid:1697",
        "neoplasm_type_descriptor": {
            "id": "civic.did:216",
            "type": "DiseaseDescriptor",
            "label": "Cancer",
            "xrefs": [
                "DOID:162"
            ],
            "disease": "ncit:C9305"
        },
        "object_descriptor": {
            "id": "civic.tid:20623",
            "type": "TherapeuticDescriptor",
            "label": "MDM2 Inhibitor AMGMDS3",
            "xrefs": [
                "ncit:C171616"
            ],
            "alternate_labels": [
                "2-[(2S,3R,4S)-2,3-bis(3-chlorophenyl)-1-[(2S)-1-ethoxy-1-oxobutan-2-yl]-4-methyl-6-oxopiperidin-4-yl]acetic Acid",
                "AMGMDS3",
                "Q59770979"
            ],
            "therapeutic": "ncit:C171616"
        }
    },
    {
        "id": "civic.eid:4890",
        "type": "VariationNeoplasmTherapeuticResponseStatement",
        "description": "Subset of 58 cancer cell lines with unaltered TP53 is sensitive to MDM2 Inhibitor AMGMDS3. None of 115 cancer cell lines with TP53 mutation and absence of WT allele are sensitive to MDM2 Inhibitor. TP53 R280T loss of function mutation is present in 1 cell line and it is insensitive to MDM2 Inhibitor AMGMDS3.",
        "method": "metakb.method:1",
        "is_reported_in": [
            {
                "id": "civic.source:1696",
                "type": "Document",
                "label": "Saiki et al., 2015, Oncotarget",
                "xrefs": [
                    "pmc:PMC4480710",
                    "pmid:25730903"
                ],
                "title": "Identifying the determinants of response to MDM2 inhibition."
            }
        ],
        "evidence_level": {
            "id": "vicc:e00009",
            "type": "Coding",
            "label": "preclinical evidence"
        },
        "target_proposition": {
            "id": "proposition:70VJb6isubZrgsl59EJgMx0cTbW5bv16",
            "type": "VariationNeoplasmTherapeuticResponseProposition",
            "subject": "ga4gh:VA.9Ztghq1JZwFk7WtS3dsbUxjlYKBdOQKy",
            "predicate": "predicts_resistance_to",
            "object": {
                "id": "ncit:C171616",
                "type": "Therapeutic"
            },
            "neoplasm_type_qualifier": {
                "id": "ncit:C9305",
                "type": "Disease"
            }
        },
        "direction": "supports",
        "subject_descriptor": "civic.vid:1698",
        "neoplasm_type_descriptor": {
            "id": "civic.did:216",
            "type": "DiseaseDescriptor",
            "label": "Cancer",
            "xrefs": [
                "DOID:162"
            ],
            "disease": "ncit:C9305"
        },
        "object_descriptor": {
            "id": "civic.tid:20623",
            "type": "TherapeuticDescriptor",
            "label": "MDM2 Inhibitor AMGMDS3",
            "xrefs": [
                "ncit:C171616"
            ],
            "alternate_labels": [
                "2-[(2S,3R,4S)-2,3-bis(3-chlorophenyl)-1-[(2S)-1-ethoxy-1-oxobutan-2-yl]-4-methyl-6-oxopiperidin-4-yl]acetic Acid",
                "AMGMDS3",
                "Q59770979"
            ],
            "therapeutic": "ncit:C171616"
        }
    },
    {
        "id": "civic.eid:4891",
        "type": "VariationNeoplasmTherapeuticResponseStatement",
        "description": "Subset of 58 cancer cell lines with unaltered TP53 is sensitive to MDM2 Inhibitor AMGMDS3. None of 115 cancer cell lines with TP53 mutation and absence of WT allele are sensitive to MDM2 Inhibitor. TP53 R158L loss of function mutation is present in 2 cell lines and all are insensitive to MDM2 Inhibitor AMGMDS3.",
        "method": "metakb.method:1",
        "is_reported_in": [
            {
                "id": "civic.source:1696",
                "type": "Document",
                "label": "Saiki et al., 2015, Oncotarget",
                "xrefs": [
                    "pmc:PMC4480710",
                    "pmid:25730903"
                ],
                "title": "Identifying the determinants of response to MDM2 inhibition."
            }
        ],
        "evidence_level": {
            "id": "vicc:e00009",
            "type": "Coding",
            "label": "preclinical evidence"
        },
        "target_proposition": {
            "id": "proposition:t-MGYPFGelmRJP2GG5GTMFX0nvHbAwsK",
            "type": "VariationNeoplasmTherapeuticResponseProposition",
            "subject": "ga4gh:VA.bgCTkQnHs9ATnyLQOwskoDFAFJB8Xvuc",
            "predicate": "predicts_resistance_to",
            "object": {
                "id": "ncit:C171616",
                "type": "Therapeutic"
            },
            "neoplasm_type_qualifier": {
                "id": "ncit:C9305",
                "type": "Disease"
            }
        },
        "direction": "supports",
        "subject_descriptor": "civic.vid:1699",
        "neoplasm_type_descriptor": {
            "id": "civic.did:216",
            "type": "DiseaseDescriptor",
            "label": "Cancer",
            "xrefs": [
                "DOID:162"
            ],
            "disease": "ncit:C9305"
        },
        "object_descriptor": {
            "id": "civic.tid:20623",
            "type": "TherapeuticDescriptor",
            "label": "MDM2 Inhibitor AMGMDS3",
            "xrefs": [
                "ncit:C171616"
            ],
            "alternate_labels": [
                "2-[(2S,3R,4S)-2,3-bis(3-chlorophenyl)-1-[(2S)-1-ethoxy-1-oxobutan-2-yl]-4-methyl-6-oxopiperidin-4-yl]acetic Acid",
                "AMGMDS3",
                "Q59770979"
            ],
            "therapeutic": "ncit:C171616"
        }
    },
    {
        "id": "civic.eid:6206",
        "type": "VariationNeoplasmTherapeuticResponseStatement",
        "description": "This preclinical study tested the sensitivity of HER2-positive breast cancer cell line BT-474 (heterozygous for PIK3CA K111N) retrovirally transduced with PIK3CA H1047R to NVP-BEZ235 (dactolisib; a dual PI3K/mTOR inhibitor). The study found that dactolisib was effective in inhibiting outgrowth of H1047R mutant-containing cells. Dactolisib was also combined with trastuzumab and/or lapatinib with similar abrogation of growth for PIK3CA H1047R expressing cells. Additionally, growth of untransduced BT-474 control cells was prevented by treatment with any monotherapy or combination of trastuzumab, lapatinib, or dactolisib. Authors concluded that PIK3CA H1047R induces resistance to lapatinib and trastuzumab in HER2 positive breast cancer cells, but resistance can be reversed by dactolisib.",
        "method": "metakb.method:1",
        "is_reported_in": [
            {
                "id": "civic.source:2486",
                "type": "Document",
                "label": "Eichhorn et al., 2008, Cancer Res.",
                "xrefs": [
                    "pmc:PMC2587064",
                    "pmid:19010894"
                ],
                "title": "Phosphatidylinositol 3-kinase hyperactivation results in lapatinib resistance that is reversed by the mTOR/phosphatidylinositol 3-kinase inhibitor NVP-BEZ235."
            }
        ],
        "evidence_level": {
            "id": "vicc:e00009",
            "type": "Coding",
            "label": "preclinical evidence"
        },
        "target_proposition": {
            "id": "proposition:C-DNBPj-C9Lu56DLdGvnCJrWBmDS3t0E",
            "type": "VariationNeoplasmTherapeuticResponseProposition",
            "subject": "ga4gh:VA.TIcXeM9bBVAIDYM4osh5rbkEVBs3LBCJ",
            "predicate": "predicts_resistance_to",
            "object": {
                "id": "ncit:C74072",
                "type": "Therapeutic"
            },
            "neoplasm_type_qualifier": {
                "id": "ncit:C53556",
                "type": "Disease"
            }
        },
        "direction": "opposes",
        "subject_descriptor": "civic.vid:107",
        "neoplasm_type_descriptor": {
            "id": "civic.did:368",
            "type": "DiseaseDescriptor",
            "label": "Her2-receptor Positive Breast Cancer",
            "xrefs": [
                "DOID:60079"
            ],
            "disease": "ncit:C53556"
        },
        "object_descriptor": {
            "id": "civic.tid:343",
            "type": "TherapeuticDescriptor",
            "label": "Dactolisib",
            "xrefs": [
                "ncit:C74072"
            ],
            "alternate_labels": [
                "BEZ235",
                "Benzeneacetonitrile, 4-(2,3-Dihydro-3-methyl-2-oxo-8-(3-quinolinyl)-1H-imidazo(4,5-c)quinolin-1-yl)-alpha,alpha-dimethyl-",
                "NVPBEZ235"
            ],
            "therapeutic": "ncit:C74072"
        }
    },
    {
        "id": "civic.eid:7401",
        "type": "VariationNeoplasmTherapeuticResponseStatement",
        "description": "A preclinical study was done in order to test the effects of a tyrosine kinase inhibitor (TKI) on the ponatinib-sensitive KIT-mutant cell line GIST-T1 derived from Gastrointestinal Stromal Tumor (GIST) patients with primary mutation 560-578 deletion and additional secondary mutation D816E. The cells were tested for Ponatinib resistance. GIST-T1/816 cells containing del 560-578 and D816E mutations (IC50: 23 nM) did not show resistance towards Ponatinib compared to GIST-T1 cells with only del 560-578 mutation (IC50: 5 nM). Ponatinib reduced phosphorylation in KIT, AKT, and ERK at higher concentrations. According to the results, the authors suggest that Ponatinib remained highly active in GIST cell lines with secondary mutation D816E.",
        "method": "metakb.method:1",
        "is_reported_in": [
            {
                "id": "civic.source:2042",
                "type": "Document",
                "label": "Garner et al., 2014, Clin. Cancer Res.",
                "xrefs": [
                    "pmc:PMC4233175",
                    "pmid:25239608"
                ],
                "title": "Ponatinib inhibits polyclonal drug-resistant KIT oncoproteins and shows therapeutic potential in heavily pretreated gastrointestinal stromal tumor (GIST) patients."
            }
        ],
        "evidence_level": {
            "id": "vicc:e00009",
            "type": "Coding",
            "label": "preclinical evidence"
        },
        "target_proposition": {
            "id": "proposition:sRDJjaBacJzMBrR4S_AbLVbWpg9Voufs",
            "type": "VariationNeoplasmTherapeuticResponseProposition",
            "subject": "ga4gh:VA.SaoIXvys127Ns4mbkzg2MNe9BOHDzb1L",
            "predicate": "predicts_resistance_to",
            "object": {
                "id": "rxcui:1364347",
                "type": "Therapeutic"
            },
            "neoplasm_type_qualifier": {
                "id": "ncit:C3868",
                "type": "Disease"
            }
        },
        "direction": "opposes",
        "subject_descriptor": "civic.vid:1559",
        "neoplasm_type_descriptor": {
            "id": "civic.did:2",
            "type": "DiseaseDescriptor",
            "label": "Gastrointestinal Stromal Tumor",
            "xrefs": [
                "DOID:9253"
            ],
            "disease": "ncit:C3868"
        },
        "object_descriptor": {
            "id": "civic.tid:55",
            "type": "TherapeuticDescriptor",
            "label": "Ponatinib",
            "extensions": [
                {
                    "type": "Extension",
                    "name": "regulatory_approval",
                    "value": {
                        "approval_rating": "FDA",
                        "has_indications": [
                            {
                                "id": "hemonc:24309",
                                "type": "DiseaseDescriptor",
                                "label": "Acute lymphoblastic leukemia",
                                "disease": "ncit:C3167"
                            },
                            {
                                "id": "hemonc:582",
                                "type": "DiseaseDescriptor",
                                "label": "Chronic myelogenous leukemia",
                                "disease": "ncit:C3174"
                            }
                        ]
                    }
                }
            ],
            "xrefs": [
                "ncit:C95777"
            ],
            "alternate_labels": [
                "AP-24534",
                "AP24534",
                "Benzamide, 3-(2-Imidazo(1,2-B)Pyridazin-3-Ylethynyl)-4-Methyl-N-(4-((4-Methyl-1- Piperazinyl)Methyl)-3-(Trifluoromethyl)Phenyl)"
            ],
            "therapeutic": "rxcui:1364347"
        }
    },
    {
        "id": "civic.eid:7413",
        "type": "VariationNeoplasmTherapeuticResponseStatement",
        "description": "Ponatinib possesses potent activity against A829P KIT mutant cells in preclinical experiments. A preclinical study tested the effect of a tyrosine kinase inhibitor (TKI) on Ba/F3 cell lines with representative primary ponatinib-sensitizing mutation del 557-558, which induced IL-3 independent growth, and secondary mutation A829P. The cells were tested for Ponatinib resistance. Ba/F3 cells with del 557-558 and A829P mutations (IC50 for growth inhibition: 2 nM) did not show resistance towards Ponatinib compared to Ba/F3 cells with the del 557-558 mutation alone (IC50: 3 nM).  Ponatinib was shown to inhibit KIT phosphorylation in moderate concentrations. Similarly, GIST-T1/829 cells with 560-578 deletion/A829P mutations (IC50 = 16 nM) were not resistant to Ponatinib compared to GIST T1 cells with 560-578 deletion alone (IC50 = 5 nM). Ponatinib inhibited phosphorylation in KIT, ERK, and AKT at moderate to high concentrations in GIST-T1/829 cells.",
        "method": "metakb.method:1",
        "is_reported_in": [
            {
                "id": "civic.source:2042",
                "type": "Document",
                "label": "Garner et al., 2014, Clin. Cancer Res.",
                "xrefs": [
                    "pmc:PMC4233175",
                    "pmid:25239608"
                ],
                "title": "Ponatinib inhibits polyclonal drug-resistant KIT oncoproteins and shows therapeutic potential in heavily pretreated gastrointestinal stromal tumor (GIST) patients."
            }
        ],
        "evidence_level": {
            "id": "vicc:e00009",
            "type": "Coding",
            "label": "preclinical evidence"
        },
        "target_proposition": {
            "id": "proposition:LpsdTOzFZSXut8kSohx_5rRzcNOvo1VO",
            "type": "VariationNeoplasmTherapeuticResponseProposition",
            "subject": "ga4gh:VA.7y1CGe4PaanVm4XfIGmysXGuSn6tOG-6",
            "predicate": "predicts_resistance_to",
            "object": {
                "id": "rxcui:1364347",
                "type": "Therapeutic"
            },
            "neoplasm_type_qualifier": {
                "id": "ncit:C3868",
                "type": "Disease"
            }
        },
        "direction": "opposes",
        "subject_descriptor": "civic.vid:990",
        "neoplasm_type_descriptor": {
            "id": "civic.did:2",
            "type": "DiseaseDescriptor",
            "label": "Gastrointestinal Stromal Tumor",
            "xrefs": [
                "DOID:9253"
            ],
            "disease": "ncit:C3868"
        },
        "object_descriptor": {
            "id": "civic.tid:55",
            "type": "TherapeuticDescriptor",
            "label": "Ponatinib",
            "extensions": [
                {
                    "type": "Extension",
                    "name": "regulatory_approval",
                    "value": {
                        "approval_rating": "FDA",
                        "has_indications": [
                            {
                                "id": "hemonc:24309",
                                "type": "DiseaseDescriptor",
                                "label": "Acute lymphoblastic leukemia",
                                "disease": "ncit:C3167"
                            },
                            {
                                "id": "hemonc:582",
                                "type": "DiseaseDescriptor",
                                "label": "Chronic myelogenous leukemia",
                                "disease": "ncit:C3174"
                            }
                        ]
                    }
                }
            ],
            "xrefs": [
                "ncit:C95777"
            ],
            "alternate_labels": [
                "AP-24534",
                "AP24534",
                "Benzamide, 3-(2-Imidazo(1,2-B)Pyridazin-3-Ylethynyl)-4-Methyl-N-(4-((4-Methyl-1- Piperazinyl)Methyl)-3-(Trifluoromethyl)Phenyl)"
            ],
            "therapeutic": "rxcui:1364347"
        }
    },
    {
        "id": "civic.eid:8337",
        "type": "VariationNeoplasmTherapeuticResponseStatement",
        "description": "The authors used saturation mutagenesis of FLT3/ITD followed by selection of transfected cells in FLT3 TKI. The FLT3/ITD Y842C mutation produced high-level resistance to KW2449, sorafenib, sunitinib and AGS324 in vitro but remained sensitive to lestaurtinib and midostaurin. Balb/c mice transplanted with the FLT3/ITD Y842C mutation confirmed resistance to sorafenib in vivo but not to lestaurtinib.",
        "method": "metakb.method:1",
        "is_reported_in": [
            {
                "id": "civic.source:3472",
                "type": "Document",
                "label": "Williams et al., 2013, Leukemia",
                "xrefs": [
                    "pmc:PMC3822911",
                    "pmid:22858906"
                ],
                "title": "Mutations of FLT3/ITD confer resistance to multiple tyrosine kinase inhibitors."
            }
        ],
        "evidence_level": {
            "id": "vicc:e00009",
            "type": "Coding",
            "label": "preclinical evidence"
        },
        "target_proposition": {
            "id": "proposition:lmrrz5ItIN5JkycnYFEP4YL98ZDGJwn5",
            "type": "VariationNeoplasmTherapeuticResponseProposition",
            "subject": "ga4gh:VA.hYF_stBVoyuIzz8G96fSEN7GBptcr6Vr",
            "predicate": "predicts_resistance_to",
            "object": {
                "id": "rxcui:495881",
                "type": "Therapeutic"
            },
            "neoplasm_type_qualifier": {
                "id": "ncit:C3171",
                "type": "Disease"
            }
        },
        "direction": "supports",
        "subject_descriptor": "civic.vid:3070",
        "neoplasm_type_descriptor": {
            "id": "civic.did:3",
            "type": "DiseaseDescriptor",
            "label": "Acute Myeloid Leukemia",
            "xrefs": [
                "DOID:9119"
            ],
            "disease": "ncit:C3171"
        },
        "object_descriptor": {
            "id": "civic.tid:6",
            "type": "TherapeuticDescriptor",
            "label": "Sorafenib",
            "extensions": [
                {
                    "type": "Extension",
                    "name": "regulatory_approval",
                    "value": {
                        "approval_rating": "FDA",
                        "has_indications": [
                            {
                                "id": "hemonc:612",
                                "type": "DiseaseDescriptor",
                                "label": "Hepatocellular carcinoma",
                                "disease": "ncit:C3099"
                            },
                            {
                                "id": "hemonc:65823",
                                "type": "DiseaseDescriptor",
                                "label": "Thyroid cancer differentiated",
                                "disease": null
                            },
                            {
                                "id": "hemonc:660",
                                "type": "DiseaseDescriptor",
                                "label": "Renal cell carcinoma",
                                "disease": "ncit:C9385"
                            }
                        ]
                    }
                }
            ],
            "xrefs": [
                "ncit:C61948"
            ],
            "alternate_labels": [
                "BA4 43 9006",
                "BAY 43-9006",
                "Bay-439006"
            ],
            "therapeutic": "rxcui:495881"
        }
    },
    {
        "id": "civic.eid:12",
        "type": "VariationNeoplasmTherapeuticResponseStatement",
        "description": "A375 cells expressing MAP2K1 P124S mutation conferred an approximately 5-fold increased resistance to selumetinib (AZD6244) induced growth inhibition when compared to untransduced cells, cells expressing wild-type MAP2K1 or cells expressing a constitutively active form. This mutation also attenuated pERK inhibition by selumetinib in these cells.",
        "method": "metakb.method:1",
        "is_reported_in": [
            {
                "id": "civic.source:58",
                "type": "Document",
                "label": "Emery et al., 2009, Proc. Natl. Acad. Sci. U.S.A.",
                "xrefs": [
                    "pmc:PMC2777185",
                    "pmid:19915144"
                ],
                "title": "MEK1 mutations confer resistance to MEK and B-RAF inhibition."
            }
        ],
        "evidence_level": {
            "id": "vicc:e00009",
            "type": "Coding",
            "label": "preclinical evidence"
        },
        "target_proposition": {
            "id": "proposition:V1azjfS4sclWqwy4mJLaiOaooifTpDIh",
            "type": "VariationNeoplasmTherapeuticResponseProposition",
            "subject": "ga4gh:VA.yzl9_KYeoW1CZXWr0VHb3_X0os3gHviA",
            "predicate": "predicts_resistance_to",
            "object": {
                "id": "rxcui:2289380",
                "type": "Therapeutic"
            },
            "neoplasm_type_qualifier": {
                "id": "ncit:C3224",
                "type": "Disease"
            }
        },
        "direction": "supports",
        "subject_descriptor": "civic.vid:82",
        "neoplasm_type_descriptor": {
            "id": "civic.did:7",
            "type": "DiseaseDescriptor",
            "label": "Melanoma",
            "xrefs": [
                "DOID:1909"
            ],
            "disease": "ncit:C3224"
        },
        "object_descriptor": {
            "id": "civic.tid:63",
            "type": "TherapeuticDescriptor",
            "label": "Selumetinib",
            "extensions": [
                {
                    "type": "Extension",
                    "name": "regulatory_approval",
                    "value": {
                        "approval_rating": "FDA",
                        "has_indications": []
                    }
                }
            ],
            "xrefs": [
                "ncit:C66939"
            ],
            "alternate_labels": [
                "ARRY-142886",
                "AZD6244",
                "MEK Inhibitor AZD6244"
            ],
            "therapeutic": "rxcui:2289380"
        }
    },
    {
        "id": "civic.eid:13",
        "type": "VariationNeoplasmTherapeuticResponseStatement",
        "description": "A375 cells expressing MAP2K1 Q56P mutation conferred an approximately 100-fold increased resistance to selumetinib (AZD6244) induced growth inhibition when compared to untransduced cells, cells expressing wild-type MAP2K1, or cells expressing a constitutively active form. This mutation also attenuated pERK inhibition by selumetinib in these cells.",
        "method": "metakb.method:1",
        "is_reported_in": [
            {
                "id": "civic.source:58",
                "type": "Document",
                "label": "Emery et al., 2009, Proc. Natl. Acad. Sci. U.S.A.",
                "xrefs": [
                    "pmc:PMC2777185",
                    "pmid:19915144"
                ],
                "title": "MEK1 mutations confer resistance to MEK and B-RAF inhibition."
            }
        ],
        "evidence_level": {
            "id": "vicc:e00009",
            "type": "Coding",
            "label": "preclinical evidence"
        },
        "target_proposition": {
            "id": "proposition:1aPcU7TMa9lfeFBY_Mugg7ujbDGqtk56",
            "type": "VariationNeoplasmTherapeuticResponseProposition",
            "subject": "ga4gh:VA.irDnXyyR0inhcZ38LFSzr4sIb6e2Lx7s",
            "predicate": "predicts_resistance_to",
            "object": {
                "id": "rxcui:2289380",
                "type": "Therapeutic"
            },
            "neoplasm_type_qualifier": {
                "id": "ncit:C3224",
                "type": "Disease"
            }
        },
        "direction": "supports",
        "subject_descriptor": "civic.vid:83",
        "neoplasm_type_descriptor": {
            "id": "civic.did:7",
            "type": "DiseaseDescriptor",
            "label": "Melanoma",
            "xrefs": [
                "DOID:1909"
            ],
            "disease": "ncit:C3224"
        },
        "object_descriptor": {
            "id": "civic.tid:63",
            "type": "TherapeuticDescriptor",
            "label": "Selumetinib",
            "extensions": [
                {
                    "type": "Extension",
                    "name": "regulatory_approval",
                    "value": {
                        "approval_rating": "FDA",
                        "has_indications": []
                    }
                }
            ],
            "xrefs": [
                "ncit:C66939"
            ],
            "alternate_labels": [
                "ARRY-142886",
                "AZD6244",
                "MEK Inhibitor AZD6244"
            ],
            "therapeutic": "rxcui:2289380"
        }
    },
    {
        "id": "civic.eid:32",
        "type": "VariationNeoplasmTherapeuticResponseStatement",
        "description": "Ba/F3 cells expressing the RANBP2-ALK fusion containing an F1174L mutation were more resistant to crizotinib treatment than Ba/F3 cells expressing RANBP2-ALK without this mutation.",
        "method": "metakb.method:1",
        "is_reported_in": [
            {
                "id": "civic.source:73",
                "type": "Document",
                "label": "Sasaki et al., 2010, Cancer Res.",
                "xrefs": [
                    "pmc:PMC3045808",
                    "pmid:21030459"
                ],
                "title": "The neuroblastoma-associated F1174L ALK mutation causes resistance to an ALK kinase inhibitor in ALK-translocated cancers."
            }
        ],
        "evidence_level": {
            "id": "vicc:e00009",
            "type": "Coding",
            "label": "preclinical evidence"
        },
        "target_proposition": {
            "id": "proposition:M9dno1HDQ-2RsR6uvyns84YT3KP6LCgX",
            "type": "VariationNeoplasmTherapeuticResponseProposition",
            "subject": "ga4gh:VA.G6vn88XVwZJkroDRXK0Vc5WRQ4p-VxYG",
            "predicate": "predicts_resistance_to",
            "object": {
                "id": "rxcui:1148495",
                "type": "Therapeutic"
            },
            "neoplasm_type_qualifier": {
                "id": "ncit:C6481",
                "type": "Disease"
            }
        },
        "direction": "supports",
        "subject_descriptor": "civic.vid:8",
        "neoplasm_type_descriptor": {
            "id": "civic.did:12",
            "type": "DiseaseDescriptor",
            "label": "Inflammatory Myofibroblastic Tumor",
            "xrefs": [
                "DOID:50905"
            ],
            "disease": "ncit:C6481"
        },
        "object_descriptor": {
            "id": "civic.tid:12",
            "type": "TherapeuticDescriptor",
            "label": "Crizotinib",
            "extensions": [
                {
                    "type": "Extension",
                    "name": "regulatory_approval",
                    "value": {
                        "approval_rating": "FDA",
                        "has_indications": [
                            {
                                "id": "hemonc:642",
                                "type": "DiseaseDescriptor",
                                "label": "Non-small cell lung cancer",
                                "disease": "ncit:C2926"
                            },
                            {
                                "id": "hemonc:25958",
                                "type": "DiseaseDescriptor",
                                "label": "Anaplastic large cell lymphoma pediatric",
                                "disease": null
                            }
                        ]
                    }
                }
            ],
            "xrefs": [
                "ncit:C74061"
            ],
            "alternate_labels": [
                "(R)-3-(1-(2,6-Dichloro-3-Fluorophenyl)Ethoxy)-5-(1-(Piperidin-4-Yl)-1h-Pyrazol-4-Yl)Pyridin-2-Amine",
                "2-Pyridinamine, 3-((1R)-1-(2,6-Dichloro-3-Fluorophenyl)Ethoxy)-5-(1-(4-Piperidinyl)-1H-Pyrazol-4-yl)-",
                "MET Tyrosine Kinase Inhibitor PF-02341066",
                "PF-02341066",
                "PF-2341066",
                "Xalkori"
            ],
            "therapeutic": "rxcui:1148495"
        }
    },
    {
        "id": "civic.eid:33",
        "type": "VariationNeoplasmTherapeuticResponseStatement",
        "description": "Ba/F3 cells expressing the EML4-ALK fusion containing an F1174L mutation were more resistant to crizotinib treatment than Ba/F3 cells expressing EML4-ALK without this mutation.",
        "method": "metakb.method:1",
        "is_reported_in": [
            {
                "id": "civic.source:73",
                "type": "Document",
                "label": "Sasaki et al., 2010, Cancer Res.",
                "xrefs": [
                    "pmc:PMC3045808",
                    "pmid:21030459"
                ],
                "title": "The neuroblastoma-associated F1174L ALK mutation causes resistance to an ALK kinase inhibitor in ALK-translocated cancers."
            }
        ],
        "evidence_level": {
            "id": "vicc:e00009",
            "type": "Coding",
            "label": "preclinical evidence"
        },
        "target_proposition": {
            "id": "proposition:g_ZgtAbpcAMZPQmTAIl0JwK489iAwS00",
            "type": "VariationNeoplasmTherapeuticResponseProposition",
            "subject": "ga4gh:VA.G6vn88XVwZJkroDRXK0Vc5WRQ4p-VxYG",
            "predicate": "predicts_resistance_to",
            "object": {
                "id": "rxcui:1148495",
                "type": "Therapeutic"
            },
            "neoplasm_type_qualifier": {
                "id": "ncit:C2926",
                "type": "Disease"
            }
        },
        "direction": "supports",
        "subject_descriptor": "civic.vid:8",
        "neoplasm_type_descriptor": {
            "id": "civic.did:8",
            "type": "DiseaseDescriptor",
            "label": "Lung Non-small Cell Carcinoma",
            "xrefs": [
                "DOID:3908"
            ],
            "disease": "ncit:C2926"
        },
        "object_descriptor": {
            "id": "civic.tid:12",
            "type": "TherapeuticDescriptor",
            "label": "Crizotinib",
            "extensions": [
                {
                    "type": "Extension",
                    "name": "regulatory_approval",
                    "value": {
                        "approval_rating": "FDA",
                        "has_indications": [
                            {
                                "id": "hemonc:642",
                                "type": "DiseaseDescriptor",
                                "label": "Non-small cell lung cancer",
                                "disease": "ncit:C2926"
                            },
                            {
                                "id": "hemonc:25958",
                                "type": "DiseaseDescriptor",
                                "label": "Anaplastic large cell lymphoma pediatric",
                                "disease": null
                            }
                        ]
                    }
                }
            ],
            "xrefs": [
                "ncit:C74061"
            ],
            "alternate_labels": [
                "(R)-3-(1-(2,6-Dichloro-3-Fluorophenyl)Ethoxy)-5-(1-(Piperidin-4-Yl)-1h-Pyrazol-4-Yl)Pyridin-2-Amine",
                "2-Pyridinamine, 3-((1R)-1-(2,6-Dichloro-3-Fluorophenyl)Ethoxy)-5-(1-(4-Piperidinyl)-1H-Pyrazol-4-yl)-",
                "MET Tyrosine Kinase Inhibitor PF-02341066",
                "PF-02341066",
                "PF-2341066",
                "Xalkori"
            ],
            "therapeutic": "rxcui:1148495"
        }
    },
    {
        "id": "civic.eid:48",
        "type": "VariationNeoplasmTherapeuticResponseStatement",
        "description": "The SMS-KCNR cell line harboring the R1275Q mutation was resistant to TAE684.",
        "method": "metakb.method:1",
        "is_reported_in": [
            {
                "id": "civic.source:79",
                "type": "Document",
                "label": "George et al., 2008, Nature",
                "xrefs": [
                    "pmc:PMC2587486",
                    "pmid:18923525"
                ],
                "title": "Activating mutations in ALK provide a therapeutic target in neuroblastoma."
            }
        ],
        "evidence_level": {
            "id": "vicc:e00009",
            "type": "Coding",
            "label": "preclinical evidence"
        },
        "target_proposition": {
            "id": "proposition:X0uWkxoENOSMF-wAYd8xe6OYLkzV27_I",
            "type": "VariationNeoplasmTherapeuticResponseProposition",
            "subject": "ga4gh:VA.eDIGsnE6r2Z4xJ1HLKHFZhShBjcUGpgJ",
            "predicate": "predicts_resistance_to",
            "object": {
                "id": "ncit:C171615",
                "type": "Therapeutic"
            },
            "neoplasm_type_qualifier": {
                "id": "ncit:C3270",
                "type": "Disease"
            }
        },
        "direction": "supports",
        "subject_descriptor": "civic.vid:9",
        "neoplasm_type_descriptor": {
            "id": "civic.did:13",
            "type": "DiseaseDescriptor",
            "label": "Neuroblastoma",
            "xrefs": [
                "DOID:769"
            ],
            "disease": "ncit:C3270"
        },
        "object_descriptor": {
            "id": "civic.tid:18",
            "type": "TherapeuticDescriptor",
            "label": "TAE684",
            "therapeutic": "ncit:C171615"
        }
    },
    {
        "id": "civic.eid:75",
        "type": "VariationNeoplasmTherapeuticResponseStatement",
        "description": "Medullary thyroid cancer cells with RET C634W mutation are insensitive to motesanib, compared to wild-type RET.",
        "method": "metakb.method:1",
        "is_reported_in": [
            {
                "id": "civic.source:90",
                "type": "Document",
                "label": "Coxon et al., 2012, J. Endocrinol. Invest.",
                "xrefs": [
                    "pmid:21422803"
                ],
                "title": "Anti-tumor activity of motesanib in a medullary thyroid cancer model."
            }
        ],
        "evidence_level": {
            "id": "vicc:e00009",
            "type": "Coding",
            "label": "preclinical evidence"
        },
        "target_proposition": {
            "id": "proposition:Af4IH_Lrf7sJtdDfg2ZlR572ykh6BoIn",
            "type": "VariationNeoplasmTherapeuticResponseProposition",
            "subject": "ga4gh:VA.rSOkzbc0najG4N-uWpBWvJwF3Vk9cXt7",
            "predicate": "predicts_resistance_to",
            "object": {
                "id": "ncit:C71896",
                "type": "Therapeutic"
            },
            "neoplasm_type_qualifier": {
                "id": "ncit:C3879",
                "type": "Disease"
            }
        },
        "direction": "supports",
        "subject_descriptor": "civic.vid:112",
        "neoplasm_type_descriptor": {
            "id": "civic.did:15",
            "type": "DiseaseDescriptor",
            "label": "Thyroid Gland Medullary Carcinoma",
            "xrefs": [
                "DOID:3973"
            ],
            "disease": "ncit:C3879"
        },
        "object_descriptor": {
            "id": "civic.tid:23",
            "type": "TherapeuticDescriptor",
            "label": "Motesanib",
            "xrefs": [
                "ncit:C71896"
            ],
            "therapeutic": "ncit:C71896"
        }
    },
    {
        "id": "civic.eid:76",
        "type": "VariationNeoplasmTherapeuticResponseStatement",
        "description": "Medullary thyroid cancer cells with RET M918T mutation are insensitive to motesanib, compared to wild-type RET.",
        "method": "metakb.method:1",
        "is_reported_in": [
            {
                "id": "civic.source:90",
                "type": "Document",
                "label": "Coxon et al., 2012, J. Endocrinol. Invest.",
                "xrefs": [
                    "pmid:21422803"
                ],
                "title": "Anti-tumor activity of motesanib in a medullary thyroid cancer model."
            }
        ],
        "evidence_level": {
            "id": "vicc:e00009",
            "type": "Coding",
            "label": "preclinical evidence"
        },
        "target_proposition": {
            "id": "proposition:uTrl0jL17Y2cm8r7g2TbuylknD3Lms1a",
            "type": "VariationNeoplasmTherapeuticResponseProposition",
            "subject": "ga4gh:VA.ld4IL6kursGxjcAXopnYRTKKS-06pP8-",
            "predicate": "predicts_resistance_to",
            "object": {
                "id": "ncit:C71896",
                "type": "Therapeutic"
            },
            "neoplasm_type_qualifier": {
                "id": "ncit:C3879",
                "type": "Disease"
            }
        },
        "direction": "supports",
        "subject_descriptor": "civic.vid:113",
        "neoplasm_type_descriptor": {
            "id": "civic.did:15",
            "type": "DiseaseDescriptor",
            "label": "Thyroid Gland Medullary Carcinoma",
            "xrefs": [
                "DOID:3973"
            ],
            "disease": "ncit:C3879"
        },
        "object_descriptor": {
            "id": "civic.tid:23",
            "type": "TherapeuticDescriptor",
            "label": "Motesanib",
            "xrefs": [
                "ncit:C71896"
            ],
            "therapeutic": "ncit:C71896"
        }
    },
    {
        "id": "civic.eid:90",
        "type": "VariationNeoplasmTherapeuticResponseStatement",
        "description": "In the setting of BRAF(V600E), NF1 loss resulted in elevated activation of RAS-GTP and resistance to RAF inhibitors.",
        "method": "metakb.method:1",
        "is_reported_in": [
            {
                "id": "civic.source:98",
                "type": "Document",
                "label": "Nissan et al., 2014, Cancer Res.",
                "xrefs": [
                    "pmc:PMC4005042",
                    "pmid:24576830"
                ],
                "title": "Loss of NF1 in cutaneous melanoma is associated with RAS activation and MEK dependence."
            }
        ],
        "evidence_level": {
            "id": "vicc:e00009",
            "type": "Coding",
            "label": "preclinical evidence"
        },
        "target_proposition": {
            "id": "proposition:s7NV3ilRg_UayHTbSMBZvncuAlM3JJdG",
            "type": "VariationNeoplasmTherapeuticResponseProposition",
            "subject": "ga4gh:VA.h313H4CQh6pogbbSJ3H5pI1cPoh9YMm_",
            "predicate": "predicts_resistance_to",
            "object": {
                "id": "rxcui:1147220",
                "type": "Therapeutic"
            },
            "neoplasm_type_qualifier": {
                "id": "ncit:C3224",
                "type": "Disease"
            }
        },
        "direction": "supports",
        "subject_descriptor": "civic.vid:12",
        "neoplasm_type_descriptor": {
            "id": "civic.did:7",
            "type": "DiseaseDescriptor",
            "label": "Melanoma",
            "xrefs": [
                "DOID:1909"
            ],
            "disease": "ncit:C3224"
        },
        "object_descriptor": {
            "id": "civic.tid:4",
            "type": "TherapeuticDescriptor",
            "label": "Vemurafenib",
            "extensions": [
                {
                    "type": "Extension",
                    "name": "regulatory_approval",
                    "value": {
                        "approval_rating": "FDA",
                        "has_indications": [
                            {
                                "id": "hemonc:629",
                                "type": "DiseaseDescriptor",
                                "label": "Melanoma",
                                "disease": "ncit:C3224"
                            },
                            {
                                "id": "hemonc:594",
                                "type": "DiseaseDescriptor",
                                "label": "Erdheim-Chester disease",
                                "disease": "ncit:C53972"
                            }
                        ]
                    }
                }
            ],
            "xrefs": [
                "ncit:C64768"
            ],
            "alternate_labels": [
                "1-propanesulfonamide, N-(3-((5-(4-chlorophenyl)-1h-pyrrolo(2,3-b)pyridin-3-yl)carbonyl)-2,4-difluorophenyl)-",
                "BRAF (V600E) Kinase Inhibitor RO5185426",
                "BRAF(V600E) Kinase Inhibitor RO5185426",
                "PLX-4032",
                "PLX4032",
                "RG 7204",
                "RG7204",
                "RO 5185426",
                "Zelboraf"
            ],
            "therapeutic": "rxcui:1147220"
        }
    },
    {
        "id": "civic.eid:125",
        "type": "VariationNeoplasmTherapeuticResponseStatement",
        "description": "Cells lines expressing ALK harboring the F1174L mutation are less sensitive to growth inhibition by crizotinib than cells expressing the R1275Q mutation. The authors conclude that this effect should be surmountable with higher doses of crizotinib and/or with higher-affinity inhibitors.",
        "method": "metakb.method:1",
        "is_reported_in": [
            {
                "id": "civic.source:119",
                "type": "Document",
                "label": "Bresler et al., 2011, Sci Transl Med",
                "xrefs": [
                    "pmc:PMC3319004",
                    "pmid:22072639"
                ],
                "title": "Differential inhibitor sensitivity of anaplastic lymphoma kinase variants found in neuroblastoma."
            }
        ],
        "evidence_level": {
            "id": "vicc:e00009",
            "type": "Coding",
            "label": "preclinical evidence"
        },
        "target_proposition": {
            "id": "proposition:YDrJ4YMUrxxCClQr8ZYI9HBAWni2b-2i",
            "type": "VariationNeoplasmTherapeuticResponseProposition",
            "subject": "ga4gh:VA.G6vn88XVwZJkroDRXK0Vc5WRQ4p-VxYG",
            "predicate": "predicts_resistance_to",
            "object": {
                "id": "rxcui:1148495",
                "type": "Therapeutic"
            },
            "neoplasm_type_qualifier": {
                "id": "ncit:C3270",
                "type": "Disease"
            }
        },
        "direction": "supports",
        "subject_descriptor": "civic.vid:8",
        "neoplasm_type_descriptor": {
            "id": "civic.did:13",
            "type": "DiseaseDescriptor",
            "label": "Neuroblastoma",
            "xrefs": [
                "DOID:769"
            ],
            "disease": "ncit:C3270"
        },
        "object_descriptor": {
            "id": "civic.tid:12",
            "type": "TherapeuticDescriptor",
            "label": "Crizotinib",
            "extensions": [
                {
                    "type": "Extension",
                    "name": "regulatory_approval",
                    "value": {
                        "approval_rating": "FDA",
                        "has_indications": [
                            {
                                "id": "hemonc:642",
                                "type": "DiseaseDescriptor",
                                "label": "Non-small cell lung cancer",
                                "disease": "ncit:C2926"
                            },
                            {
                                "id": "hemonc:25958",
                                "type": "DiseaseDescriptor",
                                "label": "Anaplastic large cell lymphoma pediatric",
                                "disease": null
                            }
                        ]
                    }
                }
            ],
            "xrefs": [
                "ncit:C74061"
            ],
            "alternate_labels": [
                "(R)-3-(1-(2,6-Dichloro-3-Fluorophenyl)Ethoxy)-5-(1-(Piperidin-4-Yl)-1h-Pyrazol-4-Yl)Pyridin-2-Amine",
                "2-Pyridinamine, 3-((1R)-1-(2,6-Dichloro-3-Fluorophenyl)Ethoxy)-5-(1-(4-Piperidinyl)-1H-Pyrazol-4-yl)-",
                "MET Tyrosine Kinase Inhibitor PF-02341066",
                "PF-02341066",
                "PF-2341066",
                "Xalkori"
            ],
            "therapeutic": "rxcui:1148495"
        }
    },
    {
        "id": "civic.eid:242",
        "type": "VariationNeoplasmTherapeuticResponseStatement",
        "description": "MCF7 cell lines harboring the L536Q mutation in the ligand-binding domain of ESR1 have shown resistance to hormone therapy.",
        "method": "metakb.method:1",
        "is_reported_in": [
            {
                "id": "civic.source:171",
                "type": "Document",
                "label": "Toy et al., 2013, Nat. Genet.",
                "xrefs": [
                    "pmc:PMC3903423",
                    "pmid:24185512"
                ],
                "title": "ESR1 ligand-binding domain mutations in hormone-resistant breast cancer."
            }
        ],
        "evidence_level": {
            "id": "vicc:e00009",
            "type": "Coding",
            "label": "preclinical evidence"
        },
        "target_proposition": {
            "id": "proposition:1pU_EXgGezEhDgb5H1TCpdv80H7JHl2C",
            "type": "VariationNeoplasmTherapeuticResponseProposition",
            "subject": "ga4gh:VA.5ZOkJ_z4WY-prWoX_bz-OKTLxQAAhME0",
            "predicate": "predicts_resistance_to",
            "object": {
                "id": "ncit:C147908",
                "type": "Therapeutic"
            },
            "neoplasm_type_qualifier": {
                "id": "ncit:C9335",
                "type": "Disease"
            }
        },
        "direction": "supports",
        "subject_descriptor": "civic.vid:46",
        "neoplasm_type_descriptor": {
            "id": "civic.did:22",
            "type": "DiseaseDescriptor",
            "label": "Breast Cancer",
            "xrefs": [
                "DOID:1612"
            ],
            "disease": "ncit:C9335"
        },
        "object_descriptor": {
            "id": "civic.tid:46",
            "type": "TherapeuticDescriptor",
            "label": "Hormone Therapy",
            "xrefs": [
                "ncit:C15445"
            ],
            "alternate_labels": [
                "Chemotherapy-Hormones/Steroids",
                "Endocrine Therapy",
                "Hormonal Therapy",
                "Hormone Treatment",
                "Hormones"
            ],
            "therapeutic": "ncit:C147908"
        }
    },
    {
        "id": "civic.eid:243",
        "type": "VariationNeoplasmTherapeuticResponseStatement",
        "description": "MCF7 cell lines harboring the D538G mutation in the ligand-binding domain of ESR1 have shown resistance to hormone therapy.",
        "method": "metakb.method:1",
        "is_reported_in": [
            {
                "id": "civic.source:171",
                "type": "Document",
                "label": "Toy et al., 2013, Nat. Genet.",
                "xrefs": [
                    "pmc:PMC3903423",
                    "pmid:24185512"
                ],
                "title": "ESR1 ligand-binding domain mutations in hormone-resistant breast cancer."
            }
        ],
        "evidence_level": {
            "id": "vicc:e00009",
            "type": "Coding",
            "label": "preclinical evidence"
        },
        "target_proposition": {
            "id": "proposition:x4zZQ3PH0ulExWPLYttRcZznxutkb_Wp",
            "type": "VariationNeoplasmTherapeuticResponseProposition",
            "subject": "ga4gh:VA.VUrBmnIanxIELmkweHMA-oSus-zpdjyL",
            "predicate": "predicts_resistance_to",
            "object": {
                "id": "ncit:C147908",
                "type": "Therapeutic"
            },
            "neoplasm_type_qualifier": {
                "id": "ncit:C9335",
                "type": "Disease"
            }
        },
        "direction": "supports",
        "subject_descriptor": "civic.vid:47",
        "neoplasm_type_descriptor": {
            "id": "civic.did:22",
            "type": "DiseaseDescriptor",
            "label": "Breast Cancer",
            "xrefs": [
                "DOID:1612"
            ],
            "disease": "ncit:C9335"
        },
        "object_descriptor": {
            "id": "civic.tid:46",
            "type": "TherapeuticDescriptor",
            "label": "Hormone Therapy",
            "xrefs": [
                "ncit:C15445"
            ],
            "alternate_labels": [
                "Chemotherapy-Hormones/Steroids",
                "Endocrine Therapy",
                "Hormonal Therapy",
                "Hormone Treatment",
                "Hormones"
            ],
            "therapeutic": "ncit:C147908"
        }
    },
    {
        "id": "civic.eid:244",
        "type": "VariationNeoplasmTherapeuticResponseStatement",
        "description": "MCF7 cell lines harboring the Y537C mutation in the ligand-binding domain of ESR1 have shown resistance to hormone therapy.",
        "method": "metakb.method:1",
        "is_reported_in": [
            {
                "id": "civic.source:171",
                "type": "Document",
                "label": "Toy et al., 2013, Nat. Genet.",
                "xrefs": [
                    "pmc:PMC3903423",
                    "pmid:24185512"
                ],
                "title": "ESR1 ligand-binding domain mutations in hormone-resistant breast cancer."
            }
        ],
        "evidence_level": {
            "id": "vicc:e00009",
            "type": "Coding",
            "label": "preclinical evidence"
        },
        "target_proposition": {
            "id": "proposition:9RUgklx9XTgAGDgnluN3_2p3s85dCrMl",
            "type": "VariationNeoplasmTherapeuticResponseProposition",
            "subject": "ga4gh:VA.FApHkwk1OD_nXJmrzBf7xUP9z0NtWl2q",
            "predicate": "predicts_resistance_to",
            "object": {
                "id": "ncit:C147908",
                "type": "Therapeutic"
            },
            "neoplasm_type_qualifier": {
                "id": "ncit:C9335",
                "type": "Disease"
            }
        },
        "direction": "supports",
        "subject_descriptor": "civic.vid:48",
        "neoplasm_type_descriptor": {
            "id": "civic.did:22",
            "type": "DiseaseDescriptor",
            "label": "Breast Cancer",
            "xrefs": [
                "DOID:1612"
            ],
            "disease": "ncit:C9335"
        },
        "object_descriptor": {
            "id": "civic.tid:46",
            "type": "TherapeuticDescriptor",
            "label": "Hormone Therapy",
            "xrefs": [
                "ncit:C15445"
            ],
            "alternate_labels": [
                "Chemotherapy-Hormones/Steroids",
                "Endocrine Therapy",
                "Hormonal Therapy",
                "Hormone Treatment",
                "Hormones"
            ],
            "therapeutic": "ncit:C147908"
        }
    },
    {
        "id": "civic.eid:245",
        "type": "VariationNeoplasmTherapeuticResponseStatement",
        "description": "MCF7 cell lines harboring the Y537N mutation in the ligand-binding domain of ESR1 have shown resistance to hormone therapy.",
        "method": "metakb.method:1",
        "is_reported_in": [
            {
                "id": "civic.source:171",
                "type": "Document",
                "label": "Toy et al., 2013, Nat. Genet.",
                "xrefs": [
                    "pmc:PMC3903423",
                    "pmid:24185512"
                ],
                "title": "ESR1 ligand-binding domain mutations in hormone-resistant breast cancer."
            }
        ],
        "evidence_level": {
            "id": "vicc:e00009",
            "type": "Coding",
            "label": "preclinical evidence"
        },
        "target_proposition": {
            "id": "proposition:HU6lk5XR8SGRiQVrmFER_9M8vZzXVX8c",
            "type": "VariationNeoplasmTherapeuticResponseProposition",
            "subject": "ga4gh:VA.P0nisTOh1cxoPjsVBzFL8qpbkMitw2Qf",
            "predicate": "predicts_resistance_to",
            "object": {
                "id": "ncit:C147908",
                "type": "Therapeutic"
            },
            "neoplasm_type_qualifier": {
                "id": "ncit:C9335",
                "type": "Disease"
            }
        },
        "direction": "supports",
        "subject_descriptor": "civic.vid:49",
        "neoplasm_type_descriptor": {
            "id": "civic.did:22",
            "type": "DiseaseDescriptor",
            "label": "Breast Cancer",
            "xrefs": [
                "DOID:1612"
            ],
            "disease": "ncit:C9335"
        },
        "object_descriptor": {
            "id": "civic.tid:46",
            "type": "TherapeuticDescriptor",
            "label": "Hormone Therapy",
            "xrefs": [
                "ncit:C15445"
            ],
            "alternate_labels": [
                "Chemotherapy-Hormones/Steroids",
                "Endocrine Therapy",
                "Hormonal Therapy",
                "Hormone Treatment",
                "Hormones"
            ],
            "therapeutic": "ncit:C147908"
        }
    },
    {
        "id": "civic.eid:246",
        "type": "VariationNeoplasmTherapeuticResponseStatement",
        "description": "MCF7 cell lines harboring the L537S mutation in the ligand-binding domain of ESR1 have shown resistance to hormone therapy.",
        "method": "metakb.method:1",
        "is_reported_in": [
            {
                "id": "civic.source:171",
                "type": "Document",
                "label": "Toy et al., 2013, Nat. Genet.",
                "xrefs": [
                    "pmc:PMC3903423",
                    "pmid:24185512"
                ],
                "title": "ESR1 ligand-binding domain mutations in hormone-resistant breast cancer."
            }
        ],
        "evidence_level": {
            "id": "vicc:e00009",
            "type": "Coding",
            "label": "preclinical evidence"
        },
        "target_proposition": {
            "id": "proposition:nGO5SG3-x2bBSHDa1gJaHfYxG2mEx1c9",
            "type": "VariationNeoplasmTherapeuticResponseProposition",
            "subject": "ga4gh:VA.PnJlRfBCZ6YxYPGMNHJQkxYTWrmTr0M4",
            "predicate": "predicts_resistance_to",
            "object": {
                "id": "ncit:C147908",
                "type": "Therapeutic"
            },
            "neoplasm_type_qualifier": {
                "id": "ncit:C9335",
                "type": "Disease"
            }
        },
        "direction": "supports",
        "subject_descriptor": "civic.vid:50",
        "neoplasm_type_descriptor": {
            "id": "civic.did:22",
            "type": "DiseaseDescriptor",
            "label": "Breast Cancer",
            "xrefs": [
                "DOID:1612"
            ],
            "disease": "ncit:C9335"
        },
        "object_descriptor": {
            "id": "civic.tid:46",
            "type": "TherapeuticDescriptor",
            "label": "Hormone Therapy",
            "xrefs": [
                "ncit:C15445"
            ],
            "alternate_labels": [
                "Chemotherapy-Hormones/Steroids",
                "Endocrine Therapy",
                "Hormonal Therapy",
                "Hormone Treatment",
                "Hormones"
            ],
            "therapeutic": "ncit:C147908"
        }
    },
    {
        "id": "civic.eid:249",
        "type": "VariationNeoplasmTherapeuticResponseStatement",
        "description": "KIT V654A results in imatinib resistance in GIST patient-derived cell lines.",
        "method": "metakb.method:1",
        "is_reported_in": [
            {
                "id": "civic.source:62",
                "type": "Document",
                "label": "Heinrich et al., 2006, J. Clin. Oncol.",
                "xrefs": [
                    "pmid:16954519"
                ],
                "title": "Molecular correlates of imatinib resistance in gastrointestinal stromal tumors."
            }
        ],
        "evidence_level": {
            "id": "vicc:e00009",
            "type": "Coding",
            "label": "preclinical evidence"
        },
        "target_proposition": {
            "id": "proposition:aNGnO1hv3ZZMDa4YO7mx1cWA2_bYL5js",
            "type": "VariationNeoplasmTherapeuticResponseProposition",
            "subject": "ga4gh:VA.CW1xXH97SiVFOHQp0rQ7-T5yYdwCE3ta",
            "predicate": "predicts_resistance_to",
            "object": {
                "id": "rxcui:282388",
                "type": "Therapeutic"
            },
            "neoplasm_type_qualifier": {
                "id": "ncit:C3868",
                "type": "Disease"
            }
        },
        "direction": "supports",
        "subject_descriptor": "civic.vid:73",
        "neoplasm_type_descriptor": {
            "id": "civic.did:2",
            "type": "DiseaseDescriptor",
            "label": "Gastrointestinal Stromal Tumor",
            "xrefs": [
                "DOID:9253"
            ],
            "disease": "ncit:C3868"
        },
        "object_descriptor": {
            "id": "civic.tid:5",
            "type": "TherapeuticDescriptor",
            "label": "Imatinib",
            "extensions": [
                {
                    "type": "Extension",
                    "name": "regulatory_approval",
                    "value": {
                        "approval_rating": "FDA",
                        "has_indications": [
                            {
                                "id": "hemonc:667",
                                "type": "DiseaseDescriptor",
                                "label": "Soft tissue sarcoma",
                                "disease": "ncit:C9306"
                            },
                            {
                                "id": "hemonc:602",
                                "type": "DiseaseDescriptor",
                                "label": "Gastrointestinal stromal tumor",
                                "disease": "ncit:C3868"
                            },
                            {
                                "id": "hemonc:616",
                                "type": "DiseaseDescriptor",
                                "label": "Hypereosinophilic syndrome",
                                "disease": "ncit:C27038"
                            },
                            {
                                "id": "hemonc:33893",
                                "type": "DiseaseDescriptor",
                                "label": "Chronic myelogenous leukemia pediatric",
                                "disease": null
                            },
                            {
                                "id": "hemonc:634",
                                "type": "DiseaseDescriptor",
                                "label": "Myelodysplastic syndrome",
                                "disease": "ncit:C3247"
                            },
                            {
                                "id": "hemonc:24309",
                                "type": "DiseaseDescriptor",
                                "label": "Acute lymphoblastic leukemia",
                                "disease": "ncit:C3167"
                            },
                            {
                                "id": "hemonc:582",
                                "type": "DiseaseDescriptor",
                                "label": "Chronic myelogenous leukemia",
                                "disease": "ncit:C3174"
                            },
                            {
                                "id": "hemonc:669",
                                "type": "DiseaseDescriptor",
                                "label": "Systemic mastocytosis",
                                "disease": "ncit:C9235"
                            }
                        ]
                    }
                }
            ],
            "xrefs": [
                "ncit:C62035"
            ],
            "alternate_labels": [
                "4-[(4-Methyl-1-piperazinyl)methyl]-N-[4-methyl-3-[[4-(3-pyridinyl)-2-pyrimidinyl]amino]phenyl]benzamide"
            ],
            "therapeutic": "rxcui:282388"
        }
    },
    {
        "id": "civic.eid:651",
        "type": "VariationNeoplasmTherapeuticResponseStatement",
        "description": "When 293T cells stably transduced with PDGFRA A842V were treated with imatinib, tyrosine phosphorylation was maintained at 1 and 10umol/L concentrations that inhibited phosphorylation of wildtype PDGFRA, consistent with resistance to this inhibitor.",
        "method": "metakb.method:1",
        "is_reported_in": [
            {
                "id": "civic.source:411",
                "type": "Document",
                "label": "Hirota et al., 2003, Gastroenterology",
                "xrefs": [
                    "pmid:12949711"
                ],
                "title": "Gain-of-function mutations of platelet-derived growth factor receptor alpha gene in gastrointestinal stromal tumors."
            }
        ],
        "evidence_level": {
            "id": "vicc:e00009",
            "type": "Coding",
            "label": "preclinical evidence"
        },
        "target_proposition": {
            "id": "proposition:XT63NpvH0QMWWy8SjzzSDlRwhki6ikVG",
            "type": "VariationNeoplasmTherapeuticResponseProposition",
            "subject": "ga4gh:VA.CaTuLaWlUwLb32qfYTW2udl2Iy02ccN6",
            "predicate": "predicts_resistance_to",
            "object": {
                "id": "rxcui:282388",
                "type": "Therapeutic"
            },
            "neoplasm_type_qualifier": {
                "id": "ncit:C3868",
                "type": "Disease"
            }
        },
        "direction": "supports",
        "subject_descriptor": "civic.vid:99",
        "neoplasm_type_descriptor": {
            "id": "civic.did:2",
            "type": "DiseaseDescriptor",
            "label": "Gastrointestinal Stromal Tumor",
            "xrefs": [
                "DOID:9253"
            ],
            "disease": "ncit:C3868"
        },
        "object_descriptor": {
            "id": "civic.tid:5",
            "type": "TherapeuticDescriptor",
            "label": "Imatinib",
            "extensions": [
                {
                    "type": "Extension",
                    "name": "regulatory_approval",
                    "value": {
                        "approval_rating": "FDA",
                        "has_indications": [
                            {
                                "id": "hemonc:667",
                                "type": "DiseaseDescriptor",
                                "label": "Soft tissue sarcoma",
                                "disease": "ncit:C9306"
                            },
                            {
                                "id": "hemonc:602",
                                "type": "DiseaseDescriptor",
                                "label": "Gastrointestinal stromal tumor",
                                "disease": "ncit:C3868"
                            },
                            {
                                "id": "hemonc:616",
                                "type": "DiseaseDescriptor",
                                "label": "Hypereosinophilic syndrome",
                                "disease": "ncit:C27038"
                            },
                            {
                                "id": "hemonc:33893",
                                "type": "DiseaseDescriptor",
                                "label": "Chronic myelogenous leukemia pediatric",
                                "disease": null
                            },
                            {
                                "id": "hemonc:634",
                                "type": "DiseaseDescriptor",
                                "label": "Myelodysplastic syndrome",
                                "disease": "ncit:C3247"
                            },
                            {
                                "id": "hemonc:24309",
                                "type": "DiseaseDescriptor",
                                "label": "Acute lymphoblastic leukemia",
                                "disease": "ncit:C3167"
                            },
                            {
                                "id": "hemonc:582",
                                "type": "DiseaseDescriptor",
                                "label": "Chronic myelogenous leukemia",
                                "disease": "ncit:C3174"
                            },
                            {
                                "id": "hemonc:669",
                                "type": "DiseaseDescriptor",
                                "label": "Systemic mastocytosis",
                                "disease": "ncit:C9235"
                            }
                        ]
                    }
                }
            ],
            "xrefs": [
                "ncit:C62035"
            ],
            "alternate_labels": [
                "4-[(4-Methyl-1-piperazinyl)methyl]-N-[4-methyl-3-[[4-(3-pyridinyl)-2-pyrimidinyl]amino]phenyl]benzamide"
            ],
            "therapeutic": "rxcui:282388"
        }
    },
    {
        "id": "civic.eid:755",
        "type": "VariationNeoplasmTherapeuticResponseStatement",
        "description": "D473 mutations were identified in 5/30 resistant basal cell carcinomas. Crystal structure indicated this mutation interacts with a water molecule in the ligand binding pocket, putatively altering its interaction with the SMO inhibitor vismodegib. SMO-/- mouse embryonic fibroblasts expressing the SMO D473G mutant maintained hedgehog signaling in the presence of the drug and had IC50 values >40 fold higher than cells expressing wildtype SMO.",
        "method": "metakb.method:1",
        "is_reported_in": [
            {
                "id": "civic.source:493",
                "type": "Document",
                "label": "Atwood et al., 2015, Cancer Cell",
                "xrefs": [
                    "pmc:PMC4357167",
                    "pmid:25759020"
                ],
                "title": "Smoothened variants explain the majority of drug resistance in basal cell carcinoma."
            }
        ],
        "evidence_level": {
            "id": "vicc:e00009",
            "type": "Coding",
            "label": "preclinical evidence"
        },
        "target_proposition": {
            "id": "proposition:ySEGToTh2YCfdokGvKhwY1WMLZM9jNCV",
            "type": "VariationNeoplasmTherapeuticResponseProposition",
            "subject": "ga4gh:VA.hyt2pj4IH9Y-SEnEF-jNElPBrIIxBwwy",
            "predicate": "predicts_resistance_to",
            "object": {
                "id": "rxcui:1242987",
                "type": "Therapeutic"
            },
            "neoplasm_type_qualifier": {
                "id": "ncit:C2921",
                "type": "Disease"
            }
        },
        "direction": "supports",
        "subject_descriptor": "civic.vid:299",
        "neoplasm_type_descriptor": {
            "id": "civic.did:314",
            "type": "DiseaseDescriptor",
            "label": "Basal Cell Carcinoma",
            "xrefs": [
                "DOID:2513"
            ],
            "disease": "ncit:C2921"
        },
        "object_descriptor": {
            "id": "civic.tid:190",
            "type": "TherapeuticDescriptor",
            "label": "Vismodegib",
            "extensions": [
                {
                    "type": "Extension",
                    "name": "regulatory_approval",
                    "value": {
                        "approval_rating": "FDA",
                        "has_indications": [
                            {
                                "id": "hemonc:587",
                                "type": "DiseaseDescriptor",
                                "label": "Cutaneous basal cell carcinoma",
                                "disease": null
                            }
                        ]
                    }
                }
            ],
            "xrefs": [
                "ncit:C74038"
            ],
            "alternate_labels": [
                "2-chloro-N-[4-chloro-3-(pyridin-2-yl)phenyl]-4-(methylsulfonyl)benzamide",
                "Erivedge",
                "GDC-0449",
                "Hedgehog Antagonist GDC-0449"
            ],
            "therapeutic": "rxcui:1242987"
        }
    },
    {
        "id": "civic.eid:1083",
        "type": "VariationNeoplasmTherapeuticResponseStatement",
        "description": "In this preclinical study on the effects of cetuximab, panitumumab or sym004 on various EGFR mutations in colorectal cancer. In NIH3T3 cells expressing EGFR with a K467T mutation, Sym004 and panitumumab bound the mutated receptor and inhibited EGFR phosphorylation in the presence of ligand while cetuximab neither bound to nor inhibited EGFR phosphorylation of the mutated receptor.",
        "method": "metakb.method:1",
        "is_reported_in": [
            {
                "id": "civic.source:746",
                "type": "Document",
                "label": "S\u00e1nchez-Mart\u00edn et al., 2016, Clin. Cancer Res.",
                "xrefs": [
                    "pmid:26888827"
                ],
                "title": "The First-in-class Anti-EGFR Antibody Mixture Sym004 Overcomes Cetuximab Resistance Mediated by EGFR Extracellular Domain Mutations in Colorectal Cancer."
            }
        ],
        "evidence_level": {
            "id": "vicc:e00009",
            "type": "Coding",
            "label": "preclinical evidence"
        },
        "target_proposition": {
            "id": "proposition:YJMKjnmCTpC0m98m5IN_jioB4jRu4hjc",
            "type": "VariationNeoplasmTherapeuticResponseProposition",
            "subject": "ga4gh:VA.K55sYmiCjFDH_nWsWNp5z-lq4Dhqrh2o",
            "predicate": "predicts_resistance_to",
            "object": {
                "id": "rxcui:318341",
                "type": "Therapeutic"
            },
            "neoplasm_type_qualifier": {
                "id": "ncit:C4978",
                "type": "Disease"
            }
        },
        "direction": "supports",
        "subject_descriptor": "civic.vid:455",
        "neoplasm_type_descriptor": {
            "id": "civic.did:11",
            "type": "DiseaseDescriptor",
            "label": "Colorectal Cancer",
            "xrefs": [
                "DOID:9256"
            ],
            "disease": "ncit:C4978"
        },
        "object_descriptor": {
            "id": "civic.tid:16",
            "type": "TherapeuticDescriptor",
            "label": "Cetuximab",
            "extensions": [
                {
                    "type": "Extension",
                    "name": "regulatory_approval",
                    "value": {
                        "approval_rating": "ChEMBL",
                        "has_indications": [
                            {
                                "id": "mesh:D002294",
                                "type": "DiseaseDescriptor",
                                "label": "Carcinoma, Squamous Cell",
                                "disease": "ncit:C2929"
                            },
                            {
                                "id": "mesh:D009369",
                                "type": "DiseaseDescriptor",
                                "label": "Neoplasms",
                                "disease": "ncit:C3262"
                            },
                            {
                                "id": "mesh:D015179",
                                "type": "DiseaseDescriptor",
                                "label": "Colorectal Neoplasms",
                                "disease": "ncit:C2956"
                            },
                            {
                                "id": "mesh:D006258",
                                "type": "DiseaseDescriptor",
                                "label": "Head and Neck Neoplasms",
                                "disease": "ncit:C4013"
                            }
                        ]
                    }
                }
            ],
            "xrefs": [
                "ncit:C1723"
            ],
            "alternate_labels": [
                "Cetuximab Biosimilar CDP-1",
                "Cetuximab Biosimilar CMAB009",
                "Cetuximab Biosimilar KL 140",
                "Chimeric Anti-EGFR Monoclonal Antibody",
                "Chimeric MoAb C225",
                "Chimeric Monoclonal Antibody C225",
                "Erbitux",
                "IMC-C225"
            ],
            "therapeutic": "rxcui:318341"
        }
    },
    {
        "id": "civic.eid:1537",
        "type": "VariationNeoplasmTherapeuticResponseStatement",
        "description": "Cells were derived from a 26-year old patient with vemurafenib resistant BRAF-mutated (V600E) cutaneous melanoma (designated 20 092 cells). Five of his metastases evaluated using whole genome sequencing contained a GNAQ (Q209P) mutation. 20 092 cells were insensitive to BRAF inhibition (PLX4720) in both proliferation assays and evaluation of pERK compared to BRAF V600E mutated, GNAQ wild-type A375P cells. Using GNAQ (Q209P) siRNA in 22 092 cells, ERK activity was suppressed and cell sensitivity to PLX4720 was increased.",
        "method": "metakb.method:1",
        "is_reported_in": [
            {
                "id": "civic.source:1021",
                "type": "Document",
                "label": "Turajlic et al., 2014, Ann. Oncol.",
                "xrefs": [
                    "pmc:PMC3999800",
                    "pmid:24504448"
                ],
                "title": "Whole-genome sequencing reveals complex mechanisms of intrinsic resistance to BRAF inhibition."
            }
        ],
        "evidence_level": {
            "id": "vicc:e00009",
            "type": "Coding",
            "label": "preclinical evidence"
        },
        "target_proposition": {
            "id": "proposition:RfqvEz928rCop3V80wsH6H7E46A096cu",
            "type": "VariationNeoplasmTherapeuticResponseProposition",
            "subject": "ga4gh:VA.QYkNQvhUn7ivhb5plpyq7Hb9EpKTXT91",
            "predicate": "predicts_resistance_to",
            "object": {
                "id": "drugbank:DB06999",
                "type": "Therapeutic"
            },
            "neoplasm_type_qualifier": {
                "id": "ncit:C3510",
                "type": "Disease"
            }
        },
        "direction": "supports",
        "subject_descriptor": "civic.vid:604",
        "neoplasm_type_descriptor": {
            "id": "civic.did:206",
            "type": "DiseaseDescriptor",
            "label": "Skin Melanoma",
            "xrefs": [
                "DOID:8923"
            ],
            "disease": "ncit:C3510"
        },
        "object_descriptor": {
            "id": "civic.tid:30",
            "type": "TherapeuticDescriptor",
            "label": "PLX4720",
            "therapeutic": "drugbank:DB06999"
        }
    },
    {
        "id": "civic.eid:2036",
        "type": "VariationNeoplasmTherapeuticResponseStatement",
        "description": "As part of a pre-clinical experiment, the efficacy of ado-trastuzumab emtansine (T-DM1) was compared to that of trastuzumab against various HER2 positive cell lines. MCF7-neo/HER2 cell line harboring PIK3CA E545K was associated with similar sensitivity to T-DM1 as PIK3CA wild-type cell line SK-BR-3; reduced cell viability was observed at concentrations >0.01 ug/mL in both cell lines. Conversely, the cell line harboring PIK3CA E545K was resistant to trastuzumab in vitro at all concentrations tested (0-10 ug/mL). Further, treatment with T-DM1 on nude mice xenografted with PIK3CA E545K-harboring cells resulted in inhibition of tumor growth. A single dose of T-DM1 >3mg/kg was sufficient to induce tumor suppression lasting >20 days after administration.",
        "method": "metakb.method:1",
        "is_reported_in": [
            {
                "id": "civic.source:1468",
                "type": "Document",
                "label": "Baselga et al., 2016, Clin. Cancer Res.",
                "xrefs": [
                    "pmid:26920887"
                ],
                "title": "Relationship between Tumor Biomarkers and Efficacy in EMILIA, a Phase III Study of Trastuzumab Emtansine in HER2-Positive Metastatic Breast Cancer."
            }
        ],
        "evidence_level": {
            "id": "vicc:e00009",
            "type": "Coding",
            "label": "preclinical evidence"
        },
        "target_proposition": {
            "id": "proposition:UhE4fIss0Z0leTHNspRbMbL-6axUAQU5",
            "type": "VariationNeoplasmTherapeuticResponseProposition",
            "subject": "ga4gh:VA.5zBiXnk0ZRCfFqRnK0fQHQwAGBWW4JE8",
            "predicate": "predicts_resistance_to",
            "object": {
                "id": "rxcui:1371041",
                "type": "Therapeutic"
            },
            "neoplasm_type_qualifier": {
                "id": "ncit:C53556",
                "type": "Disease"
            }
        },
        "direction": "opposes",
        "subject_descriptor": "civic.vid:104",
        "neoplasm_type_descriptor": {
            "id": "civic.did:368",
            "type": "DiseaseDescriptor",
            "label": "Her2-receptor Positive Breast Cancer",
            "xrefs": [
                "DOID:60079"
            ],
            "disease": "ncit:C53556"
        },
        "object_descriptor": {
            "id": "civic.tid:457",
            "type": "TherapeuticDescriptor",
            "label": "Trastuzumab Emtansine",
            "xrefs": [
                "ncit:C82492"
            ],
            "alternate_labels": [
                "ADO-TRASTUZUMAB EMTANSINE",
                "Ado Trastuzumab Emtansine",
                "Immunoglobulin G1, Anti-(Human P185neu Receptor) (Human-Mouse Monoclonal RhuMab HER2 Gamma1-Chain), Disulfide With Human-Mouse Monoclonal RhuMab HER2 Light Chain, Dimer, Tetraamide With N2'-(3-((1-((4-carboxycyclohexyl)methyl)-2,5-dioxo-3-pyrrolidinyl)thio)-1-oxopropyl)-N2'-deacetylMaytansine",
                "Kadcyla",
                "PRO132365",
                "RO5304020",
                "T-DM1",
                "Trastuzumab-DM1",
                "Trastuzumab-MCC-DM1",
                "Trastuzumab-MCC-DM1 Antibody-Drug Conjugate",
                "Trastuzumab-MCC-DM1 Immunoconjugate"
            ],
            "therapeutic": "rxcui:1371041"
        }
    },
    {
        "id": "civic.eid:2103",
        "type": "VariationNeoplasmTherapeuticResponseStatement",
        "description": "As part of a pre-clinical experiment, the efficacy of ado-trastuzumab emtansine (T-DM1) was compared to that of trastuzumab against various HER2 positive cell lines. HCC1954 and KPL-4 cell lines expressing PIK3CA H1047R were associated with similar sensitivity to T-DM1 as PIK3CA wild-type cell line SK-BR-3; reduced cell viability was observed at concentrations > 0.01 ug/mL in all three cell lines. Conversely, the cell lines harboring PIK3CA H1047R were resistant to trastuzumab in vitro at all concentrations tested (0-10 ug/mL). Further, treatment with T-DM1 on SCID mice xenografted with KPL-4 (PIK3CA H1047R cells) resulted in inhibition of tumor growth. A single dose of T-DM1 >5mg/kg was sufficient to induce tumor regression >20 days after administration.",
        "method": "metakb.method:1",
        "is_reported_in": [
            {
                "id": "civic.source:1468",
                "type": "Document",
                "label": "Baselga et al., 2016, Clin. Cancer Res.",
                "xrefs": [
                    "pmid:26920887"
                ],
                "title": "Relationship between Tumor Biomarkers and Efficacy in EMILIA, a Phase III Study of Trastuzumab Emtansine in HER2-Positive Metastatic Breast Cancer."
            }
        ],
        "evidence_level": {
            "id": "vicc:e00009",
            "type": "Coding",
            "label": "preclinical evidence"
        },
        "target_proposition": {
            "id": "proposition:RJQ1tYuqX5vViijw1HblZXgUPiCv7aXb",
            "type": "VariationNeoplasmTherapeuticResponseProposition",
            "subject": "ga4gh:VA.TIcXeM9bBVAIDYM4osh5rbkEVBs3LBCJ",
            "predicate": "predicts_resistance_to",
            "object": {
                "id": "rxcui:1371041",
                "type": "Therapeutic"
            },
            "neoplasm_type_qualifier": {
                "id": "ncit:C53556",
                "type": "Disease"
            }
        },
        "direction": "opposes",
        "subject_descriptor": "civic.vid:107",
        "neoplasm_type_descriptor": {
            "id": "civic.did:368",
            "type": "DiseaseDescriptor",
            "label": "Her2-receptor Positive Breast Cancer",
            "xrefs": [
                "DOID:60079"
            ],
            "disease": "ncit:C53556"
        },
        "object_descriptor": {
            "id": "civic.tid:457",
            "type": "TherapeuticDescriptor",
            "label": "Trastuzumab Emtansine",
            "xrefs": [
                "ncit:C82492"
            ],
            "alternate_labels": [
                "ADO-TRASTUZUMAB EMTANSINE",
                "Ado Trastuzumab Emtansine",
                "Immunoglobulin G1, Anti-(Human P185neu Receptor) (Human-Mouse Monoclonal RhuMab HER2 Gamma1-Chain), Disulfide With Human-Mouse Monoclonal RhuMab HER2 Light Chain, Dimer, Tetraamide With N2'-(3-((1-((4-carboxycyclohexyl)methyl)-2,5-dioxo-3-pyrrolidinyl)thio)-1-oxopropyl)-N2'-deacetylMaytansine",
                "Kadcyla",
                "PRO132365",
                "RO5304020",
                "T-DM1",
                "Trastuzumab-DM1",
                "Trastuzumab-MCC-DM1",
                "Trastuzumab-MCC-DM1 Antibody-Drug Conjugate",
                "Trastuzumab-MCC-DM1 Immunoconjugate"
            ],
            "therapeutic": "rxcui:1371041"
        }
    },
    {
        "id": "civic.eid:2221",
        "type": "VariationNeoplasmTherapeuticResponseStatement",
        "description": "Primary peripheral blood mononuclear cells were taken from chronic lymphocytic leukemia patients, some of whom had prior therapy. Cells were treated with doxorubicin to induce double-strand (DSB) and p21 induction was monitored by qPCR. To confirm wild type p53, parallel cell cultures were treated with fludarabine generating single-strand breaks, in addition to DSB, and monitored for adequate p21 induction. A patient sample had the T2666A variant of ATM, confirmed by sanger sequencing, in trans with a loss of function 11q deletion found in 91% of cells by FISH. Western blot showed null ATM expression. Treatment with doxorubicin resulted in a p21 expression level of less than 300% that of untreated wild-type controls. This was much lower than the median expression level of treated controls which was 815% that of untreated controls, supporting resistance.",
        "method": "metakb.method:1",
        "is_reported_in": [
            {
                "id": "civic.source:1541",
                "type": "Document",
                "label": "Navrkalova et al., 2013, Haematologica",
                "xrefs": [
                    "pmc:PMC3696617",
                    "pmid:23585524"
                ],
                "title": "ATM mutations uniformly lead to ATM dysfunction in chronic lymphocytic leukemia: application of functional test using doxorubicin."
            }
        ],
        "evidence_level": {
            "id": "vicc:e00009",
            "type": "Coding",
            "label": "preclinical evidence"
        },
        "target_proposition": {
            "id": "proposition:VZ1RStELV9VVB6vC9Aarex37hjjdEk6g",
            "type": "VariationNeoplasmTherapeuticResponseProposition",
            "subject": "ga4gh:VA.Q2S35WrvyuYDN2dEQAdqNoykhqqOPJHP",
            "predicate": "predicts_resistance_to",
            "object": {
                "id": "rxcui:142433",
                "type": "Therapeutic"
            },
            "neoplasm_type_qualifier": {
                "id": "ncit:C3163",
                "type": "Disease"
            }
        },
        "direction": "supports",
        "subject_descriptor": "civic.vid:901",
        "neoplasm_type_descriptor": {
            "id": "civic.did:52",
            "type": "DiseaseDescriptor",
            "label": "Chronic Lymphocytic Leukemia",
            "xrefs": [
                "DOID:1040"
            ],
            "disease": "ncit:C3163"
        },
        "object_descriptor": {
            "id": "civic.tid:68",
            "type": "TherapeuticDescriptor",
            "label": "Doxorubicin",
            "extensions": [
                {
                    "type": "Extension",
                    "name": "regulatory_approval",
                    "value": {
                        "approval_rating": "FDA",
                        "has_indications": [
                            {
                                "id": "hemonc:666",
                                "type": "DiseaseDescriptor",
                                "label": "Small cell lung cancer",
                                "disease": "ncit:C4917"
                            },
                            {
                                "id": "hemonc:667",
                                "type": "DiseaseDescriptor",
                                "label": "Soft tissue sarcoma",
                                "disease": "ncit:C9306"
                            },
                            {
                                "id": "hemonc:614",
                                "type": "DiseaseDescriptor",
                                "label": "Hodgkin lymphoma",
                                "disease": "ncit:C9357"
                            },
                            {
                                "id": "hemonc:572",
                                "type": "DiseaseDescriptor",
                                "label": "Breast cancer",
                                "disease": "ncit:C9335"
                            },
                            {
                                "id": "hemonc:601",
                                "type": "DiseaseDescriptor",
                                "label": "Gastric cancer",
                                "disease": "ncit:C9331"
                            },
                            {
                                "id": "hemonc:675",
                                "type": "DiseaseDescriptor",
                                "label": "Thyroid cancer",
                                "disease": "ncit:C7510"
                            },
                            {
                                "id": "hemonc:552",
                                "type": "DiseaseDescriptor",
                                "label": "Acute myeloid leukemia",
                                "disease": "ncit:C3171"
                            },
                            {
                                "id": "hemonc:569",
                                "type": "DiseaseDescriptor",
                                "label": "Bladder cancer",
                                "disease": "ncit:C9334"
                            },
                            {
                                "id": "hemonc:645",
                                "type": "DiseaseDescriptor",
                                "label": "Ovarian cancer",
                                "disease": "ncit:C7431"
                            }
                        ]
                    }
                }
            ],
            "xrefs": [
                "ncit:C456"
            ],
            "alternate_labels": [
                "(8S-cis)-10-[(3-Amino-2,3,6-trideoxy-alpha-L-lyxo-hexopyranosyl)oxy]-7,8,9,10-tetrahydro-6,8,11-trihydroxy-8-(hydroacetyl)-1-methoxy-5,12-naphthacenedione",
                "(8S-cis)-10-[(3-Amino-2,3,6-trideoxy-alpha-L-lyxo-hexopyranosyl)oxy]-7,8,9,10-tetrahydro-6,8,11-trihydroxy-8-(hydroxyacetyl)-1-methoxy-5,12-naphthacenedione",
                "14-Hydroxydaunomycin",
                "Adriablastin",
                "Hydroxydaunomycin",
                "Hydroxyl Daunorubicin",
                "Hydroxyldaunorubicin"
            ],
            "therapeutic": "rxcui:142433"
        }
    },
    {
        "id": "civic.eid:2223",
        "type": "VariationNeoplasmTherapeuticResponseStatement",
        "description": "Primary peripheral blood mononuclear cells were taken from chronic lymphocytic leukemia patients, some of whom had prior therapy. The effect of the R3008C variant on ATM expression was tested by western blot, and the effect on ATM function was tested by treating with doxorubicin to induce double-strand breaks (DSB) and monitoring p21 induction. To confirm wild type p53, parallel cell cultures were treated with fludarabine generating single-strand breaks, in addition to DSB, and monitored for adequate p21 induction. In a patient sample with the R3008C variant of ATM in trans with a wild-type allele, confirmed by sanger sequencing, western blot showed stable ATM expression. Treatment with doxorubicin resulted in a p21 expression level of less than 300% that of untreated wild-type controls. This was much lower than the median expression level of treated controls which was 815% that of untreated controls, supporting resistance. The authors propose that this variant has a dominant-negative effect.",
        "method": "metakb.method:1",
        "is_reported_in": [
            {
                "id": "civic.source:1541",
                "type": "Document",
                "label": "Navrkalova et al., 2013, Haematologica",
                "xrefs": [
                    "pmc:PMC3696617",
                    "pmid:23585524"
                ],
                "title": "ATM mutations uniformly lead to ATM dysfunction in chronic lymphocytic leukemia: application of functional test using doxorubicin."
            }
        ],
        "evidence_level": {
            "id": "vicc:e00009",
            "type": "Coding",
            "label": "preclinical evidence"
        },
        "target_proposition": {
            "id": "proposition:5Blwf-ZNUaIUX8kNFEoxL4aT2Fsiz0Mf",
            "type": "VariationNeoplasmTherapeuticResponseProposition",
            "subject": "ga4gh:VA.To8S93QbZgfmwzt9nUu-BiWFs2Os_TPf",
            "predicate": "predicts_resistance_to",
            "object": {
                "id": "rxcui:142433",
                "type": "Therapeutic"
            },
            "neoplasm_type_qualifier": {
                "id": "ncit:C3163",
                "type": "Disease"
            }
        },
        "direction": "supports",
        "subject_descriptor": "civic.vid:903",
        "neoplasm_type_descriptor": {
            "id": "civic.did:52",
            "type": "DiseaseDescriptor",
            "label": "Chronic Lymphocytic Leukemia",
            "xrefs": [
                "DOID:1040"
            ],
            "disease": "ncit:C3163"
        },
        "object_descriptor": {
            "id": "civic.tid:68",
            "type": "TherapeuticDescriptor",
            "label": "Doxorubicin",
            "extensions": [
                {
                    "type": "Extension",
                    "name": "regulatory_approval",
                    "value": {
                        "approval_rating": "FDA",
                        "has_indications": [
                            {
                                "id": "hemonc:666",
                                "type": "DiseaseDescriptor",
                                "label": "Small cell lung cancer",
                                "disease": "ncit:C4917"
                            },
                            {
                                "id": "hemonc:667",
                                "type": "DiseaseDescriptor",
                                "label": "Soft tissue sarcoma",
                                "disease": "ncit:C9306"
                            },
                            {
                                "id": "hemonc:614",
                                "type": "DiseaseDescriptor",
                                "label": "Hodgkin lymphoma",
                                "disease": "ncit:C9357"
                            },
                            {
                                "id": "hemonc:572",
                                "type": "DiseaseDescriptor",
                                "label": "Breast cancer",
                                "disease": "ncit:C9335"
                            },
                            {
                                "id": "hemonc:601",
                                "type": "DiseaseDescriptor",
                                "label": "Gastric cancer",
                                "disease": "ncit:C9331"
                            },
                            {
                                "id": "hemonc:675",
                                "type": "DiseaseDescriptor",
                                "label": "Thyroid cancer",
                                "disease": "ncit:C7510"
                            },
                            {
                                "id": "hemonc:552",
                                "type": "DiseaseDescriptor",
                                "label": "Acute myeloid leukemia",
                                "disease": "ncit:C3171"
                            },
                            {
                                "id": "hemonc:569",
                                "type": "DiseaseDescriptor",
                                "label": "Bladder cancer",
                                "disease": "ncit:C9334"
                            },
                            {
                                "id": "hemonc:645",
                                "type": "DiseaseDescriptor",
                                "label": "Ovarian cancer",
                                "disease": "ncit:C7431"
                            }
                        ]
                    }
                }
            ],
            "xrefs": [
                "ncit:C456"
            ],
            "alternate_labels": [
                "(8S-cis)-10-[(3-Amino-2,3,6-trideoxy-alpha-L-lyxo-hexopyranosyl)oxy]-7,8,9,10-tetrahydro-6,8,11-trihydroxy-8-(hydroacetyl)-1-methoxy-5,12-naphthacenedione",
                "(8S-cis)-10-[(3-Amino-2,3,6-trideoxy-alpha-L-lyxo-hexopyranosyl)oxy]-7,8,9,10-tetrahydro-6,8,11-trihydroxy-8-(hydroxyacetyl)-1-methoxy-5,12-naphthacenedione",
                "14-Hydroxydaunomycin",
                "Adriablastin",
                "Hydroxydaunomycin",
                "Hydroxyl Daunorubicin",
                "Hydroxyldaunorubicin"
            ],
            "therapeutic": "rxcui:142433"
        }
    },
    {
        "id": "civic.eid:2346",
        "type": "VariationNeoplasmTherapeuticResponseStatement",
        "description": "As part of a pre-clinical experiment, the efficacy of ado-trastuzumab emtansine (T-DM1) was compared to that of trastuzumab against various HER2 positive cell lines. EFM-192A cell line expressing PIK3CA C420R was associated with similar sensitivity to T-DM1 as PIK3CA wild-type cell line SK-BR-3; substantially reduced cell viability was observed at concentrations > 0.01 ug/mL in both cell lines. Conversely, when treated with trastuzumab, the cell line harboring PIK3CA C420R experienced a smaller reduction in cell viability.",
        "method": "metakb.method:1",
        "is_reported_in": [
            {
                "id": "civic.source:1468",
                "type": "Document",
                "label": "Baselga et al., 2016, Clin. Cancer Res.",
                "xrefs": [
                    "pmid:26920887"
                ],
                "title": "Relationship between Tumor Biomarkers and Efficacy in EMILIA, a Phase III Study of Trastuzumab Emtansine in HER2-Positive Metastatic Breast Cancer."
            }
        ],
        "evidence_level": {
            "id": "vicc:e00009",
            "type": "Coding",
            "label": "preclinical evidence"
        },
        "target_proposition": {
            "id": "proposition:c4jWmXgjxoGrbI07i9MRLJbkx7aSxIah",
            "type": "VariationNeoplasmTherapeuticResponseProposition",
            "subject": "ga4gh:VA.gSEj555FrQu0uZMZcSDcGpE5p5TdBwX7",
            "predicate": "predicts_resistance_to",
            "object": {
                "id": "rxcui:1371041",
                "type": "Therapeutic"
            },
            "neoplasm_type_qualifier": {
                "id": "ncit:C53556",
                "type": "Disease"
            }
        },
        "direction": "opposes",
        "subject_descriptor": "civic.vid:931",
        "neoplasm_type_descriptor": {
            "id": "civic.did:368",
            "type": "DiseaseDescriptor",
            "label": "Her2-receptor Positive Breast Cancer",
            "xrefs": [
                "DOID:60079"
            ],
            "disease": "ncit:C53556"
        },
        "object_descriptor": {
            "id": "civic.tid:457",
            "type": "TherapeuticDescriptor",
            "label": "Trastuzumab Emtansine",
            "xrefs": [
                "ncit:C82492"
            ],
            "alternate_labels": [
                "ADO-TRASTUZUMAB EMTANSINE",
                "Ado Trastuzumab Emtansine",
                "Immunoglobulin G1, Anti-(Human P185neu Receptor) (Human-Mouse Monoclonal RhuMab HER2 Gamma1-Chain), Disulfide With Human-Mouse Monoclonal RhuMab HER2 Light Chain, Dimer, Tetraamide With N2'-(3-((1-((4-carboxycyclohexyl)methyl)-2,5-dioxo-3-pyrrolidinyl)thio)-1-oxopropyl)-N2'-deacetylMaytansine",
                "Kadcyla",
                "PRO132365",
                "RO5304020",
                "T-DM1",
                "Trastuzumab-DM1",
                "Trastuzumab-MCC-DM1",
                "Trastuzumab-MCC-DM1 Antibody-Drug Conjugate",
                "Trastuzumab-MCC-DM1 Immunoconjugate"
            ],
            "therapeutic": "rxcui:1371041"
        }
    },
    {
        "id": "civic.eid:2832",
        "type": "VariationNeoplasmTherapeuticResponseStatement",
        "description": "Primary peripheral blood mononuclear cells were taken from chronic lymphocytic leukemia patients, some of whom had prior therapy. The effect of the K293* variant on ATM expression was tested by western blot, and the effect on ATM function was tested by treating with doxorubicin to induce double-strand breaks (DSB) and monitoring p21 induction. To confirm wild type p53, parallel cell cultures were treated with fludarabine generating single-strand breaks, in addition to DSB, and monitored for adequate p21 induction. A patient sample had the K293* variant of ATM, confirmed by sanger sequencing, in trans with a loss of function 11q deletion found in 92% of cells by FISH. Western blot showed null ATM expression. Treatment with doxorubicin resulted in a p21 expression level of less than 300% that of untreated wild-type controls. This was much lower than the median expression level of treated controls which was 815% that of untreated controls, supporting resistance.",
        "method": "metakb.method:1",
        "is_reported_in": [
            {
                "id": "civic.source:1541",
                "type": "Document",
                "label": "Navrkalova et al., 2013, Haematologica",
                "xrefs": [
                    "pmc:PMC3696617",
                    "pmid:23585524"
                ],
                "title": "ATM mutations uniformly lead to ATM dysfunction in chronic lymphocytic leukemia: application of functional test using doxorubicin."
            }
        ],
        "evidence_level": {
            "id": "vicc:e00009",
            "type": "Coding",
            "label": "preclinical evidence"
        },
        "target_proposition": {
            "id": "proposition:WRpZz3qgcFPdu1NCOA1RzkSkzWtanHiK",
            "type": "VariationNeoplasmTherapeuticResponseProposition",
            "subject": "ga4gh:VA.SnNHiwjxElDYSwi_3-tFVQ9UqFshM3Pd",
            "predicate": "predicts_resistance_to",
            "object": {
                "id": "rxcui:142433",
                "type": "Therapeutic"
            },
            "neoplasm_type_qualifier": {
                "id": "ncit:C3163",
                "type": "Disease"
            }
        },
        "direction": "supports",
        "subject_descriptor": "civic.vid:1155",
        "neoplasm_type_descriptor": {
            "id": "civic.did:52",
            "type": "DiseaseDescriptor",
            "label": "Chronic Lymphocytic Leukemia",
            "xrefs": [
                "DOID:1040"
            ],
            "disease": "ncit:C3163"
        },
        "object_descriptor": {
            "id": "civic.tid:68",
            "type": "TherapeuticDescriptor",
            "label": "Doxorubicin",
            "extensions": [
                {
                    "type": "Extension",
                    "name": "regulatory_approval",
                    "value": {
                        "approval_rating": "FDA",
                        "has_indications": [
                            {
                                "id": "hemonc:666",
                                "type": "DiseaseDescriptor",
                                "label": "Small cell lung cancer",
                                "disease": "ncit:C4917"
                            },
                            {
                                "id": "hemonc:667",
                                "type": "DiseaseDescriptor",
                                "label": "Soft tissue sarcoma",
                                "disease": "ncit:C9306"
                            },
                            {
                                "id": "hemonc:614",
                                "type": "DiseaseDescriptor",
                                "label": "Hodgkin lymphoma",
                                "disease": "ncit:C9357"
                            },
                            {
                                "id": "hemonc:572",
                                "type": "DiseaseDescriptor",
                                "label": "Breast cancer",
                                "disease": "ncit:C9335"
                            },
                            {
                                "id": "hemonc:601",
                                "type": "DiseaseDescriptor",
                                "label": "Gastric cancer",
                                "disease": "ncit:C9331"
                            },
                            {
                                "id": "hemonc:675",
                                "type": "DiseaseDescriptor",
                                "label": "Thyroid cancer",
                                "disease": "ncit:C7510"
                            },
                            {
                                "id": "hemonc:552",
                                "type": "DiseaseDescriptor",
                                "label": "Acute myeloid leukemia",
                                "disease": "ncit:C3171"
                            },
                            {
                                "id": "hemonc:569",
                                "type": "DiseaseDescriptor",
                                "label": "Bladder cancer",
                                "disease": "ncit:C9334"
                            },
                            {
                                "id": "hemonc:645",
                                "type": "DiseaseDescriptor",
                                "label": "Ovarian cancer",
                                "disease": "ncit:C7431"
                            }
                        ]
                    }
                }
            ],
            "xrefs": [
                "ncit:C456"
            ],
            "alternate_labels": [
                "(8S-cis)-10-[(3-Amino-2,3,6-trideoxy-alpha-L-lyxo-hexopyranosyl)oxy]-7,8,9,10-tetrahydro-6,8,11-trihydroxy-8-(hydroacetyl)-1-methoxy-5,12-naphthacenedione",
                "(8S-cis)-10-[(3-Amino-2,3,6-trideoxy-alpha-L-lyxo-hexopyranosyl)oxy]-7,8,9,10-tetrahydro-6,8,11-trihydroxy-8-(hydroxyacetyl)-1-methoxy-5,12-naphthacenedione",
                "14-Hydroxydaunomycin",
                "Adriablastin",
                "Hydroxydaunomycin",
                "Hydroxyl Daunorubicin",
                "Hydroxyldaunorubicin"
            ],
            "therapeutic": "rxcui:142433"
        }
    },
    {
        "id": "civic.eid:2835",
        "type": "VariationNeoplasmTherapeuticResponseStatement",
        "description": "Primary peripheral blood mononuclear cells were taken from chronic lymphocytic leukemia patients, some of whom had prior therapy. The effect of the F1025L variant on ATM expression was tested by western blot, and the effect on ATM function was tested by treating with doxorubicin to induce double-strand breaks (DSB) and monitoring p21 induction. To confirm wild type p53, parallel cell cultures were treated with fludarabine generating single-strand breaks, in addition to DSB, and monitored for adequate p21 induction. A patient sample had the F1025L variant of ATM, confirmed by sanger sequencing, in trans with a loss of function 11q deletion found in 93% of cells by FISH. Western blot showed stable ATM expression. Treatment with doxorubicin resulted in a p21 expression level of less than 300% that of untreated wild-type controls. This was much lower than the median expression level of treated controls which was 815% that of untreated controls, supporting resistance.",
        "method": "metakb.method:1",
        "is_reported_in": [
            {
                "id": "civic.source:1541",
                "type": "Document",
                "label": "Navrkalova et al., 2013, Haematologica",
                "xrefs": [
                    "pmc:PMC3696617",
                    "pmid:23585524"
                ],
                "title": "ATM mutations uniformly lead to ATM dysfunction in chronic lymphocytic leukemia: application of functional test using doxorubicin."
            }
        ],
        "evidence_level": {
            "id": "vicc:e00009",
            "type": "Coding",
            "label": "preclinical evidence"
        },
        "target_proposition": {
            "id": "proposition:gy8hW4dxynWadsCnL-mM1kBn8kq3-UoH",
            "type": "VariationNeoplasmTherapeuticResponseProposition",
            "subject": "ga4gh:VA.DsNqZZtkjmBwWYy9SCQPY7PoEb6yrTRk",
            "predicate": "predicts_resistance_to",
            "object": {
                "id": "rxcui:142433",
                "type": "Therapeutic"
            },
            "neoplasm_type_qualifier": {
                "id": "ncit:C3163",
                "type": "Disease"
            }
        },
        "direction": "supports",
        "subject_descriptor": "civic.vid:1158",
        "neoplasm_type_descriptor": {
            "id": "civic.did:52",
            "type": "DiseaseDescriptor",
            "label": "Chronic Lymphocytic Leukemia",
            "xrefs": [
                "DOID:1040"
            ],
            "disease": "ncit:C3163"
        },
        "object_descriptor": {
            "id": "civic.tid:68",
            "type": "TherapeuticDescriptor",
            "label": "Doxorubicin",
            "extensions": [
                {
                    "type": "Extension",
                    "name": "regulatory_approval",
                    "value": {
                        "approval_rating": "FDA",
                        "has_indications": [
                            {
                                "id": "hemonc:666",
                                "type": "DiseaseDescriptor",
                                "label": "Small cell lung cancer",
                                "disease": "ncit:C4917"
                            },
                            {
                                "id": "hemonc:667",
                                "type": "DiseaseDescriptor",
                                "label": "Soft tissue sarcoma",
                                "disease": "ncit:C9306"
                            },
                            {
                                "id": "hemonc:614",
                                "type": "DiseaseDescriptor",
                                "label": "Hodgkin lymphoma",
                                "disease": "ncit:C9357"
                            },
                            {
                                "id": "hemonc:572",
                                "type": "DiseaseDescriptor",
                                "label": "Breast cancer",
                                "disease": "ncit:C9335"
                            },
                            {
                                "id": "hemonc:601",
                                "type": "DiseaseDescriptor",
                                "label": "Gastric cancer",
                                "disease": "ncit:C9331"
                            },
                            {
                                "id": "hemonc:675",
                                "type": "DiseaseDescriptor",
                                "label": "Thyroid cancer",
                                "disease": "ncit:C7510"
                            },
                            {
                                "id": "hemonc:552",
                                "type": "DiseaseDescriptor",
                                "label": "Acute myeloid leukemia",
                                "disease": "ncit:C3171"
                            },
                            {
                                "id": "hemonc:569",
                                "type": "DiseaseDescriptor",
                                "label": "Bladder cancer",
                                "disease": "ncit:C9334"
                            },
                            {
                                "id": "hemonc:645",
                                "type": "DiseaseDescriptor",
                                "label": "Ovarian cancer",
                                "disease": "ncit:C7431"
                            }
                        ]
                    }
                }
            ],
            "xrefs": [
                "ncit:C456"
            ],
            "alternate_labels": [
                "(8S-cis)-10-[(3-Amino-2,3,6-trideoxy-alpha-L-lyxo-hexopyranosyl)oxy]-7,8,9,10-tetrahydro-6,8,11-trihydroxy-8-(hydroacetyl)-1-methoxy-5,12-naphthacenedione",
                "(8S-cis)-10-[(3-Amino-2,3,6-trideoxy-alpha-L-lyxo-hexopyranosyl)oxy]-7,8,9,10-tetrahydro-6,8,11-trihydroxy-8-(hydroxyacetyl)-1-methoxy-5,12-naphthacenedione",
                "14-Hydroxydaunomycin",
                "Adriablastin",
                "Hydroxydaunomycin",
                "Hydroxyl Daunorubicin",
                "Hydroxyldaunorubicin"
            ],
            "therapeutic": "rxcui:142433"
        }
    },
    {
        "id": "civic.eid:2839",
        "type": "VariationNeoplasmTherapeuticResponseStatement",
        "description": "Primary peripheral blood mononuclear cells were taken from chronic lymphocytic leukemia patients, some of whom had prior therapy. The effect of the E2187* variant on ATM expression was tested by western blot, and the effect on ATM function was tested by treating with doxorubicin to induce double-strand breaks (DSB) and monitoring p21 induction. To confirm wild type p53, parallel cell cultures were treated with fludarabine generating single-strand breaks, in addition to DSB, and monitored for adequate p21 induction. A patient sample had the E2187* variant of ATM, confirmed by sanger sequencing, in trans with a loss of function 11q deletion found in 96% of cells by FISH. Western blot showed null ATM expression. Treatment with doxorubicin resulted in a p21 expression level of less than 300% that of untreated wild-type controls. This was much lower than the median expression level of treated controls which was 815% that of untreated controls, supporting resistance.",
        "method": "metakb.method:1",
        "is_reported_in": [
            {
                "id": "civic.source:1541",
                "type": "Document",
                "label": "Navrkalova et al., 2013, Haematologica",
                "xrefs": [
                    "pmc:PMC3696617",
                    "pmid:23585524"
                ],
                "title": "ATM mutations uniformly lead to ATM dysfunction in chronic lymphocytic leukemia: application of functional test using doxorubicin."
            }
        ],
        "evidence_level": {
            "id": "vicc:e00009",
            "type": "Coding",
            "label": "preclinical evidence"
        },
        "target_proposition": {
            "id": "proposition:7D4A2WPWZuGyCbsZenfR0-udUlheRD3Z",
            "type": "VariationNeoplasmTherapeuticResponseProposition",
            "subject": "ga4gh:VA.Xy0pE6GL2go3zYEteqG2O4RcIRGnRF84",
            "predicate": "predicts_resistance_to",
            "object": {
                "id": "rxcui:142433",
                "type": "Therapeutic"
            },
            "neoplasm_type_qualifier": {
                "id": "ncit:C3163",
                "type": "Disease"
            }
        },
        "direction": "supports",
        "subject_descriptor": "civic.vid:1162",
        "neoplasm_type_descriptor": {
            "id": "civic.did:52",
            "type": "DiseaseDescriptor",
            "label": "Chronic Lymphocytic Leukemia",
            "xrefs": [
                "DOID:1040"
            ],
            "disease": "ncit:C3163"
        },
        "object_descriptor": {
            "id": "civic.tid:68",
            "type": "TherapeuticDescriptor",
            "label": "Doxorubicin",
            "extensions": [
                {
                    "type": "Extension",
                    "name": "regulatory_approval",
                    "value": {
                        "approval_rating": "FDA",
                        "has_indications": [
                            {
                                "id": "hemonc:666",
                                "type": "DiseaseDescriptor",
                                "label": "Small cell lung cancer",
                                "disease": "ncit:C4917"
                            },
                            {
                                "id": "hemonc:667",
                                "type": "DiseaseDescriptor",
                                "label": "Soft tissue sarcoma",
                                "disease": "ncit:C9306"
                            },
                            {
                                "id": "hemonc:614",
                                "type": "DiseaseDescriptor",
                                "label": "Hodgkin lymphoma",
                                "disease": "ncit:C9357"
                            },
                            {
                                "id": "hemonc:572",
                                "type": "DiseaseDescriptor",
                                "label": "Breast cancer",
                                "disease": "ncit:C9335"
                            },
                            {
                                "id": "hemonc:601",
                                "type": "DiseaseDescriptor",
                                "label": "Gastric cancer",
                                "disease": "ncit:C9331"
                            },
                            {
                                "id": "hemonc:675",
                                "type": "DiseaseDescriptor",
                                "label": "Thyroid cancer",
                                "disease": "ncit:C7510"
                            },
                            {
                                "id": "hemonc:552",
                                "type": "DiseaseDescriptor",
                                "label": "Acute myeloid leukemia",
                                "disease": "ncit:C3171"
                            },
                            {
                                "id": "hemonc:569",
                                "type": "DiseaseDescriptor",
                                "label": "Bladder cancer",
                                "disease": "ncit:C9334"
                            },
                            {
                                "id": "hemonc:645",
                                "type": "DiseaseDescriptor",
                                "label": "Ovarian cancer",
                                "disease": "ncit:C7431"
                            }
                        ]
                    }
                }
            ],
            "xrefs": [
                "ncit:C456"
            ],
            "alternate_labels": [
                "(8S-cis)-10-[(3-Amino-2,3,6-trideoxy-alpha-L-lyxo-hexopyranosyl)oxy]-7,8,9,10-tetrahydro-6,8,11-trihydroxy-8-(hydroacetyl)-1-methoxy-5,12-naphthacenedione",
                "(8S-cis)-10-[(3-Amino-2,3,6-trideoxy-alpha-L-lyxo-hexopyranosyl)oxy]-7,8,9,10-tetrahydro-6,8,11-trihydroxy-8-(hydroxyacetyl)-1-methoxy-5,12-naphthacenedione",
                "14-Hydroxydaunomycin",
                "Adriablastin",
                "Hydroxydaunomycin",
                "Hydroxyl Daunorubicin",
                "Hydroxyldaunorubicin"
            ],
            "therapeutic": "rxcui:142433"
        }
    },
    {
        "id": "civic.eid:2840",
        "type": "VariationNeoplasmTherapeuticResponseStatement",
        "description": "Primary peripheral blood mononuclear cells were taken from chronic lymphocytic leukemia patients, some of whom had prior therapy. The effect of the L2427P variant on ATM expression was tested by western blot, and the effect on ATM function was tested by treating with doxorubicin to induce double-strand breaks (DSB) and monitoring p21 induction. To confirm wild type p53, parallel cell cultures were treated with fludarabine generating single-strand breaks, in addition to DSB, and monitored for adequate p21 induction. A patient sample had the L2427P variant of ATM, confirmed by sanger sequencing, in trans with a loss of function 11q deletion found in 94% of cells by FISH. Western blot showed stable ATM expression. Treatment with doxorubicin resulted in a p21 expression level of less than 300% that of untreated wild-type controls. This was much lower than the median expression level of treated controls which was 815% that of untreated controls, supporting resistance.",
        "method": "metakb.method:1",
        "is_reported_in": [
            {
                "id": "civic.source:1541",
                "type": "Document",
                "label": "Navrkalova et al., 2013, Haematologica",
                "xrefs": [
                    "pmc:PMC3696617",
                    "pmid:23585524"
                ],
                "title": "ATM mutations uniformly lead to ATM dysfunction in chronic lymphocytic leukemia: application of functional test using doxorubicin."
            }
        ],
        "evidence_level": {
            "id": "vicc:e00009",
            "type": "Coding",
            "label": "preclinical evidence"
        },
        "target_proposition": {
            "id": "proposition:e3Xi6bjhOveF7nk7QJE1VyZketcJcTIW",
            "type": "VariationNeoplasmTherapeuticResponseProposition",
            "subject": "ga4gh:VA.-_I6gBvaWqmpoQiy7JOPcnb8W_1Qg2qt",
            "predicate": "predicts_resistance_to",
            "object": {
                "id": "rxcui:142433",
                "type": "Therapeutic"
            },
            "neoplasm_type_qualifier": {
                "id": "ncit:C3163",
                "type": "Disease"
            }
        },
        "direction": "supports",
        "subject_descriptor": "civic.vid:1163",
        "neoplasm_type_descriptor": {
            "id": "civic.did:52",
            "type": "DiseaseDescriptor",
            "label": "Chronic Lymphocytic Leukemia",
            "xrefs": [
                "DOID:1040"
            ],
            "disease": "ncit:C3163"
        },
        "object_descriptor": {
            "id": "civic.tid:68",
            "type": "TherapeuticDescriptor",
            "label": "Doxorubicin",
            "extensions": [
                {
                    "type": "Extension",
                    "name": "regulatory_approval",
                    "value": {
                        "approval_rating": "FDA",
                        "has_indications": [
                            {
                                "id": "hemonc:666",
                                "type": "DiseaseDescriptor",
                                "label": "Small cell lung cancer",
                                "disease": "ncit:C4917"
                            },
                            {
                                "id": "hemonc:667",
                                "type": "DiseaseDescriptor",
                                "label": "Soft tissue sarcoma",
                                "disease": "ncit:C9306"
                            },
                            {
                                "id": "hemonc:614",
                                "type": "DiseaseDescriptor",
                                "label": "Hodgkin lymphoma",
                                "disease": "ncit:C9357"
                            },
                            {
                                "id": "hemonc:572",
                                "type": "DiseaseDescriptor",
                                "label": "Breast cancer",
                                "disease": "ncit:C9335"
                            },
                            {
                                "id": "hemonc:601",
                                "type": "DiseaseDescriptor",
                                "label": "Gastric cancer",
                                "disease": "ncit:C9331"
                            },
                            {
                                "id": "hemonc:675",
                                "type": "DiseaseDescriptor",
                                "label": "Thyroid cancer",
                                "disease": "ncit:C7510"
                            },
                            {
                                "id": "hemonc:552",
                                "type": "DiseaseDescriptor",
                                "label": "Acute myeloid leukemia",
                                "disease": "ncit:C3171"
                            },
                            {
                                "id": "hemonc:569",
                                "type": "DiseaseDescriptor",
                                "label": "Bladder cancer",
                                "disease": "ncit:C9334"
                            },
                            {
                                "id": "hemonc:645",
                                "type": "DiseaseDescriptor",
                                "label": "Ovarian cancer",
                                "disease": "ncit:C7431"
                            }
                        ]
                    }
                }
            ],
            "xrefs": [
                "ncit:C456"
            ],
            "alternate_labels": [
                "(8S-cis)-10-[(3-Amino-2,3,6-trideoxy-alpha-L-lyxo-hexopyranosyl)oxy]-7,8,9,10-tetrahydro-6,8,11-trihydroxy-8-(hydroacetyl)-1-methoxy-5,12-naphthacenedione",
                "(8S-cis)-10-[(3-Amino-2,3,6-trideoxy-alpha-L-lyxo-hexopyranosyl)oxy]-7,8,9,10-tetrahydro-6,8,11-trihydroxy-8-(hydroxyacetyl)-1-methoxy-5,12-naphthacenedione",
                "14-Hydroxydaunomycin",
                "Adriablastin",
                "Hydroxydaunomycin",
                "Hydroxyl Daunorubicin",
                "Hydroxyldaunorubicin"
            ],
            "therapeutic": "rxcui:142433"
        }
    },
    {
        "id": "civic.eid:2841",
        "type": "VariationNeoplasmTherapeuticResponseStatement",
        "description": "Primary peripheral blood mononuclear cells were taken from chronic lymphocytic leukemia patients, some of whom had prior therapy. The effect of the F2732V variant on ATM expression was tested by western blot, and the effect on ATM function was tested by treating with doxorubicin to induce double-strand breaks (DSB) and monitoring p21 induction. To confirm wild type p53, parallel cell cultures were treated with fludarabine generating single-strand breaks, in addition to DSB, and monitored for adequate p21 induction. A patient sample had the F2732V variant of ATM, confirmed by sanger sequencing, in trans with a loss of function 11q deletion found in 98% of cells by FISH. Western blot showed stable ATM expression. Treatment with doxorubicin resulted in a p21 expression level of less than 300% that of untreated wild-type controls. This was much lower than the median expression level of treated controls which was 815% that of untreated controls, supporting resistance.",
        "method": "metakb.method:1",
        "is_reported_in": [
            {
                "id": "civic.source:1541",
                "type": "Document",
                "label": "Navrkalova et al., 2013, Haematologica",
                "xrefs": [
                    "pmc:PMC3696617",
                    "pmid:23585524"
                ],
                "title": "ATM mutations uniformly lead to ATM dysfunction in chronic lymphocytic leukemia: application of functional test using doxorubicin."
            }
        ],
        "evidence_level": {
            "id": "vicc:e00009",
            "type": "Coding",
            "label": "preclinical evidence"
        },
        "target_proposition": {
            "id": "proposition:dH0Gfr691SaSZlmMroj6AbFk8I25fp3V",
            "type": "VariationNeoplasmTherapeuticResponseProposition",
            "subject": "ga4gh:VA.vhBZUX844n7cC8W0Sx71rTBMSiW_BvQ3",
            "predicate": "predicts_resistance_to",
            "object": {
                "id": "rxcui:142433",
                "type": "Therapeutic"
            },
            "neoplasm_type_qualifier": {
                "id": "ncit:C3163",
                "type": "Disease"
            }
        },
        "direction": "supports",
        "subject_descriptor": "civic.vid:1164",
        "neoplasm_type_descriptor": {
            "id": "civic.did:52",
            "type": "DiseaseDescriptor",
            "label": "Chronic Lymphocytic Leukemia",
            "xrefs": [
                "DOID:1040"
            ],
            "disease": "ncit:C3163"
        },
        "object_descriptor": {
            "id": "civic.tid:68",
            "type": "TherapeuticDescriptor",
            "label": "Doxorubicin",
            "extensions": [
                {
                    "type": "Extension",
                    "name": "regulatory_approval",
                    "value": {
                        "approval_rating": "FDA",
                        "has_indications": [
                            {
                                "id": "hemonc:666",
                                "type": "DiseaseDescriptor",
                                "label": "Small cell lung cancer",
                                "disease": "ncit:C4917"
                            },
                            {
                                "id": "hemonc:667",
                                "type": "DiseaseDescriptor",
                                "label": "Soft tissue sarcoma",
                                "disease": "ncit:C9306"
                            },
                            {
                                "id": "hemonc:614",
                                "type": "DiseaseDescriptor",
                                "label": "Hodgkin lymphoma",
                                "disease": "ncit:C9357"
                            },
                            {
                                "id": "hemonc:572",
                                "type": "DiseaseDescriptor",
                                "label": "Breast cancer",
                                "disease": "ncit:C9335"
                            },
                            {
                                "id": "hemonc:601",
                                "type": "DiseaseDescriptor",
                                "label": "Gastric cancer",
                                "disease": "ncit:C9331"
                            },
                            {
                                "id": "hemonc:675",
                                "type": "DiseaseDescriptor",
                                "label": "Thyroid cancer",
                                "disease": "ncit:C7510"
                            },
                            {
                                "id": "hemonc:552",
                                "type": "DiseaseDescriptor",
                                "label": "Acute myeloid leukemia",
                                "disease": "ncit:C3171"
                            },
                            {
                                "id": "hemonc:569",
                                "type": "DiseaseDescriptor",
                                "label": "Bladder cancer",
                                "disease": "ncit:C9334"
                            },
                            {
                                "id": "hemonc:645",
                                "type": "DiseaseDescriptor",
                                "label": "Ovarian cancer",
                                "disease": "ncit:C7431"
                            }
                        ]
                    }
                }
            ],
            "xrefs": [
                "ncit:C456"
            ],
            "alternate_labels": [
                "(8S-cis)-10-[(3-Amino-2,3,6-trideoxy-alpha-L-lyxo-hexopyranosyl)oxy]-7,8,9,10-tetrahydro-6,8,11-trihydroxy-8-(hydroacetyl)-1-methoxy-5,12-naphthacenedione",
                "(8S-cis)-10-[(3-Amino-2,3,6-trideoxy-alpha-L-lyxo-hexopyranosyl)oxy]-7,8,9,10-tetrahydro-6,8,11-trihydroxy-8-(hydroxyacetyl)-1-methoxy-5,12-naphthacenedione",
                "14-Hydroxydaunomycin",
                "Adriablastin",
                "Hydroxydaunomycin",
                "Hydroxyl Daunorubicin",
                "Hydroxyldaunorubicin"
            ],
            "therapeutic": "rxcui:142433"
        }
    },
    {
        "id": "civic.eid:2845",
        "type": "VariationNeoplasmTherapeuticResponseStatement",
        "description": "Primary peripheral blood mononuclear cells were taken from chronic lymphocytic leukemia patients, some of whom had prior therapy. The effect of the D1682H variant on ATM expression was tested by western blot, and the effect on ATM function was tested by treating with doxorubicin to induce double-strand breaks (DSB) and monitoring p21 induction. To confirm wild type p53, parallel cell cultures were treated with fludarabine generating single-strand breaks, in addition to DSB, and monitored for adequate p21 induction. A patient sample had the D1682H variant of ATM, confirmed by sanger sequencing, in trans with a loss of function 11q deletion found in 93% of cells by FISH. Western blot showed stable ATM expression. Treatment with doxorubicin resulted in a p21 expression level of less than 300% that of untreated wild-type controls. This was much lower than the median expression level of treated controls which was 815% that of untreated controls, supporting resistance.",
        "method": "metakb.method:1",
        "is_reported_in": [
            {
                "id": "civic.source:1541",
                "type": "Document",
                "label": "Navrkalova et al., 2013, Haematologica",
                "xrefs": [
                    "pmc:PMC3696617",
                    "pmid:23585524"
                ],
                "title": "ATM mutations uniformly lead to ATM dysfunction in chronic lymphocytic leukemia: application of functional test using doxorubicin."
            }
        ],
        "evidence_level": {
            "id": "vicc:e00009",
            "type": "Coding",
            "label": "preclinical evidence"
        },
        "target_proposition": {
            "id": "proposition:qL5Bj4bPc_0c0BPm5ovVAr44VftRlJk5",
            "type": "VariationNeoplasmTherapeuticResponseProposition",
            "subject": "ga4gh:VA.R5WWfv7CUYjx7LyTJVkrCQR7gjEWGcnU",
            "predicate": "predicts_resistance_to",
            "object": {
                "id": "rxcui:142433",
                "type": "Therapeutic"
            },
            "neoplasm_type_qualifier": {
                "id": "ncit:C3163",
                "type": "Disease"
            }
        },
        "direction": "supports",
        "subject_descriptor": "civic.vid:1168",
        "neoplasm_type_descriptor": {
            "id": "civic.did:52",
            "type": "DiseaseDescriptor",
            "label": "Chronic Lymphocytic Leukemia",
            "xrefs": [
                "DOID:1040"
            ],
            "disease": "ncit:C3163"
        },
        "object_descriptor": {
            "id": "civic.tid:68",
            "type": "TherapeuticDescriptor",
            "label": "Doxorubicin",
            "extensions": [
                {
                    "type": "Extension",
                    "name": "regulatory_approval",
                    "value": {
                        "approval_rating": "FDA",
                        "has_indications": [
                            {
                                "id": "hemonc:666",
                                "type": "DiseaseDescriptor",
                                "label": "Small cell lung cancer",
                                "disease": "ncit:C4917"
                            },
                            {
                                "id": "hemonc:667",
                                "type": "DiseaseDescriptor",
                                "label": "Soft tissue sarcoma",
                                "disease": "ncit:C9306"
                            },
                            {
                                "id": "hemonc:614",
                                "type": "DiseaseDescriptor",
                                "label": "Hodgkin lymphoma",
                                "disease": "ncit:C9357"
                            },
                            {
                                "id": "hemonc:572",
                                "type": "DiseaseDescriptor",
                                "label": "Breast cancer",
                                "disease": "ncit:C9335"
                            },
                            {
                                "id": "hemonc:601",
                                "type": "DiseaseDescriptor",
                                "label": "Gastric cancer",
                                "disease": "ncit:C9331"
                            },
                            {
                                "id": "hemonc:675",
                                "type": "DiseaseDescriptor",
                                "label": "Thyroid cancer",
                                "disease": "ncit:C7510"
                            },
                            {
                                "id": "hemonc:552",
                                "type": "DiseaseDescriptor",
                                "label": "Acute myeloid leukemia",
                                "disease": "ncit:C3171"
                            },
                            {
                                "id": "hemonc:569",
                                "type": "DiseaseDescriptor",
                                "label": "Bladder cancer",
                                "disease": "ncit:C9334"
                            },
                            {
                                "id": "hemonc:645",
                                "type": "DiseaseDescriptor",
                                "label": "Ovarian cancer",
                                "disease": "ncit:C7431"
                            }
                        ]
                    }
                }
            ],
            "xrefs": [
                "ncit:C456"
            ],
            "alternate_labels": [
                "(8S-cis)-10-[(3-Amino-2,3,6-trideoxy-alpha-L-lyxo-hexopyranosyl)oxy]-7,8,9,10-tetrahydro-6,8,11-trihydroxy-8-(hydroacetyl)-1-methoxy-5,12-naphthacenedione",
                "(8S-cis)-10-[(3-Amino-2,3,6-trideoxy-alpha-L-lyxo-hexopyranosyl)oxy]-7,8,9,10-tetrahydro-6,8,11-trihydroxy-8-(hydroxyacetyl)-1-methoxy-5,12-naphthacenedione",
                "14-Hydroxydaunomycin",
                "Adriablastin",
                "Hydroxydaunomycin",
                "Hydroxyl Daunorubicin",
                "Hydroxyldaunorubicin"
            ],
            "therapeutic": "rxcui:142433"
        }
    },
    {
        "id": "civic.eid:2846",
        "type": "VariationNeoplasmTherapeuticResponseStatement",
        "description": "Primary peripheral blood mononuclear cells were taken from chronic lymphocytic leukemia patients, some of whom had prior therapy. The effect of the A2062V variant on ATM expression was tested by western blot, and the effect on ATM function was tested by treating with doxorubicin to induce double-strand breaks (DSB) and monitoring p21 induction. To confirm wild type p53, parallel cell cultures were treated with fludarabine generating single-strand breaks, in addition to DSB, and monitored for adequate p21 induction. A patient sample had the A2062V variant of ATM, confirmed by sanger sequencing, in trans with a loss of function 11q deletion found in 87% of cells by FISH. Western blot showed stable ATM expression. Treatment with doxorubicin resulted in a p21 expression level of less than 300% that of untreated wild-type controls. This was much lower than the median expression level of treated controls which was 815% that of untreated controls, supporting resistance.",
        "method": "metakb.method:1",
        "is_reported_in": [
            {
                "id": "civic.source:1541",
                "type": "Document",
                "label": "Navrkalova et al., 2013, Haematologica",
                "xrefs": [
                    "pmc:PMC3696617",
                    "pmid:23585524"
                ],
                "title": "ATM mutations uniformly lead to ATM dysfunction in chronic lymphocytic leukemia: application of functional test using doxorubicin."
            }
        ],
        "evidence_level": {
            "id": "vicc:e00009",
            "type": "Coding",
            "label": "preclinical evidence"
        },
        "target_proposition": {
            "id": "proposition:O3HfL85BIqonVo6c_LPE0Dk2H0Y7OHiH",
            "type": "VariationNeoplasmTherapeuticResponseProposition",
            "subject": "ga4gh:VA.ylGgZvYUv6RQT8ODt_vMdmHz7Hk_qySB",
            "predicate": "predicts_resistance_to",
            "object": {
                "id": "rxcui:142433",
                "type": "Therapeutic"
            },
            "neoplasm_type_qualifier": {
                "id": "ncit:C3163",
                "type": "Disease"
            }
        },
        "direction": "supports",
        "subject_descriptor": "civic.vid:1169",
        "neoplasm_type_descriptor": {
            "id": "civic.did:52",
            "type": "DiseaseDescriptor",
            "label": "Chronic Lymphocytic Leukemia",
            "xrefs": [
                "DOID:1040"
            ],
            "disease": "ncit:C3163"
        },
        "object_descriptor": {
            "id": "civic.tid:68",
            "type": "TherapeuticDescriptor",
            "label": "Doxorubicin",
            "extensions": [
                {
                    "type": "Extension",
                    "name": "regulatory_approval",
                    "value": {
                        "approval_rating": "FDA",
                        "has_indications": [
                            {
                                "id": "hemonc:666",
                                "type": "DiseaseDescriptor",
                                "label": "Small cell lung cancer",
                                "disease": "ncit:C4917"
                            },
                            {
                                "id": "hemonc:667",
                                "type": "DiseaseDescriptor",
                                "label": "Soft tissue sarcoma",
                                "disease": "ncit:C9306"
                            },
                            {
                                "id": "hemonc:614",
                                "type": "DiseaseDescriptor",
                                "label": "Hodgkin lymphoma",
                                "disease": "ncit:C9357"
                            },
                            {
                                "id": "hemonc:572",
                                "type": "DiseaseDescriptor",
                                "label": "Breast cancer",
                                "disease": "ncit:C9335"
                            },
                            {
                                "id": "hemonc:601",
                                "type": "DiseaseDescriptor",
                                "label": "Gastric cancer",
                                "disease": "ncit:C9331"
                            },
                            {
                                "id": "hemonc:675",
                                "type": "DiseaseDescriptor",
                                "label": "Thyroid cancer",
                                "disease": "ncit:C7510"
                            },
                            {
                                "id": "hemonc:552",
                                "type": "DiseaseDescriptor",
                                "label": "Acute myeloid leukemia",
                                "disease": "ncit:C3171"
                            },
                            {
                                "id": "hemonc:569",
                                "type": "DiseaseDescriptor",
                                "label": "Bladder cancer",
                                "disease": "ncit:C9334"
                            },
                            {
                                "id": "hemonc:645",
                                "type": "DiseaseDescriptor",
                                "label": "Ovarian cancer",
                                "disease": "ncit:C7431"
                            }
                        ]
                    }
                }
            ],
            "xrefs": [
                "ncit:C456"
            ],
            "alternate_labels": [
                "(8S-cis)-10-[(3-Amino-2,3,6-trideoxy-alpha-L-lyxo-hexopyranosyl)oxy]-7,8,9,10-tetrahydro-6,8,11-trihydroxy-8-(hydroacetyl)-1-methoxy-5,12-naphthacenedione",
                "(8S-cis)-10-[(3-Amino-2,3,6-trideoxy-alpha-L-lyxo-hexopyranosyl)oxy]-7,8,9,10-tetrahydro-6,8,11-trihydroxy-8-(hydroxyacetyl)-1-methoxy-5,12-naphthacenedione",
                "14-Hydroxydaunomycin",
                "Adriablastin",
                "Hydroxydaunomycin",
                "Hydroxyl Daunorubicin",
                "Hydroxyldaunorubicin"
            ],
            "therapeutic": "rxcui:142433"
        }
    },
    {
        "id": "civic.eid:2849",
        "type": "VariationNeoplasmTherapeuticResponseStatement",
        "description": "Primary peripheral blood mononuclear cells were taken from chronic lymphocytic leukemia patients, some of whom had prior therapy. The effect of the C2488Y variant on ATM expression was tested by western blot, and the effect on ATM function was tested by treating with doxorubicin to induce double-strand breaks (DSB) and monitoring p21 induction. To confirm wild type p53, parallel cell cultures were treated with fludarabine generating single-strand breaks, in addition to DSB, and monitored for adequate p21 induction. A patient sample had the C2488Y variant of ATM, confirmed by sanger sequencing, in trans with a loss of function 11q deletion found in 90% of cells by FISH. Western blot showed stable ATM expression. Treatment with doxorubicin resulted in a p21 expression level of less than 300% that of untreated wild-type controls. This was much lower than the median expression level of treated controls which was 815% that of untreated controls, supporting resistance.",
        "method": "metakb.method:1",
        "is_reported_in": [
            {
                "id": "civic.source:1541",
                "type": "Document",
                "label": "Navrkalova et al., 2013, Haematologica",
                "xrefs": [
                    "pmc:PMC3696617",
                    "pmid:23585524"
                ],
                "title": "ATM mutations uniformly lead to ATM dysfunction in chronic lymphocytic leukemia: application of functional test using doxorubicin."
            }
        ],
        "evidence_level": {
            "id": "vicc:e00009",
            "type": "Coding",
            "label": "preclinical evidence"
        },
        "target_proposition": {
            "id": "proposition:OdoIzvtqD0vTJwVdNdhkAcHz1SVo9x4a",
            "type": "VariationNeoplasmTherapeuticResponseProposition",
            "subject": "ga4gh:VA.zRieVFQoxthGnTV-n5M7mbnxDXMoULBH",
            "predicate": "predicts_resistance_to",
            "object": {
                "id": "rxcui:142433",
                "type": "Therapeutic"
            },
            "neoplasm_type_qualifier": {
                "id": "ncit:C3163",
                "type": "Disease"
            }
        },
        "direction": "supports",
        "subject_descriptor": "civic.vid:1172",
        "neoplasm_type_descriptor": {
            "id": "civic.did:52",
            "type": "DiseaseDescriptor",
            "label": "Chronic Lymphocytic Leukemia",
            "xrefs": [
                "DOID:1040"
            ],
            "disease": "ncit:C3163"
        },
        "object_descriptor": {
            "id": "civic.tid:68",
            "type": "TherapeuticDescriptor",
            "label": "Doxorubicin",
            "extensions": [
                {
                    "type": "Extension",
                    "name": "regulatory_approval",
                    "value": {
                        "approval_rating": "FDA",
                        "has_indications": [
                            {
                                "id": "hemonc:666",
                                "type": "DiseaseDescriptor",
                                "label": "Small cell lung cancer",
                                "disease": "ncit:C4917"
                            },
                            {
                                "id": "hemonc:667",
                                "type": "DiseaseDescriptor",
                                "label": "Soft tissue sarcoma",
                                "disease": "ncit:C9306"
                            },
                            {
                                "id": "hemonc:614",
                                "type": "DiseaseDescriptor",
                                "label": "Hodgkin lymphoma",
                                "disease": "ncit:C9357"
                            },
                            {
                                "id": "hemonc:572",
                                "type": "DiseaseDescriptor",
                                "label": "Breast cancer",
                                "disease": "ncit:C9335"
                            },
                            {
                                "id": "hemonc:601",
                                "type": "DiseaseDescriptor",
                                "label": "Gastric cancer",
                                "disease": "ncit:C9331"
                            },
                            {
                                "id": "hemonc:675",
                                "type": "DiseaseDescriptor",
                                "label": "Thyroid cancer",
                                "disease": "ncit:C7510"
                            },
                            {
                                "id": "hemonc:552",
                                "type": "DiseaseDescriptor",
                                "label": "Acute myeloid leukemia",
                                "disease": "ncit:C3171"
                            },
                            {
                                "id": "hemonc:569",
                                "type": "DiseaseDescriptor",
                                "label": "Bladder cancer",
                                "disease": "ncit:C9334"
                            },
                            {
                                "id": "hemonc:645",
                                "type": "DiseaseDescriptor",
                                "label": "Ovarian cancer",
                                "disease": "ncit:C7431"
                            }
                        ]
                    }
                }
            ],
            "xrefs": [
                "ncit:C456"
            ],
            "alternate_labels": [
                "(8S-cis)-10-[(3-Amino-2,3,6-trideoxy-alpha-L-lyxo-hexopyranosyl)oxy]-7,8,9,10-tetrahydro-6,8,11-trihydroxy-8-(hydroacetyl)-1-methoxy-5,12-naphthacenedione",
                "(8S-cis)-10-[(3-Amino-2,3,6-trideoxy-alpha-L-lyxo-hexopyranosyl)oxy]-7,8,9,10-tetrahydro-6,8,11-trihydroxy-8-(hydroxyacetyl)-1-methoxy-5,12-naphthacenedione",
                "14-Hydroxydaunomycin",
                "Adriablastin",
                "Hydroxydaunomycin",
                "Hydroxyl Daunorubicin",
                "Hydroxyldaunorubicin"
            ],
            "therapeutic": "rxcui:142433"
        }
    },
    {
        "id": "civic.eid:2866",
        "type": "VariationNeoplasmTherapeuticResponseStatement",
        "description": "As part of a pre-clinical experiment, the efficacy of ado-trastuzumab emtansine (T-DM1) was evaluated against various HER2 positive cell lines. BT-474 cell line expressing PIK3CA K111N was associated with similar sensitivity to T-DM1 as PIK3CA wild-type cell line SK-BR-3; reduced cell viability was observed at concentrations > 0.01 ug/mL in both cell lines. Conversely, when treated with trastuzumab, the cell line harboring PIK3CA K111N experienced a smaller reduction in cell viability. Further, treatment with T-DM1 on SCID mice xenografted with PIK3CA K111N cells resulted in inhibition of tumor growth. A single dose of T-DM1 >5mg/kg was sufficient to induce tumor regression >20 days after administration.",
        "method": "metakb.method:1",
        "is_reported_in": [
            {
                "id": "civic.source:1468",
                "type": "Document",
                "label": "Baselga et al., 2016, Clin. Cancer Res.",
                "xrefs": [
                    "pmid:26920887"
                ],
                "title": "Relationship between Tumor Biomarkers and Efficacy in EMILIA, a Phase III Study of Trastuzumab Emtansine in HER2-Positive Metastatic Breast Cancer."
            }
        ],
        "evidence_level": {
            "id": "vicc:e00009",
            "type": "Coding",
            "label": "preclinical evidence"
        },
        "target_proposition": {
            "id": "proposition:SoGfcMqPfbkxZcBrcnPV37RfdDiuE8Ag",
            "type": "VariationNeoplasmTherapeuticResponseProposition",
            "subject": "ga4gh:VA.MwhPgqLyRggo95FGBET65hs3Dbmm0jW1",
            "predicate": "predicts_resistance_to",
            "object": {
                "id": "rxcui:1371041",
                "type": "Therapeutic"
            },
            "neoplasm_type_qualifier": {
                "id": "ncit:C53556",
                "type": "Disease"
            }
        },
        "direction": "opposes",
        "subject_descriptor": "civic.vid:1234",
        "neoplasm_type_descriptor": {
            "id": "civic.did:368",
            "type": "DiseaseDescriptor",
            "label": "Her2-receptor Positive Breast Cancer",
            "xrefs": [
                "DOID:60079"
            ],
            "disease": "ncit:C53556"
        },
        "object_descriptor": {
            "id": "civic.tid:457",
            "type": "TherapeuticDescriptor",
            "label": "Trastuzumab Emtansine",
            "xrefs": [
                "ncit:C82492"
            ],
            "alternate_labels": [
                "ADO-TRASTUZUMAB EMTANSINE",
                "Ado Trastuzumab Emtansine",
                "Immunoglobulin G1, Anti-(Human P185neu Receptor) (Human-Mouse Monoclonal RhuMab HER2 Gamma1-Chain), Disulfide With Human-Mouse Monoclonal RhuMab HER2 Light Chain, Dimer, Tetraamide With N2'-(3-((1-((4-carboxycyclohexyl)methyl)-2,5-dioxo-3-pyrrolidinyl)thio)-1-oxopropyl)-N2'-deacetylMaytansine",
                "Kadcyla",
                "PRO132365",
                "RO5304020",
                "T-DM1",
                "Trastuzumab-DM1",
                "Trastuzumab-MCC-DM1",
                "Trastuzumab-MCC-DM1 Antibody-Drug Conjugate",
                "Trastuzumab-MCC-DM1 Immunoconjugate"
            ],
            "therapeutic": "rxcui:1371041"
        }
    },
    {
        "id": "civic.eid:2867",
        "type": "VariationNeoplasmTherapeuticResponseStatement",
        "description": "As part of a pre-clinical experiment, the efficacy of ado-trastuzumab emtansine (T-DM1) was evaluated against various HER2 positive cell lines. ZR-75-30 cell line expressing PIK3CA I391M was associated with similar sensitivity to T-DM1 as PIK3CA wild-type cell line SK-BR-3; reduced cell viability was observed at concentrations > 0.01 ug/mL in both cell lines. When treated with trastuzumab, the cell line harboring PIK3CA I391M experienced similar reduction in cell viability.",
        "method": "metakb.method:1",
        "is_reported_in": [
            {
                "id": "civic.source:1468",
                "type": "Document",
                "label": "Baselga et al., 2016, Clin. Cancer Res.",
                "xrefs": [
                    "pmid:26920887"
                ],
                "title": "Relationship between Tumor Biomarkers and Efficacy in EMILIA, a Phase III Study of Trastuzumab Emtansine in HER2-Positive Metastatic Breast Cancer."
            }
        ],
        "evidence_level": {
            "id": "vicc:e00009",
            "type": "Coding",
            "label": "preclinical evidence"
        },
        "target_proposition": {
            "id": "proposition:4kYFluiWAcz4s14H4QP9g6sqwppE1Bxx",
            "type": "VariationNeoplasmTherapeuticResponseProposition",
            "subject": "ga4gh:VA.85QZR4K49RijmSG0hPIy9BQRNQBKuFgj",
            "predicate": "predicts_resistance_to",
            "object": {
                "id": "rxcui:1371041",
                "type": "Therapeutic"
            },
            "neoplasm_type_qualifier": {
                "id": "ncit:C53556",
                "type": "Disease"
            }
        },
        "direction": "opposes",
        "subject_descriptor": "civic.vid:1235",
        "neoplasm_type_descriptor": {
            "id": "civic.did:368",
            "type": "DiseaseDescriptor",
            "label": "Her2-receptor Positive Breast Cancer",
            "xrefs": [
                "DOID:60079"
            ],
            "disease": "ncit:C53556"
        },
        "object_descriptor": {
            "id": "civic.tid:457",
            "type": "TherapeuticDescriptor",
            "label": "Trastuzumab Emtansine",
            "xrefs": [
                "ncit:C82492"
            ],
            "alternate_labels": [
                "ADO-TRASTUZUMAB EMTANSINE",
                "Ado Trastuzumab Emtansine",
                "Immunoglobulin G1, Anti-(Human P185neu Receptor) (Human-Mouse Monoclonal RhuMab HER2 Gamma1-Chain), Disulfide With Human-Mouse Monoclonal RhuMab HER2 Light Chain, Dimer, Tetraamide With N2'-(3-((1-((4-carboxycyclohexyl)methyl)-2,5-dioxo-3-pyrrolidinyl)thio)-1-oxopropyl)-N2'-deacetylMaytansine",
                "Kadcyla",
                "PRO132365",
                "RO5304020",
                "T-DM1",
                "Trastuzumab-DM1",
                "Trastuzumab-MCC-DM1",
                "Trastuzumab-MCC-DM1 Antibody-Drug Conjugate",
                "Trastuzumab-MCC-DM1 Immunoconjugate"
            ],
            "therapeutic": "rxcui:1371041"
        }
    },
    {
        "id": "civic.eid:2943",
        "type": "VariationNeoplasmTherapeuticResponseStatement",
        "description": "Preclinical data supporting resistance of Exon 4 mutations, in particular A146T, to cetuximab and sensitivity to PD0325901. This study involved treatment of mice bearing A146T KRAS xenografts treated with PD0325901 or cetuximab.",
        "method": "metakb.method:1",
        "is_reported_in": [
            {
                "id": "civic.source:1632",
                "type": "Document",
                "label": "Janakiraman et al., 2010, Cancer Res.",
                "xrefs": [
                    "pmc:PMC2943514",
                    "pmid:20570890"
                ],
                "title": "Genomic and biological characterization of exon 4 KRAS mutations in human cancer."
            }
        ],
        "evidence_level": {
            "id": "vicc:e00009",
            "type": "Coding",
            "label": "preclinical evidence"
        },
        "target_proposition": {
            "id": "proposition:RDjRbb67fdvGyULrd0ygmwcjxdgUi3Av",
            "type": "VariationNeoplasmTherapeuticResponseProposition",
            "subject": "ga4gh:VA.3uCfDUOYdVAjM2BG0xyWDioC6fPY1yn4",
            "predicate": "predicts_resistance_to",
            "object": {
                "id": "rxcui:318341",
                "type": "Therapeutic"
            },
            "neoplasm_type_qualifier": {
                "id": "ncit:C4978",
                "type": "Disease"
            }
        },
        "direction": "supports",
        "subject_descriptor": "civic.vid:906",
        "neoplasm_type_descriptor": {
            "id": "civic.did:11",
            "type": "DiseaseDescriptor",
            "label": "Colorectal Cancer",
            "xrefs": [
                "DOID:9256"
            ],
            "disease": "ncit:C4978"
        },
        "object_descriptor": {
            "id": "civic.tid:16",
            "type": "TherapeuticDescriptor",
            "label": "Cetuximab",
            "extensions": [
                {
                    "type": "Extension",
                    "name": "regulatory_approval",
                    "value": {
                        "approval_rating": "ChEMBL",
                        "has_indications": [
                            {
                                "id": "mesh:D002294",
                                "type": "DiseaseDescriptor",
                                "label": "Carcinoma, Squamous Cell",
                                "disease": "ncit:C2929"
                            },
                            {
                                "id": "mesh:D009369",
                                "type": "DiseaseDescriptor",
                                "label": "Neoplasms",
                                "disease": "ncit:C3262"
                            },
                            {
                                "id": "mesh:D015179",
                                "type": "DiseaseDescriptor",
                                "label": "Colorectal Neoplasms",
                                "disease": "ncit:C2956"
                            },
                            {
                                "id": "mesh:D006258",
                                "type": "DiseaseDescriptor",
                                "label": "Head and Neck Neoplasms",
                                "disease": "ncit:C4013"
                            }
                        ]
                    }
                }
            ],
            "xrefs": [
                "ncit:C1723"
            ],
            "alternate_labels": [
                "Cetuximab Biosimilar CDP-1",
                "Cetuximab Biosimilar CMAB009",
                "Cetuximab Biosimilar KL 140",
                "Chimeric Anti-EGFR Monoclonal Antibody",
                "Chimeric MoAb C225",
                "Chimeric Monoclonal Antibody C225",
                "Erbitux",
                "IMC-C225"
            ],
            "therapeutic": "rxcui:318341"
        }
    },
    {
        "id": "civic.eid:2985",
        "type": "VariationNeoplasmTherapeuticResponseStatement",
        "description": "Authors tested various cervical cancer cell lines (CaSki, SiHa and HeLa) for their responses to cisplatin, radiation therapy, and GDC-0941. CaSki cells that are heterozygous for the PIK3CA-E545K mutation were significantly more resistant to cisplatin or cisplatin plus radiation than either HeLa or SiHa cells that express only wild-type PIK3CA. Similarly, HeLa cells engineered to stably express PIK3CA E545K were more resistant to cisplatin or cisplatin plus radiation than cells expressing only wild-type PIK3CA or with PIK3CA depleted. Cells expressing the PIK3CA-E545K mutation also had constitutive PI3K pathway activation and increased cellular migration and each of these phenotypes was reversed by treatment with the PI3K inhibitor GDC-0941 (pictilisib).",
        "method": "metakb.method:1",
        "is_reported_in": [
            {
                "id": "civic.source:1708",
                "type": "Document",
                "label": "Arjumand et al., 2016, Oncotarget",
                "xrefs": [
                    "pmc:PMC5347702",
                    "pmid:27489350"
                ],
                "title": "Phosphatidyl inositol-3 kinase (PIK3CA) E545K mutation confers cisplatin resistance and a migratory phenotype in cervical cancer cells."
            }
        ],
        "evidence_level": {
            "id": "vicc:e00009",
            "type": "Coding",
            "label": "preclinical evidence"
        },
        "target_proposition": {
            "id": "proposition:5bojufpOoUGtRGfz0eIocSetw-fvXiou",
            "type": "VariationNeoplasmTherapeuticResponseProposition",
            "subject": "ga4gh:VA.5zBiXnk0ZRCfFqRnK0fQHQwAGBWW4JE8",
            "predicate": "predicts_resistance_to",
            "object": {
                "id": "rxcui:2555",
                "type": "Therapeutic"
            },
            "neoplasm_type_qualifier": {
                "id": "ncit:C9311",
                "type": "Disease"
            }
        },
        "direction": "supports",
        "subject_descriptor": "civic.vid:104",
        "neoplasm_type_descriptor": {
            "id": "civic.did:159",
            "type": "DiseaseDescriptor",
            "label": "Cervical Cancer",
            "xrefs": [
                "DOID:4362"
            ],
            "disease": "ncit:C9311"
        },
        "object_descriptor": {
            "id": "civic.tid:326",
            "type": "TherapeuticDescriptor",
            "label": "Cisplatin",
            "extensions": [
                {
                    "type": "Extension",
                    "name": "regulatory_approval",
                    "value": {
                        "approval_rating": "FDA",
                        "has_indications": [
                            {
                                "id": "hemonc:569",
                                "type": "DiseaseDescriptor",
                                "label": "Bladder cancer",
                                "disease": "ncit:C9334"
                            },
                            {
                                "id": "hemonc:671",
                                "type": "DiseaseDescriptor",
                                "label": "Testicular cancer",
                                "disease": "ncit:C7251"
                            },
                            {
                                "id": "hemonc:645",
                                "type": "DiseaseDescriptor",
                                "label": "Ovarian cancer",
                                "disease": "ncit:C7431"
                            }
                        ]
                    }
                }
            ],
            "xrefs": [
                "ncit:C376"
            ],
            "alternate_labels": [
                "(SP-4-2)-Diamminedichloroplatinum",
                "Abiplatin",
                "Blastolem",
                "Briplatin",
                "CDDP",
                "Cis-diammine-dichloroplatinum",
                "Cis-diamminedichloridoplatinum",
                "Cis-diamminedichloro Platinum (II)",
                "Cis-diamminedichloroplatinum",
                "Cis-dichloroammine Platinum (II)",
                "Cis-platinous Diamine Dichloride",
                "Cis-platinum",
                "Cis-platinum II",
                "Cis-platinum II Diamine Dichloride",
                "Cismaplat",
                "Cisplatina",
                "Cisplatinum",
                "Cisplatyl",
                "Citoplatino",
                "Citosin",
                "Cysplatyna",
                "DDP",
                "Lederplatin",
                "Metaplatin",
                "Neoplatin",
                "Peyrone's Chloride",
                "Peyrone's Salt",
                "Placis",
                "Plastistil",
                "Platamine",
                "Platiblastin",
                "Platiblastin-S",
                "Platinex",
                "Platinol",
                "Platinol- AQ",
                "Platinol-AQ",
                "Platinol-AQ VHA Plus",
                "Platinoxan",
                "Platinum",
                "Platinum Diamminodichloride",
                "Platinum, Diaminedichloro-, Cis- (8CI)",
                "Platiran",
                "Platistin",
                "Platosin"
            ],
            "therapeutic": "rxcui:2555"
        }
    },
    {
        "id": "civic.eid:3007",
        "type": "VariationNeoplasmTherapeuticResponseStatement",
        "description": "Murine Ba/F3 cells with FLT3-D835V mutations were evaluated as non-responsive to MLN518 (Tandutinib). Cells with single FLT3 (D835V) mutants were resistant to MLN518(IC50 > 10uM) whereas cells with FLT3 (ITD) mutants were not resistant to MLN518 (IC50 0.55uM).",
        "method": "metakb.method:1",
        "is_reported_in": [
            {
                "id": "civic.source:367",
                "type": "Document",
                "label": "Clark et al., 2004, Blood",
                "xrefs": [
                    "pmid:15256420"
                ],
                "title": "Variable sensitivity of FLT3 activation loop mutations to the small molecule tyrosine kinase inhibitor MLN518."
            }
        ],
        "evidence_level": {
            "id": "vicc:e00009",
            "type": "Coding",
            "label": "preclinical evidence"
        },
        "target_proposition": {
            "id": "proposition:qUxiJb1zm8BL7k9P8q1DFRA8G02WM01u",
            "type": "VariationNeoplasmTherapeuticResponseProposition",
            "subject": "ga4gh:VA.SDb8DfOl6qRgEqJm82LWxhv2Z76CMSh4",
            "predicate": "predicts_resistance_to",
            "object": {
                "id": "ncit:C48404",
                "type": "Therapeutic"
            },
            "neoplasm_type_qualifier": {
                "id": "ncit:C3171",
                "type": "Disease"
            }
        },
        "direction": "supports",
        "subject_descriptor": "civic.vid:1302",
        "neoplasm_type_descriptor": {
            "id": "civic.did:3",
            "type": "DiseaseDescriptor",
            "label": "Acute Myeloid Leukemia",
            "xrefs": [
                "DOID:9119"
            ],
            "disease": "ncit:C3171"
        },
        "object_descriptor": {
            "id": "civic.tid:503",
            "type": "TherapeuticDescriptor",
            "label": "Tandutinib",
            "xrefs": [
                "ncit:C48404"
            ],
            "alternate_labels": [
                "1-Piperazinecarboxamide, 4-(6-Methoxy-7-(3-(1-piperidinyl)propoxy)-4-quinazolinyl)-N-(4-(1-methylethoxy)phenyl)-",
                "CT53518",
                "MLN 518",
                "MLN518"
            ],
            "therapeutic": "ncit:C48404"
        }
    },
    {
        "id": "civic.eid:3733",
        "type": "VariationNeoplasmTherapeuticResponseStatement",
        "description": "In an in vitro study, a RKO cell line expressing BRAF V600E (a known vemurafenib sensitizing mutation) and PIK3CA H1047R co-mutation demonstrated reduced sensitivity to vemurafenib treatment. Resistance was determined by assessing cellular proliferation and AKT phosphorylation.",
        "method": "metakb.method:1",
        "is_reported_in": [
            {
                "id": "civic.source:108",
                "type": "Document",
                "label": "Yang et al., 2012, Cancer Res.",
                "xrefs": [
                    "pmid:22180495"
                ],
                "title": "Antitumor activity of BRAF inhibitor vemurafenib in preclinical models of BRAF-mutant colorectal cancer."
            }
        ],
        "evidence_level": {
            "id": "vicc:e00009",
            "type": "Coding",
            "label": "preclinical evidence"
        },
        "target_proposition": {
            "id": "proposition:7DUBSsCEnDwTV2Kh1QnykNS5U_FyDOps",
            "type": "VariationNeoplasmTherapeuticResponseProposition",
            "subject": "ga4gh:VA.TIcXeM9bBVAIDYM4osh5rbkEVBs3LBCJ",
            "predicate": "predicts_resistance_to",
            "object": {
                "id": "rxcui:1147220",
                "type": "Therapeutic"
            },
            "neoplasm_type_qualifier": {
                "id": "ncit:C4978",
                "type": "Disease"
            }
        },
        "direction": "supports",
        "subject_descriptor": "civic.vid:107",
        "neoplasm_type_descriptor": {
            "id": "civic.did:11",
            "type": "DiseaseDescriptor",
            "label": "Colorectal Cancer",
            "xrefs": [
                "DOID:9256"
            ],
            "disease": "ncit:C4978"
        },
        "object_descriptor": {
            "id": "civic.tid:4",
            "type": "TherapeuticDescriptor",
            "label": "Vemurafenib",
            "extensions": [
                {
                    "type": "Extension",
                    "name": "regulatory_approval",
                    "value": {
                        "approval_rating": "FDA",
                        "has_indications": [
                            {
                                "id": "hemonc:629",
                                "type": "DiseaseDescriptor",
                                "label": "Melanoma",
                                "disease": "ncit:C3224"
                            },
                            {
                                "id": "hemonc:594",
                                "type": "DiseaseDescriptor",
                                "label": "Erdheim-Chester disease",
                                "disease": "ncit:C53972"
                            }
                        ]
                    }
                }
            ],
            "xrefs": [
                "ncit:C64768"
            ],
            "alternate_labels": [
                "1-propanesulfonamide, N-(3-((5-(4-chlorophenyl)-1h-pyrrolo(2,3-b)pyridin-3-yl)carbonyl)-2,4-difluorophenyl)-",
                "BRAF (V600E) Kinase Inhibitor RO5185426",
                "BRAF(V600E) Kinase Inhibitor RO5185426",
                "PLX-4032",
                "PLX4032",
                "RG 7204",
                "RG7204",
                "RO 5185426",
                "Zelboraf"
            ],
            "therapeutic": "rxcui:1147220"
        }
    },
    {
        "id": "civic.eid:3958",
        "type": "VariationNeoplasmTherapeuticResponseStatement",
        "description": "In an in vitro study, a MCAS cell line expressing KRAS G12D mutation was associated with reduced sensitivity to cetuximab treatment as compared to RMUG-L and OMC-1 cells expressing wild-type KRAS. Resistance was determined by assessing cell growth. Further, in an in vivo experiment, KRAS G12D expressing MCAS xenografts in nude mice had reduced response to cetuximab, as compared to KRAS wild-type expressing RMUG-L xenografts. Resistance was determined by assessing tumor growth.",
        "method": "metakb.method:1",
        "is_reported_in": [
            {
                "id": "civic.source:2024",
                "type": "Document",
                "label": "Sato et al., 2012, Oncol. Rep.",
                "xrefs": [
                    "pmid:22246397"
                ],
                "title": "Cetuximab inhibits the growth of mucinous ovarian carcinoma tumor cells lacking KRAS gene mutations."
            }
        ],
        "evidence_level": {
            "id": "vicc:e00009",
            "type": "Coding",
            "label": "preclinical evidence"
        },
        "target_proposition": {
            "id": "proposition:hxDm3RcJ-VZI7TPEWeKKrVmMsZmWK5Gi",
            "type": "VariationNeoplasmTherapeuticResponseProposition",
            "subject": "ga4gh:VA.jSiuIG2uZEbml8MfCtZi3J9jPBCBiaPw",
            "predicate": "predicts_resistance_to",
            "object": {
                "id": "rxcui:318341",
                "type": "Therapeutic"
            },
            "neoplasm_type_qualifier": {
                "id": "ncit:C7431",
                "type": "Disease"
            }
        },
        "direction": "supports",
        "subject_descriptor": "civic.vid:79",
        "neoplasm_type_descriptor": {
            "id": "civic.did:20",
            "type": "DiseaseDescriptor",
            "label": "Ovarian Cancer",
            "xrefs": [
                "DOID:2394"
            ],
            "disease": "ncit:C7431"
        },
        "object_descriptor": {
            "id": "civic.tid:16",
            "type": "TherapeuticDescriptor",
            "label": "Cetuximab",
            "extensions": [
                {
                    "type": "Extension",
                    "name": "regulatory_approval",
                    "value": {
                        "approval_rating": "ChEMBL",
                        "has_indications": [
                            {
                                "id": "mesh:D002294",
                                "type": "DiseaseDescriptor",
                                "label": "Carcinoma, Squamous Cell",
                                "disease": "ncit:C2929"
                            },
                            {
                                "id": "mesh:D009369",
                                "type": "DiseaseDescriptor",
                                "label": "Neoplasms",
                                "disease": "ncit:C3262"
                            },
                            {
                                "id": "mesh:D015179",
                                "type": "DiseaseDescriptor",
                                "label": "Colorectal Neoplasms",
                                "disease": "ncit:C2956"
                            },
                            {
                                "id": "mesh:D006258",
                                "type": "DiseaseDescriptor",
                                "label": "Head and Neck Neoplasms",
                                "disease": "ncit:C4013"
                            }
                        ]
                    }
                }
            ],
            "xrefs": [
                "ncit:C1723"
            ],
            "alternate_labels": [
                "Cetuximab Biosimilar CDP-1",
                "Cetuximab Biosimilar CMAB009",
                "Cetuximab Biosimilar KL 140",
                "Chimeric Anti-EGFR Monoclonal Antibody",
                "Chimeric MoAb C225",
                "Chimeric Monoclonal Antibody C225",
                "Erbitux",
                "IMC-C225"
            ],
            "therapeutic": "rxcui:318341"
        }
    },
    {
        "id": "civic.eid:4167",
        "type": "VariationNeoplasmTherapeuticResponseStatement",
        "description": "A preclinical study tested the effect of a tyrosine kinase inhibitor (TKI) on Ba/F3 cell lines with primary ponatinib-sensitizing del 557-558 mutation, which induced IL-3 independent growth, and secondary mutation N822K. The cells were tested for Ponatinib resistance. Ba/F3 cells with del 557-558 and N822K mutations did not show resistance towards Ponatinib (IC50 for growth inhibition: 3 nM) compared to Ba/F3 cells with del 557-558  alone (IC50: 3 nM). Ponatinib inhibited KIT phosphorylation at moderate concentrations. The results suggest that N822K does not induce Ponatinib resistance.",
        "method": "metakb.method:1",
        "is_reported_in": [
            {
                "id": "civic.source:2042",
                "type": "Document",
                "label": "Garner et al., 2014, Clin. Cancer Res.",
                "xrefs": [
                    "pmc:PMC4233175",
                    "pmid:25239608"
                ],
                "title": "Ponatinib inhibits polyclonal drug-resistant KIT oncoproteins and shows therapeutic potential in heavily pretreated gastrointestinal stromal tumor (GIST) patients."
            }
        ],
        "evidence_level": {
            "id": "vicc:e00009",
            "type": "Coding",
            "label": "preclinical evidence"
        },
        "target_proposition": {
            "id": "proposition:AAWMc-hrRb7s1ZVE5wsMVGb5hueiM6u8",
            "type": "VariationNeoplasmTherapeuticResponseProposition",
            "subject": "ga4gh:VA.x1hF9GSdbmVTlsrasMgH_mt4t2-TmEn1",
            "predicate": "predicts_resistance_to",
            "object": {
                "id": "rxcui:1364347",
                "type": "Therapeutic"
            },
            "neoplasm_type_qualifier": {
                "id": "ncit:C3868",
                "type": "Disease"
            }
        },
        "direction": "opposes",
        "subject_descriptor": "civic.vid:1263",
        "neoplasm_type_descriptor": {
            "id": "civic.did:2",
            "type": "DiseaseDescriptor",
            "label": "Gastrointestinal Stromal Tumor",
            "xrefs": [
                "DOID:9253"
            ],
            "disease": "ncit:C3868"
        },
        "object_descriptor": {
            "id": "civic.tid:55",
            "type": "TherapeuticDescriptor",
            "label": "Ponatinib",
            "extensions": [
                {
                    "type": "Extension",
                    "name": "regulatory_approval",
                    "value": {
                        "approval_rating": "FDA",
                        "has_indications": [
                            {
                                "id": "hemonc:24309",
                                "type": "DiseaseDescriptor",
                                "label": "Acute lymphoblastic leukemia",
                                "disease": "ncit:C3167"
                            },
                            {
                                "id": "hemonc:582",
                                "type": "DiseaseDescriptor",
                                "label": "Chronic myelogenous leukemia",
                                "disease": "ncit:C3174"
                            }
                        ]
                    }
                }
            ],
            "xrefs": [
                "ncit:C95777"
            ],
            "alternate_labels": [
                "AP-24534",
                "AP24534",
                "Benzamide, 3-(2-Imidazo(1,2-B)Pyridazin-3-Ylethynyl)-4-Methyl-N-(4-((4-Methyl-1- Piperazinyl)Methyl)-3-(Trifluoromethyl)Phenyl)"
            ],
            "therapeutic": "rxcui:1364347"
        }
    },
    {
        "id": "civic.eid:4169",
        "type": "VariationNeoplasmTherapeuticResponseStatement",
        "description": "A preclinical study tested the effects of tyrosine kinase inhibitor (TKI) on Ba/F3 cell lines with primary regorafenib-sensitizing mutation del 557-558, which induced IL-3 independent growth, and secondary mutation N822K. The cells were tested for Regorafenib resistance. Ba/F3 cells with del 557-558 and N822K mutations did show resistance towards Regorafenib (IC50 for growth inhibition: 131 +- 9 nM) compared to Ba/F3 cells with the del 557-558 mutation (IC50 for growth inhibition: 30 +- 14 nM). Regorafenib inhibited KIT phosphorylation only at high concentrations. The results suggest that N822K does induce Regorafenib resistance.",
        "method": "metakb.method:1",
        "is_reported_in": [
            {
                "id": "civic.source:2042",
                "type": "Document",
                "label": "Garner et al., 2014, Clin. Cancer Res.",
                "xrefs": [
                    "pmc:PMC4233175",
                    "pmid:25239608"
                ],
                "title": "Ponatinib inhibits polyclonal drug-resistant KIT oncoproteins and shows therapeutic potential in heavily pretreated gastrointestinal stromal tumor (GIST) patients."
            }
        ],
        "evidence_level": {
            "id": "vicc:e00009",
            "type": "Coding",
            "label": "preclinical evidence"
        },
        "target_proposition": {
            "id": "proposition:9zZr_91zEe56FU7LcA9uBqXHfSVrqNWq",
            "type": "VariationNeoplasmTherapeuticResponseProposition",
            "subject": "ga4gh:VA.x1hF9GSdbmVTlsrasMgH_mt4t2-TmEn1",
            "predicate": "predicts_resistance_to",
            "object": {
                "id": "rxcui:1312397",
                "type": "Therapeutic"
            },
            "neoplasm_type_qualifier": {
                "id": "ncit:C3868",
                "type": "Disease"
            }
        },
        "direction": "supports",
        "subject_descriptor": "civic.vid:1263",
        "neoplasm_type_descriptor": {
            "id": "civic.did:2",
            "type": "DiseaseDescriptor",
            "label": "Gastrointestinal Stromal Tumor",
            "xrefs": [
                "DOID:9253"
            ],
            "disease": "ncit:C3868"
        },
        "object_descriptor": {
            "id": "civic.tid:27",
            "type": "TherapeuticDescriptor",
            "label": "Regorafenib",
            "extensions": [
                {
                    "type": "Extension",
                    "name": "regulatory_approval",
                    "value": {
                        "approval_rating": "ChEMBL",
                        "has_indications": [
                            {
                                "id": "mesh:D009369",
                                "type": "DiseaseDescriptor",
                                "label": "Neoplasms",
                                "disease": "ncit:C3262"
                            },
                            {
                                "id": "mesh:D015179",
                                "type": "DiseaseDescriptor",
                                "label": "Colorectal Neoplasms",
                                "disease": "ncit:C2956"
                            }
                        ]
                    }
                }
            ],
            "xrefs": [
                "ncit:C78204"
            ],
            "alternate_labels": [
                "4-(4-(((4-chloro-3-(trifluoromethyl)phenyl)carbamoyl)amino)-3-fluorophenoxy)-N-methylpyridine-2-carboxamide",
                "BAY 73-4506",
                "REGORAFENIB ANHYDROUS",
                "Stivarga"
            ],
            "therapeutic": "rxcui:1312397"
        }
    },
    {
        "id": "civic.eid:4521",
        "type": "VariationNeoplasmTherapeuticResponseStatement",
        "description": "An in vitro study of M229 (a human melanoma cell line) endogenously expressing wildtype AKT3 and BRAF V600E (a known BRAF inhibitor sensitizing mutation) found that cells virally induced to stably over-express AKT3 E17K were significantly more resistant to BRAF inhibition via vemurafenib than cells transduced with empty vectors (40% vs 20% survival, p = .0033).",
        "method": "metakb.method:1",
        "is_reported_in": [
            {
                "id": "civic.source:1941",
                "type": "Document",
                "label": "Shi et al., 2014, Cancer Discov",
                "xrefs": [
                    "pmc:PMC3936420",
                    "pmid:24265155"
                ],
                "title": "Acquired resistance and clonal evolution in melanoma during BRAF inhibitor therapy."
            }
        ],
        "evidence_level": {
            "id": "vicc:e00009",
            "type": "Coding",
            "label": "preclinical evidence"
        },
        "target_proposition": {
            "id": "proposition:hw8jVmn0Yy5cFet1qIhOFpMQCM8u0p3x",
            "type": "VariationNeoplasmTherapeuticResponseProposition",
            "subject": "ga4gh:VA.dDEqcxz4HCtU5NFIDMd5GIfcyWqL5HN4",
            "predicate": "predicts_resistance_to",
            "object": {
                "id": "rxcui:1147220",
                "type": "Therapeutic"
            },
            "neoplasm_type_qualifier": {
                "id": "ncit:C3224",
                "type": "Disease"
            }
        },
        "direction": "supports",
        "subject_descriptor": "civic.vid:1227",
        "neoplasm_type_descriptor": {
            "id": "civic.did:7",
            "type": "DiseaseDescriptor",
            "label": "Melanoma",
            "xrefs": [
                "DOID:1909"
            ],
            "disease": "ncit:C3224"
        },
        "object_descriptor": {
            "id": "civic.tid:4",
            "type": "TherapeuticDescriptor",
            "label": "Vemurafenib",
            "extensions": [
                {
                    "type": "Extension",
                    "name": "regulatory_approval",
                    "value": {
                        "approval_rating": "FDA",
                        "has_indications": [
                            {
                                "id": "hemonc:629",
                                "type": "DiseaseDescriptor",
                                "label": "Melanoma",
                                "disease": "ncit:C3224"
                            },
                            {
                                "id": "hemonc:594",
                                "type": "DiseaseDescriptor",
                                "label": "Erdheim-Chester disease",
                                "disease": "ncit:C53972"
                            }
                        ]
                    }
                }
            ],
            "xrefs": [
                "ncit:C64768"
            ],
            "alternate_labels": [
                "1-propanesulfonamide, N-(3-((5-(4-chlorophenyl)-1h-pyrrolo(2,3-b)pyridin-3-yl)carbonyl)-2,4-difluorophenyl)-",
                "BRAF (V600E) Kinase Inhibitor RO5185426",
                "BRAF(V600E) Kinase Inhibitor RO5185426",
                "PLX-4032",
                "PLX4032",
                "RG 7204",
                "RG7204",
                "RO 5185426",
                "Zelboraf"
            ],
            "therapeutic": "rxcui:1147220"
        }
    },
    {
        "id": "civic.eid:4783",
        "type": "VariationNeoplasmTherapeuticResponseStatement",
        "description": "An in vitro study of WM2664 (a human melanoma cell line) endogenously expressing wildtype PIK3R2 and BRAF V600D (a known BRAF inhibitor sensitizing mutation) found that cells virally induced to stably over-express PIK3R2 N561D were significantly more resistant to vemurafenib (a BRAF inhibitor) than cells transduced with an empty vector (40% vs 0% survival at the highest concentration, p < .0001).",
        "method": "metakb.method:1",
        "is_reported_in": [
            {
                "id": "civic.source:1941",
                "type": "Document",
                "label": "Shi et al., 2014, Cancer Discov",
                "xrefs": [
                    "pmc:PMC3936420",
                    "pmid:24265155"
                ],
                "title": "Acquired resistance and clonal evolution in melanoma during BRAF inhibitor therapy."
            }
        ],
        "evidence_level": {
            "id": "vicc:e00009",
            "type": "Coding",
            "label": "preclinical evidence"
        },
        "target_proposition": {
            "id": "proposition:Q7_0_9nwv2bKvEwgCsZ1YLzipsq5m1uM",
            "type": "VariationNeoplasmTherapeuticResponseProposition",
            "subject": "ga4gh:VA.VqK773vLUUqBwBpE3ER4-XSXVh349TMB",
            "predicate": "predicts_resistance_to",
            "object": {
                "id": "rxcui:1147220",
                "type": "Therapeutic"
            },
            "neoplasm_type_qualifier": {
                "id": "ncit:C3224",
                "type": "Disease"
            }
        },
        "direction": "supports",
        "subject_descriptor": "civic.vid:1652",
        "neoplasm_type_descriptor": {
            "id": "civic.did:7",
            "type": "DiseaseDescriptor",
            "label": "Melanoma",
            "xrefs": [
                "DOID:1909"
            ],
            "disease": "ncit:C3224"
        },
        "object_descriptor": {
            "id": "civic.tid:4",
            "type": "TherapeuticDescriptor",
            "label": "Vemurafenib",
            "extensions": [
                {
                    "type": "Extension",
                    "name": "regulatory_approval",
                    "value": {
                        "approval_rating": "FDA",
                        "has_indications": [
                            {
                                "id": "hemonc:629",
                                "type": "DiseaseDescriptor",
                                "label": "Melanoma",
                                "disease": "ncit:C3224"
                            },
                            {
                                "id": "hemonc:594",
                                "type": "DiseaseDescriptor",
                                "label": "Erdheim-Chester disease",
                                "disease": "ncit:C53972"
                            }
                        ]
                    }
                }
            ],
            "xrefs": [
                "ncit:C64768"
            ],
            "alternate_labels": [
                "1-propanesulfonamide, N-(3-((5-(4-chlorophenyl)-1h-pyrrolo(2,3-b)pyridin-3-yl)carbonyl)-2,4-difluorophenyl)-",
                "BRAF (V600E) Kinase Inhibitor RO5185426",
                "BRAF(V600E) Kinase Inhibitor RO5185426",
                "PLX-4032",
                "PLX4032",
                "RG 7204",
                "RG7204",
                "RO 5185426",
                "Zelboraf"
            ],
            "therapeutic": "rxcui:1147220"
        }
    },
    {
        "id": "civic.eid:4885",
        "type": "VariationNeoplasmTherapeuticResponseStatement",
        "description": "Subset of 58 cancer cell lines with unaltered TP53 is sensitive to MDM2 Inhibitor AMGMDS3. None of 115 cancer cell lines with TP53 mutation and absence of WT allele are sensitive to MDM2 Inhibitor. TP53 M237I loss of function mutation is present in 1 cell line (T98G, glioblastoma) and it is insensitive to MDM2 Inhibitor AMGMDS3 (IC50: 49.97uM).",
        "method": "metakb.method:1",
        "is_reported_in": [
            {
                "id": "civic.source:1696",
                "type": "Document",
                "label": "Saiki et al., 2015, Oncotarget",
                "xrefs": [
                    "pmc:PMC4480710",
                    "pmid:25730903"
                ],
                "title": "Identifying the determinants of response to MDM2 inhibition."
            }
        ],
        "evidence_level": {
            "id": "vicc:e00009",
            "type": "Coding",
            "label": "preclinical evidence"
        },
        "target_proposition": {
            "id": "proposition:1356rlb1Hxjeni6fGny4K4eepyLNKgNi",
            "type": "VariationNeoplasmTherapeuticResponseProposition",
            "subject": "ga4gh:VA.oIP_Wv6LX8o9-TpPmpT_4mBK7JBtgYg2",
            "predicate": "predicts_resistance_to",
            "object": {
                "id": "ncit:C171616",
                "type": "Therapeutic"
            },
            "neoplasm_type_qualifier": {
                "id": "ncit:C3058",
                "type": "Disease"
            }
        },
        "direction": "supports",
        "subject_descriptor": "civic.vid:1066",
        "neoplasm_type_descriptor": {
            "id": "civic.did:19",
            "type": "DiseaseDescriptor",
            "label": "Glioblastoma",
            "xrefs": [
                "DOID:3068"
            ],
            "disease": "ncit:C3058"
        },
        "object_descriptor": {
            "id": "civic.tid:20623",
            "type": "TherapeuticDescriptor",
            "label": "MDM2 Inhibitor AMGMDS3",
            "xrefs": [
                "ncit:C171616"
            ],
            "alternate_labels": [
                "2-[(2S,3R,4S)-2,3-bis(3-chlorophenyl)-1-[(2S)-1-ethoxy-1-oxobutan-2-yl]-4-methyl-6-oxopiperidin-4-yl]acetic Acid",
                "AMGMDS3",
                "Q59770979"
            ],
            "therapeutic": "ncit:C171616"
        }
    },
    {
        "id": "civic.eid:4886",
        "type": "VariationNeoplasmTherapeuticResponseStatement",
        "description": "Subset of 58 cancer cell lines with unaltered TP53 is sensitive to MDM2 Inhibitor AMGMDS3. None of 115 cancer cell lines with TP53 mutation and absence of WT allele are sensitive to MDM2 Inhibitor. TP53 R158H loss of function mutation is present in 1 cell line (SW954) and it is insensitive to MDM2 Inhibitor AMGMDS3.",
        "method": "metakb.method:1",
        "is_reported_in": [
            {
                "id": "civic.source:1696",
                "type": "Document",
                "label": "Saiki et al., 2015, Oncotarget",
                "xrefs": [
                    "pmc:PMC4480710",
                    "pmid:25730903"
                ],
                "title": "Identifying the determinants of response to MDM2 inhibition."
            }
        ],
        "evidence_level": {
            "id": "vicc:e00009",
            "type": "Coding",
            "label": "preclinical evidence"
        },
        "target_proposition": {
            "id": "proposition:ObSfbnkawn5_DRdYYMngwLfSFR_wEPmD",
            "type": "VariationNeoplasmTherapeuticResponseProposition",
            "subject": "ga4gh:VA.J34fq_QemA86Fe5wU6IlVdCp7WPLgAw6",
            "predicate": "predicts_resistance_to",
            "object": {
                "id": "ncit:C171616",
                "type": "Therapeutic"
            },
            "neoplasm_type_qualifier": {
                "id": "ncit:C4052",
                "type": "Disease"
            }
        },
        "direction": "supports",
        "subject_descriptor": "civic.vid:1695",
        "neoplasm_type_descriptor": {
            "id": "civic.did:117",
            "type": "DiseaseDescriptor",
            "label": "Vulva Squamous Cell Carcinoma",
            "xrefs": [
                "DOID:2101"
            ],
            "disease": "ncit:C4052"
        },
        "object_descriptor": {
            "id": "civic.tid:20623",
            "type": "TherapeuticDescriptor",
            "label": "MDM2 Inhibitor AMGMDS3",
            "xrefs": [
                "ncit:C171616"
            ],
            "alternate_labels": [
                "2-[(2S,3R,4S)-2,3-bis(3-chlorophenyl)-1-[(2S)-1-ethoxy-1-oxobutan-2-yl]-4-methyl-6-oxopiperidin-4-yl]acetic Acid",
                "AMGMDS3",
                "Q59770979"
            ],
            "therapeutic": "ncit:C171616"
        }
    },
    {
        "id": "civic.eid:6002",
        "type": "VariationNeoplasmTherapeuticResponseStatement",
        "description": "In this preclinical study, melanoma cell lines harboring the kinase-dead G469E- and D594G mutations were identified. These cell lines were resitant to MEK-Inhibition but underwent apoptosis after shRNA-mediated CRAF knowdown or Treatment with the pan-RAF Inhibitor sorafenib.",
        "method": "metakb.method:1",
        "is_reported_in": [
            {
                "id": "civic.source:337",
                "type": "Document",
                "label": "Smalley et al., 2009, Oncogene",
                "xrefs": [
                    "pmc:PMC2898184",
                    "pmid:18794803"
                ],
                "title": "CRAF inhibition induces apoptosis in melanoma cells with non-V600E BRAF mutations."
            }
        ],
        "evidence_level": {
            "id": "vicc:e00009",
            "type": "Coding",
            "label": "preclinical evidence"
        },
        "target_proposition": {
            "id": "proposition:0uK1jvl5h0EwHwPvEz302aN89SyR4Amy",
            "type": "VariationNeoplasmTherapeuticResponseProposition",
            "subject": "ga4gh:VA.SzzRSKeY5NnQaBmR2-lVrxJjOMOg4_aX",
            "predicate": "predicts_resistance_to",
            "object": {
                "id": "iuphar.ligand:5282",
                "type": "Therapeutic"
            },
            "neoplasm_type_qualifier": {
                "id": "ncit:C3510",
                "type": "Disease"
            }
        },
        "direction": "supports",
        "subject_descriptor": "civic.vid:611",
        "neoplasm_type_descriptor": {
            "id": "civic.did:206",
            "type": "DiseaseDescriptor",
            "label": "Skin Melanoma",
            "xrefs": [
                "DOID:8923"
            ],
            "disease": "ncit:C3510"
        },
        "object_descriptor": {
            "id": "civic.tid:568",
            "type": "TherapeuticDescriptor",
            "label": "U0126",
            "therapeutic": "iuphar.ligand:5282"
        }
    },
    {
        "id": "civic.eid:6004",
        "type": "VariationNeoplasmTherapeuticResponseStatement",
        "description": "In this preclinical study, melanoma cell lines harboring the kinase-dead G469E- and D594G mutations were identified. These cell lines were resitant to MEK-Inhibition (U0126) but underwent apoptosis after shRNA-mediated CRAF knowdown or treatment with the pan-RAF inhibitor sorafenib.",
        "method": "metakb.method:1",
        "is_reported_in": [
            {
                "id": "civic.source:337",
                "type": "Document",
                "label": "Smalley et al., 2009, Oncogene",
                "xrefs": [
                    "pmc:PMC2898184",
                    "pmid:18794803"
                ],
                "title": "CRAF inhibition induces apoptosis in melanoma cells with non-V600E BRAF mutations."
            }
        ],
        "evidence_level": {
            "id": "vicc:e00009",
            "type": "Coding",
            "label": "preclinical evidence"
        },
        "target_proposition": {
            "id": "proposition:LFdjqFhNARKN8acHrPV2cD8UBgqKIne8",
            "type": "VariationNeoplasmTherapeuticResponseProposition",
            "subject": "ga4gh:VA.qhJpha5rN0z-Rg2lOjtAhH1UhB9CaRJ-",
            "predicate": "predicts_resistance_to",
            "object": {
                "id": "iuphar.ligand:5282",
                "type": "Therapeutic"
            },
            "neoplasm_type_qualifier": {
                "id": "ncit:C3510",
                "type": "Disease"
            }
        },
        "direction": "supports",
        "subject_descriptor": "civic.vid:993",
        "neoplasm_type_descriptor": {
            "id": "civic.did:206",
            "type": "DiseaseDescriptor",
            "label": "Skin Melanoma",
            "xrefs": [
                "DOID:8923"
            ],
            "disease": "ncit:C3510"
        },
        "object_descriptor": {
            "id": "civic.tid:568",
            "type": "TherapeuticDescriptor",
            "label": "U0126",
            "therapeutic": "iuphar.ligand:5282"
        }
    },
    {
        "id": "civic.eid:6213",
        "type": "VariationNeoplasmTherapeuticResponseStatement",
        "description": "This preclinical study tested the sensitivity of HER2-positive breast cancer cell line BT-474 (heterozygous for PIK3CA K111N) retrovirally transduced with PIK3CA E545K to NVP-BEZ235 (dactolisib; a dual PI3K/mTOR inhibitor). The study found that dactolisib was effective in inhibiting outgrowth of E545K mutant-containing cells. Dactolisib was also combined with trastuzumab and/or lapatinib with similar abrogation of growth for PIK3CA E545K expressing cells. Growth of untransduced BT-474 control cells was prevented by treatment with any monotherapy or combination of trastuzumab, lapatinib, or dactolisib.",
        "method": "metakb.method:1",
        "is_reported_in": [
            {
                "id": "civic.source:2486",
                "type": "Document",
                "label": "Eichhorn et al., 2008, Cancer Res.",
                "xrefs": [
                    "pmc:PMC2587064",
                    "pmid:19010894"
                ],
                "title": "Phosphatidylinositol 3-kinase hyperactivation results in lapatinib resistance that is reversed by the mTOR/phosphatidylinositol 3-kinase inhibitor NVP-BEZ235."
            }
        ],
        "evidence_level": {
            "id": "vicc:e00009",
            "type": "Coding",
            "label": "preclinical evidence"
        },
        "target_proposition": {
            "id": "proposition:8H_mqH07KUfL_Q9w_q7AXuWIgQXTzcVr",
            "type": "VariationNeoplasmTherapeuticResponseProposition",
            "subject": "ga4gh:VA.5zBiXnk0ZRCfFqRnK0fQHQwAGBWW4JE8",
            "predicate": "predicts_resistance_to",
            "object": {
                "id": "ncit:C74072",
                "type": "Therapeutic"
            },
            "neoplasm_type_qualifier": {
                "id": "ncit:C53556",
                "type": "Disease"
            }
        },
        "direction": "opposes",
        "subject_descriptor": "civic.vid:104",
        "neoplasm_type_descriptor": {
            "id": "civic.did:368",
            "type": "DiseaseDescriptor",
            "label": "Her2-receptor Positive Breast Cancer",
            "xrefs": [
                "DOID:60079"
            ],
            "disease": "ncit:C53556"
        },
        "object_descriptor": {
            "id": "civic.tid:343",
            "type": "TherapeuticDescriptor",
            "label": "Dactolisib",
            "xrefs": [
                "ncit:C74072"
            ],
            "alternate_labels": [
                "BEZ235",
                "Benzeneacetonitrile, 4-(2,3-Dihydro-3-methyl-2-oxo-8-(3-quinolinyl)-1H-imidazo(4,5-c)quinolin-1-yl)-alpha,alpha-dimethyl-",
                "NVPBEZ235"
            ],
            "therapeutic": "ncit:C74072"
        }
    },
    {
        "id": "civic.eid:8336",
        "type": "VariationNeoplasmTherapeuticResponseStatement",
        "description": "The authors used saturation mutagenesis of FLT3/ITD followed by selection of transfected cells in FLT3 TKI. The FLT3/ITD Y842C mutation produced high-level resistance to KW2449, sorafenib, sunitinib and AGS324 in vitro but remained sensitive to lestaurtinib and midostaurin. Balb/c mice transplanted with the FLT3/ITD Y842C mutation confirmed resistance to sorafenib in vivo but not to lestaurtinib.",
        "method": "metakb.method:1",
        "is_reported_in": [
            {
                "id": "civic.source:3472",
                "type": "Document",
                "label": "Williams et al., 2013, Leukemia",
                "xrefs": [
                    "pmc:PMC3822911",
                    "pmid:22858906"
                ],
                "title": "Mutations of FLT3/ITD confer resistance to multiple tyrosine kinase inhibitors."
            }
        ],
        "evidence_level": {
            "id": "vicc:e00009",
            "type": "Coding",
            "label": "preclinical evidence"
        },
        "target_proposition": {
            "id": "proposition:t7-fACbkhNPLFqH02luFN_HJYTWYTcqQ",
            "type": "VariationNeoplasmTherapeuticResponseProposition",
            "subject": "ga4gh:VA.hYF_stBVoyuIzz8G96fSEN7GBptcr6Vr",
            "predicate": "predicts_resistance_to",
            "object": {
                "id": "ncit:C116858",
                "type": "Therapeutic"
            },
            "neoplasm_type_qualifier": {
                "id": "ncit:C3171",
                "type": "Disease"
            }
        },
        "direction": "supports",
        "subject_descriptor": "civic.vid:3070",
        "neoplasm_type_descriptor": {
            "id": "civic.did:3",
            "type": "DiseaseDescriptor",
            "label": "Acute Myeloid Leukemia",
            "xrefs": [
                "DOID:9119"
            ],
            "disease": "ncit:C3171"
        },
        "object_descriptor": {
            "id": "civic.tid:1629",
            "type": "TherapeuticDescriptor",
            "label": "FLT3/ABL/Aurora Kinase Inhibitor KW-2449",
            "xrefs": [
                "ncit:C116858"
            ],
            "alternate_labels": [
                "KW-2449"
            ],
            "therapeutic": "ncit:C116858"
        }
    },
    {
        "id": "civic.eid:8338",
        "type": "VariationNeoplasmTherapeuticResponseStatement",
        "description": "The authors used saturation mutagenesis of FLT3/ITD followed by selection of transfected cells in FLT3 TKI. The FLT3/ITD Y842C mutation produced high-level resistance to KW2449, sorafenib, sunitinib and AGS324 in vitro but remained sensitive to lestaurtinib and midostaurin. Balb/c mice transplanted with the FLT3/ITD Y842C mutation confirmed resistance to sorafenib in vivo but not to lestaurtinib.",
        "method": "metakb.method:1",
        "is_reported_in": [
            {
                "id": "civic.source:3472",
                "type": "Document",
                "label": "Williams et al., 2013, Leukemia",
                "xrefs": [
                    "pmc:PMC3822911",
                    "pmid:22858906"
                ],
                "title": "Mutations of FLT3/ITD confer resistance to multiple tyrosine kinase inhibitors."
            }
        ],
        "evidence_level": {
            "id": "vicc:e00009",
            "type": "Coding",
            "label": "preclinical evidence"
        },
        "target_proposition": {
            "id": "proposition:FUduXl_oEvlDg8k46HKQAKnvBtAFuxyE",
            "type": "VariationNeoplasmTherapeuticResponseProposition",
            "subject": "ga4gh:VA.hYF_stBVoyuIzz8G96fSEN7GBptcr6Vr",
            "predicate": "predicts_resistance_to",
            "object": {
                "id": "rxcui:357977",
                "type": "Therapeutic"
            },
            "neoplasm_type_qualifier": {
                "id": "ncit:C3171",
                "type": "Disease"
            }
        },
        "direction": "supports",
        "subject_descriptor": "civic.vid:3070",
        "neoplasm_type_descriptor": {
            "id": "civic.did:3",
            "type": "DiseaseDescriptor",
            "label": "Acute Myeloid Leukemia",
            "xrefs": [
                "DOID:9119"
            ],
            "disease": "ncit:C3171"
        },
        "object_descriptor": {
            "id": "civic.tid:157",
            "type": "TherapeuticDescriptor",
            "label": "Sunitinib",
            "extensions": [
                {
                    "type": "Extension",
                    "name": "regulatory_approval",
                    "value": {
                        "approval_rating": "FDA",
                        "has_indications": [
                            {
                                "id": "hemonc:602",
                                "type": "DiseaseDescriptor",
                                "label": "Gastrointestinal stromal tumor",
                                "disease": "ncit:C3868"
                            },
                            {
                                "id": "hemonc:647",
                                "type": "DiseaseDescriptor",
                                "label": "Pancreatic NET",
                                "disease": "ncit:C27720"
                            },
                            {
                                "id": "hemonc:660",
                                "type": "DiseaseDescriptor",
                                "label": "Renal cell carcinoma",
                                "disease": "ncit:C9385"
                            }
                        ]
                    }
                }
            ],
            "xrefs": [
                "ncit:C71622"
            ],
            "alternate_labels": [
                "1H-Pyrrole-3-carboxamide, N-(2-(diethylamino)ethyl)-5-((Z)-(5-fluoro-1,2-dihydro-2-oxo-3H-indol-3-ylidene)methyl)-2,4-dimethyl-"
            ],
            "therapeutic": "rxcui:357977"
        }
    },
    {
        "id": "civic.eid:8341",
        "type": "VariationNeoplasmTherapeuticResponseStatement",
        "description": "A screen using saturation mutagenesis of FLT3/ITD followed by selection of transfected TF1 cells in FLT3 TKIs identified F691L. Cytotoxicity assessed by MTT demonstrated Ba/F3 cells expressing FLT3/ITD F691L conferred moderate resistance to lestaurtinib (IC50: 8nM) compared to FLT3/ITD control cells (IC50: 2nM). Immunoblotting showed lestaurtinib was able to partially inhibit FLT3 autophosphorylation and the activation of downstream pathways in Ba/F3 FLT3/ITD F691L cells. Structural modeling revealed F691 to be located in the ATP binding cleft. The authors hypothesize this amino acid change weakens inhibitor affinity as this residue likely makes direct contact with FLT3 TKIs.",
        "method": "metakb.method:1",
        "is_reported_in": [
            {
                "id": "civic.source:3472",
                "type": "Document",
                "label": "Williams et al., 2013, Leukemia",
                "xrefs": [
                    "pmc:PMC3822911",
                    "pmid:22858906"
                ],
                "title": "Mutations of FLT3/ITD confer resistance to multiple tyrosine kinase inhibitors."
            }
        ],
        "evidence_level": {
            "id": "vicc:e00009",
            "type": "Coding",
            "label": "preclinical evidence"
        },
        "target_proposition": {
            "id": "proposition:P6mceecwqjZz8aoVFju55S6SOLDhdzSW",
            "type": "VariationNeoplasmTherapeuticResponseProposition",
            "subject": "ga4gh:VA.alBmNUrND2Qcobv2zz7socu-8G727NX9",
            "predicate": "predicts_resistance_to",
            "object": {
                "id": "ncit:C48402",
                "type": "Therapeutic"
            },
            "neoplasm_type_qualifier": {
                "id": "ncit:C3171",
                "type": "Disease"
            }
        },
        "direction": "supports",
        "subject_descriptor": "civic.vid:3071",
        "neoplasm_type_descriptor": {
            "id": "civic.did:3",
            "type": "DiseaseDescriptor",
            "label": "Acute Myeloid Leukemia",
            "xrefs": [
                "DOID:9119"
            ],
            "disease": "ncit:C3171"
        },
        "object_descriptor": {
            "id": "civic.tid:260",
            "type": "TherapeuticDescriptor",
            "label": "Lestaurtinib",
            "xrefs": [
                "ncit:C48402"
            ],
            "alternate_labels": [
                "9,12-Epoxy-1H-diindolo(1,2,3-fg:3',2',1'-kl)pyrrolo(3,4-i)(1,6)benzodiazocin-1-one, 2,3,9,10,11,12-hexahydro-10-hydroxy-10-(hydroxymethyl)-9-methyl-, (9S,10S,12R)-",
                "CEP-701",
                "KT-5555",
                "SPM-924"
            ],
            "therapeutic": "ncit:C48402"
        }
    },
    {
        "id": "civic.eid:8342",
        "type": "VariationNeoplasmTherapeuticResponseStatement",
        "description": "A screen using saturation mutagenesis of FLT3/ITD followed by selection of transfected TF1 cells in the FLT3 TKI midostaurin identified F691L in 1 of 400 clones. Cytotoxicity assessed by MTT demonstrated Ba/F3 cells expressing FLT3/ITD F691L conferred moderate resistance to midostaurin (IC50: 18nM) compared to FLT3/ITD control cells (IC50: 4nM). Immunoblotting showed midostaurin was able to partially inhibit FLT3 autophosphorylation and the activation of downstream pathways in Ba/F3 FLT3/ITD F691L cells. Structural modeling revealed F691 to be located in the ATP binding cleft. The authors hypothesize this amino acid change weakens inhibitor affinity as this residue likely makes direct contact with FLT3 TKIs.",
        "method": "metakb.method:1",
        "is_reported_in": [
            {
                "id": "civic.source:3472",
                "type": "Document",
                "label": "Williams et al., 2013, Leukemia",
                "xrefs": [
                    "pmc:PMC3822911",
                    "pmid:22858906"
                ],
                "title": "Mutations of FLT3/ITD confer resistance to multiple tyrosine kinase inhibitors."
            }
        ],
        "evidence_level": {
            "id": "vicc:e00009",
            "type": "Coding",
            "label": "preclinical evidence"
        },
        "target_proposition": {
            "id": "proposition:KO5ByVBzJFTbP2pkyk2ODwQdgfK4IhBo",
            "type": "VariationNeoplasmTherapeuticResponseProposition",
            "subject": "ga4gh:VA.alBmNUrND2Qcobv2zz7socu-8G727NX9",
            "predicate": "predicts_resistance_to",
            "object": {
                "id": "rxcui:1919083",
                "type": "Therapeutic"
            },
            "neoplasm_type_qualifier": {
                "id": "ncit:C3171",
                "type": "Disease"
            }
        },
        "direction": "supports",
        "subject_descriptor": "civic.vid:3071",
        "neoplasm_type_descriptor": {
            "id": "civic.did:3",
            "type": "DiseaseDescriptor",
            "label": "Acute Myeloid Leukemia",
            "xrefs": [
                "DOID:9119"
            ],
            "disease": "ncit:C3171"
        },
        "object_descriptor": {
            "id": "civic.tid:323",
            "type": "TherapeuticDescriptor",
            "label": "Midostaurin",
            "extensions": [
                {
                    "type": "Extension",
                    "name": "regulatory_approval",
                    "value": {
                        "approval_rating": "FDA",
                        "has_indications": [
                            {
                                "id": "hemonc:669",
                                "type": "DiseaseDescriptor",
                                "label": "Systemic mastocytosis",
                                "disease": "ncit:C9235"
                            },
                            {
                                "id": "hemonc:552",
                                "type": "DiseaseDescriptor",
                                "label": "Acute myeloid leukemia",
                                "disease": "ncit:C3171"
                            }
                        ]
                    }
                }
            ],
            "xrefs": [
                "ncit:C1872"
            ],
            "alternate_labels": [
                "CGP 41251",
                "CGP41251",
                "N-Benzoyl-Staurosporine",
                "N-Benzoylstaurosporine",
                "PKC-412",
                "PKC412",
                "Rydapt"
            ],
            "therapeutic": "rxcui:1919083"
        }
    },
    {
        "id": "civic.eid:8376",
        "type": "VariationNeoplasmTherapeuticResponseStatement",
        "description": "Rs4;11 cells overexpressing BCL2 F104I exhibited >40-fold greater resistance to venetoclax after 24-hour treatment (IC50 not reached) than Rs4;11 overexpressing BCL2 WT cells as determined by cell titer glo measured cytotoxicity assays. Plasmon resonance protein binding assays demonstrated marked impairment (300 fold) of venetoclax binding to F104I (Ki=5.9 nM) veresus WT (Ki=.018nM). The authors pointed out reduction in binding was a similar magnitude as that observed previously with the BCL2 G101V and F104L.",
        "method": "metakb.method:1",
        "is_reported_in": [
            {
                "id": "civic.source:3502",
                "type": "Document",
                "label": "Blombery et al., 2019, Br. J. Haematol.",
                "xrefs": [
                    "pmid:31234236"
                ],
                "title": "Characterization of a novel venetoclax resistance mutation (BCL2 Phe104Ile) observed in follicular lymphoma."
            }
        ],
        "evidence_level": {
            "id": "vicc:e00009",
            "type": "Coding",
            "label": "preclinical evidence"
        },
        "target_proposition": {
            "id": "proposition:b-ICx3_0XquQYSfb0KiMLHPo_W7H6wlC",
            "type": "VariationNeoplasmTherapeuticResponseProposition",
            "subject": "ga4gh:VA._ZzqdXiiqCOs9iTFtw5ac6N6_lT9vbfe",
            "predicate": "predicts_resistance_to",
            "object": {
                "id": "rxcui:1747556",
                "type": "Therapeutic"
            },
            "neoplasm_type_qualifier": {
                "id": "ncit:C3209",
                "type": "Disease"
            }
        },
        "direction": "supports",
        "subject_descriptor": "civic.vid:3082",
        "neoplasm_type_descriptor": {
            "id": "civic.did:51",
            "type": "DiseaseDescriptor",
            "label": "Follicular Lymphoma",
            "xrefs": [
                "DOID:50873"
            ],
            "disease": "ncit:C3209"
        },
        "object_descriptor": {
            "id": "civic.tid:574",
            "type": "TherapeuticDescriptor",
            "label": "Venetoclax",
            "extensions": [
                {
                    "type": "Extension",
                    "name": "regulatory_approval",
                    "value": {
                        "approval_rating": "FDA",
                        "has_indications": [
                            {
                                "id": "hemonc:581",
                                "type": "DiseaseDescriptor",
                                "label": "Chronic lymphocytic leukemia",
                                "disease": "ncit:C3163"
                            },
                            {
                                "id": "hemonc:552",
                                "type": "DiseaseDescriptor",
                                "label": "Acute myeloid leukemia",
                                "disease": "ncit:C3171"
                            }
                        ]
                    }
                }
            ],
            "xrefs": [
                "ncit:C103147"
            ],
            "alternate_labels": [
                "4-(4-((2-(4-Chlorophenyl)-4,4-dimethylcyclohex-1-en-1-yl)methyl)piperazin-1-yl)-N-((3-nitro-4-((tetrahydro-2H-pyran-4-ylmethyl)amino)phenyl)sulfonyl)-2-(1H-pyrrolo(2,3-b)pyridin-5-yloxy)benzamide",
                "ABT-0199",
                "ABT-199",
                "ABT199",
                "GDC-0199",
                "RG7601",
                "Venclexta",
                "Venclyxto"
            ],
            "therapeutic": "rxcui:1747556"
        }
    },
    {
        "id": "civic.eid:8642",
        "type": "VariationNeoplasmTherapeuticResponseStatement",
        "description": "Bladder cancer cell line 97-7 expressing endogenous FGFR3 S249C (IC50 44.6ug/ml) was resistant to cisplatin compared to two FGFR3 wild-type cell lines, 5637 (IC50 2.07ug/ml) and T24 (IC50 1.58ug/ml) as shown by a CCK-8 colorimetric cytotoxicity. Western blot revealed the ratio of phosphorylated-Akt/total Akt was higher in the 97-7 cells than in the wild-type cells, which was reversed by siRNA knockdown of FGFR3. Inhibition of Akt signaling by treatment with GDC0068 or LY294002 increased the cisplatin sensitivity of 97-7 cells (IC50 4.17ug/ml & 8.91ug/ml respectively).",
        "method": "metakb.method:1",
        "is_reported_in": [
            {
                "id": "civic.source:3631",
                "type": "Document",
                "label": "Xie et al., 2019, Exp Ther Med",
                "xrefs": [
                    "pmc:PMC6601368",
                    "pmid:31316618"
                ],
                "title": "FGFR3S249C mutation promotes chemoresistance by activating Akt signaling in bladder cancer cells."
            }
        ],
        "evidence_level": {
            "id": "vicc:e00009",
            "type": "Coding",
            "label": "preclinical evidence"
        },
        "target_proposition": {
            "id": "proposition:Kqo7c0OyeQrMG82Rm9rkSg6WiwKGEXXw",
            "type": "VariationNeoplasmTherapeuticResponseProposition",
            "subject": "ga4gh:VA.FNHAUxkAFnYKIjkp3qxbDsoN31F2i-wp",
            "predicate": "predicts_resistance_to",
            "object": {
                "id": "rxcui:2555",
                "type": "Therapeutic"
            },
            "neoplasm_type_qualifier": {
                "id": "ncit:C2930",
                "type": "Disease"
            }
        },
        "direction": "supports",
        "subject_descriptor": "civic.vid:628",
        "neoplasm_type_descriptor": {
            "id": "civic.did:642",
            "type": "DiseaseDescriptor",
            "label": "Transitional Cell Carcinoma",
            "xrefs": [
                "DOID:2671"
            ],
            "disease": "ncit:C2930"
        },
        "object_descriptor": {
            "id": "civic.tid:326",
            "type": "TherapeuticDescriptor",
            "label": "Cisplatin",
            "extensions": [
                {
                    "type": "Extension",
                    "name": "regulatory_approval",
                    "value": {
                        "approval_rating": "FDA",
                        "has_indications": [
                            {
                                "id": "hemonc:569",
                                "type": "DiseaseDescriptor",
                                "label": "Bladder cancer",
                                "disease": "ncit:C9334"
                            },
                            {
                                "id": "hemonc:671",
                                "type": "DiseaseDescriptor",
                                "label": "Testicular cancer",
                                "disease": "ncit:C7251"
                            },
                            {
                                "id": "hemonc:645",
                                "type": "DiseaseDescriptor",
                                "label": "Ovarian cancer",
                                "disease": "ncit:C7431"
                            }
                        ]
                    }
                }
            ],
            "xrefs": [
                "ncit:C376"
            ],
            "alternate_labels": [
                "(SP-4-2)-Diamminedichloroplatinum",
                "Abiplatin",
                "Blastolem",
                "Briplatin",
                "CDDP",
                "Cis-diammine-dichloroplatinum",
                "Cis-diamminedichloridoplatinum",
                "Cis-diamminedichloro Platinum (II)",
                "Cis-diamminedichloroplatinum",
                "Cis-dichloroammine Platinum (II)",
                "Cis-platinous Diamine Dichloride",
                "Cis-platinum",
                "Cis-platinum II",
                "Cis-platinum II Diamine Dichloride",
                "Cismaplat",
                "Cisplatina",
                "Cisplatinum",
                "Cisplatyl",
                "Citoplatino",
                "Citosin",
                "Cysplatyna",
                "DDP",
                "Lederplatin",
                "Metaplatin",
                "Neoplatin",
                "Peyrone's Chloride",
                "Peyrone's Salt",
                "Placis",
                "Plastistil",
                "Platamine",
                "Platiblastin",
                "Platiblastin-S",
                "Platinex",
                "Platinol",
                "Platinol- AQ",
                "Platinol-AQ",
                "Platinol-AQ VHA Plus",
                "Platinoxan",
                "Platinum",
                "Platinum Diamminodichloride",
                "Platinum, Diaminedichloro-, Cis- (8CI)",
                "Platiran",
                "Platistin",
                "Platosin"
            ],
            "therapeutic": "rxcui:2555"
        }
    },
    {
        "id": "civic.eid:8654",
        "type": "VariationNeoplasmTherapeuticResponseStatement",
        "description": "A screen using saturation mutagenesis of FLT3/ITD followed by selection of transfected TF1 cells in FLT3 TKIs identified Y842C. Cytotoxicity assessed by MTT demonstrated Ba/F3 cells expressing FLT3/ITD Y842C conferred high-level resistance to Quizartinib (AC220) (IC50: 20nM) compared to FLT3/ITD control cells (IC50: 1nM). Unlike in FLT3/ITD control cells, immunoblotting showed Quizartinib was unable to inhibit FLT3 autophosphorylation and the activation of downstream pathways in Ba/F3 FLT3/ITD Y842C cells. Structural modeling revealed Y842 to be located in the activation loop. The authors hypothesize altered conformation interferes with drug interaction.",
        "method": "metakb.method:1",
        "is_reported_in": [
            {
                "id": "civic.source:3472",
                "type": "Document",
                "label": "Williams et al., 2013, Leukemia",
                "xrefs": [
                    "pmc:PMC3822911",
                    "pmid:22858906"
                ],
                "title": "Mutations of FLT3/ITD confer resistance to multiple tyrosine kinase inhibitors."
            }
        ],
        "evidence_level": {
            "id": "vicc:e00009",
            "type": "Coding",
            "label": "preclinical evidence"
        },
        "target_proposition": {
            "id": "proposition:BOWjG8-rKYAlB4oIuIF5T9VAm0TZca5Z",
            "type": "VariationNeoplasmTherapeuticResponseProposition",
            "subject": "ga4gh:VA.hYF_stBVoyuIzz8G96fSEN7GBptcr6Vr",
            "predicate": "predicts_resistance_to",
            "object": {
                "id": "ncit:C68936",
                "type": "Therapeutic"
            },
            "neoplasm_type_qualifier": {
                "id": "ncit:C3171",
                "type": "Disease"
            }
        },
        "direction": "supports",
        "subject_descriptor": "civic.vid:3070",
        "neoplasm_type_descriptor": {
            "id": "civic.did:3",
            "type": "DiseaseDescriptor",
            "label": "Acute Myeloid Leukemia",
            "xrefs": [
                "DOID:9119"
            ],
            "disease": "ncit:C3171"
        },
        "object_descriptor": {
            "id": "civic.tid:505",
            "type": "TherapeuticDescriptor",
            "label": "Quizartinib",
            "xrefs": [
                "ncit:C68936"
            ],
            "alternate_labels": [
                "(2E)-N-(4-(3-Chloro-4-Fluoroanilino)-7-(((3S)-Oxolan-3-Yl)Oxy)Quinoxazolin-6-yl)-4-(Dimethylamino)but-2-Enamide",
                "AC-220",
                "AC010220",
                "AC220",
                "N-(5-tert-butyl-isoxazol-3-yl)-N'-{4-[7-(2-morpholin-4-yl-ethoxy)imidazo [2,1-b] [1,3] Benzothiazol 2-yl]phenyl}urea"
            ],
            "therapeutic": "ncit:C68936"
        }
    },
    {
        "id": "civic.eid:8841",
        "type": "VariationNeoplasmTherapeuticResponseStatement",
        "description": "This study described the similar crystal structures of BCL-2 wild-type and G101V when bound to venetoclax. Steady state competition surface plasmon resonance experiments demonstrated a ~177 fold decrease in venetoclax affinity for G101V (Ki=3.2nM) versus WT (Ki=.018nM). Resistance is acquired by a knock-on effect in the P2 pocket of V101 on an adjacent residue, E152 as affinity for venetoclax was restored in BCL2 G101V through the introduction of an E152A mutation (Ki =.002nM). Additionally, BCL2 G101V maintains similar affinity for apoptotic BH3 peptides, which assists in the prevention of apoptosis.",
        "method": "metakb.method:1",
        "is_reported_in": [
            {
                "id": "civic.source:3500",
                "type": "Document",
                "label": "Birkinshaw et al., 2019, Nat Commun",
                "xrefs": [
                    "pmc:PMC6547681",
                    "pmid:31160589"
                ],
                "title": "Structures of BCL-2 in complex with venetoclax reveal the molecular basis of resistance mutations."
            }
        ],
        "evidence_level": {
            "id": "vicc:e00009",
            "type": "Coding",
            "label": "preclinical evidence"
        },
        "target_proposition": {
            "id": "proposition:1Y0dZ0HwuKmn2eZJUxillHwOpe4g16dx",
            "type": "VariationNeoplasmTherapeuticResponseProposition",
            "subject": "ga4gh:VA.W2DykRCbXOXmqZLLiZeELFbtnqJvuqOW",
            "predicate": "predicts_resistance_to",
            "object": {
                "id": "rxcui:1747556",
                "type": "Therapeutic"
            },
            "neoplasm_type_qualifier": {
                "id": "ncit:C3163",
                "type": "Disease"
            }
        },
        "direction": "supports",
        "subject_descriptor": "civic.vid:2960",
        "neoplasm_type_descriptor": {
            "id": "civic.did:52",
            "type": "DiseaseDescriptor",
            "label": "Chronic Lymphocytic Leukemia",
            "xrefs": [
                "DOID:1040"
            ],
            "disease": "ncit:C3163"
        },
        "object_descriptor": {
            "id": "civic.tid:574",
            "type": "TherapeuticDescriptor",
            "label": "Venetoclax",
            "extensions": [
                {
                    "type": "Extension",
                    "name": "regulatory_approval",
                    "value": {
                        "approval_rating": "FDA",
                        "has_indications": [
                            {
                                "id": "hemonc:581",
                                "type": "DiseaseDescriptor",
                                "label": "Chronic lymphocytic leukemia",
                                "disease": "ncit:C3163"
                            },
                            {
                                "id": "hemonc:552",
                                "type": "DiseaseDescriptor",
                                "label": "Acute myeloid leukemia",
                                "disease": "ncit:C3171"
                            }
                        ]
                    }
                }
            ],
            "xrefs": [
                "ncit:C103147"
            ],
            "alternate_labels": [
                "4-(4-((2-(4-Chlorophenyl)-4,4-dimethylcyclohex-1-en-1-yl)methyl)piperazin-1-yl)-N-((3-nitro-4-((tetrahydro-2H-pyran-4-ylmethyl)amino)phenyl)sulfonyl)-2-(1H-pyrrolo(2,3-b)pyridin-5-yloxy)benzamide",
                "ABT-0199",
                "ABT-199",
                "ABT199",
                "GDC-0199",
                "RG7601",
                "Venclexta",
                "Venclyxto"
            ],
            "therapeutic": "rxcui:1747556"
        }
    },
    {
        "id": "civic.eid:9945",
        "type": "VariationNeoplasmTherapeuticResponseStatement",
        "description": "Foundation panel results of baseline tumour samples from 48 patients with diffuse large B cell lymphoma identified PIM1 mutations in 6 patient samples, 5 of which were the DLBCL-ABC subtype. Four out of the 5 DLBCL-ABC patients with PIM1 mutations had stable disease or progressive disease when treated with ibrutinib, suggesting innate resistance to ibrutinib therapy. Three PIM1 mutations L2V, P81S, and S97N were investigated in cell lines studies. Cells transduced with L2V, P81S, and S97N were resistant to ibrutinib compared to cells transduced with wild type PIM1. Combined treatment of PIM1 mutant lines with ibrutinib and a pan-PIM inhibitor, AZD-1208, partially rescued sensitivity to ibrutinib.",
        "method": "metakb.method:1",
        "is_reported_in": [
            {
                "id": "civic.source:4212",
                "type": "Document",
                "label": "Kuo et al., 2016, Am J Cancer Res",
                "xrefs": [
                    "pmc:PMC5126268",
                    "pmid:27904766"
                ],
                "title": "The role of PIM1 in the ibrutinib-resistant ABC subtype of diffuse large B-cell lymphoma."
            }
        ],
        "evidence_level": {
            "id": "vicc:e00009",
            "type": "Coding",
            "label": "preclinical evidence"
        },
        "target_proposition": {
            "id": "proposition:ZgSHkSkUA8ZCltvlaXuLYTKNdsqF_j8h",
            "type": "VariationNeoplasmTherapeuticResponseProposition",
            "subject": "ga4gh:VA.aP0xMmanUEUlDokkHAiLYfvmo_PNEjbF",
            "predicate": "predicts_resistance_to",
            "object": {
                "id": "rxcui:1442981",
                "type": "Therapeutic"
            },
            "neoplasm_type_qualifier": {
                "id": "ncit:C36081",
                "type": "Disease"
            }
        },
        "direction": "supports",
        "subject_descriptor": "civic.vid:3643",
        "neoplasm_type_descriptor": {
            "id": "civic.did:3090",
            "type": "DiseaseDescriptor",
            "label": "Diffuse Large B-cell Lymphoma Activated B-cell Type",
            "xrefs": [
                "DOID:80996"
            ],
            "disease": "ncit:C36081"
        },
        "object_descriptor": {
            "id": "civic.tid:227",
            "type": "TherapeuticDescriptor",
            "label": "Ibrutinib",
            "extensions": [
                {
                    "type": "Extension",
                    "name": "regulatory_approval",
                    "value": {
                        "approval_rating": "ChEMBL",
                        "has_indications": [
                            {
                                "id": "mesh:D015451",
                                "type": "DiseaseDescriptor",
                                "label": "Leukemia, Lymphocytic, Chronic, B-Cell",
                                "disease": "ncit:C3163"
                            },
                            {
                                "id": "mesh:D020522",
                                "type": "DiseaseDescriptor",
                                "label": "Lymphoma, Mantle-Cell",
                                "disease": "ncit:C4337"
                            },
                            {
                                "id": "mesh:D008258",
                                "type": "DiseaseDescriptor",
                                "label": "Waldenstrom Macroglobulinemia",
                                "disease": "ncit:C80307"
                            }
                        ]
                    }
                }
            ],
            "xrefs": [
                "ncit:C81934"
            ],
            "alternate_labels": [
                "2-Propen-1-one, 1-((3R)-3-(4-amino-3-(4-phenoxyphenyl)-1h-pyrazolo(3,4-d)pyrimidin-1-yl)-1-piperidinyl)-",
                "BTK Inhibitor PCI-32765",
                "CRA-032765",
                "Imbruvica",
                "PCI-32765"
            ],
            "therapeutic": "rxcui:1442981"
        }
    },
    {
        "id": "civic.eid:9946",
        "type": "VariationNeoplasmTherapeuticResponseStatement",
        "description": "Foundation panel results of baseline tumour samples from 48 patients with diffuse large B cell lymphoma identified PIM1 mutations in 6 patient samples, 5 of which were the DLBCL-ABC subtype. Four out of the 5 DLBCL-ABC patients with PIM1 mutations had stable disease or progressive disease when treated with ibrutinib, suggesting innate resistance to ibrutinib therapy. Three PIM1 mutations L2V, P81S, and S97N were investigated in cell lines studies. Cells transduced with L2V, P81S, and S97N were resistant to ibrutinib compared to cells transduced with wild type PIM1. Combined treatment of PIM1 mutant lines with ibrutinib and a pan-PIM inhibitor, AZD-1208, partially rescued sensitivity to ibrutinib.",
        "method": "metakb.method:1",
        "is_reported_in": [
            {
                "id": "civic.source:4212",
                "type": "Document",
                "label": "Kuo et al., 2016, Am J Cancer Res",
                "xrefs": [
                    "pmc:PMC5126268",
                    "pmid:27904766"
                ],
                "title": "The role of PIM1 in the ibrutinib-resistant ABC subtype of diffuse large B-cell lymphoma."
            }
        ],
        "evidence_level": {
            "id": "vicc:e00009",
            "type": "Coding",
            "label": "preclinical evidence"
        },
        "target_proposition": {
            "id": "proposition:FAKEAkWWgHAz8lCYg7NovFaBjhM7u0l3",
            "type": "VariationNeoplasmTherapeuticResponseProposition",
            "subject": "ga4gh:VA.s00v7sgfPv7r71Cj-ps1MYobW16SE8mb",
            "predicate": "predicts_resistance_to",
            "object": {
                "id": "rxcui:1442981",
                "type": "Therapeutic"
            },
            "neoplasm_type_qualifier": {
                "id": "ncit:C36081",
                "type": "Disease"
            }
        },
        "direction": "supports",
        "subject_descriptor": "civic.vid:3644",
        "neoplasm_type_descriptor": {
            "id": "civic.did:3090",
            "type": "DiseaseDescriptor",
            "label": "Diffuse Large B-cell Lymphoma Activated B-cell Type",
            "xrefs": [
                "DOID:80996"
            ],
            "disease": "ncit:C36081"
        },
        "object_descriptor": {
            "id": "civic.tid:227",
            "type": "TherapeuticDescriptor",
            "label": "Ibrutinib",
            "extensions": [
                {
                    "type": "Extension",
                    "name": "regulatory_approval",
                    "value": {
                        "approval_rating": "ChEMBL",
                        "has_indications": [
                            {
                                "id": "mesh:D015451",
                                "type": "DiseaseDescriptor",
                                "label": "Leukemia, Lymphocytic, Chronic, B-Cell",
                                "disease": "ncit:C3163"
                            },
                            {
                                "id": "mesh:D020522",
                                "type": "DiseaseDescriptor",
                                "label": "Lymphoma, Mantle-Cell",
                                "disease": "ncit:C4337"
                            },
                            {
                                "id": "mesh:D008258",
                                "type": "DiseaseDescriptor",
                                "label": "Waldenstrom Macroglobulinemia",
                                "disease": "ncit:C80307"
                            }
                        ]
                    }
                }
            ],
            "xrefs": [
                "ncit:C81934"
            ],
            "alternate_labels": [
                "2-Propen-1-one, 1-((3R)-3-(4-amino-3-(4-phenoxyphenyl)-1h-pyrazolo(3,4-d)pyrimidin-1-yl)-1-piperidinyl)-",
                "BTK Inhibitor PCI-32765",
                "CRA-032765",
                "Imbruvica",
                "PCI-32765"
            ],
            "therapeutic": "rxcui:1442981"
        }
    },
    {
        "id": "civic.eid:9947",
        "type": "VariationNeoplasmTherapeuticResponseStatement",
        "description": "Foundation panel results of baseline tumour samples from 48 patients with diffuse large B cell lymphoma identified PIM1 mutations in 6 patient samples, 5 of which were the DLBCL-ABC subtype. Four out of the 5 DLBCL-ABC patients with PIM1 mutations had stable disease or progressive disease when treated with ibrutinib, suggesting innate resistance to ibrutinib therapy. Three PIM1 mutations L2V, P81S, and S97N were investigated in cell lines (TMD8) studies. Cells transduced with L2V, P81S, and S97N were resistant to ibrutinib compared to cells transduced with wild type PIM1. Combined treatment of PIM1 mutant lines with ibrutinib and a pan-PIM inhibitor, AZD-1208, partially rescued sensitivity to ibrutinib.",
        "method": "metakb.method:1",
        "is_reported_in": [
            {
                "id": "civic.source:4212",
                "type": "Document",
                "label": "Kuo et al., 2016, Am J Cancer Res",
                "xrefs": [
                    "pmc:PMC5126268",
                    "pmid:27904766"
                ],
                "title": "The role of PIM1 in the ibrutinib-resistant ABC subtype of diffuse large B-cell lymphoma."
            }
        ],
        "evidence_level": {
            "id": "vicc:e00009",
            "type": "Coding",
            "label": "preclinical evidence"
        },
        "target_proposition": {
            "id": "proposition:jNNEAP2eUZwL1HG2kWhMTDKFyoXBpVoB",
            "type": "VariationNeoplasmTherapeuticResponseProposition",
            "subject": "ga4gh:VA.WqqnpAZ7EK10TsO8oxNzzByf0B19r1R0",
            "predicate": "predicts_resistance_to",
            "object": {
                "id": "rxcui:1442981",
                "type": "Therapeutic"
            },
            "neoplasm_type_qualifier": {
                "id": "ncit:C36081",
                "type": "Disease"
            }
        },
        "direction": "supports",
        "subject_descriptor": "civic.vid:3645",
        "neoplasm_type_descriptor": {
            "id": "civic.did:3090",
            "type": "DiseaseDescriptor",
            "label": "Diffuse Large B-cell Lymphoma Activated B-cell Type",
            "xrefs": [
                "DOID:80996"
            ],
            "disease": "ncit:C36081"
        },
        "object_descriptor": {
            "id": "civic.tid:227",
            "type": "TherapeuticDescriptor",
            "label": "Ibrutinib",
            "extensions": [
                {
                    "type": "Extension",
                    "name": "regulatory_approval",
                    "value": {
                        "approval_rating": "ChEMBL",
                        "has_indications": [
                            {
                                "id": "mesh:D015451",
                                "type": "DiseaseDescriptor",
                                "label": "Leukemia, Lymphocytic, Chronic, B-Cell",
                                "disease": "ncit:C3163"
                            },
                            {
                                "id": "mesh:D020522",
                                "type": "DiseaseDescriptor",
                                "label": "Lymphoma, Mantle-Cell",
                                "disease": "ncit:C4337"
                            },
                            {
                                "id": "mesh:D008258",
                                "type": "DiseaseDescriptor",
                                "label": "Waldenstrom Macroglobulinemia",
                                "disease": "ncit:C80307"
                            }
                        ]
                    }
                }
            ],
            "xrefs": [
                "ncit:C81934"
            ],
            "alternate_labels": [
                "2-Propen-1-one, 1-((3R)-3-(4-amino-3-(4-phenoxyphenyl)-1h-pyrazolo(3,4-d)pyrimidin-1-yl)-1-piperidinyl)-",
                "BTK Inhibitor PCI-32765",
                "CRA-032765",
                "Imbruvica",
                "PCI-32765"
            ],
            "therapeutic": "rxcui:1442981"
        }
    },
    {
        "id": "civic.eid:1171",
        "type": "VariationNeoplasmTherapeuticResponseStatement",
        "description": "HCC827 cell lines harboring activated PI3K (HCC827 p110\u03b1 E545K cells) were more resistant to gefitinib in vitro (IC50, 1 \u03bcM) compared with those harboring GFP alone (IC50, 0.01 \u03bcM). The presence of p110\u03b1 E545K also protected HCC827 cells from gefitinib-mediated apoptosis.",
        "method": "metakb.method:1",
        "is_reported_in": [
            {
                "id": "civic.source:808",
                "type": "Document",
                "label": "Engelman et al., 2006, J. Clin. Invest.",
                "xrefs": [
                    "pmc:PMC1570180",
                    "pmid:16906227"
                ],
                "title": "Allelic dilution obscures detection of a biologically significant resistance mutation in EGFR-amplified lung cancer."
            }
        ],
        "evidence_level": {
            "id": "vicc:e00009",
            "type": "Coding",
            "label": "preclinical evidence"
        },
        "target_proposition": {
            "id": "proposition:BQa0f6KC7aYH0B99bNVLit2Vgyub29xq",
            "type": "VariationNeoplasmTherapeuticResponseProposition",
            "subject": "ga4gh:VA.5zBiXnk0ZRCfFqRnK0fQHQwAGBWW4JE8",
            "predicate": "predicts_resistance_to",
            "object": {
                "id": "rxcui:328134",
                "type": "Therapeutic"
            },
            "neoplasm_type_qualifier": {
                "id": "ncit:C3512",
                "type": "Disease"
            }
        },
        "direction": "supports",
        "subject_descriptor": "civic.vid:104",
        "neoplasm_type_descriptor": {
            "id": "civic.did:30",
            "type": "DiseaseDescriptor",
            "label": "Lung Adenocarcinoma",
            "xrefs": [
                "DOID:3910"
            ],
            "disease": "ncit:C3512"
        },
        "object_descriptor": {
            "id": "civic.tid:14",
            "type": "TherapeuticDescriptor",
            "label": "Gefitinib",
            "extensions": [
                {
                    "type": "Extension",
                    "name": "regulatory_approval",
                    "value": {
                        "approval_rating": "FDA",
                        "has_indications": [
                            {
                                "id": "hemonc:642",
                                "type": "DiseaseDescriptor",
                                "label": "Non-small cell lung cancer",
                                "disease": "ncit:C2926"
                            }
                        ]
                    }
                }
            ],
            "xrefs": [
                "ncit:C1855"
            ],
            "alternate_labels": [
                "4-(3'-Chloro-4'-fluoroanilino)-7-methoxy-6-(3-morpholinopropoxy)quinazoline",
                "Iressa",
                "N-(3-chloro-4-fluorophenyl)-7-methoxy-6-[3-(4-morpholin) Propoxy]-4-quinazolinamine",
                "ZD 1839",
                "ZD1839"
            ],
            "therapeutic": "rxcui:328134"
        }
    },
    {
        "id": "civic.eid:1453",
        "type": "VariationNeoplasmTherapeuticResponseStatement",
        "description": "PI3K mutant E545K was overexpressed in the trastuzumab sensitive HER2 BT474 breast cancer cell line, and significant resistance to trastuzumab was induced in comparison to control cells.",
        "method": "metakb.method:1",
        "is_reported_in": [
            {
                "id": "civic.source:981",
                "type": "Document",
                "label": "Serra et al., 2008, Cancer Res.",
                "xrefs": [
                    "pmid:18829560"
                ],
                "title": "NVP-BEZ235, a dual PI3K/mTOR inhibitor, prevents PI3K signaling and inhibits the growth of cancer cells with activating PI3K mutations."
            }
        ],
        "evidence_level": {
            "id": "vicc:e00009",
            "type": "Coding",
            "label": "preclinical evidence"
        },
        "target_proposition": {
            "id": "proposition:desKNJAFooL9t1omnjR5wXtKTxuyJz6d",
            "type": "VariationNeoplasmTherapeuticResponseProposition",
            "subject": "ga4gh:VA.5zBiXnk0ZRCfFqRnK0fQHQwAGBWW4JE8",
            "predicate": "predicts_resistance_to",
            "object": {
                "id": "rxcui:2103478",
                "type": "Therapeutic"
            },
            "neoplasm_type_qualifier": {
                "id": "ncit:C53556",
                "type": "Disease"
            }
        },
        "direction": "supports",
        "subject_descriptor": "civic.vid:104",
        "neoplasm_type_descriptor": {
            "id": "civic.did:368",
            "type": "DiseaseDescriptor",
            "label": "Her2-receptor Positive Breast Cancer",
            "xrefs": [
                "DOID:60079"
            ],
            "disease": "ncit:C53556"
        },
        "object_descriptor": {
            "id": "civic.tid:84",
            "type": "TherapeuticDescriptor",
            "label": "Trastuzumab",
            "extensions": [
                {
                    "type": "Extension",
                    "name": "regulatory_approval",
                    "value": {
                        "approval_rating": "ChEMBL",
                        "has_indications": [
                            {
                                "id": "mesh:D001943",
                                "type": "DiseaseDescriptor",
                                "label": "Breast Neoplasms",
                                "disease": "ncit:C2910"
                            },
                            {
                                "id": "mesh:D009369",
                                "type": "DiseaseDescriptor",
                                "label": "Neoplasms",
                                "disease": "ncit:C3262"
                            }
                        ]
                    }
                }
            ],
            "xrefs": [
                "ncit:C1647"
            ],
            "alternate_labels": [
                "ABP 980",
                "ALT02",
                "Anti-ERB-2",
                "Anti-HER2/c-erbB2 Monoclonal Antibody",
                "Anti-c-ERB-2",
                "Anti-c-erbB2 Monoclonal Antibody",
                "Anti-erbB-2",
                "Anti-erbB2 Monoclonal Antibody",
                "Anti-p185-HER2",
                "C-erb-2 Monoclonal Antibody",
                "HER2 Monoclonal Antibody",
                "Herceptin",
                "Herceptin Biosimilar PF-05280014",
                "Herceptin Trastuzumab Biosimilar PF-05280014",
                "Herzuma",
                "Immunoglobulin G 1 (Human-Mouse Monoclonal RhuMab HER2gamma1-Chain Antihuman P185(Sup C-erbB2) Receptor), Disulfide With Human-Mouse Monoclonal RhuMab HER2 Light Chain, Dimer",
                "Kanjinti",
                "MoAb HER2",
                "Monoclonal Antibody C-erb-2",
                "Monoclonal Antibody HER2",
                "Ogivri",
                "Ontruzant",
                "PF-05280014",
                "RO0452317",
                "RhuMAb HER2",
                "SB3",
                "Trastuzumab Biosimilar ABP 980",
                "Trastuzumab Biosimilar ALT02",
                "Trastuzumab Biosimilar EG12014",
                "Trastuzumab Biosimilar HLX02",
                "Trastuzumab Biosimilar PF-05280014",
                "Trastuzumab Biosimilar SB3",
                "Trastuzumab Biosimilar SIBP-01",
                "Trastuzumab-anns",
                "Trastuzumab-dkst",
                "Trastuzumab-dttb",
                "Trastuzumab-pkrb",
                "Trastuzumab-qyyp",
                "Trazimera"
            ],
            "therapeutic": "rxcui:2103478"
        }
    },
    {
        "id": "civic.eid:1474",
        "type": "VariationNeoplasmTherapeuticResponseStatement",
        "description": "Preclinical study in melanoma cell lines. NRAS Q61K, in addition to the BRAF V600E mutation was associated with resistance to vemurafenib but sensitivity to AZD6244 (selumetinib) in vitro in the acquired resistant cell line M249-AR4 and in the patient-derived acquired resistant cell line M376.",
        "method": "metakb.method:1",
        "is_reported_in": [
            {
                "id": "civic.source:988",
                "type": "Document",
                "label": "Atefi et al., 2011, PLoS ONE",
                "xrefs": [
                    "pmc:PMC3237573",
                    "pmid:22194965"
                ],
                "title": "Reversing melanoma cross-resistance to BRAF and MEK inhibitors by co-targeting the AKT/mTOR pathway."
            }
        ],
        "evidence_level": {
            "id": "vicc:e00009",
            "type": "Coding",
            "label": "preclinical evidence"
        },
        "target_proposition": {
            "id": "proposition:3N0v7K1aHgekLJ1o87o2H8_YR9yo4hhc",
            "type": "VariationNeoplasmTherapeuticResponseProposition",
            "subject": "ga4gh:VA.NHUtQ1IbZA9ZlH8wKbaMNF0W7esiwPKj",
            "predicate": "predicts_resistance_to",
            "object": {
                "id": "rxcui:1147220",
                "type": "Therapeutic"
            },
            "neoplasm_type_qualifier": {
                "id": "ncit:C3510",
                "type": "Disease"
            }
        },
        "direction": "supports",
        "subject_descriptor": "civic.vid:427",
        "neoplasm_type_descriptor": {
            "id": "civic.did:206",
            "type": "DiseaseDescriptor",
            "label": "Skin Melanoma",
            "xrefs": [
                "DOID:8923"
            ],
            "disease": "ncit:C3510"
        },
        "object_descriptor": {
            "id": "civic.tid:4",
            "type": "TherapeuticDescriptor",
            "label": "Vemurafenib",
            "extensions": [
                {
                    "type": "Extension",
                    "name": "regulatory_approval",
                    "value": {
                        "approval_rating": "FDA",
                        "has_indications": [
                            {
                                "id": "hemonc:629",
                                "type": "DiseaseDescriptor",
                                "label": "Melanoma",
                                "disease": "ncit:C3224"
                            },
                            {
                                "id": "hemonc:594",
                                "type": "DiseaseDescriptor",
                                "label": "Erdheim-Chester disease",
                                "disease": "ncit:C53972"
                            }
                        ]
                    }
                }
            ],
            "xrefs": [
                "ncit:C64768"
            ],
            "alternate_labels": [
                "1-propanesulfonamide, N-(3-((5-(4-chlorophenyl)-1h-pyrrolo(2,3-b)pyridin-3-yl)carbonyl)-2,4-difluorophenyl)-",
                "BRAF (V600E) Kinase Inhibitor RO5185426",
                "BRAF(V600E) Kinase Inhibitor RO5185426",
                "PLX-4032",
                "PLX4032",
                "RG 7204",
                "RG7204",
                "RO 5185426",
                "Zelboraf"
            ],
            "therapeutic": "rxcui:1147220"
        }
    },
    {
        "id": "civic.eid:1727",
        "type": "VariationNeoplasmTherapeuticResponseStatement",
        "description": "ESR1 S463P variants were observed after extensive treatment with hormonal therapy (aromatase inhibition). Expression of the S463P mutant was found to induce modest activity in the absence of hormone. This mutation displayed elevated levels of Ser118 phosphorylation compared to wild-type ER\u03b1 and appeared to possess estrogen-independent activity.",
        "method": "metakb.method:1",
        "is_reported_in": [
            {
                "id": "civic.source:171",
                "type": "Document",
                "label": "Toy et al., 2013, Nat. Genet.",
                "xrefs": [
                    "pmc:PMC3903423",
                    "pmid:24185512"
                ],
                "title": "ESR1 ligand-binding domain mutations in hormone-resistant breast cancer."
            }
        ],
        "evidence_level": {
            "id": "vicc:e00009",
            "type": "Coding",
            "label": "preclinical evidence"
        },
        "target_proposition": {
            "id": "proposition:tRLO2sHCwZoEMnW9IOzLR95_sYwMy8UW",
            "type": "VariationNeoplasmTherapeuticResponseProposition",
            "subject": "ga4gh:VA.sY73k3V_TN0fv2d2TyZ7pIkRVNpmqqzH",
            "predicate": "predicts_resistance_to",
            "object": {
                "id": "ncit:C1740",
                "type": "Therapeutic"
            },
            "neoplasm_type_qualifier": {
                "id": "mondo:0006512",
                "type": "Disease"
            }
        },
        "direction": "supports",
        "subject_descriptor": "civic.vid:692",
        "neoplasm_type_descriptor": {
            "id": "civic.did:28",
            "type": "DiseaseDescriptor",
            "label": "Estrogen-receptor Positive Breast Cancer",
            "xrefs": [
                "DOID:60075"
            ],
            "disease": "mondo:0006512"
        },
        "object_descriptor": {
            "id": "civic.tid:407",
            "type": "TherapeuticDescriptor",
            "label": "Aromatase Inhibitor",
            "xrefs": [
                "ncit:C1740"
            ],
            "therapeutic": "ncit:C1740"
        }
    },
    {
        "id": "civic.eid:2012",
        "type": "VariationNeoplasmTherapeuticResponseStatement",
        "description": "In in vitro experiments, myeloma cell lines expressing activating NRAS and KRAS mutations are less sensitive to the apoptosis-inducing effects of dexamethasone, doxorubicin, and melphalan in comparison to cells with wildtype RAS.",
        "method": "metakb.method:1",
        "is_reported_in": [
            {
                "id": "civic.source:1420",
                "type": "Document",
                "label": "Rowley et al., 2000, Blood",
                "xrefs": [
                    "pmid:11050000"
                ],
                "title": "Heterogeneity in therapeutic response of genetically altered myeloma cell lines to interleukin 6, dexamethasone, doxorubicin, and melphalan."
            }
        ],
        "evidence_level": {
            "id": "vicc:e00009",
            "type": "Coding",
            "label": "preclinical evidence"
        },
        "target_proposition": {
            "id": "proposition:Tw0j-lqFEJG91PXFplmJiTzsyomYoUag",
            "type": "VariationNeoplasmTherapeuticResponseProposition",
            "subject": "ga4gh:VA.U3kUAWKJKEeDyAbv3JsDVQlu9HeEG0WJ",
            "predicate": "predicts_resistance_to",
            "object": {
                "id": "rxcui:6718",
                "type": "Therapeutic"
            },
            "neoplasm_type_qualifier": {
                "id": "ncit:C3242",
                "type": "Disease"
            }
        },
        "direction": "supports",
        "subject_descriptor": "civic.vid:148",
        "neoplasm_type_descriptor": {
            "id": "civic.did:41",
            "type": "DiseaseDescriptor",
            "label": "Multiple Myeloma",
            "xrefs": [
                "DOID:9538"
            ],
            "disease": "ncit:C3242"
        },
        "object_descriptor": {
            "id": "civic.tid:328",
            "type": "TherapeuticDescriptor",
            "label": "Melphalan",
            "extensions": [
                {
                    "type": "Extension",
                    "name": "regulatory_approval",
                    "value": {
                        "approval_rating": "FDA",
                        "has_indications": [
                            {
                                "id": "hemonc:633",
                                "type": "DiseaseDescriptor",
                                "label": "Multiple myeloma",
                                "disease": "ncit:C3242"
                            },
                            {
                                "id": "hemonc:645",
                                "type": "DiseaseDescriptor",
                                "label": "Ovarian cancer",
                                "disease": "ncit:C7431"
                            }
                        ]
                    }
                }
            ],
            "xrefs": [
                "ncit:C633"
            ],
            "alternate_labels": [
                "4-[bis(2-chloroethyl)amino]-L-phenylalanine",
                "Alanine Nitrogen Mustard",
                "CB-3025",
                "L-PAM",
                "L-Phenylalanine Mustard",
                "L-Sarcolysin",
                "L-Sarcolysin Phenylalanine Mustard",
                "L-Sarcolysine",
                "Melphalanum",
                "P-di(chloroethyl)amino-L-phenylalanine",
                "Phenylalanine Mustard",
                "Phenylalanine Nitrogen Mustard",
                "Sarcoclorin",
                "Sarkolysin",
                "WR-19813"
            ],
            "therapeutic": "rxcui:6718"
        }
    },
    {
        "id": "civic.eid:2013",
        "type": "VariationNeoplasmTherapeuticResponseStatement",
        "description": "In in vitro experiments, myeloma cell lines expressing activating NRAS and KRAS mutations are less sensitive to the apoptosis-inducing effects of dexamethasone, doxorubicin, and melphalan in comparison to cells with wildtype RAS.",
        "method": "metakb.method:1",
        "is_reported_in": [
            {
                "id": "civic.source:1421",
                "type": "Document",
                "label": "Rowley et al., 2002, Oncogene",
                "xrefs": [
                    "pmid:12483530"
                ],
                "title": "Activation of N-ras and K-ras induced by interleukin-6 in a myeloma cell line: implications for disease progression and therapeutic response."
            }
        ],
        "evidence_level": {
            "id": "vicc:e00009",
            "type": "Coding",
            "label": "preclinical evidence"
        },
        "target_proposition": {
            "id": "proposition:Tw0j-lqFEJG91PXFplmJiTzsyomYoUag",
            "type": "VariationNeoplasmTherapeuticResponseProposition",
            "subject": "ga4gh:VA.U3kUAWKJKEeDyAbv3JsDVQlu9HeEG0WJ",
            "predicate": "predicts_resistance_to",
            "object": {
                "id": "rxcui:6718",
                "type": "Therapeutic"
            },
            "neoplasm_type_qualifier": {
                "id": "ncit:C3242",
                "type": "Disease"
            }
        },
        "direction": "supports",
        "subject_descriptor": "civic.vid:148",
        "neoplasm_type_descriptor": {
            "id": "civic.did:41",
            "type": "DiseaseDescriptor",
            "label": "Multiple Myeloma",
            "xrefs": [
                "DOID:9538"
            ],
            "disease": "ncit:C3242"
        },
        "object_descriptor": {
            "id": "civic.tid:328",
            "type": "TherapeuticDescriptor",
            "label": "Melphalan",
            "extensions": [
                {
                    "type": "Extension",
                    "name": "regulatory_approval",
                    "value": {
                        "approval_rating": "FDA",
                        "has_indications": [
                            {
                                "id": "hemonc:633",
                                "type": "DiseaseDescriptor",
                                "label": "Multiple myeloma",
                                "disease": "ncit:C3242"
                            },
                            {
                                "id": "hemonc:645",
                                "type": "DiseaseDescriptor",
                                "label": "Ovarian cancer",
                                "disease": "ncit:C7431"
                            }
                        ]
                    }
                }
            ],
            "xrefs": [
                "ncit:C633"
            ],
            "alternate_labels": [
                "4-[bis(2-chloroethyl)amino]-L-phenylalanine",
                "Alanine Nitrogen Mustard",
                "CB-3025",
                "L-PAM",
                "L-Phenylalanine Mustard",
                "L-Sarcolysin",
                "L-Sarcolysin Phenylalanine Mustard",
                "L-Sarcolysine",
                "Melphalanum",
                "P-di(chloroethyl)amino-L-phenylalanine",
                "Phenylalanine Mustard",
                "Phenylalanine Nitrogen Mustard",
                "Sarcoclorin",
                "Sarkolysin",
                "WR-19813"
            ],
            "therapeutic": "rxcui:6718"
        }
    },
    {
        "id": "civic.eid:2014",
        "type": "VariationNeoplasmTherapeuticResponseStatement",
        "description": "In in vitro experiments, myeloma cell lines expressing activating NRAS and KRAS mutations are less sensitive to the apoptosis-inducing effects of dexamethasone, doxorubicin, and melphalan in comparison to cells with wildtype RAS.",
        "method": "metakb.method:1",
        "is_reported_in": [
            {
                "id": "civic.source:1422",
                "type": "Document",
                "label": "Hoang et al., 2006, Blood",
                "xrefs": [
                    "pmc:PMC1895799",
                    "pmid:16497971"
                ],
                "title": "Oncogenic RAS mutations in myeloma cells selectively induce cox-2 expression, which participates in enhanced adhesion to fibronectin and chemoresistance."
            }
        ],
        "evidence_level": {
            "id": "vicc:e00009",
            "type": "Coding",
            "label": "preclinical evidence"
        },
        "target_proposition": {
            "id": "proposition:Tw0j-lqFEJG91PXFplmJiTzsyomYoUag",
            "type": "VariationNeoplasmTherapeuticResponseProposition",
            "subject": "ga4gh:VA.U3kUAWKJKEeDyAbv3JsDVQlu9HeEG0WJ",
            "predicate": "predicts_resistance_to",
            "object": {
                "id": "rxcui:6718",
                "type": "Therapeutic"
            },
            "neoplasm_type_qualifier": {
                "id": "ncit:C3242",
                "type": "Disease"
            }
        },
        "direction": "supports",
        "subject_descriptor": "civic.vid:148",
        "neoplasm_type_descriptor": {
            "id": "civic.did:41",
            "type": "DiseaseDescriptor",
            "label": "Multiple Myeloma",
            "xrefs": [
                "DOID:9538"
            ],
            "disease": "ncit:C3242"
        },
        "object_descriptor": {
            "id": "civic.tid:328",
            "type": "TherapeuticDescriptor",
            "label": "Melphalan",
            "extensions": [
                {
                    "type": "Extension",
                    "name": "regulatory_approval",
                    "value": {
                        "approval_rating": "FDA",
                        "has_indications": [
                            {
                                "id": "hemonc:633",
                                "type": "DiseaseDescriptor",
                                "label": "Multiple myeloma",
                                "disease": "ncit:C3242"
                            },
                            {
                                "id": "hemonc:645",
                                "type": "DiseaseDescriptor",
                                "label": "Ovarian cancer",
                                "disease": "ncit:C7431"
                            }
                        ]
                    }
                }
            ],
            "xrefs": [
                "ncit:C633"
            ],
            "alternate_labels": [
                "4-[bis(2-chloroethyl)amino]-L-phenylalanine",
                "Alanine Nitrogen Mustard",
                "CB-3025",
                "L-PAM",
                "L-Phenylalanine Mustard",
                "L-Sarcolysin",
                "L-Sarcolysin Phenylalanine Mustard",
                "L-Sarcolysine",
                "Melphalanum",
                "P-di(chloroethyl)amino-L-phenylalanine",
                "Phenylalanine Mustard",
                "Phenylalanine Nitrogen Mustard",
                "Sarcoclorin",
                "Sarkolysin",
                "WR-19813"
            ],
            "therapeutic": "rxcui:6718"
        }
    },
    {
        "id": "civic.eid:2250",
        "type": "VariationNeoplasmTherapeuticResponseStatement",
        "description": "In in vitro experiments, myeloma cell lines expressing activating NRAS and KRAS mutations are less sensitive to the apoptosis-inducing effects of dexamethasone, doxorubicin, and melphalan in comparison to cells with wildtype RAS.",
        "method": "metakb.method:1",
        "is_reported_in": [
            {
                "id": "civic.source:1420",
                "type": "Document",
                "label": "Rowley et al., 2000, Blood",
                "xrefs": [
                    "pmid:11050000"
                ],
                "title": "Heterogeneity in therapeutic response of genetically altered myeloma cell lines to interleukin 6, dexamethasone, doxorubicin, and melphalan."
            }
        ],
        "evidence_level": {
            "id": "vicc:e00009",
            "type": "Coding",
            "label": "preclinical evidence"
        },
        "target_proposition": {
            "id": "proposition:1Sa3QxRYxqz93Sii4mEhoHsVJVgyduzJ",
            "type": "VariationNeoplasmTherapeuticResponseProposition",
            "subject": "ga4gh:VA.jSiuIG2uZEbml8MfCtZi3J9jPBCBiaPw",
            "predicate": "predicts_resistance_to",
            "object": {
                "id": "rxcui:6718",
                "type": "Therapeutic"
            },
            "neoplasm_type_qualifier": {
                "id": "ncit:C3242",
                "type": "Disease"
            }
        },
        "direction": "supports",
        "subject_descriptor": "civic.vid:79",
        "neoplasm_type_descriptor": {
            "id": "civic.did:41",
            "type": "DiseaseDescriptor",
            "label": "Multiple Myeloma",
            "xrefs": [
                "DOID:9538"
            ],
            "disease": "ncit:C3242"
        },
        "object_descriptor": {
            "id": "civic.tid:328",
            "type": "TherapeuticDescriptor",
            "label": "Melphalan",
            "extensions": [
                {
                    "type": "Extension",
                    "name": "regulatory_approval",
                    "value": {
                        "approval_rating": "FDA",
                        "has_indications": [
                            {
                                "id": "hemonc:633",
                                "type": "DiseaseDescriptor",
                                "label": "Multiple myeloma",
                                "disease": "ncit:C3242"
                            },
                            {
                                "id": "hemonc:645",
                                "type": "DiseaseDescriptor",
                                "label": "Ovarian cancer",
                                "disease": "ncit:C7431"
                            }
                        ]
                    }
                }
            ],
            "xrefs": [
                "ncit:C633"
            ],
            "alternate_labels": [
                "4-[bis(2-chloroethyl)amino]-L-phenylalanine",
                "Alanine Nitrogen Mustard",
                "CB-3025",
                "L-PAM",
                "L-Phenylalanine Mustard",
                "L-Sarcolysin",
                "L-Sarcolysin Phenylalanine Mustard",
                "L-Sarcolysine",
                "Melphalanum",
                "P-di(chloroethyl)amino-L-phenylalanine",
                "Phenylalanine Mustard",
                "Phenylalanine Nitrogen Mustard",
                "Sarcoclorin",
                "Sarkolysin",
                "WR-19813"
            ],
            "therapeutic": "rxcui:6718"
        }
    },
    {
        "id": "civic.eid:2252",
        "type": "VariationNeoplasmTherapeuticResponseStatement",
        "description": "In in vitro experiments, myeloma cell lines expressing activating NRAS and KRAS mutations are less sensitive to the apoptosis-inducing effects of dexamethasone, doxorubicin, and melphalan in comparison to cells with wildtype RAS.",
        "method": "metakb.method:1",
        "is_reported_in": [
            {
                "id": "civic.source:1422",
                "type": "Document",
                "label": "Hoang et al., 2006, Blood",
                "xrefs": [
                    "pmc:PMC1895799",
                    "pmid:16497971"
                ],
                "title": "Oncogenic RAS mutations in myeloma cells selectively induce cox-2 expression, which participates in enhanced adhesion to fibronectin and chemoresistance."
            }
        ],
        "evidence_level": {
            "id": "vicc:e00009",
            "type": "Coding",
            "label": "preclinical evidence"
        },
        "target_proposition": {
            "id": "proposition:1Sa3QxRYxqz93Sii4mEhoHsVJVgyduzJ",
            "type": "VariationNeoplasmTherapeuticResponseProposition",
            "subject": "ga4gh:VA.jSiuIG2uZEbml8MfCtZi3J9jPBCBiaPw",
            "predicate": "predicts_resistance_to",
            "object": {
                "id": "rxcui:6718",
                "type": "Therapeutic"
            },
            "neoplasm_type_qualifier": {
                "id": "ncit:C3242",
                "type": "Disease"
            }
        },
        "direction": "supports",
        "subject_descriptor": "civic.vid:79",
        "neoplasm_type_descriptor": {
            "id": "civic.did:41",
            "type": "DiseaseDescriptor",
            "label": "Multiple Myeloma",
            "xrefs": [
                "DOID:9538"
            ],
            "disease": "ncit:C3242"
        },
        "object_descriptor": {
            "id": "civic.tid:328",
            "type": "TherapeuticDescriptor",
            "label": "Melphalan",
            "extensions": [
                {
                    "type": "Extension",
                    "name": "regulatory_approval",
                    "value": {
                        "approval_rating": "FDA",
                        "has_indications": [
                            {
                                "id": "hemonc:633",
                                "type": "DiseaseDescriptor",
                                "label": "Multiple myeloma",
                                "disease": "ncit:C3242"
                            },
                            {
                                "id": "hemonc:645",
                                "type": "DiseaseDescriptor",
                                "label": "Ovarian cancer",
                                "disease": "ncit:C7431"
                            }
                        ]
                    }
                }
            ],
            "xrefs": [
                "ncit:C633"
            ],
            "alternate_labels": [
                "4-[bis(2-chloroethyl)amino]-L-phenylalanine",
                "Alanine Nitrogen Mustard",
                "CB-3025",
                "L-PAM",
                "L-Phenylalanine Mustard",
                "L-Sarcolysin",
                "L-Sarcolysin Phenylalanine Mustard",
                "L-Sarcolysine",
                "Melphalanum",
                "P-di(chloroethyl)amino-L-phenylalanine",
                "Phenylalanine Mustard",
                "Phenylalanine Nitrogen Mustard",
                "Sarcoclorin",
                "Sarkolysin",
                "WR-19813"
            ],
            "therapeutic": "rxcui:6718"
        }
    },
    {
        "id": "civic.eid:2261",
        "type": "VariationNeoplasmTherapeuticResponseStatement",
        "description": "In in vitro experiments, myeloma cell lines expressing activating NRAS and KRAS mutations are less sensitive to the apoptosis-inducing effects of dexamethasone, doxorubicin, and melphalan in comparison to cells with wildtype RAS.",
        "method": "metakb.method:1",
        "is_reported_in": [
            {
                "id": "civic.source:1420",
                "type": "Document",
                "label": "Rowley et al., 2000, Blood",
                "xrefs": [
                    "pmid:11050000"
                ],
                "title": "Heterogeneity in therapeutic response of genetically altered myeloma cell lines to interleukin 6, dexamethasone, doxorubicin, and melphalan."
            }
        ],
        "evidence_level": {
            "id": "vicc:e00009",
            "type": "Coding",
            "label": "preclinical evidence"
        },
        "target_proposition": {
            "id": "proposition:JpdscSmtl0tP4LlgMLwyPbbZcZkyaIFx",
            "type": "VariationNeoplasmTherapeuticResponseProposition",
            "subject": "ga4gh:VA.rpL2_d2q0gdks_VPk_0JVl90aJG9-bEd",
            "predicate": "predicts_resistance_to",
            "object": {
                "id": "rxcui:6718",
                "type": "Therapeutic"
            },
            "neoplasm_type_qualifier": {
                "id": "ncit:C3242",
                "type": "Disease"
            }
        },
        "direction": "supports",
        "subject_descriptor": "civic.vid:78",
        "neoplasm_type_descriptor": {
            "id": "civic.did:41",
            "type": "DiseaseDescriptor",
            "label": "Multiple Myeloma",
            "xrefs": [
                "DOID:9538"
            ],
            "disease": "ncit:C3242"
        },
        "object_descriptor": {
            "id": "civic.tid:328",
            "type": "TherapeuticDescriptor",
            "label": "Melphalan",
            "extensions": [
                {
                    "type": "Extension",
                    "name": "regulatory_approval",
                    "value": {
                        "approval_rating": "FDA",
                        "has_indications": [
                            {
                                "id": "hemonc:633",
                                "type": "DiseaseDescriptor",
                                "label": "Multiple myeloma",
                                "disease": "ncit:C3242"
                            },
                            {
                                "id": "hemonc:645",
                                "type": "DiseaseDescriptor",
                                "label": "Ovarian cancer",
                                "disease": "ncit:C7431"
                            }
                        ]
                    }
                }
            ],
            "xrefs": [
                "ncit:C633"
            ],
            "alternate_labels": [
                "4-[bis(2-chloroethyl)amino]-L-phenylalanine",
                "Alanine Nitrogen Mustard",
                "CB-3025",
                "L-PAM",
                "L-Phenylalanine Mustard",
                "L-Sarcolysin",
                "L-Sarcolysin Phenylalanine Mustard",
                "L-Sarcolysine",
                "Melphalanum",
                "P-di(chloroethyl)amino-L-phenylalanine",
                "Phenylalanine Mustard",
                "Phenylalanine Nitrogen Mustard",
                "Sarcoclorin",
                "Sarkolysin",
                "WR-19813"
            ],
            "therapeutic": "rxcui:6718"
        }
    },
    {
        "id": "civic.eid:2263",
        "type": "VariationNeoplasmTherapeuticResponseStatement",
        "description": "In in vitro experiments, myeloma cell lines expressing activating NRAS and KRAS mutations are less sensitive to the apoptosis-inducing effects of dexamethasone, doxorubicin, and melphalan in comparison to cells with wildtype RAS.",
        "method": "metakb.method:1",
        "is_reported_in": [
            {
                "id": "civic.source:1422",
                "type": "Document",
                "label": "Hoang et al., 2006, Blood",
                "xrefs": [
                    "pmc:PMC1895799",
                    "pmid:16497971"
                ],
                "title": "Oncogenic RAS mutations in myeloma cells selectively induce cox-2 expression, which participates in enhanced adhesion to fibronectin and chemoresistance."
            }
        ],
        "evidence_level": {
            "id": "vicc:e00009",
            "type": "Coding",
            "label": "preclinical evidence"
        },
        "target_proposition": {
            "id": "proposition:JpdscSmtl0tP4LlgMLwyPbbZcZkyaIFx",
            "type": "VariationNeoplasmTherapeuticResponseProposition",
            "subject": "ga4gh:VA.rpL2_d2q0gdks_VPk_0JVl90aJG9-bEd",
            "predicate": "predicts_resistance_to",
            "object": {
                "id": "rxcui:6718",
                "type": "Therapeutic"
            },
            "neoplasm_type_qualifier": {
                "id": "ncit:C3242",
                "type": "Disease"
            }
        },
        "direction": "supports",
        "subject_descriptor": "civic.vid:78",
        "neoplasm_type_descriptor": {
            "id": "civic.did:41",
            "type": "DiseaseDescriptor",
            "label": "Multiple Myeloma",
            "xrefs": [
                "DOID:9538"
            ],
            "disease": "ncit:C3242"
        },
        "object_descriptor": {
            "id": "civic.tid:328",
            "type": "TherapeuticDescriptor",
            "label": "Melphalan",
            "extensions": [
                {
                    "type": "Extension",
                    "name": "regulatory_approval",
                    "value": {
                        "approval_rating": "FDA",
                        "has_indications": [
                            {
                                "id": "hemonc:633",
                                "type": "DiseaseDescriptor",
                                "label": "Multiple myeloma",
                                "disease": "ncit:C3242"
                            },
                            {
                                "id": "hemonc:645",
                                "type": "DiseaseDescriptor",
                                "label": "Ovarian cancer",
                                "disease": "ncit:C7431"
                            }
                        ]
                    }
                }
            ],
            "xrefs": [
                "ncit:C633"
            ],
            "alternate_labels": [
                "4-[bis(2-chloroethyl)amino]-L-phenylalanine",
                "Alanine Nitrogen Mustard",
                "CB-3025",
                "L-PAM",
                "L-Phenylalanine Mustard",
                "L-Sarcolysin",
                "L-Sarcolysin Phenylalanine Mustard",
                "L-Sarcolysine",
                "Melphalanum",
                "P-di(chloroethyl)amino-L-phenylalanine",
                "Phenylalanine Mustard",
                "Phenylalanine Nitrogen Mustard",
                "Sarcoclorin",
                "Sarkolysin",
                "WR-19813"
            ],
            "therapeutic": "rxcui:6718"
        }
    },
    {
        "id": "civic.eid:2277",
        "type": "VariationNeoplasmTherapeuticResponseStatement",
        "description": "In in vitro experiments, myeloma cell lines expressing activating NRAS and KRAS mutations are less sensitive to the apoptosis-inducing effects of dexamethasone, doxorubicin, and melphalan in comparison to cells with wildtype RAS.",
        "method": "metakb.method:1",
        "is_reported_in": [
            {
                "id": "civic.source:1420",
                "type": "Document",
                "label": "Rowley et al., 2000, Blood",
                "xrefs": [
                    "pmid:11050000"
                ],
                "title": "Heterogeneity in therapeutic response of genetically altered myeloma cell lines to interleukin 6, dexamethasone, doxorubicin, and melphalan."
            }
        ],
        "evidence_level": {
            "id": "vicc:e00009",
            "type": "Coding",
            "label": "preclinical evidence"
        },
        "target_proposition": {
            "id": "proposition:DADVpjI5RMfxgPq1_fZCX1MHAPT7OvPJ",
            "type": "VariationNeoplasmTherapeuticResponseProposition",
            "subject": "ga4gh:VA.QVdzWvpiRTgBHwV39EuVg6VZVGOLxdUS",
            "predicate": "predicts_resistance_to",
            "object": {
                "id": "rxcui:6718",
                "type": "Therapeutic"
            },
            "neoplasm_type_qualifier": {
                "id": "ncit:C3242",
                "type": "Disease"
            }
        },
        "direction": "supports",
        "subject_descriptor": "civic.vid:913",
        "neoplasm_type_descriptor": {
            "id": "civic.did:41",
            "type": "DiseaseDescriptor",
            "label": "Multiple Myeloma",
            "xrefs": [
                "DOID:9538"
            ],
            "disease": "ncit:C3242"
        },
        "object_descriptor": {
            "id": "civic.tid:328",
            "type": "TherapeuticDescriptor",
            "label": "Melphalan",
            "extensions": [
                {
                    "type": "Extension",
                    "name": "regulatory_approval",
                    "value": {
                        "approval_rating": "FDA",
                        "has_indications": [
                            {
                                "id": "hemonc:633",
                                "type": "DiseaseDescriptor",
                                "label": "Multiple myeloma",
                                "disease": "ncit:C3242"
                            },
                            {
                                "id": "hemonc:645",
                                "type": "DiseaseDescriptor",
                                "label": "Ovarian cancer",
                                "disease": "ncit:C7431"
                            }
                        ]
                    }
                }
            ],
            "xrefs": [
                "ncit:C633"
            ],
            "alternate_labels": [
                "4-[bis(2-chloroethyl)amino]-L-phenylalanine",
                "Alanine Nitrogen Mustard",
                "CB-3025",
                "L-PAM",
                "L-Phenylalanine Mustard",
                "L-Sarcolysin",
                "L-Sarcolysin Phenylalanine Mustard",
                "L-Sarcolysine",
                "Melphalanum",
                "P-di(chloroethyl)amino-L-phenylalanine",
                "Phenylalanine Mustard",
                "Phenylalanine Nitrogen Mustard",
                "Sarcoclorin",
                "Sarkolysin",
                "WR-19813"
            ],
            "therapeutic": "rxcui:6718"
        }
    },
    {
        "id": "civic.eid:2278",
        "type": "VariationNeoplasmTherapeuticResponseStatement",
        "description": "In in vitro experiments, myeloma cell lines expressing activating NRAS and KRAS mutations are less sensitive to the apoptosis-inducing effects of dexamethasone, doxorubicin, and melphalan in comparison to cells with wildtype RAS.",
        "method": "metakb.method:1",
        "is_reported_in": [
            {
                "id": "civic.source:1421",
                "type": "Document",
                "label": "Rowley et al., 2002, Oncogene",
                "xrefs": [
                    "pmid:12483530"
                ],
                "title": "Activation of N-ras and K-ras induced by interleukin-6 in a myeloma cell line: implications for disease progression and therapeutic response."
            }
        ],
        "evidence_level": {
            "id": "vicc:e00009",
            "type": "Coding",
            "label": "preclinical evidence"
        },
        "target_proposition": {
            "id": "proposition:DADVpjI5RMfxgPq1_fZCX1MHAPT7OvPJ",
            "type": "VariationNeoplasmTherapeuticResponseProposition",
            "subject": "ga4gh:VA.QVdzWvpiRTgBHwV39EuVg6VZVGOLxdUS",
            "predicate": "predicts_resistance_to",
            "object": {
                "id": "rxcui:6718",
                "type": "Therapeutic"
            },
            "neoplasm_type_qualifier": {
                "id": "ncit:C3242",
                "type": "Disease"
            }
        },
        "direction": "supports",
        "subject_descriptor": "civic.vid:913",
        "neoplasm_type_descriptor": {
            "id": "civic.did:41",
            "type": "DiseaseDescriptor",
            "label": "Multiple Myeloma",
            "xrefs": [
                "DOID:9538"
            ],
            "disease": "ncit:C3242"
        },
        "object_descriptor": {
            "id": "civic.tid:328",
            "type": "TherapeuticDescriptor",
            "label": "Melphalan",
            "extensions": [
                {
                    "type": "Extension",
                    "name": "regulatory_approval",
                    "value": {
                        "approval_rating": "FDA",
                        "has_indications": [
                            {
                                "id": "hemonc:633",
                                "type": "DiseaseDescriptor",
                                "label": "Multiple myeloma",
                                "disease": "ncit:C3242"
                            },
                            {
                                "id": "hemonc:645",
                                "type": "DiseaseDescriptor",
                                "label": "Ovarian cancer",
                                "disease": "ncit:C7431"
                            }
                        ]
                    }
                }
            ],
            "xrefs": [
                "ncit:C633"
            ],
            "alternate_labels": [
                "4-[bis(2-chloroethyl)amino]-L-phenylalanine",
                "Alanine Nitrogen Mustard",
                "CB-3025",
                "L-PAM",
                "L-Phenylalanine Mustard",
                "L-Sarcolysin",
                "L-Sarcolysin Phenylalanine Mustard",
                "L-Sarcolysine",
                "Melphalanum",
                "P-di(chloroethyl)amino-L-phenylalanine",
                "Phenylalanine Mustard",
                "Phenylalanine Nitrogen Mustard",
                "Sarcoclorin",
                "Sarkolysin",
                "WR-19813"
            ],
            "therapeutic": "rxcui:6718"
        }
    },
    {
        "id": "civic.eid:2279",
        "type": "VariationNeoplasmTherapeuticResponseStatement",
        "description": "In in vitro experiments, myeloma cell lines expressing activating NRAS and KRAS mutations are less sensitive to the apoptosis-inducing effects of dexamethasone, doxorubicin, and melphalan in comparison to cells with wildtype RAS.",
        "method": "metakb.method:1",
        "is_reported_in": [
            {
                "id": "civic.source:1422",
                "type": "Document",
                "label": "Hoang et al., 2006, Blood",
                "xrefs": [
                    "pmc:PMC1895799",
                    "pmid:16497971"
                ],
                "title": "Oncogenic RAS mutations in myeloma cells selectively induce cox-2 expression, which participates in enhanced adhesion to fibronectin and chemoresistance."
            }
        ],
        "evidence_level": {
            "id": "vicc:e00009",
            "type": "Coding",
            "label": "preclinical evidence"
        },
        "target_proposition": {
            "id": "proposition:DADVpjI5RMfxgPq1_fZCX1MHAPT7OvPJ",
            "type": "VariationNeoplasmTherapeuticResponseProposition",
            "subject": "ga4gh:VA.QVdzWvpiRTgBHwV39EuVg6VZVGOLxdUS",
            "predicate": "predicts_resistance_to",
            "object": {
                "id": "rxcui:6718",
                "type": "Therapeutic"
            },
            "neoplasm_type_qualifier": {
                "id": "ncit:C3242",
                "type": "Disease"
            }
        },
        "direction": "supports",
        "subject_descriptor": "civic.vid:913",
        "neoplasm_type_descriptor": {
            "id": "civic.did:41",
            "type": "DiseaseDescriptor",
            "label": "Multiple Myeloma",
            "xrefs": [
                "DOID:9538"
            ],
            "disease": "ncit:C3242"
        },
        "object_descriptor": {
            "id": "civic.tid:328",
            "type": "TherapeuticDescriptor",
            "label": "Melphalan",
            "extensions": [
                {
                    "type": "Extension",
                    "name": "regulatory_approval",
                    "value": {
                        "approval_rating": "FDA",
                        "has_indications": [
                            {
                                "id": "hemonc:633",
                                "type": "DiseaseDescriptor",
                                "label": "Multiple myeloma",
                                "disease": "ncit:C3242"
                            },
                            {
                                "id": "hemonc:645",
                                "type": "DiseaseDescriptor",
                                "label": "Ovarian cancer",
                                "disease": "ncit:C7431"
                            }
                        ]
                    }
                }
            ],
            "xrefs": [
                "ncit:C633"
            ],
            "alternate_labels": [
                "4-[bis(2-chloroethyl)amino]-L-phenylalanine",
                "Alanine Nitrogen Mustard",
                "CB-3025",
                "L-PAM",
                "L-Phenylalanine Mustard",
                "L-Sarcolysin",
                "L-Sarcolysin Phenylalanine Mustard",
                "L-Sarcolysine",
                "Melphalanum",
                "P-di(chloroethyl)amino-L-phenylalanine",
                "Phenylalanine Mustard",
                "Phenylalanine Nitrogen Mustard",
                "Sarcoclorin",
                "Sarkolysin",
                "WR-19813"
            ],
            "therapeutic": "rxcui:6718"
        }
    },
    {
        "id": "civic.eid:2445",
        "type": "VariationNeoplasmTherapeuticResponseStatement",
        "description": "In an in vitro study of imatinib sensitivity, KIT N822H was cloned into a plasmid by site-directed mutagenesis of KIT WT cDNA. Chinese hamster ovary cells were transiently transfected with the plasmid. Cells were treated with control media or media containing various concentrations of imatinib for 90 minutes. Protein lysates from the transfected cells were examined for phosphorylated tyrosine, a measure of KIT activation. Cells expressing KIT N822H were as sensitive to imatinib as ligand activated wildtype KIT (IC50: 100-200 nmol/L).",
        "method": "metakb.method:1",
        "is_reported_in": [
            {
                "id": "civic.source:412",
                "type": "Document",
                "label": "Heinrich et al., 2003, J. Clin. Oncol.",
                "xrefs": [
                    "pmid:14645423"
                ],
                "title": "Kinase mutations and imatinib response in patients with metastatic gastrointestinal stromal tumor."
            }
        ],
        "evidence_level": {
            "id": "vicc:e00009",
            "type": "Coding",
            "label": "preclinical evidence"
        },
        "target_proposition": {
            "id": "proposition:VZY9ZJ_NpqE1M-jD9pUZZDaIDhacKBQW",
            "type": "VariationNeoplasmTherapeuticResponseProposition",
            "subject": "ga4gh:VA.1hiFwlYqyUZp6seEX9tIvVsOwS351O3U",
            "predicate": "predicts_resistance_to",
            "object": {
                "id": "rxcui:282388",
                "type": "Therapeutic"
            },
            "neoplasm_type_qualifier": {
                "id": "ncit:C9305",
                "type": "Disease"
            }
        },
        "direction": "opposes",
        "subject_descriptor": "civic.vid:987",
        "neoplasm_type_descriptor": {
            "id": "civic.did:216",
            "type": "DiseaseDescriptor",
            "label": "Cancer",
            "xrefs": [
                "DOID:162"
            ],
            "disease": "ncit:C9305"
        },
        "object_descriptor": {
            "id": "civic.tid:5",
            "type": "TherapeuticDescriptor",
            "label": "Imatinib",
            "extensions": [
                {
                    "type": "Extension",
                    "name": "regulatory_approval",
                    "value": {
                        "approval_rating": "FDA",
                        "has_indications": [
                            {
                                "id": "hemonc:667",
                                "type": "DiseaseDescriptor",
                                "label": "Soft tissue sarcoma",
                                "disease": "ncit:C9306"
                            },
                            {
                                "id": "hemonc:602",
                                "type": "DiseaseDescriptor",
                                "label": "Gastrointestinal stromal tumor",
                                "disease": "ncit:C3868"
                            },
                            {
                                "id": "hemonc:616",
                                "type": "DiseaseDescriptor",
                                "label": "Hypereosinophilic syndrome",
                                "disease": "ncit:C27038"
                            },
                            {
                                "id": "hemonc:33893",
                                "type": "DiseaseDescriptor",
                                "label": "Chronic myelogenous leukemia pediatric",
                                "disease": null
                            },
                            {
                                "id": "hemonc:634",
                                "type": "DiseaseDescriptor",
                                "label": "Myelodysplastic syndrome",
                                "disease": "ncit:C3247"
                            },
                            {
                                "id": "hemonc:24309",
                                "type": "DiseaseDescriptor",
                                "label": "Acute lymphoblastic leukemia",
                                "disease": "ncit:C3167"
                            },
                            {
                                "id": "hemonc:582",
                                "type": "DiseaseDescriptor",
                                "label": "Chronic myelogenous leukemia",
                                "disease": "ncit:C3174"
                            },
                            {
                                "id": "hemonc:669",
                                "type": "DiseaseDescriptor",
                                "label": "Systemic mastocytosis",
                                "disease": "ncit:C9235"
                            }
                        ]
                    }
                }
            ],
            "xrefs": [
                "ncit:C62035"
            ],
            "alternate_labels": [
                "4-[(4-Methyl-1-piperazinyl)methyl]-N-[4-methyl-3-[[4-(3-pyridinyl)-2-pyrimidinyl]amino]phenyl]benzamide"
            ],
            "therapeutic": "rxcui:282388"
        }
    },
    {
        "id": "civic.eid:2451",
        "type": "VariationNeoplasmTherapeuticResponseStatement",
        "description": "In an in vitro study of imatinib sensitivity, KIT D816V was cloned into a plasmid by site-directed mutagenesis of KIT WT cDNA. Chinese hamster ovary cells were transiently transfected with the plasmid. Cells were treated with control media or media containing various concentrations of imatinib for 90 minutes. Protein lysates from the transfected cells were examined for phosphorylated tyrosine, a measure of KIT activation. Cells expressing KIT D816V were resistant to imatinib up to 10 umol/L.",
        "method": "metakb.method:1",
        "is_reported_in": [
            {
                "id": "civic.source:412",
                "type": "Document",
                "label": "Heinrich et al., 2003, J. Clin. Oncol.",
                "xrefs": [
                    "pmid:14645423"
                ],
                "title": "Kinase mutations and imatinib response in patients with metastatic gastrointestinal stromal tumor."
            }
        ],
        "evidence_level": {
            "id": "vicc:e00009",
            "type": "Coding",
            "label": "preclinical evidence"
        },
        "target_proposition": {
            "id": "proposition:OBcn0zF1MPc2s0JljTGL_6gsWYCaBj9Y",
            "type": "VariationNeoplasmTherapeuticResponseProposition",
            "subject": "ga4gh:VA.nMt7siwiRwJd_T_l46fg_fFaPZ7-H4sN",
            "predicate": "predicts_resistance_to",
            "object": {
                "id": "rxcui:282388",
                "type": "Therapeutic"
            },
            "neoplasm_type_qualifier": {
                "id": "ncit:C9305",
                "type": "Disease"
            }
        },
        "direction": "supports",
        "subject_descriptor": "civic.vid:65",
        "neoplasm_type_descriptor": {
            "id": "civic.did:216",
            "type": "DiseaseDescriptor",
            "label": "Cancer",
            "xrefs": [
                "DOID:162"
            ],
            "disease": "ncit:C9305"
        },
        "object_descriptor": {
            "id": "civic.tid:5",
            "type": "TherapeuticDescriptor",
            "label": "Imatinib",
            "extensions": [
                {
                    "type": "Extension",
                    "name": "regulatory_approval",
                    "value": {
                        "approval_rating": "FDA",
                        "has_indications": [
                            {
                                "id": "hemonc:667",
                                "type": "DiseaseDescriptor",
                                "label": "Soft tissue sarcoma",
                                "disease": "ncit:C9306"
                            },
                            {
                                "id": "hemonc:602",
                                "type": "DiseaseDescriptor",
                                "label": "Gastrointestinal stromal tumor",
                                "disease": "ncit:C3868"
                            },
                            {
                                "id": "hemonc:616",
                                "type": "DiseaseDescriptor",
                                "label": "Hypereosinophilic syndrome",
                                "disease": "ncit:C27038"
                            },
                            {
                                "id": "hemonc:33893",
                                "type": "DiseaseDescriptor",
                                "label": "Chronic myelogenous leukemia pediatric",
                                "disease": null
                            },
                            {
                                "id": "hemonc:634",
                                "type": "DiseaseDescriptor",
                                "label": "Myelodysplastic syndrome",
                                "disease": "ncit:C3247"
                            },
                            {
                                "id": "hemonc:24309",
                                "type": "DiseaseDescriptor",
                                "label": "Acute lymphoblastic leukemia",
                                "disease": "ncit:C3167"
                            },
                            {
                                "id": "hemonc:582",
                                "type": "DiseaseDescriptor",
                                "label": "Chronic myelogenous leukemia",
                                "disease": "ncit:C3174"
                            },
                            {
                                "id": "hemonc:669",
                                "type": "DiseaseDescriptor",
                                "label": "Systemic mastocytosis",
                                "disease": "ncit:C9235"
                            }
                        ]
                    }
                }
            ],
            "xrefs": [
                "ncit:C62035"
            ],
            "alternate_labels": [
                "4-[(4-Methyl-1-piperazinyl)methyl]-N-[4-methyl-3-[[4-(3-pyridinyl)-2-pyrimidinyl]amino]phenyl]benzamide"
            ],
            "therapeutic": "rxcui:282388"
        }
    },
    {
        "id": "civic.eid:2454",
        "type": "VariationNeoplasmTherapeuticResponseStatement",
        "description": "In an in vitro study of imatinib sensitivity, PDGFRA V561D was cloned into a plasmid by site-directed mutagenesis of PDGFRA WT cDNA. Chinese hamster ovary cells were transiently transfected with the plasmid. The cells were treated with control media or media containing various concentrations of imatinib for 90 minutes. Protein lysates from the transfected cells were examined for phosphorylated tyrosine, a measure of PDGFRA activation. Cells expressing PDGFRA V561D were as sensitive to imatinib as ligand activated wildtype PDGFRA (IC50: 100-200 nmol/L).",
        "method": "metakb.method:1",
        "is_reported_in": [
            {
                "id": "civic.source:412",
                "type": "Document",
                "label": "Heinrich et al., 2003, J. Clin. Oncol.",
                "xrefs": [
                    "pmid:14645423"
                ],
                "title": "Kinase mutations and imatinib response in patients with metastatic gastrointestinal stromal tumor."
            }
        ],
        "evidence_level": {
            "id": "vicc:e00009",
            "type": "Coding",
            "label": "preclinical evidence"
        },
        "target_proposition": {
            "id": "proposition:-xN_xeEUq0fac4KIaVJ3IN0SC4hNUHeR",
            "type": "VariationNeoplasmTherapeuticResponseProposition",
            "subject": "ga4gh:VA.PmR2KGO2d96zDOFtI79sijmIhGO2v-a0",
            "predicate": "predicts_resistance_to",
            "object": {
                "id": "rxcui:282388",
                "type": "Therapeutic"
            },
            "neoplasm_type_qualifier": {
                "id": "ncit:C9305",
                "type": "Disease"
            }
        },
        "direction": "opposes",
        "subject_descriptor": "civic.vid:941",
        "neoplasm_type_descriptor": {
            "id": "civic.did:216",
            "type": "DiseaseDescriptor",
            "label": "Cancer",
            "xrefs": [
                "DOID:162"
            ],
            "disease": "ncit:C9305"
        },
        "object_descriptor": {
            "id": "civic.tid:5",
            "type": "TherapeuticDescriptor",
            "label": "Imatinib",
            "extensions": [
                {
                    "type": "Extension",
                    "name": "regulatory_approval",
                    "value": {
                        "approval_rating": "FDA",
                        "has_indications": [
                            {
                                "id": "hemonc:667",
                                "type": "DiseaseDescriptor",
                                "label": "Soft tissue sarcoma",
                                "disease": "ncit:C9306"
                            },
                            {
                                "id": "hemonc:602",
                                "type": "DiseaseDescriptor",
                                "label": "Gastrointestinal stromal tumor",
                                "disease": "ncit:C3868"
                            },
                            {
                                "id": "hemonc:616",
                                "type": "DiseaseDescriptor",
                                "label": "Hypereosinophilic syndrome",
                                "disease": "ncit:C27038"
                            },
                            {
                                "id": "hemonc:33893",
                                "type": "DiseaseDescriptor",
                                "label": "Chronic myelogenous leukemia pediatric",
                                "disease": null
                            },
                            {
                                "id": "hemonc:634",
                                "type": "DiseaseDescriptor",
                                "label": "Myelodysplastic syndrome",
                                "disease": "ncit:C3247"
                            },
                            {
                                "id": "hemonc:24309",
                                "type": "DiseaseDescriptor",
                                "label": "Acute lymphoblastic leukemia",
                                "disease": "ncit:C3167"
                            },
                            {
                                "id": "hemonc:582",
                                "type": "DiseaseDescriptor",
                                "label": "Chronic myelogenous leukemia",
                                "disease": "ncit:C3174"
                            },
                            {
                                "id": "hemonc:669",
                                "type": "DiseaseDescriptor",
                                "label": "Systemic mastocytosis",
                                "disease": "ncit:C9235"
                            }
                        ]
                    }
                }
            ],
            "xrefs": [
                "ncit:C62035"
            ],
            "alternate_labels": [
                "4-[(4-Methyl-1-piperazinyl)methyl]-N-[4-methyl-3-[[4-(3-pyridinyl)-2-pyrimidinyl]amino]phenyl]benzamide"
            ],
            "therapeutic": "rxcui:282388"
        }
    },
    {
        "id": "civic.eid:2463",
        "type": "VariationNeoplasmTherapeuticResponseStatement",
        "description": "In an in vitro study of imatinib sensitivity, PDGFRA D842V was cloned into a plasmid by site-directed mutagenesis of PDGFRA WT cDNA. Chinese hamster ovary cells were transiently transfected with the plasmid. The cells were treated with control media or media containing various concentrations of imatinib for 90 minutes. Protein lysates from the transfected cells were examined for phosphorylated tyrosine, a measure of PDGFRA activation. Cells expressing PDGFRA D842V required 10-20 fold higher concentrations of imatinib as ligand activated wildtype PDGFRA (IC50: 1-2 umol/L).",
        "method": "metakb.method:1",
        "is_reported_in": [
            {
                "id": "civic.source:412",
                "type": "Document",
                "label": "Heinrich et al., 2003, J. Clin. Oncol.",
                "xrefs": [
                    "pmid:14645423"
                ],
                "title": "Kinase mutations and imatinib response in patients with metastatic gastrointestinal stromal tumor."
            }
        ],
        "evidence_level": {
            "id": "vicc:e00009",
            "type": "Coding",
            "label": "preclinical evidence"
        },
        "target_proposition": {
            "id": "proposition:4wAwz4JpInBDLo3whjYGXvXng0zm5369",
            "type": "VariationNeoplasmTherapeuticResponseProposition",
            "subject": "ga4gh:VA.CaTuLaWlUwLb32qfYTW2udl2Iy02ccN6",
            "predicate": "predicts_resistance_to",
            "object": {
                "id": "rxcui:282388",
                "type": "Therapeutic"
            },
            "neoplasm_type_qualifier": {
                "id": "ncit:C9305",
                "type": "Disease"
            }
        },
        "direction": "supports",
        "subject_descriptor": "civic.vid:99",
        "neoplasm_type_descriptor": {
            "id": "civic.did:216",
            "type": "DiseaseDescriptor",
            "label": "Cancer",
            "xrefs": [
                "DOID:162"
            ],
            "disease": "ncit:C9305"
        },
        "object_descriptor": {
            "id": "civic.tid:5",
            "type": "TherapeuticDescriptor",
            "label": "Imatinib",
            "extensions": [
                {
                    "type": "Extension",
                    "name": "regulatory_approval",
                    "value": {
                        "approval_rating": "FDA",
                        "has_indications": [
                            {
                                "id": "hemonc:667",
                                "type": "DiseaseDescriptor",
                                "label": "Soft tissue sarcoma",
                                "disease": "ncit:C9306"
                            },
                            {
                                "id": "hemonc:602",
                                "type": "DiseaseDescriptor",
                                "label": "Gastrointestinal stromal tumor",
                                "disease": "ncit:C3868"
                            },
                            {
                                "id": "hemonc:616",
                                "type": "DiseaseDescriptor",
                                "label": "Hypereosinophilic syndrome",
                                "disease": "ncit:C27038"
                            },
                            {
                                "id": "hemonc:33893",
                                "type": "DiseaseDescriptor",
                                "label": "Chronic myelogenous leukemia pediatric",
                                "disease": null
                            },
                            {
                                "id": "hemonc:634",
                                "type": "DiseaseDescriptor",
                                "label": "Myelodysplastic syndrome",
                                "disease": "ncit:C3247"
                            },
                            {
                                "id": "hemonc:24309",
                                "type": "DiseaseDescriptor",
                                "label": "Acute lymphoblastic leukemia",
                                "disease": "ncit:C3167"
                            },
                            {
                                "id": "hemonc:582",
                                "type": "DiseaseDescriptor",
                                "label": "Chronic myelogenous leukemia",
                                "disease": "ncit:C3174"
                            },
                            {
                                "id": "hemonc:669",
                                "type": "DiseaseDescriptor",
                                "label": "Systemic mastocytosis",
                                "disease": "ncit:C9235"
                            }
                        ]
                    }
                }
            ],
            "xrefs": [
                "ncit:C62035"
            ],
            "alternate_labels": [
                "4-[(4-Methyl-1-piperazinyl)methyl]-N-[4-methyl-3-[[4-(3-pyridinyl)-2-pyrimidinyl]amino]phenyl]benzamide"
            ],
            "therapeutic": "rxcui:282388"
        }
    },
    {
        "id": "civic.eid:2469",
        "type": "VariationNeoplasmTherapeuticResponseStatement",
        "description": "In an in vitro study of imatinib sensitivity, KIT V560G was cloned into a plasmid by site-directed mutagenesis of KIT WT cDNA. Chinese hamster ovary cells were transiently transfected with the plasmid. The cells were treated with control media or media containing various concentrations of imatinib for 90 minutes. Protein lysates from the transfected cells were examined for the presence of phosphorylated tyrosine, a measure of KIT activation. Cells expressing KIT V560G were as sensitive to imatinib as ligand activated wildtype KIT (IC50: 100-200 nmol/L).",
        "method": "metakb.method:1",
        "is_reported_in": [
            {
                "id": "civic.source:412",
                "type": "Document",
                "label": "Heinrich et al., 2003, J. Clin. Oncol.",
                "xrefs": [
                    "pmid:14645423"
                ],
                "title": "Kinase mutations and imatinib response in patients with metastatic gastrointestinal stromal tumor."
            }
        ],
        "evidence_level": {
            "id": "vicc:e00009",
            "type": "Coding",
            "label": "preclinical evidence"
        },
        "target_proposition": {
            "id": "proposition:Q1lzj3L295gz_euOLgz1THOjb184lJj7",
            "type": "VariationNeoplasmTherapeuticResponseProposition",
            "subject": "ga4gh:VA.TZi8JJHH5GGyPAu35PyoWm3HBUhfmXhe",
            "predicate": "predicts_resistance_to",
            "object": {
                "id": "rxcui:282388",
                "type": "Therapeutic"
            },
            "neoplasm_type_qualifier": {
                "id": "ncit:C9305",
                "type": "Disease"
            }
        },
        "direction": "opposes",
        "subject_descriptor": "civic.vid:972",
        "neoplasm_type_descriptor": {
            "id": "civic.did:216",
            "type": "DiseaseDescriptor",
            "label": "Cancer",
            "xrefs": [
                "DOID:162"
            ],
            "disease": "ncit:C9305"
        },
        "object_descriptor": {
            "id": "civic.tid:5",
            "type": "TherapeuticDescriptor",
            "label": "Imatinib",
            "extensions": [
                {
                    "type": "Extension",
                    "name": "regulatory_approval",
                    "value": {
                        "approval_rating": "FDA",
                        "has_indications": [
                            {
                                "id": "hemonc:667",
                                "type": "DiseaseDescriptor",
                                "label": "Soft tissue sarcoma",
                                "disease": "ncit:C9306"
                            },
                            {
                                "id": "hemonc:602",
                                "type": "DiseaseDescriptor",
                                "label": "Gastrointestinal stromal tumor",
                                "disease": "ncit:C3868"
                            },
                            {
                                "id": "hemonc:616",
                                "type": "DiseaseDescriptor",
                                "label": "Hypereosinophilic syndrome",
                                "disease": "ncit:C27038"
                            },
                            {
                                "id": "hemonc:33893",
                                "type": "DiseaseDescriptor",
                                "label": "Chronic myelogenous leukemia pediatric",
                                "disease": null
                            },
                            {
                                "id": "hemonc:634",
                                "type": "DiseaseDescriptor",
                                "label": "Myelodysplastic syndrome",
                                "disease": "ncit:C3247"
                            },
                            {
                                "id": "hemonc:24309",
                                "type": "DiseaseDescriptor",
                                "label": "Acute lymphoblastic leukemia",
                                "disease": "ncit:C3167"
                            },
                            {
                                "id": "hemonc:582",
                                "type": "DiseaseDescriptor",
                                "label": "Chronic myelogenous leukemia",
                                "disease": "ncit:C3174"
                            },
                            {
                                "id": "hemonc:669",
                                "type": "DiseaseDescriptor",
                                "label": "Systemic mastocytosis",
                                "disease": "ncit:C9235"
                            }
                        ]
                    }
                }
            ],
            "xrefs": [
                "ncit:C62035"
            ],
            "alternate_labels": [
                "4-[(4-Methyl-1-piperazinyl)methyl]-N-[4-methyl-3-[[4-(3-pyridinyl)-2-pyrimidinyl]amino]phenyl]benzamide"
            ],
            "therapeutic": "rxcui:282388"
        }
    },
    {
        "id": "civic.eid:2472",
        "type": "VariationNeoplasmTherapeuticResponseStatement",
        "description": "In an in vitro study of imatinib sensitivity, KIT K642E was cloned into a plasmid by site-directed mutagenesis of KIT WT cDNA. Chinese hamster ovary cells were transiently transfected with the plasmid. Cells were treated with control media or media containing various concentrations of imatinib for 90 minutes. Then, protein lysates from the transfected cells were examined for phosphorylated tyrosine, a measure of KIT activation. Cells expressing KIT K642E were as sensitive to imatinib as ligand activated wildtype KIT (IC50: 100-200 nmol/L).",
        "method": "metakb.method:1",
        "is_reported_in": [
            {
                "id": "civic.source:412",
                "type": "Document",
                "label": "Heinrich et al., 2003, J. Clin. Oncol.",
                "xrefs": [
                    "pmid:14645423"
                ],
                "title": "Kinase mutations and imatinib response in patients with metastatic gastrointestinal stromal tumor."
            }
        ],
        "evidence_level": {
            "id": "vicc:e00009",
            "type": "Coding",
            "label": "preclinical evidence"
        },
        "target_proposition": {
            "id": "proposition:FRKx3lIwShOkc1Oo8nqmaPEVZJ1LIfc5",
            "type": "VariationNeoplasmTherapeuticResponseProposition",
            "subject": "ga4gh:VA.qqyXsR4-bT1oCgmCJM4qHholRwDQ602L",
            "predicate": "predicts_resistance_to",
            "object": {
                "id": "rxcui:282388",
                "type": "Therapeutic"
            },
            "neoplasm_type_qualifier": {
                "id": "ncit:C9305",
                "type": "Disease"
            }
        },
        "direction": "opposes",
        "subject_descriptor": "civic.vid:978",
        "neoplasm_type_descriptor": {
            "id": "civic.did:216",
            "type": "DiseaseDescriptor",
            "label": "Cancer",
            "xrefs": [
                "DOID:162"
            ],
            "disease": "ncit:C9305"
        },
        "object_descriptor": {
            "id": "civic.tid:5",
            "type": "TherapeuticDescriptor",
            "label": "Imatinib",
            "extensions": [
                {
                    "type": "Extension",
                    "name": "regulatory_approval",
                    "value": {
                        "approval_rating": "FDA",
                        "has_indications": [
                            {
                                "id": "hemonc:667",
                                "type": "DiseaseDescriptor",
                                "label": "Soft tissue sarcoma",
                                "disease": "ncit:C9306"
                            },
                            {
                                "id": "hemonc:602",
                                "type": "DiseaseDescriptor",
                                "label": "Gastrointestinal stromal tumor",
                                "disease": "ncit:C3868"
                            },
                            {
                                "id": "hemonc:616",
                                "type": "DiseaseDescriptor",
                                "label": "Hypereosinophilic syndrome",
                                "disease": "ncit:C27038"
                            },
                            {
                                "id": "hemonc:33893",
                                "type": "DiseaseDescriptor",
                                "label": "Chronic myelogenous leukemia pediatric",
                                "disease": null
                            },
                            {
                                "id": "hemonc:634",
                                "type": "DiseaseDescriptor",
                                "label": "Myelodysplastic syndrome",
                                "disease": "ncit:C3247"
                            },
                            {
                                "id": "hemonc:24309",
                                "type": "DiseaseDescriptor",
                                "label": "Acute lymphoblastic leukemia",
                                "disease": "ncit:C3167"
                            },
                            {
                                "id": "hemonc:582",
                                "type": "DiseaseDescriptor",
                                "label": "Chronic myelogenous leukemia",
                                "disease": "ncit:C3174"
                            },
                            {
                                "id": "hemonc:669",
                                "type": "DiseaseDescriptor",
                                "label": "Systemic mastocytosis",
                                "disease": "ncit:C9235"
                            }
                        ]
                    }
                }
            ],
            "xrefs": [
                "ncit:C62035"
            ],
            "alternate_labels": [
                "4-[(4-Methyl-1-piperazinyl)methyl]-N-[4-methyl-3-[[4-(3-pyridinyl)-2-pyrimidinyl]amino]phenyl]benzamide"
            ],
            "therapeutic": "rxcui:282388"
        }
    },
    {
        "id": "civic.eid:2481",
        "type": "VariationNeoplasmTherapeuticResponseStatement",
        "description": "In an in vitro study of imatinib sensitivity, KIT W557_K558del was cloned into a plasmid by site-directed mutagenesis of KIT WT cDNA. Chinese hamster ovary cells were transiently transfected with the plasmid. Cells were treated with control media or media containing various concentrations of imatinib for 90 minutes. Protein lysates from the transfected cells were examined for phosphorylated tyrosine, a measure of KIT activation. Cells expressing KIT W557_K558del were as sensitive to imatinib as ligand activated wildtype KIT (IC50: 100-200 nmol/L).",
        "method": "metakb.method:1",
        "is_reported_in": [
            {
                "id": "civic.source:412",
                "type": "Document",
                "label": "Heinrich et al., 2003, J. Clin. Oncol.",
                "xrefs": [
                    "pmid:14645423"
                ],
                "title": "Kinase mutations and imatinib response in patients with metastatic gastrointestinal stromal tumor."
            }
        ],
        "evidence_level": {
            "id": "vicc:e00009",
            "type": "Coding",
            "label": "preclinical evidence"
        },
        "target_proposition": {
            "id": "proposition:VoPNvhNVKfg3xdR3v36DGQhB5l_Wr-G7",
            "type": "VariationNeoplasmTherapeuticResponseProposition",
            "subject": "ga4gh:VA.2gBgJAKNHo14J6N0g8ZYsewGjZK1O2tQ",
            "predicate": "predicts_resistance_to",
            "object": {
                "id": "rxcui:282388",
                "type": "Therapeutic"
            },
            "neoplasm_type_qualifier": {
                "id": "ncit:C9305",
                "type": "Disease"
            }
        },
        "direction": "opposes",
        "subject_descriptor": "civic.vid:961",
        "neoplasm_type_descriptor": {
            "id": "civic.did:216",
            "type": "DiseaseDescriptor",
            "label": "Cancer",
            "xrefs": [
                "DOID:162"
            ],
            "disease": "ncit:C9305"
        },
        "object_descriptor": {
            "id": "civic.tid:5",
            "type": "TherapeuticDescriptor",
            "label": "Imatinib",
            "extensions": [
                {
                    "type": "Extension",
                    "name": "regulatory_approval",
                    "value": {
                        "approval_rating": "FDA",
                        "has_indications": [
                            {
                                "id": "hemonc:667",
                                "type": "DiseaseDescriptor",
                                "label": "Soft tissue sarcoma",
                                "disease": "ncit:C9306"
                            },
                            {
                                "id": "hemonc:602",
                                "type": "DiseaseDescriptor",
                                "label": "Gastrointestinal stromal tumor",
                                "disease": "ncit:C3868"
                            },
                            {
                                "id": "hemonc:616",
                                "type": "DiseaseDescriptor",
                                "label": "Hypereosinophilic syndrome",
                                "disease": "ncit:C27038"
                            },
                            {
                                "id": "hemonc:33893",
                                "type": "DiseaseDescriptor",
                                "label": "Chronic myelogenous leukemia pediatric",
                                "disease": null
                            },
                            {
                                "id": "hemonc:634",
                                "type": "DiseaseDescriptor",
                                "label": "Myelodysplastic syndrome",
                                "disease": "ncit:C3247"
                            },
                            {
                                "id": "hemonc:24309",
                                "type": "DiseaseDescriptor",
                                "label": "Acute lymphoblastic leukemia",
                                "disease": "ncit:C3167"
                            },
                            {
                                "id": "hemonc:582",
                                "type": "DiseaseDescriptor",
                                "label": "Chronic myelogenous leukemia",
                                "disease": "ncit:C3174"
                            },
                            {
                                "id": "hemonc:669",
                                "type": "DiseaseDescriptor",
                                "label": "Systemic mastocytosis",
                                "disease": "ncit:C9235"
                            }
                        ]
                    }
                }
            ],
            "xrefs": [
                "ncit:C62035"
            ],
            "alternate_labels": [
                "4-[(4-Methyl-1-piperazinyl)methyl]-N-[4-methyl-3-[[4-(3-pyridinyl)-2-pyrimidinyl]amino]phenyl]benzamide"
            ],
            "therapeutic": "rxcui:282388"
        }
    },
    {
        "id": "civic.eid:2484",
        "type": "VariationNeoplasmTherapeuticResponseStatement",
        "description": "In an in vitro study of imatinib sensitivity, KIT Y503_F504insAY was cloned into a plasmid by site-directed mutagenesis of KIT WT cDNA. Chinese hamster ovary cells were transiently transfected with the plasmid. Cells were treated with control media or media containing various concentrations of imatinib for 90 minutes. Then, protein lysates from the transfected cells were examined for phosphorylated tyrosine, a measure of KIT activation. Cells expressing KIT Y503_F504insAY were as sensitive to imatinib as ligand activated wildtype KIT (IC50: 100-200 nmol/L).",
        "method": "metakb.method:1",
        "is_reported_in": [
            {
                "id": "civic.source:412",
                "type": "Document",
                "label": "Heinrich et al., 2003, J. Clin. Oncol.",
                "xrefs": [
                    "pmid:14645423"
                ],
                "title": "Kinase mutations and imatinib response in patients with metastatic gastrointestinal stromal tumor."
            }
        ],
        "evidence_level": {
            "id": "vicc:e00009",
            "type": "Coding",
            "label": "preclinical evidence"
        },
        "target_proposition": {
            "id": "proposition:hnaDX4UkS75ZznY5Fr6YVn-gnLWaEw2u",
            "type": "VariationNeoplasmTherapeuticResponseProposition",
            "subject": "ga4gh:VA.nNvZsJYuz0nRzWuLxxZN9AXKkux3fCEN",
            "predicate": "predicts_resistance_to",
            "object": {
                "id": "rxcui:282388",
                "type": "Therapeutic"
            },
            "neoplasm_type_qualifier": {
                "id": "ncit:C9305",
                "type": "Disease"
            }
        },
        "direction": "opposes",
        "subject_descriptor": "civic.vid:946",
        "neoplasm_type_descriptor": {
            "id": "civic.did:216",
            "type": "DiseaseDescriptor",
            "label": "Cancer",
            "xrefs": [
                "DOID:162"
            ],
            "disease": "ncit:C9305"
        },
        "object_descriptor": {
            "id": "civic.tid:5",
            "type": "TherapeuticDescriptor",
            "label": "Imatinib",
            "extensions": [
                {
                    "type": "Extension",
                    "name": "regulatory_approval",
                    "value": {
                        "approval_rating": "FDA",
                        "has_indications": [
                            {
                                "id": "hemonc:667",
                                "type": "DiseaseDescriptor",
                                "label": "Soft tissue sarcoma",
                                "disease": "ncit:C9306"
                            },
                            {
                                "id": "hemonc:602",
                                "type": "DiseaseDescriptor",
                                "label": "Gastrointestinal stromal tumor",
                                "disease": "ncit:C3868"
                            },
                            {
                                "id": "hemonc:616",
                                "type": "DiseaseDescriptor",
                                "label": "Hypereosinophilic syndrome",
                                "disease": "ncit:C27038"
                            },
                            {
                                "id": "hemonc:33893",
                                "type": "DiseaseDescriptor",
                                "label": "Chronic myelogenous leukemia pediatric",
                                "disease": null
                            },
                            {
                                "id": "hemonc:634",
                                "type": "DiseaseDescriptor",
                                "label": "Myelodysplastic syndrome",
                                "disease": "ncit:C3247"
                            },
                            {
                                "id": "hemonc:24309",
                                "type": "DiseaseDescriptor",
                                "label": "Acute lymphoblastic leukemia",
                                "disease": "ncit:C3167"
                            },
                            {
                                "id": "hemonc:582",
                                "type": "DiseaseDescriptor",
                                "label": "Chronic myelogenous leukemia",
                                "disease": "ncit:C3174"
                            },
                            {
                                "id": "hemonc:669",
                                "type": "DiseaseDescriptor",
                                "label": "Systemic mastocytosis",
                                "disease": "ncit:C9235"
                            }
                        ]
                    }
                }
            ],
            "xrefs": [
                "ncit:C62035"
            ],
            "alternate_labels": [
                "4-[(4-Methyl-1-piperazinyl)methyl]-N-[4-methyl-3-[[4-(3-pyridinyl)-2-pyrimidinyl]amino]phenyl]benzamide"
            ],
            "therapeutic": "rxcui:282388"
        }
    },
    {
        "id": "civic.eid:2837",
        "type": "VariationNeoplasmTherapeuticResponseStatement",
        "description": "Primary peripheral blood mononuclear cells were taken from chronic lymphocytic leukemia patients, some of whom had prior therapy. The effect of the D1930V variant on ATM expression was tested by western blot, and the effect on ATM function was tested by treating with doxorubicin to induce double-strand breaks (DSB) and monitoring p21 induction. To confirm wild type p53, parallel cell cultures were treated with fludarabine generating single-strand breaks, in addition to DSB, and monitored for adequate p21 induction. A patient sample had the D1930V variant of ATM, confirmed by sanger sequencing, in trans with a loss of function 11q deletion found in 88% of cells by FISH. Western blot showed null ATM expression. Treatment with doxorubicin resulted in p21 expression greater than 300% that of untreated wild-type controls. This was considered by the authors to be similar to treated wild-type controls with a median expression level 815% that of untreated controls suggesting this variant does not support resistance.",
        "method": "metakb.method:1",
        "is_reported_in": [
            {
                "id": "civic.source:1541",
                "type": "Document",
                "label": "Navrkalova et al., 2013, Haematologica",
                "xrefs": [
                    "pmc:PMC3696617",
                    "pmid:23585524"
                ],
                "title": "ATM mutations uniformly lead to ATM dysfunction in chronic lymphocytic leukemia: application of functional test using doxorubicin."
            }
        ],
        "evidence_level": {
            "id": "vicc:e00009",
            "type": "Coding",
            "label": "preclinical evidence"
        },
        "target_proposition": {
            "id": "proposition:WQ34ZBqeP1n0ieEUlOA3Q5GIMl1I3cKf",
            "type": "VariationNeoplasmTherapeuticResponseProposition",
            "subject": "ga4gh:VA.It5QO3hhuuPpeF1AKVeSiQ1bxVmtW_EI",
            "predicate": "predicts_resistance_to",
            "object": {
                "id": "rxcui:142433",
                "type": "Therapeutic"
            },
            "neoplasm_type_qualifier": {
                "id": "ncit:C3163",
                "type": "Disease"
            }
        },
        "direction": "supports",
        "subject_descriptor": "civic.vid:1160",
        "neoplasm_type_descriptor": {
            "id": "civic.did:52",
            "type": "DiseaseDescriptor",
            "label": "Chronic Lymphocytic Leukemia",
            "xrefs": [
                "DOID:1040"
            ],
            "disease": "ncit:C3163"
        },
        "object_descriptor": {
            "id": "civic.tid:68",
            "type": "TherapeuticDescriptor",
            "label": "Doxorubicin",
            "extensions": [
                {
                    "type": "Extension",
                    "name": "regulatory_approval",
                    "value": {
                        "approval_rating": "FDA",
                        "has_indications": [
                            {
                                "id": "hemonc:666",
                                "type": "DiseaseDescriptor",
                                "label": "Small cell lung cancer",
                                "disease": "ncit:C4917"
                            },
                            {
                                "id": "hemonc:667",
                                "type": "DiseaseDescriptor",
                                "label": "Soft tissue sarcoma",
                                "disease": "ncit:C9306"
                            },
                            {
                                "id": "hemonc:614",
                                "type": "DiseaseDescriptor",
                                "label": "Hodgkin lymphoma",
                                "disease": "ncit:C9357"
                            },
                            {
                                "id": "hemonc:572",
                                "type": "DiseaseDescriptor",
                                "label": "Breast cancer",
                                "disease": "ncit:C9335"
                            },
                            {
                                "id": "hemonc:601",
                                "type": "DiseaseDescriptor",
                                "label": "Gastric cancer",
                                "disease": "ncit:C9331"
                            },
                            {
                                "id": "hemonc:675",
                                "type": "DiseaseDescriptor",
                                "label": "Thyroid cancer",
                                "disease": "ncit:C7510"
                            },
                            {
                                "id": "hemonc:552",
                                "type": "DiseaseDescriptor",
                                "label": "Acute myeloid leukemia",
                                "disease": "ncit:C3171"
                            },
                            {
                                "id": "hemonc:569",
                                "type": "DiseaseDescriptor",
                                "label": "Bladder cancer",
                                "disease": "ncit:C9334"
                            },
                            {
                                "id": "hemonc:645",
                                "type": "DiseaseDescriptor",
                                "label": "Ovarian cancer",
                                "disease": "ncit:C7431"
                            }
                        ]
                    }
                }
            ],
            "xrefs": [
                "ncit:C456"
            ],
            "alternate_labels": [
                "(8S-cis)-10-[(3-Amino-2,3,6-trideoxy-alpha-L-lyxo-hexopyranosyl)oxy]-7,8,9,10-tetrahydro-6,8,11-trihydroxy-8-(hydroacetyl)-1-methoxy-5,12-naphthacenedione",
                "(8S-cis)-10-[(3-Amino-2,3,6-trideoxy-alpha-L-lyxo-hexopyranosyl)oxy]-7,8,9,10-tetrahydro-6,8,11-trihydroxy-8-(hydroxyacetyl)-1-methoxy-5,12-naphthacenedione",
                "14-Hydroxydaunomycin",
                "Adriablastin",
                "Hydroxydaunomycin",
                "Hydroxyl Daunorubicin",
                "Hydroxyldaunorubicin"
            ],
            "therapeutic": "rxcui:142433"
        }
    },
    {
        "id": "civic.eid:3710",
        "type": "VariationNeoplasmTherapeuticResponseStatement",
        "description": "In an in vitro study, a human colon adenocarcinoma SW48 cell line virally transduced to express KRAS G12A demonstrated resistance to regorafenib treatment (IC50: 330.13 nM vs. 114.28 nM, P<0.01, reported errantly as 3301.13nM in the source) compared to SW48 cells expressing KRAS wild-type. Resistance was determined by assessing cell viability. Authors concluded that KRAS G12A was more strongly resistant to regorafenib than KRAS wt and other KRAS G12/G13 mutations.",
        "method": "metakb.method:1",
        "is_reported_in": [
            {
                "id": "civic.source:1935",
                "type": "Document",
                "label": "Camaj et al., 2015, Future Oncol",
                "xrefs": [
                    "pmid:26161928"
                ],
                "title": "KRAS exon 2 mutations influence activity of regorafenib in an SW48-based disease model of colorectal cancer."
            }
        ],
        "evidence_level": {
            "id": "vicc:e00009",
            "type": "Coding",
            "label": "preclinical evidence"
        },
        "target_proposition": {
            "id": "proposition:QTBIX5Qbpy32hab7psJQJ2edqIzeEKog",
            "type": "VariationNeoplasmTherapeuticResponseProposition",
            "subject": "ga4gh:VA.U3kUAWKJKEeDyAbv3JsDVQlu9HeEG0WJ",
            "predicate": "predicts_resistance_to",
            "object": {
                "id": "rxcui:1312397",
                "type": "Therapeutic"
            },
            "neoplasm_type_qualifier": {
                "id": "ncit:C4978",
                "type": "Disease"
            }
        },
        "direction": "supports",
        "subject_descriptor": "civic.vid:148",
        "neoplasm_type_descriptor": {
            "id": "civic.did:11",
            "type": "DiseaseDescriptor",
            "label": "Colorectal Cancer",
            "xrefs": [
                "DOID:9256"
            ],
            "disease": "ncit:C4978"
        },
        "object_descriptor": {
            "id": "civic.tid:27",
            "type": "TherapeuticDescriptor",
            "label": "Regorafenib",
            "extensions": [
                {
                    "type": "Extension",
                    "name": "regulatory_approval",
                    "value": {
                        "approval_rating": "ChEMBL",
                        "has_indications": [
                            {
                                "id": "mesh:D009369",
                                "type": "DiseaseDescriptor",
                                "label": "Neoplasms",
                                "disease": "ncit:C3262"
                            },
                            {
                                "id": "mesh:D015179",
                                "type": "DiseaseDescriptor",
                                "label": "Colorectal Neoplasms",
                                "disease": "ncit:C2956"
                            }
                        ]
                    }
                }
            ],
            "xrefs": [
                "ncit:C78204"
            ],
            "alternate_labels": [
                "4-(4-(((4-chloro-3-(trifluoromethyl)phenyl)carbamoyl)amino)-3-fluorophenoxy)-N-methylpyridine-2-carboxamide",
                "BAY 73-4506",
                "REGORAFENIB ANHYDROUS",
                "Stivarga"
            ],
            "therapeutic": "rxcui:1312397"
        }
    },
    {
        "id": "civic.eid:3722",
        "type": "VariationNeoplasmTherapeuticResponseStatement",
        "description": "An in vitro study of M229 (a human melanoma cell line) endogenously expressing wildtype PIK3CA and BRAF V600E (a known BRAF inhibitor sensitizing mutation) used PIK3CA E545K as a positive control for testing resistance to BRAF inhibition by vemurafenib. M229 cells virally transduced with PIK3CA E545K were significantly more resistant to vemurafenib-mediated growth suppression than cells transduced with empty vectors (50% vs 20% survival at the highest concentration, p <.0001). Furthermore, E545K appears to confer more resistance to vemurafenib than PIK3CA D350G and similar levels of resistance as E545G. Resistance was determined by assessing cell survival.",
        "method": "metakb.method:1",
        "is_reported_in": [
            {
                "id": "civic.source:1941",
                "type": "Document",
                "label": "Shi et al., 2014, Cancer Discov",
                "xrefs": [
                    "pmc:PMC3936420",
                    "pmid:24265155"
                ],
                "title": "Acquired resistance and clonal evolution in melanoma during BRAF inhibitor therapy."
            }
        ],
        "evidence_level": {
            "id": "vicc:e00009",
            "type": "Coding",
            "label": "preclinical evidence"
        },
        "target_proposition": {
            "id": "proposition:om23Bqg2hisE2j8mNEAByuIjZMEkklrt",
            "type": "VariationNeoplasmTherapeuticResponseProposition",
            "subject": "ga4gh:VA.5zBiXnk0ZRCfFqRnK0fQHQwAGBWW4JE8",
            "predicate": "predicts_resistance_to",
            "object": {
                "id": "rxcui:1147220",
                "type": "Therapeutic"
            },
            "neoplasm_type_qualifier": {
                "id": "ncit:C3224",
                "type": "Disease"
            }
        },
        "direction": "supports",
        "subject_descriptor": "civic.vid:104",
        "neoplasm_type_descriptor": {
            "id": "civic.did:7",
            "type": "DiseaseDescriptor",
            "label": "Melanoma",
            "xrefs": [
                "DOID:1909"
            ],
            "disease": "ncit:C3224"
        },
        "object_descriptor": {
            "id": "civic.tid:4",
            "type": "TherapeuticDescriptor",
            "label": "Vemurafenib",
            "extensions": [
                {
                    "type": "Extension",
                    "name": "regulatory_approval",
                    "value": {
                        "approval_rating": "FDA",
                        "has_indications": [
                            {
                                "id": "hemonc:629",
                                "type": "DiseaseDescriptor",
                                "label": "Melanoma",
                                "disease": "ncit:C3224"
                            },
                            {
                                "id": "hemonc:594",
                                "type": "DiseaseDescriptor",
                                "label": "Erdheim-Chester disease",
                                "disease": "ncit:C53972"
                            }
                        ]
                    }
                }
            ],
            "xrefs": [
                "ncit:C64768"
            ],
            "alternate_labels": [
                "1-propanesulfonamide, N-(3-((5-(4-chlorophenyl)-1h-pyrrolo(2,3-b)pyridin-3-yl)carbonyl)-2,4-difluorophenyl)-",
                "BRAF (V600E) Kinase Inhibitor RO5185426",
                "BRAF(V600E) Kinase Inhibitor RO5185426",
                "PLX-4032",
                "PLX4032",
                "RG 7204",
                "RG7204",
                "RO 5185426",
                "Zelboraf"
            ],
            "therapeutic": "rxcui:1147220"
        }
    },
    {
        "id": "civic.eid:3724",
        "type": "VariationNeoplasmTherapeuticResponseStatement",
        "description": "An in vitro study of M229 (a human melanoma cell line) endogenously expressing wildtype PIK3CA and BRAF V600E (a known BRAF inhibitor sensitizing mutation) found that cells virally induced to stably over-express PIK3CA E545G were significantly more resistant to BRAF inhibition by vemurafenib than cells transduced with an empty vector (50% vs 20% survival at the highest concentration, p < .0001). Though statistics were not provided, E545G appears to confer similar levels of resistance to vemurafenib as the positive control variant, PIK3CA E545K.",
        "method": "metakb.method:1",
        "is_reported_in": [
            {
                "id": "civic.source:1941",
                "type": "Document",
                "label": "Shi et al., 2014, Cancer Discov",
                "xrefs": [
                    "pmc:PMC3936420",
                    "pmid:24265155"
                ],
                "title": "Acquired resistance and clonal evolution in melanoma during BRAF inhibitor therapy."
            }
        ],
        "evidence_level": {
            "id": "vicc:e00009",
            "type": "Coding",
            "label": "preclinical evidence"
        },
        "target_proposition": {
            "id": "proposition:SL_Fy43hFX6hzEsBkdEu0sxG8gOpJUsM",
            "type": "VariationNeoplasmTherapeuticResponseProposition",
            "subject": "ga4gh:VA.7NSMwTRR_yBpn8GqpL2Ux_8OD5PbOqjC",
            "predicate": "predicts_resistance_to",
            "object": {
                "id": "rxcui:1147220",
                "type": "Therapeutic"
            },
            "neoplasm_type_qualifier": {
                "id": "ncit:C3224",
                "type": "Disease"
            }
        },
        "direction": "supports",
        "subject_descriptor": "civic.vid:883",
        "neoplasm_type_descriptor": {
            "id": "civic.did:7",
            "type": "DiseaseDescriptor",
            "label": "Melanoma",
            "xrefs": [
                "DOID:1909"
            ],
            "disease": "ncit:C3224"
        },
        "object_descriptor": {
            "id": "civic.tid:4",
            "type": "TherapeuticDescriptor",
            "label": "Vemurafenib",
            "extensions": [
                {
                    "type": "Extension",
                    "name": "regulatory_approval",
                    "value": {
                        "approval_rating": "FDA",
                        "has_indications": [
                            {
                                "id": "hemonc:629",
                                "type": "DiseaseDescriptor",
                                "label": "Melanoma",
                                "disease": "ncit:C3224"
                            },
                            {
                                "id": "hemonc:594",
                                "type": "DiseaseDescriptor",
                                "label": "Erdheim-Chester disease",
                                "disease": "ncit:C53972"
                            }
                        ]
                    }
                }
            ],
            "xrefs": [
                "ncit:C64768"
            ],
            "alternate_labels": [
                "1-propanesulfonamide, N-(3-((5-(4-chlorophenyl)-1h-pyrrolo(2,3-b)pyridin-3-yl)carbonyl)-2,4-difluorophenyl)-",
                "BRAF (V600E) Kinase Inhibitor RO5185426",
                "BRAF(V600E) Kinase Inhibitor RO5185426",
                "PLX-4032",
                "PLX4032",
                "RG 7204",
                "RG7204",
                "RO 5185426",
                "Zelboraf"
            ],
            "therapeutic": "rxcui:1147220"
        }
    },
    {
        "id": "civic.eid:3924",
        "type": "VariationNeoplasmTherapeuticResponseStatement",
        "description": "In an in vitro study, a human colon adenocarcinoma SW48 cell line expressing KRAS G12V mutation demonstrated resistance to regorafenib treatment (IC50: 241.90 nM vs. 114.28 nM, P<0.01) compared to SW48 cells expressing KRAS wildtype. Resistance was determined by assessing cell viability. Regorafenib significantly reduced BRAF, Erk1/2 and Elk phosphorylation compared to wildtype, as assessed by western blot. Authors concluded that KRAS G12A was more resistant to regorafenib than KRAS wt, and intermediately resistant compared to other common KRAS mutations.",
        "method": "metakb.method:1",
        "is_reported_in": [
            {
                "id": "civic.source:1935",
                "type": "Document",
                "label": "Camaj et al., 2015, Future Oncol",
                "xrefs": [
                    "pmid:26161928"
                ],
                "title": "KRAS exon 2 mutations influence activity of regorafenib in an SW48-based disease model of colorectal cancer."
            }
        ],
        "evidence_level": {
            "id": "vicc:e00009",
            "type": "Coding",
            "label": "preclinical evidence"
        },
        "target_proposition": {
            "id": "proposition:BVX6D_q-DEbyuCe8nmss8i2EOG2k_mY1",
            "type": "VariationNeoplasmTherapeuticResponseProposition",
            "subject": "ga4gh:VA.VBKi2jNxAs378IqOBsveoPrYQjWPngQq",
            "predicate": "predicts_resistance_to",
            "object": {
                "id": "rxcui:1312397",
                "type": "Therapeutic"
            },
            "neoplasm_type_qualifier": {
                "id": "ncit:C4978",
                "type": "Disease"
            }
        },
        "direction": "supports",
        "subject_descriptor": "civic.vid:425",
        "neoplasm_type_descriptor": {
            "id": "civic.did:11",
            "type": "DiseaseDescriptor",
            "label": "Colorectal Cancer",
            "xrefs": [
                "DOID:9256"
            ],
            "disease": "ncit:C4978"
        },
        "object_descriptor": {
            "id": "civic.tid:27",
            "type": "TherapeuticDescriptor",
            "label": "Regorafenib",
            "extensions": [
                {
                    "type": "Extension",
                    "name": "regulatory_approval",
                    "value": {
                        "approval_rating": "ChEMBL",
                        "has_indications": [
                            {
                                "id": "mesh:D009369",
                                "type": "DiseaseDescriptor",
                                "label": "Neoplasms",
                                "disease": "ncit:C3262"
                            },
                            {
                                "id": "mesh:D015179",
                                "type": "DiseaseDescriptor",
                                "label": "Colorectal Neoplasms",
                                "disease": "ncit:C2956"
                            }
                        ]
                    }
                }
            ],
            "xrefs": [
                "ncit:C78204"
            ],
            "alternate_labels": [
                "4-(4-(((4-chloro-3-(trifluoromethyl)phenyl)carbamoyl)amino)-3-fluorophenoxy)-N-methylpyridine-2-carboxamide",
                "BAY 73-4506",
                "REGORAFENIB ANHYDROUS",
                "Stivarga"
            ],
            "therapeutic": "rxcui:1312397"
        }
    },
    {
        "id": "civic.eid:3957",
        "type": "VariationNeoplasmTherapeuticResponseStatement",
        "description": "In vitro studies of M229 (a human melanoma cell line) endogenously expressing wildtype KRAS and BRAF V600E (a known BRAF inhibitor sensitizing mutation) found that cells virally induced to stably over-express KRAS4a G12D or KRAS4b G12D  were more resistant to vemurafenib (a BRAF inhibitor) than cells transduced with empty vectors (90% vs 10% survival).",
        "method": "metakb.method:1",
        "is_reported_in": [
            {
                "id": "civic.source:1941",
                "type": "Document",
                "label": "Shi et al., 2014, Cancer Discov",
                "xrefs": [
                    "pmc:PMC3936420",
                    "pmid:24265155"
                ],
                "title": "Acquired resistance and clonal evolution in melanoma during BRAF inhibitor therapy."
            }
        ],
        "evidence_level": {
            "id": "vicc:e00009",
            "type": "Coding",
            "label": "preclinical evidence"
        },
        "target_proposition": {
            "id": "proposition:Ywzi4619qFuSv6iLQlizo3fDCE_ZKMiA",
            "type": "VariationNeoplasmTherapeuticResponseProposition",
            "subject": "ga4gh:VA.jSiuIG2uZEbml8MfCtZi3J9jPBCBiaPw",
            "predicate": "predicts_resistance_to",
            "object": {
                "id": "rxcui:1147220",
                "type": "Therapeutic"
            },
            "neoplasm_type_qualifier": {
                "id": "ncit:C3224",
                "type": "Disease"
            }
        },
        "direction": "supports",
        "subject_descriptor": "civic.vid:79",
        "neoplasm_type_descriptor": {
            "id": "civic.did:7",
            "type": "DiseaseDescriptor",
            "label": "Melanoma",
            "xrefs": [
                "DOID:1909"
            ],
            "disease": "ncit:C3224"
        },
        "object_descriptor": {
            "id": "civic.tid:4",
            "type": "TherapeuticDescriptor",
            "label": "Vemurafenib",
            "extensions": [
                {
                    "type": "Extension",
                    "name": "regulatory_approval",
                    "value": {
                        "approval_rating": "FDA",
                        "has_indications": [
                            {
                                "id": "hemonc:629",
                                "type": "DiseaseDescriptor",
                                "label": "Melanoma",
                                "disease": "ncit:C3224"
                            },
                            {
                                "id": "hemonc:594",
                                "type": "DiseaseDescriptor",
                                "label": "Erdheim-Chester disease",
                                "disease": "ncit:C53972"
                            }
                        ]
                    }
                }
            ],
            "xrefs": [
                "ncit:C64768"
            ],
            "alternate_labels": [
                "1-propanesulfonamide, N-(3-((5-(4-chlorophenyl)-1h-pyrrolo(2,3-b)pyridin-3-yl)carbonyl)-2,4-difluorophenyl)-",
                "BRAF (V600E) Kinase Inhibitor RO5185426",
                "BRAF(V600E) Kinase Inhibitor RO5185426",
                "PLX-4032",
                "PLX4032",
                "RG 7204",
                "RG7204",
                "RO 5185426",
                "Zelboraf"
            ],
            "therapeutic": "rxcui:1147220"
        }
    },
    {
        "id": "civic.eid:3973",
        "type": "VariationNeoplasmTherapeuticResponseStatement",
        "description": "In an in vitro study, a human colon adenocarcinoma SW48 cell line expressing KRAS G12C mutation demonstrated resistance to regorafenib treatment (IC50: 386.22 nM vs. 114.28 nM, P<0.01) compared to SW48 cells expressing KRAS wild-type. Resistance was determined by assessing cell viability. In vivo, KRAS G12C expressing SW48 cells were injected into NOD/SCID mice. Treatment with regorafenib did not lead to a significant delay of tumor growth. Mice injected with KRAS wt cells did not significantly respond to regorafenib, although a trend was seen toward better response. IHC analysis of mouse tissue revealed no significant change in markers of proliferation (Ki67), angiogenesis (CD31) and apoptosis (TUNEL) in KRAS G12C expressing mice treated with regorafenib compared to KRAS wt expressing mice whose tumors displayed more pronounced changes. Authors concluded that G12C was more resistant to regorafenib than KRAS wt and other common KRAS G12/G13 mutants.",
        "method": "metakb.method:1",
        "is_reported_in": [
            {
                "id": "civic.source:1935",
                "type": "Document",
                "label": "Camaj et al., 2015, Future Oncol",
                "xrefs": [
                    "pmid:26161928"
                ],
                "title": "KRAS exon 2 mutations influence activity of regorafenib in an SW48-based disease model of colorectal cancer."
            }
        ],
        "evidence_level": {
            "id": "vicc:e00009",
            "type": "Coding",
            "label": "preclinical evidence"
        },
        "target_proposition": {
            "id": "proposition:5rEhcKlm6SQAEZ5mzuo8V2snmslek5Z6",
            "type": "VariationNeoplasmTherapeuticResponseProposition",
            "subject": "ga4gh:VA.rpL2_d2q0gdks_VPk_0JVl90aJG9-bEd",
            "predicate": "predicts_resistance_to",
            "object": {
                "id": "rxcui:1312397",
                "type": "Therapeutic"
            },
            "neoplasm_type_qualifier": {
                "id": "ncit:C4978",
                "type": "Disease"
            }
        },
        "direction": "supports",
        "subject_descriptor": "civic.vid:78",
        "neoplasm_type_descriptor": {
            "id": "civic.did:11",
            "type": "DiseaseDescriptor",
            "label": "Colorectal Cancer",
            "xrefs": [
                "DOID:9256"
            ],
            "disease": "ncit:C4978"
        },
        "object_descriptor": {
            "id": "civic.tid:27",
            "type": "TherapeuticDescriptor",
            "label": "Regorafenib",
            "extensions": [
                {
                    "type": "Extension",
                    "name": "regulatory_approval",
                    "value": {
                        "approval_rating": "ChEMBL",
                        "has_indications": [
                            {
                                "id": "mesh:D009369",
                                "type": "DiseaseDescriptor",
                                "label": "Neoplasms",
                                "disease": "ncit:C3262"
                            },
                            {
                                "id": "mesh:D015179",
                                "type": "DiseaseDescriptor",
                                "label": "Colorectal Neoplasms",
                                "disease": "ncit:C2956"
                            }
                        ]
                    }
                }
            ],
            "xrefs": [
                "ncit:C78204"
            ],
            "alternate_labels": [
                "4-(4-(((4-chloro-3-(trifluoromethyl)phenyl)carbamoyl)amino)-3-fluorophenoxy)-N-methylpyridine-2-carboxamide",
                "BAY 73-4506",
                "REGORAFENIB ANHYDROUS",
                "Stivarga"
            ],
            "therapeutic": "rxcui:1312397"
        }
    },
    {
        "id": "civic.eid:4012",
        "type": "VariationNeoplasmTherapeuticResponseStatement",
        "description": "In an in vitro study, a human colon adenocarcinoma SW48 cell line expressing KRAS G12S mutation demonstrated resistance to regorafenib treatment (IC50: 264.23 nM vs. 114.28 nM, P<0.01) compared to SW48 cells expressing KRAS wild-type. Resistance was determined by assessing cell viability. Authors concluded that KRAS G12S was more resistant to regorafenib than KRAS wt, and intermediately resistant compared to other common KRAS G12/G13 mutations.",
        "method": "metakb.method:1",
        "is_reported_in": [
            {
                "id": "civic.source:1935",
                "type": "Document",
                "label": "Camaj et al., 2015, Future Oncol",
                "xrefs": [
                    "pmid:26161928"
                ],
                "title": "KRAS exon 2 mutations influence activity of regorafenib in an SW48-based disease model of colorectal cancer."
            }
        ],
        "evidence_level": {
            "id": "vicc:e00009",
            "type": "Coding",
            "label": "preclinical evidence"
        },
        "target_proposition": {
            "id": "proposition:slJIDGiDqamg7FyaNaZd-RHTdbFdaaXJ",
            "type": "VariationNeoplasmTherapeuticResponseProposition",
            "subject": "ga4gh:VA.QVdzWvpiRTgBHwV39EuVg6VZVGOLxdUS",
            "predicate": "predicts_resistance_to",
            "object": {
                "id": "rxcui:1312397",
                "type": "Therapeutic"
            },
            "neoplasm_type_qualifier": {
                "id": "ncit:C4978",
                "type": "Disease"
            }
        },
        "direction": "supports",
        "subject_descriptor": "civic.vid:913",
        "neoplasm_type_descriptor": {
            "id": "civic.did:11",
            "type": "DiseaseDescriptor",
            "label": "Colorectal Cancer",
            "xrefs": [
                "DOID:9256"
            ],
            "disease": "ncit:C4978"
        },
        "object_descriptor": {
            "id": "civic.tid:27",
            "type": "TherapeuticDescriptor",
            "label": "Regorafenib",
            "extensions": [
                {
                    "type": "Extension",
                    "name": "regulatory_approval",
                    "value": {
                        "approval_rating": "ChEMBL",
                        "has_indications": [
                            {
                                "id": "mesh:D009369",
                                "type": "DiseaseDescriptor",
                                "label": "Neoplasms",
                                "disease": "ncit:C3262"
                            },
                            {
                                "id": "mesh:D015179",
                                "type": "DiseaseDescriptor",
                                "label": "Colorectal Neoplasms",
                                "disease": "ncit:C2956"
                            }
                        ]
                    }
                }
            ],
            "xrefs": [
                "ncit:C78204"
            ],
            "alternate_labels": [
                "4-(4-(((4-chloro-3-(trifluoromethyl)phenyl)carbamoyl)amino)-3-fluorophenoxy)-N-methylpyridine-2-carboxamide",
                "BAY 73-4506",
                "REGORAFENIB ANHYDROUS",
                "Stivarga"
            ],
            "therapeutic": "rxcui:1312397"
        }
    },
    {
        "id": "civic.eid:4056",
        "type": "VariationNeoplasmTherapeuticResponseStatement",
        "description": "In an in vitro study, Chinese hamster ovary cells expressing PDGFRA V561D mutation demonstrated sensitivity to sunitinib treatment (IC50<100), though this sensitivity was indistinguishable from Chinese hamster ovary cells expressing wild-type PDGFRA. Sensitivity was determined by assessing PDGFRA auto-phosphorylation.",
        "method": "metakb.method:1",
        "is_reported_in": [
            {
                "id": "civic.source:965",
                "type": "Document",
                "label": "Heinrich et al., 2008, J. Clin. Oncol.",
                "xrefs": [
                    "pmc:PMC2651076",
                    "pmid:18955458"
                ],
                "title": "Primary and secondary kinase genotypes correlate with the biological and clinical activity of sunitinib in imatinib-resistant gastrointestinal stromal tumor."
            }
        ],
        "evidence_level": {
            "id": "vicc:e00009",
            "type": "Coding",
            "label": "preclinical evidence"
        },
        "target_proposition": {
            "id": "proposition:2O1AVZOC5jsj8037pM-_fJw7EVte9aew",
            "type": "VariationNeoplasmTherapeuticResponseProposition",
            "subject": "ga4gh:VA.PmR2KGO2d96zDOFtI79sijmIhGO2v-a0",
            "predicate": "predicts_resistance_to",
            "object": {
                "id": "rxcui:357977",
                "type": "Therapeutic"
            },
            "neoplasm_type_qualifier": {
                "id": "ncit:C9305",
                "type": "Disease"
            }
        },
        "direction": "opposes",
        "subject_descriptor": "civic.vid:941",
        "neoplasm_type_descriptor": {
            "id": "civic.did:216",
            "type": "DiseaseDescriptor",
            "label": "Cancer",
            "xrefs": [
                "DOID:162"
            ],
            "disease": "ncit:C9305"
        },
        "object_descriptor": {
            "id": "civic.tid:157",
            "type": "TherapeuticDescriptor",
            "label": "Sunitinib",
            "extensions": [
                {
                    "type": "Extension",
                    "name": "regulatory_approval",
                    "value": {
                        "approval_rating": "FDA",
                        "has_indications": [
                            {
                                "id": "hemonc:602",
                                "type": "DiseaseDescriptor",
                                "label": "Gastrointestinal stromal tumor",
                                "disease": "ncit:C3868"
                            },
                            {
                                "id": "hemonc:647",
                                "type": "DiseaseDescriptor",
                                "label": "Pancreatic NET",
                                "disease": "ncit:C27720"
                            },
                            {
                                "id": "hemonc:660",
                                "type": "DiseaseDescriptor",
                                "label": "Renal cell carcinoma",
                                "disease": "ncit:C9385"
                            }
                        ]
                    }
                }
            ],
            "xrefs": [
                "ncit:C71622"
            ],
            "alternate_labels": [
                "1H-Pyrrole-3-carboxamide, N-(2-(diethylamino)ethyl)-5-((Z)-(5-fluoro-1,2-dihydro-2-oxo-3H-indol-3-ylidene)methyl)-2,4-dimethyl-"
            ],
            "therapeutic": "rxcui:357977"
        }
    },
    {
        "id": "civic.eid:4060",
        "type": "VariationNeoplasmTherapeuticResponseStatement",
        "description": "In an in vitro study, Chinese hamster ovary cells expressing PDGFRA D842V mutation demonstrated reduced sensitivity to sunitinib treatment (IC50>1000 vs. IC50<100), compared to Chinese hamster ovary cells expressing wild-type PDGFRA. Sensitivity was determined by assessing PDGFRA auto-phosphorylation.",
        "method": "metakb.method:1",
        "is_reported_in": [
            {
                "id": "civic.source:965",
                "type": "Document",
                "label": "Heinrich et al., 2008, J. Clin. Oncol.",
                "xrefs": [
                    "pmc:PMC2651076",
                    "pmid:18955458"
                ],
                "title": "Primary and secondary kinase genotypes correlate with the biological and clinical activity of sunitinib in imatinib-resistant gastrointestinal stromal tumor."
            }
        ],
        "evidence_level": {
            "id": "vicc:e00009",
            "type": "Coding",
            "label": "preclinical evidence"
        },
        "target_proposition": {
            "id": "proposition:iIUD9SPwZOOp5xlj4OSrGxihgQb0F5HS",
            "type": "VariationNeoplasmTherapeuticResponseProposition",
            "subject": "ga4gh:VA.CaTuLaWlUwLb32qfYTW2udl2Iy02ccN6",
            "predicate": "predicts_resistance_to",
            "object": {
                "id": "rxcui:357977",
                "type": "Therapeutic"
            },
            "neoplasm_type_qualifier": {
                "id": "ncit:C9305",
                "type": "Disease"
            }
        },
        "direction": "supports",
        "subject_descriptor": "civic.vid:99",
        "neoplasm_type_descriptor": {
            "id": "civic.did:216",
            "type": "DiseaseDescriptor",
            "label": "Cancer",
            "xrefs": [
                "DOID:162"
            ],
            "disease": "ncit:C9305"
        },
        "object_descriptor": {
            "id": "civic.tid:157",
            "type": "TherapeuticDescriptor",
            "label": "Sunitinib",
            "extensions": [
                {
                    "type": "Extension",
                    "name": "regulatory_approval",
                    "value": {
                        "approval_rating": "FDA",
                        "has_indications": [
                            {
                                "id": "hemonc:602",
                                "type": "DiseaseDescriptor",
                                "label": "Gastrointestinal stromal tumor",
                                "disease": "ncit:C3868"
                            },
                            {
                                "id": "hemonc:647",
                                "type": "DiseaseDescriptor",
                                "label": "Pancreatic NET",
                                "disease": "ncit:C27720"
                            },
                            {
                                "id": "hemonc:660",
                                "type": "DiseaseDescriptor",
                                "label": "Renal cell carcinoma",
                                "disease": "ncit:C9385"
                            }
                        ]
                    }
                }
            ],
            "xrefs": [
                "ncit:C71622"
            ],
            "alternate_labels": [
                "1H-Pyrrole-3-carboxamide, N-(2-(diethylamino)ethyl)-5-((Z)-(5-fluoro-1,2-dihydro-2-oxo-3H-indol-3-ylidene)methyl)-2,4-dimethyl-"
            ],
            "therapeutic": "rxcui:357977"
        }
    },
    {
        "id": "civic.eid:4077",
        "type": "VariationNeoplasmTherapeuticResponseStatement",
        "description": "In an in vitro study, Chinese hamster ovary cells expressing KIT V560D demonstrated comparable sensitivity to sunitinib treatment compared to cells expressing ligand activated wild-type KIT (IC50<100 nmol/L). Sensitivity was determined by assessing KIT auto-phosphorylation.",
        "method": "metakb.method:1",
        "is_reported_in": [
            {
                "id": "civic.source:965",
                "type": "Document",
                "label": "Heinrich et al., 2008, J. Clin. Oncol.",
                "xrefs": [
                    "pmc:PMC2651076",
                    "pmid:18955458"
                ],
                "title": "Primary and secondary kinase genotypes correlate with the biological and clinical activity of sunitinib in imatinib-resistant gastrointestinal stromal tumor."
            }
        ],
        "evidence_level": {
            "id": "vicc:e00009",
            "type": "Coding",
            "label": "preclinical evidence"
        },
        "target_proposition": {
            "id": "proposition:oSqb5yGW3Nd4oUguJwAko3c0vCBAib1Q",
            "type": "VariationNeoplasmTherapeuticResponseProposition",
            "subject": "ga4gh:VA.RiEsKFN3rMG6tsUuTa8OiOOucsjmMOVc",
            "predicate": "predicts_resistance_to",
            "object": {
                "id": "rxcui:357977",
                "type": "Therapeutic"
            },
            "neoplasm_type_qualifier": {
                "id": "ncit:C9305",
                "type": "Disease"
            }
        },
        "direction": "opposes",
        "subject_descriptor": "civic.vid:971",
        "neoplasm_type_descriptor": {
            "id": "civic.did:216",
            "type": "DiseaseDescriptor",
            "label": "Cancer",
            "xrefs": [
                "DOID:162"
            ],
            "disease": "ncit:C9305"
        },
        "object_descriptor": {
            "id": "civic.tid:157",
            "type": "TherapeuticDescriptor",
            "label": "Sunitinib",
            "extensions": [
                {
                    "type": "Extension",
                    "name": "regulatory_approval",
                    "value": {
                        "approval_rating": "FDA",
                        "has_indications": [
                            {
                                "id": "hemonc:602",
                                "type": "DiseaseDescriptor",
                                "label": "Gastrointestinal stromal tumor",
                                "disease": "ncit:C3868"
                            },
                            {
                                "id": "hemonc:647",
                                "type": "DiseaseDescriptor",
                                "label": "Pancreatic NET",
                                "disease": "ncit:C27720"
                            },
                            {
                                "id": "hemonc:660",
                                "type": "DiseaseDescriptor",
                                "label": "Renal cell carcinoma",
                                "disease": "ncit:C9385"
                            }
                        ]
                    }
                }
            ],
            "xrefs": [
                "ncit:C71622"
            ],
            "alternate_labels": [
                "1H-Pyrrole-3-carboxamide, N-(2-(diethylamino)ethyl)-5-((Z)-(5-fluoro-1,2-dihydro-2-oxo-3H-indol-3-ylidene)methyl)-2,4-dimethyl-"
            ],
            "therapeutic": "rxcui:357977"
        }
    },
    {
        "id": "civic.eid:4100",
        "type": "VariationNeoplasmTherapeuticResponseStatement",
        "description": "In an in vitro study, Chinese hamster ovary cells expressing KIT A502_Y503INSAY demonstrated comparable sensitivity to sunitinib treatment compared to CHO cells expressing ligand activated wild-type KIT (IC50<100 nmol/L). Sensitivity was determined by assessing KIT auto-phosphorylation.",
        "method": "metakb.method:1",
        "is_reported_in": [
            {
                "id": "civic.source:965",
                "type": "Document",
                "label": "Heinrich et al., 2008, J. Clin. Oncol.",
                "xrefs": [
                    "pmc:PMC2651076",
                    "pmid:18955458"
                ],
                "title": "Primary and secondary kinase genotypes correlate with the biological and clinical activity of sunitinib in imatinib-resistant gastrointestinal stromal tumor."
            }
        ],
        "evidence_level": {
            "id": "vicc:e00009",
            "type": "Coding",
            "label": "preclinical evidence"
        },
        "target_proposition": {
            "id": "proposition:-47Bm0nFB8M5aw4NKmB6dPjzuZ9pZxm2",
            "type": "VariationNeoplasmTherapeuticResponseProposition",
            "subject": "ga4gh:VA.wz6wMfy1414Bg53uDpoW0GtkipcMyumU",
            "predicate": "predicts_resistance_to",
            "object": {
                "id": "rxcui:357977",
                "type": "Therapeutic"
            },
            "neoplasm_type_qualifier": {
                "id": "ncit:C9305",
                "type": "Disease"
            }
        },
        "direction": "opposes",
        "subject_descriptor": "civic.vid:1558",
        "neoplasm_type_descriptor": {
            "id": "civic.did:216",
            "type": "DiseaseDescriptor",
            "label": "Cancer",
            "xrefs": [
                "DOID:162"
            ],
            "disease": "ncit:C9305"
        },
        "object_descriptor": {
            "id": "civic.tid:157",
            "type": "TherapeuticDescriptor",
            "label": "Sunitinib",
            "extensions": [
                {
                    "type": "Extension",
                    "name": "regulatory_approval",
                    "value": {
                        "approval_rating": "FDA",
                        "has_indications": [
                            {
                                "id": "hemonc:602",
                                "type": "DiseaseDescriptor",
                                "label": "Gastrointestinal stromal tumor",
                                "disease": "ncit:C3868"
                            },
                            {
                                "id": "hemonc:647",
                                "type": "DiseaseDescriptor",
                                "label": "Pancreatic NET",
                                "disease": "ncit:C27720"
                            },
                            {
                                "id": "hemonc:660",
                                "type": "DiseaseDescriptor",
                                "label": "Renal cell carcinoma",
                                "disease": "ncit:C9385"
                            }
                        ]
                    }
                }
            ],
            "xrefs": [
                "ncit:C71622"
            ],
            "alternate_labels": [
                "1H-Pyrrole-3-carboxamide, N-(2-(diethylamino)ethyl)-5-((Z)-(5-fluoro-1,2-dihydro-2-oxo-3H-indol-3-ylidene)methyl)-2,4-dimethyl-"
            ],
            "therapeutic": "rxcui:357977"
        }
    },
    {
        "id": "civic.eid:4498",
        "type": "VariationNeoplasmTherapeuticResponseStatement",
        "description": "In an in vitro study, a M229 cell line endogenously expressing BRAF V600E mutation (a known vemurafenib sensitizing mutation) and overexpressing AKT1 Q79K mutation was associated with resistance to vemurafenib treatment, as compared to cells expressing BRAF V600E mutation and wildtype AKT1. Resistance was determined by assessing cell survival.",
        "method": "metakb.method:1",
        "is_reported_in": [
            {
                "id": "civic.source:1941",
                "type": "Document",
                "label": "Shi et al., 2014, Cancer Discov",
                "xrefs": [
                    "pmc:PMC3936420",
                    "pmid:24265155"
                ],
                "title": "Acquired resistance and clonal evolution in melanoma during BRAF inhibitor therapy."
            }
        ],
        "evidence_level": {
            "id": "vicc:e00009",
            "type": "Coding",
            "label": "preclinical evidence"
        },
        "target_proposition": {
            "id": "proposition:w-TRxF-vzBMkYBkX0mtGfCnMKrt2yDXz",
            "type": "VariationNeoplasmTherapeuticResponseProposition",
            "subject": "ga4gh:VA.gI0FOE6Esplrs92wp0CJWOeriC8srpYN",
            "predicate": "predicts_resistance_to",
            "object": {
                "id": "rxcui:1147220",
                "type": "Therapeutic"
            },
            "neoplasm_type_qualifier": {
                "id": "ncit:C3224",
                "type": "Disease"
            }
        },
        "direction": "supports",
        "subject_descriptor": "civic.vid:169",
        "neoplasm_type_descriptor": {
            "id": "civic.did:7",
            "type": "DiseaseDescriptor",
            "label": "Melanoma",
            "xrefs": [
                "DOID:1909"
            ],
            "disease": "ncit:C3224"
        },
        "object_descriptor": {
            "id": "civic.tid:4",
            "type": "TherapeuticDescriptor",
            "label": "Vemurafenib",
            "extensions": [
                {
                    "type": "Extension",
                    "name": "regulatory_approval",
                    "value": {
                        "approval_rating": "FDA",
                        "has_indications": [
                            {
                                "id": "hemonc:629",
                                "type": "DiseaseDescriptor",
                                "label": "Melanoma",
                                "disease": "ncit:C3224"
                            },
                            {
                                "id": "hemonc:594",
                                "type": "DiseaseDescriptor",
                                "label": "Erdheim-Chester disease",
                                "disease": "ncit:C53972"
                            }
                        ]
                    }
                }
            ],
            "xrefs": [
                "ncit:C64768"
            ],
            "alternate_labels": [
                "1-propanesulfonamide, N-(3-((5-(4-chlorophenyl)-1h-pyrrolo(2,3-b)pyridin-3-yl)carbonyl)-2,4-difluorophenyl)-",
                "BRAF (V600E) Kinase Inhibitor RO5185426",
                "BRAF(V600E) Kinase Inhibitor RO5185426",
                "PLX-4032",
                "PLX4032",
                "RG 7204",
                "RG7204",
                "RO 5185426",
                "Zelboraf"
            ],
            "therapeutic": "rxcui:1147220"
        }
    },
    {
        "id": "civic.eid:4784",
        "type": "VariationNeoplasmTherapeuticResponseStatement",
        "description": "An in vitro study of M229 (a human melanoma cell line) endogenously expressing wildtype PIK3CA and BRAF V600E (a known BRAF inhibitor sensitizing mutation) found that cells virally induced to stably over-express PIK3CA D350G were significantly more resistant to BRAF inhibition by vemurafenib  than cells transduced with empty vectors (40% vs 20% survival at the highest concentration, p=.0148). Though statistics were not provided, D350G appears to confer less resistance to vemurafenib than the positive control variant, PIK3CA E545K.",
        "method": "metakb.method:1",
        "is_reported_in": [
            {
                "id": "civic.source:1941",
                "type": "Document",
                "label": "Shi et al., 2014, Cancer Discov",
                "xrefs": [
                    "pmc:PMC3936420",
                    "pmid:24265155"
                ],
                "title": "Acquired resistance and clonal evolution in melanoma during BRAF inhibitor therapy."
            }
        ],
        "evidence_level": {
            "id": "vicc:e00009",
            "type": "Coding",
            "label": "preclinical evidence"
        },
        "target_proposition": {
            "id": "proposition:HfaPSsJEoYLotl2Phf-Kr8HDZ6ltVgjG",
            "type": "VariationNeoplasmTherapeuticResponseProposition",
            "subject": "ga4gh:VA.78e11s6zb_99DWGCz8hfSLSqWxS5tCF9",
            "predicate": "predicts_resistance_to",
            "object": {
                "id": "rxcui:1147220",
                "type": "Therapeutic"
            },
            "neoplasm_type_qualifier": {
                "id": "ncit:C3224",
                "type": "Disease"
            }
        },
        "direction": "supports",
        "subject_descriptor": "civic.vid:1653",
        "neoplasm_type_descriptor": {
            "id": "civic.did:7",
            "type": "DiseaseDescriptor",
            "label": "Melanoma",
            "xrefs": [
                "DOID:1909"
            ],
            "disease": "ncit:C3224"
        },
        "object_descriptor": {
            "id": "civic.tid:4",
            "type": "TherapeuticDescriptor",
            "label": "Vemurafenib",
            "extensions": [
                {
                    "type": "Extension",
                    "name": "regulatory_approval",
                    "value": {
                        "approval_rating": "FDA",
                        "has_indications": [
                            {
                                "id": "hemonc:629",
                                "type": "DiseaseDescriptor",
                                "label": "Melanoma",
                                "disease": "ncit:C3224"
                            },
                            {
                                "id": "hemonc:594",
                                "type": "DiseaseDescriptor",
                                "label": "Erdheim-Chester disease",
                                "disease": "ncit:C53972"
                            }
                        ]
                    }
                }
            ],
            "xrefs": [
                "ncit:C64768"
            ],
            "alternate_labels": [
                "1-propanesulfonamide, N-(3-((5-(4-chlorophenyl)-1h-pyrrolo(2,3-b)pyridin-3-yl)carbonyl)-2,4-difluorophenyl)-",
                "BRAF (V600E) Kinase Inhibitor RO5185426",
                "BRAF(V600E) Kinase Inhibitor RO5185426",
                "PLX-4032",
                "PLX4032",
                "RG 7204",
                "RG7204",
                "RO 5185426",
                "Zelboraf"
            ],
            "therapeutic": "rxcui:1147220"
        }
    },
    {
        "id": "civic.eid:5346",
        "type": "VariationNeoplasmTherapeuticResponseStatement",
        "description": "In an in vitro study, Chinese hamster ovary cells expressing PDGFRA D842V mutation demonstrated reduced sensitivity to imatinib treatment (IC50=2,500 vs. IC50<100), compared to Chinese hamster ovary cells expressing wild-type PDGFRA. Sensitivity was determined by assessing PDGFRA auto-phosphorylation.",
        "method": "metakb.method:1",
        "is_reported_in": [
            {
                "id": "civic.source:965",
                "type": "Document",
                "label": "Heinrich et al., 2008, J. Clin. Oncol.",
                "xrefs": [
                    "pmc:PMC2651076",
                    "pmid:18955458"
                ],
                "title": "Primary and secondary kinase genotypes correlate with the biological and clinical activity of sunitinib in imatinib-resistant gastrointestinal stromal tumor."
            }
        ],
        "evidence_level": {
            "id": "vicc:e00009",
            "type": "Coding",
            "label": "preclinical evidence"
        },
        "target_proposition": {
            "id": "proposition:4wAwz4JpInBDLo3whjYGXvXng0zm5369",
            "type": "VariationNeoplasmTherapeuticResponseProposition",
            "subject": "ga4gh:VA.CaTuLaWlUwLb32qfYTW2udl2Iy02ccN6",
            "predicate": "predicts_resistance_to",
            "object": {
                "id": "rxcui:282388",
                "type": "Therapeutic"
            },
            "neoplasm_type_qualifier": {
                "id": "ncit:C9305",
                "type": "Disease"
            }
        },
        "direction": "supports",
        "subject_descriptor": "civic.vid:99",
        "neoplasm_type_descriptor": {
            "id": "civic.did:216",
            "type": "DiseaseDescriptor",
            "label": "Cancer",
            "xrefs": [
                "DOID:162"
            ],
            "disease": "ncit:C9305"
        },
        "object_descriptor": {
            "id": "civic.tid:537",
            "type": "TherapeuticDescriptor",
            "label": "Imatinib Mesylate",
            "extensions": [
                {
                    "type": "Extension",
                    "name": "regulatory_approval",
                    "value": {
                        "approval_rating": "FDA",
                        "has_indications": [
                            {
                                "id": "hemonc:667",
                                "type": "DiseaseDescriptor",
                                "label": "Soft tissue sarcoma",
                                "disease": "ncit:C9306"
                            },
                            {
                                "id": "hemonc:602",
                                "type": "DiseaseDescriptor",
                                "label": "Gastrointestinal stromal tumor",
                                "disease": "ncit:C3868"
                            },
                            {
                                "id": "hemonc:616",
                                "type": "DiseaseDescriptor",
                                "label": "Hypereosinophilic syndrome",
                                "disease": "ncit:C27038"
                            },
                            {
                                "id": "hemonc:33893",
                                "type": "DiseaseDescriptor",
                                "label": "Chronic myelogenous leukemia pediatric",
                                "disease": null
                            },
                            {
                                "id": "hemonc:634",
                                "type": "DiseaseDescriptor",
                                "label": "Myelodysplastic syndrome",
                                "disease": "ncit:C3247"
                            },
                            {
                                "id": "hemonc:24309",
                                "type": "DiseaseDescriptor",
                                "label": "Acute lymphoblastic leukemia",
                                "disease": "ncit:C3167"
                            },
                            {
                                "id": "hemonc:582",
                                "type": "DiseaseDescriptor",
                                "label": "Chronic myelogenous leukemia",
                                "disease": "ncit:C3174"
                            },
                            {
                                "id": "hemonc:669",
                                "type": "DiseaseDescriptor",
                                "label": "Systemic mastocytosis",
                                "disease": "ncit:C9235"
                            }
                        ]
                    }
                }
            ],
            "xrefs": [
                "ncit:C1687"
            ],
            "alternate_labels": [
                "4-[(4-Methyl-1-piperazinyl)methyl]-N-[4-methyl-3-[[4-(3-pyridinyl)-2-pyrimidinyl]amino]phenyl]benzamide Monomethanesulfonate",
                "CGP 57148",
                "CGP57148B",
                "Gleevec",
                "Glivec",
                "STI 571",
                "STI-571",
                "STI571"
            ],
            "therapeutic": "rxcui:282388"
        }
    },
    {
        "id": "civic.eid:5347",
        "type": "VariationNeoplasmTherapeuticResponseStatement",
        "description": "In an in vitro study, Chinese hamster ovary cells expressing PDGFRA V561D mutation demonstrated sensitivity to imatinib treatment (IC50<100), though this sensitivity was indistinguishable from Chinese hamster ovary cells expressing wild-type PDGFRA. Sensitivity was determined by assessing PDGFRA auto-phosphorylation.",
        "method": "metakb.method:1",
        "is_reported_in": [
            {
                "id": "civic.source:965",
                "type": "Document",
                "label": "Heinrich et al., 2008, J. Clin. Oncol.",
                "xrefs": [
                    "pmc:PMC2651076",
                    "pmid:18955458"
                ],
                "title": "Primary and secondary kinase genotypes correlate with the biological and clinical activity of sunitinib in imatinib-resistant gastrointestinal stromal tumor."
            }
        ],
        "evidence_level": {
            "id": "vicc:e00009",
            "type": "Coding",
            "label": "preclinical evidence"
        },
        "target_proposition": {
            "id": "proposition:-xN_xeEUq0fac4KIaVJ3IN0SC4hNUHeR",
            "type": "VariationNeoplasmTherapeuticResponseProposition",
            "subject": "ga4gh:VA.PmR2KGO2d96zDOFtI79sijmIhGO2v-a0",
            "predicate": "predicts_resistance_to",
            "object": {
                "id": "rxcui:282388",
                "type": "Therapeutic"
            },
            "neoplasm_type_qualifier": {
                "id": "ncit:C9305",
                "type": "Disease"
            }
        },
        "direction": "opposes",
        "subject_descriptor": "civic.vid:941",
        "neoplasm_type_descriptor": {
            "id": "civic.did:216",
            "type": "DiseaseDescriptor",
            "label": "Cancer",
            "xrefs": [
                "DOID:162"
            ],
            "disease": "ncit:C9305"
        },
        "object_descriptor": {
            "id": "civic.tid:537",
            "type": "TherapeuticDescriptor",
            "label": "Imatinib Mesylate",
            "extensions": [
                {
                    "type": "Extension",
                    "name": "regulatory_approval",
                    "value": {
                        "approval_rating": "FDA",
                        "has_indications": [
                            {
                                "id": "hemonc:667",
                                "type": "DiseaseDescriptor",
                                "label": "Soft tissue sarcoma",
                                "disease": "ncit:C9306"
                            },
                            {
                                "id": "hemonc:602",
                                "type": "DiseaseDescriptor",
                                "label": "Gastrointestinal stromal tumor",
                                "disease": "ncit:C3868"
                            },
                            {
                                "id": "hemonc:616",
                                "type": "DiseaseDescriptor",
                                "label": "Hypereosinophilic syndrome",
                                "disease": "ncit:C27038"
                            },
                            {
                                "id": "hemonc:33893",
                                "type": "DiseaseDescriptor",
                                "label": "Chronic myelogenous leukemia pediatric",
                                "disease": null
                            },
                            {
                                "id": "hemonc:634",
                                "type": "DiseaseDescriptor",
                                "label": "Myelodysplastic syndrome",
                                "disease": "ncit:C3247"
                            },
                            {
                                "id": "hemonc:24309",
                                "type": "DiseaseDescriptor",
                                "label": "Acute lymphoblastic leukemia",
                                "disease": "ncit:C3167"
                            },
                            {
                                "id": "hemonc:582",
                                "type": "DiseaseDescriptor",
                                "label": "Chronic myelogenous leukemia",
                                "disease": "ncit:C3174"
                            },
                            {
                                "id": "hemonc:669",
                                "type": "DiseaseDescriptor",
                                "label": "Systemic mastocytosis",
                                "disease": "ncit:C9235"
                            }
                        ]
                    }
                }
            ],
            "xrefs": [
                "ncit:C1687"
            ],
            "alternate_labels": [
                "4-[(4-Methyl-1-piperazinyl)methyl]-N-[4-methyl-3-[[4-(3-pyridinyl)-2-pyrimidinyl]amino]phenyl]benzamide Monomethanesulfonate",
                "CGP 57148",
                "CGP57148B",
                "Gleevec",
                "Glivec",
                "STI 571",
                "STI-571",
                "STI571"
            ],
            "therapeutic": "rxcui:282388"
        }
    },
    {
        "id": "civic.eid:8547",
        "type": "VariationNeoplasmTherapeuticResponseStatement",
        "description": "As part of a pre-clinical experiment, the efficacy of trastuzumab was evaluated against various HER2 positive cell lines. MCF7-neo/HER2 cell line harboring PIK3CA E545K was associated with resistance to trastuzumab compared to PIK3CA wild-type cell line SK-BR-3, at all concentrations tested (0-10 ug/mL).",
        "method": "metakb.method:1",
        "is_reported_in": [
            {
                "id": "civic.source:1468",
                "type": "Document",
                "label": "Baselga et al., 2016, Clin. Cancer Res.",
                "xrefs": [
                    "pmid:26920887"
                ],
                "title": "Relationship between Tumor Biomarkers and Efficacy in EMILIA, a Phase III Study of Trastuzumab Emtansine in HER2-Positive Metastatic Breast Cancer."
            }
        ],
        "evidence_level": {
            "id": "vicc:e00009",
            "type": "Coding",
            "label": "preclinical evidence"
        },
        "target_proposition": {
            "id": "proposition:desKNJAFooL9t1omnjR5wXtKTxuyJz6d",
            "type": "VariationNeoplasmTherapeuticResponseProposition",
            "subject": "ga4gh:VA.5zBiXnk0ZRCfFqRnK0fQHQwAGBWW4JE8",
            "predicate": "predicts_resistance_to",
            "object": {
                "id": "rxcui:2103478",
                "type": "Therapeutic"
            },
            "neoplasm_type_qualifier": {
                "id": "ncit:C53556",
                "type": "Disease"
            }
        },
        "direction": "supports",
        "subject_descriptor": "civic.vid:104",
        "neoplasm_type_descriptor": {
            "id": "civic.did:368",
            "type": "DiseaseDescriptor",
            "label": "Her2-receptor Positive Breast Cancer",
            "xrefs": [
                "DOID:60079"
            ],
            "disease": "ncit:C53556"
        },
        "object_descriptor": {
            "id": "civic.tid:84",
            "type": "TherapeuticDescriptor",
            "label": "Trastuzumab",
            "extensions": [
                {
                    "type": "Extension",
                    "name": "regulatory_approval",
                    "value": {
                        "approval_rating": "ChEMBL",
                        "has_indications": [
                            {
                                "id": "mesh:D001943",
                                "type": "DiseaseDescriptor",
                                "label": "Breast Neoplasms",
                                "disease": "ncit:C2910"
                            },
                            {
                                "id": "mesh:D009369",
                                "type": "DiseaseDescriptor",
                                "label": "Neoplasms",
                                "disease": "ncit:C3262"
                            }
                        ]
                    }
                }
            ],
            "xrefs": [
                "ncit:C1647"
            ],
            "alternate_labels": [
                "ABP 980",
                "ALT02",
                "Anti-ERB-2",
                "Anti-HER2/c-erbB2 Monoclonal Antibody",
                "Anti-c-ERB-2",
                "Anti-c-erbB2 Monoclonal Antibody",
                "Anti-erbB-2",
                "Anti-erbB2 Monoclonal Antibody",
                "Anti-p185-HER2",
                "C-erb-2 Monoclonal Antibody",
                "HER2 Monoclonal Antibody",
                "Herceptin",
                "Herceptin Biosimilar PF-05280014",
                "Herceptin Trastuzumab Biosimilar PF-05280014",
                "Herzuma",
                "Immunoglobulin G 1 (Human-Mouse Monoclonal RhuMab HER2gamma1-Chain Antihuman P185(Sup C-erbB2) Receptor), Disulfide With Human-Mouse Monoclonal RhuMab HER2 Light Chain, Dimer",
                "Kanjinti",
                "MoAb HER2",
                "Monoclonal Antibody C-erb-2",
                "Monoclonal Antibody HER2",
                "Ogivri",
                "Ontruzant",
                "PF-05280014",
                "RO0452317",
                "RhuMAb HER2",
                "SB3",
                "Trastuzumab Biosimilar ABP 980",
                "Trastuzumab Biosimilar ALT02",
                "Trastuzumab Biosimilar EG12014",
                "Trastuzumab Biosimilar HLX02",
                "Trastuzumab Biosimilar PF-05280014",
                "Trastuzumab Biosimilar SB3",
                "Trastuzumab Biosimilar SIBP-01",
                "Trastuzumab-anns",
                "Trastuzumab-dkst",
                "Trastuzumab-dttb",
                "Trastuzumab-pkrb",
                "Trastuzumab-qyyp",
                "Trazimera"
            ],
            "therapeutic": "rxcui:2103478"
        }
    },
    {
        "id": "civic.eid:8548",
        "type": "VariationNeoplasmTherapeuticResponseStatement",
        "description": "As part of a pre-clinical experiment, the efficacy of trastuzumab was evaluated against various HER2 positive cell lines. CC1954 and KPL-4 cell lines expressing PIK3CA H1047R were associated with resistance to trastuzumab compared to PIK3CA wild-type cell line SK-BR-3, at all concentrations tested (0-10 ug/mL).",
        "method": "metakb.method:1",
        "is_reported_in": [
            {
                "id": "civic.source:1468",
                "type": "Document",
                "label": "Baselga et al., 2016, Clin. Cancer Res.",
                "xrefs": [
                    "pmid:26920887"
                ],
                "title": "Relationship between Tumor Biomarkers and Efficacy in EMILIA, a Phase III Study of Trastuzumab Emtansine in HER2-Positive Metastatic Breast Cancer."
            }
        ],
        "evidence_level": {
            "id": "vicc:e00009",
            "type": "Coding",
            "label": "preclinical evidence"
        },
        "target_proposition": {
            "id": "proposition:_GrAGad44C40DPxk2nbOP9tPhZQUKGve",
            "type": "VariationNeoplasmTherapeuticResponseProposition",
            "subject": "ga4gh:VA.TIcXeM9bBVAIDYM4osh5rbkEVBs3LBCJ",
            "predicate": "predicts_resistance_to",
            "object": {
                "id": "rxcui:2103478",
                "type": "Therapeutic"
            },
            "neoplasm_type_qualifier": {
                "id": "ncit:C53556",
                "type": "Disease"
            }
        },
        "direction": "supports",
        "subject_descriptor": "civic.vid:107",
        "neoplasm_type_descriptor": {
            "id": "civic.did:368",
            "type": "DiseaseDescriptor",
            "label": "Her2-receptor Positive Breast Cancer",
            "xrefs": [
                "DOID:60079"
            ],
            "disease": "ncit:C53556"
        },
        "object_descriptor": {
            "id": "civic.tid:84",
            "type": "TherapeuticDescriptor",
            "label": "Trastuzumab",
            "extensions": [
                {
                    "type": "Extension",
                    "name": "regulatory_approval",
                    "value": {
                        "approval_rating": "ChEMBL",
                        "has_indications": [
                            {
                                "id": "mesh:D001943",
                                "type": "DiseaseDescriptor",
                                "label": "Breast Neoplasms",
                                "disease": "ncit:C2910"
                            },
                            {
                                "id": "mesh:D009369",
                                "type": "DiseaseDescriptor",
                                "label": "Neoplasms",
                                "disease": "ncit:C3262"
                            }
                        ]
                    }
                }
            ],
            "xrefs": [
                "ncit:C1647"
            ],
            "alternate_labels": [
                "ABP 980",
                "ALT02",
                "Anti-ERB-2",
                "Anti-HER2/c-erbB2 Monoclonal Antibody",
                "Anti-c-ERB-2",
                "Anti-c-erbB2 Monoclonal Antibody",
                "Anti-erbB-2",
                "Anti-erbB2 Monoclonal Antibody",
                "Anti-p185-HER2",
                "C-erb-2 Monoclonal Antibody",
                "HER2 Monoclonal Antibody",
                "Herceptin",
                "Herceptin Biosimilar PF-05280014",
                "Herceptin Trastuzumab Biosimilar PF-05280014",
                "Herzuma",
                "Immunoglobulin G 1 (Human-Mouse Monoclonal RhuMab HER2gamma1-Chain Antihuman P185(Sup C-erbB2) Receptor), Disulfide With Human-Mouse Monoclonal RhuMab HER2 Light Chain, Dimer",
                "Kanjinti",
                "MoAb HER2",
                "Monoclonal Antibody C-erb-2",
                "Monoclonal Antibody HER2",
                "Ogivri",
                "Ontruzant",
                "PF-05280014",
                "RO0452317",
                "RhuMAb HER2",
                "SB3",
                "Trastuzumab Biosimilar ABP 980",
                "Trastuzumab Biosimilar ALT02",
                "Trastuzumab Biosimilar EG12014",
                "Trastuzumab Biosimilar HLX02",
                "Trastuzumab Biosimilar PF-05280014",
                "Trastuzumab Biosimilar SB3",
                "Trastuzumab Biosimilar SIBP-01",
                "Trastuzumab-anns",
                "Trastuzumab-dkst",
                "Trastuzumab-dttb",
                "Trastuzumab-pkrb",
                "Trastuzumab-qyyp",
                "Trazimera"
            ],
            "therapeutic": "rxcui:2103478"
        }
    },
    {
        "id": "civic.eid:8549",
        "type": "VariationNeoplasmTherapeuticResponseStatement",
        "description": "As part of a pre-clinical experiment, the efficacy of trastuzumab was evaluated against various HER2 positive cell lines. EFM-192A cell line expressing PIK3CA C420R was associated with resistance to trastuzumab compared to PIK3CA wild-type cell line SK-BR-3, at all concentrations tested (0-10 ug/mL).",
        "method": "metakb.method:1",
        "is_reported_in": [
            {
                "id": "civic.source:1468",
                "type": "Document",
                "label": "Baselga et al., 2016, Clin. Cancer Res.",
                "xrefs": [
                    "pmid:26920887"
                ],
                "title": "Relationship between Tumor Biomarkers and Efficacy in EMILIA, a Phase III Study of Trastuzumab Emtansine in HER2-Positive Metastatic Breast Cancer."
            }
        ],
        "evidence_level": {
            "id": "vicc:e00009",
            "type": "Coding",
            "label": "preclinical evidence"
        },
        "target_proposition": {
            "id": "proposition:Kl6s1I_CbVIhQQlkIS8URjfYMKlcgHXc",
            "type": "VariationNeoplasmTherapeuticResponseProposition",
            "subject": "ga4gh:VA.gSEj555FrQu0uZMZcSDcGpE5p5TdBwX7",
            "predicate": "predicts_resistance_to",
            "object": {
                "id": "rxcui:2103478",
                "type": "Therapeutic"
            },
            "neoplasm_type_qualifier": {
                "id": "ncit:C53556",
                "type": "Disease"
            }
        },
        "direction": "supports",
        "subject_descriptor": "civic.vid:931",
        "neoplasm_type_descriptor": {
            "id": "civic.did:368",
            "type": "DiseaseDescriptor",
            "label": "Her2-receptor Positive Breast Cancer",
            "xrefs": [
                "DOID:60079"
            ],
            "disease": "ncit:C53556"
        },
        "object_descriptor": {
            "id": "civic.tid:84",
            "type": "TherapeuticDescriptor",
            "label": "Trastuzumab",
            "extensions": [
                {
                    "type": "Extension",
                    "name": "regulatory_approval",
                    "value": {
                        "approval_rating": "ChEMBL",
                        "has_indications": [
                            {
                                "id": "mesh:D001943",
                                "type": "DiseaseDescriptor",
                                "label": "Breast Neoplasms",
                                "disease": "ncit:C2910"
                            },
                            {
                                "id": "mesh:D009369",
                                "type": "DiseaseDescriptor",
                                "label": "Neoplasms",
                                "disease": "ncit:C3262"
                            }
                        ]
                    }
                }
            ],
            "xrefs": [
                "ncit:C1647"
            ],
            "alternate_labels": [
                "ABP 980",
                "ALT02",
                "Anti-ERB-2",
                "Anti-HER2/c-erbB2 Monoclonal Antibody",
                "Anti-c-ERB-2",
                "Anti-c-erbB2 Monoclonal Antibody",
                "Anti-erbB-2",
                "Anti-erbB2 Monoclonal Antibody",
                "Anti-p185-HER2",
                "C-erb-2 Monoclonal Antibody",
                "HER2 Monoclonal Antibody",
                "Herceptin",
                "Herceptin Biosimilar PF-05280014",
                "Herceptin Trastuzumab Biosimilar PF-05280014",
                "Herzuma",
                "Immunoglobulin G 1 (Human-Mouse Monoclonal RhuMab HER2gamma1-Chain Antihuman P185(Sup C-erbB2) Receptor), Disulfide With Human-Mouse Monoclonal RhuMab HER2 Light Chain, Dimer",
                "Kanjinti",
                "MoAb HER2",
                "Monoclonal Antibody C-erb-2",
                "Monoclonal Antibody HER2",
                "Ogivri",
                "Ontruzant",
                "PF-05280014",
                "RO0452317",
                "RhuMAb HER2",
                "SB3",
                "Trastuzumab Biosimilar ABP 980",
                "Trastuzumab Biosimilar ALT02",
                "Trastuzumab Biosimilar EG12014",
                "Trastuzumab Biosimilar HLX02",
                "Trastuzumab Biosimilar PF-05280014",
                "Trastuzumab Biosimilar SB3",
                "Trastuzumab Biosimilar SIBP-01",
                "Trastuzumab-anns",
                "Trastuzumab-dkst",
                "Trastuzumab-dttb",
                "Trastuzumab-pkrb",
                "Trastuzumab-qyyp",
                "Trazimera"
            ],
            "therapeutic": "rxcui:2103478"
        }
    },
    {
        "id": "civic.eid:8662",
        "type": "VariationNeoplasmTherapeuticResponseStatement",
        "description": "As part of a pre-clinical experiment, the efficacy of trastuzumab was evaluated against various HER2 positive cell lines in cell viability assays. BT-474 cell line expressing PIK3CA K111N was associated with similar sensitivity to trastuzumab as PIK3CA wild-type cell line SK-BR-3, at all concentrations tested (0-10 ug/mL).",
        "method": "metakb.method:1",
        "is_reported_in": [
            {
                "id": "civic.source:1468",
                "type": "Document",
                "label": "Baselga et al., 2016, Clin. Cancer Res.",
                "xrefs": [
                    "pmid:26920887"
                ],
                "title": "Relationship between Tumor Biomarkers and Efficacy in EMILIA, a Phase III Study of Trastuzumab Emtansine in HER2-Positive Metastatic Breast Cancer."
            }
        ],
        "evidence_level": {
            "id": "vicc:e00009",
            "type": "Coding",
            "label": "preclinical evidence"
        },
        "target_proposition": {
            "id": "proposition:ra3GmtMjZISXUhxnATIq8JK14R_DpRnM",
            "type": "VariationNeoplasmTherapeuticResponseProposition",
            "subject": "ga4gh:VA.MwhPgqLyRggo95FGBET65hs3Dbmm0jW1",
            "predicate": "predicts_resistance_to",
            "object": {
                "id": "rxcui:2103478",
                "type": "Therapeutic"
            },
            "neoplasm_type_qualifier": {
                "id": "ncit:C53556",
                "type": "Disease"
            }
        },
        "direction": "opposes",
        "subject_descriptor": "civic.vid:1234",
        "neoplasm_type_descriptor": {
            "id": "civic.did:368",
            "type": "DiseaseDescriptor",
            "label": "Her2-receptor Positive Breast Cancer",
            "xrefs": [
                "DOID:60079"
            ],
            "disease": "ncit:C53556"
        },
        "object_descriptor": {
            "id": "civic.tid:84",
            "type": "TherapeuticDescriptor",
            "label": "Trastuzumab",
            "extensions": [
                {
                    "type": "Extension",
                    "name": "regulatory_approval",
                    "value": {
                        "approval_rating": "ChEMBL",
                        "has_indications": [
                            {
                                "id": "mesh:D001943",
                                "type": "DiseaseDescriptor",
                                "label": "Breast Neoplasms",
                                "disease": "ncit:C2910"
                            },
                            {
                                "id": "mesh:D009369",
                                "type": "DiseaseDescriptor",
                                "label": "Neoplasms",
                                "disease": "ncit:C3262"
                            }
                        ]
                    }
                }
            ],
            "xrefs": [
                "ncit:C1647"
            ],
            "alternate_labels": [
                "ABP 980",
                "ALT02",
                "Anti-ERB-2",
                "Anti-HER2/c-erbB2 Monoclonal Antibody",
                "Anti-c-ERB-2",
                "Anti-c-erbB2 Monoclonal Antibody",
                "Anti-erbB-2",
                "Anti-erbB2 Monoclonal Antibody",
                "Anti-p185-HER2",
                "C-erb-2 Monoclonal Antibody",
                "HER2 Monoclonal Antibody",
                "Herceptin",
                "Herceptin Biosimilar PF-05280014",
                "Herceptin Trastuzumab Biosimilar PF-05280014",
                "Herzuma",
                "Immunoglobulin G 1 (Human-Mouse Monoclonal RhuMab HER2gamma1-Chain Antihuman P185(Sup C-erbB2) Receptor), Disulfide With Human-Mouse Monoclonal RhuMab HER2 Light Chain, Dimer",
                "Kanjinti",
                "MoAb HER2",
                "Monoclonal Antibody C-erb-2",
                "Monoclonal Antibody HER2",
                "Ogivri",
                "Ontruzant",
                "PF-05280014",
                "RO0452317",
                "RhuMAb HER2",
                "SB3",
                "Trastuzumab Biosimilar ABP 980",
                "Trastuzumab Biosimilar ALT02",
                "Trastuzumab Biosimilar EG12014",
                "Trastuzumab Biosimilar HLX02",
                "Trastuzumab Biosimilar PF-05280014",
                "Trastuzumab Biosimilar SB3",
                "Trastuzumab Biosimilar SIBP-01",
                "Trastuzumab-anns",
                "Trastuzumab-dkst",
                "Trastuzumab-dttb",
                "Trastuzumab-pkrb",
                "Trastuzumab-qyyp",
                "Trazimera"
            ],
            "therapeutic": "rxcui:2103478"
        }
    },
    {
        "id": "civic.eid:8663",
        "type": "VariationNeoplasmTherapeuticResponseStatement",
        "description": "As part of a pre-clinical experiment, the efficacy of trastuzumab was evaluated against various HER2 positive cell lines using cell viability assays. ZR-75-30 cell line expressing PIK3CA I391M was associated with similar sensitivity to trastuzumab compared to PIK3CA wild-type cell line SK-BR-3, at all concentrations tested (0-10 ug/mL).",
        "method": "metakb.method:1",
        "is_reported_in": [
            {
                "id": "civic.source:1468",
                "type": "Document",
                "label": "Baselga et al., 2016, Clin. Cancer Res.",
                "xrefs": [
                    "pmid:26920887"
                ],
                "title": "Relationship between Tumor Biomarkers and Efficacy in EMILIA, a Phase III Study of Trastuzumab Emtansine in HER2-Positive Metastatic Breast Cancer."
            }
        ],
        "evidence_level": {
            "id": "vicc:e00009",
            "type": "Coding",
            "label": "preclinical evidence"
        },
        "target_proposition": {
            "id": "proposition:1xWTPr--T7lrUpwHUtF2qZ8di5fsbSfz",
            "type": "VariationNeoplasmTherapeuticResponseProposition",
            "subject": "ga4gh:VA.85QZR4K49RijmSG0hPIy9BQRNQBKuFgj",
            "predicate": "predicts_resistance_to",
            "object": {
                "id": "rxcui:2103478",
                "type": "Therapeutic"
            },
            "neoplasm_type_qualifier": {
                "id": "ncit:C53556",
                "type": "Disease"
            }
        },
        "direction": "opposes",
        "subject_descriptor": "civic.vid:1235",
        "neoplasm_type_descriptor": {
            "id": "civic.did:368",
            "type": "DiseaseDescriptor",
            "label": "Her2-receptor Positive Breast Cancer",
            "xrefs": [
                "DOID:60079"
            ],
            "disease": "ncit:C53556"
        },
        "object_descriptor": {
            "id": "civic.tid:84",
            "type": "TherapeuticDescriptor",
            "label": "Trastuzumab",
            "extensions": [
                {
                    "type": "Extension",
                    "name": "regulatory_approval",
                    "value": {
                        "approval_rating": "ChEMBL",
                        "has_indications": [
                            {
                                "id": "mesh:D001943",
                                "type": "DiseaseDescriptor",
                                "label": "Breast Neoplasms",
                                "disease": "ncit:C2910"
                            },
                            {
                                "id": "mesh:D009369",
                                "type": "DiseaseDescriptor",
                                "label": "Neoplasms",
                                "disease": "ncit:C3262"
                            }
                        ]
                    }
                }
            ],
            "xrefs": [
                "ncit:C1647"
            ],
            "alternate_labels": [
                "ABP 980",
                "ALT02",
                "Anti-ERB-2",
                "Anti-HER2/c-erbB2 Monoclonal Antibody",
                "Anti-c-ERB-2",
                "Anti-c-erbB2 Monoclonal Antibody",
                "Anti-erbB-2",
                "Anti-erbB2 Monoclonal Antibody",
                "Anti-p185-HER2",
                "C-erb-2 Monoclonal Antibody",
                "HER2 Monoclonal Antibody",
                "Herceptin",
                "Herceptin Biosimilar PF-05280014",
                "Herceptin Trastuzumab Biosimilar PF-05280014",
                "Herzuma",
                "Immunoglobulin G 1 (Human-Mouse Monoclonal RhuMab HER2gamma1-Chain Antihuman P185(Sup C-erbB2) Receptor), Disulfide With Human-Mouse Monoclonal RhuMab HER2 Light Chain, Dimer",
                "Kanjinti",
                "MoAb HER2",
                "Monoclonal Antibody C-erb-2",
                "Monoclonal Antibody HER2",
                "Ogivri",
                "Ontruzant",
                "PF-05280014",
                "RO0452317",
                "RhuMAb HER2",
                "SB3",
                "Trastuzumab Biosimilar ABP 980",
                "Trastuzumab Biosimilar ALT02",
                "Trastuzumab Biosimilar EG12014",
                "Trastuzumab Biosimilar HLX02",
                "Trastuzumab Biosimilar PF-05280014",
                "Trastuzumab Biosimilar SB3",
                "Trastuzumab Biosimilar SIBP-01",
                "Trastuzumab-anns",
                "Trastuzumab-dkst",
                "Trastuzumab-dttb",
                "Trastuzumab-pkrb",
                "Trastuzumab-qyyp",
                "Trazimera"
            ],
            "therapeutic": "rxcui:2103478"
        }
    },
    {
        "id": "civic.eid:3889",
        "type": "VariationNeoplasmTherapeuticResponseStatement",
        "description": "In an in vitro study, a human colon adenocarcinoma SW48 cell line expressing KRAS G13D mutation demonstrated resistance to regorafenib treatment (IC50: 172.23 nM vs. 114.28 nM, P<0.01) compared to SW48 cells expressing KRAS wild-type. Resistance was determined by assessing cell viability. Authors concluded that KRAS G13D is more resistant to regorafenib than KRAS wt, but more sensitive than common KRAS G12 mutations.",
        "method": "metakb.method:1",
        "is_reported_in": [
            {
                "id": "civic.source:1935",
                "type": "Document",
                "label": "Camaj et al., 2015, Future Oncol",
                "xrefs": [
                    "pmid:26161928"
                ],
                "title": "KRAS exon 2 mutations influence activity of regorafenib in an SW48-based disease model of colorectal cancer."
            }
        ],
        "evidence_level": {
            "id": "vicc:e00009",
            "type": "Coding",
            "label": "preclinical evidence"
        },
        "target_proposition": {
            "id": "proposition:bAtc-Af-8-sIJGDG8bqAIin1qHgH9Hz3",
            "type": "VariationNeoplasmTherapeuticResponseProposition",
            "subject": "ga4gh:VA.tO-mdKyTxDxR376-vWkR2RgI2gpOvBhQ",
            "predicate": "predicts_resistance_to",
            "object": {
                "id": "rxcui:1312397",
                "type": "Therapeutic"
            },
            "neoplasm_type_qualifier": {
                "id": "ncit:C4978",
                "type": "Disease"
            }
        },
        "direction": "supports",
        "subject_descriptor": "civic.vid:81",
        "neoplasm_type_descriptor": {
            "id": "civic.did:11",
            "type": "DiseaseDescriptor",
            "label": "Colorectal Cancer",
            "xrefs": [
                "DOID:9256"
            ],
            "disease": "ncit:C4978"
        },
        "object_descriptor": {
            "id": "civic.tid:27",
            "type": "TherapeuticDescriptor",
            "label": "Regorafenib",
            "extensions": [
                {
                    "type": "Extension",
                    "name": "regulatory_approval",
                    "value": {
                        "approval_rating": "ChEMBL",
                        "has_indications": [
                            {
                                "id": "mesh:D009369",
                                "type": "DiseaseDescriptor",
                                "label": "Neoplasms",
                                "disease": "ncit:C3262"
                            },
                            {
                                "id": "mesh:D015179",
                                "type": "DiseaseDescriptor",
                                "label": "Colorectal Neoplasms",
                                "disease": "ncit:C2956"
                            }
                        ]
                    }
                }
            ],
            "xrefs": [
                "ncit:C78204"
            ],
            "alternate_labels": [
                "4-(4-(((4-chloro-3-(trifluoromethyl)phenyl)carbamoyl)amino)-3-fluorophenoxy)-N-methylpyridine-2-carboxamide",
                "BAY 73-4506",
                "REGORAFENIB ANHYDROUS",
                "Stivarga"
            ],
            "therapeutic": "rxcui:1312397"
        }
    },
    {
        "id": "civic.eid:3946",
        "type": "VariationNeoplasmTherapeuticResponseStatement",
        "description": "In an in vitro study, a human colon adenocarcinoma SW48 cell line expressing KRAS G12D mutation demonstrated resistance to regorafenib treatment (IC50: 195.01nM vs. 114.28 nM P<0.01) compared to SW48 cells expressing KRAS wild-type. Resistance was determined by assessing cell viability. Authors concluded that KRAS G12D was more resistant to regorafenib than KRAS wt, and intermediately resistant compared to other common KRAS G12/G13 mutations.",
        "method": "metakb.method:1",
        "is_reported_in": [
            {
                "id": "civic.source:1935",
                "type": "Document",
                "label": "Camaj et al., 2015, Future Oncol",
                "xrefs": [
                    "pmid:26161928"
                ],
                "title": "KRAS exon 2 mutations influence activity of regorafenib in an SW48-based disease model of colorectal cancer."
            }
        ],
        "evidence_level": {
            "id": "vicc:e00009",
            "type": "Coding",
            "label": "preclinical evidence"
        },
        "target_proposition": {
            "id": "proposition:Fm54Yy1dy2lIrS3uLR19W_4RGrDj83pv",
            "type": "VariationNeoplasmTherapeuticResponseProposition",
            "subject": "ga4gh:VA.jSiuIG2uZEbml8MfCtZi3J9jPBCBiaPw",
            "predicate": "predicts_resistance_to",
            "object": {
                "id": "rxcui:1312397",
                "type": "Therapeutic"
            },
            "neoplasm_type_qualifier": {
                "id": "ncit:C4978",
                "type": "Disease"
            }
        },
        "direction": "supports",
        "subject_descriptor": "civic.vid:79",
        "neoplasm_type_descriptor": {
            "id": "civic.did:11",
            "type": "DiseaseDescriptor",
            "label": "Colorectal Cancer",
            "xrefs": [
                "DOID:9256"
            ],
            "disease": "ncit:C4978"
        },
        "object_descriptor": {
            "id": "civic.tid:27",
            "type": "TherapeuticDescriptor",
            "label": "Regorafenib",
            "extensions": [
                {
                    "type": "Extension",
                    "name": "regulatory_approval",
                    "value": {
                        "approval_rating": "ChEMBL",
                        "has_indications": [
                            {
                                "id": "mesh:D009369",
                                "type": "DiseaseDescriptor",
                                "label": "Neoplasms",
                                "disease": "ncit:C3262"
                            },
                            {
                                "id": "mesh:D015179",
                                "type": "DiseaseDescriptor",
                                "label": "Colorectal Neoplasms",
                                "disease": "ncit:C2956"
                            }
                        ]
                    }
                }
            ],
            "xrefs": [
                "ncit:C78204"
            ],
            "alternate_labels": [
                "4-(4-(((4-chloro-3-(trifluoromethyl)phenyl)carbamoyl)amino)-3-fluorophenoxy)-N-methylpyridine-2-carboxamide",
                "BAY 73-4506",
                "REGORAFENIB ANHYDROUS",
                "Stivarga"
            ],
            "therapeutic": "rxcui:1312397"
        }
    },
    {
        "id": "civic.eid:3991",
        "type": "VariationNeoplasmTherapeuticResponseStatement",
        "description": "In an in vitro study, a human colon adenocarcinoma SW48 cell line expressing KRAS G12R mutation demonstrated resistance to regorafenib treatment (IC50: 181.77 nM vs. 114.28 nM, P<0.01) compared to SW48 cells expressing KRAS wild-type. Resistance was determined by assessing cell viability. Authors concluded that KRAS G12R was resistant to regorafenib compared to wildtype but was less resistant than other common KRAS G12/G13 mutations.",
        "method": "metakb.method:1",
        "is_reported_in": [
            {
                "id": "civic.source:1935",
                "type": "Document",
                "label": "Camaj et al., 2015, Future Oncol",
                "xrefs": [
                    "pmid:26161928"
                ],
                "title": "KRAS exon 2 mutations influence activity of regorafenib in an SW48-based disease model of colorectal cancer."
            }
        ],
        "evidence_level": {
            "id": "vicc:e00009",
            "type": "Coding",
            "label": "preclinical evidence"
        },
        "target_proposition": {
            "id": "proposition:KSJXjaqja0P4isoTPx4vOztsuMbCjy9w",
            "type": "VariationNeoplasmTherapeuticResponseProposition",
            "subject": "ga4gh:VA._AIonI6Sp_E7tTUN81jJbNG3tERDCkVk",
            "predicate": "predicts_resistance_to",
            "object": {
                "id": "rxcui:1312397",
                "type": "Therapeutic"
            },
            "neoplasm_type_qualifier": {
                "id": "ncit:C4978",
                "type": "Disease"
            }
        },
        "direction": "supports",
        "subject_descriptor": "civic.vid:530",
        "neoplasm_type_descriptor": {
            "id": "civic.did:11",
            "type": "DiseaseDescriptor",
            "label": "Colorectal Cancer",
            "xrefs": [
                "DOID:9256"
            ],
            "disease": "ncit:C4978"
        },
        "object_descriptor": {
            "id": "civic.tid:27",
            "type": "TherapeuticDescriptor",
            "label": "Regorafenib",
            "extensions": [
                {
                    "type": "Extension",
                    "name": "regulatory_approval",
                    "value": {
                        "approval_rating": "ChEMBL",
                        "has_indications": [
                            {
                                "id": "mesh:D009369",
                                "type": "DiseaseDescriptor",
                                "label": "Neoplasms",
                                "disease": "ncit:C3262"
                            },
                            {
                                "id": "mesh:D015179",
                                "type": "DiseaseDescriptor",
                                "label": "Colorectal Neoplasms",
                                "disease": "ncit:C2956"
                            }
                        ]
                    }
                }
            ],
            "xrefs": [
                "ncit:C78204"
            ],
            "alternate_labels": [
                "4-(4-(((4-chloro-3-(trifluoromethyl)phenyl)carbamoyl)amino)-3-fluorophenoxy)-N-methylpyridine-2-carboxamide",
                "BAY 73-4506",
                "REGORAFENIB ANHYDROUS",
                "Stivarga"
            ],
            "therapeutic": "rxcui:1312397"
        }
    },
    {
        "id": "civic.eid:4029",
        "type": "VariationNeoplasmTherapeuticResponseStatement",
        "description": "In an in vitro study, a M229 cell line endogenously expressing BRAF V600E mutation (a known vemurafenib sensitizing mutation) and overexpressing AKT1 E17K mutation was associated with resistance to vemurafenib treatment, as compared to cells expressing BRAF V600E mutation and wildtype AKT1. Resistance was determined by assessing cell survival.",
        "method": "metakb.method:1",
        "is_reported_in": [
            {
                "id": "civic.source:1941",
                "type": "Document",
                "label": "Shi et al., 2014, Cancer Discov",
                "xrefs": [
                    "pmc:PMC3936420",
                    "pmid:24265155"
                ],
                "title": "Acquired resistance and clonal evolution in melanoma during BRAF inhibitor therapy."
            }
        ],
        "evidence_level": {
            "id": "vicc:e00009",
            "type": "Coding",
            "label": "preclinical evidence"
        },
        "target_proposition": {
            "id": "proposition:lTXrhZex53tbhd1MXL0-JAzqXKZtEmRK",
            "type": "VariationNeoplasmTherapeuticResponseProposition",
            "subject": "ga4gh:VA._veAF5iFKxk_oSX9jnfNc4AHp8MvUCKO",
            "predicate": "predicts_resistance_to",
            "object": {
                "id": "rxcui:1147220",
                "type": "Therapeutic"
            },
            "neoplasm_type_qualifier": {
                "id": "ncit:C3224",
                "type": "Disease"
            }
        },
        "direction": "supports",
        "subject_descriptor": "civic.vid:4",
        "neoplasm_type_descriptor": {
            "id": "civic.did:7",
            "type": "DiseaseDescriptor",
            "label": "Melanoma",
            "xrefs": [
                "DOID:1909"
            ],
            "disease": "ncit:C3224"
        },
        "object_descriptor": {
            "id": "civic.tid:4",
            "type": "TherapeuticDescriptor",
            "label": "Vemurafenib",
            "extensions": [
                {
                    "type": "Extension",
                    "name": "regulatory_approval",
                    "value": {
                        "approval_rating": "FDA",
                        "has_indications": [
                            {
                                "id": "hemonc:629",
                                "type": "DiseaseDescriptor",
                                "label": "Melanoma",
                                "disease": "ncit:C3224"
                            },
                            {
                                "id": "hemonc:594",
                                "type": "DiseaseDescriptor",
                                "label": "Erdheim-Chester disease",
                                "disease": "ncit:C53972"
                            }
                        ]
                    }
                }
            ],
            "xrefs": [
                "ncit:C64768"
            ],
            "alternate_labels": [
                "1-propanesulfonamide, N-(3-((5-(4-chlorophenyl)-1h-pyrrolo(2,3-b)pyridin-3-yl)carbonyl)-2,4-difluorophenyl)-",
                "BRAF (V600E) Kinase Inhibitor RO5185426",
                "BRAF(V600E) Kinase Inhibitor RO5185426",
                "PLX-4032",
                "PLX4032",
                "RG 7204",
                "RG7204",
                "RO 5185426",
                "Zelboraf"
            ],
            "therapeutic": "rxcui:1147220"
        }
    },
    {
        "id": "civic.eid:8007",
        "type": "VariationNeoplasmTherapeuticResponseStatement",
        "description": "As part of a preclinical study, the efficacy of PI-103 was evaluated for several cell lines of breast cancer. Sensitivity and resistance was categorized as less than and more than an IC50 of 1umol/L, respectively, with a maximum tested concentration of 20 umol/L. KPL1 is a luminal-like breast cancer cell line harboring PIK3CA E542K, and it had an IC50 of 7.62uM.",
        "method": "metakb.method:1",
        "is_reported_in": [
            {
                "id": "civic.source:1435",
                "type": "Document",
                "label": "O'Brien et al., 2010, Clin. Cancer Res.",
                "xrefs": [
                    "pmid:20453058"
                ],
                "title": "Predictive biomarkers of sensitivity to the phosphatidylinositol 3' kinase inhibitor GDC-0941 in breast cancer preclinical models."
            }
        ],
        "evidence_level": {
            "id": "vicc:e00009",
            "type": "Coding",
            "label": "preclinical evidence"
        },
        "target_proposition": {
            "id": "proposition:vaY8Fjm5kdr7FBGZIxtIZBzAVYOeeM9C",
            "type": "VariationNeoplasmTherapeuticResponseProposition",
            "subject": "ga4gh:VA.RTy0UiMi4D-aTPKvZBR3e3FXhFy4doaD",
            "predicate": "predicts_resistance_to",
            "object": {
                "id": "iuphar.ligand:5701",
                "type": "Therapeutic"
            },
            "neoplasm_type_qualifier": {
                "id": "ncit:C9335",
                "type": "Disease"
            }
        },
        "direction": "supports",
        "subject_descriptor": "civic.vid:103",
        "neoplasm_type_descriptor": {
            "id": "civic.did:22",
            "type": "DiseaseDescriptor",
            "label": "Breast Cancer",
            "xrefs": [
                "DOID:1612"
            ],
            "disease": "ncit:C9335"
        },
        "object_descriptor": {
            "id": "civic.tid:19830",
            "type": "TherapeuticDescriptor",
            "label": "PI-103",
            "therapeutic": "iuphar.ligand:5701"
        }
    },
    {
        "id": "civic.eid:8008",
        "type": "VariationNeoplasmTherapeuticResponseStatement",
        "description": "As part of a preclinical study, the efficacy of PI-103 was evaluated for several cell lines of breast cancer. Sensitivity and resistance was categorized as less than and more than an IC50 of 1umol/L, respectively, with a maximum tested concentration of 20 umol/L. MCF7 is a luminal-like breast cancer cell line harboring PIK3CA E545K, and it had an IC50 of 1.53uM.",
        "method": "metakb.method:1",
        "is_reported_in": [
            {
                "id": "civic.source:1435",
                "type": "Document",
                "label": "O'Brien et al., 2010, Clin. Cancer Res.",
                "xrefs": [
                    "pmid:20453058"
                ],
                "title": "Predictive biomarkers of sensitivity to the phosphatidylinositol 3' kinase inhibitor GDC-0941 in breast cancer preclinical models."
            }
        ],
        "evidence_level": {
            "id": "vicc:e00009",
            "type": "Coding",
            "label": "preclinical evidence"
        },
        "target_proposition": {
            "id": "proposition:DgKaqxFMw3e61DMW-0tQJkHD4bw7iRzv",
            "type": "VariationNeoplasmTherapeuticResponseProposition",
            "subject": "ga4gh:VA.5zBiXnk0ZRCfFqRnK0fQHQwAGBWW4JE8",
            "predicate": "predicts_resistance_to",
            "object": {
                "id": "iuphar.ligand:5701",
                "type": "Therapeutic"
            },
            "neoplasm_type_qualifier": {
                "id": "ncit:C9335",
                "type": "Disease"
            }
        },
        "direction": "supports",
        "subject_descriptor": "civic.vid:104",
        "neoplasm_type_descriptor": {
            "id": "civic.did:22",
            "type": "DiseaseDescriptor",
            "label": "Breast Cancer",
            "xrefs": [
                "DOID:1612"
            ],
            "disease": "ncit:C9335"
        },
        "object_descriptor": {
            "id": "civic.tid:19830",
            "type": "TherapeuticDescriptor",
            "label": "PI-103",
            "therapeutic": "iuphar.ligand:5701"
        }
    },
    {
        "id": "civic.eid:1209",
        "type": "VariationNeoplasmTherapeuticResponseStatement",
        "description": "The P47S (rs1800371) variant of TP53 is observed in 1.5% in African Americans and between 6% and 8% in certain African populations but has not been detected in Caucasian Americans. This paper reports functional studies of this variant. Mouse models with this variant show an increase in spontaneous tumor formation. 16 out of 20 (80%) of S47 homozygous mice developed cancer between 12 and 18 months of age. Cancers predominantly included hepatocellular carcinoma, B-cell lymphoma, and histiocytic sarcoma, as well as other\ntumor types. In S47/wild-type heterozygote mice an increased cancer incidence, with a predisposition for hepatocellular carcinoma, was also found. Mouse embryonic fibroblasts and human lymphoblastoid cell lines with S47 mutations were significantly less sensitive to cisplatinum treatment compared to TP53 wild-type cells (apoptosis and viability).",
        "method": "metakb.method:1",
        "is_reported_in": [
            {
                "id": "civic.source:834",
                "type": "Document",
                "label": "Jennis et al., 2016, Genes Dev.",
                "xrefs": [
                    "pmc:PMC4840298",
                    "pmid:27034505"
                ],
                "title": "An African-specific polymorphism in the TP53 gene impairs p53 tumor suppressor function in a mouse model."
            }
        ],
        "evidence_level": {
            "id": "vicc:e00010",
            "type": "Coding",
            "label": "inferential evidence"
        },
        "target_proposition": {
            "id": "proposition:OZMdO9Wzd6Z74Ce_9XymPApaFyIGzrdq",
            "type": "VariationNeoplasmTherapeuticResponseProposition",
            "subject": "ga4gh:VA.77LTqg70IhQdX3kzFa3LZE_E0tQTdG-0",
            "predicate": "predicts_resistance_to",
            "object": {
                "id": "rxcui:2555",
                "type": "Therapeutic"
            },
            "neoplasm_type_qualifier": {
                "id": "ncit:C9305",
                "type": "Disease"
            }
        },
        "direction": "supports",
        "subject_descriptor": "civic.vid:504",
        "neoplasm_type_descriptor": {
            "id": "civic.did:216",
            "type": "DiseaseDescriptor",
            "label": "Cancer",
            "xrefs": [
                "DOID:162"
            ],
            "disease": "ncit:C9305"
        },
        "object_descriptor": {
            "id": "civic.tid:326",
            "type": "TherapeuticDescriptor",
            "label": "Cisplatin",
            "extensions": [
                {
                    "type": "Extension",
                    "name": "regulatory_approval",
                    "value": {
                        "approval_rating": "FDA",
                        "has_indications": [
                            {
                                "id": "hemonc:569",
                                "type": "DiseaseDescriptor",
                                "label": "Bladder cancer",
                                "disease": "ncit:C9334"
                            },
                            {
                                "id": "hemonc:671",
                                "type": "DiseaseDescriptor",
                                "label": "Testicular cancer",
                                "disease": "ncit:C7251"
                            },
                            {
                                "id": "hemonc:645",
                                "type": "DiseaseDescriptor",
                                "label": "Ovarian cancer",
                                "disease": "ncit:C7431"
                            }
                        ]
                    }
                }
            ],
            "xrefs": [
                "ncit:C376"
            ],
            "alternate_labels": [
                "(SP-4-2)-Diamminedichloroplatinum",
                "Abiplatin",
                "Blastolem",
                "Briplatin",
                "CDDP",
                "Cis-diammine-dichloroplatinum",
                "Cis-diamminedichloridoplatinum",
                "Cis-diamminedichloro Platinum (II)",
                "Cis-diamminedichloroplatinum",
                "Cis-dichloroammine Platinum (II)",
                "Cis-platinous Diamine Dichloride",
                "Cis-platinum",
                "Cis-platinum II",
                "Cis-platinum II Diamine Dichloride",
                "Cismaplat",
                "Cisplatina",
                "Cisplatinum",
                "Cisplatyl",
                "Citoplatino",
                "Citosin",
                "Cysplatyna",
                "DDP",
                "Lederplatin",
                "Metaplatin",
                "Neoplatin",
                "Peyrone's Chloride",
                "Peyrone's Salt",
                "Placis",
                "Plastistil",
                "Platamine",
                "Platiblastin",
                "Platiblastin-S",
                "Platinex",
                "Platinol",
                "Platinol- AQ",
                "Platinol-AQ",
                "Platinol-AQ VHA Plus",
                "Platinoxan",
                "Platinum",
                "Platinum Diamminodichloride",
                "Platinum, Diaminedichloro-, Cis- (8CI)",
                "Platiran",
                "Platistin",
                "Platosin"
            ],
            "therapeutic": "rxcui:2555"
        }
    }
]